0001104659-24-033746.txt : 20240313 0001104659-24-033746.hdr.sgml : 20240313 20240313073648 ACCESSION NUMBER: 0001104659-24-033746 CONFORMED SUBMISSION TYPE: 40-F PUBLIC DOCUMENT COUNT: 116 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240313 DATE AS OF CHANGE: 20240313 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ayr Wellness Inc. CENTRAL INDEX KEY: 0001847462 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 981500584 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 40-F SEC ACT: 1934 Act SEC FILE NUMBER: 333-253466 FILM NUMBER: 24744584 BUSINESS ADDRESS: STREET 1: 199 BAY STREET STREET 2: SUITE 5300 CITY: TORONTO STATE: A6 ZIP: M5L 1B9 BUSINESS PHONE: 949-574-3860 MAIL ADDRESS: STREET 1: 666 BURRARD ST STREET 2: SUITE 1700 CITY: VANCOUVER STATE: A1 ZIP: V6C 2X8 40-F 1 ayr-20231231x40f.htm FORM 40-F
0001847462FYAyr Wellness Inc.false0001847462ayr:SubordinateRestrictedAndLimitedVotingSharesMember2023-12-310001847462ayr:MultipleVotingSharesMember2023-12-310001847462dei:BusinessContactMember2023-01-012023-12-3100018474622023-01-012023-12-310001847462us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-12-310001847462us-gaap:TreasuryStockCommonMember2022-01-012022-12-310001847462ayr:SubordinateRestrictedAndLimitedVotingSharesAndTreasurySharesMember2022-01-012022-12-310001847462ayr:ScenarioOtherThanRelatedToBusinessAcquisitionsMemberayr:SubordinateRestrictedAndLimitedVotingSharesMember2023-01-012023-12-310001847462ayr:ScenarioOtherThanRelatedToBusinessAcquisitionsMemberayr:ExchangeableSharesMember2023-01-012023-12-310001847462ayr:LeviaMemberayr:SubordinateRestrictedAndLimitedVotingSharesMember2023-01-012023-12-310001847462ayr:LeviaMemberayr:ExchangeableSharesMember2023-01-012023-12-310001847462ayr:HerbalRemediesDispensariesLlcMemberayr:SubordinateRestrictedAndLimitedVotingSharesMember2023-01-012023-12-310001847462ayr:HerbalRemediesDispensariesLlcMemberayr:ExchangeableSharesMember2023-01-012023-12-310001847462ayr:BlueCamoLlcMemberayr:ExchangeableSharesMember2023-01-012023-12-310001847462ayr:ScenarioOtherThanRelatedToBusinessAcquisitionsMemberayr:SubordinateRestrictedAndLimitedVotingSharesMember2022-01-012022-12-310001847462ayr:CanntechPaLlcMemberayr:SubordinateRestrictedAndLimitedVotingSharesMember2022-01-012022-12-310001847462ayr:CanntechPaLlcMemberayr:ExchangeableSharesMember2022-01-012022-12-310001847462ayr:BlueCamoLlcMemberayr:SubordinateRestrictedAndLimitedVotingSharesMember2022-01-012022-12-310001847462ayr:BlueCamoLlcMemberayr:ExchangeableSharesMember2022-01-012022-12-310001847462ayr:TahoeHydroponicsCompanyLlcMemberayr:ExchangeableSharesMember2023-01-012023-12-310001847462ayr:GsdNjLlcMemberayr:ExchangeableSharesMember2023-01-012023-12-310001847462ayr:HerbalRemediesDispensariesLlcMemberayr:ExchangeableSharesMember2022-01-012022-12-310001847462ayr:CultivaunaLlcMemberayr:ExchangeableSharesMember2022-01-012022-12-310001847462us-gaap:RetainedEarningsMember2023-12-310001847462us-gaap:NoncontrollingInterestMember2023-12-310001847462us-gaap:AdditionalPaidInCapitalMember2023-12-310001847462us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001847462us-gaap:RetainedEarningsMember2022-12-310001847462us-gaap:NoncontrollingInterestMember2022-12-310001847462us-gaap:AdditionalPaidInCapitalMember2022-12-310001847462us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001847462us-gaap:RetainedEarningsMember2021-12-310001847462us-gaap:AdditionalPaidInCapitalMember2021-12-310001847462us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001847462us-gaap:EmployeeStockOptionMember2023-01-012023-12-310001847462us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001847462ayr:MarketBasedAwardsMember2023-12-310001847462ayr:MarketAndPerformanceBasedRsusMember2023-12-310001847462us-gaap:PerformanceSharesMember2022-12-310001847462us-gaap:RestrictedStockUnitsRSUMember2021-12-310001847462srt:MinimumMemberus-gaap:RestrictedStockUnitsRSUMember2023-01-012023-12-310001847462srt:MaximumMemberus-gaap:RestrictedStockUnitsRSUMember2023-01-012023-12-310001847462us-gaap:NonrelatedPartyMember2023-01-012023-12-310001847462us-gaap:NonrelatedPartyMember2022-01-012022-12-310001847462srt:MinimumMemberus-gaap:OfficeEquipmentMember2023-12-310001847462srt:MinimumMemberus-gaap:FurnitureAndFixturesMember2023-12-310001847462srt:MinimumMemberus-gaap:EquipmentMember2023-12-310001847462srt:MaximumMemberus-gaap:OfficeEquipmentMember2023-12-310001847462srt:MaximumMemberus-gaap:FurnitureAndFixturesMember2023-12-310001847462srt:MaximumMemberus-gaap:EquipmentMember2023-12-310001847462us-gaap:VehiclesMember2023-12-310001847462us-gaap:LeaseholdImprovementsMember2023-12-310001847462us-gaap:LandMember2023-12-310001847462us-gaap:FurnitureAndFixturesMember2023-12-310001847462us-gaap:ConstructionInProgressMember2023-12-310001847462us-gaap:BuildingMember2023-12-310001847462us-gaap:VehiclesMember2022-12-310001847462us-gaap:LeaseholdImprovementsMember2022-12-310001847462us-gaap:LandMember2022-12-310001847462us-gaap:FurnitureAndFixturesMember2022-12-310001847462us-gaap:ConstructionInProgressMember2022-12-310001847462us-gaap:BuildingMember2022-12-310001847462us-gaap:RetainedEarningsMember2023-01-012023-12-310001847462us-gaap:RetainedEarningsMember2022-01-012022-12-310001847462us-gaap:SeniorNotesMember2021-11-122021-11-120001847462ayr:NewMoneyNotesMemberus-gaap:SubsequentEventMember2024-03-142024-03-140001847462ayr:NewDebtSecuritiesMemberus-gaap:SubsequentEventMember2024-01-012024-03-140001847462ayr:RelatedPartyPromissoryNotesMember2023-07-072023-07-070001847462ayr:MercerParkL.p.Memberus-gaap:RelatedPartyMember2022-12-310001847462ayr:LoanAgreementWithCommunityBankMember2023-03-242023-03-240001847462us-gaap:SeniorNotesMember2023-12-3100018474622022-06-300001847462ayr:MercerParkL.p.Memberus-gaap:RelatedPartyMember2023-01-012023-12-310001847462ayr:ParmaWellnessCenterLlcMember2022-01-012022-12-310001847462ayr:ParmaWellnessCenterLlcMember2023-01-012023-12-310001847462us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-01-012023-12-310001847462ayr:TahoeHydroponicsCompanyLlcAndNvGreenIncMember2023-01-012023-12-310001847462us-gaap:SeniorNotesMember2022-12-310001847462us-gaap:SeniorNotesMember2021-12-310001847462us-gaap:RelatedPartyMember2023-01-012023-12-310001847462us-gaap:TradeNamesMember2022-12-310001847462us-gaap:LicensingAgreementsMember2022-12-310001847462us-gaap:LicenseMember2022-12-310001847462ayr:HostCommunityAgreementsMember2022-12-310001847462ayr:StandaloneDeliveryLicenseMember2023-12-310001847462ayr:AreaCultivatorLicenseMember2023-12-310001847462ayr:MercerParkL.p.Memberus-gaap:RelatedPartyMember2022-01-012022-12-310001847462us-gaap:TradeNamesMember2023-12-310001847462us-gaap:LicensingAgreementsMember2023-12-310001847462us-gaap:LicenseMember2023-12-310001847462ayr:HostCommunityAgreementsMember2023-12-310001847462ayr:LandOfLincolnDispensaryLlcMemberayr:ConditionalAdultUseDispensaryLicensesMember2023-11-020001847462us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-12-310001847462us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-12-310001847462us-gaap:RestrictedStockUnitsRSUMember2023-12-310001847462us-gaap:RestrictedStockUnitsRSUMember2022-12-310001847462us-gaap:StateAndLocalJurisdictionMember2023-12-310001847462us-gaap:StateAndLocalJurisdictionMember2022-12-310001847462ayr:LoanAgreementDueMay2024Member2023-07-072023-07-070001847462ayr:TahoeHydroponicsCompanyLlcMemberayr:RelatedPartyPromissoryNotesMember2023-05-012023-05-310001847462ayr:HerbalRemediesDispensariesLlcMemberayr:RelatedPartyPromissoryNotesMember2022-05-252022-05-250001847462ayr:PaNaturalMedicineLlcMemberayr:NonRelatedPartyNoteMember2022-03-012022-03-010001847462ayr:LivfreeWellnessLlcMember2023-10-312023-10-310001847462ayr:SeniorSecuredNotesDueDecember102026Memberus-gaap:SubsequentEventMember2024-03-140001847462ayr:SeniorNotesWithInterestRate12.5Due2024Memberus-gaap:SubsequentEventMember2024-03-140001847462ayr:SeniorNotesWithInterestRate12.5Due2024Member2024-03-140001847462ayr:LivfreeWellnessLlcMember2023-11-010001847462ayr:LoanAgreementWithCommunityBankMember2023-03-240001847462ayr:LoanAgreementWithCommunityBankMember2022-03-170001847462srt:MinimumMemberayr:LoanAgreementWithCommunityBankMember2022-05-160001847462us-gaap:SubsequentEventMember2024-03-140001847462ayr:LoanAgreementDueMay2024Member2023-07-070001847462ayr:TahoeHydroponicsCompanyLlcMemberayr:RelatedPartyPromissoryNotesMember2023-05-310001847462ayr:RelatedPartyPromissoryNotesMember2023-05-310001847462ayr:ContingentConsiderationVendorTakeBackPromissoryNotesMember2023-05-310001847462ayr:HerbalRemediesDispensariesLlcMemberayr:RelatedPartyPromissoryNotesMember2022-05-250001847462ayr:PaNaturalMedicineLlcMemberayr:NonRelatedPartyNoteMember2022-03-010001847462us-gaap:SeniorNotesMember2021-11-120001847462ayr:DebtPayablesOtherThanNotesMember2022-12-310001847462ayr:DebtPayablesOtherThanNotesMember2021-12-310001847462ayr:LoanAgreementDueMay2024Memberayr:FiveYearFederalHomeLoanBankRateMember2023-07-072023-07-070001847462ayr:LoanAgreementWithCommunityBankMember2022-05-162022-05-160001847462ayr:ThirdPartyLeaseObligationMember2023-12-310001847462us-gaap:TreasuryStockCommonMember2023-12-310001847462us-gaap:TreasuryStockCommonMember2022-12-310001847462us-gaap:TreasuryStockCommonMember2021-12-310001847462ayr:SubordinateRestrictedAndLimitedVotingSharesMember2021-12-310001847462ayr:MultipleVotingSharesMember2021-12-310001847462ayr:ExchangeableSharesMember2021-12-310001847462ayr:MultipleVotingSharesMember2023-01-012023-12-310001847462ayr:MultipleVotingSharesMember2022-01-012022-12-310001847462ayr:ExchangeableSharesMember2022-01-012022-12-310001847462ayr:ExchangeableSharesMember2023-12-310001847462ayr:SubordinateRestrictedAndLimitedVotingSharesMember2022-12-310001847462ayr:MultipleVotingSharesMember2022-12-310001847462ayr:ExchangeableSharesMember2022-12-310001847462us-gaap:WarrantMember2021-12-310001847462ayr:AntiDilutiveWarrantsMemberus-gaap:SubsequentEventMember2024-03-140001847462ayr:LandOfLincolnDispensaryLlcMember2023-11-020001847462ayr:CultivaunaLlcMemberus-gaap:TradeNamesMember2022-02-150001847462ayr:CultivaunaLlcMemberayr:HostCommunityAgreementsMember2022-02-150001847462ayr:TahoeHydroponicsCompanyLlcMemberayr:PromissoryNoteMember2023-05-012023-05-310001847462ayr:TahoeHydroponicsCompanyLlcMemberayr:ConvertibleNoteMember2023-05-012023-05-310001847462ayr:TahoeHydroponicsCompanyLlcMemberayr:ExchangeableSharesMember2023-05-012023-05-310001847462ayr:BusinessAcquisitionsMember2023-12-310001847462ayr:TahoeHydroponicsCompanyLlcMember2023-05-310001847462ayr:ParmaWellnessCenterLlcMember2021-03-300001847462us-gaap:WarrantMember2023-01-012023-12-310001847462us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-12-310001847462us-gaap:EmployeeStockOptionMember2023-01-012023-12-310001847462us-gaap:WarrantMember2022-01-012022-12-310001847462us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001847462us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001847462stpr:CT2023-01-012023-12-310001847462us-gaap:SeniorNotesMember2023-01-012023-12-310001847462us-gaap:SeniorNotesMember2022-01-012022-12-310001847462us-gaap:TradeNamesMember2023-01-012023-12-310001847462us-gaap:LicensingAgreementsMember2023-01-012023-12-310001847462us-gaap:LicenseMember2023-01-012023-12-310001847462ayr:HostCommunityAgreementsMember2023-01-012023-12-310001847462srt:MinimumMember2023-01-012023-12-310001847462srt:MaximumMember2023-01-012023-12-310001847462us-gaap:WarrantMember2023-12-310001847462us-gaap:WarrantMember2022-12-310001847462us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310001847462us-gaap:NoncontrollingInterestMember2023-01-012023-12-310001847462us-gaap:AdditionalPaidInCapitalMember2023-01-012023-12-310001847462ayr:ExchangeableSharesMember2023-01-012023-12-310001847462us-gaap:RelatedPartyMember2022-01-012022-12-310001847462us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-12-310001847462ayr:SubordinateRestrictedAndLimitedVotingSharesMember2023-01-012023-12-310001847462us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001847462ayr:SubordinateRestrictedAndLimitedVotingSharesMember2022-01-012022-12-310001847462ayr:Q22022AcquisitionsMemberayr:HerbalRemediesDispensariesLlcMember2023-01-012023-12-310001847462ayr:Q12022AcquisitionsMemberayr:CultivaunaLlcMember2023-01-012023-12-310001847462ayr:SeniorNotesWithInterestRate12.5Due2024Memberus-gaap:SubsequentEventMember2024-01-012024-03-1400018474622021-05-022021-05-020001847462ayr:DebtPayablesOtherThanNotesMember2023-01-012023-12-310001847462ayr:DailyReleafLlcHeavenWellnessLlcAndTwiceWellnessLlcMember2023-01-012023-12-310001847462ayr:BoardMemberMemberus-gaap:RelatedPartyMember2023-01-012023-12-310001847462ayr:BoardMemberMemberus-gaap:RelatedPartyMember2022-01-012022-12-310001847462ayr:BackstopNoteholdersMemberayr:SubordinateRestrictedAndLimitedVotingSharesMemberus-gaap:SubsequentEventMember2024-03-142024-03-140001847462ayr:SubordinateRestrictedAndLimitedVotingSharesMemberus-gaap:SubsequentEventMember2024-03-142024-03-1400018474622022-02-012022-02-280001847462ayr:LandOfLincolnDispensaryLlcMember2023-11-022023-11-020001847462us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-01-012022-12-310001847462ayr:TahoeHydroponicsCompanyLlcAndNvGreenIncMember2022-01-012022-12-310001847462us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberayr:BlueCamoLlcMember2023-03-2700018474622022-06-012022-06-300001847462us-gaap:NoncontrollingInterestMember2022-01-012022-12-310001847462ayr:SiraNaturalsIncMember2023-01-012023-12-310001847462ayr:GsdNjLlcMember2023-01-012023-12-310001847462us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberayr:BlueCamoLlcMember2023-03-272023-03-270001847462ayr:BusinessAcquisitionsMember2023-01-012023-12-310001847462us-gaap:SegmentDiscontinuedOperationsMemberayr:BlueCamoLlcMember2023-12-310001847462us-gaap:DiscontinuedOperationsHeldforsaleMemberayr:BlueCamoLlcMember2022-01-012022-12-310001847462us-gaap:DiscontinuedOperationsHeldforsaleMemberayr:BlueCamoLlcMember2022-12-310001847462us-gaap:DiscontinuedOperationsHeldforsaleMemberayr:BlueCamoLlcMember2023-01-012023-12-310001847462ayr:ContingentConsiderationVendorTakeBackPromissoryNotesMemberayr:SeniorSecuredNotesMember2023-12-310001847462ayr:FiveYearFederalHomeLoanBankRateMember2023-07-072023-07-070001847462ayr:LivfreeWellnessLlcMember2023-10-310001847462ayr:NewMoneyNotesMemberus-gaap:SubsequentEventMember2024-01-012024-03-140001847462ayr:NinePointEightPercentSecuredPromissoryNotesMember2023-10-312023-10-310001847462srt:MinimumMemberayr:NinePointEightPercentSecuredPromissoryNotesMember2023-05-012023-05-310001847462ayr:LoanAgreementWithCommunityBankMember2022-03-172022-03-170001847462ayr:SiraNaturalsInc.Member2023-05-112023-05-110001847462us-gaap:RelatedPartyMember2023-12-310001847462us-gaap:NonrelatedPartyMember2023-12-310001847462ayr:SiraNaturalsInc.Memberayr:RelatedPartyPromissoryNotesMember2023-05-110001847462ayr:GsdAcquisitionMemberayr:RelatedPartyPromissoryNotesMember2023-05-110001847462ayr:DebtPayablesOtherThanNotesMember2023-12-310001847462ayr:DebtPayablesOtherThanNotesMember2022-01-012022-12-310001847462us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-12-310001847462ayr:TahoeHydroponicsCompanyLlcAndNvGreenIncMember2023-12-310001847462ayr:ParmaWellnessCenterLlcMember2023-12-310001847462ayr:DailyReleafLlcHeavenWellnessLlcAndTwiceWellnessLlcMember2023-12-310001847462us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-12-310001847462ayr:TahoeHydroponicsCompanyLlcAndNvGreenIncMember2022-12-310001847462ayr:ParmaWellnessCenterLlcMember2022-12-310001847462us-gaap:CostOfSalesMember2023-01-012023-12-310001847462us-gaap:CostOfSalesMember2022-01-012022-12-310001847462us-gaap:FairValueInputsLevel3Member2022-12-3100018474622023-12-310001847462us-gaap:WarrantMember2023-01-012023-12-310001847462us-gaap:WarrantMember2022-01-012022-12-310001847462ayr:AntiDilutiveWarrantsMemberus-gaap:SubsequentEventMember2024-03-142024-03-1400018474622022-12-3100018474622021-12-310001847462us-gaap:DiscontinuedOperationsHeldforsaleMemberayr:BlueCamoLlcMember2023-12-3100018474622022-01-012022-12-310001847462ayr:HerbalRemediesDispensariesLlcMember2022-05-250001847462ayr:CultivaunaLlcMember2022-02-150001847462ayr:GsdAcquisitionMember2023-05-110001847462ayr:GsdAcquisitionMember2023-05-112023-05-110001847462ayr:GsdAcquisitionMemberayr:RelatedPartyPromissoryNotesMember2023-05-112023-05-110001847462ayr:GsdAcquisitionMember2023-01-012023-12-310001847462srt:MinimumMemberayr:TahoeHydroponicsCompanyLlcMember2023-05-012023-05-310001847462srt:MaximumMemberayr:TahoeHydroponicsCompanyLlcMember2023-05-012023-05-310001847462srt:MinimumMemberayr:HerbalRemediesDispensariesLlcMember2022-05-252022-05-250001847462srt:MaximumMemberayr:HerbalRemediesDispensariesLlcMember2022-05-252022-05-250001847462srt:MinimumMemberayr:CultivaunaLlcMember2022-02-152022-02-150001847462srt:MaximumMemberayr:CultivaunaLlcMember2022-02-152022-02-150001847462ayr:TahoeHydroponicsCompanyLlcMember2023-05-012023-05-310001847462ayr:HerbalRemediesDispensariesLlcMember2022-05-252022-05-250001847462ayr:CultivaunaLlcMember2022-02-152022-02-150001847462us-gaap:LandMember2022-06-012022-06-300001847462ayr:BuildingsAndImprovementsMember2022-06-012022-06-30iso4217:USDxbrli:pureiso4217:USDxbrli:sharesayr:itemayr:entityutr:sqftayr:segmentxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 40-F

REGISTRATION STATEMENT PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

ANNUAL REPORT PURSUANT TO SECTION 13(a) OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2023

Commission File Number 333-253466

Graphic

AYR WELLNESS INC.

(Exact name of Registrant as specified in its charter)

British Columbia, Canada

(Province or other jurisdiction of incorporation or organization)

2833

(Primary Standard Industrial Classification Code Number (if applicable))

98-1500584

(I.R.S. Employer Identification Number (if applicable))

2601 South Bayshore Drive, Suite 900

Miami, FL, 33133

(786) 885-0397

(Address and telephone number of Registrant’s principal executive offices)

C T Corporation System

1015 15th Street N.W., Suite 1000

Washington, DC 20005

(202) 572-3133

(Name, address (including zip code) and telephone number (including area code)

of agent for service in the United States)

Securities registered or to be registered pursuant to Section 12(b) of the Act:

   

Title of each class

    

Trading Symbol(s)

    

Name of each exchange on which registered

Securities registered or to be registered pursuant to Section 12(g) of the Act:  Not Applicable.

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:  Subordinate Voting Shares, Restricted Voting Shares

and Limited Voting Shares, no par value.

For annual reports, indicate by check mark the information filed with this Form:

Annual information form

Audited annual financial statements

Number of outstanding shares of each of the issuer’s classes of

capital or common stock as of December 31, 2023:

64,574,077 Subordinate Voting Shares, Restricted Voting Shares and Limited Voting Shares, no par value.

3,696,486 Multiple Voting Shares, no par value

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.   Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes     No  

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act. Emerging growth company  

If an emerging growth company that prepares is financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 13(a) of the Exchange Act.

† The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b).

EXPLANATORY NOTE

Ayr Wellness Inc. (the “Company” or the “Registrant”) is a Canadian issuer that is permitted, under the multijurisdictional disclosure system adopted in the United States (the “U.S.”), to prepare this Annual Report on Form 40-F (this “Annual Report”) pursuant to Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), in accordance with Canadian disclosure requirements, which are different from those of the U.S. The Company is a “foreign private issuer” as defined in Rule 3b-4 under the Exchange Act and Rule 405 under the Securities Act of 1933, as amended. Equity securities of the Company are accordingly exempt from Sections 14(a), 14(b), 14(c), 14(f) and 16 of the Exchange Act pursuant to Rule 3a12-3 thereunder.

FORWARD-LOOKING STATEMENTS

This Annual Report and the documents incorporated by reference herein contain certain “forward-looking statements” and “forward-looking information” within the meaning of applicable securities laws, including Canadian securities laws and United States securities laws (collectively, “forward-looking statements”). All information, other than statements of historical facts, included in this Annual Report and the documents incorporated by reference herein, including estimates, plans, expectations, opinions, forecasts, projections, targets and guidance, constitutes forward-looking statements. Forward-looking statements include statements that are predictive in nature, depend upon or refer to future events or conditions, or include words such as “pro forma”, “expects”, “anticipates”, “plans”, “believes”, “estimates”, “intends”, “targets”, “projects”, “forecasts”, “seeks”, “likely” or negative versions thereof and other similar expressions, or future or conditional verbs such as “may”, “will”, “should”, “would” and “could”.

By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of material factors, many of which are beyond the parties’ control, could affect operations, business, financial condition, performance and results of the parties that may be expressed or implied by such forward-looking statements and could cause actual results to differ materially from current expectations of estimated or anticipated events or results.

These factors include, but are not limited to, the following:

laws and regulations and any amendments thereto applicable to our business and the impact thereof, including uncertainty regarding the application of U.S. state and federal law to U.S. cannabis products and the scope of any regulations by the U.S. Food and Drug Administration, the U.S. Drug Enforcement Administration, the U.S. Federal Trade Commission, the U.S. Patent and Trademark Office, the U.S. Department of Agriculture and any state equivalent regulatory agencies over U.S. cannabis products;
climate change impacting economic factors such as prices and supply chain disruption, as well as governmental response through laws or regulations regarding greenhouse gas emissions;
assumptions and expectations described in the Company’s critical accounting policies and estimates;
changes in U.S. generally accepted accounting principles or their interpretation and the adoption and impact of certain accounting pronouncements;
the number of users of cannabis or the size of the regulated cannabis market in the United States;
the potential time frame for the implementation of legislation to legalize and regulate medical or adult-use cannabis (and the consumer products derived from each of the foregoing) in the United States,  and the potential form the legislation and regulations will take;
the Company’s future financial and operating performance and anticipated profitability;
future performance, results and terms of strategic initiatives, strategic agreements, and supply agreements;
the market for the Company’s current and proposed products and services, as well as the Company’s ability to capture market share;
the benefits and applications of the Company’s products and services and expected sales thereof;
development of affiliated brands, product diversification and future corporate development;
anticipated investment in and results of research and development;
inventory and production capacity, including discussions of plans or potential for expansion of capacity at existing or new facilities;
future expenditures, strategic investments, and capital activities;
the competitive landscape in which the Company operates and the Company’s market expertise;
the Company’s ability to comply with its debt covenants;
the Company’s ability to secure further equity or debt financing, if required;
the Company’s ability to refinance its indebtedness and the terms of any such financing;
the risk of significant dilution from the issuances of equity or convertible debt securities and settlement of contingent consideration;
the level of demand for cannabis products, including the Company’s product and third-party products sold by the Company;
the Company’s ability to mitigate risks relating to the cannabis industry, the larger economy such as inflation or fluctuations in interest rates, breaches of and unauthorized access to the Company’s systems and related cybersecurity risks, money laundering, litigation, and health pandemics;
risks related to maintaining cash deposits in excess of federally insured limits;
the ability to gain appropriate regulatory approvals including for announced acquisitions in the timeframe anticipated;
the application for additional licenses and the grant of licenses or renewals of existing licenses that have been applied for;
the rollout of new dispensaries, including the number of planned dispensaries to be opened in the future and the timing and location in respect of the same, and related forecasts;
the Company’s ability to hit anticipated development targets of cultivation and production projects;
the Company’s ability to mitigate the risk of contamination and other risks inherent in the agricultural sector;
the ability to successfully integrate and maintain employees from recent acquisitions;
risks related to the Company’s cash flows from operations;
the ability to develop the Company’s brands and meet growth objectives;
risks related to limited market data and difficulty to forecast results;
the concentrated voting control of the Company;
market volatility and the risks associated with selling of a substantial amount of subordinate voting shares, restricted voting shares and limited voting shares of the Company;
the risk of natural hazards related to severe and extreme weather and climate events;
product liability claims related to the products the Company cultivates, produces, and sells;
the risk of significant pricing pressures which are often market specific and can be caused by an oversupply of cannabis in the market and may be transitory from period to period; and
other events or conditions that may occur in the future.

No assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this Annual Report and the documents incorporated by reference herein should not be unduly relied upon, and the Company does not undertake any

obligation to revise or update any forward-looking information or statements other than as required by applicable law. In making these statements, in addition to those described above and elsewhere herein, the parties have made assumptions with respect to, without limitation, receipt of requisite regulatory approvals on a timely basis, receipt and/or maintenance of required licenses and third-party consents in a timely manner, successful integration of the Company’s and its subsidiaries’ operations, and no unplanned materially adverse changes to its facilities, assets, customer base and the economic conditions affecting the Company’s current and proposed operations. These assumptions, although considered reasonable by the Company at the time of preparation, may prove to be incorrect. In addition, the Company has assumed that there will be no material adverse change to the current regulatory landscape affecting the cannabis industry and has also assumed that the Company will remain compliant in the future with all State and local laws, regulations and rules imposed upon it by law. The Company’s forward-looking statements are expressly qualified in its entirety by this cautionary statement.

NOTE TO UNITED STATES READERS - DIFFERENCES IN UNITED STATES AND CANADIAN REPORTING PRACTICES

The Registrant is permitted, under the multi-jurisdictional disclosure system adopted by the United States Securities and Exchange Commission (the “SEC”), to prepare this Annual Report in accordance with Canadian disclosure requirements, which differ from those of the United States.

ANNUAL INFORMATION FORM

The Registrant’s Annual Information Form for the fiscal year ended December 31, 2023 is filed as Exhibit 99.1 to this Annual Report (the “AIF”) and is incorporated by reference herein.

AUDITED ANNUAL FINANCIAL STATEMENTS

The audited consolidated financial statements of the Registrant for the years ended December 31, 2023 and 2022, including the report of the independent registered public accounting firm thereon, are filed as Exhibit 99.2 to this Annual Report and are incorporated by reference herein.

MANAGEMENT’S DISCUSSION AND ANALYSIS

Management’s Discussion and Analysis of the Registrant for the years ended December 31, 2023 and 2022, is filed as Exhibit 99.3 to this Annual Report (the “MD&A”) and is incorporated by reference herein.

TAX MATTERS

Purchasing, holding, or disposing of the Company’s securities may have tax consequences under the laws of the U.S. and Canada that are not described in this Annual Report.

CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

As of the end of the period covered by this Annual Report, the Company carried out an evaluation, under the supervision of the Company's Chief Executive Officer (the “CEO”) and Chief Financial Officer (the “CFO”), of the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act). Based upon that evaluation, the Company's CEO and CFO have concluded that, as of the end of the period covered by this Annual Report, the Company's disclosure controls and procedures are effective to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and (ii) accumulated and communicated to the Company's management, including its principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure.

While the Company's principal executive officer and principal financial officer believe that the Company's disclosure controls and procedures provide a reasonable level of assurance that they are effective, they do not expect that the Company's disclosure controls and procedures or internal control over financial reporting will prevent all errors or fraud. A control system, no matter how well conceived or operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.

Management's Annual Report on Internal Control over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule 13a-15(f) under the Exchange Act. The Company's management has employed a framework consistent with Exchange Act Rule 13a-15(c), to evaluate the Company's internal control over financial reporting described below. A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

A company's internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements. It should be noted that a control system, no matter how well conceived or operated, can only provide reasonable assurance, not absolute assurance, that the objectives of the control system are met. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with policies and procedures may deteriorate.

Management, including the CEO and CFO, is responsible for establishing and maintaining adequate internal control over financial reporting, and uses the Committee of Sponsoring Organizations of the Treadway Commission (2013) framework on Internal Control - Integrated Framework (2013) to evaluate the effectiveness of the Company’s internal controls over financial reporting. Based on this evaluation, management concluded that the Company's internal control over financial reporting was effective as at December 31, 2023, and provided a reasonable assurance of the reliability of the Company's financial reporting and preparation of financial statements.

Attestation Report of the Independent Registered Public Accounting Firm

This Annual Report does not include an attestation report of the Company’s independent registered public accounting firm because emerging growth companies are exempt from this requirement for so long as they remain emerging growth companies.

Changes in Internal Control over Financial Reporting

There have been no changes in the Company’s internal control over financial reporting during the quarter and for the year ended December 31, 2023 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

AUDIT COMMITTEE FINANCIAL EXPERT

The Board of Directors has determined that Charlie Miles qualifies as financial expert (as defined in Item 407 (d)(5)(ii) of Regulation S-K under the Exchange Act), has financial management expertise (pursuant to section 303A.07 of the NYSE Listed Company Manual) and is independent (as determined under Exchange Act Rule 10A-3).

The SEC has indicated that the designation or identification of a person as an audit committee financial expert does not make such person an “expert” for any purpose, impose any duties, obligations or liability on such person that are greater than those imposed on members of the audit committee and the board of directors who do not carry this designation or identification, or affect the duties, obligations or liability of any other member of the audit committee or board of directors.

PRE-APPROVAL OF AUDIT AND NON-AUDIT SERVICES PROVIDED BY INDEPENDENT AUDITOR

The Audit Committee Charter sets out responsibilities regarding the provision of non-audit services by the Company’s external auditors and requires the Audit Committee to pre-approve all permitted non-audit services to be provided by the Company’s external auditors, in accordance with applicable law.

PRINCIPAL ACCOUNTANT FEES AND SERVICES

The information provided under the heading “Audit Committee – External Auditor Service Fees” contained in the AIF, filed as Exhibit 99.1 hereto, is incorporated by reference herein.

OFF-BALANCE SHEET ARRANGEMENTS

The information provided under the heading “Off-Balance Sheet Arrangements” contained in the MD&A, filed as Exhibit 99.3 hereto, is incorporated by reference herein.

CONTRACTUAL OBLIGATIONS

The discussion and analysis of the Company’s material cash requirements from known contractual and other obligations is provided under the heading “Liquidity and Capital Resources as of December 31, 2023 and 2022” contained in the MD&A, filed as Exhibit 99.3 hereto, is incorporated by reference herein.

CODE OF ETHICS

The Company has adopted a Code of Business Conduct and Ethics that applies to directors, officers and employees of, and consultants to, the Company (the “Code”). The Company undertakes to provide copies of the Code without charge. Requests for copies of the Code should be sent to IR@AyrWellness.com. The Code meets the requirements for a “code of ethics” within the meaning of that term in General Instruction 9(b) of the Form 40-F.

All waivers of the Code with respect to any of the employees, officers or directors covered by it will be promptly disclosed as required by applicable securities rules and regulations. During the fiscal year ended December 31, 2023, the Company did not waive or implicitly waive any provision of the Code with respect to any of the Company’s principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions.

NOTICES PURSUANT TO REGULATION BTR

There were no notices required by Rule 104 of Regulation BTR that the Company sent during the year ended December 31, 2023 concerning any equity security subject to a blackout period under Rule 101 of Regulation BTR.

MINE SAFETY DISCLOSURE

Not Applicable.

DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

Not applicable.

RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION

Not applicable.

UNDERTAKING

The Company undertakes to make available, in person or by telephone, representatives to respond to inquiries made by SEC staff, and to furnish promptly, when requested to do so by SEC staff, information relating to: the securities registered pursuant to Form 40-F; the securities in relation to which the obligation to file an annual report on Form 40-F arises; or transactions in said securities.

CONSENT TO SERVICE OF PROCESS

The Company has previously filed with the SEC a written consent to service of process on Form F-X. Any change to the name or address of the Company’s agent for service shall be communicated promptly to the SEC by amendment to the Form F-X referencing the file number of the Company.

SIGNATURES

Pursuant to the requirements of the Exchange Act, the Registrant certifies that it meets all of the requirements for filing on Form 40-F and has duly caused this annual report to be signed on its behalf by the undersigned, thereto duly authorized.

DATED this 13th day of March, 2024.

AYR WELLNESS INC.

 

 

By:

/s/ David Goubert

Name:

David Goubert

Title:

Chief Executive Officer

EXHIBIT INDEX

The following documents are being filed with the SEC as Exhibits to this Form 40-F:

Exhibit
Number

    

Description

99.1

Annual Information Form dated March 13, 2024 for the fiscal year ended December 31, 2023

99.2

Audited Consolidated Financial Statements for the years ended December 31, 2023 and 2022 and the Report of Independent Registered Public Accounting Firm (Marcum LLP, PCAOB ID 688)

99.3

Management’s Discussion and Analysis for the years ended December 31, 2023 and 2022

99.4

Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the U.S. Securities Exchange Act of 1934, as amended

99.5

Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the U.S. Securities Exchange Act of 1934, as amended

99.6

Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

99.7

Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

99.8

Consent of Marcum LLP

101

Interactive Data File (formatted as Inline XBRL)

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

EX-99.1 2 ayr-20231231xex99d1.htm EXHIBIT 99.1

Table of Contents

Exhibit 99.1

AYR WELLNESS INC.

ANNUAL INFORMATION FORM

As of and for the Year Ended December 31, 2023

Dated March 13, 2024


TABLE OF CONTENTS

AYR WELLNESS INC.

2

EXPLANATORY NOTES

3

FORWARD-LOOKING INFORMATION

3

MARKET AND INDUSTRY DATA

5

CORPORATE STRUCTURE

5

Name, Address and Incorporation

5

Intercompany Relationships

6

GENERAL DEVELOPMENT OF THE BUSINESS

8

Historical Summary

8

Subsequent Developments

9

DESCRIPTION OF THE BUSINESS

10

Strategy

10

Growth

11

Licenses

11

Employees

13

Foreign Operations

13

Investment Policies

13

No Bankruptcy Proceedings

14

CANNABIS MARKET OVERVIEW

14

Exposure to U.S. Marijuana Related Activities

16

U.S. Federal Regulatory Environment

16

U.S. Federal Enforcement Priorities

17

State Regulatory Environment

17

Nevada

17

Massachusetts

18

Pennsylvania

19

Florida

20

Ohio

21

New Jersey

22

Connecticut

23

Illinois

24

Compliance with State Regulatory Frameworks

25

Non-Compliance with State and Local Cannabis Laws

28

Ability to Access Public and Private Capital

28

RISK FACTORS

29

Risks Related to Legality of Cannabis

29

Business Structure Risks

36

General Regulatory and Legal Risks

39

Risks Related to Ayr’s Business

44

Market and Economy Risks

51

Environmental Risks

52

Tax Risks

53

(i)


DIVIDENDS

55

DESCRIPTION OF SHARE CAPITAL

55

Equity Shares

56

Multiple Voting Shares

58

Compliance Provisions

59

Warrants

60

Coattail Agreement

61

Debt Securities

61

MARKET FOR SECURITIES

62

TRADING PRICE AND VOLUME

62

SECURITIES SUBJECT TO CONTRACTUAL RESTRICTION ON TRANSFER

63

Directors and Officers

63

Shareholdings of Directors and Executive Officers

66

Corporate Cease Trade Orders, Bankruptcies, Penalties or Sanctions

66

Conflicts of Interest and Interests of Management and Others in Material Transactions

66

PROMOTER

67

LEGAL PROCEEDINGS AND REGULATORY ACTIONS

67

AUDITORS, TRANSFER AGENT AND REGISTRAR

67

MATERIAL CONTRACTS

67

INTERESTS OF EXPERTS

68

AUDIT COMMITTEE

68

AUDIT COMMITTEE CHARTER

68

COMPOSITION OF AUDIT COMMITTEE

68

EXTERNAL AUDITOR SERVICE FEES

68

Audit Fees

68

Audit-Related Fees

68

Tax Services Fees

69

All Other Fees

69

CYBERSECURITY

69

ADDITIONAL INFORMATION

70

APPENDIX A

A-1

(ii)


AYR WELLNESS INC.

Ayr Wellness Inc. (the “Company” or “Ayr” or “we” or “us”) derives a substantial portion of its revenues from the cannabis industry in certain states (“States”, each a “State”) of the United States of America (“U.S.” or “United States”), which industry is illegal under U.S. federal law. Ayr is a vertically-integrated multi-State operator in the U.S. cannabis sector, with a portfolio of cannabis assets in the States of Massachusetts, Nevada, Pennsylvania, Florida, New Jersey, Ohio, Illinois and Connecticut (not yet in operation as of the date hereof). Currently, through its operating companies, Ayr is a leading cultivator, manufacturer and retailer of cannabis products and branded cannabis packaged goods, and is engaged in the manufacture, possession, use, sale or distribution of cannabis and/or holds licenses in the adult-use and/or medicinal cannabis marketplace in the States of Massachusetts, Nevada, Pennsylvania, Florida, New Jersey, Ohio, Illinois and Connecticut (not yet in operation as of the date hereof).

The United States federal government regulates drugs through the Controlled Substances Act (21 U.S.C.§ 811) (the “CSA”), which places controlled substances, including marijuana (defined as all parts of the plant Cannabis sativa L. containing more than 0.3 percent tetrahydrocannabinol (“THC”)), in a schedule. Marijuana (also referred to herein as cannabis) is currently classified as a Schedule I drug. Under United States federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States, and a lack of accepted safety for the use of the drug under medical supervision. The United States Food and Drug Administration (“FDA”) has not approved marijuana as a safe and effective drug for any indication.

In the United States, marijuana is largely regulated at the State level. State laws permitted use or possession of cannabis are in direct conflict with the federal CSA, which makes cannabis use and possession federally illegal. Although certain states authorize medical or adult-use cannabis production and distribution by licensed or registered entities, under U.S. federal law, the possession, use, cultivation, and transfer of cannabis and any related drug paraphernalia is illegal and any such acts are criminal acts under federal law. The Supremacy Clause of the United States Constitution establishes that the United States Constitution and federal laws made pursuant to it are paramount and, in case of conflict between federal and State law, the federal law shall apply. Ayr faces significant risks for operating in an industry that is illegal under U.S. federal law, including the risk of potential enforcement of such federal laws against Ayr or its affiliates.

Additionally, under United States federal law, it is a violation of federal money laundering statutes for financial institutions to accept proceeds from distribution of Schedule I controlled substances, including cannabis.  For this reason, banks and other institutions in the United States (whether or not they have a U.S. federal charter) could be prosecuted for providing financial services to cannabis-touching businesses even if their operations are legal under State law. The U.S. Department of the Treasury’s Financial Crimes Enforcement Network (“FinCEN”) issued a memorandum (the “FinCEN Memorandum”) which outlined pathways for financial institutions to provide financial services in compliance with federal enforcement priorities.  Nonetheless, many banks and financial institutions in the United States and Canada remain hesitant or unwilling to provide financial services to cannabis businesses. This creates the necessity for some cannabis businesses to conduct their operations primarily or entirely in cash, with attendant security and other risks.

Under President Barack Obama, the U.S. government attempted to address the inconsistencies between federal and State regulation of cannabis in a memorandum sent by then-Deputy Attorney General James Cole to all United States Attorneys in August 2013 (the “Cole Memorandum”). The Cole Memorandum acknowledged that notwithstanding the designation of cannabis as a controlled substance at the federal level in the United States, several States have enacted laws relating to cannabis for medical and recreational purposes, and that conduct in compliance with the laws of those jurisdictions were less likely to be an enforcement priority for the U.S. Department of Justice (the “U.S. DOJ”). The Cole Memorandum listed the type of threats related to cannabis on which the U.S. DOJ should focus.  The list included preventing the distribution of cannabis to minors, and preventing the diversion of cannabis from State-legal jurisdictions into the illicit market, among other things. It did not provide guidelines for acceptable State regulatory schemes.

In March 2017, then newly-appointed Attorney General Jeff Sessions, a long-time opponent of State-regulated medical and recreational cannabis, noted limited federal resources and acknowledged that much of the Cole Memorandum had merit; however, he had previously stated that he did not believe it had been implemented effectively. On January 4, 2018, Sessions issued a new memorandum (known as the “Sessions Memorandum”) which rescinded the Cole Memorandum, and directed all U.S. Attorneys to enforce the laws enacted by the United States Congress according to already-established principles. The Sessions Memorandum did not direct prosecutors to enforce federal law against persons and entities operating in compliance with State regulatory schemes, and there was no direction to give such enforcement any particular priority. Later-appointed Attorney General William Barr stated that he did not intend to pursue prosecution against parties who are involved in the cannabis business, and are compliant with State law, pursuant to the Cole Memorandum.


The administration of President Joseph Biden began in 2021, and the head of the U.S. DOJ is now Attorney General Merrick Garland. During his confirmation hearings in the Senate on February 22, 2021, Garland confirmed that he would not prioritize pursuing cannabis prosecutions in states that have legalized and that are regulating the use of cannabis, both for medical and adult use. However, he has expressed continued concern over international transport of large amounts of illicit cannabis from other nations—namely Mexico—and large-scale domestic cultivation of illicit cannabis (including the environmental impact of those operations).

On October 6, 2022, the Biden administration released a “Statement from President Biden on Marijuana Reform.”  In that statement, Biden announced three planned steps: (1) federal pardons for simple possession offenses; (2) encouraging governors to enact similar State pardons; and (3) a request that the Secretary of Health and Human Services and the Attorney General “initiate the administrative process to review expeditiously how marijuana is scheduled under federal law.”  Biden also expressed the view that laws concerning “trafficking, marketing, and under-age sales should stay in place.”

After approximately 11 months of review, on August 29, 2023, HHS Assistant Secretary of Health, Rachel Levine, sent a letter to U.S. Drug Enforcement Administration Administrator, Anne Milgram, in which she communicated a recommendation from FDA that cannabis be reclassified from Schedule I to Schedule III of the CSA. DEA is expected to release a final decision on whether and how it will reschedule cannabis in the coming months. If and when DEA releases a draft rule, there will be a public comment period followed by hearings before a final rule is promulgated. Any final rule could also be subject to legal challenges.

While the administration’s current position indicates that enforcement against state-legal operators will not be given priority, there is ‎no guarantee that the position of the U.S. DOJ will not change. Moreover, even if cannabis is removed from a Schedule I designation, it remains to be seen whether or how it might be designated. If after administrative review cannabis remains a scheduled controlled substance, use and possession would still be subject to restriction and regulation under federal law.

The United States Congress has also made moves toward cannabis reform in recent years. In July 2022, Senator Cory Booker, along with Majority Leader Chuck Schumer, and Finance Committee Chair Ron Wyden, introduced the Cannabis Administration and Opportunity Act (the “CAOA”). That bill would remove cannabis from the list of controlled substances under the CSA, and allow states to implement their own cannabis programs subject to health and safety oversight by FDA in a manner similar to alcohol and tobacco. Among other things, the CAOA contains reforms designed to give state-legal operators better access to financial services.  After its introduction in 2022 and referral to the Senate Finance Committee, there has been no further action to move the legislation forward.  The 2022 midterm elections resulted in Republicans taking narrow control of the House of Representatives. Democrats maintained their already-narrow control of the Senate. The upcoming 2024 election cycle will determine control of both Congress and the Presidency, which further increases the uncertainty of legislative or administrative reforms.

There is no guarantee that State laws legalizing and regulating the sale and use of cannabis will not be repealed or overturned, or that local governmental authorities will not limit the applicability of State laws within their respective jurisdictions. Unless and until the United States Congress amends the CSA with respect to medical and/or adult-use cannabis (and as to the timing or scope of any such potential amendments there can be no assurance), there is a risk that U.S. federal authorities may enforce current U.S. federal law. Currently, in the absence of uniform federal guidance, as had been established by the Cole Memorandum, enforcement priorities are determined by respective United States Attorneys, and notwithstanding public statements to the contrary, federal law enforcement could enforce the CSA and its criminal prohibition on commercial cannabis activity.  If the U.S. federal government begins to enforce U.S. federal laws relating to cannabis in States where the sale and use of cannabis is currently legal, or if existing applicable State laws are repealed or curtailed, Ayr’s results of operations, financial condition and prospects would be materially adversely affected. See “U.S. Federal Enforcement Priorities”.

In light of the political and regulatory uncertainty surrounding the treatment of U.S. cannabis-related activities, including the rescission of the Cole Memorandum discussed above, on February 8, 2018, the Canadian Securities Administrators published a staff notice 51-352 (Revised) – Issuers with U.S. Marijuana-Related Activities (“Staff Notice 51-352”) setting out the Canadian Securities Administrator’s disclosure expectations for specific risks facing issuers with cannabis-related activities in the United States. Staff Notice 51-352 includes additional disclosure expectations that apply to all issuers with U.S. cannabis-related activities, including those with direct and indirect involvement in the cultivation and distribution of cannabis, as well as issuers that provide goods and services to third parties involved in the U.S. cannabis industry.

Ayr’s involvement in the U.S. cannabis market may subject Ayr to heightened scrutiny by regulators, stock exchanges, clearing agencies and other U.S. and Canadian authorities. There can be no assurance that this heightened scrutiny will not in turn lead to the imposition of certain restrictions on Ayr’s ability to operate in the U.S. or any other jurisdiction. There are a number of risks associated with the business of Ayr. See “Cannabis Market Overview” and “Risk Factors”.


EXPLANATORY NOTES

Unless otherwise indicated, the information appearing in this annual information form (“AIF”) is stated as of December 31, 2023, and all amounts are in United States dollars unless otherwise indicated.

FORWARD-LOOKING INFORMATION

This AIF and the documents incorporated by reference herein contain certain “forward-looking statements” and “forward-looking information” within the meaning of applicable securities laws, including Canadian securities laws and United States securities laws (collectively, “forward-looking statements”). All information, other than statements of historical facts, included in this AIF and the documents incorporated by reference herein, including estimates, plans, expectations, opinions, forecasts, projections, targets and guidance, constitutes forward-looking information. Forward-looking statements include statements that are predictive in nature, depend upon or refer to future events or conditions, or include words such as “pro forma”, “expects”, “anticipates”, “plans”, “believes”, “estimates”, “intends”, “targets”, “projects”, “forecasts”, “seeks”, “likely” or negative versions thereof and other similar expressions, or future or conditional verbs such as “may”, “will”, “should”, “would” and “could”.

By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of material factors, many of which are beyond the parties’ control, could affect operations, business, financial condition, performance and results of the parties that may be expressed or implied by such forward-looking statements and could cause actual results to differ materially from current expectations of estimated or anticipated events or results.

These factors include, but are not limited to, the following:

·

laws and regulations and any amendments thereto applicable to our business and the impact thereof, including uncertainty regarding the application of U.S. state and federal law to U.S. cannabis products and the scope of any regulations by the U.S. Food and Drug Administration, the U.S. Drug Enforcement Administration (“DEA”), the U.S. Federal Trade Commission, the U.S. Patent and Trademark Office, the U.S. Department of Agriculture and any state equivalent regulatory agencies over U.S. cannabis products;

·

climate change impacting economic factors such as prices and supply chain disruption, as well as governmental response through laws or regulations regarding greenhouse gas emissions;

·

assumptions and expectations described in the Company’s critical accounting policies and estimates;

·

changes in U.S. generally accepted accounting principles or their interpretation and the adoption and impact of certain accounting pronouncements;

·

the number of users of cannabis or the size of the regulated cannabis market in the United States;

·

the potential time frame for the implementation of legislation to legalize and regulate medical or adult-use cannabis (and the consumer products derived from each of the foregoing) in the United States, and the potential form the legislation and regulations will take;

·

the Company’s future financial and operating performance and anticipated profitability;

·

future performance, results and terms of strategic initiatives, strategic agreements, and supply agreements;

·

the market for the Company’s current and proposed products and services, as well as the Company’s ability to capture market share;

·

the benefits and applications of the Company’s products and services and expected sales thereof;

·

development of affiliated brands, product diversification and future corporate development;

·

anticipated investment in and results of research and development;

·

inventory and production capacity, including discussions of plans or potential for expansion of capacity at existing or new facilities;


·

future expenditures, strategic investments, and capital activities;

·

the competitive landscape in which the Company operates and the Company’s market expertise;

·

the Company’s ability to comply with its debt covenants;

·

the Company’s ability to secure further equity or debt financing, if required;

·

the Company’s ability to refinance its indebtedness and the terms of any such financing;

·

the risk of significant dilution from the issuances of equity or convertible debt securities and settlement of contingent consideration;

·

the level of demand for cannabis products, including the Company’s product and third-party products sold by the Company;

·

the Company’s ability to mitigate risks relating to the cannabis industry, the larger economy such as inflation or fluctuations in interest rates, breaches of and unauthorized access to the Company’s systems and related cybersecurity risks, money laundering, litigation, and health pandemics;

·

risks related to maintaining cash deposits in excess of federally insured limits;

·

the ability to gain appropriate regulatory approvals including for announced acquisitions in the timeframe anticipated;

·

the application for additional licenses and the grant of licenses or renewals of existing licenses that have been applied for;

·

the rollout of new dispensaries, including the number of planned dispensaries to be opened in the future and the timing and location in respect of the same, and related forecasts;

·

the Company’s ability to hit anticipated development targets of cultivation and production projects;

·

the Company's ability to mitigate the risk of contamination and other risks inherent in the agricultural sector;

·

the ability to successfully integrate and maintain employees from recent acquisitions;

·

risks related to the Company’s liquidity;

·

the ability to develop the Company’s brands and meet growth objectives;

·

risks related to limited market data and difficulty to forecast results;

·

the concentrated voting control of the Company;

·

market volatility and the risks associated with selling of a substantial amount of Equity Shares (as defined in this AIF);

·

the risk of natural hazards related to severe and extreme weather and climate events;

·

product liability claims related to the products the Company cultivates, produces, and sells;

·

the risk of significant pricing pressures which are often market specific and can be caused by an oversupply of cannabis in the market and may be transitory from period to period; and

·

other events or conditions that may occur in the future.

See “Risk Factors” for further details. No assurance can be given that these expectations will prove to be correct and such forward-looking information included in this AIF should not be unduly relied upon, and the Company does not undertake any obligation to revise or update any forward-looking information or statements other than as required by applicable law. In making these statements, in addition to those described above and elsewhere herein, the parties have made assumptions with respect to, without limitation, receipt of requisite regulatory


approvals on a timely basis, receipt and/or maintenance of required licenses and third-party consents in a timely manner, successful integration of the Company’s and its subsidiaries’ operations, and no unplanned materially adverse changes to its facilities, assets, customer base and the economic conditions affecting the Company’s current and proposed operations. These assumptions, although considered reasonable by the Company at the time of preparation, may prove to be incorrect. In addition, the Company has assumed that there will be no material adverse change to the current regulatory landscape affecting the cannabis industry and has also assumed that the Company will remain compliant in the future with all State and local laws, regulations and rules imposed upon it by law. The Company’s forward-looking information is expressly qualified in its entirety by this cautionary statement.

MARKET AND INDUSTRY DATA

This AIF includes market and industry data that has been obtained from third-party sources, including industry publications. The Company believes that the industry data is accurate and that its estimates and assumptions are reasonable, but there is no assurance as to the accuracy or completeness of this data. Third party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance as to the accuracy or completeness of included information. Although the data is believed to be reliable, the Company has not independently verified any of the data from third-party sources referred to in this AIF or ascertained the underlying economic assumptions relied upon by such sources.

CORPORATE STRUCTURE

Name, Address and Incorporation

The Company (formerly known as “Cannabis Strategies Acquisition Corp.” and “Ayr Strategies Inc.”, respectively) was incorporated on July 31, 2017 under the Business Corporations Act (Ontario). Ayr continued on May 24, 2019 into British Columbia under the Business Corporations Act (British Columbia) (“BCBCA”), changed its name to “Ayr Strategies Inc.”, and amended its financial year-end from September 30 to December 31 in connection with its Qualifying Transaction. The Company changed its name to “Ayr Wellness Inc.” on February 11, 2020. The registered office of the Company is located at 666 Burrard Street, Suite 1700, Vancouver, British Columbia V6C 2X8. The head office of the Company is located at 2601 South Bayshore Drive, Suite 900, Miami, FL, 33133.

The subordinate voting shares, restricted voting shares and limited voting shares of the Company (the “Subordinate Voting Shares”, “Restricted Voting Shares” and “Limited Voting Shares”, respectively, and collectively, the “Equity Shares”) are listed under the single symbol “AYR.A” on the Canadian Stock Exchange (the “CSE”). The Equity Shares are also quoted on the Over-the-Counter Market in the United States under the symbol “AYRWF”. The Anti-Dilutive Warrants (as defined below), which were issued in connection with the Arrangement (as defined below), are listed under the symbol “AYR.WT.U” on the CSE. The Anti-Dilutive Warrants are exercisable for Equity Shares at $2.12 per share until February 7, 2026 and are only exercisable by non-U.S. persons and accredited investors as such terms are defined under applicable United States securities laws. See “General Development of the Business – Subsequent Developments – Completion of Previously Announced Debt Restructuring”. The multiple voting shares of the Company (the “Multiple Voting Shares”), Exchangeable Shares (as defined below), and the Mercer Warrants (as defined below) are unlisted. The Multiple Voting Shares and the Equity Shares are together referred to herein as the “Shares”.

Ayr’s 12.5% senior secured notes due December 10, 2024 (the “2024 Notes”) began trading on the CSE effective April 21, 2021 under the symbol “AYR.NT.U”. The 2024 Notes, in the aggregate principal amount of $110 million, were initially issued on December 10, 2020 through a private placement led by Canaccord Genuity Corp. On November 12, 2021, an additional approximately $147 million in 2024 Notes were issued. Pursuant to the Arrangement, on February 7, 2024, 100% of the issued and outstanding 2024 Notes were assigned by the holders thereof (the “Senior Noteholders”) to Ayr Wellness Canada Holdings Inc. (“Ayr Wellness Canada”), a wholly owned subsidiary of the Company, in exchange for, among other things, an equivalent aggregate principal amount of new 13.0% senior secured notes due December 10, 2026 of Ayr Wellness Canada (the “2026 Exchange Notes”). See “General Development of the Business – Subsequent Developments – Completion of Previously Announced Debt Restructuring”.


Intercompany Relationships

The following is an organizational summary of the Company as of the date hereof:

Subsidiaries

State of Operation

Purpose

242 Cannabis LLC

FL

Real Estate

Amethyst Health LLC

NY

Joint Venture

Ayr Foundation Inc.

FL

Not-for-Profit Community Engagement

Ayr NJ LLC

NJ

Corporate - Holding Company

Ayr Ohio LLC

OH

Corporate - Holding Company

Ayr Wellness Canada Holdings Inc.

CAD

Corporate - Holding Company

Ayr Wellness Holdings, LLC

NV

Corporate - Holding Company

Ayr Wellness Inc.

British Columbia, CAD

Parent Company

Ayr Wellness NJ LLC

NJ

Cultivation, Production, Retail

BP Solutions LLC

NV

Payroll

Cannapunch of Nevada LLC

NV

Production

CannTech PA, LLC

PA

Cultivation, Production, Retail

Connecticut Cultivation Solutions, LLC

CT

Cultivation

Connecticut Retail Solutions II LLC

CT

Retail

Connecticut Retail Solutions LLC

CT

Retail

CSAC Acquisition AZ Corp.

AZ

Corporate - Holding Company

CSAC Acquisition Connecticut LLC

CT

Corporate - Holding Company

CSAC Acquisition FL Corp.

FL

Corporate - Holding Company

CSAC Acquisition IL Corp.

IL

Corporate - Holding Company

CSAC Acquisition IL II Corp.

IL

Corporate - Holding Company

CSAC Acquisition Inc.

NV

Corporate - Holding Company

CSAC Acquisition MA Corp.

MA

Corporate - Holding Company

CSAC Acquisition MA II Corp.

MA

Corporate - Holding Company

CSAC Acquisition NJ Corp.

NJ

Corporate - Holding Company

CSAC Acquisition NV Corp.

NV

Corporate - Holding Company

CSAC Acquisition NY Corp.

NY

Corporate - Holding Company

CSAC Acquisition PA Corp.

PA

Corporate - Holding Company

CSAC Acquisition PA II Corp.

PA

Corporate - Holding Company

CSAC Acquisition TX Corp.

TX

Corporate - Holding Company

CSAC LLC

NV

Corporate - Holding Company

CSAC Holdings Inc.

NV

Corporate - Holding Company

CSAC Ohio, LLC

OH

Production

Cultivauna, LLC d/b/a Levia

MA

Production

DFMMJ Investments LLC d/b/a Ayr Cannabis Dispensary

FL

Cultivation, Production, Retail


Subsidiaries

State of Operation

Purpose

CSAC Acquisition TX Corp.

TX

Corporate - Holding Company

CSAC LLC

NV

Corporate - Holding Company

Dochouse LLC

PA

Cultivation and Production

DWC Investments, LLC

NV

Real Estate

Eskar LLC

MA

Real Estate

Green Garden, LLC

NJ

Joint Venture

Green Light Holdings, LLC

OH

Real Estate

Green Light Management, LLC

OH

Managed Services - Cultivation

Herbal Remedies Dispensaries, LLC

IL

Retail

Klymb Project Management, Inc.

NV

Real Estate

Kynd-Strainz LLC

NV

Retail

Land of Lincoln Dispensary LLC

IL

Retail

Lemon Aide LLC

NV

Retail

Livfree Wellness LLC

NV

Cultivation, Production, Retail

Mercer Strategies FL, LLC

FL

Payroll

Mercer Strategies MA, LLC

MA

Payroll

Mercer Strategies PA, LLC

PA

Payroll

NV Green, Inc.

NV

Managed Services - Production

PA Natural Medicine LLC

PA

Retail

Parker RE MA, LLC

MA

Real Estate

Parker RE PA, LLC

PA

Real Estate

Parker Solutions FL, LLC

FL

Payroll

Parker Solutions IL, LLC

IL

Payroll

Parker Solutions MA LLC

MA

Payroll

Parker Solutions NJ LLC

NJ

Payroll

Parker Solutions OH, LLC

OH

Payroll

Parker Solutions PA, LLC

PA

Payroll

Parma Wellness Center LLC

OH

Managed Services - Cultivation

Sira Naturals, Inc.

MA

Cultivation, Production, Retail

Tahoe Capital Company

NV

Corporate - Holding Company

Tahoe Hydroponics Company, LLC

NV

Cultivation and Production

Tahoe-Reno Botanicals, LLC

NV

Cultivation

Tahoe-Reno Extractions, LLC

NV

Production

On September 12, 2018, Ayr incorporated a wholly-owned subsidiary in Nevada, United States, named CSAC Holdings Inc., to facilitate the Qualifying Transaction (as defined below). On September 17, 2018, CSAC Holdings Inc. incorporated a wholly-owned subsidiary in Nevada, United States, named CSAC Acquisition Inc. (“CSAC AcquisitionCo”). On May 24, 2019, the Company completed its acquisitions of control of the target businesses of: (i) Washoe Wellness, LLC (“Washoe”), a Nevada limited liability company, (ii) The Canopy NV, LLC (“Canopy”), a Nevada limited liability company, (iii) Sira Naturals, Inc. (“Sira”), a Massachusetts corporation, (iv) LivFree Wellness, LLC (“LivFree”), a Nevada limited liability company, and (v) CannaPunch of Nevada LLC (“CannaPunch”), a Nevada limited liability company, and entered into either a services agreement or operations agreement with Washoe, Canopy and LivFree pending regulatory approval for the consummation of the transaction, which collectively constituted its qualifying transaction (collectively, the “Qualifying


Transaction”). Subsequent to the Qualifying Transaction, the Company expanded its operations into the States of Pennsylvania, Florida, New Jersey, Massachusetts, Nevada, Ohio, Illinois and Connecticut (not yet in operation as of the date hereof).

Ayr’s principal shareholder, Mercer Park CB, L.P. (“Mercer”), is a limited partnership formed under the laws of the State of Delaware, of which Mercer Park CB GP, LLC is the general partner, and which is indirectly controlled by Jonathan Sandelman. Mercer is a privately- held family office based in New York, United States, the executive leadership and entrepreneurial expertise, investment and deal experience and network of which have been a critical component of Ayr’s success to date. Mercer Park, L.P., the parent of Mercer, provides services to the Company pursuant to a services agreement.

GENERAL DEVELOPMENT OF THE BUSINESS

Historical Summary

Initial Public Offering

In 2017, the Company completed its initial public offering (the “Offering”). Concurrent with the completion of the Offering, Mercer, Kamaldeep Thindal and Charles Miles (or persons or companies controlled by them) (collectively with Mercer, the “Founders”) purchased an aggregate of 3,434,298 Class B shares of the Company (each, a “Class B Share”), consisting of 3,415,438 Class B Shares purchased by Mercer, 9,430 Class B Shares purchased by Kamaldeep Thindal, and 9,430 Class B Shares purchased by Charles Miles. In addition, Mercer purchased an aggregate of 262,188 Class B units of the Company (each, a “Class B Unit”) at C$10.00 per Class B Unit and 2,621,870 warrants (the “Founders’ Warrants”) at C$1.00 per Founders’ Warrant. Each Class B Unit consisted of one Class B Share, one Warrant and one Right. The Founders’ Warrants were subject to substantially the same terms and conditions as the Warrants underlying the Class A Restricted Voting units of the Company (the “Class A Restricted Voting Units”) and Class B Units, except that they were not subject to early termination. The Rights underlying the Class B Units were subject to the same terms and conditions as the Rights underlying the Class A Restricted Voting Units.

Qualifying Transaction

On May 24, 2019, Ayr completed its acquisitions which qualified as its Qualifying Transaction, the businesses of which are briefly summarized below under “Ayr’s Businesses”. The Company’s businesses operate in the cultivation, manufacturing, branding and/or retail, as applicable, of cannabis products in the states of Massachusetts and Nevada.

The aggregate purchase price consideration for the Qualifying Transaction payable by Ayr was comprised of a combination of cash, debt and the issuance of non-voting Exchangeable Shares of CSAC AcquisitionCo (the “Exchangeable Shares”) to the vendors thereof, which are exchangeable, on a one-for-one basis, into Subordinate Voting Shares, at the option of the holder, and are designed to be economically equivalent (without taking into account tax consequences) to the Subordinate Voting Shares.

Any summary information of certain material terms from definitive agreements, as may have been amended, in respect of the acquisitions of Washoe, Canopy, Sira, LivFree, and CannaPunch (collectively, the “Definitive Agreements”) is not exhaustive and is qualified in its entirety by reference to the terms of the Definitive Agreements, which may be found on Ayr’s profile on SEDAR+ at www.sedarplus.ca.

Ayr previously provided administrative, consulting, and operations services to licensed cannabis establishments in the State of Nevada, specifically to the businesses of Washoe, Canopy and LivFree, through separate services and operations agreements governed by Nevada law, pending regulatory approval to transfer the applicable Washoe, Canopy and LivFree cannabis licenses to the Company. Washoe, Canopy, and LivFree received regulatory approval to transfer such licenses to the Company on April 27, 2021. Effective September 21, 2021, the Washoe, Canopy and LivFree licensed entities were transferred to the Company, such that CSAC AcquisitionCo now wholly- owns LivFree Wellness LLC, Tahoe-Reno Botanicals, LLC, Tahoe-Reno Extractions, LLC, Kynd-Strains LLC and Lemon-Aide LLC.

In connection with each Definitive Agreement, Ayr entered into the corresponding support agreement as well as an exchange rights agreements with CSAC AcquisitionCo and the respective holders of the Exchangeable Shares (collectively, the “Exchange Rights Agreements”) for the benefit of the sellers under each Definitive Agreement, whereby Ayr agreed to make certain covenants in favor of the sellers to protect their rights as holders of Exchangeable Shares. Among other things, Ayr agreed to reserve an amount of applicable Subordinate Voting Shares for issuance upon exchange of the Exchangeable Shares, and upon notice to Ayr and CSAC AcquisitionCo, Ayr will issue such number of applicable Subordinate Voting Shares to a holder of Exchangeable Shares in exchange for the Exchangeable Shares of such holder, subject to the terms specified in the Exchange Rights Agreements. Additionally, Ayr has an overriding liquidation call right under the Exchange Rights Agreements to purchase all, but not less than all, of the Exchangeable Shares from the holders thereof upon a proposed liquidation, dissolution or winding-up of CSAC AcquisitionCo, as well as a redemption call right and retraction call right on the Exchangeable Shares, in each case for the consideration set forth in such agreements.


The description of the Exchange Rights Agreement is not exhaustive and qualified in its entirety by reference to the terms of such agreements, which may be found on Ayr’s profile on SEDAR+ at www.sedarplus.ca. Further information about the Company and its operations can be obtained at www.ir.ayrwellness.com and under the Company’s profile at www.sec.gov and www.sedarplus.ca. The information contained on such website are not a part of, nor are they incorporated by reference into, this AIF.

Subsequent Developments

LivFree Amendment

On November 1, 2023, the Company announced that on October 31, 2023 it had entered into an agreement with LivFree to amend certain terms of the promissory note dated May 24, 2019 (the “LivFree Note”) executed in connection with the Company’s acquisition of LivFree. The amendments to the LivFree Note:

provide an extension of two years from the initial maturity date, resulting in a maturity date of May 24, 2026;

defer repayment of approximately $5 million of accrued PIK interest until May 24, 2026;

convert interest on the LivFree Note from PIK to monthly cash interest;

increase the interest rate on the LivFree Note to 10.0% per annum; and

require a $3 million payment to LivFree on closing of the Arrangement, which payment has been made and applied to the outstanding principal amount due under the LivFree Note.

As a result of the amendments to the LivFree Note, as of November 1, 2023, the Company announced that it reached contingent agreements to defer principal, amortization or accrued interest payments for two years on an aggregate amount, net of payments, of approximately $87 million of debt obligations, including contingent agreements with holders of approximately $73.3 million aggregate principal amount of vendor take-back promissory notes (“Vendor Notes”), representing 86.5% of the outstanding principal amount of all Vendor Notes maturing before 2027. Upon completion of the Arrangement on February 7, 2024, the conditions to each of the Vendor Note amendments were fulfilled.

Completion of Previously Announced Debt Restructuring

On February 7, 2024, the Company announced that it completed the previously announced plan of arrangement (the “Arrangement”) under Section 192 of the Canada Business Corporations Act involving the Company and Ayr Wellness Canada, pursuant to which:

100% of the issued and outstanding 2024 Notes, in an aggregate principal amount of $243.25 million, were assigned by the Senior Noteholders to Ayr Wellness Canada in exchange for an equivalent aggregate principal amount of new 2026 Exchange Notes, which obligations are guaranteed by the Company and each of the Company’s other direct and indirect subsidiaries and secured by all or substantially all of the assets and properties of Ayr Wellness Canada, the Company and each guaranteeing subsidiary, subject to certain exemptions;

29,040,126 Equity Shares (the “New Exchange Shares”) were issued to the Senior Noteholders (being equal to approximately 24.9% of the issued and outstanding shares of the Company on closing of the Arrangement (excluding the Mercer Warrants, the Anti-Dilutive Warrants and certain treasury shares);

a Senior Noteholder (i) subscribed for $50 million aggregate principal amount of additional 13.0% senior secured notes due December 10, 2026 of Ayr Wellness Canada (the “Additional 2026 Notes”, and together with the 2026 Exchange Notes, the “2026 Notes”), issued at a 20% original issue discount (resulting in $40 million of gross proceeds to the Company), and (ii) was issued 5,947,980 Equity Shares (the “Backstop Premium”) in consideration for the commitment to purchase the Additional 2026 Notes pursuant to a backstop commitment letter in favour of the Company dated October 31, 2023;

in order to reduce the dilutive effect of the New Exchange Shares and the Backstop Premium on existing shareholders, the existing shareholders of the Company as of the close of business on February 5, 2024 (i.e., including the holders of the Multiple Voting Shares and Exchangeable Shares (as defined below) but excluding the recipients of the New Exchange Shares and the Backstop Premium) were issued 23,045,965 Equity Share purchase warrants to acquire approximately 16.5% of the outstanding shares of the Company (including the New Exchange Shares and the Backstop Premium, but excluding the Mercer Warrants and certain treasury


shares) on a fully-diluted and pro-forma basis (assuming their exercise in full) (the “Anti-Dilutive Warrants”). If fully exercised, the Anti-Dilutive Warrants will dilute the New Exchange Shares and the Backstop Premium from approximately 30% to approximately 24.9% of the fully diluted outstanding shares of the Company. The Anti-Dilutive Warrants are exercisable at $2.12 per share until February 7, 2026 and are only exercisable by non-U.S. persons and accredited investors as such terms are defined under applicable United States securities laws; and

certain Senior Noteholders holding approximately 99% of the aggregate outstanding principal amount of the 2024 Notes (the “Majority Senior Noteholders”) were granted (i) the right to appoint one independent director (with no affiliation to competitors of the Company) to the Company’s board of directors (the “Board”), (ii) the right to continue to nominate one independent director at each annual meeting of the Company until the earlier of the repayment or refinancing of the 2026 Exchange Notes or the Majority Senior Noteholders cease to hold a majority of the 2026 Exchange Notes held as of closing of the Arrangement, and (iii) customary pre-emptive rights to acquire additional equity of the Company to maintain their respective proportionate equity interests. The Majority Senior Noteholders have chosen Jared Cohen as their nominee, who is expected to be appointed to the Board once all regulatory approvals in connection with such appointment are obtained; if required, another member of the Board is expected to resign in connection with such appointment.

The Company intends to wind-up Ayr Wellness Canada in the near future, pursuant to which all of the assets and liabilities of Ayr Wellness Canada, including the 2026 Notes, will become the assets and liabilities of the Company. Upon completion of same, the 2024 Notes will be cancelled and the 2026 Notes will become direct obligations of the Company.

As a result of the Arrangement and related, previously disclosed transactions, the Company has retired or extended the maturity of nearly $400 million in debt (including the debt described under “General Development of the Business – Subsequent Developments – LivFree Amendment” above) in the past year and now has limited debt maturities until 2026.

DESCRIPTION OF THE BUSINESS

Ayr Wellness Inc. is a national cannabis consumer packed goods company and retailer. Founded in 2019 and headquartered in Miami, Florida since 2021 the Company is focused on delivering high quality cannabis products and a premium customer experience throughout its footprint. As of December 31, 2023, the Company has operations in eight U.S. States and employs roughly 2,300 people. The Company, through its subsidiaries and affiliates, holds, operates and manages licenses and permits in the States of Florida, Illinois, Massachusetts, Nevada, New Jersey, Ohio, Pennsylvania and Connecticut (not yet in operation as of the date hereof).

The Company’s strategy is to vertically integrate through the consolidation of cultivation, production, distribution, and dispensation of cannabis brands and products at scale. The Company’s portfolio of consumer-packaged goods brands includes Kynd, Origyn Extracts, Levia, STiX Preroll Co., Secret Orchard, and Entourage, among others. The Company distributes and markets its products to Ayr-owned retail stores and to third-party licensed retail cannabis stores throughout Ayr’s operating footprint.

The Company owns and operates a chain of cannabis retail stores under brand names including Ayr, Liberty Health Sciences, and The Dispensary. Ayr owns stores under other names, primarily where stores acquired still retain their pre-acquisition branding, though the Company intends to unify its retail footprint under the “Ayr” retail brand name over time. The income of Ayr’s retail stores derives primarily from the sale of cannabis products, with an immaterial portion of income resulting from the sale of other merchandise (such as cannabis accessories). As of December 31, 2023, Ayr operates 91 retail stores, located across Ayr’s portfolio.

Strategy

The Company’s business strategy is to evaluate each market opportunity pursuant to the relevant local competitive and regulatory landscape, supply/demand dynamics, and growth potential. The Company evaluates the economic viability of each opportunity before making capital allocation decisions and may decide to participate in one or more facets of the supply chain based on the dynamics mentioned above. The Company targets best-in-class assets in relevant markets with large addressable populations in states with disciplined license structures that are either currently or soon expected to be approved for adult-use cannabis sales. By establishing a substantial presence in markets that have the greatest growth potential, the Company expects to be well‐positioned for future growth in adult‐use cannabis as the market continues to expand.


Growth

The Company remains focused on pursuing acquisition opportunities in markets with disciplined license structures that complement its existing portfolio while deepening its presence in current markets. The Company’s financial capacity will help the Company emerge as an even stronger player in this capital constrained industry. The Company plans to implement its growth strategy by targeting acquisition opportunities in jurisdictions with disciplined license structures, applying for de novo licenses and deepening its presence in its current markets.

Targeting acquisition opportunities in limited licenses jurisdictions. The Company is pursuing acquisition opportunities in limited license markets with high barriers to entry.

Applying for de novo licenses and pursuing strategic partnerships. The Company is actively seeking additional avenues of growth in its existing markets and other key markets.

Deepening its presence in current markets. The Company currently operates in markets with disciplined license structures, where State- level restrictions limit the number of cannabis licenses awarded, resulting in high barriers to entry, limited market participants, and long- term competitive advantages.

Licenses

The following table provides a list of the licenses granted to companies and facilities operated by, or to which operational support is provided by, the Company as of March 13, 2024.

Licensed Entity

d/b/a

Licensed Address

Type

Title

Cert. | Lic. Number

Exp. Date

Function

Class

LivFree Wellness LLC

3900 Ponderosa Way, Las Vegas, NV 89118

Certificate

Cannabis Compliance Board – Medical Marijuana Cultivation

74378723704914675084

6/30/2024

Cultivation

M

License

Cannabis Compliance Board – Adult-Use Marijuana Cultivation

68096361433916615303

10/31/2024

Cultivation

AU

Certificate

Cannabis Compliance Board – Medical Marijuana Production

52864127312203226338

6/30/2024

Production

M

License

Cannabis Compliance Board – Adult-Use Marijuana Production

59998657224967428496

10/31/2024

Production

AU

The Dispensary

8605 S Eastern Ave Las Vegas, NV 89123

License

Cannabis Compliance Board – Adult-Use Retail Store

64345737726226352455

11/30/2024

Retail

AU

5347 S. Decatur, Las Vegas, NV 89118

Certificate

Cannabis Compliance Board – Medical Marijuana Dispensary

60215712221216816750

6/30/2024

Retail

M

License

Cannabis Compliance Board – Adult-Use Retail Store

71224329369156133247

6/30/2024

Retail

AU

License

Cannabis Compliance Board – Adult-Use Distribution

14504799651148975256

6/30/2024

Distribution

AU

50 N. Gibson, Henderson, NV 89014

Certificate

Cannabis Compliance Board – Medical Marijuana Dispensary

54403159919762505142

6/30/2024

Retail

M

License

Cannabis Compliance Board – Adult-Use Retail Store

08792343110299625005

9/30/2024

Retail

AU

100 W. Plumb Lane, Reno, NV 89509

Certificate

Cannabis Compliance Board – Medical Marijuana Dispensary

04186481440349513323

6/30/2024

Retail

M

License

Cannabis Compliance Board – Adult-Use Retail Store

71702389611437559364

6/30/2024

Retail

AU

435 Eureka Avenue, Reno, NV 89512

Certificate

Cannabis Compliance Board – Medical Marijuana Cultivation

96804690721657828547

6/30/2024

Cultivation

M

License

Cannabis Compliance Board – Adult-Use Marijuana Cultivation

94104154254817748080

11/30/2024

Cultivation

AU

License

Cannabis Compliance Board – Medical Marijuana Production

56693629355290417097

11/30/2024

Production

AU

Certificate

Cannabis Compliance Board – Medical Marijuana Production

18668881888004789228

6/30/2024

Production

M

Tahoe-Reno Botanicals LLC

Kynd Cannabis Company

1645 Crane Way, Sparks, NV 89431

Certificate

Cannabis Compliance Board – Medical Marijuana Cultivation

82842542964915513809

6/30/2024

Cultivation

M

License

Cannabis Compliance Board – Adult-Use Marijuana Cultivation

20856188563796491040

6/30/2024

Cultivation

AU

Tahoe-Reno Extractions LLC

1645 Crane Way, Sparks, NV 89431

Certificate

Cannabis Compliance Board – Medical Marijuana Production

12078072637090304628

6/30/2024

Production

M

License

Cannabis Compliance Board – Adult-Use Production

76163748746660781629

6/30/2024

Production

AU

License

Cannabis Compliance Board – Adult-Use Distribution

77027711033924812731

6/30/2024

Distribution

AU

Kynd-Strainz LLC

MYNT Cannabis Dispensary

132 E. Second St., Reno, NV 89501

Certificate

Cannabis Compliance Board – Medical Marijuana Dispensary

97519348303293892007

6/30/2024

Retail

M

License

Cannabis Compliance Board – Adult-Use Retail Store

46934338604709544132

6/30/2024

Retail

AU


Lemon Aide, LLC

340 Lemmon Drive, Reno, NV 89506

Certificate

Cannabis Compliance Board – Medical Marijuana Dispensary

80994578239784321818

6/30/2024

Retail

M

License

Cannabis Compliance Board – Adult-Use Retail Store

13244303247046007918

6/30/2024

Retail

AU

NV Green Inc.

1475 Hymer Ave Suite A, Sparks, NV 89431

License

Cannabis Compliance Board – Adult-Use Marijuana Cultivation

80476394983467584488

8/31/2024

Cultivation

AU

License

Cannabis Compliance Board – Adult-Use Marijuana Production

08300436904530710396

8/31/2024

Production

AU

Certificate

Cannabis Compliance Board – Medical Marijuana Cultivation

33102338992967161675

6/30/2024

Cultivation

M

Certificate

Cannabis Compliance Board – Medical Marijuana Production

51157511271279283787

6/30/2024

Production

M

Tahoe Hydroponics Company LLC

3535 Arrowhead Dr Ste B, Carson City, NV 89706

Certificate

Cannabis Compliance Board – Medical Marijuana Cultivation

97712183133535367749

6/30/2024

Cultivation

M

License

Cannabis Compliance Board – Adult-Use Marijuana Cultivation

15066280419696569275

6/30/2024

Cultivation

AU

License

Cannabis Compliance Board – Adult-Use Distribution

33766980341791854561

6/30/2024

Distribution

AU

Ayr Wellness NJ, LLC

950 US Highway 1, Woodbridge, NJ 07095

License

CRC – Cultivate and Process Medicinal Marijuana

MC000067

12/31/2024

Cultivation and Production

M

License

CRC – Dispense Medicinal Marijuana

MRE000018

12/31/2024

Retail

M

License

CRC – Class 1 Cultivator

C000067

10/11/2024

Cultivation

AU

License

CRC – Class 5 Retailer

RE000018

6/5/2024

Retail

AU

2536 Rt. 22, Union, NJ 07083

License

CRC – Class 5 Retailer

RE000017

6/5/2024

Retail

AU

License

CRC – Dispense Medicinal Marijuana

MRE000017

12/31/2024

Retail

M

2000 East Park Blvd Suite 2002, South Brunswick, NJ 08512

License

CRC – Class 2 Manufacturer

MM000033

12/31/2024

Production

AU

1719 Oak Street Lakewood NJ 08701

License

CRC – Cultivate and Process Medicinal Marijuana

MC000200

12/31/2024

Cultivation and Production

M

59 NJ-35, Eatontown, NJ 07724

License

CRC – Dispense Medicinal Marijuana

MRE000016

12/31/2024

Retail

M

License

CRC – Class 5 Retailer

RE000016

6/5/2024

Retail

AU

Sira Naturals, Inc.

AYR Cannabis Dispensary 

48 North Beacon Street, Watertown, MA 02472

License

CCC – Registered Marijuana Dispensary

MTC325

9/18/2024

Retail

M

License

CCC – Marijuana Establishment License (Retailer)

MR283886

9/18/2024

Retail

AU

827-829 Boylston Street Boston, MA 02116

License

CCC – Marijuana Establishment License (Retailer)

MR283946

9/18/2024

Retail

AU

240 Elm Street, Somerville, MA 02144

License

CCC – Registered Marijuana Dispensary

MTC245

9/18/2024

Retail

M

License

CCC – Marijuana Establishment License (Retailer)

MR282672

9/18/2024

Retail

AU

29 Franklin Street, Needham, MA 02492

License

CCC – Registered Marijuana Dispensary

MTC625

9/18/2024

Retail

M

13 Commercial Way, Milford, MA 01757

License

CCC – Marijuana Establishment License (Cultivation/Tier 3 – Indoor)

MC281252

9/30/2024

Cultivation

AU

License

CCC – Marijuana Establishment License (Product Manufacturer)

MP281303

10/12/2024

Production

AU

License

CCC – Marijuana Establishment License (Transporter)

MX281310

10/12/2024

Distribution

AU

License

CCC – Marijuana Establishment License (Cultivation)

MTC245-C

9/18/2024

Cultivation

M

License

CCC – Marijuana Establishment License (Product Manufacturer)

MTC245-P

9/18/2024

Production

M

1 Industrial Way, Milford MA 01751

License

CCC – Marijuana Establishment License (Cultivation/Tier 3 – Indoor)

MC282015

9/16/2024

Cultivation

AU

5-7 Industrial Way, Milford, MA 01757

License

CCC – Marijuana Establishment License (Cultivation/Tier 8 – Indoor)

MC283066

9/18/2024

Cultivation

AU

License

CCC – Marijuana Establishment License (Product Manufacturer)

MP281613

9/18/2024

Production

AU

Cultivauna, LLC

Ayr Wellness 

68 Tenney Street, Georgetown, MA 01833

License

CCC – Marijuana Establishment License (Product Manufacturer)

MP281871

1/16/2025

Production

AU

CSAC Ohio LLC

844 East Tallmadge Avenue, Akron, Ohio, 44310

License

OH Department of Commerce – Medical Marijuana Processor Operating License

MMCPP00102

12/1/2024

Production

M

Parma Wellness Center, LLC

12795 Corporate Drive, Parma, Ohio 44130

License

OH Department of Commerce – Medical Marijuana Cultivator Operating License

MMCPC00025

10/3/2024

Cultivation

M

Daily Releaf, LLC(1)

AYR Dispensary

4918 Airway Road, Riverside, Ohio 45431

License

OH Department of Commerce – Medical Marijuana Dispensary

MMD.0700145

6/30/2025

Retail

M

Twice the Wellness LLC(1)

27900 Chagrin Boulevard, Suites 900B and 900C, Woodmere, Ohio 44122

License

OH Department of Commerce – Medical Marijuana Dispensary

MMD.0700158

6/30/2025

Retail

M


Heaven Wellness, LLC(1)

6722 State Route 132, Goshen, Ohio 45122

License

OH Department of Commerce – Medical Marijuana Dispensary

MMD.0700138

6/30/2025

Retail

M

DFMMJ Investments, LLC

AYR Cannabis Dispensary

18770 N County Road 225, Gainesville, Florida, 32609

License

OMMU – Medical Marijuana Treatment Center

MMTC-2015-0002*

7/31/2024

Cultivate, Process, Transport, Retail

M

CannTech PA, LLC

AYR Wellness

535 Keystone Drive, Warrendale, PA 15086

Permit

PA Department of Health Office of Medical Marijuana – Grower/Processor Facility

CR04-GP20-5701

2/20/2025

Cultivation

M

809 Sampson Street, New Castle, PA 16101

Permit

PA Department of Health Office of Medical Marijuana – Dispensary Facility

CR04-D20-6701 A

2/20/2025

Retail

M

505 W. Germantown Pike, Plymouth Meeting, PA 19462

Permit

PA Department of Health Office of Medical Marijuana – Dispensary Facility

CR04-D20-6701 B

2/20/2025

Retail

M

112 Northtowne Square, Gibsonia PA 15044

Permit

PA Department of Health Office of Medical Marijuana – Dispensary Facility

CR04-D20-6701 C

2/20/2025

Retail

M

712 Lancaster Ave., Bryn Mawr, PA 19010

Permit

PA Department of Health Office of Medical Marijuana – Dispensary Facility

CR04-D20-6701 D

2/20/2025

Retail

M

801 Horsham Rd, Montgomeryville, PA 18936

Permit

PA Department of Health Office of Medical Marijuana – Dispensary Facility

CR04-D20-6701 E

2/20/2025

Retail

M

2244 Oakland Ave, Indiana, PA 15701

Permit

PA Department of Health Office of Medical Marijuana – Dispensary Facility

CR04-D20-6701 F

2/20/2025

Retail

M

DocHouse LLC

740 Ann St Pottsville, PA 17901

Permit

PA Department of Health Office of Medical Marijuana – Grower/Processor Facility

GP18-1002

7/31/2024

Cultivation

M

PA Natural Medicine LLC

261-269 Columbia Mall Dr., Bloomsburg, PA 17815

Permit

PA Department of Health Office of Medical Marijuana – Dispensary Facility

D-4007-17 A

6/29/2024

Retail

M

1420 N. Susquehanna Trail, Selinsgrove, PA 17870

Permit

PA Department of Health Office of Medical Marijuana – Dispensary Facility

D-4007-17 B

6/29/2024

Retail

M

2105 N. Atherton St., State College, PA 16803

Permit

PA Department of Health Office of Medical Marijuana – Dispensary Facility

D-4007-17 C

6/29/2024

Retail

M

Herbal Remedies Dispensaries, LLC

AYR Cannabis Dispensary

4440 Broadway Street Suite 1 Quincy, IL 62305

License

IDFPR – Registered Medical Cannabis Dispensing Organization

280.000004

9/24/2024

Retail

M

4440 Broadway Street Suite 1 Quincy, IL 62305

License

IDFPR – Adult Use Dispensing Organization

284.000137

3/31/2026

Retail

AU

1837 Broadway Street Quincy, IL 62301

License

IDFPR – Adult Use Dispensing Organization

284.000138

3/31/2026

Retail

AU

Note:

(1)

Entered into an Option Agreement and Support Services Agreement with AYR Ohio LLC pending regulatory approval for the license transfers by the Ohio Department of Commerce.

As of December 31, 2023, intangible assets had a net book value of $687,987,765 (excluding goodwill) and consisted of the following: Licenses, Right-to-use Licenses, Host community agreements and Trade name / brand which have useful lives of 15, 15, 15, and 5 years, respectively. Amortization is recorded on a straight-line basis over their estimated useful lives, which do not exceed the contractual period, if any. See Note 9 to the Company's consolidated financial statements for the year ended December 31, 2023.

Employees

As of December 31, 2023, the Company had approximately 2,300 employees. The Company seeks to attract, hire and promote the most qualified and diverse candidates for each position. Based on both acquisitions and hires, the Company leverages experience from multiple individuals that have been in the regulated cannabis market. The Company draws upon this knowledge base and proven training program to develop and educate employees. With policies and procedures that have successfully been rolled out in multiple markets, the Company uses these proven policies and procedures where applicable to other businesses in order to meet the operational expectations for each market. The Company seeks to ensure that staff are appropriately trained and ensure the safety and welfare of employees at the Company’s facilities. Leveraging existing operations in legal adult use States, all new employees receive true hands-on training prior to starting in their new market. Setting the tone from the top, the Company’s executive team goes above and beyond to seek to ensure that all individuals within the Company are held to the highest standards, particularly with respect to compliance.

Foreign Operations

The Company does not currently have any foreign operations outside of the United States. Neither the Company nor any reportable segment of the Company has any dependence upon foreign operations outside of the United States.

Investment Policies

The Company may provide working capital facilities to its acquisition targets in order to fund development of assets prior to completion of the acquisitions, where it is to the benefit of the Company to do so.


No Bankruptcy Proceedings

There are presently no bankruptcy, receivership, or similar proceedings against the Company or any of its subsidiaries, including voluntary bankruptcy, receivership, or similar proceedings, nor have there been any such proceedings within the three (3) most recently completed financial years.

CANNABIS MARKET OVERVIEW

On February 8, 2018, the Canadian Securities Administrators revised their previously released Staff Notice 51-352, which provides specific disclosure expectations for issuers that currently have, or are in the process of developing, cannabis-related activities in the United States as permitted within a particular State’s regulatory framework. All issuers with U.S. cannabis-related activities are expected to clearly and prominently disclose certain prescribed information in disclosure documents. As a result of the Company’s existing cannabis operations and/or assets in Massachusetts, Nevada, Pennsylvania, Florida, New Jersey, Ohio, Illinois and Connecticut (not yet in operation as of the date hereof), Ayr provides the following disclosure:

The legalization and regulation of marijuana for medical and recreational use is implemented at the State level in the United States. State laws regulating cannabis are in direct conflict with the CSA, which makes cannabis use and possession federally illegal. Although certain States and territories of the United States authorize medical or adult-use cannabis production and distribution by licensed or registered entities, under United States federal law, the possession, use, cultivation, and transfer of cannabis and any related drug paraphernalia is illegal and any such acts are criminal acts under federal law under any and all circumstances under the CSA. Although the Company’s business activities are believed to be compliant with applicable U.S. State and local law in the jurisdictions where Ayr operates, strict compliance with State and local laws with respect to cannabis may neither absolve Ayr of liability under United States federal law, nor may it provide a defense to any federal proceeding which may be brought against Ayr.

The following table is intended to assist readers in identifying those parts of this AIF that address the disclosure expectations outlined in Staff Notice 51-352.

Industry Involvement

    

Specific Disclosure Necessary to Fairly Present all Material Facts, Risks and Uncertainties

    

AIF Cross-Reference

All Issuers with U.S. Marijuana – Related Activities

Describe the nature of the issuer’s involvement in the U.S. marijuana industry and include the disclosures indicated for at least one of the direct, indirect and ancillary industry involvement types noted in this table.

-

Description of the Business

-

Cover page

-

(disclosure in bold typeface)

-

Cannabis Market Overview (disclosure in bold typeface)

Prominently state that marijuana is illegal under U.S. federal law and that enforcement of relevant laws is a significant risk.

-

Cover page

-

(disclosure in bold typeface)

-

Federal Regulatory Environment

-

U.S. Federal Enforcement Priorities

-

Risk Factors – While legal under applicable U.S. State law, Ayr’s business activities are illegal under U.S. federal law

-

Risk Factors – The approach to the enforcement of cannabis laws may be subject to change or may not proceed as previously outlined

Discuss any statements and other available guidance made by federal authorities or prosecutors regarding the risk of enforcement action in any jurisdiction where

-

Risk Factors Risks Related to Legality of Cannabis


Industry Involvement

    

Specific Disclosure Necessary to Fairly Present all Material Facts, Risks and Uncertainties

    

AIF Cross-Reference

the issuer conducts U.S. marijuana-related activities.

Outline related risks including, among others, the risk that third-party service providers could suspend or withdraw services and the risk that regulatory bodies could impose certain restrictions on the issuer’s ability to operate in the U.S.

Given the illegality of marijuana under U.S. federal law, discuss the issuer’s ability to access both public and private capital and indicate what financing options are / are not available in order to support continuing operations.

-

Risk Factors – Service providers could suspend or withdraw service

-

Risk Factors – While legal under applicable U.S. State law, Ayr’s business activities are illegal under U.S. federal law

-

Ability to Access Public and Private Capital

-

Risk Factors - Ayr may be subject to restricted access to banking in the United States and Canada

-

Risk Factors - Ayr’s investments in the U.S. are subject to applicable anti-money laundering laws and regulations

Quantify the issuer’s balance sheet and operating statement exposure to U.S. marijuana related activities.

Disclose if legal advice has not been obtained, either in the form of a legal opinion or otherwise, regarding (a) compliance with applicable State regulatory frameworks and (b) potential exposure and implications arising from U.S. federal law.

-

Exposure to U.S. Marijuana Related Activities

-

The Company has received and continues to receive legal input regarding (a) compliance with applicable State regulatory frameworks and (b) potential exposure and implications arising from U.S. federal law in certain respects. The Company receives such advice on an ongoing basis but does not have a formal legal opinion on such matters.

U.S. Marijuana Issuers with direct involvement in cultivation or distribution

Outline the regulations for U.S. States in which the issuer operates and confirm how the issuer complies with applicable licensing requirements and the regulatory framework enacted by the applicable U.S. State.

-

Cannabis Market Overview – Nevada

-

Cannabis Market Overview – Massachusetts

-

Cannabis Market Overview – Pennsylvania

-

Cannabis Market Overview – Florida

-

Cannabis Market Overview – Ohio

-

Cannabis Market Overview – New Jersey

-

Cannabis Market Overview – Connecticut

-

Cannabis Market Overview – Illinois

-

State Regulatory Landscapes

Discuss the issuer’s program for monitoring compliance with U.S. State law on an ongoing basis, outline internal compliance procedures and provide a positive statement indicating that the issuer is in compliance with U.S. State law and the related licensing

-

Cannabis Market Overview – Compliance with State Regulatory Frameworks


Industry Involvement

    

Specific Disclosure Necessary to Fairly Present all Material Facts, Risks and Uncertainties

    

AIF Cross-Reference

framework. Promptly disclose any non-compliance, citations or notices of violation which may have an impact on the issuer’s license, business activities or operations.

In accordance with Staff Notice 51-352, below is a discussion of the federal and State-level U.S. regulatory regimes in those jurisdictions where Ayr is directly or indirectly involved through its subsidiaries. Ayr is currently indirectly engaged in the manufacture, possession, use, sale or distribution of cannabis and/or holds licenses in the adult-use and/or medicinal cannabis marketplace in the States of Massachusetts, Nevada, Pennsylvania, Florida, New Jersey, Ohio, Illinois and Connecticut (not yet in operation as of the date hereof). In accordance with Staff Notice 51-352, Ayr will evaluate, monitor and reassess this disclosure, and any related risks, on an ongoing basis and the same will be supplemented and amended to investors in public filings, including in the event of government policy changes or the introduction of new or amended guidance, laws or regulations regarding cannabis regulation. As noted under “Non-Compliance with State and Local Cannabis Laws” below, Ayr intends to cause its businesses to promptly remedy any known occurrences of non-compliance with applicable State and local cannabis rules and regulations, and Ayr intends to publicly disclose any non-compliance, citations or notices of violation which may have an impact on its licenses, business activities or operations.

Exposure to U.S. Marijuana Related Activities

As of December 31, 2023, 100% of the businesses was directly derived from United States cannabis-related activities. As such, the Company’s exposure to United States cannabis related activities is 100%.

U.S. Federal Regulatory Environment

The federal government of the United States regulates controlled substances through the CSA, which places controlled substances on one of five schedules. Currently, marijuana is classified as a Schedule I controlled substance. A Schedule I controlled substance means the DEA considers it to have a high potential for abuse, no accepted medical treatment, and a lack of accepted safety for the use of it even under medical supervision. Overall, the United States federal government has specifically reserved the right to enforce federal law regarding the sale and disbursement of medical or adult-use marijuana even if such sale and disbursement is sanctioned by State law. Accordingly, there are a number of significant risks associated with the business of the Company and unless and until the United States Congress amends the CSA with respect to medical and/or adult-use cannabis (and as to the timing or scope of any such potential amendments there can be no assurance), there is a significant risk that federal authorities may enforce current federal law, and the business of the Company may be deemed to be producing, cultivating, extracting, or dispensing cannabis or aiding or abetting or otherwise engaging in a conspiracy to commit such acts in violation of federal law in the United States.

The Company’s operations, to the Company’s knowledge, are in compliance with applicable State laws, regulations and licensing requirements in the jurisdictions where the Company operates. Additionally, the Company uses the same proprietary, best-practices policies and procedures in its managed facilities as in its owned facilities in order to ensure systematic operations and, as such, to the Company’s knowledge, the facilities that the Company operates are in compliance with applicable State laws, regulations and licensing requirements. Nonetheless, for the reasons described above and risks described under “Forward-Looking Information”, but not limited to these reasons, there are significant risks associated with the business of the Company. Readers are strongly encouraged to carefully read all the risk factors contained herein.

The following sections describe the legal and regulatory landscape in respect of the States in which the Company currently operates. As discussed above, State laws in the U.S. regulating cannabis are in direct conflict with the CSA. Although certain States and territories of the U.S. authorize medical and/or recreational cannabis cultivation, manufacturing, production, distribution and sales by licensed or registered entities, under U.S. federal law, the cultivation, manufacture, distribution, possession, use, and transfer of cannabis and any related drug paraphernalia, unless specifically exempt, is illegal and any such acts are criminal acts under the CSA. Even though the Company’s activities may be compliant with applicable State laws, strict compliance with State laws with respect to cannabis may neither absolve the Company of liability under U.S. federal law, nor may it provide a defense to any federal proceeding which may be brought against the Company.

While the Company’s compliance controls have been developed to mitigate the risk of violations of a license arising, there is no assurance that the Company’s licenses will be renewed in the future in a timely manner. Any unexpected delays or costs associated with the licensing renewal process could impede the ongoing or planned operations of the Company and have a material adverse effect on the Company’s business, financial condition, results of operations or prospects.


As a result of the November 2020 U.S. federal election, President Joseph R. Biden is now in office. There can be no assurance as to the position any administration may take on marijuana and the Biden administration could decide to enforce the federal laws strongly. Any enforcement of current federal laws could cause significant financial damage to the Company and its shareholders. Further, future presidential administrations may want to treat marijuana differently and potentially enforce the federal laws more aggressively. Further, control of the United States federal government is now divided between the Democratic Party, which holds control of the Presidency and the Senate, and the Republican Party, which holds control of the House of Representatives; given the state of such divided government, the prospects of federal marijuana legalization remain unclear.

U.S. Federal Enforcement Priorities

Due to the current federal regulatory environment in the United States, as further described herein, Ayr may become the subject of heightened scrutiny by regulators, stock exchanges and other authorities in Canada and the U.S. As a result, Ayr may be subject to significant direct and indirect interaction with public officials. There can be no assurance that this heightened scrutiny will not in turn lead to the imposition of certain restrictions on Ayr’s ability to invest in the U.S. or any other jurisdiction. See “Risk Factors – While legal under applicable U.S. State law, Ayr’s business activities are illegal under U.S. federal law and “Risk Factors – The approach to the enforcement of cannabis laws may be subject to change or may not proceed as previously outlined”.

Changes in government policy or public opinion can significantly influence the regulation of the cannabis industry in Canada, the United States and elsewhere. A negative shift in the public’s perception of cannabis in the U.S. or any other applicable jurisdiction could affect future legislation or regulation. Among other things, such a shift could cause State jurisdictions to abandon initiatives or proposals to legalize cannabis, thereby limiting the number of new State jurisdictions into which Ayr could expand. Any inability to fully implement Ayr’s expansion strategy may have a material adverse effect on Ayr’s business, financial condition and results of operations. See “Risk Factors”.

Further, violations of any U.S. federal laws and regulations could result in significant fines, penalties, administrative sanctions, convictions or settlements arising from criminal charges or civil proceedings conducted by either the U.S. federal government or private citizens (who have the right to seek private relief for Ayr’s “aiding and abetting” activities that violate U.S. federal law), including, but not limited to, disgorgement of profits, cessation of business activities or divestiture. This could have a material adverse effect on Ayr, including on its reputation and ability to conduct business, its holding (directly or indirectly) of cannabis licenses in the U.S., the listing of its securities on various stock exchanges, its financial position, operating results, profitability or liquidity, or the market price of its publicly-traded shares. In addition, it is difficult for Ayr to estimate the time or resources that would be needed for the investigation or final resolution of any such matters because, in part, the time and resources that may be needed are dependent on the nature and extent of any information requested by the applicable authorities involved, and such time or resources could be substantial. See “Risk Factors – Risks Related to Legality of Cannabis”.

State Regulatory Environment

Nevada

Nevada Regulatory Landscape

In November 2000, Nevada voters passed the “Medical Marijuana Act” (Question 9) for the second time, which is mandated for any ballot measures that seek to amend the State’s constitution. Medical use was officially made exempt from prosecution in June 2001 with the passage of Assembly Bill 453, which took effect in October later that year, however personal cultivation of marijuana for private medical use was the only available means of acquisition.

In June 2013, the Nevada legislature passed Senate Bill 374, “An Act Relating to Medical Marijuana,” providing for the licensing of medical cannabis business establishments for commercial operations.

In November 2016, Nevada voters passed the “Initiative to Regulate and Tax Marijuana” (Question 2), allowing licensed cannabis establishments to engage in the sale of adult-use cannabis in the State beginning July 2017. As of July 2020, the Nevada Cannabis Compliance Board (the “CCB”) governs and administers regulatory oversight for the medical and adult-use cannabis programs.

In June 2021, the Nevada legislature passed Assembly Bill 341, “An Act Relating to Cannabis,” authorizing the CCB to implement regulations and issue licenses for the operation of alcohol-free consumption lounges where adults may purchase and consume cannabis products on-site, whether at stand-alone businesses or attached to existing retail stores. In June 2023, Governor Lombardo signed into law a bill that more than doubled the personal possession limit, consolidated licensing rules, and broadened eligibility for participation in the market by those with prior felony convictions.


Cities and counties in Nevada are allowed to determine the number of local cannabis licenses they will issue, up to the maximum number as allocated by the statute.

Licenses and Regulations

The CCB licenses and regulates five types of cannabis establishments: cultivation, production, independent testing, distribution, and retail stores. Cultivation establishments may sell usable cannabis to retail stores, production establishments, and to other cultivation establishments, but not directly to customers. Production establishments are authorized to make products such as concentrates, edibles, ointments and tinctures, and likewise sell to other production establishments and retail stores,

Ayr, through its owned and managed entities, operates four cultivation facilities, three production facilities, six dispensaries, and two distribution facilities in the State of Nevada. Under applicable laws, the licenses issued for these facilities permit the businesses to cultivate, manufacture, process, package, sell, purchase, and transport cannabis pursuant to the license types and Nevada regulations.

CCB regulations apply to all aspects of cannabis seed-to-sale operations including record keeping; employee and principal officer background checks and establishment agent card requirements; cannabis inventory labeling, quality and tracking; safe and secure storage practices; audio/visual and physical security at licensed facilities; secure product transportation measures; and financial, labor and governance reporting of the licensee and its affiliates. Regulators may conduct announced or unannounced inspections of licensees to assess compliance with applicable laws and regulations.  

The Company is not aware of any specific risks associated with providing administrative, consulting and operations services to licensed cannabis establishments in Nevada such as are provided to the Nevada Managed Entities by the Company. To the knowledge of management of the Company, there have not been any statements or guidance made by federal authorities or prosecutors regarding the risk of enforcement action specific to the State of Nevada. For more information on federal enforcement and the risks associated with the U.S. cannabis regulatory environment generally, see, without limitation, “Risk Factors – Risks Related to Legality of Cannabis”.

Massachusetts

Massachusetts Regulatory Landscape

In November 2008, Massachusetts voters approved the Massachusetts “Sensible Marijuana Policy Initiative,” known as “Question 2,” which decriminalized the possession of small amounts of cannabis punishable by a reduced fine and eliminated reporting of the offense to the state’s criminal history board.

In November 2012, voters approved the Massachusetts “Medical Marijuana Initiative,” known as “Question 3”. That same year, the legislature passed “An Act for the Humanitarian Medical Use of Marijuana” within Chapter 369 of the Acts of 2012 which thereby established the Medical Use of Marijuana Program (“MUMP”) for the registration and authorization of qualifying patients, personal caregivers, Medical Marijuana Treatment Centers (“MMTCs”), and authorized MMTC agents to engage in the cultivation, production, and commercial sale of medical marijuana. MMTC licenses are vertically integrated licenses and authorize each MMTC to operate one cultivation facility, one processing facility and three dispensary locations.  

In November 2016, Massachusetts voters approved the Massachusetts “Legalization, Regulation and Taxation of Marijuana Initiative,” known as “Question 4,” which legalized the licensed recreational or “adult-use” distribution and sale of cannabis in the Commonwealth. In December 2016, Governor Baker signed omnibus legislation amending the initiative to clarify municipal land-use regulations and extend the commencement date for legal licensed recreational cannabis sales by six months, to July 2018.

In July 2017, the Massachusetts legislature approved House Bill 3818, “An Act to Ensure Safe Access to Marijuana,” which became Chapter 55 of the Acts of 2017, and, among other things, established the Cannabis Control Commission (“CCC”) to implement and administer laws enabling access to medical and adult-use cannabis. Among its oversight and regulatory duties, the CCC issues licensure for the adult-use cultivation, processing and dispensary facilities (collectively, “Marijuana Establishments”), and MMTCs.

In November 2018, after further extensions, the CCC issued the first notices for marijuana retail establishments to commence adult-use operations in the Commonwealth.

In August 2022, the Massachusetts legislature passed S. 3096, “An Act Relative to Equity in the Cannabis Industry,” which became Chapter 180 of the Acts of 2022, that clarifies and limits the authority of municipalities to request percentage-based annual Community Impact Fees and other donations or fees under the statutorily required Host Community Agreements with those municipalities.


Licenses and Regulations

The CCC oversees the issuance and annual renewal of licensure for both medical and adult-use marijuana businesses within the Commonwealth. MMTCs are vertically integrated businesses that cultivate, process, and retail marijuana and marijuana products for medical use. MMTCs may also deliver products to registered qualifying patients.

The CCC categorizes all adult-use cannabis businesses as Marijuana Establishments (“ME”), which include craft marijuana cooperatives, cultivators (indoor and outdoor), independent testing laboratories, couriers, delivery operators, research facilities, microbusinesses, product manufacturers, retailers, standards laboratories, and transporters.

The Company holds three adult-use cultivator licenses, three adult-use product manufacturer licenses, three adult-use marijuana retailer licenses and one adult-use transportation license in the Commonwealth. In addition, the Company owns three MMTC licenses in the Commonwealth, which authorizes the cultivation and product manufacturing of medical-use cannabis and dispensing to qualifying patients at three dispensary locations. Under its various MMTC and ME licenses, the Company currently operates one medical cannabis only, two co-located adult-use and medical cannabis stores, and one adult-use only store in the Commonwealth.

CCC regulations apply to all aspects of cannabis seed-to-sale operations including record keeping; employee and principal officer background checks and badging requirements; inventory labeling, quality and tracking; safe and secure storage practices; audio/visual and physical security at licensed facilities; secure product transportation measures; and financial, labor and governance reporting of the licensee and its affiliates. Regulators may conduct announced or unannounced inspections of licensees to assess compliance with applicable laws and regulations.  

The Company also maintains municipal permits and statutorily required Host Community Agreements in the cities and towns in which it operates in the Commonwealth.

In 2018, then Massachusetts US Attorney Andrew Lelling indicated that the US Attorney’s resources regarding prosecuting marijuana would be focused on overproduction, targeted sales to minors and organized crime and interstate transportation of drug proceeds. In October 2023, President Biden appointed Joshua Levy as Massachusetts U.S. Attorney. She has not issued guidance on priorities for marijuana prosecution. For more information on federal enforcement and the risks associated with the U.S. cannabis regulatory environment generally, see, without limitation, “Risk Factors – Risks Related to Legality of Cannabis”.

Pennsylvania

Pennsylvania Regulatory Landscape

In April 2016, Governor Wolf signed into law Senate Bill 3, the “Medical Marijuana Act” (“Act 16”), providing access for State residents with one of 17 qualifying conditions, including epilepsy, chronic pain, and post-traumatic stress disorder to purchase, possess, and consume medical cannabis. Under the implementing regulations set by the Pennsylvania Department of Health (“PA DOH”), which administers all aspects of the Commonwealth’s medical marijuana program, retail sales began in February 2018. Later in April 2018, the PA DOH authorized dry flower as an approved product for sale and consumption (in addition to the already approved product forms of concentrates, pills and tinctures) and expanded the list of eligible qualifying conditions to include cancer remission therapy, opioid-addiction therapy, neurodegenerative disorders and spastic movement disorders.

In July 2019, the PA DOH further expanded the list of qualifying medical conditions to include anxiety disorders and Tourette’s syndrome, increasing the total number of qualifying conditions to 23.

In June 2021, Governor Wolf signed into law House Bill 1024, “An Act Amending the Act of April 17, 2016 (P.L.84, No.16)” (“Act 44”), further expanding the definition of serious medical condition to include other conditions as recommended by the Medical Marijuana Advisory Board and approved by the Secretary of Health. The changes also permit dispensaries greater operational flexibility, including providing limited, on-site outdoor order pickups, remote patient consultations, and increasing the allowed medical dosages from a 30 to 90 days’ supply.

In July 2022, Governor Wolf signed House Bill 331, “An Act… Providing for Legitimate Cannabis-Related Business and Incentive-Based Savings Program” (“Act 52”), which authorizes and grants protections under Pennsylvania law for financial institutions and insurers to provide services to, or for the benefit of a “legitimate cannabis-related business.” Act 52 states that financial institutions and insurers are not obligated to provide services to marijuana businesses within the Commonwealth and requires that any marijuana businesses receiving financial or insurance services from a provider within Pennsylvania must disclose any suspension or revocation of marijuana-related permits, registrations, or certifications to the financial institution and/or insurer within five business days.


In October 2022, the PA DOH finalized and republished its medical marijuana regulations, which thereafter became effective in March 2023. These final regulations mirror the temporary regulations and reflect the PA DOH’s focus on addressing the growth and evolution of the medical marijuana program, specifically regarding changes in ownership, packaging and labeling requirements, signage and security, and product testing.

Licenses and Regulations

Program rules require all participants in the supply chain – referred to as “Medical Marijuana Organizations” or “MMOs” – to be licensed by the PA DOH. There are two permit types: Grower/Processor permits, which authorize plant cultivation, manufacturing, packaging, and transportation of finished products, and Dispensary permits, which authorize acquisition of finished products from Grower/Processor permit holders and the retail sale of same to registered patients. Permits are subject to an annual renewal process, which includes fees and compliance requirements for MMOs. Act 16 established a marijuana research program whereby accredited medical schools may partner with an acute care hospital licensed in the Commonwealth that has been approved and certified by the PA DOH to enter a contract with a clinical registrant (“CR”) for the purpose of designing and conducting studies through marijuana research. CRs hold a permit as both a grower/processor and a dispensary, and through the dispensary permit are authorized to operate dispensaries at up to six locations in any region of the Commonwealth.

Through its subsidiaries, Ayr holds a CR permit authorizing growing/processing and dispensing at six locations, a second grower/processor permit authorizing operations at a separate facility, and a dispensary permit that authorizes three additional locations to conduct the sale of medical marijuana to registered patients.

PA DOH regulations apply to all aspects of cannabis seed-to-sale operations including record keeping; employee and principal officer background checks and badging requirements; inventory labeling, quality and tracking; safe and secure storage practices; audio/visual and physical security at licensed facilities; secure product transportation measures; and financial, labor and governance reporting of the licensee and its affiliates. Regulators may conduct announced or unannounced inspections of licensees to assess compliance with applicable laws and regulations.

The Company is not aware of any specific risks associated with operating in Pennsylvania. To the knowledge of management of the Company, there have not been any statements or guidance made by federal authorities or prosecutors regarding the risk of enforcement action specific to the State of Pennsylvania. For more information on federal enforcement and the risks associated with the U.S. cannabis regulatory environment generally, see, without limitation, “Risk Factors – Risks Related to Legality of Cannabis”.

Florida

Florida Regulatory Landscape

In June 2014, the Florida Legislature passed Senate Bill 1030, the “Compassionate Medical Cannabis Act” (“CMCA”), which authorized dispensing organizations (“DO”) approved by the Florida Department of Health (the “FL DOH”) to manufacture, possess, sell, and dispense low-THC cannabis oil for medical use by patients suffering from epilepsy, cancer, and ALS.

In March 2016, Governor Scott signed into law House Bill 307, “An Act Relating to the Medical Use of Cannabis,” which expanded upon the previously enacted Senate Bill 1052, the “Right to Try Act,” by allowing an eligible patient with a terminal condition to use full potency medical cannabis without cannabinoid composition requirements or THC limits. The bill amended the CMCA to increase regulatory oversight by the ODH and created new standards for DOs, including for growing, processing, testing, packaging, labeling, dispensing, distributing, and transporting of cannabis.  

In November 2016, the Florida “Medical Marijuana Legalization Initiative,” also known as Amendment 2 (“Medical Initiative”), was introduced by citizen referendum and passed with a 71.3% majority. This initiative amended the State’s constitution to legalize the medical use of cannabis with a doctor’s recommendation for treatment of 11 listed debilitating medical conditions, including chronic non-malignant pain. The Medical Initiative and the expanded qualifying medical conditions became effective January 2017.

In June 2017, the Florida House of Representatives and Florida Senate passed respective legislation to implement the expanded program by replacing large portions of the existing CMCA. As amended, §381.986 provided licenses to operate as Medical Marijuana Treatment Centers (“MMTCs”) to all entities that held an active, unrestricted licenses to cultivate, process, transport, and dispense low-THC cannabis or medical cannabis before July 1, 2017, as well as an additional 10 entities. The law also provides for another four licenses to be issued for every 100,000 patients added to the state’s medical marijuana registry and allows MMTCs to open an unlimited number of dispensaries. Furthermore, the amendment renamed the Office of Compassionate Use, which was previously administering the state’s medicinal cannabis


program, to the Office of Medical Marijuana Use (“OMMU”) which currently regulates MMTCs and testing laboratories, issues patient registration cards, and promulgates guidance for businesses and individuals partaking in the Florida medical cannabis industry.

As of February 2024, there are 25 licensed MMTCs in Florida. The OMMU is currently scoring the applications for an additional 22 MMTC licenses. Additionally, the Florida Supreme Court is considering a proposed amendment to the Florida Constitution that would authorize the use of recreational marijuana for adults 21 and older. If the Court rules in favor of the initiative, it will appear on the ballot in Florida in November 2024. A proposed amendment requires the approval of 60% of voters to pass.

Licenses and Regulations

Subsection 381.986(8)(a) of the Florida Statutes provides a vertically-integrated regulatory framework that requires each MMTC to cultivate, process, dispense, and deliver their own medical cannabis through directly held facilities, retail storefronts and delivery vehicles. There is no state-imposed limitation on the permitted size, or number, of cultivation, processing, or retail facilities, nor is there a limit on the number of plants that may be grown. Dispensaries may be located in any appropriately zoned location throughout Florida as long as the local government has not prohibited MMTC dispensaries in their respective municipality. Provided there is not a ban, a dispensary may locate in any site that meets the applicable municipal zoning requirements, and such zoning requirements cannot be stricter than the requirements applicable to a pharmacy. Additionally, the location must be at least 500 feet from public or private elementary, middle, and secondary schools pursuant to State law, and some municipalities impose additional distance separation requirements.

Licenses issued by the OMMU are renewed biennially so long as the licensee continues to meet the requirements of the law, submits the renewal application in a timely and complete manner, and pays the renewal fee in full.

Ayr owns and operates an MMTC license which includes a cultivating and processing facility located in Gainesville and 63 active retail storefronts positioned throughout the State.

OMMU regulations apply to all aspects of cannabis seed-to-sale operations including record keeping; employee and principal officer background checks and badging requirements; inventory labeling, quality and tracking; safe and secure storage practices; audio/visual and physical security at licensed facilities; secure product transportation measures; and financial, labor and governance reporting of the licensee and its affiliates. Regulators may conduct announced or unannounced inspections of licensees to assess compliance with applicable laws and regulations.  

The Company is not aware of any specific risks associated with operating in Florida. To the knowledge of management of the Company, there have not been any statements or guidance made by federal authorities or prosecutors regarding the risk of enforcement action specific to the State of Florida. For more information on federal enforcement and the risks associated with the U.S. cannabis regulatory environment generally, see, without limitation, “Risk Factors – Risks Related to Legality of Cannabis”.

Ohio

Ohio Regulatory Landscape

In June 2016, Governor Kasich signed into law House Bill 523 which legalized medical marijuana in Ohio and was later made effective in September 2016 with the establishment of the Ohio Medical Marijuana Control Program (“MMCP”). The MMCP has been amended over the years with the last change in House Bill 33 in 2023 which moved the regulation of dispensaries and oversight of the Patient & Caregiver Registry to the Ohio Department of Commerce effective January 2024. Under current law, regulatory oversight is shared by two State departments: (a) the Ohio Department of Commerce with respect to overseeing and licensing cultivators, processors, dispensaries and testing laboratories; and (b) the State Medical Board of Ohio with respect to the certifying of physicians to recommend medical marijuana and adding to the list of qualifying conditions for which it could be recommended. The MMCP is governed by Chapter 3796 of the Ohio Revised Code and sales of medical marijuana began in January 2019.

Several forms of medical marijuana are legal in Ohio, these include: inhalation of plant material by vaporization (combustion is prohibited), oils, tinctures, edibles, patches, lotions, creams, or ointments for topical administration.  In September 2021, the Board voted to approve sublingual products (including strips, sprays, salves, dissolving tablets, lozenges, and films).

In November 2023, Ohio voters approved Issue 2, the “Marijuana Legalization Initiative,” making Ohio the twenty-fourth State in the United States to legalize the adult-use of marijuana. The initiated statute is found in Ohio Revised Code Chapter 3780 and is subject to amendment by the Ohio General Assembly. Issue 2 went into effect in December 2023. Issue 2 created the Ohio Division of Cannabis Control (“DCC”) with sole regulatory and enforcement jurisdiction over Ohio cannabis license holders, operators, employees, patients and caregivers. The


DCC is charged with publishing and implementing rules and processes for existing licensees to expand into the adult-use market in or around September 2024, and thereafter establish mechanisms by which new licenses will be issued to prospective qualifying candidates.

Licenses and Regulations

The DCC regulates and licenses cultivators, processors, dispensaries, patients & caregivers, and testing laboratories. Cultivators can grow, harvest, package, and transport medical marijuana currently. Dispensaries can currently sell medical marijuana to qualifying patients and caregivers. Processors can currently manufacture medical marijuana products. Cultivator and processor license must be renewed annually at least 30 days prior to the expiration date listed on the Certificate of Operation issued by the State. Dispensary licenses are renewed every two years. The Ohio medical licensing structure permits, but does not require, vertical integration.

Ayr owns and operates an active licensed processor facility; and owns a 49% share with full management services rights to an active licensed Level I cultivation facility. Ayr (through one of its wholly owned subsidiaries) also provides support services to three active dispensaries, but does not hold any ownership or control in those licensed dispensaries.

DCC regulations apply to all aspects of cannabis seed-to-sale operations including record keeping; employee and principal officer background checks and badging requirements; inventory labeling, quality and tracking; safe and secure storage practices; audio/visual and physical security at licensed facilities; secure product transportation measures; and financial, labor and governance reporting of the licensee and its affiliates. Regulators may conduct announced or unannounced inspections of licensees to assess compliance with applicable laws and regulations.  

The Company is not aware of any specific risks associated with operating in Ohio though there are several bills pending in the Ohio General Assembly which if passed could amend the laws either related to the medical marijuana or adult use program. To the knowledge of management of the Company, there have not been any statements or guidance made by federal authorities or prosecutors regarding the risk of enforcement action specific to the State of Ohio. For more information on federal enforcement and the risks associated with the U.S. cannabis regulatory environment generally, see, without limitation, “Risk Factors – Risks Related to Legality of Cannabis”.

New Jersey

New Jersey Regulatory Landscape

In January 2010, Governor Corzine signed into law the “Compassionate Use Medical Marijuana Act” (“CUMMA”), which legalized medical marijuana and allowed qualified patients with debilitating conditions to access medical marijuana products at alternative treatment centers (“ATC”) with a recommendation written by a registered physician.

In September 2013, Governor Christie signed into law amendments to CUMMA which modified the certification process for qualifying patients and expanded the available means of packaging and distributing medical cannabis.

In March 2018, in response to Governor Murphy’s Executive Order No. 6, the New Jersey Department of Health (“NJ DOH”) proposed to expand the medical marijuana program through the adoption of over 20 reform measures. These included the addition of chronic pain and anxiety to the list of debilitating conditions, a reduction of patient registration fees, and authorization for ATCs to apply, permit, and operate up to two additional dispensaries.

In July 2019, Governor Murphy signed the “Jake Honig Compassionate Use Medical Cannabis Act” (“Jake Honig Act”), which reformed the medical program by (1) establishing a new regulatory body that took over responsibility from the NJ DOH, the Cannabis Regulatory Commission (“CRC”), (2) increasing the monthly amount that patients may purchase, (3) authorizing the production and sale of additional edible forms of cannabis, (4) instituting employment protections for registered patients, (5) providing reciprocity for patients registered with other State medical programs, and (6) authorizing home delivery to patients.  

In November 2020, New Jersey voters approved New Jersey Public Question 1, which amended the State’s constitution to legalize the recreational use of cannabis by people ages 21 and older.

In February 2021, Governor Murphy signed into law the “Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act” (“CREAMM”) legalizing personal-use cannabis for adults 21 years and older and authorizing the CRC to design, implement, and promulgate rules and activities for a safe, robust industry, as well as to continue development of the medical program in furtherance of improved patient access.  


In August 2021, the CRC specially adopted the first set of rules and regulations governing the adult use cannabis program. In November 2021, the Executive Director issued guidance to ATCs on the steps and required items to submit applications for expansion into the adult-use market. In April 2022, the first adult-use sales began in the State.

In February 2023, the initial set of rules regulating the adult-use cannabis market were amended and readopted by the CRC. These rules introduced three new classes of licenses to the adult-use program: wholesalers, distributors, and delivery services.

Licenses and Regulations

ATCs are permitted to operate vertically integrated cannabis businesses which allows the licensee to obtain individual permits for the cultivation, manufacture, and retail sale of medical cannabis to registered qualifying patients. ATCs are permitted to operate a maximum of three dispensary facilities. The CRC, which now governs both the medical and personal-use programs, regulates seven kinds of licenses in the personal-use program: cultivator, manufacturer, wholesaler, distributor, retailer, delivery service, and testing laboratory. Qualifying businesses may apply as Social Equity, Diversely-Owned, and Impact Zone applicants. Personal-use businesses may integrate vertically by holding any combination of a cultivator, manufacturer, retailer, and delivery service license simultaneously or hold a wholesale and a distributor license; however, all personal-use license holders can only have one business in each class. The CRC also permits the operation of cultivator, manufacturer, distributor, retailer, or delivery service microbusinesses meeting certain specific criteria regarding number of employees, total canopy size, and amount of cannabis plants and usable cannabis held each month.

Ayr currently holds a license to operate as an Expanded Alternative Treatment Center, inclusive of one adult-use/medical cultivation facility, one adult-use/medical product manufacturing facility, one medical cultivation facility, and three adult-use/medical retail dispensaries in the State of New Jersey.

CRC regulations apply to all aspects of cannabis seed-to-sale operations including record keeping; employee and principal officer background checks and badging requirements; inventory labeling, quality and tracking; safe and secure storage practices; audio/visual and physical security at licensed facilities; product transportation measures; and financial, labor and governance reporting of the licensee and its affiliates. Regulators may conduct announced or unannounced inspections of licensees to assess compliance with applicable laws and regulations.

The Company is not aware of any specific risks associated with operating in New Jersey. To the knowledge of management of the Company, there have not been any statements or guidance made by federal authorities or prosecutors regarding the risk of enforcement action specific to the State of New Jersey. For more information on federal enforcement and the risks associated with the U.S. cannabis regulatory environment generally, see, without limitation, “Risk Factors – Risks Related to Legality of Cannabis”.

Connecticut

Connecticut Regulatory Landscape

In June 2012, Governor Malloy signed into law House Bill 5389, “An Act Concerning the Palliative Use of Marijuana” (“Medical Act”), providing for the use of marijuana in the State by qualified registered patients and to be administered by the Department of Consumer Protection (“DCP”). The DCP adopted formal rules for the medical program in September 2013 with under advisement from the Board of Physicians which reviews petitions to add and remove qualifying conditions.

In May 2016, Governor Malloy signed House Bill 5450 which provided authorization for patients 18 years or younger to qualify for certain types of medical marijuana with written consent by doctors, specialists, and parents or guardians. The bill also expanded the list of debilitating conditions in the Medical Act for which a patient could register.

Signed into law by Governor Lamont in June 2021 and effective as of July 2021, Senate Bill 1201, “Responsible and Equitable Regulation of Adult-Use Cannabis Act” (“Adult Use Act”) legalized cannabis for adults 21 and older, implemented a regulated system of licensed cultivators, manufacturers, retailers, and delivery services, and expunged thousands of past records. The first adult-use sales in the State began in January 2023.

Licenses and Regulations

The Adult Use Act established a limited licensing process for specific license types, including cultivation, micro-cultivation, product manufacturing, food and beverage manufacturing, product packaging, transportation, delivery, and retail. It also established licensing priority and other benefits for Social Equity Applicants, which are defined as businesses that are at least 65% owned and controlled by an individual or individuals who meet certain residency and income requirements. The Adult Use Act created a cannabis cultivation license for Social


Equity Applicants who locate the cultivation facility in one of the designated areas of the State disproportionately affected by cannabis prohibition. This license is known as a Section 149 Cultivator license.

Ayr and its Social Equity partner hold a provisional Section 149 Cultivator license. The Section 149 Cultivator license allows for the creation of two equity joint ventures, which can be in any license type other than cultivation, including but not limited to retail, manufacturing, and delivery. The Section 149 Cultivator license is the only adult-use license type in Connecticut that allows for vertical operations. Ayr and its Social Equity partner hold two provisional retail licenses pursuant to the Section 149 classification. Ayr also holds a provisional delivery service license.

DCP regulations apply to all aspects of cannabis seed-to-sale operations including record keeping; employee and principal officer background checks and badging requirements; inventory labeling, quality and tracking; safe and secure storage practices; audio/visual and physical security at licensed facilities; secure product transportation measures; and financial, labor and governance reporting of the licensee and its affiliates. Regulators may conduct announced or unannounced inspections of licensees to assess compliance with applicable laws and regulations.  

The Company is not aware of any specific risks associated with operating in Connecticut. To the knowledge of management of the Company, there have not been any statements or guidance made by federal authorities or prosecutors regarding the risk of enforcement action specific to the State of Connecticut. For more information on federal enforcement and the risks associated with the U.S. cannabis regulatory environment generally, see without limitation, “Risk Factors – Risks Related to Legality of Cannabis”.

Illinois

Illinois Regulatory Landscape

In August 2013, Governor Quinn signed into law the “Compassionate Use of Medical Cannabis Pilot Program Act” (“Compassionate Use Act”), which went into effect in January 2014 and legalized the use of medical cannabis in Illinois under the joint oversight of the Illinois Department of Financial and Professional Regulation (“IDFPR”) and Illinois Department of Agriculture (“ILDOA”). The Compassionate Use Act took effect as a four-year pilot program in which qualifying patients, caregivers, growers, and vendors could apply for access and licensure to operate.

In August 2018, Governor Rauner signed into law Senate Bill 336, the “Alternatives to Opioids Act,” adding those who might otherwise seek opioids for pain management to the list of those eligible for medical marijuana.

In August 2019, Governor Pritzker signed into law Senate Bill 2023, “An Act Concerning Regulation,” legislation that expanded and made permanent Illinois’ medical cannabis program. The law eliminated the sunset provision to the Compassionate Use Act, adds to the list of more than 50 qualifying medical conditions, and expands the range of medical professionals who can certify eligibility of applicants to the program.

In June 2019, Governor Pritzker signed into law House Bill 1438, the “Cannabis Regulation and Tax Act” (“CRTA”), legalizing the sale, possession, and consumption of adult use of cannabis. Existing cultivation centers were permitted to begin producing cannabis for adult use. Each existing medical dispensary was permitted to sell adult-use cannabis as well, and each existing dispensary received a “plus one” adult use dispensary. Sales of adult-use cannabis began in January 2020. The CRTA also authorized automatic expungements of convictions involving up to 30 grams and established a social equity licensing program whereby qualified business applicants can garner additional points towards their application for new licenses made available by the CRTA and access financial resources for start-up costs.  

Licensing and Regulations

There are five categories of cannabis licenses in Illinois: (i) cultivation center/processing; (ii) dispensary; (iii) craft grower/processing; (iv) infuser; and (v) transporting. Cultivation center/processing and dispensary licenses can be for medical or adult-use cannabis, which must be licensed separately. All dispensaries are licensed by the IDFPR. The remaining categories are licensed by the ILDOA. Licenses are valid for a period of one year and must be renewed annually.

Ayr owns and operates one medical dispensary license and two active adult-use dispensary licenses. Under this license structure, one retail store has both medical and adult-use, and the second retail store is adult-use only.

Ayr also holds provisional licenses for two adult-use dispensaries, both of which are currently in development towards final licensure.


IDFPR regulations apply to all aspects of cannabis seed-to-sale operations including record keeping; employee and principal officer background checks and badging requirements; inventory labeling, quality and tracking; safe and secure storage practices; audio/visual and physical security at licensed facilities; secure product transportation measures; and financial, labor and governance reporting of the licensee and its affiliates. Regulators may conduct announced or unannounced inspections of licensees to assess compliance with applicable laws and regulations.  

The Company is not aware of any specific risks associated with operating in Illinois. To the knowledge of management of the Company, there have not been any statements or guidance made by federal authorities or prosecutors regarding the risk of enforcement action specific to the State of Illinois. For more information on federal enforcement and the risks associated with the U.S. cannabis regulatory environment generally, see without limitation, “Risk Factors – Risks Related to Legality of Cannabis”.

Compliance with State Regulatory Frameworks

Each of the cannabis establishments of the Company possess licenses and operates cannabis facilities in compliance with applicable licensing requirements and the regulatory framework enacted by each State, and maintains the appropriate licenses for the cultivation, manufacture, production, distribution, operation of dispensaries, and/or transport of medical cannabis, as applicable.

None of the cannabis businesses of the Company have experienced any instances of non-compliance which may have an impact on its licenses, business activities or operations which has not been remedied, nor are such businesses subject to any outstanding notices of violation by any State which may have a material impact on such businesses’ licenses, business activities or operations. As noted under “Non-Compliance with State and Local Cannabis Laws” below, Ayr intends to promptly remedy any known occurrences of non-compliance with applicable State and local cannabis rules and regulations and, on behalf of businesses for which it provides operational support, Ayr intends to publicly disclose any non-compliance, citations or notices of violation which may have an impact on its licenses, business activities or operations.

Each of the cannabis businesses use a seed-to-sale-capable control system for tracking and tracing cannabis plants and products. These solutions have been specifically designed to satisfy the applicable reporting requirements associated with regulated cannabis activities. In addition to the software-based control systems, each licensed cannabis establishment has designated a set of operating procedures, including employee training in respect of such procedures, to secure compliance.

Standard operating procedures in respect of regulatory compliance were developed by each licensed cannabis establishment and reviewed with the applicable regulators during each of the establishment’s initial licensing processes and are reviewed on a continuous basis by virtue of ongoing inspections and reviews by the applicable regulatory authorities. Managers and employees at each of the licensed cannabis establishment are empowered to identify key business processes that should be formally documented to seek to assure safety and regulatory compliance.

Each of the licensed cannabis establishments have detailed standard operating procedures in respect of building security, cash management, security of financial instruments, security monitoring systems, security of information, and general security and safety.

Each of the licensed cannabis establishments utilizes a security system around the perimeter of each dispensary designed to prevent and detect diversion, theft or less of marijuana, utilizing commercial grade security and surveillance equipment in compliance with State regulatory requirements.

Additionally, each of the licensed cannabis establishments have detailed standard operating procedures and protocols for inventory and storage processes, including responsibility for management, inventory limits, inventory counts and reviews, facility reporting, cannabis inventory receipts, a waste disposal plan, salvage and solid waste disposal.

Inventory Management Requirements: Each of the licensed cannabis establishments maintains policies and procedures and employs industry-specific software to track inventory and to seek to ensure strict regulatory compliance at both the retail and wholesale levels, as applicable. These processes include, as applicable:

·

wholesale transfer;

·

inventory intake;

·

inventory management;

·

retail transactions; and

·

sales data tracking and reporting.


Procedures exist to ensure each of the applicable licensed cannabis establishments tracks its cumulative inventory of seeds, plants, and usable marijuana. Generally, these inventory control systems are designed to:

·

establish and maintain a perpetual inventory system which adequately documents the flow of materials through the manufacturing process;

·

establish procedures which reconcile the raw material used to the finished product on the basis of each job; and

·

seek to ensure the absence of significant variances between system outputs and physical inventory counts.

For cultivation and production facilities, for each lot received at a facility, such inventory control systems are designed to document:

·

the batch or lot number, as applicable;

·

the strain of the marijuana seeds or marijuana cuttings planted;

·

the number of marijuana seeds or marijuana cuttings planted;

·

the date on which the marijuana seeds or cuttings were planted;

·

a log or schedule of chemical additives used in the cultivation, including nonorganic pesticides, herbicides and fertilizers;

·

the number of marijuana plants grown to maturity;

·

harvest information, including:

o

the date of harvest;

o

the final yield weight of processed usable marijuana; and

o

the name and agent registration card number of the agents responsible for the harvest;

·

marijuana flowers in process in all locations;

·

marijuana in storage by location;

·

marijuana in locked containers awaiting disposal; and

·

an audit trail of all material inventory adjustments.

Retail dispensaries maintain current and complete books and records and sales reports, including invoices that reflect all purchases and sales of marijuana made to and by the applicable dispensary, that are available from electronic verification systems, point of sale systems, and/or inventory control systems (which may be separate systems or functionalities combined into a single system) and are stored in secure safe rooms. Such records include:

·

in respect of dispensary inventory:

o

the date and time of delivery of each purchase or transfer from a cultivation or production facility;

o

the quantity, type and form and price of marijuana and infused or edible products purchased from a cultivation or production facility in each purchase as well as related products;

o

invoices and delivery documents, showing entry into the inventory control system; and

o

the quantity of marijuana still available for sale at the dispensary; and

·

in respect of dispensary retail sales:

o

the date and time of each retail sale;

o

the quantity, type, form, and price of marijuana distributed or dispensed;

o

the price paid or consideration given for the marijuana;

o

identifying information of the purchaser (i.e., name and address, and card number in the case of medical marijuana transactions); and

o

identifying information of the employee conducting the transaction (i.e., the name, initials, or employee identification number of the person who dispensed or sold the marijuana).

All invoices and delivery documents must be systematically filed and maintained for a period of five years from date of delivery and must show a legible and complete statement of terms and conditions for each purchase.

Sales records must be compliant with all of the applicable policies and procedures according to applicable documented plans of the licensed cannabis establishments, State laws and regulations, and must include for regulatory authority reporting and internal tracking purposes:

·

the date and time of each sale;

·

the method of distribution (on-site or delivery);

·

the quantity, form, and price marijuana and any other products dispensed;

·

the consideration given;

·

the name, address, and identification number of the marijuana as recorded on the electronic verification system; and


·

the names, initials, or employee identification numbers of the individuals who packaged, dispensed, delivered, and sold the marijuana.

Disposal of Inventory: All marijuana waste, including waste composed of or containing finished marijuana, must be stored, secured, and managed in accordance with applicable State and local statutes, ordinances, and regulations. All waste disposed by the applicable licensed cannabis establishments is recorded in the relevant inventory control system, including:

·

a description of and reason for the marijuana being disposed of, including, if applicable, the number of failed or other unusable marijuana plants;

·

the date of disposal;

·

confirmation that the marijuana was rendered unusable before disposal;

·

the method of disposal; and

·

the name and card number of the agents responsible for the disposal.

Only specifically authorized employees can destroy product. A list of authorized employees that may destroy product is required to be maintained at each business facility. Permissions are defined by agent and password protected. The destroyed weight and the reason for destruction is required and recorded. The inventory control systems of the licensed cannabis establishments can generate reports on destroyed material at any point in the destruction process.

In addition to controls over inventory, State regulatory frameworks specify guidelines in respect of general security.

General Security Guidelines: The applicable business’ general security guidelines include:

·

background checks for current/new employees, particularly if the employee is to be accessing restricted areas;

·

maintaining video surveillance of facilities;

·

maintaining visitor logs;

·

providing for and maintaining secure perimeters for facilities;

·

requesting employees to watch for suspicious activities;

·

keeping all access system credentials, access codes, access cards, passwords, etc., in a way that is designed to be secure and accessible only to specifically authorized personnel;

·

retrieving keys and employment identification cards from an employee and changing computer access passwords when their employment ends;

·

arranging for prompt and safe disposal of materials;

·

all employees being required to be trained on emergency procedures; and

·

posting emergency response numbers, including fire, law enforcement, and executive team in several locations in each facility.

Cash Management: As noted above, the licensed cannabis establishments have detailed standard operating procedures and protocols for cash management, including internal controls and cash security procedures. Examples of such standard operating procedures and protocols used by certain of the dispensaries of the licensed cannabis establishments to which the Company provides operational support include, without limitation:

·

random review of cash register drawers by dispensary supervisors;

·

random removal of cash from cash register drawers by dispensary supervisors and placement of such cash into a secure vault;

·

insertion of all cash from cash registers drawers into a secure vault at the end of each day;

·

recording of daily cash intake by supervisors on a “Register Close” sheet and daily reconciliation of such values against daily sales reports and the prior day’s recording of total cash on-hand;

·

recording of all disbursements on a disbursement form; and

·

daily audits of total cash on hand and investigations in respect of any noted variances.

The licensed cannabis establishments have worked with internal personnel and advisors to help prescribe and/or implement measures designed to seek to ensure compliance with applicable State laws on an ongoing basis, including:

·

correspondence and updates with regulators;

·

ongoing monitoring of compliance with operating procedures and regulations by on-site management; and

·

appropriate employee training for all standard operating procedures.


The licensed cannabis establishments enlist their internal compliance personnel, whose responsibilities include monitoring the day-to-day activities, ensuring that the established standard operating procedures are being adhered to, identifying any non-compliance matters and putting into place the necessary modifications to seek to ensure compliance.

While the licensed cannabis establishments are compliant with State and local cannabis laws, their cannabis-related activities remain illegal under United States federal law. See “Risk Factors”.

Non-Compliance with State and Local Cannabis Laws

From time to time, as with all businesses and all rules, it is anticipated that the Company, through its subsidiaries and establishments to which the Company provides operational support, may experience incidences of non-compliance with applicable rules and regulations, which may include minor matters such as:

·

staying open slightly too late due to an excess of customers at stated closing time;

·

minor inventory discrepancies with regulatory reporting software;

·

missing fields in regulatory reports;

·

improper illumination of exterior of facilitates;

·

packaging and labels out of compliance with most recent regulatory guidelines; and

·

partial obstruction of camera views.

In addition, either on an inspection basis or in response to complaints, such as from neighbours, customers or former employees, State or local regulators may among other things issue “Notice of Violation” letters. Such regulatory actions could lead to the requirement to submit a corrective action plan, or, in more serious cases, lead to penalties and/or amendments, suspensions or revocations of licenses or otherwise have an impact on Ayr’s licenses, business activities, operational support activities or operations.

Ayr has implemented regular compliance reviews to seek to ensure compliance with applicable State and local cannabis rules and regulations. Ayr intends to promptly remedy any material known occurrences of non-compliance with applicable State and local cannabis rules and regulations and Ayr intends to publicly disclose any material non-compliance, citations or notices of violation which may have an impact on its licenses, business activities, operational support activities or operations.

Except as disclosed below, none of the cannabis businesses of the Company have experienced any instances of non-compliance which may have an impact on its licenses, business activities or operations which has not been remedied, nor are such businesses subject to any outstanding notices of violation by any State which may have a material impact on such businesses’ licenses, business activities or operations.

In late February 2024, a notice of violation was issued to the Company in respect of its Florida operations by the FL DOH. The notice alleges that the Company dispensed approximately 24 thousand units of unapproved seeded flower product, which is not permitted under Florida regulations. The FL DOH proposed a fine of approximately $2.4 million, or $100.00 per unit, and ordered the Company to submit a written corrective action plan. The Company has submitted a written corrective action plan but is exercising its right to a formal administrative hearing with respect to the proposed fine. In addition, the Company is seeking to negotiate a mutually acceptable remedy which would if reached result in the settlement of the formal administrative hearing. If a fine is assessed, the Company would have the right to seek judicial review. There can be no assurances that the Company’s efforts will be successful in whole or in part. In addition, the Company has disciplined responsible staff members and has supplemented its employee educational compliance efforts and enhanced its operating procedures.

As a separate matter, the Company has self-reported to the FL DOH the inadvertent distribution of THC-infused gummies to certain staff members. Again, the Company has disciplined responsible staff members and has supplemented its employee educational compliance efforts and enhanced its operating procedures. It is possible that the FL DOH may seek to assess fines or other penalties in respect of this matter as well.

Ability to Access Public and Private Capital

Ayr has historically had and will continue to have access to equity financing from the public capital markets by virtue of its status as a reporting issuer in each of the provinces and territories of Canada.

Ayr has access to equity and debt financing from the prospectus exempt (private placement) markets in Canada and the U.S. and has relationships with sources of private capital (such as funds and high net worth individuals) that could be investigated at a higher cost of capital.


While Ayr is unable to obtain traditional bank financing in the U.S. or financing from other U.S. federally regulated entities, it currently has access to equity financing through markets in Canada and the U.S. Since the use of marijuana is illegal under U.S. federal law, and in light of concerns in the banking industry regarding money laundering and other federal financial crime related to marijuana, U.S. banks have been reluctant to accept deposit funds from businesses involved with the marijuana industry. Consequently, businesses involved in the marijuana industry often have difficulty finding a bank willing to accept their business. Likewise, marijuana businesses have limited, if any, access to credit card processing services. As a result, marijuana businesses in the U.S. are largely cash-based. This complicates the implementation of financial controls and increases security issues.

Commercial banks, private equity firms and venture capital firms have approached the cannabis industry cautiously to date. However, there are increasing numbers of high net worth individuals and family offices that have made meaningful investments in companies and businesses similar to Ayr’s. Although there has been an increase in the amount of private financing available over the last several years, there is neither a broad nor deep pool of institutional capital that is available to cannabis license holders and license applicants. There can be no assurance that additional financing, if raised privately, will be available to Ayr when needed or on terms which are acceptable to Ayr. Ayr’s inability to raise financing to fund capital expenditures or acquisitions could limit its growth and may have a material adverse effect upon future profitability. See “Risk Factors – Ayr may be subject to restricted access to banking services in the United States and Canada.

RISK FACTORS

The Company is subject to various risks and uncertainties and an investment in securities of the Company should be considered highly speculative. Prior to making an investment decision, investors should consider the investment risks set forth below and those described elsewhere in this AIF, which are in addition to the usual risks associated with an investment in a business at an early stage of development. The Company considers the risks set forth below to be the most significant, but do not consider them to be all the risks associated with an investment in securities of the Company.

The following information is a summary only of certain risk factors and is qualified in its entirety by reference to, and must be read in conjunction with, the detailed information appearing elsewhere in this AIF. Additional risks and uncertainties not presently known to Ayr or currently deemed immaterial by Ayr may also impair the operations of Ayr. If any such risks actually occur, shareholders of Ayr could lose all or part of their investment and the business, financial condition, liquidity, results of operations and prospects of Ayr could be materially adversely affected and the ability of Ayr to implement its growth plans could be adversely affected. Prospective investors should consult with their professional advisors to assess any investment in the Company.

Risks Related to Legality of Cannabis

While legal under applicable U.S. State law, Ayr’s business activities are illegal under U.S. federal law.

Investors are cautioned that in the United States, cannabis is largely regulated at the State level. To Ayr’s knowledge, as of the date hereof, some form of cannabis has been legalized in approximately 39 States, the District of Columbia, and the territories of Guam, U.S. Virgin Islands, Northern Mariana Islands and Puerto Rico. Additional States have pending legislation regarding the same. Although each State in which Ayr will operate authorizes, as applicable, medical and/or adult-use cannabis production and distribution by licensed or registered entities, and numerous other States have legalized cannabis in some form, under U.S. federal law, the possession, use, cultivation, and transfer of non-hemp cannabis and any related drug paraphernalia is illegal, and any such acts are criminal acts under federal law under any and all circumstances under the CSA. The concepts of “medical cannabis”, “retail cannabis” and “adult-use cannabis” do not exist under U.S. federal law. Marijuana is a Schedule I drug under the CSA. Under U.S. federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the U.S., and a lack of safety for the use of the drug under medical supervision. Although Ayr believes its businesses are compliant with applicable U.S. State and local law, strict compliance with State and local laws with respect to cannabis may not absolve Ayr of liability under U.S. federal law, nor may it provide a defense to any federal proceeding which may be brought against Ayr. Any such proceedings brought against the Ayr may result in a material adverse effect on Ayr.

Since the possession and use of non-hemp cannabis and any related drug paraphernalia is illegal under U.S. federal law, Ayr may be deemed to be aiding and abetting illegal activities. The Company’s businesses manufacture and/or distribute medical and adult-use cannabis. As a result, U.S. law enforcement authorities, in their attempt to regulate the illegal use of cannabis and any related drug paraphernalia, may seek to bring an action or actions against Ayr, including, but not limited to, a claim regarding the possession, use and sale of cannabis, and/or aiding and abetting another’s criminal activities. The U.S. federal aiding and abetting statute provides that anyone who “commits an offense or aids, abets, counsels, commands, induces or procures its commission, is punishable as a principal.” As a result, the U.S. DOJ, under the current administration, could allege that Ayr has “aided and abetted” violations of federal law by providing financing and services to the Company. Under these circumstances, the federal prosecutor could seek to seize the assets of Ayr, and to recover the “illicit profits” previously distributed to shareholders resulting from any of the foregoing. In these circumstances, Ayr’s operations would cease,


shareholders may lose their entire investment and directors, officers and/or shareholders may be left to defend any criminal charges against them at their own expense and, if convicted, be sent to federal prison. Such an action would result in a material adverse effect on Ayr.

U.S. Customs and Border Protection (“CBP”) enforces the laws of the United States. Crossing the border while in violation of the CSA and other related federal laws may result in denied admission, seizures, fines and apprehension. CBP officers administer the Immigration and Nationality Act to determine the admissibility of travelers, who are non-U.S. citizens, into the United States. An investment in Ayr, if it became known to CBP, could have an impact on a shareholder’s admissibility into the United States and could lead to a lifetime ban on admission. See “Risk Factors – U.S. border officials could deny entry of non-U.S. citizens into the U.S. to employees of or investors in companies with cannabis operations in the United States and Canada”.

The Company derives 100% of their revenues from the cannabis industry in certain States, which industry is illegal under U.S. federal law. Even where the Company’s cannabis-related activities are compliant with applicable State and local law, such activities remain illegal under U.S. federal law.

The enforcement of relevant laws is a significant risk.

Medical cannabis has been protected against enforcement by enacted legislation from the United States Congress in the form of what is commonly called the “Rohrabacher-Blumenauer Amendment”, which prevents federal prosecutors from using federal funds to impede the implementation of medical cannabis laws enacted at the State-level, subject to the United States Congress restoring such funding. Notably, this amendment has always applied to only medical cannabis programs, and has no effect on pursuit of recreational cannabis activities. The amendment has historically been passed as an amendment to omnibus appropriations bills, which by their nature expire at the end of a fiscal year or other defined term. Subsequent to the issuance of the Sessions Memorandum by then Attorney General Sessions on January 4, 2018, the United States Congress passed its omnibus appropriations bill, SJ 1662, which for the fourth consecutive year contained the Rohrabacher-Blumenauer Amendment language (referred to in 2018 as the Leahy Amendment) and continued the protections for the medical cannabis marketplace and its lawful participants from interference by the U.S. DOJ up and through the 2018 appropriations deadline of September 30, 2018.

The deadline passed, but the Rohrbacher-Leahy Amendment remained in effect by virtue of a continuing resolution under which the entire 2018 budget continued to operate. Following the expiration of the continuing resolution on December 7, 2018, the United States Congress failed to agree upon an appropriations bill, and the United States government entered a partial shutdown. The Rohrabacher-Leahy Amendment was no longer in effect during the partial shutdown. The partial shutdown ended on January 25, 2019 when the United States Congress passed an appropriations bill funding the United States government through February 15, 2019. This temporary appropriations bill included language similar to the Rohrabacher Leahy Amendment (now referred to as the “Joyce/Leahy Amendment”). On February 15, 2019, the amendment was renewed through the signing of the Fiscal Year 2019 omnibus spending bill, effective through September 30, 2019. On September 27, 2019, the amendment was renewed through a stopgap spending bill, and it was renewed again on November 21, 2019. On December 20, 2019, the amendment was renewed by the signing of the Fiscal Year 2020 omnibus spending bill, effective through September 30, 2020. That legislation also contained a provision continuing to block Washington, D.C. from using its own local tax dollars to implement a legal marijuana sales program.

In July 2020, the House of Representatives passed the “Blumenauer-McClintock-Norton-Lee amendment,” to the Commerce, Justice, Science (CJS) Appropriations bill. That amendment was included in a series of stopgap spending bills from September 2020 through the end of December 2020. On December 27, 2020, the amendment was renewed through the signing of the Fiscal Year 2021 spending bill, which was effective through September 30, 2021. Following the expiration of the Fiscal Year 2021 bill, President Biden has renewed the amendment through a series of stopgap spending bills, with the most recent extension effective through March 11, 2022. On March 10, 2022, the Fiscal Year 2022 omnibus appropriations bill including the amendment was signed into law by President Biden.

Should the Joyce/Leahy amendments language not be included in future appropriations packages, there can be no assurance that the federal government will not seek to prosecute cases involving medical cannabis businesses that are otherwise compliant with State law.

Such potential proceedings could involve significant restrictions being imposed upon Ayr or third parties, while diverting the attention of key executives. Such proceedings could have a material adverse effect on Ayr, even if such proceedings were concluded successfully in favor of Ayr.

Violations of any federal laws and regulations could result in significant fines, penalties, administrative sanctions, convictions or settlements arising from civil proceedings conducted by either the federal government or private citizens, or criminal charges, including, but not limited to, disgorgement of profits, cessation of business activities or divestiture. This could have a material adverse effect on Ayr, including its reputation and ability to conduct business, its holding (directly or indirectly) of medical and adult-use cannabis licenses in the United States, its financial position, operating results, profitability or liquidity or the market price of its publicly-traded shares. In addition, it will be difficult


for Ayr to estimate the time or resources that would be needed for the investigation of any such matters or its final resolution because, in part, the time and resources that may be needed are dependent on the nature and extent of any information requested by the applicable authorities involved, and such time or resources could be substantial.

The approach to the enforcement of cannabis laws may be subject to change or may not proceed as previously outlined.

As a result of the conflicting views between State legislatures and the federal government regarding cannabis, investments in cannabis businesses in the U.S. are subject to inconsistent legislation and regulation. The response to this inconsistency was addressed in the Cole Memorandum addressed to all United States district attorneys acknowledging that notwithstanding the designation of cannabis as a controlled substance at the federal level in the United States, several States have enacted laws relating to cannabis for medical purposes.

The Cole Memorandum outlined certain priorities for the U.S. DOJ relating to the prosecution of cannabis offenses. In particular, the Cole Memorandum noted that in jurisdictions that have enacted laws legalizing cannabis in some form and that have also implemented strong and effective regulatory and enforcement systems to control the cultivation, distribution, sale and possession of cannabis, conduct in compliance with those laws and regulations is less likely to be a priority at the federal level. Notably, however, the U.S. DOJ has never provided specific guidelines for what regulatory and enforcement systems it deems sufficient under the Cole Memorandum standard.

In light of limited investigative and prosecutorial resources, the Cole Memorandum concluded that the U.S. DOJ should be focused on addressing only the most significant threats related to cannabis. States where medical cannabis had been legalized were not characterized as a high priority. In March 2017, then newly appointed Attorney General Jeff Sessions again noted limited federal resources and acknowledged that much of the Cole Memorandum had merit; however, he had previously stated that he did not believe it had been implemented effectively and, on January 4, 2018, Sessions issued the Sessions Memorandum, which rescinded the Cole Memorandum. The Sessions Memorandum rescinded previous nationwide guidance specific to the prosecutorial authority of United States Attorneys relative to cannabis enforcement on the basis that they are unnecessary, given the well-established principles governing federal prosecution that are already in place. Those principles are included in chapter 9.27.000 of the USAM and require federal prosecutors deciding which cases to prosecute to weigh all relevant considerations, including federal law enforcement priorities set by the Attorney General, the seriousness of the crime, the deterrent effect of criminal prosecution, and the cumulative impact of particular crimes on the community.

As a result of the Sessions Memorandum, federal prosecutors are now free to utilize their prosecutorial discretion to decide whether to prosecute cannabis activities despite the existence of State-level laws that may be inconsistent with federal prohibitions. No direction was given to federal prosecutors in the Sessions Memorandum as to the priority they should ascribe to such cannabis activities, and resultantly it is uncertain how active U.S. federal prosecutors will be in relation to such activities.

As discussed above, should the Joyce/Leahy amendment not be renewed, there can be no assurance that the federal government will not seek to prosecute cases involving medical cannabis businesses that are otherwise compliant with State law.

The Sessions Memorandum did not discuss the treatment of medical cannabis by federal prosecutors. While dozens of U.S. attorneys from across the country have affirmed that their view of federal enforcement priorities has not changed, there can be no assurances that such views are universally held or will continue in the near future. In California, at least one U.S. Attorney has made comments indicating a desire to enforce the CSA, stating that the Sessions Memorandum and the rescission of the Cole Memorandum “returns trust and local control to federal prosecutors” to enforce the CSA. These and other so called “enforcement hawks” in California or elsewhere may choose to enforce the CSA in accordance with federal policies prior to the issuance of the Cole Memorandum. As such, there can be no assurance that the federal government will not seek to prosecute cases involving cannabis businesses that are otherwise compliant with State law.

On November 7, 2018, Mr. Sessions tendered his resignation as Attorney General at the request of President Donald Trump. Following Mr. Sessions’ resignation, Matthew Whitaker began serving as Acting United States Attorney General, and William Barr was eventually appointed to the role. Mr. Barr was a former Attorney General under George H.W. Bush, with an anti-drug stance during his tenure. During his Senate confirmation hearing, Mr. Barr stated that he disagrees with efforts by States to legalize marijuana, but will not go after marijuana companies in states that legalized it under Obama administration policies. He stated further that he would not upset settled expectations that have arisen as a result of the Cole Memorandum. In June 2020, a federal prosecutor accused Mr. Barr of ordering “politically motivated” antitrust reviews of 10 marijuana business mergers, allegedly because he personally did not support their underlying business in the marijuana industry. At least one of those investigations allegedly resulted in the collapse of a proposed merger between two large cannabis businesses.

On January 20, 2021, Joseph R. Biden was inaugurated as President of the United States. During the campaign, President Biden expressed support for nationwide decriminalization of cannabis, but has not yet supported full legalization for medial or recreational use. President Biden appointed former District of Columbia Court of Appeals Judge Merrick Garland to serve as Attorney General, and his nomination was confirmed by the Senate on March 10, 2021. During his confirmation hearing, in response to a question from Senator Cory Booker,


Garland did not confirm whether he would reinstate the Cole Memorandum, but indicated that enforcement of federal cannabis laws “does not seem to me a useful use of limited resources.”

Going forward, there can be no assurance as to the position the new administration or any future administration, U.S. DOJ, FBI, or other governmental agency may take on marijuana. A new administration could decide to enforce the federal laws strongly. Any enforcement of current federal laws could cause significant financial damage to the Company and its shareholders. Further, future presidential administrations may want to treat marijuana differently and potentially enforce the federal laws more aggressively. Ayr regularly monitors the activities of the current administration in this regard.

Any potential proceedings to enforce federal cannabis laws could involve significant restrictions being imposed upon Ayr or third parties, while diverting the attention of key executives. Such proceedings could have a material adverse effect on Ayr, as well as Ayr’s reputation, even if such proceedings were concluded successfully in favor of Ayr. In the extreme case, such proceedings could ultimately involve the prosecution of key executives of Ayr or the seizure of corporate assets; however as of the date hereof, Ayr believes that proceedings of this nature are remote.

Ayr may be subject to restricted access to banking services in the United States and Canada.

In February 2014, FinCEN issued guidance through the FinCEN Memorandum (which is not law) with respect to financial institutions providing banking services to cannabis businesses. This guidance includes burdensome due diligence expectations and reporting requirements and does not provide any safe harbors or legal defenses from examination or regulatory or criminal enforcement actions by the U.S. DOJ, FinCEN or other federal regulators. Thus, many banks and other financial institutions in the United States choose not to provide banking services to cannabis-related businesses or rely on this guidance, which can be amended or revoked at any time by the sitting presidential administration and/or agency head. In addition to the foregoing, banks may refuse to process debit card payments, and credit card companies generally refuse to process credit card payments for cannabis-related businesses. This has led cannabis businesses to rely on cash transactions with consumers and restricts access to other financial services such as insurance products or financing.  Lack of access to financial services increases the cost of doing business.  Reliance on large amounts of cash transactions at dispensaries also presents an increased risk of crime such as robbery or burglary.  While alternative solutions such as cashless ATMs have emerged to allow cashless transactions at dispensaries, some have noted that they are not popular with consumers.  In general, Ayr may have limited or no access to banking or other financial services in the United States. The inability, or limitation of Ayr’s ability, to open and maintain bank accounts, obtain other banking services and/or accept credit card and debit card payments may make it difficult for Ayr to operate and conduct its business as planned or to operate efficiently. Ayr does not consider this to be a risk at the current time in Nevada.

The United States Congress has on several occasions considered legislation titled the Secure and Fair Enforcement Banking Act (the "Safe Banking Act"). That legislation would preclude federal regulators from punishing financial services providers for doing business with state-legal cannabis businesses.  It would also establish that funds obtained from otherwise state-regulated and compliant businesses are not proceeds of illegal activity, and provide other protections for banks, insurers, and other financial institutions serving state-legal cannabis businesses.  Critics of the legislation argue that financial institutions are already banking cannabis businesses, and passage would merely formalize existing relationships without assuaging the concerns of traditional financial institutions or alleviating existing problems.  The United States House of Representatives has passed the SAFE Banking Act on several occasions, most recently in 2022.  However, the United States Senate has not yet allowed the SAFE Banking Act to proceed to the Senate floor for a vote. While it is expected that the SAFE Banking Act will be introduced again in 2024, its prospects for passage remains unclear. Moreover, the impact of the legislation if passed is also unclear.

Additionally, Canadian banks may potentially refuse to provide banking services to companies engaged in U.S. cannabis activities while it is illegal under U.S. federal law.

While there are increasing numbers of high net worth individuals and family offices that have made meaningful investments in companies and businesses similar to the Company, and although there has been an increase in the amount of private financing available over the last several years, there is neither a broad nor deep pool of institutional capital that is available to cannabis license holders and license applicants. There can be no assurance that additional financing, if raised privately, will be available to Ayr when needed or on terms which are acceptable to Ayr. Ayr’s inability to raise financing to fund capital expenditures or acquisitions could limit its growth and may have a material adverse effect upon future profitability.

The differing regulatory requirements across State jurisdictions may hinder or otherwise prevent Ayr from achieving economies of scale.

Traditional rules of investing may prove to be imperfect in the cannabis industry. For example, while it would be common for investment managers to purchase equity in companies in different States to reach economies of scale and to conduct business across State lines, such an investment thesis may not be feasible in the cannabis industry because of varying State-by-State legislation. Applicable regulations in many


States may require advance disclosure of and approval of State regulators to accomplish an investment. As no two regulated markets in the cannabis industry are exactly the same, doing business across State lines may not be possible or commercially practicable. As a result, Ayr may be limited to identifying opportunities in individual States, which may have the effect of slowing the growth prospects of Ayr.

Risk of legal, regulatory or other political change.

The success of the business strategy of Ayr depends on the legality of the cannabis industry. The political environment surrounding the cannabis industry in general can be volatile and the regulatory framework remains in flux. To Ayr’s knowledge, as of the date hereof, some form of cannabis has been legalized in approximately 39 States, the District of Columbia, and the territories of Guam, U.S. Virgin Islands, Northern Mariana Islands and Puerto Rico; however, the risk remains that a shift in the regulatory or political realm could occur and have a drastic impact on the industry as a whole, adversely impacting Ayr’s business, results of operations, financial condition or prospects.

Delays in enactment of new State or federal regulations could restrict the ability of Ayr to reach strategic growth targets. The growth strategy of Ayr is contingent upon certain federal and State regulations being enacted to facilitate the legalization of medical and adult-use marijuana. If such regulations are not enacted, or enacted but subsequently repealed or amended, or enacted with prolonged phase-in periods, the growth targets of Ayr could be negatively impacted, and thus, the effect on the return of investor capital, could be detrimental.

Ayr is unable to predict with certainty when and how the outcome of these complex regulatory and legislative proceedings will affect its business and growth.

Further, there is no guarantee that State laws legalizing and regulating the sale and use of cannabis will not be repealed or overturned, or that local governmental authorities will not limit the applicability of State laws within their respective jurisdictions, including prohibiting ownership of cannabis businesses by public companies. If the federal government begins to enforce federal laws relating to cannabis in States where the sale and use of cannabis is currently legal under State law, or if existing applicable State laws are repealed or curtailed, Ayr’s business, results of operations, financial condition and prospects would be materially adversely affected. It is also important to note that local and city ordinances may strictly limit and/or restrict disbursement of marijuana in a manner that will make it extremely difficult or impossible to transact business in that jurisdiction, which may adversely affect Ayr’s continued operations. Federal actions against individuals or entities engaged in the cannabis industry or a repeal of applicable marijuana legislation could adversely affect Ayr and its business, results of operations, financial condition and prospects.

Ayr is also aware that multiple States are considering special taxes or fees on businesses in the cannabis industry. It is a potential yet unknown risk at this time that other States are in the process of reviewing such additional fees and taxation. Should such special taxes or fees be adopted, this could have a material adverse effect upon Ayr’s business, results of operations, financial condition or prospects.

Overall, the medical and adult-use cannabis industry is subject to significant regulatory change at both the State and federal level. For instance, in Massachusetts, the State’s Department of Public Health recently transferred the medical cannabis program, which it has been regulating since 2013, to the Cannabis Control Commission (the current regulator of the State’s adult-use cannabis program). The inability of Ayr to respond to the changing regulatory landscape may cause it to not be successful in capturing significant market share and could otherwise harm its business, results of operations, financial condition or prospects.

The cannabis industry is a new industry that may not succeed.

Should the U.S. federal government change course and decide to prosecute those dealing in medical or adult-use cannabis under applicable law, there may not be any market for Ayr’s products and services. It is a new industry subject to extensive regulation, and there can be no assurance that it will grow, flourish or continue to the extent necessary to permit Ayr to succeed. Ayr is treating the cannabis industry as a deregulating industry with significant unsatisfied demand for its proposed products and will adjust its future operations, product mix and market strategy as the industry develops and matures.

Ayr’s operations in the U.S. cannabis market may become the subject of heightened scrutiny.

For the reasons set forth above, Ayr’s existing operations in the U.S., and any future operations or investments, may become the subject of heightened scrutiny by regulators, stock exchanges and other authorities in Canada and the U.S. As a result, Ayr may be subject to significant direct and indirect interaction with public officials. There can be no assurance that this heightened scrutiny will not in turn lead to the imposition of certain restrictions on Ayr’s ability to operate or invest in the U.S. or any other jurisdiction, in addition to those described herein.

Given the heightened risk profile associated with cannabis in the U.S., CDS Clearing and Depository Services Inc. (“CDS”) may implement procedures or protocols that would prohibit or significantly curtail the ability of CDS to settle trades for cannabis companies that have


cannabis businesses or assets in the U.S. On February 8, 2018, following discussions with the Canadian Securities Administrators and recognized Canadian securities exchanges, the TMX Group announced the signing of a Memorandum of Understanding (“TMX MOU”) with the Neo Exchange Inc., the CSE, the Toronto Stock Exchange, and the TSX Venture Exchange. The TMX MOU outlines the parties’ understanding of Canada’s regulatory framework applicable to the rules, procedures, and regulatory oversight of the exchanges and CDS as it relates to issuers with cannabis-related activities in the U.S. The TMX MOU confirms, with respect to the clearing of listed securities, that CDS relies on the exchanges to review the conduct of listed issuers. As a result, there is no CDS ban on the clearing of securities of issuers with cannabis-related activities in the U.S. However, there can be no guarantee that this approach to regulation will continue in the future. If such a ban were to be implemented, it would have a material adverse effect on the ability of holders of Equity Shares to make and settle trades. In particular, Equity Shares would become highly illiquid as until an alternative was implemented, investors would have no ability to effect a trade of Equity Shares through the facilities of a stock exchange.

In light of the political and regulatory uncertainty surrounding the treatment of U.S. cannabis-related activities, including the rescission of the Cole Memorandum discussed above, on February 8, 2018, the Canadian Securities Administrators revised their previously released Staff Notice - 51-352 Issuers with U.S. Marijuana-Related Activities setting out their disclosure expectations for specific risks facing issuers with cannabis-related activities in the U.S. The Staff Notice confirms that a disclosure-based approach remains appropriate for issuers with U.S. cannabis-related activities. The Staff Notice includes additional disclosure expectations that apply to all issuers with U.S. cannabis-related activities, including those with direct and indirect involvement in the cultivation and distribution of cannabis, as well as issuers that provide goods and services to third parties involved in the U.S. cannabis industry. Ayr views the Staff Notice favorably, as it provides increased transparency and greater certainty regarding the views of its exchange and its regulator of existing operations and strategic business plan as well as Ayr’s ability to pursue further investment and opportunities in Ayr.

Government policy changes or public opinion may also result in a significant influence over the regulation of the cannabis industry in Canada, the U.S. or elsewhere. A negative shift in the public’s perception of medical and/or adult-use cannabis in the U.S. or any other applicable jurisdiction could affect future legislation or regulation. Among other things, such a shift could cause State jurisdictions to abandon initiatives or proposals to legalize medical and/or adult-use cannabis, thereby limiting the number of new State jurisdictions into which Ayr could expand. Any inability to fully implement Ayr’s expansion strategy may result in a material adverse effect on Ayr’s business, financial condition, results of operations or prospects.

Regulatory scrutiny of Ayr’s industry may negatively impact its ability to raise additional capital.

Ayr’s business activities rely on newly established and/or developing laws and regulations in the various States in which Ayr operates. These laws and regulations are rapidly evolving and subject to change with minimal notice. Regulatory changes may adversely affect Ayr’s profitability or cause it to cease operations entirely. The cannabis industry may come under the scrutiny or further scrutiny by the FDA, Securities and Exchange Commission, the U.S. DOJ, the Financial Industry Regulatory Advisory or other federal, State or non- governmental regulatory authorities or self-regulatory organizations that supervise or regulate the production, distribution, sale or use of cannabis for medical and/or adult-use purposes in the U.S. It is impossible to determine the extent of the impact of any new laws, regulations or initiatives that may be proposed, or whether any proposals will become law. The regulatory uncertainty surrounding Ayr’s industry may adversely affect the business and operations of Ayr, including without limitation, the costs to remain compliant with applicable laws and the impairment of its ability to raise additional capital, create a public trading market in the U.S. for securities of Ayr or to find a suitable acquirer, which could reduce, delay or eliminate any return on investment in Ayr.


Ayr’s investments in the U.S. are subject to applicable anti-money laundering laws and regulations.

Because the manufacture, distribution, and dispensation of cannabis remains illegal under the CSA, banks and other financial institutions providing services to cannabis-related businesses risk violation of federal anti-money laundering statutes (18 U.S.C. §§ 1956 and 1957), the unlicensed money-remitter statute (18 U.S.C. § 1960) and the U.S. Bank Secrecy Act, as amended by Title III of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT Act), the Proceeds of Crime (Money Laundering) and Terrorist Financing Act (Canada), as amended and the rules and regulations thereunder, the Criminal Code (Canada) and other related or similar rules, regulations or guidelines, issued, administered or enforced by governmental authorities in the United States and Canada. These statutes can impose criminal liability for engaging in certain financial and monetary transactions with the proceeds of a “specified unlawful activity” such as distributing controlled substances which are illegal under U.S. federal law, including cannabis, and for failing to identify or report financial transactions that involve the proceeds of cannabis-related violations of the CSA. As a result, a majority of the United States’ banks and financial institutions have refused to open bank accounts for the deposit of funds from businesses involved with the cannabis industry. Others have agreed to accept deposits from medical cannabis sales, but not recreational cannabis sales. The inability to open bank accounts with certain institutions could materially and adversely affect the business of Ayr. See “Risk Factors - Ayr may be subject to restricted access to banking in the United States and Canada”.

In February 2014, the U.S. Department of the Treasury’s Financial Crimes Enforcement Network issued the FinCEN Memorandum providing instructions to banks seeking to provide services to cannabis-related businesses. The FinCEN Memorandum states that in some circumstances, it is permissible for banks to provide services to cannabis-related businesses without risking prosecution for violation of federal money laundering laws. It refers to supplementary guidance that Deputy Attorney General Cole issued to federal prosecutors in the 2014 Cole Memorandum relating to the prosecution of money laundering offenses predicated on cannabis-related violations of the CSA. It is unclear at this time whether the current administration will follow the guidelines of the FinCEN Memorandum.

In the event that any of Ayr’s operations, or any proceeds thereof, any dividends or distributions therefrom, or any profits or revenues accruing from such operations in the U.S. were found to be in violation of money laundering legislation or otherwise, such transactions may be viewed as proceeds of crime under one or more of the statutes noted above or any other applicable legislation. This could restrict or otherwise jeopardize the ability of Ayr to declare or pay dividends, effect other distributions or subsequently repatriate such funds back to Canada. Furthermore, while Ayr has no current intention to declare or pay dividends on the Equity Shares in the foreseeable future, in the event that a determination was made that Ayr’s proceeds from operations (or any future operations or investments in the U.S.) could reasonably be shown to constitute proceeds of crime, Ayr may decide or be required to suspend declaring or paying dividends without advance notice and for an indefinite period of time.

Any re-classification of cannabis or changes in U.S. controlled substance laws and regulations may affect Ayr’s business.

If cannabis and/or CBD is re-categorized as a Schedule II or lower controlled substance, the ability to conduct research on the medical benefits of cannabis would most likely be simpler and more accessible; however, if cannabis is re-categorized as a Schedule II or other controlled substance, the resulting re-classification would result in the requirement for FDA approval if medical claims are made for Ayr’s products such as medical cannabis. As a result, the manufacture, importation, exportation, domestic distribution, storage, sale and use of such products may be subject to a significant degree of regulation by the DEA. In that case, Ayr may be required to be registered (licensed) to perform these activities and have the security, control, recordkeeping, reporting and inventory mechanisms required by the DEA to prevent drug loss and diversion. Obtaining the necessary registrations may result in delay of the manufacturing or distribution of Ayr’s anticipated products. The DEA conducts periodic inspections of certain registered establishments that handle controlled substances. Failure to maintain compliance could have a material adverse effect on Ayr’s business, financial condition and results of operations. The DEA may seek civil penalties, refuse to renew necessary registrations, or initiate proceedings to restrict, suspend or revoke those registrations. In certain circumstances, violations could lead to criminal proceedings.

The availability of favorable locations may be severely restricted.

In Massachusetts and other States, the local municipality has authority to choose where any cannabis establishment will be located. These authorized areas are frequently removed from other retail operations.

Because the cannabis industry remains illegal under U.S. federal law, the disadvantaged tax status of businesses deriving their income from cannabis, and the reluctance of the banking industry to support cannabis businesses, it may be difficult for Ayr to locate and obtain the rights to operate at various preferred locations. Property owners may violate their mortgages by leasing to Ayr, and those property owners that are willing to allow use of their facilities may require payment of above fair market value rents to reflect the scarcity of such locations and the risks and costs of providing such facilities.


U.S. border officials could deny entry of non-U.S. citizens into the U.S. to employees of or investors in companies with cannabis operations in the United States and Canada.

Because cannabis remains illegal under U.S. federal law, those employed at or investing in legal and licensed Canadian cannabis companies could face detention, denial of entry or lifetime bans from the U.S. for their business associations with U.S. cannabis businesses. Entry happens at the sole discretion of CBP officers on duty, and these officers have wide latitude to ask questions to determine the admissibility of a non-U.S. citizen or foreign national. The government of Canada has started warning travelers on its website that previous use of cannabis, or any substance prohibited by U.S. federal laws, could mean denial of entry to the U.S. Business or financial involvement in the legal cannabis industry in Canada or in the United States could also be reason enough for U.S. border guards to deny entry. On September 21, 2018, CBP released a statement outlining its current position with respect to enforcement of the laws of the United States. It stated that Canada’s legalization of cannabis will not change CBP enforcement of United States laws regarding controlled substances and because cannabis continues to be a controlled substance under United States law, working in or facilitating the proliferation of the legal marijuana industry in U.S. States where it is deemed legal or Canada may affect admissibility to the U.S. As a result, CBP has affirmed that, employees, directors, officers, managers and investors of companies involved in business activities related to cannabis in the U.S. or Canada (such as Ayr), who are not U.S. citizens face the risk of being barred from entry into the United States for life. On October 9, 2018, CBP released an additional statement regarding the admissibility of Canadian citizens working in the legal cannabis industry. CBP stated that a Canadian citizen working in or facilitating the proliferation of the legal cannabis industry in Canada coming into the U.S. for reasons unrelated to the cannabis industry will generally be admissible to the U.S.; however, if such person is found to be coming into the U.S. for reasons related to the cannabis industry, such person may be deemed inadmissible and/or banned from entry for life.

Business Structure Risks

Ayr’s multi-class structure will have the effect of concentrating voting control and the ability to influence corporate matters with the Founders.

The Multiple Voting Shares have 25 votes per share, whereas the Equity Shares have one vote per share except that the Limited Voting Shares have no rights to vote for the election of directors. As of December 31, 2023, Mercer holds 3,677,626 Multiple Voting Shares and approximately 62.0% of the voting power of the outstanding voting shares of Ayr (which omits Exchangeable Shares and includes Limited Voting Shares) and a higher percentage in respect of the election of directors and would therefore have significant influence over the management and affairs of Ayr and over all matters requiring shareholder approval, including the election of directors and significant corporate transactions. In addition, because of the 25-to-1 voting ratio between the Multiple Voting Shares and Equity Shares, the holders of Multiple Voting Shares will control a majority of the combined voting power of Ayr’s voting shares even though the Multiple Voting Shares will represent a substantially reduced percentage of the total outstanding shares of Ayr. The concentrated voting control of the holders of Multiple Voting Shares will limit the ability of the holders of Equity Shares to influence corporate matters for the foreseeable future, including the election of directors (other than in respect of the Limited Voting Shares, which do not have any entitlement to vote in respect of the election of directors) as well as with respect to Ayr’s decisions to amend its share capital, create and issue additional classes of shares, make significant acquisitions, sell significant assets or parts of its business, merge with other companies and/or undertake other significant transactions. As a result, holders of Multiple Voting Shares will have the ability to influence or control many matters affecting Ayr and actions may be taken that the holders of Equity Shares may not view as beneficial. The market price of the Equity Shares could be adversely affected due to the significant influence and voting power of the holders of Multiple Voting Shares. Additionally, the significant voting interest of the holders of Multiple Voting Shares could discourage transactions involving a change of control, including transactions in which an investor, as a holder of the Equity Shares, might otherwise receive a premium for the Equity Shares over the then-current market price, or discourage competing proposals if a going private transaction is proposed by one or more holders of Multiple Voting Shares.

At the holder’s option, the Multiple Voting Shares will be convertible, on a one-for-one basis, into Equity Shares. In addition, the Multiple Voting Shares will be automatically converted, without further act or formality, into Equity Shares on the earliest of (i) the fifth (5th) anniversary of May 24, 2019, (ii) the date on which such Multiple Voting Shares are held or controlled by a person who is not a Permitted Holder (as defined in the Company’s articles) under the Company’s articles, and (iii) the date on which the aggregate number of Multiple Voting Shares issued and outstanding represents less than one-third of the number of Multiple Voting Shares issued and outstanding at the close of business on the first date of issuance, being May 24, 2019.


Loss of Foreign Private Issuer status.

The Company is a “foreign private issuer” (“FPI”) as defined in Rule 405 under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), and Rule 3b-4 under the U.S. Securities Exchange Act of 1934, as amended (the “U.S. Exchange Act”). If, as of the last business day of the Company’s second fiscal quarter for any year, more than 50% of the Company’s outstanding voting securities (as determined under Rule 405 of the U.S. Securities Act) are directly or indirectly held of record by residents of the United States, the Company will no longer meet the definition of an FPI, which may have adverse consequences on the Company’s ability to raise capital in private placements or Canadian prospectus offerings. In addition, the loss of the Company’s FPI status may result in increased reporting requirements and increased audit, legal and administration costs. These increased costs may significantly affect the Company’s business, financial condition and results of operations.

The term “foreign private issuer” is defined as any non-U.S. corporation, other than a foreign government, except any issuer meeting the following conditions:

(a)

more than 50% of the outstanding voting securities of such issuer are, directly or indirectly, held of record by residents of the United States; and

(b)

any one of the following:

(i)

the majority of the executive officers or directors are United States citizens or residents, or

(ii)

more than 50% of the assets of the issuer are located in the United States, or

(iii)

the business of the issuer is administered principally in the United States.

A “holder of record” is defined by Rule 12g5-1 under the U.S. Exchange Act. Generally speaking, the holder identified on the record of security holders is considered as the record holder. In December 2016, the United States Securities and Exchange Commission (the “SEC”) issued a Compliance and Disclosure Interpretation to clarify that issuers with multiple classes of voting stock carrying different voting rights may, for the purposes of calculating compliance with this threshold, examine either (i) the combined voting power of its share classes, or (ii) the number of voting securities, in each case held of record by U.S. residents. Based on this interpretation, each issued and outstanding Multiple Voting Share is counted as one voting security and each issued and outstanding Subordinate Voting Share and Restricted Voting Share is counted as one voting security for the purposes of determining the 50% U.S. resident threshold, and the Company is a “foreign private issuer”. The Limited Voting Shares are not counted as “voting securities” under the definition of “foreign private issuer” as they do not have any entitlement to vote for the election of directors of the Company. Should the SEC’s guidance and interpretation change, the Company may lose its FPI status.

The Company’s Status as an “Emerging Growth Company” under United States securities laws.

The Company is an “emerging growth company” as defined in section 3(a) of the U.S. Exchange Act (as amended by the Jumpstart Our Business Startups Act (the “JOBS Act”), enacted on April 5, 2012), and the Company will continue to qualify as an emerging growth company until the earliest to occur of: (i) the last day of the fiscal year during which the Company has total annual gross revenues of $1.235 billion (as such amount is indexed for inflation every five years by the SEC) or more; (ii) the last day of the fiscal year of the Company following the fifth (5th) anniversary of the date of the first sale of common equity securities of the Company pursuant to an effective registration statement under the U.S. Securities Act; (iii) the date on which the Company has, during the previous three (3)-year period, issued more than $1 billion in non-convertible debt; and (iv) the date on which the Company is deemed to be a “large accelerated filer”, as defined in Rule 12b-2 under the U.S. Exchange Act. The Company will qualify as a large accelerated filer (and would cease to be an emerging growth company) at such time when on the last business day of its second fiscal quarter of such year the aggregate worldwide market value of its common equity held by non-affiliates will be $700 million or more.

For so long as the Company remains an emerging growth company, it is permitted to and intends to rely upon exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include not being required to comply with the auditor attestation requirements of Section 404 of the JOBS Act (“Section 404”). The Company takes advantage of some, but not all, of the available exemptions available to emerging growth companies. The Company cannot predict whether investors will find the Equity Shares less attractive because the Company relies upon certain of these exemptions. If some investors find the Equity Shares less attractive as a result, there may be a less active trading market for the Equity Shares and the price per Equity Share may be more volatile. On the other hand, if the Company no longer qualifies as an emerging growth company, the Company would be required to divert additional management time and attention from the Company’s development and other business activities and incur increased legal


and financial costs to comply with the additional associated reporting requirements, which could negatively impact the Company’s business, financial condition and results of operations.

Our internal controls over financial reporting may not be effective and our independent registered public accounting firm may not be able to certify as to their effectiveness, which could have a significant and adverse effect on our business and reputation.

As a U.S. public company, we are required to evaluate our internal controls over financial reporting. If we fail to achieve and maintain the adequacy of our internal controls, as such standards are modified, supplemented, or amended from time to time, we may not be able to ensure that we can conclude on an ongoing basis that we have effective internal controls over financial reporting in accordance with Section 404. We cannot be certain as to the timing of completion of our evaluation, testing and any remediation actions or the impact of the same on our operations. If we are not able to implement the requirements of Section 404 in a timely manner or with adequate compliance, our independent registered public accounting firm may issue an adverse opinion due to ineffective internal controls over financial reporting and we may be subject to sanctions or investigation by regulatory authorities, such as the SEC. As a result, there could be a negative reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. In addition, we may be required to incur costs in improving our internal control system and the hiring of additional personnel. Any such action could negatively affect our results of operations and cash flows.

Liquidity.

As reflected in the audited consolidated financial statements of the Company for the years ended December 31, 2023 and 2022 and related management’s discussion and analysis, the Company had consolidated negative working capital of $7,258,000 as of December 31, 2023 and has incurred net losses from continuing operations for years ended December 31, 2023 and December 31, 2022. The Company’s approach to managing its liquidity risk is to seek to ensure that it will have sufficient liquidity to meet its liabilities as they come due. The Company’s short-term liquidity requirements consist primarily of funds necessary to maintain operations, repay borrowings and other general business needs. The Company plans to use existing funds, as well as funds from the future sale of products, to fund short-term working capital needs for at least the next 12 months.

In addition, the Company continues to take actions designed to improve the Company’s operations and cash position, including but not limited to: (i) targeting continued growth of sales from its consolidated operations; (ii) continued cost-savings and efficiency optimization efforts; (iii) utilizing the future proceeds from an employee retention credit up to $12,354,000 of which $5,238,000 was included in current receivables; (iv) addressing its debt maturity profile, in this regard, subsequent to December 31, 2023 the Company completed the debt restructuring transaction contemplated in its October 31, 2023 support agreement with the Majority Senior Noteholders, which resulted in the effective extension via exchange of the maturity date of the 2024 Notes for an additional two years and the crystallization of the previously-announced deferral of certain current debts payable; (v) managing the timing and amount of certain expenses as well as capital expenditures; and (vi) seeking to take advantage of future potential financing (equity and/or debt) opportunities, including additional gross cash proceeds of $40,000,000 received February 2024 related to the issuance of new debt securities (refer to Note 19 to the Company’s consolidated financial statements for the years ended December 31, 2023 and 2022 for additional information). While the contemplated debt restructuring transactions in respect of the Arrangement and the Vendor Notes have been completed, management cannot provide any assurances that the Company will continue to be successful in accomplishing its business plans; if it is not, the Company may be forced to take other steps, including among others decelerating its growth or curtailing certain of its operations pending obtaining additional capital.

Dilution.

The offering price of Equity Shares or other securities that are convertible, exercisable or exchangeable into Equity Shares may significantly exceed the net tangible book value per share of the Equity Shares. Accordingly, a purchaser of Equity Shares or other securities that are convertible, exercisable or exchangeable into Equity Shares may incur immediate and substantial dilution of his, her or its investment. If outstanding options and warrants to purchase Equity Shares are exercised or securities convertible into Equity Shares are converted, additional dilution will occur. The Company may sell additional Equity Shares or other securities that are convertible, exercisable or exchangeable into Equity Shares in subsequent offerings or may issue additional Equity Shares or other securities to finance future acquisitions. The Company cannot predict the size or nature of future sales or issuances of securities or the effect, if any, that such future sales and issuances will have on the market price of the Equity Shares. Sales or issuances of substantial numbers of Equity Shares or other securities that are convertible, exercisable or exchangeable into Equity Shares, or the perception that such sales or issuances could occur, may adversely affect prevailing market prices of the Equity Shares. With any additional sale or issuance of Equity Shares or other securities that are convertible, exercisable or exchangeable into Equity Shares, investors will suffer dilution to their voting power and economic interest in the Company. Furthermore, to the extent holders of the Company’s stock options or other convertible securities convert or exercise their securities and sell the Equity Shares they receive, the trading price of the Equity Shares on the CSE and the OTCQX® Best Market operated by OTC Markets Group, Inc (the “OTCQX”) may decrease due to the additional amount of Equity Shares available in the market. In


addition, earn-out rights that are payable in Exchangeable Shares or Equity Shares may also lead to material dilution (no earn-out rights are currently outstanding).

General Regulatory and Legal Risks

Ayr may be subject to the risk of civil asset forfeiture.

Because the cannabis industry remains illegal under U.S. federal law, any property owned by participants in the cannabis industry which are either used in the course of conducting such business, or are the proceeds of such business, could be subject to seizure by law enforcement and subsequent civil asset forfeiture. Even if the owner of the property were never charged with a crime, the property in question could still be seized and subject to an administrative proceeding by which, with minimal due process, it could be subject to forfeiture.

Ayr may lack access to U.S. bankruptcy protections.

Because the use of cannabis is illegal under U.S. federal law, many courts have denied cannabis businesses bankruptcy protections, thus making it very difficult for lenders to recoup their investments in the cannabis industry in the event of a bankruptcy. If Ayr was to experience a bankruptcy, there is no guarantee that U.S. federal bankruptcy protections would be available to Ayr’s U.S. operations, which could have a material adverse effect on Ayr.

Ayr may be subject to the risk of an inability to enforce its contracts.

It is a fundamental principle of law that a contract will not be enforced if it involves a violation of law or public policy. Because cannabis remains illegal at a federal level, judges in multiple States have on a number of occasions refused to enforce contracts for the repayment of money when the loan was used in connection with activities that violate federal law, even if there is no violation of State law. There remains doubt and uncertainty that Ayr will be able to legally enforce contracts it enters into if necessary. Ayr cannot be assured that it will have a remedy for breach of contract, which would have a material adverse effect on Ayr.

Ayr may be subject to the risk of changes in Canadian laws or regulations, or a failure to comply with any such laws and regulations.

Ayr is subject to laws and regulations enacted by the federal and provincial governments of Canada. In particular, Ayr will be required to comply with certain Canadian securities law, income tax law and the CSE and other legal and regulatory requirements. Compliance with, and monitoring of, applicable laws and regulations may be difficult, time consuming and costly. Those laws and regulations and their interpretation and application also may change from time to time and those changes could have a material adverse effect on Ayr’s business, investments and results of operations. In addition, a failure to comply with applicable laws or regulations, as interpreted and applied, could result in a material adverse effect on Ayr’s business, financial condition, results of operations or prospects.

Ayr is subject to general regulatory and licensing risks.

The Company is subject to a variety of laws, regulations and guidelines relating to the manufacture, management, transportation, storage and disposal of marijuana, including laws and regulations relating to health and safety, the conduct of operations and the protection of the environment. Achievement of Ayr’s business objectives is contingent, in part, upon compliance with applicable regulatory requirements and obtaining all requisite regulatory approvals. Changes to such laws, regulations and guidelines due to matters beyond the control of Ayr may result in a material adverse effect on Ayr’s business, financial condition, results of operations or prospects.

Certain of the Company’s businesses may be required to obtain or renew further government permits and licenses for its current and contemplated operations. Obtaining, amending or renewing the necessary governmental permits and licenses can be a time-consuming process potentially involving numerous regulatory agencies, public hearings and costly undertakings on the Company’s part. The duration and success of the Company’s efforts to obtain, amend and renew permits and licenses are contingent upon many variables not within its control, including the interpretation of applicable requirements implemented by the relevant permitting or licensing authority. The Company may not be able to obtain, amend or renew permits or licenses that are necessary to its operations or to achieve the growth of its business. Any unexpected delays or costs associated with the permitting and licensing process could impede the ongoing or proposed operations of the Company. To the extent necessary, permits or licenses are not obtained, amended or renewed, or are subsequently suspended or revoked, the Company may be curtailed or prohibited from proceeding with ongoing operations or planned development and commercialization activities. Such curtailment or prohibition may result in a material adverse effect on Ayr’s business, financial condition, results of operations or prospects.

Several of the licenses held by the Company are subject to renewal on an annual or periodic basis; however, they are generally renewed, as a matter of course, if the license holder continues to operate in compliance with applicable legislation and regulations and without any


material change to its operations. For example, Massachusetts’ medical and adult-use cannabis programs each require annual renewal of registrations. These renewals are contingent upon the registration holder’s past and continued ability to meet the statutory and regulatory requirements of the given program. Compliance personnel of each of the Company’s businesses check renewal dates for licenses to ensure that licenses are renewed as and when required. Ayr has implemented an additional centralized review of such renewal process.

While Ayr believes that its compliance controls have been developed to mitigate the risk of any violations of any licenses they hold arising, there is no assurance that the Company’s licenses will be renewed by each applicable regulatory authority in the future in a timely manner. Any unexpected delays or costs associated with the licensing renewal process for any of the licenses held by the Company could impede the ongoing or planned operations of the Company and have a material adverse effect on Ayr’s business, financial condition, results of operations or prospects.

Ayr may become involved in a number of government or agency proceedings, investigations and audits. The outcome of any regulatory or agency proceedings, investigations, audits, and other contingencies could harm Ayr’s reputation, require Ayr to take, or refrain from taking, actions that could harm its operations or require Ayr to pay substantial amounts of money, harming its financial condition. There can be no assurance that any pending or future regulatory or agency proceedings, investigations and audits will not result in substantial costs or a diversion of management’s attention and resources or have a material adverse impact on Ayr’s business, financial condition, results of operations or prospects.

Nevada regulatory regime and transfer and grant of licenses.

The business and activities of Ayr are heavily regulated in Nevada. Ayr’s operations are subject to various laws, regulations and guidelines by governmental authorities, relating to the manufacture, marketing, management, transportation, storage, sale, pricing and disposal of medical marijuana and cannabis oil, and also including laws and regulations relating to health and safety, insurance coverage, the conduct of operations and the protection of the environment. Laws and regulations, applied generally, grant the Nevada Cannabis Compliance Board (as successor regulatory agency to the Nevada Taxation Department over the Nevada cannabis industry) and self-regulatory bodies broad administrative discretion over the activities of Ayr in Nevada, including the power to limit or restrict business activities as well as impose additional disclosure requirements on Ayr’s products and services. Achievement of Ayr’s business objectives is contingent, in part, upon compliance with regulatory requirements enacted by the Nevada Cannabis Compliance Board and other governmental authorities and obtaining all regulatory approvals from the Nevada Cannabis Compliance Board and other governmental authorities, where necessary, for the sale of its cannabis products.

Ayr will incur ongoing costs and obligations related to regulatory compliance and obtaining new licenses. Failure to comply with regulations may lead to possible sanctions including the revocation or imposition of additional conditions on licenses to operate Ayr’s business, the suspension or expulsion from the Nevada cannabis market or of its key personnel, and the imposition of fines and censures. In addition, changes in regulations, more vigorous enforcement thereof or other unanticipated events could require extensive changes to Ayr’s operations, increased compliance costs or give rise to material liabilities, which could have a material adverse effect on the business, results of operations and financial condition of Ayr.

Limitations on ownership of licenses.

In certain States, the cannabis laws and regulations limit not only the number of cannabis licenses issued, but also the number of cannabis licenses that one person may own. For example, in Massachusetts, no person may have an ownership interest, or control over, more than three medical licenses or three adult-use licenses in any category - for example, cultivation, product manufacturing, transport or retail. Ayr believes that, where such restrictions apply, it may still capture significant share of revenue in the market through the provision of management or support services and similar arrangements with other operators. Nevertheless, such limitations on the acquisition of ownership of additional licenses within certain States may limit Ayr’s ability to grow organically or to increase its market share in such States.

Regulatory action and approvals from the Food and Drug Administration.

The Company’s cannabis-based products are supplied to patients diagnosed with certain medical conditions. However, the Company’s cannabis-based products are not approved by the FDA as “drugs” or for the diagnosis, cure, mitigation, treatment, or prevention of any disease. Accordingly, the FDA may regard any promotion of the cannabis-based products as the promotion of an unapproved drug in violation of the Food, Drug and Cosmetic Act (“FDCA”).

In recent years, the FDA has issued letters to a number of companies selling products that contain CBD oil derived from hemp warning them that the marketing of their products violates the FDCA. FDA enforcement action against the Company could result in a number of negative consequences, including fines, disgorgement of profits, recalls or seizures of products, or a partial or total suspension of the Company’s


production or distribution of its products. Any such event could have a material adverse effect on Ayr’s business, prospects, financial condition, and operating results.

Risks related to acquisitions.

Material acquisitions, dispositions and other strategic transactions involve a number of risks, including: (i) potential disruption of the Company’s ongoing business; (ii) distraction of management; (iii) the Company may become more financially leveraged; (iv) the anticipated benefits and cost savings of those transactions may not be realized fully or at all or may take longer to realize than expected; (v) increasing the scope and complexity of the Company’s operations; and (vi) loss or reduction of control over certain of the Company’s assets. Additionally, Ayr may issue additional Equity Shares in connection with such transactions, which would dilute an Ayr shareholder’s holdings in Ayr or indirect holdings in Ayr.

The Company could incur additional transaction and integration related costs or other factors such as the failure to realize all of the benefits from the acquisition of businesses or strategic assets. All of these factors could cause dilution to the Company’s earnings per share or decrease or delay the anticipated accretive effect of the acquisition and cause a decrease in the market price of the Company’s securities.

The Company may not be able to successfully integrate and combine the operations, personnel and technology infrastructure of any such acquired company with its existing operations. If integration is not managed successfully by the Company’s management, the Company may experience interruptions in its business activities, deterioration in its employee and customer relationships, increased costs of integration and harm to its reputation, all of which could have a material adverse effect on the Company’s business, financial condition and results of operations. The Company may experience difficulties in combining corporate cultures, maintaining employee morale and retaining key employees. The integration of any such acquired companies may also impose substantial demands on management. There is no assurance that these acquisitions will be successfully integrated in a timely manner.

Such transactions could involve other risks, including the assumption of unidentified or unknown liabilities, disputes or contingencies, for which the Company, as a successor owner, may be responsible, and/or changes in the industry, location, or regulatory or political environment in which these investments are located, that the Company’s due diligence review may not adequately uncover and that may arise after entering into such transactions. Although the Company has and expects to continue to realize strategic, operational and financial benefits as a result of the Company’s mergers and acquisitions, the Company cannot predict whether and to what extent such benefits will be achieved.

Furthermore, any future merger or acquisition may result in diversion of management’s attention from other business concerns, and such transactions may be dilutive to the Company’s financial results and/or result in impairment charges and write-offs.

The presence of one or more material liabilities of an acquired company that are unknown to Ayr at the time of acquisition could have a material adverse effect on the business, results of operations, prospects and financial condition of Ayr. A strategic transaction may result in a significant change in the nature of Ayr’s business, operations and strategy. In addition, Ayr may encounter unforeseen obstacles or costs in implementing a strategic transaction or integrating any acquired business into Ayr’s operations.

Risks related to expansion strategy.

There is no guarantee that the Company’s expansion strategy will be completed, nor is there any guarantee that the Company will be able to expand into additional jurisdictions. There is also no guarantee that the Company’s intentions to acquire and/or construct additional cannabis production, manufacturing, distribution or sales facilities, and to expand the Company’s marketing and sales initiatives will be successful. Any such activities will require, among other things, various regulatory approvals, licenses and permits and there is no guarantee that all required approvals, licenses and permits will be obtained in a timely fashion or at all. There is also no guarantee that the Company will be able to complete any of the foregoing activities as anticipated or at all.

The Company’s failure to successfully execute its expansion strategy (including receiving required regulatory approvals, licenses and permits) could adversely affect the Company’s business, financial condition and results of operations and may result in the Company failing to meet anticipated or future demand for its cannabis products, when and if it arises.

Risks related to evaluating prospective target businesses.

Although the Company has identified specific criteria and guidelines for evaluating prospective target businesses, it is possible that a target business with which the Company enters into a transaction will not have all of these positive attributes. If the Company consummates a transaction with a target that does not meet some or all of these guidelines, such transaction may not prove to be successful. In addition, there is no guarantee that an investment that meets the criteria and guidelines established by the Company will prove to be successful.


Risks related to transactions that are not consummated.

The Company anticipates that the investigation of each specific target business and the negotiation, drafting, and execution of relevant agreements, disclosure documents, and other instruments will require substantial management time and attention and substantial costs for accountants, attorneys and other experts. If the Company decides not to complete a specific transaction, the costs incurred up to that point for the proposed transaction likely would not be recoverable. Furthermore, if the Company reaches an agreement relating to a specific target business, the Company may fail to consummate the transaction for any number of reasons, including those beyond its control. Any such event will result in losses to the Company of the related costs incurred which could materially adversely affect subsequent attempts to locate and acquire or merge with another business.

Risks related to loss of officers and directors.

The Company’s operations are dependent upon a relatively small group of individuals and, in particular, its officers and directors. The Company believes that its success will depend on the continued service of its officers and directors. In addition, the Company’s officers and directors are not required to commit any specified amount of time to the Company’s affairs and, accordingly, may have conflicts of interest in allocating management time among various business activities, including identifying potential acquisitions and monitoring the related due diligence. The Company does not have key-man insurance on the life of any of its directors or officers. The unexpected loss of the services of one or more of its directors or officers could have a detrimental effect on the Company, its operations and its ability to make acquisitions.

Risks related to conflicts of interest.

The Company engages in the business of identifying and combining with one or more businesses. The Company’s officers and directors may now be, or may in the future become, affiliated with entities that are engaged in a similar business.

The Company’s officers and directors also may become aware of business opportunities which may be appropriate for presentation to the Company and the other entities to which it owes duties. In the course of its other business activities, the Company’s officers and directors may owe similar or other duties, and may have obligations, to other entities or pursuant to other outside business arrangements, including seeking and presenting investment and business opportunities. Accordingly, they may have conflicts of interest in determining to which entity a particular business opportunity should be presented. These conflicts may not be resolved in the Company’s favor, as the Company’s officers and directors are not required to present investment and business opportunities to the Company in priority to other entities with which they are affiliated or to which they owe duties.

The Company has not adopted a policy that expressly prohibits its directors, officers, security holders, affiliates or associates from having a direct or indirect financial interest in any investment to be acquired or disposed of by the Company or in any transaction to which it is a party or has an interest. In fact, even though it is not the Company’s current intentions to do so, they may enter into a transaction with a target business that is affiliated with the Company’s directors or officers.

Business risks related to the cannabis industry.

Scientific research related to the benefits of marijuana remains in early stages, is subject to a number of important assumptions and may prove to be inaccurate.

Research in Canada, the U.S. and internationally regarding the medical benefits, viability, safety, efficacy and dosing of cannabis or isolated cannabinoids remains in early stages. To Ayr’s knowledge, there have been relatively few clinical trials on the benefits of cannabis or isolated cannabinoids. Any statements made in this AIF concerning the potential medical benefits of cannabinoids are based on published articles and reports. As a result, any statements made in this AIF are subject to the experimental parameters, qualifications, assumptions and limitations in the studies that have been completed.

Although Ayr believes that the articles and reports, and details of research studies and clinical trials that are publicly available reasonably support its beliefs regarding the medical benefits, viability, safety, efficacy and dosing of cannabis, future research and clinical trials may prove such statements to be incorrect, or could raise concerns regarding and perceptions relating to cannabis. Given these risks, uncertainties and assumptions, prospective and current Ayr shareholders should not place undue reliance on such articles and reports. Future research studies and clinical trials may draw opposing conclusions to those stated in this AIF or reach negative conclusions regarding the viability, safety, efficacy, dosing, social acceptance or other facts and perceptions related to medical cannabis, which may result in a material adverse effect on Ayr’s business, financial condition, results of operations or prospects.

Competition in the cannabis industry is intense and increased competition by larger and better-financed competitors could materially and adversely affect the business, financial condition and results of operations of Ayr.


Ayr expects to face intense competition in the cannabis industry, some of which can be expected to come from companies with longer operating histories and more financial resources, manufacturing and marketing experience than Ayr. In addition, there is potential that the cannabis industry will undergo consolidation, creating larger companies with financial resources, manufacturing and marketing capabilities, and products that will be greater than those of Ayr. As a result of this competition, Ayr may be unable to maintain its operations or develop them as currently proposed on terms it considers to be acceptable or at all. Increased competition by larger, better- financed competitors with geographic advantages may result in a material adverse effect on Ayr’s business, financial condition, results of operations or prospects.

Negative publicity or consumer perception may affect the success of Ayr’s business.

The success of the cannabis industry may be significantly influenced by the public’s perception of marijuana. Both the medical and adult- use of marijuana are controversial topics, and there is no guarantee that future scientific research, publicity, regulations, medical opinion and public opinion relating to marijuana will be favorable. The cannabis industry is an early-stage business that is constantly evolving with no guarantee of viability. The market for medical and adult-use marijuana is uncertain, and any adverse or negative publicity, scientific research, limiting regulations, medical opinion and public opinion (whether or not accurate or with merit) relating to the consumption of marijuana, whether in Canada, the U.S. or elsewhere, may have a material adverse effect on Ayr’s operational results, consumer base and financial results.

Public perception can be significantly influenced by scientific research or findings, regulatory investigations, litigation, media attention and other publicity regarding the consumption of marijuana products. There can be no assurance that future scientific research or findings, regulatory investigations, litigation, media attention or other publicity will be favorable to the marijuana market or any particular product, or consistent with earlier publicity. Future research reports, findings, regulatory investigations, litigation, media attention or other publicity that are perceived as less favorable than, or that question, earlier research reports, findings or other publicity could have a material adverse effect on the demand for adult-use or medical marijuana and on the business, results of operations, financial condition, cash flows or prospects of Ayr.

Further, adverse publicity reports or other media attention regarding the safety, efficacy and quality of marijuana in general, or associating the consumption of adult-use and medical marijuana with illness or other negative effects or events, could have such a material adverse effect. There is no assurance that such adverse publicity reports or other media attention will not arise. Among other things, a negative shift in the public’s perception of cannabis in the United States or any other applicable jurisdiction could cause State jurisdictions to abandon initiatives or proposals to legalize medical and/or adult-use cannabis, thereby limiting the number of new State jurisdictions into which Ayr could expand. Any inability to fully implement Ayr’s expansion strategy may have a material adverse effect on Ayr’s business, results of operations or prospects.

Results of future clinical research may negatively impact the cannabis industry.

Research in Canada, the U.S. and internationally regarding the medical benefits, viability, safety, efficacy, dosing and social acceptance of cannabis or isolated cannabinoids (such as CBD and THC) remains in early stages. There have been relatively few clinical trials on the benefits of cannabis or isolated cannabinoids (such as CBD and THC) and future research and clinical trials may discredit the medical benefits, viability, safety, efficacy, and social acceptance of cannabis or could raise concerns regarding, and perceptions relating to, cannabis. Given these risks, uncertainties and assumptions, prospective purchasers of Ayr’s securities should not place undue reliance on such articles and reports. Future research studies and clinical trials may draw opposing conclusions to those stated in this AIF or reach negative conclusions regarding the medical benefits, viability, safety, efficacy, dosing, social acceptance or other facts and perceptions related to cannabis, which could have a material adverse effect on the demand for Ayr’s products with the potential to lead to a material adverse effect on Ayr’s business, financial condition, results of operations or prospects.

The cannabis industry is difficult to forecast.

Ayr must rely largely on its own market research to forecast sales as detailed forecasts are not generally obtainable from other sources at this early stage of the cannabis industry. A failure in the demand for its products to materialize as a result of competition, technological change or other factors could have a material adverse effect on the business, results of operations, financial condition or prospects of Ayr.

Reliable data on the medical and adult-use cannabis industry is not available.

As a result of recent and ongoing regulatory and policy changes in the medical and adult-use cannabis industry, the market data available is limited and unreliable. Federal and State laws prevent widespread participation and hinder market research. Therefore, market research and projections by Ayr of estimated total retail sales, demographics, demand, and similar consumer research, are based on assumptions from limited and unreliable market data, and generally represent the personal opinions of Ayr’s management team as of the date of this AIF.


Ayr may be subject to the risk of constraints on marketing products.

The development of Ayr’s business and operating results may be hindered by applicable restrictions on sales and marketing activities imposed by government regulatory bodies. The regulatory environment in the U.S. limits companies’ abilities to compete for market share in a manner similar to other industries. If Ayr is unable to effectively market its products and compete for market share, or if the costs of compliance with government legislation and regulation cannot be absorbed through increased selling prices for its products, Ayr’s sales and results of operations or prospects could be adversely affected.

Risks Related to Ayr’s Business

Ayr has a limited operating history.

As a high-growth enterprise, Ayr does not have a history of profitability. As such, Ayr has no immediate prospect of generating profit from its intended operations. Ayr is therefore subject to many of the risks common to early-stage enterprises, including under-capitalization, cash shortages, limitations with respect to personnel, financial, and other resources and lack of revenues. There is no assurance that Ayr will be successful in achieving a return on its shareholders’ investment and the likelihood of success must be considered in light of the early stage of operations.

Ayr will be reliant on its management team.

The success of Ayr is dependent upon the ability, expertise, judgment, discretion and good faith of its senior management. While employment agreements or management agreements are customarily used as a primary method of retaining the services of key employees, these agreements cannot assure the continued services of such employees. Any loss of the services of such individuals could have a material adverse effect on Ayr’s business, operating results, financial condition or prospects.

News media have reported that U.S. immigration authorities have increased scrutiny of Canadian citizens who are crossing the U.S.- Canada border with respect to persons involved in cannabis businesses in the U.S. There have been a number of Canadians barred from entering the U.S. as a result of an investment in or act related to U.S. cannabis businesses. In some cases, entry has been barred for extended periods of time. Ayr employees traveling from Canada to the U.S. for the benefit of Ayr may encounter enhanced scrutiny by U.S. immigration authorities that may result in the employee not being permitted to enter the U.S. for a specified period of time. If this happens to Ayr employees, then this may reduce our ability to effectively manage our business in the U.S.

Certain of Ayr’s officers and directors may now be, and all of them may in the future become, affiliated with entities engaged in business activities similar to those intended to be conducted by Ayr and, accordingly, may have conflicts of interest in allocating their time and determining to which entity a particular business opportunity should be presented.

Ayr’s officers and directors also may become aware of business opportunities which may be appropriate for presentation to Ayr and the other entities to which they owe duties. In the course of their other business activities, Ayr’s officers and directors may owe similar or other duties, and may have obligations, to other entities or pursuant to other outside business arrangements, including seeking and presenting investment and business opportunities. Accordingly, they may have conflicts of interest in determining to which entity a particular business opportunity should be presented. These conflicts may not be resolved in our favor, as Ayr’s officers and directors are not required to present investment and business opportunities to Ayr in priority to other entities with which they are affiliated or to which they owe duties, and such conflicts may result in a material adverse effect on Ayr’s business, financial condition, results of operations or prospects.

Ayr may be subject to the risk of competition from synthetic production and technological advances.

The pharmaceutical industry may attempt to dominate the cannabis industry, and in particular, legal marijuana, through the development and distribution of synthetic products which emulate the effects and treatment of organic marijuana. If they are successful, the widespread popularity of such synthetic products could change the demand, volume and profitability of the cannabis industry. This could adversely affect the ability of Ayr to secure long-term profitability and success through the sustainable and profitable operation of its business. There may be unknown additional regulatory fees and taxes that may be assessed in the future that may result in a material adverse effect on Ayr’s business, financial condition, results of operations or prospects.

Ayr may be subject to the risks associated with fraudulent or illegal activity by its employees, contractors and consultants.

Ayr is exposed to the risk that its employees, independent contractors and consultants may engage in fraudulent or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to Ayr that violates: (i) government regulations; (ii) manufacturing standards; (iii) federal and provincial healthcare fraud and abuse laws and


regulations; or (iv) laws that require the true, complete and accurate reporting of financial information or data. It may not always be possible for Ayr to identify and deter misconduct by its employees and other third parties, and the precautions taken by Ayr to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting Ayr from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against Ayr, and it is not successful in defending itself or asserting its rights, those actions could have a significant impact on Ayr’s business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of Ayr’s operations, any of which could have a material adverse effect on Ayr’s business, financial condition, results of operations or prospects.

Certain events or developments in the cannabis industry more generally may impact Ayr’s reputation.

Damage to Ayr’s reputation can be the result of the actual or perceived occurrence of any number of events, and could include any negative publicity, whether true or not. Cannabis has often been associated with various other narcotics, violence and criminal activities, the risk of which is that our business might attract negative publicity. There is also risk that the action(s) of other participants, companies and service providers in the cannabis industry may negatively affect the reputation of the industry as a whole and thereby negatively impact the reputation of Ayr. The increased usage of social media and other web-based tools used to generate, publish and discuss user- generated content and to connect with other users has made it increasingly easier for individuals and groups to communicate and share opinions and views in regard to Ayr and its activities, whether true or not, and the cannabis industry in general, whether true or not. Ayr does not ultimately have direct control over how it or the cannabis industry is perceived by others. Reputation loss may result in decreased investor confidence, increased challenges in developing and maintaining community relations and an impediment to Ayr’s overall ability to advance its business strategy and realize on its growth prospects, thereby having a material adverse effect on Ayr’s business, financial condition, results of operations or prospects.

Ayr may be subject to advertising and promotional risk in the event it cannot effectively implement a successful branding strategy.

Ayr’s future growth and profitability may depend on the effectiveness and efficiency of advertising and promotional costs, including its ability to (i) create brand recognition for any products we may develop or sell; (ii) determine appropriate advertising strategies, messages and media; and (iii) maintain acceptable operating margins on such costs. There can be no assurance that advertising and promotional costs will result in revenues for Ayr’s business in the future or will generate awareness for any of Ayr’s products. In addition, no assurance can be given that Ayr will be able to manage our advertising and promotional costs on a cost-effective basis.

The cannabis industry in Canada, including both the medical and adult-use cannabis markets, is in its early development stage and restrictions on advertising, marketing and branding of cannabis companies and products by Health Canada, various medical associations, other governmental or quasi-governmental bodies or voluntary industry associations may adversely affect Ayr’s ability to conduct sales and marketing activities and to create brand recognition, and could potentially result in a material adverse effect on Ayr’s business, financial condition, results of operations or prospects.

Certain of the Company’s businesses are subject to product liability regimes and strict product recall requirements.

Certain of the Company’s businesses are distributors of products designed to be ingested by humans. Accordingly, Ayr faces the risk of exposure to product liability claims, regulatory action and litigation if any of its businesses’ products are alleged to have caused significant loss or injury. In addition, the sale of cannabis products involves the risk of injury to consumers due to tampering by unauthorized third parties or product contamination. Previously unknown adverse reactions resulting from human consumption of cannabis products alone or in combination with other medications or substances could occur. Ayr may be subject to various product liability claims, including, among others, that specific cannabis products caused injury or illness, or include inadequate warnings concerning possible side effects or interactions with other substances. A product liability claim or regulatory action against Ayr could result in increased costs, could adversely affect our reputation with Ayr’s clients and consumers generally, and may result in a material adverse effect on Ayr’s business, financial condition, results of operations or prospects.

In addition, manufacturers and distributors of products are sometimes subject to the recall or return of their products for a variety of reasons, including product defects, such as contamination, unintended harmful side effects or interactions with other substances, packaging safety and inadequate or inaccurate labelling disclosure. To the extent any products are recalled due to an alleged product defect or for any other reason, Ayr could be required to incur the unexpected expense of the recall and any legal proceedings that might arise in connection with the recall. Ayr may lose a significant amount of sales and may not be able to replace those sales at an acceptable margin or at all. In addition, a product recall may require significant management attention. Moreover, a recall for any of the foregoing reasons could lead to decreased demand and could have a material adverse effect on Ayr. Product recalls may lead to increased scrutiny of operations by applicable regulatory agencies, requiring further management attention and potential legal fees and other expenses.


Ayr may not be able to successfully develop new products or find a market for their sale.

The cannabis industry is in its early stages of development and Ayr, and its competitors, may seek to introduce new products in the future. In attempting to keep pace with any new market developments, Ayr may need to expend significant amounts of capital in order to successfully develop and generate revenues from new products introduced by Ayr. Ayr may also be required to obtain additional regulatory approvals from Health Canada and any other applicable regulatory authorities, which may take significant amounts of time. Ayr may not be successful in developing effective and safe new products, bringing such products to market in time to be effectively commercialized, or obtaining any required regulatory approvals, which, together with any capital expenditures made in the course of such product development and regulatory approval processes, may result in a material adverse effect on Ayr’s business, financial condition, results of operations or prospects.

Ayr will be reliant on third-party suppliers, manufacturers and contractors.

Ayr intends to maintain a full supply chain for the provision of products and services to the regulated cannabis industry. Due to the uncertain regulatory landscape for regulating cannabis in Canada and the U.S. and the perception that they may be exposed to reputational risk as a result of Ayr’s cannabis-related business activities, Ayr’s third-party suppliers, manufacturers and contractors may elect, at any time, to decline or withdraw services necessary for Ayr’s operations. Loss of these suppliers, manufacturers and contractors may result in a material adverse effect on Ayr’s business, financial condition, results of operations or prospects.

Ayr will be reliant on key inputs.

The marijuana business is dependent on a number of key inputs and their related costs including raw materials and supplies related to growing operations, as well as electricity, water and other local utilities. Any significant interruption or negative change in the availability or economics of the supply chain for key inputs could materially impact the business, financial condition, results of operations or prospects of Ayr. Some of these inputs may only be available from a single supplier or a limited group of suppliers. If a sole source supplier was to go out of business, Ayr might be unable to find a replacement for such source in a timely manner or at all. If a sole source supplier were to be acquired by a competitor, that competitor may elect not to sell to Ayr in the future. Any inability to secure required supplies and services or to do so on appropriate terms could have a materially adverse impact on the business, financial condition, results of operations or prospects of Ayr.

Ayr will be reliant on equipment and skilled labor.

The ability of Ayr to compete and grow will be dependent on it having access, at a reasonable cost and in a timely manner, to skilled labor, equipment, parts and components. No assurances can be given that Ayr will be successful in maintaining its required supply of skilled labor, equipment, parts and components. It is also possible that the final costs of the major equipment contemplated by Ayr’s capital expenditure plans may be significantly greater than anticipated by Ayr’s management, and may be greater than funds available to Ayr, in which circumstance Ayr may curtail, or extend the timeframes for completing, its capital expenditure plans. This may result in a material adverse effect on Ayr’s business, financial condition, results of operations or prospects.

Service providers could suspend or withdraw service.

As a result of any adverse change to the approach in enforcement of United States cannabis laws, adverse regulatory or political change, additional scrutiny by regulatory authorities, adverse change in public perception in respect of the consumption of marijuana or otherwise, third-party service providers to Ayr could suspend or withdraw their services, which may have a material adverse effect on Ayr’s business, revenues, operating results, financial condition or prospects.

Ayr may be subject to the risk of litigation.

Ayr may become party to litigation from time to time in the ordinary course of business which could adversely affect its business. Should any litigation in which Ayr becomes involved be determined against Ayr, such a decision could adversely affect Ayr’s ability to continue operating and the market price for the Equity Shares. Even if Ayr is involved in litigation and wins, litigation can redirect significant company resources.

Ayr may be subject to risks related to the protection and enforcement of intellectual property rights and may become subject to allegations that Ayr is in violation of intellectual property rights of third parties.

The ownership and protection of intellectual property rights may be a significant aspect of Ayr’s future success. Ayr may rely on trade secrets, technical know-how and proprietary information that are not protected by patents to maintain its competitive position. Ayr will try to protect such intellectual property by entering into confidentiality agreements with parties that have access to it, such as Ayr’s partners,


collaborators, employees and consultants. Any of these parties may breach these agreements and we may not have adequate remedies for any specific breach. In addition, trade secrets and technical know-how, which are not protected by patents, may otherwise become known to or be independently developed by competitors, in which event Ayr could be materially adversely affected.

Unauthorized parties may attempt to replicate or otherwise obtain and use Ayr’s products, trade secrets, technical know-how and proprietary information. Policing the unauthorized use Ayr’s future intellectual property rights could be difficult, expensive, time- consuming and unpredictable, as may be enforcing these rights against unauthorized use by others. Identifying unauthorized use of intellectual property rights is difficult as Ayr may be unable to effectively monitor and evaluate the products being distributed by its competitors, including parties such as unlicensed dispensaries, and the processes used to produce such products. In addition, in any infringement proceeding, some or all of Ayr’s future trademarks, patents or other intellectual property rights or other proprietary know- how, or arrangements or agreements seeking to protect the same for the benefit of Ayr, may be found invalid, unenforceable, anti- competitive or not infringed. An adverse result in any litigation or defense proceedings could put one or more of Ayr’s future trademarks, patents or other intellectual property rights at risk of being invalidated or interpreted narrowly. Any or all of these events could result in a material adverse effect on Ayr’s business, financial condition, results of operations or prospects.

In addition, other parties may claim that Ayr’s products infringe on their proprietary and perhaps patent-protected rights. Such claims, whether or not meritorious, may result in the expenditure of significant financial and managerial resources, legal fees, injunctions, temporary restraining orders and/or require the payment of damages. As well, Ayr may need to obtain licenses from third parties who allege that Ayr has infringed on their lawful rights. However, such licenses may not be available on terms acceptable to Ayr or at all. In addition, Ayr may not be able to obtain or utilize on terms that are favorable to it, or at all, licenses or other rights with respect to intellectual property that it does not own.

Ayr may be subject to risks related to information technology systems, including cyber-attacks.

Ayr’s operations may depend, in part, on how well it and its suppliers protect networks, equipment, information technology systems and software against damage from a number of threats, including, but not limited to, cable cuts, damage to physical plants, natural disasters, intentional damage and destruction, fire, power loss, hacking, computer viruses, vandalism and theft. Ayr’s operations may also depend on the timely maintenance, upgrade and replacement of networks, equipment, information technology (“IT”) systems and software, as well as pre-emptive expenses to mitigate the risks of failures. Any of these and other events could result in information system failures, delays and/or increase in capital expenses. The failure of information systems or a component of information systems could, depending on the nature of any such failure, adversely impact Ayr’s reputation and results of operations. Ayr’s risk and exposure to these matters cannot be fully mitigated because of, among other things, the evolving nature of these threats. As a result, cyber security and the continued development and enhancement of controls, processes and practices designed to protect systems, computers, software, data and networks from attack, damage or unauthorized access may become a priority to ensure the ongoing success and security of the business. As cyber threats continue to evolve, Ayr may be required to expend additional resources to continue to modify or enhance protective measures or to investigate and remediate any security vulnerabilities.

Ayr may be subject to risks related to security breaches.

Given the nature of the Company’s product and its lack of legal availability outside of channels approved by the government of the United States, as well as the concentration of inventory in its facilities, despite meeting or exceeding all legislative security requirements, there remains a risk of shrinkage as well as theft. A security breach at one of the Company’s facilities could expose Ayr to additional liability and to potentially costly litigation, increase expenses relating to the resolution and future prevention of these breaches and may deter potential patients from choosing Ayr’s products.

In addition, the Company collects and stores personal information about its patients and is responsible for protecting that information from privacy breaches in accordance with applicable laws. A privacy breach may occur through procedural or process failure, information technology malfunction, or deliberate unauthorized intrusions. Theft of data for competitive purposes, particularly patient lists and preferences, is an ongoing risk whether perpetrated via employee collusion or negligence or through deliberate cyber-attack. Any such theft or privacy breach would have a material adverse effect on Ayr’s business, financial condition and results of operations or prospects.

Ayr may be subject to risks related to violations of corruption and anti-bribery laws.

The Company is subject to applicable laws which generally prohibit companies and employees from engaging in bribery or other prohibited payments to foreign officials for the purpose of obtaining or retaining business. Ayr’s employees or other agents may, without its knowledge and despite its efforts, engage in prohibited conduct, whether prohibited under the Company’s policies and procedures or under anti‐bribery laws, for which the Company may be directly or indirectly held responsible. There can be no assurance that Ayr’s internal control policies and procedures from time to time in effect will protect it from recklessness, fraudulent behavior, dishonesty or other inappropriate acts


committed by its affiliates, employees, contractors or agents. If the Company’s employees or other agents are found to have engaged in such practices, the Corporation could suffer severe penalties and other consequences that may have a material adverse effect on Ayr’s business, financial condition and results of operations or prospects.

Ayr may be subject to risks related to high bonding and insurance coverage.

There is a risk that a greater number of State regulatory agencies will begin requiring entities engaged in certain aspects of the business or industry of legal marijuana to post a bond or significant fees when applying, for example, for a dispensary license or renewal as a guarantee of payment of sales and franchise tax. Ayr is not able to quantify at this time the potential scope for such bonds or fees in the States in which it currently or may in the future operate. Any bonds or fees of material amounts could have a negative impact on the ultimate success of Ayr’s business.

Ayr’s business is subject to a number of risks and hazards generally, including adverse environmental conditions, accidents, labor disputes and changes in the regulatory environment. Such occurrences could result in damage to assets, personal injury or death, environmental damage, delays in operations, monetary losses and possible legal liability.

Although Ayr maintains insurance to protect against certain risks in such amounts as it considers to be reasonable, its insurance does not cover all the potential risks associated with its operations. Ayr may also be unable to maintain insurance to cover these risks at economically feasible premiums. Insurance coverage may not continue to be available or may not be adequate to cover any resulting liability. Moreover, insurance against risks such as environmental pollution or other hazards encountered in the operations of Ayr is not generally available on acceptable terms. Ayr might also become subject to liability for pollution or other hazards which may not be insured against, or which Ayr may elect not to insure against because of premium costs or other reasons. Losses from these events may cause Ayr to incur significant costs that could have a material adverse effect upon its business, results of operations, financial condition or prospects.

Ayr may be subject to transportation risks.

Ayr’s business involves, both directly and indirectly, the production, sale and distribution of cannabis products. Due to the perishable nature of such products, Ayr depends on fast and efficient direct and third-party transportation services to distribute its product. Any prolonged disruption of third-party transportation services could have an adverse effect on Ayr. Rising costs associated with the third-party transportation services which will be used by Ayr to ship its proposed products may also adversely impact the business of Ayr.

Ayr’s share price may be vulnerable to rising energy costs.

Ayr’s business may involve, directly or indirectly, the production of cannabis products which will consume considerable energy, making Ayr vulnerable to rising energy costs. Rising or volatile energy costs may adversely impact the business of Ayr and its ability to operate profitably.

Ayr may be subject to risks inherent in the agricultural sector.

As a cannabis consumer packaged goods company and retailer, Ayr’s business may involve, directly or indirectly, the growing of cannabis, thus exposing Ayr to certain agricultural risks. One particular risk is that of contaminated cannabis products, which can pose health issues to cannabis users. There are reports that marijuana users have higher levels of heavy metals in their blood and are more prone to developing fungal infections. Risks of contamination are especially elevated for marijuana products since hemp is a bioaccumulator plant, meaning it can absorb and store pollutants such as pesticides and heavy metals from the soil it is planted in. Even when grown indoors under climate controlled conditions monitored by trained personnel, there can be no assurance that natural elements, such as insects and plant diseases, will not have a material adverse effect on the production of cannabis products and on Ayr’s business, financial condition, results of operations or prospects of Ayr. Furthermore, regulatory agencies in the United States have set limits on the how much pathogens, toxins and other compounds can be present in agricultural materials. If hemp used in Ayr’s products is found to exceed the permitted limits, those products may need to be destroyed, which may have a material adverse effect on Ayr’s business or financial condition.

Management of growth may prove to be difficult.

Ayr may be subject to growth-related risks including capacity constraints and pressure on its internal systems and controls. The ability of Ayr to manage growth effectively will require it to continue to implement and improve its operational and financial systems and to expand, train and manage its employee base. The inability of Ayr to deal with this growth may result in a material adverse effect on Ayr’s business, financial condition, results of operations or prospects.


Ayr may be subject to the risks of leverage.

Ayr utilizes leverage in connection with Ayr’s investments in the form of secured or unsecured indebtedness (including the 2026 Notes). Although Ayr seeks to use leverage in a manner it believes is prudent, such leverage increases the exposure of an investment to adverse economic factors such as downturns in the economy or deterioration in the condition of the investment. If Ayr defaults on secured indebtedness (including the 2026 Notes), the lender may foreclose and Ayr could lose its entire investment in the security for such loan. If Ayr defaults on unsecured indebtedness, the terms of the loan may require Ayr to repay the principal amount of the loan and any interest accrued thereon in addition to heavy penalties that may be imposed. Because Ayr may engage in financings where several investments are cross-collateralized, multiple investments may be subject to the risk of loss.

As a result, Ayr could lose its interest in performing investments in the event such investments are cross-collateralized with poorly performing or non-performing investments. In addition to leveraging Ayr’s investments, Ayr may borrow funds in its own name for various purposes, and may withhold or apply from distributions amounts necessary to repay such borrowings. The interest expense and such other costs incurred in connection with such borrowings may not be recovered by income from investments purchased by Ayr. If investments fail to cover the cost of such borrowings, the value of the investments held by Ayr would decrease faster than if there had been no such borrowings. Additionally, if the investments fail to perform to expectation, the interests of investors in Ayr could be subordinated to such leverage, which will compound any such adverse consequences.

Risks related to the difficulty of attracting and retaining personnel.

Ayr’s success depends to a significant degree upon its ability to attract, retain and motivate highly skilled and qualified personnel. Failure to attract and retain necessary technical personnel, sales and marketing personnel and skilled management could adversely affect Ayr’s business. If Ayr fails to attract, train and retain sufficient numbers of these highly qualified people, its prospects, business, financial condition and results of operations will be materially and adversely affected.

Co-investment risk in terms of control over Ayr’s investments.

Ayr has co-invested and may continue to co-invest in one or more investments with certain strategic investors and/or other third parties through joint ventures or other entities, which parties in certain cases may have different interests or superior rights to those of Ayr. Although it is Ayr’s intent to retain control and other superior rights over Ayr’s investments, under certain circumstances it may be possible that Ayr relinquishes such rights over certain of its investments and, therefore, may have a limited ability to protect its position therein. In addition, even when Ayr does maintain a control position with respect to its investments, Ayr’s investments may be subject to typical risks associated with third-party involvement, including the possibility that a third-party may have financial difficulties resulting in a negative impact on such investment, may have economic or business interests or goals that are inconsistent with those of Ayr, or may be in a position to take (or block) action in a manner contrary to Ayr’s objectives. Ayr may also, in certain circumstances, be liable for the actions of its third-party partners or co-investors. Co-investments by third parties may or may not be on substantially the same terms and conditions as Ayr, and such different terms may be disadvantageous to Ayr.

Reliance on services agreement could adversely affect prospects and results.

Ayr provides administrative, consulting, and operations services to Tahoe Hydro through a separate management agreement governed by Nevada law. In exchange for providing these services, Ayr receives management fees which are a key source of revenue. Payment of such fees is dependent on the continuing validity and enforceability of the service agreement. If such agreement is found to be invalid or unenforceable or is terminated by the counterparty, this could have a material adverse effect on the business, prospects, financial condition, and operating results. If ultimate approval of license transfers is not able to be obtained, this could have a material adverse effect on Ayr.

Liabilities arising from Ayr’s website accessibility.

Internet websites are visible by people everywhere, not just in jurisdictions where the activities described therein are considered legal. As a result, to the extent Ayr sells services or products via web-based links targeting only jurisdictions in which such sales or services are compliant with State law, Ayr may face legal action in other jurisdictions which are not the intended object of any of Ayr’s marketing efforts for engaging in any web-based activity that results in sales into such jurisdictions deemed illegal under applicable laws.

Ayr is subject to the costs of being a public company.

As a public issuer, Ayr is subject to the reporting requirements and rules and regulations under the applicable Canadian securities laws and rules of any stock exchange on which Ayr’s securities may be listed from time to time. Additional or new regulatory requirements may be adopted in the future. The requirements of existing and potential future rules and regulations will increase Ayr’s legal, accounting and


financial compliance costs, make some activities more difficult, time-consuming or costly and may also place undue strain on its personnel, systems and resources, which could adversely affect its business and financial condition.

Certain remedies may be limited to Ayr.

Pursuant to its governing documents, Ayr and the shareholders of Ayr may be prevented from recovering damages for alleged errors or omissions made by the members of the Board and the Company’s officers. Ayr’s governing documents also provide that Ayr will, to the fullest extent permitted by law, indemnify members of the Board and the Company’s officers for certain liabilities incurred by them by virtue of their acts on behalf of Ayr.

Ayr may have difficulty enforcing judgments and effecting service of process on directors and officers.

The directors and officers of Ayr reside outside of Canada. Most or all of the assets of such persons may be located outside of Canada. Therefore, it may not be possible for Ayr shareholders to collect or to enforce judgments obtained in Canadian courts predicated upon the civil liability provisions of applicable Canadian securities laws against such persons. Moreover, it may not be possible for Ayr shareholders to effect service of process within Canada upon such persons.

Past performance is not indicative of future results.

The prior investment and operational performance of any of the Company’s businesses are not indicative of the future operating results of Ayr. There can be no assurance that the historical operating results achieved by any of the Company’s businesses or their affiliates will be achieved by Ayr, and Ayr’s performance may be materially different.

Financial projections may prove materially inaccurate or incorrect.

Any Ayr financial estimates, projections and other forward-looking information or statements included in this AIF were prepared by Ayr without the benefit of reliable historical industry information or other information customarily used in preparing such estimates, projections and other forward-looking information or statements. Such forward-looking information or statements are based on assumptions of future events that may or may not occur, which assumptions may not be disclosed in this AIF. Ayr shareholders should inquire of Ayr and become familiar with the assumptions underlying any estimates, projections or other forward-looking information or statements. Projections are inherently subject to varying degrees of uncertainty and their achievability depends on the timing and probability of a complex series of future events. There is no assurance that the assumptions upon which these projections are based will be realized. Actual results may differ materially from projected results for a number of reasons including increases in operation expenses, changes or shifts in regulatory rules, undiscovered and unanticipated adverse industry and economic conditions, and unanticipated competition. Accordingly, Ayr shareholders should not rely on any projections to indicate the actual results Ayr might achieve.

Ayr may not pay dividends.

Ayr does not anticipate paying any dividends on the Equity Shares or the Multiple Voting Shares in the foreseeable future. Dividends paid by Ayr would be subject to tax and, potentially, withholdings. See “Dividends”.

Ayr may be vulnerable to attacks on privacy systems, cyber-attacks and security of sensitive information.

The Company’s operations depend, in part, on how well it and its suppliers protect networks, equipment, IT systems and software against damage from a number of threats, including, but not limited to, cable cuts, damage to physical plants, natural disasters, intentional damage and destruction, fire, power loss, hacking, computer viruses, vandalism and theft. The Company’s operations also depend on the timely maintenance, upgrade and replacement of networks, equipment, IT systems and software, as well as pre-emptive expenses to mitigate the risks of failures. Any of these and other events could result in information system failures, delays and/or increase in capital expenses. Throughout the Company’s operations, the Company receives, retains and transmits certain confidential information, including personally identifiable information that Ayr’s customers provide to purchase products or services, interact with the Company’s personnel, or otherwise communicate with Ayr.

A privacy breach may occur through procedural or process failure, IT malfunction, or deliberate unauthorized intrusions. Theft of data for competitive purposes, particularly customer lists and preferences, is an ongoing risk whether perpetrated via employee collusion or negligence or through deliberate cyber-attack. Any such theft or privacy breach would have a material adverse effect on Ayr’s business, financial condition and results of operations. Ayr has not experienced any material losses to date relating to cyber-attacks or other information security breaches, but there can be no assurance that the Company will not incur such losses in the future.


The theft, destruction, loss, misappropriation, or release of sensitive and/or confidential information or intellectual property or interference with our IT systems or the technology systems of third parties on which we rely, could result in business disruption, negative publicity, brand damage, loss of employee confidence, violation of privacy laws, loss of customers, potential liability and competitive disadvantage. The Company’s risk and exposure to these matters cannot be fully mitigated because of, among other things, the evolving nature of these threats. As a result, cyber security and the continued development and enhancement of controls, processes and practices is designed to protect systems, computers, software, data and networks from attack, damage or unauthorized access is a priority. As cyber threats continue to evolve, Ayr may be required to expend additional resources to continue to modify or enhance protective measures or to investigate and remediate any security vulnerabilities.

Ayr may be vulnerable to risks related to maintaining cash deposits in excess of federally insured limits.

We maintain domestic cash deposits in Federal Deposit Insurance Corporation (“FDIC”) insured banks that exceed the FDIC insurance limits. Bank failures, events involving limited liquidity, defaults, non-performance, or other adverse developments that affect financial institutions, or concerns or rumors about such events, may lead to liquidity constraints. There can be no assurance that our deposits in excess of the FDIC or other comparable insurance limits will be backstopped by the United States government, or that any bank or financial institution with which we do business will be able to obtain needed liquidity from other banks, government institutions, or by acquisition in the event of a failure or liquidity crisis.

For example, on March 10, 2023, Silicon Valley Bank was closed by the California Department of Financial Protection and Innovation, which appointed the FDIC as receiver. Similarly, on March 12, 2023, Signature Bank and Silvergate Capital Corp. were each swept into receivership. Although we do not have any accounts at or business relationships with these banks, we may be negatively impacted by other disruptions to the United States banking system caused by these or similar developments and due to the fact that most banks and other financial institutions have not been willing to provide banking services to cannabis-related businesses, where available, we tend to rely upon smaller, regional banks and may be negatively impacted by other disruptions to the United States banking system caused by these or similar developments. The failure of a bank, or other adverse conditions in the financial or credit markets impacting financial institutions at which we maintain balances, could adversely impact our liquidity and financial performance.

Market and Economy Risks

Ayr may be vulnerable to currency exchange fluctuations.

Due to Ayr’s present operations in the United States, and its intention to continue future operations outside Canada, Ayr is expected to be exposed to significant currency fluctuations. Recent events in the global financial markets have been coupled with increased volatility in the currency markets. Currently, all of Ayr’s revenue is earned in U.S. dollars. Fluctuations in the exchange rate between the U.S. dollar and the Canadian dollar may have a material adverse effect on Ayr’s business, financial position or results of operations or prospects.

Ayr may be subject to market price volatility risks.

The market price of the Equity Shares may be subject to wide fluctuations in response to many factors, including variations in the operating results of Ayr, divergence in financial results from analysts’ expectations, changes in earnings estimates by stock market analysts, changes in the business prospects for Ayr, general economic conditions, legislative changes, and other events and factors outside of Ayr’s control. In addition, stock markets have from time to time experienced extreme price and volume fluctuations, which, as well as general economic and political conditions, could adversely affect the market price for the Equity Shares.

There may be restrictions on the market for the Equity Shares.

Notwithstanding that the Equity Shares are listed on the CSE (and excluding the Multiple Voting Shares which will not be listed securities), various regulatory regimes in the United States forbid the transfer of such Equity Shares in quantities that exceed published thresholds without receiving advanced approval of the State regulators. Failure to obtain approval may result in Ayr’s licenses in that State being revoked.

There is a limited market for the Equity Shares.

Notwithstanding that the Equity Shares are listed on the CSE (and excluding the Multiple Voting Shares which will not be listed securities), there can be no assurance that an active and liquid market for such Equity Shares will develop or be maintained and an Ayr shareholder may find it difficult to resell any securities of Ayr.


Ayr may be subject to the risks posed by sales by existing Ayr shareholders.

Sales of a substantial number of Equity Shares (and excluding the Multiple Voting Shares which will not be listed securities) in the public market could occur at any time by existing holders of such Equity Shares. These sales, or the market perception that the holders of a large number of Equity Shares intend to sell Equity Shares, could reduce the market price of the Equity Shares. If this occurs and continues, it could impair Ayr’s ability to raise additional capital through the sale of securities.

Global financial conditions and the future economic shocks may impair Ayr’s financial condition.

Following the onset of the credit crisis in 2007-2008, global financial conditions were characterized by extreme volatility and several major financial institutions either went into bankruptcy or were rescued by governmental authorities. While global financial conditions subsequently stabilized, there remains considerable risk in the system given the extraordinary measures adopted by government authorities to achieve that stability. Global financial conditions could suddenly and rapidly destabilize in response to future economic shocks, as government authorities may have limited resources to respond to future crises.

Future economic shocks may be precipitated by a number of causes, including a rise in the price of oil, geopolitical instability and natural disasters. Any sudden or rapid destabilization of global economic conditions could impact Ayr’s ability to obtain equity or debt financing in the future on terms favorable to Ayr. Additionally, any such occurrence could cause decreases in asset values that are deemed to be other than temporary, which may result in impairment losses. Further, in such an event, Ayr’s operations and financial condition could be adversely impacted. See Note 8, 9 and 10 to the Company’s consolidated financial statements for the year ended December 31, 2023.

Furthermore, general market, political and economic conditions, including, for example, inflation, interest and currency exchange rates, structural changes in the cannabis industry, supply and demand for commodities, political developments, legislative or regulatory changes, social or labor unrest and stock market trends will affect Ayr’s operating environment and its operating costs, profit margins and share price. Any negative events in the global economy could have a material adverse effect on Ayr’s business, financial condition, results of operations or prospects.

Ayr is exposed to changes in interest rates.

The Company is exposed to interest rate risk from fluctuations in interest rates which could adversely affect the operations or financial performance of the Company. Ayr is exposed to changes in market interest rates on cash, cash equivalents, bank indebtedness and long- term debt. Debt issued at variable rates expose the Company to cash flow interest rate risk. Debt issued at fixed rates exposes the Company to fair value interest rate risk. Ayr’s borrowings, current and future, will require interest payments and need to be repaid or refinanced, which could require the company to divert funds identified for other purposes to debt service and could create additional cash demands or impair its liquidity position and add financial risk. Diverting funds identified for other purposes for debt service may adversely affect business and growth prospects.

Ayr is exposed to high levels of inflation.

High levels of inflation could adversely affect consumer spending patterns and results in a reduction in consumption of cannabis products, including Ayr’s products. These conditions could also worsen cash flows, liquidity and access to capital for Ayr and cause other financial hardships for the Company and its suppliers, distributors, retailers and clients, thereby adversely impacting Ayr’s ability to produce and distribute its products.

Ayr’s profitability can be adversely affected to the extent it is faced with cost increases for wages and other labor-related expenses, insurance, and utilities, especially to the extent it is unable to recover such increased costs through increases in the prices for its services, due to one or more of general economic conditions, competitive conditions or contractual provisions in contracts.

Environmental Risks

Ayr may be subject to significant environmental regulations and risks.

Ayr’s operations are subject to environmental regulation in the various jurisdictions in which it operates. These regulations mandate, among other things, the maintenance of air and water quality standards and land reclamation. They also set forth limitations on the generation, transportation, storage and disposal of solid and hazardous waste. Environmental legislation is evolving in a manner which will require stricter standards and enforcement, increased fines and penalties for non-compliance, more stringent environmental assessments of proposed projects and a heightened degree of responsibility for companies and their officers, directors (or the equivalent thereof) and employees. There is no assurance that future changes in environmental regulation, if any, will not adversely affect Ayr’s operations.


Government approvals and permits are currently, and may in the future, be required in connection with Ayr’s operations. To the extent such approvals are required and not obtained, Ayr may be curtailed or prohibited from its proposed production of medical marijuana or from proceeding with the development of its operations as currently proposed.

Failure to comply with applicable laws, regulations and permitting requirements may result in enforcement actions thereunder, including orders issued by regulatory or judicial authorities causing operations to cease or be curtailed, and may include corrective measures requiring capital expenditures, installation of additional equipment, or remedial actions. Ayr may be required to compensate those suffering loss or damage by reason of its operations and may have civil or criminal fines or penalties imposed for violations of applicable laws or regulations.

Amendments to current laws, regulations and permits governing the production of medical marijuana, or more stringent implementation thereof, could have a material adverse impact on Ayr and cause increases in expenses, capital expenditures or production costs or reduction in levels of production or require abandonment or delays in development. The cost of compliance with changes in governmental regulations has the potential to reduce the imposition of fines or penalties as well as criminal charges against the Company for violations of applicable laws or regulations.

Ayr may be subject to unknown environmental risks.

There can be no assurance that Ayr will not encounter hazardous conditions at the facilities where it operates its businesses, such as asbestos or lead, in excess of expectations that may delay the development of its businesses. Upon encountering a hazardous condition, work at the facilities of Ayr may be suspended. The presence of other hazardous conditions may require significant expenditure of Ayr’s resources to correct the condition. Such conditions could have a material impact on the investment returns of Ayr.

Ayr may be adversely affected by climate change and climate change regulations.

Climate change is occurring around the world and may impact Ayr’s business in numerous ways. Such change could impact the price of raw materials and packaging. Rising temperatures and increased frequency of extreme weather, such as storms, hurricanes, floods, and droughts could cause increased disruption to the production and distribution of the Company’s products and have an adverse impact on consumer demand and spending. Severe weather conditions may also occur with higher frequency or may be less predictable in the future due to the effects of climate change.

Legislative and regulatory authorities in North America and internationally will likely continue to consider numerous measures related to climate change and greenhouse gas emissions. In order to produce, manufacture and distribute products, Ayr and its suppliers will need to use fuels, electricity and various other inputs that results in the release of greenhouse gas emissions. Concerns about the environmental impacts of greenhouse gas emissions and global climate change may result in environmental taxes, charges, regulatory schemes, assessments or penalties, which could restrict or negatively impact Ayr’s operations. The Company may not be able to pass any resulting cost increases along to its customer base. Any enactment of laws or passage of regulations regarding greenhouse gas emissions or other climate change legislation in North America or any other international jurisdiction where the Company conducts business could adversely affect its financial condition and results of operations.

While the Company has insurance policies in place that may cover some of the costs associated with extreme weather events and fires, it is possible such policies will not fully cover the damages and impacts associated with such events. The cost of such insurance coverage may become increasingly more expensive and such policies may be subject to limitations in the future, in which case the Company may bear more or all of the costs associated with extreme weather events and fires.

Tax Risks

Dual tax residence of Ayr.

Ayr is and will continue to be treated as a U.S. corporation for U.S. federal income tax purposes under section 7874(b) of the United States Internal Revenue Code of 1986, as amended (the “Code”) (although no tax ruling has been sought or obtained in this regard). As a result, Ayr is and will continue to be considered a U.S. domestic corporation for U.S. federal income tax purposes and therefore subject to U.S. federal income tax on its worldwide income. For Canadian tax purposes, however, Ayr is and will continue to be treated as a Canadian resident company (as defined in the Income Tax Act (Canada), as amended from time to time, including the regulations thereunder) for Canadian federal income tax purposes. Consequently, Ayr is and will continue to be subject to income tax both in Canada and the U.S., which could have a material adverse effect on its financial condition and results of operations.


The deduction of certain expenses of Ayr may be restricted.

As the Company operates in the cannabis industry, the Company is subject to the limits of Section 280E of the United States Internal Revenue Code (“Section 280E”), under which the Company is generally only allowed to deduct expenses directly related to the cost of goods sold. The U.S. Internal Revenue Service (“IRS”) has applied Section 280E broadly in tax audits against various cannabis businesses in the U.S. that are permitted under applicable state laws, seeking substantial sums in tax liabilities, interest and penalties resulting from underpayment of taxes due to the lack of deductibility of otherwise ordinary business expenses, the deduction of which is prohibited by Section 280E. Although the IRS issued a clarification allowing the deduction of certain expenses that can be categorized as cost of goods sold, the scope of such items is interpreted very narrowly, and the bulk of operating costs and general administrative costs are not permitted to be deducted. Therefore, businesses in the state-legal cannabis industry are subject to higher effective tax rates and thus may be less profitable than they would be otherwise. This would change if cannabis were to be rescheduled under Schedule III of the CSA. In addition, certain states, including Connecticut, Illinois, Massachusetts and New Jersey, do not conform to Section 280E and, accordingly, the Company generally deducts all operating expenses on its income tax returns in these states.

Dividends paid by Ayr may be subject to withholding tax.

It is unlikely that Ayr will pay any dividends on the Equity Shares in the foreseeable future. However, dividends received by holders who are residents of Canada for purpose of the Tax Act will be subject to U.S. withholding tax. Any such dividends may not qualify for a reduced rate of withholding tax under the Canada-United States Tax Convention (1980) as amended. In addition, a foreign tax credit or a deduction in respect of foreign taxes may not be available.

Dividends received by U.S. shareholders will not be subject to U.S. withholding tax but will be subject to Canadian withholding tax. Dividends paid by Ayr will be characterized as U.S. source income for purposes of the foreign tax credit rules under the Code. Accordingly, U.S. shareholders generally will not be able to claim a credit for any Canadian tax withheld unless, depending on the circumstances, they have an excess foreign tax credit limitation due to other foreign source income that is subject to a low or zero rate of foreign tax.

Dividends received by shareholders that are neither Canadian nor U.S. shareholders will be subject to U.S. withholding tax and will also be subject to Canadian withholding tax. These dividends may not qualify for a reduced rate of U.S. withholding tax under any income tax treaty otherwise applicable to a shareholder of Ayr, subject to examination of the relevant treaty. These dividends may however qualify for a reduced rate of Canadian withholding tax under any income tax treaty otherwise applicable to a shareholder of Ayr, subject to examination of the relevant treaty.

The transfer of Equity Shares may be subject to U.S. estate and generation-skipping transfer tax.

Because the Equity Shares will be treated as shares of a U.S. domestic corporation, the U.S. estate and generation-skipping transfer tax rules generally may apply to a non-U.S. holder of Equity Shares. Each shareholder should seek tax advice, based on such shareholder’s particular facts and circumstances, from an independent tax advisor.

Recent and proposed legislation in the United States Congress, including changes in United States tax law, may adversely impact Ayr and the value of the Equity Shares.

Changes to United States tax laws (which changes may have retroactive application) could adversely affect Ayr or holders of Equity Shares. In recent years, many changes to U.S. federal income tax laws have been proposed and made, and additional changes to United States federal income tax laws are likely to continue to occur in the future.

The United States Congress continuously considers numerous items of legislation which may be enacted prospectively or with retroactive effect, which legislation could adversely impact Ayr’s financial performance and the value of the Equity Shares. In particular, legislation known as the Inflation Reduction Act, passed in 2022, created some significant corporate tax law changes.

Among other changes, the Inflation Reduction Act enacted a new corporate alternative minimum tax (CAMT) imposing a 15% minimum tax on the adjusted financial statement income of large corporations for taxable years after December 31, 2022.  This new CAMT generally applies to large corporations with average annual financial statement income exceeding $1 billion.  The United States Internal Revenue Service has issued Notice 2023-97, which provides interim guidance pending the issuance of proposed regulations implementing the CAMT.  In particular, Notice 2023-97 clarifies which corporations are subject to the CAMT and how it is calculated. Existing guidance is subject to change, and final regulations are forthcoming.

The CAMT may result in greater U.S. tax liabilities for Ayr, which could negatively impact the value of the Equity Shares.  In addition, the impact of further changes to guidance, regulations, or other United States tax laws will remain uncertain.


EACH SHAREHOLDER SHOULD SEEK TAX ADVICE, BASED ON SUCH SHAREHOLDER’S PARTICULAR CIRCUMSTANCES, FROM AN INDEPENDENT TAX ADVISOR.

DIVIDENDS

The Company has not paid any cash dividends on its shares to date and does not anticipate paying any dividends in the foreseeable future. Subordinate Voting Shares and Multiple Voting Shares would be entitled to dividends on an equal per share basis, if, as and when declared by the Board.

DESCRIPTION OF SHARE CAPITAL

The Company is authorized to issue an unlimited number of Multiple Voting Shares and an unlimited number of Equity Shares, each without nominal or par value. The Equity Shares are “restricted securities” within the meaning of such term under applicable Canadian securities laws.

On December 3, 2020, the Company amended its constating documents (the “Capital Structure Amendments”) to, among other things, (i) create and set the terms of the Restricted Voting Shares and Limited Voting Shares, including applying coattail terms to such shares similar to those applicable to the Subordinate Voting Shares as more particularly described below, and (ii) amend the terms of the existing Multiple Voting Shares and Subordinate Voting Shares, including by amending the requirements in respect of who may hold Subordinate Voting Shares. The Company implemented the Capital Structure Amendments in order to seek to maintain its “foreign private issuer” (“FPI”) status under U.S. securities laws and thereby avoid a commensurate material increase in its ongoing costs. This has been accomplished by implementing a mandatory conversion mechanism in the Company’s share capital to decrease the number of shares eligible to be voted for directors of the Company if the Company’s FPI Threshold (as defined below) is exceeded. Each of the classes of Equity Shares is, as further described below, economically identical and mandatorily inter-convertible (continuously and without formality) based on (i) the holder’s status as a U.S. Person or Non-U.S. Person (each as defined below), and (ii) the status of the Company’s FPI Threshold. The Capital Structure Amendments were approved at the Company’s annual general and special meetings of shareholders on November 4, 2020 by, inter alia, a majority of the minority holders of Subordinate Voting Shares (i.e., other than those held by holders of Multiple Voting Shares and other persons not permitted to vote thereon under Ontario Securities Commission Rule 56-501 – Restricted Shares).

On June 24, 2021, at the annual and special meetings of the shareholders of the Company, a special resolution of all of the holders of the Equity Shares, and Multiple Voting Shares, voting together as if they were a single class of shares, was passed to amend and restate the Company’s articles in order to revise certain defined terms to better reflect applicable statutory provisions and to make certain other administrative changes.

The Company has received exemptive relief from the Canadian securities regulatory authorities such that, inter alia, each class of Equity Shares may be aggregated for the purposes of certain securities law reporting thresholds, including in respect of certain take-over bid and issuer bid rules and the early warning requirements under National Instrument 62-104 - Take-Over Bid and Issuer Bids (“NI 62-104”). See “Exemptions”.

The following description summarizes the material terms of Ayr’s share capital. This summary is not exhaustive and is qualified in its entirety by reference to Ayr’s articles, which is filed on SEDAR+ at www.sedarplus.ca.

As of February 7, 2024, the closing date of the Arrangement, the Company had the following Equity Shares, or securities convertible, exercisable or exchangeable into Equity Shares, outstanding:

Equity Shares

    

99,621,5431

Multiple Voting Shares

 

3,696,486

Exchangeable Shares

 

9,638,486

Mercer Warrants2

2,874,058

Anti- Dilutive Warrants

 

23,045,965


1 Includes 645,298 Equity Shares that are held by the Company in treasury (under applicable corporate law, such shares are not entitled to be voted or receive dividends).

2 See “Promoter”.


Equity Shares

Exercise of Voting Rights

The holders of each class of Equity Shares will be entitled to receive notice of, to attend (if applicable, virtually) and to vote at all meetings of shareholders of the Company, except that they will not be able to vote (but will be entitled to receive notice of, to attend (if applicable, virtually) and to speak) at those meetings at which the holders of a specific class are entitled to vote separately as a class under the BCBCA, and except that holders of Limited Voting Shares will not be entitled to vote for the election of directors. The Subordinate Voting Shares and Restricted Voting Shares carry one vote per share on all matters. The Limited Voting Shares carry one vote per share on all matters except the election of directors, as the holders of Limited Voting Shares do not have any entitlement to vote in respect of the election for directors of the Company. The Equity Shares are “restricted securities” within the meaning of such term under applicable Canadian securities laws.

In connection with any Change of Control Transaction (as defined below) requiring approval of all classes of Shares under the BCBCA, holders of the Shares shall be treated equally and identically, on a per share basis, unless different treatment of the shares of each such class is approved by a majority of the votes cast by the holders of outstanding Subordinate Voting Shares, Restricted Voting Shares and/or Limited Voting Shares, as applicable, in respect of a resolution approving such Change of Control Transaction, voting separately as a class at a meeting of the holders of that class called and held for such purpose.

For purposes herein, a “Change of Control Transaction” means an amalgamation, arrangement, recapitalization, business combination or similar transaction of the Company, other than an amalgamation, arrangement, recapitalization, business combination or similar transaction that would result in (i) the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the continuing entity or its direct or indirect parent) more than fifty percent (50%) of the total voting power of the voting securities of the Company, the continuing entity or its direct or indirect parent, and more than fifty percent (50%) of the total number of outstanding shares of the Company, the continuing entity or its direct or indirect parent, in each case as outstanding immediately after such transaction, and (ii) the shareholders of the Company immediately prior to the transaction owning voting securities of the Company, the continuing entity or its direct or indirect parent immediately following the transaction in substantially the same proportions (vis-a-vis each other) as such shareholders owned the voting securities of the Company immediately prior to the transaction (provided that in neither event shall the exercise of any exchangeable shares of a subsidiary of the Company that are exchangeable into shares of the Company be taken into account in such determination).

Notwithstanding the foregoing, the holders of Subordinate Voting Shares, Restricted Voting Shares and Limited Voting Shares, as applicable, are each entitled to vote as a separate class, in addition to any other vote of shareholders that may be required, in respect of any alteration, repeal or amendment of the Articles, which would: (i) adversely affect the rights or special rights of the holders of Subordinate Voting Shares, Restricted Voting Shares and/or Limited Voting Shares, as applicable (including an amendment to the terms of the Company’s articles which provide that any Multiple Voting Shares sold or transferred to a person that is not a Permitted Holder (as defined in the Company’s articles) shall be automatically converted into Subordinate Voting Shares and/or Restricted Voting Shares, as applicable); (ii) affect the holders of the Shares differently, on a per share basis; or (iii) except as otherwise set forth in the Company’s articles, as amended, create any class or series of shares ranking equal to or senior to the Subordinate Voting Shares, Restricted Voting Shares and/or Limited Voting Shares, as applicable; and in each case such alteration, repeal or amendment shall not be effective unless a resolution in respect thereof is approved by a majority of the votes cast by holders of outstanding Subordinate Voting Shares, Restricted Voting Shares and/or Limited Voting Shares, as applicable.

As long as any Subordinate Voting Shares remain outstanding, the Company will not, without the consent of the holders of the Subordinate Voting Shares by separate special resolution alter or amend the Company’s articles if the result would (i) prejudice or interfere with any right or special right attached to the Subordinate Voting Shares, or (ii) affect the rights or special rights of holders of the Subordinate Voting Shares or Multiple Voting Shares on a per share basis, as provided in the Company’s articles.

Dividends

Holders of Equity Shares are entitled to receive, as and when declared by the Board, dividends in cash or property of the Company. No dividend will be declared or paid on any class of Shares unless the Company simultaneously declares or pays, as applicable, equivalent dividends (on a per share basis) on all classes of Shares then issued and outstanding. Each class of Equity Shares shall rank equally with the other classes of Shares as to dividends on a share-for-share basis, without preference or distinction. In the event of the payment of a dividend in the form of shares, holders of Subordinate Voting Shares, Restricted Voting Shares and Limited Voting Shares shall receive Subordinate Voting Shares, Restricted Voting Shares and Limited Voting Shares, respectively, unless otherwise determined by the Board, provided an equal number of shares is declared as a dividend or distribution on a per-share basis, without preference or distinction, in each case.


Subdivision or Consolidation

No subdivision or consolidation of any class of Equity Shares shall occur unless simultaneously, all other classes of Shares are subdivided or consolidated or otherwise adjusted in the same manner so as to maintain and preserve the relative rights of the holders of each of the classes of Shares.

Liquidation, Dissolution or Winding-Up

In the case of liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, or in the event of any other distribution of assets of the Company for the purposes of a dissolution or winding-up of the Company, the holders of Subordinate Voting Shares are entitled, subject to the prior rights of the holders of any shares of the Company ranking in priority to the Subordinate Voting Shares, to receive the Company’s remaining property and are entitled to share equally, on a share for share basis, with all other classes of Shares in all distributions of such assets.

Rights to Subscribe; Pre-Emptive Rights

The holders of Equity Shares are not entitled to a right of first refusal to subscribe for, purchase or receive any part of any issue of shares, or bonds, debentures or other securities of the Company now or in the future.

Conversion

For the purposes of the Equity Shares, (i) a “U.S. Person” means resident of the United States, and a “Non-U.S. Person” is any person who is not a U.S. Person, and (ii) “held of record” has the meaning set forth in Rule 12g5-1 of the U.S. Exchange Act. Person. Under the Company’s articles, where Subordinate Voting Shares are held of record, directly or indirectly, or jointly by (i) one or more U.S. Persons, and (ii) one or more Non-U.S. Persons, such Subordinate Voting Shares shall be deemed to be held of record by a U.S. Person. At the request of the Company, beneficial shareholders and actual or proposed transferees are required to respond to enquiries regarding their status as U.S. Persons or Non-U.S. Persons, and are required to provide declarations or other documents with respect thereto, as may be necessary or desirable, in the discretion of the Company, failing which they would, in the Company’s discretion, be deemed to be U.S. Persons.

If, at any given time, the Subordinate Voting Shares are held of record by U.S. Persons, they will be automatically converted, without further act or formality, on a one-for-one basis into Restricted Voting Shares. If, at any given time, the Restricted Voting Shares or the Limited Voting Shares are held of record by Non-U.S. Persons, they will be automatically converted, without further act or formality, on a one-for-one basis into Subordinate Voting Shares.

Notwithstanding the foregoing, if, at any given time, the total number of Restricted Voting Shares represents a number equal to or in excess of the formulaic threshold set forth below (the “FPI Threshold”), then the minimum number of Restricted Voting Shares required to stay within the FPI Threshold will be automatically converted, without further act or formality, on a pro rata basis across all registered holders of Restricted Voting Shares (rounded up to the next nearest whole number of shares), on a one-for-one basis, into Limited Voting Shares:

(0.50 x Aggregate Number of Multiple Voting Shares, Subordinate Voting Shares and Restricted Voting Shares) – (Aggregate Number of Multiple Voting Shares held, beneficially owned or controlled by U.S. Persons)

If, at any given time, the total number of Restricted Voting Shares represents a number below the FPI Threshold, then a number of Limited Voting Shares will be automatically converted, without further act or formality, on a pro rata basis across all registered holders of Limited Voting Shares (rounded down to the next nearest whole number of shares), on a one-for-one basis, into Restricted Voting Shares, to the maximum extent possible such that the Restricted Voting Shares then represent a number of Shares that is one share less than the FPI Threshold.

The Company has received exemptive relief from the Canadian securities regulatory authorities such that, inter alia, each class of Equity Shares may be aggregated for the purposes of certain securities law reporting thresholds, including in respect of certain take-over bid and issuer bid rules and the early warning requirements under NI 62-104. See “Exemptions”.

If an offer is made to purchase any class of Shares (other than a class of Equity Shares) and such offer is one which is required, pursuant to applicable securities legislation or the rules of a stock exchange on which such Shares that are subject to the offer are then listed, to be made to all or substantially all the holders of such Shares in a given province of Canada to which these requirements apply (assuming that the offeree was a resident in Ontario), each Subordinate Voting Share, Restricted Voting Share and/or Limited Voting Share shall become convertible, at the option of the holder, on a one-for-one basis, into such class of Shares that are subject to the offer, at any time while such offer is in effect until the date prescribed by applicable securities legislation for the offeror to take up and pay for such shares as are to be


acquired pursuant to such offer. The conversion right may only be exercised in respect of Subordinate Voting Shares, Restricted Voting Shares and/or Limited Voting Shares, as applicable, for the purpose of depositing the resulting Shares pursuant to the offer, and for no other reason, including with respect to voting rights attached thereto, which are deemed to remain subject to the provisions concerning voting rights for Subordinate Voting Shares, Restricted Voting Shares and/or Limited Voting Shares, as applicable, notwithstanding their conversion. The transfer agent is required to deposit the resulting Shares pursuant to such offer on behalf of such holder.

Should the applicable Shares issued upon such conversion and tendered in response to such offer be withdrawn by shareholders of the Company or not taken up by the offeror, or should the offer be abandoned or withdrawn, then each Share resulting from such conversion shall be automatically reconverted, without any further act on the part of the Company or on the part of the holder, into one Subordinate Voting Share, Restricted Voting Share or Limited Voting Share, as applicable.

Constraints on Share Ownership

Subject to certain specified exceptions set out in the Company’s articles, as amended, (i) the Subordinate Voting Shares may only be held of record by Non-U.S. Persons, and (ii) the Restricted Voting Shares and Limited Voting Shares may only be held of record by U.S. Persons.

Renamed as Common Shares

At the effective time that there are no Multiple Voting Shares issued and outstanding (by the conversion of all Multiple Voting Shares, in accordance with their terms, into Subordinate Voting Shares or Restricted Voting Shares, as applicable), the Subordinate Voting Shares will henceforth be named and referred to as “Common Shares”.

Multiple Voting Shares

Exercise of Voting Rights

The holders of Multiple Voting Shares will be entitled to receive notice of, to attend (if applicable, virtually) and to vote at all meetings of shareholders of the Company, except that they will not be able to vote (but will be entitled to receive notice of, to attend (if applicable, virtually) and to speak) at those meetings at which the holders of a specific class are entitled to vote separately as a class under the BCBCA. The Multiple Voting Shares carry 25 votes per share.

In connection with any Change of Control Transaction requiring approval of the holders of all classes of Shares under the BCBCA, holders of the Shares shall be treated equally and identically, on a per share basis, unless different treatment of the shares of each such class is approved by a majority of the votes cast by the holders of outstanding Multiple Voting Shares or their proxyholders in respect of a resolution approving such Change of Control Transaction, voting separately as a class at a meeting of the holders of that class called and held for such purpose.

Notwithstanding the foregoing, the holders of Multiple Voting Shares shall be entitled to vote as a separate class, in addition to any other vote of shareholders that may be required, in respect of any alteration, repeal or amendment of the Company’s articles which would: (i) adversely affect the rights or special rights of the holders of Multiple Voting Shares (including an amendment to the terms of the Company’s which provide that any Multiple Voting Shares sold or transferred to a person that is not a Permitted Holder (as defined in the Company’s articles) shall be automatically converted into Subordinate Voting Shares or Restricted Voting Shares); or (ii) affect the holders of the Multiple Voting Shares and Subordinate Voting Shares, Restricted Voting Shares and/or Limited Voting Shares, as applicable, differently, on a per share basis; or (iii) except as otherwise set forth in the Company’s, create any class or series of shares ranking equal to or senior to the Multiple Voting Shares; and in each case such alteration, repeal or amendment shall not be effective unless a resolution in respect thereof is approved by a majority of the votes cast by holders of outstanding Multiple Voting Shares.

Dividends

Holders of Multiple Voting Shares shall be entitled to receive, as and when declared by the Board, dividends in cash or property of the Company. No dividend will be declared or paid on any class of Equity Shares unless the Company simultaneously declares or pays, as applicable, equivalent dividends (on a per share basis) on the Multiple Voting Shares. The Multiple Voting Shares shall rank equally with the Equity Shares as to dividends on a share-for-share basis, without preference or distinction. In the event of the payment of a dividend in the form of shares, holders of Multiple Voting Shares shall receive Multiple Voting Shares, unless otherwise determined by the Board, provided an equal number of shares is declared as a dividend or distribution on a per-share basis, without preference or distinction, in each case.


Subdivision or Consolidation

No subdivision or consolidation of the Multiple Voting Shares shall occur unless simultaneously each class of Equity Shares is subdivided or consolidated or otherwise adjusted in the same manner so as to maintain and preserve the relative rights of the holders of the Multiple Voting Shares and the Equity Shares.

Liquidation, Dissolution or Winding-Up

In the case of liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, or in the event of any other distribution of assets of the Company for the purposes of a dissolution or winding-up of the Company, the holders of Multiple Voting Shares are entitled, subject to the prior rights of the holders of any shares of the Company ranking in priority to the Multiple Voting Shares, to receive the Company’s remaining property and are entitled to share equally, on a share for share basis, with the Subordinate Voting Shares in all distributions of such assets.

Rights to Subscribe; Pre-Emptive Rights

The holders of Multiple Voting Shares are not entitled to a right of first refusal to subscribe for, purchase or receive any part of any issue of shares, or bonds, debentures or other securities of the Company now or in the future.

Conversion

At the holder’s option, the Multiple Voting Shares are convertible, on a one-for-one basis, into Subordinate Voting Shares or Restricted Voting Shares, as applicable. In addition, the Multiple Voting Shares will be automatically converted, without further act or formality, into Subordinate Voting Shares or Restricted Voting Shares, as applicable, on the earliest of (i) the fifth anniversary of May 24, 2019, (ii) the date on which such Multiple Voting Shares are held or controlled by a person who is not a Permitted Holder (as defined in the Company’s articles) under the Company’s articles, and (iii) the date on which the aggregate number of Multiple Voting Shares issued and outstanding represents less than one-third of the number of Multiple Voting Shares issued and outstanding at the close of business on the first date of issuance, being May 24, 2019. The Multiple Voting Shares are currently expected to convert automatically into Equity Shares on May 24, 2024.

The Multiple Voting Shares are subject to coat-tail provisions, as set forth in the Company’s articles.

Compliance Provisions

The Company’s notice of articles and articles contain, in respect of the Equity Shares and Multiple Voting Shares, certain provisions to facilitate compliance with applicable regulatory and/or licensing regulations (the “Compliance Provisions”). The Compliance Provisions include a combination of certain remedies such as an automatic suspension of voting and/or dividend rights, a discretionary right to force a share transfer to a third party and/or a discretionary redemption right in favour of Ayr, in each case to seek to ensure that Ayr and its subsidiaries are able to comply with applicable regulatory and licensing regulations. The purpose of the Compliance Provisions is to provide Ayr with a means of protecting itself from having a shareholder, or as determined by the Board, a group of shareholders acting jointly or in concert, with an ownership interest of, whether of record or beneficially (or having the power to exercise control or direction over) (“Owning or Controlling”), five percent (5%) or more of the issued and outstanding Shares, or such other number as is determined by the Board from time to time, and: (i) who a governmental authority granting licenses to, or otherwise governing the operations of, Ayr or its subsidiaries has determined to be unsuitable to own Shares; (ii) whose ownership of Shares may reasonably result in the loss, suspension or revocation (or similar action) with respect to any licenses or permits relating to Ayr’s or its subsidiaries’ conduct of business (being the conduct of any activities relating to the cultivation, manufacturing and dispensing of cannabis and cannabis-derived products in the United States, which include the owning and operating of cannabis licenses) or in Ayr being unable to obtain any new licenses or permits in the normal course, all as determined by the Board; or (iii) who have not been determined by the applicable regulatory authority to be an acceptable person or otherwise have not received the requisite consent of such regulatory authority to own the Shares, in each case within a reasonable time period acceptable to the Board or prior to acquiring any Shares (in each case, an “Unsuitable Person”). The ownership restrictions in Ayr’s notice of articles and articles are also subject to an exemption for applicable depositaries and clearing houses as well as underwriters (as defined in the Securities Act (Ontario)) in the course of a distribution of securities of Ayr.

Notwithstanding the foregoing, the Compliance Provisions provide that any shareholder (or group of shareholders acting jointly or in concert) proposing to Own or Control five percent (5%) or more of the issued and outstanding Shares (or such other number as is determined by the Board from time to time) will be required to provide not less than 30 days’ advance written notice to Ayr by mail sent to Ayr’s registered office to the attention of the Jonathan Sandelman, the Company’s corporate secretary (the “Corporate Secretary”), and to obtain all necessary regulatory approvals. Upon any such shareholder(s) Owning or Controlling five percent (5%) or more of the issued and outstanding


Shares (or such other number as is determined by the Board from time to time), and having not received the requisite approval of any applicable regulatory authority to own the Shares, the Compliance Provisions will provide: (i) that such shareholder(s) may, in the discretion of the Board, be prohibited from exercising any voting rights and/or receiving any dividends from Ayr, unless and until all requisite regulatory approvals are obtained; and (ii) Ayr with a right, but not the obligation, at its option, upon notice to the Unsuitable Person, to: (A) redeem any or all Shares directly or indirectly held by an Unsuitable Person; and/or (B) forcibly transfer any or all Shares directly or indirectly held directly or indirectly by an Unsuitable Person to a third party. Such rights are required in order for Ayr to comply with regulations in various jurisdictions where Ayr or its subsidiaries conduct business or are expected to conduct business.

Upon receipt by the holder of a notice to redeem or to transfer any or all of its Shares, the holder will be entitled to receive, as consideration therefor, no less than 95% of the lesser of: (i) the closing price of the Equity Shares on the CSE (or the then principal exchange on which Ayr’s securities are quoted for trading) on the trading day immediately prior to the closing of the redemption or transfer (or the average of the last bid and last asking prices if there was no trading on the specified date); and (ii) the five-day volume weighted average price of the Equity Shares on the CSE (or the then principal exchange on which CSAC’s securities are quoted for trading) for the five trading days immediately prior to the closing of the redemption or transfer (or the average of the last bid and last asking prices if there was no trading on the specified dates).

Further, a holder of Shares is prohibited from acquiring five percent (5%) or more of the issued and outstanding Shares, directly or indirectly, in one or more transactions, without providing 30 days’ advance written notice to Ayr by mail sent to Ayr’s registered office to the attention of the Corporate Secretary. The foregoing restriction will not apply to the ownership, acquisition or disposition of Shares as a result of: (i) transfer of Shares occurring by operation of law including, inter alia, the transfer of Shares to a trustee in bankruptcy, (ii) an acquisition or proposed acquisition by one or more underwriters who hold Shares for the purposes of distribution to the public or for the benefit of a third party provided that such third party is in compliance with the foregoing restriction, or (iii) conversion, exchange or exercise of securities issued by Ayr or a subsidiary into or for Shares in accordance with their respective terms. If the Board reasonably believes that any such holder of the Shares may have failed to comply with the foregoing restrictions, Ayr may apply to the Supreme Court of British Columbia, or any other court of competent jurisdiction, for an order directing that such shareholder disclose the number of Shares directly or indirectly held.

Ayr may not be able to exercise such rights in full or at all, including its redemption rights. Under the BCBCA, a corporation may not make any payment to redeem shares if there are reasonable grounds for believing that the company is unable to pay its liabilities as they become due in the ordinary course of its business or if making the payment of the redemption price or providing the consideration would cause the company to be unable to pay its liabilities as they become due in the ordinary course of its business. Furthermore, Ayr may become subject to contractual restrictions on its ability to redeem its Shares by, for example, entering into a secured credit facility subject to such restrictions. In the event that restrictions prohibit Ayr from exercising its redemption rights in part or in full, Ayr will not be able to exercise its redemption rights absent a waiver of such restrictions, which Ayr may not be able to obtain on acceptable terms or at all.

Warrants

Mercer Warrants

Each Subordinate Voting Share purchase warrant of the Company (each, a “Warrant”) is exercisable to purchase one Equity Share at a price of $9.07 per share, subject to the following adjustments. The Mercer Warrant Agreement provides that the exercise price and number of Equity Shares issuable on exercise of the Warrants may be adjusted in certain circumstances, including in the event of a stock dividend, extraordinary dividend or a recapitalization, reorganization, merger or consolidation. The Warrants will not, however, be adjusted for issuances of Equity Share at a price below their exercise price. The exercise of the Warrants by any holder in the United States, or that is a U.S. person (as such term is defined in Regulation S of the Securities Act), may only be effected in compliance with an exemption from the registration requirements of the U.S. Securities Act and applicable state “blue sky” securities laws. A Warrant holder does not have the rights or privileges of holders of shares or any voting rights until it exercises its Warrants and receives corresponding Equity Shares. After the issuance of corresponding Equity Shares upon exercise of the Warrants, a Warrant holder will be entitled to one vote for each share held of record on all matters to be voted on by shareholders. All of the Warrants other than the Mercer Warrants expired on September 30, 2021, in accordance with the terms of the Mercer Warrant Agreement. There are 2,874,058 Mercer Warrants to purchase the same number of Equity Shares issued and outstanding as of the date hereof. The Mercer Warrants were issued in connection with the qualifying transaction of the Company, and are exercisable at $9.07 per share until May 24, 2024. See “Promoter”.

Anti-Dilutive Warrants

There were 23,045,965 Anti-Dilutive Warrants to purchase the same number of Equity Shares issued and outstanding as of February 7, 2024. The Anti-Dilutive Warrants were issued in connection with the Arrangement and are listed on the CSE under the trading symbol “AYR.WT.U”. The Anti-Dilutive Warrants are exercisable at $2.12 per share until February 7, 2026 and are only exercisable by non-U.S.


persons and accredited investors as such terms are defined under applicable United States securities laws. See “General Development of the Business – Subsequent Developments – Completion of Previously Announced Debt Restructuring”.

Coattail Agreement

Under applicable Canadian law, an offer to purchase Multiple Voting Shares would not necessarily require that an offer be made to purchase the Subordinate Voting Shares, Restricted Voting Shares and/or Limited Voting Shares. In accordance with the rules applicable to most senior issuers in Canada, in the event of a take-over bid, the holders of Equity Shares would be entitled to participate on an equal footing with holders of Multiple Voting Shares. In connection with the Qualifying Transaction, the owners of all the outstanding Multiple Voting Shares entered into a customary coattail agreement with Ayr and Odyssey, as trustee (the “Coattail Agreement”). The Coattail Agreement contains provisions customary for multi-class listed corporations designed to prevent transactions that otherwise would deprive the holders of Equity Shares of rights under applicable provincial take-over bid legislation to which they would have been entitled if the Multiple Voting Shares had been a class of Equity Shares. The undertakings in the Coattail Agreement would not apply to prevent a sale by any holder of Multiple Voting Shares if concurrently an offer is made to purchase Equity Shares that:

(a)

offers a price per Equity Share in the same form of consideration and at least as high as the highest price per share paid pursuant to the take-over bid for the Multiple Voting Shares (on an as-converted basis to Equity Shares);

(b)

provides that the percentage of outstanding Equity Shares to be taken up (exclusive of shares owned immediately prior to the offer by the offeror or persons acting jointly or in concert with the offeror) is at least as high as the percentage of Multiple Voting Shares to be sold (exclusive of Multiple Voting Shares owned immediately prior to the offer by the offeror or persons acting jointly or in concert with the offeror);

(c)

as no condition attached other than the right not to take up and pay for Equity Shares or Multiple Voting Shares tendered if no shares are purchased pursuant to the offer for Multiple Voting Shares; and

(d)

is in all other material respects identical to the offer for Multiple Voting Shares.

In addition, the terms of the Coattail Agreement do not prevent the transfer of Multiple Voting Shares by a holder to certain permitted holders, including without limitation, the Founders and persons controlled by them. The conversion of Multiple Voting Shares into Equity Shares would not constitute a disposition of Multiple Voting Shares for the purposes of the Coattail Agreement.

Under the Coattail Agreement, any disposition of Multiple Voting Shares (including a transfer to a pledgee as security) by a holder of Multiple Voting Shares party to the agreement would be conditional upon the transferee or pledgee abiding by the terms of the Coattail Agreement. The Coattail Agreement contain provisions for authorizing action by the trustee to enforce the rights under the Coattail Agreement on behalf of the holders of the Equity Shares, which obligation is conditional on Ayr or holders of the Equity Shares providing such funds and indemnity as the trustee may require. No holder of Equity Shares would have the right, other than through the trustee, to institute any action or proceeding or to exercise any other remedy to enforce any rights arising under the Coattail Agreement unless the trustee fails to act on a request authorized by holders of not less than 10% of the outstanding Equity Shares, and reasonable funds and indemnity have been provided to the trustee. Ayr agrees to pay the reasonable costs of any action that may be taken in good faith by holders of Equity Shares, as the case may be, pursuant to the Coattail Agreement.

The Coattail Agreement may not be amended, and no provision thereof may be waived, unless, prior to giving effect to such amendment or waiver, the following have been obtained:

(a)

the consent of the applicable securities regulatory authority in Canada; and

(b)

the approval of at least 662/3% of the votes cast by holders of each of the Subordinate Voting Shares, Restricted Voting Shares and Limited Voting Shares, excluding votes attached to Equity Shares, if any, held by the holders of Multiple Voting Shares, their affiliates and any persons who have an agreement to purchase Multiple Voting Shares on terms which would constitute a sale or disposition for purposes of the Coattail Agreement other than as permitted thereby.

No provision of the Coattail Agreement would limit the rights of any holders of Equity Shares under applicable law.

Debt Securities

Pursuant to the Arrangement, 100% of the 2024 Notes, in an aggregate principal amount of $243.25 million, were assigned by the Senior Noteholders to Ayr Wellness Canada, a wholly owned subsidiary of the Company, in exchange for the 2026 Exchange Notes, which


obligations are guaranteed by the Company and each of the Company’s other direct and indirect subsidiaries and secured by all or substantially all of the assets and properties of Ayr Wellness Canada, the Company and each guaranteeing subsidiary, subject to certain exemptions. In addition, a Senior Noteholder, inter alia, subscribed for $50 million aggregate principal amount of Additional 2026 Notes, issued at a 20% original issue discount (resulting in $40 million of gross proceeds to the Company). The 2026 Notes pay interest of 13.0% per annum (semi-annually) and mature on December 10, 2026. The Company intends to wind-up Ayr Wellness Canada in the near future, pursuant to which all of the assets and liabilities of Ayr Wellness Canada, including the 2026 Notes, will become the assets and liabilities of the Company. Upon completion of same, the 2024 Notes will be cancelled. See “General Development of the Business – Subsequent Developments – Completion of Previously Announced Debt Restructuring”.

MARKET FOR SECURITIES

TRADING PRICE AND VOLUME

As of December 29, 2023, being the last trading day of the year ended December 31, 2023, the closing price of the Equity Shares on the CSE was C$2.43. As of March 12, 2024, the closing price of the Equity Shares and the Anti-Dilutive Warrants on the CSE was C$2.24 and US$0.65, respectively.

The Equity Shares and Anti-Dilutive Warrants are currently listed on the CSE under the trading symbols “AYR.A” and “AYR.WT.U”, respectively. The Equity Shares are quoted on the OTCQX under the symbol “AYRWF”.

The 2024 Notes began trading on the CSE on April 21, 2021 under the symbol “AYR.NT.U” and were delisted on February 7, 2024 following completion of the Arrangement. The Multiple Voting Shares and the Mercer Warrants are unlisted.

Equity Shares

The following table sets forth information relating to the price range and volume traded for the Equity Shares (AYR.A) on a monthly basis for each month in the fiscal year ended December 31, 2023 in which the Equity Shares were listed for trading:

High Price 

Low Price

Month

    

(C$)

    

 (C$)

    

Traded Volume

December 2023

3.93

2.07

3,094,968

November 2023

 

3.17

 

1.49

 

4,537,858

October 2023

 

3.46

 

1.47

 

3,831,193

September 2023

 

4.45

 

1.66

 

6,457,458

August 2023

 

2.00

 

1.07

 

1,729,113

July 2023

 

1.78

 

1.16

 

2,533,371

June 2023

 

1.43

 

1.09

 

1,392,925

May 2023

 

1.87

 

0.92

 

3,429,378

April 2023

 

1.17

 

0.78

 

2,110,481

March 2023

 

1.57

 

0.86

 

3,206,063

February 2023

 

1.87

 

1.53

 

2,346,893

January 2023

 

1.97

 

1.60

 

1,991,932


SECURITIES SUBJECT TO CONTRACTUAL RESTRICTION ON TRANSFER

The Multiple Voting Shares and certain of the Exchangeable Shares are subject to contractual transfer restrictions.

Directors and Officers

Names, Occupations and Security Holdings

The names and municipality of residence of the directors of the Board, their position with the Company, their principal occupation, the date upon which they became a director of the Company and the number of voting or other securities beneficially owned by each of them, or over which control or direction is exercised by each of them as of December 31, 2023, are as follows: (which, for greater certainty, does not include any securities issued in connection with the Arrangement):

Name and

    

Position Held 

    

    

Director

    

Holdings (Security, Number, 

Place of Residence

in the Company

Principal Occupation(1)

Since

Percentage of Class)

Jonathan Sandelman Miami, FL

    

Executive Chair

    

Chief Executive Officer, Mercer Park, L.P.

    

September 25, 2017

    

Equity Shares

    

1,034,272

(2)(3)

1.60

%  

 

Multiple Voting Shares

 

3,677,626

(4)

99.49

%  

Mercer Warrants

 

2,874,058

(5)

100

%  

Charles Miles Brooklyn, NY

 

Director

(6)(7)

Consultant, Recapture Partners

(8)

September 25, 2017

 

Equity Shares

 

232,763

0.36

%  

 

Multiple Voting Shares

 

9,430

 

0.26

%  

Mercer Warrants

 

Nil

 

N/A

Louis F. Karger Needham, MA

 

Director

 

Manager, Founder and owner of Panther Properties Management LLC and Panther Residential Management LLC

May 24, 2019

 

Equity Shares

 

20,934

(9)

0.03

%  

Multiple Voting Shares

 

Nil

 

N/A

Mercer Warrants

 

Nil

 

N/A

Glenn Isaacson New York, NY

 

Director

(7)

President of Bradford Allen’s New York office; Previously Vice Chairman, Cushman & Wakefield

August 25, 2020

 

Equity Shares

 

156,214

0.24

%  

Multiple Voting Shares

 

Nil

 

N/A

 

 

Mercer Warrants

 

Nil

 

N/A

Michael Warren San Francisco, CA

 

Director

(7)

Managing Director, Allspring Global Investments;Previously Managing Director, Wells Fargo Asset Management

August 3, 2023

 

Equity Shares

 

Nil

N/A

Multiple Voting Shares

 

Nil

N/A

Mercer Warrants

 

Nil

N/A

Joyce Johnson -Miller Chicago, IL

 

Director

(7)

Chairwoman, Pacific Gate Capital Management

January 20, 2022

 

Equity Shares

 

3,537

0.01

%

 

Multiple Voting Shares

 

Nil

N/A

Mercer Warrants

 

Nil

N/A

Notes:

(1)Each director has been at their principal occupation for at least five years unless otherwise specified herein.

(2)

26,218 of such Equity Shares are beneficially owed by Mercer. Mercer is a limited partnership of which Mercer Park CB GP, LLC is the general partner and which itself is indirectly controlled by Jonathan Sandelman.

(3)

Jonathan Sandelman also directly owns unvested exchangeable restricted stock units (“RSUs”) to acquire 111,850 Exchangeable Shares and unvested performance restricted stock units (“PRSUs”) to acquire 250,000 Exchangeable Shares.

(4)

478,7116 of such Equity Shares are beneficially owed by Mercer. Mercer is a limited partnership of which Mercer Park CB GP,


LLC is the general partner and which itself is indirectly controlled by Jonathan Sandelman.

(5)

Such warrants are beneficially owned by Mercer. Mercer is a limited partnership of which Mercer Park CB GP, LLC is the general partner and which itself is indirectly controlled by Jonathan Sandelman.

(6)Member of the Compensation, Nominating and Corporate Governance Committee.

(7)Member of the Audit Committee.

(8)

Charles Miles previously worked at Bloomberg LLP as an equity option trader, and prior to his tenure at Bloomberg, co-founded Claris Capital Management and served as Chief Information Officer.

(9)

Louis Karger also indirectly owns 275,979 Membership Interests held through Green Partners Investor LLC and Green Partners Sponsor I, LLC.


The names and municipality of residence of the non-director officers of the Company, their position with the Company, their principal occupation, the date upon which they became a director of the Company and the number of voting or other securities beneficially owned by each of them, or over which control or direction is exercised by each of them as of December 31, 2023, are as follows (which, for greater certainty, does not include any securities issued in connection with the Arrangement):

Name and

    

Position Held 

    

Principal

    

    

Holdings (Security, Number, 

Place of Residence

in the Company

 Occupation(1)

Officer Since

Percentage of Class)

David Goubert Davie, FL

    

President and Chief Executive Officer

    

President and Chief Executive Officer of Ayr; Previously President and Chief Customer Officer, Neiman Marcus and Senior Vice President of Retail, Starboard Cruise Service

    

November 1, 2022

    

Equity Shares

    

575,692

(2)

0.89

%  

 

Multiple Voting Shares

 

Nil

N/A

 

Mercer Warrants

 

Nil

N/A

Brad Asher Miami, FL

 

Chief Financial Officer

Chief Financial Officer of Ayr

November 14, 2019

 

Equity Shares

 

29,203

(3)

0.05

%  

 

Multiple Voting Shares

 

Nil

N/A

 

Mercer Warrants

Nil

N/A

George DeNardo

Chief Operating Officer

Chief Operating Officer of Ayr; Previously Senior Vice President of Operations, Columbia Care

November 13, 2023

Multiple Voting Shares

Nil

N/A

Mercer Warrants

Nil

N/A

Equity Shares

Nil

(4)

N/A


Jamie Mendola San Francisco, CA

 

Chief Business Development Officer

Chief Business Development Officer of Ayr; Previously Director, Monaker Group and Founder and Chief Investment Officer, Pacific Grove Capital LP

May 24, 2019

 

Equity Shares

 

234,462

(5)

0.36

%  

Multiple Voting Shares

 

Nil

N/A

Mercer Warrants

 

Nil

N/A

Notes:

(1)Each officer has been at their principal occupation for at least five years unless otherwise specified herein.

(2)

David Goubert also directly owns unvested RSUs to acquire 461,538 Exchangeable Shares.

(3)

Brad Asher also directly owns unvested RSUs to acquire 640,000 Exchangeable Shares and unvested PRSUs to acquire 250,000 Exchangeable Shares.

(4)

George DeNardo also directly owns unvested RSUs to acquire 200,000 Exchangeable Shares.

(5)

Jamie Mendola also directly owns unvested RSUs to acquire 722,500 Exchangeable Shares and unvested PRSUs to acquire 250,000 Exchangeable Shares.


Shareholdings of Directors and Executive Officers

As of December 31, 2023, as a group (including director appointments subsequent to December 31, 2023), the directors and executive officers of the Company beneficially own, or control or direct, directly or indirectly (i) 2,287,077 Equity Shares and Exchangeable Shares, representing 3.54% of the Company’s issued and outstanding shares (excluding Multiple Voting Shares), and (ii) 3,687,056 Multiple Voting Shares, representing 99.75% of such class of securities, and (iii) 5,974,133 of the Company’s total issued and outstanding shares, representing 7.67% of the Company’s total issued and outstanding shares.

Jonathan Sandelman holds the position of Chief Executive Officer of the parent company of Mercer and therefore may through such role have significant influence over the shares of the Company owned by Mercer.

Corporate Cease Trade Orders, Bankruptcies, Penalties or Sanctions

To the knowledge of the Company and based upon information provided by the directors and executive officers, none of the Company’s directors and executive officers is, or within ten years prior to the date hereof has been, a director, chief executive officer or chief financial officer of any company (including the Company) that (i) was subject to a cease trade order, an order similar to a cease trade order, or an order that denied the relevant company access to any exemption under securities legislation, that was in effect for a period of more than 30 consecutive days, that was issued while the director or executive officer was acting in the capacity as director, chief executive officer or chief financial officer, or (ii) was subject to a cease trade order, an order similar to a cease trade order, or an order that denied the relevant company access to any exemption under securities legislation, that was in effect for a period of more than 30 consecutive days, that was issued after the director or executive officer ceased to be a director, chief executive officer or chief financial officer and which resulted from an event that occurred while that person was acting in the capacity as director, chief executive officer or chief financial officer.

To the knowledge of the Company and based upon information provided by the directors and executive officers, none of the Company’s directors and executive officers is, or (i) within ten years prior to the date hereof has been, a director or executive officer of any company (including the Company) that, while that person was acting in that capacity, or within a year of that person ceasing to act in that capacity, became bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency or was subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver, receiver manager or trustee appointed to hold its assets, or (ii) has, within ten years prior to the date hereof, become bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency, or become subject to or instituted any proceedings, arrangement or compromise with creditors, or had a receiver, receiver manager or trustee appointed to hold the assets of the director or executive officer.

To the knowledge of the Company and based upon information provided by the directors, except for the following, none of the Company’s directors and executive officers has (i) been subject to any penalties or sanctions imposed by a court relating to securities legislation or by a securities regulatory authority or has entered into a settlement agreement with a securities regulatory authority, or (ii) been subject to any penalties or sanctions imposed by a court or regulatory body that would likely be considered important to a reasonable investor in making an investment decision.

Conflicts of Interest and Interests of Management and Others in Material Transactions

To the best of the Company’s knowledge, other than as disclosed below and elsewhere in this AIF, there are no known existing or potential material conflicts of interest among the Company or a subsidiary of the Company and a director or officer of the Company or a subsidiary of the Company as a result of their outside business interests except that: (i) certain of the Company’s or its subsidiaries’ directors and officers serve as directors and officers of other companies, and therefore it is possible that a conflict may arise between their duties to the Company and their duties as a director or officer of such other companies, and (ii) certain of the Company’s or its subsidiaries’ directors and officers have portfolio investments consisting of minority stakes in businesses that may compete directly or indirectly with the Company or act as a customer of, or supplier to, the Company. The BCBCA requires, among other things, that the directors and executive officers of Ayr act honestly and in good faith with a view to the best interest of Ayr, to disclose any personal interest which they may have in any material contract or transaction which is proposed to be entered into with Ayr and, in the case of directors, to abstain from voting as a director for the approval of any such contract or transaction. To the extent that conflicts of interest arise, such conflicts are required to be resolved in accordance with the provisions of the BCBCA.

Certain of the directors of the Company are formerly vendors of certain of the businesses comprising the Company’s Qualifying Transaction, namely Louis Karger for Sira and Mark Smith for CannaPunch, and so while it is possible that a dispute may arise pursuant to the respective Definitive Agreement, there are no current material disputes or claims.


PROMOTER

Mercer was considered a promoter of Ayr within the meaning of applicable securities legislation at the time of the Offering.

As of December 31, 2023, Mercer owns, of record and beneficially, (i) 3,677,626 Multiple Voting Shares, representing approximately 99.5% of the issued and outstanding Multiple Voting Shares, (ii) 2,874,058 Equity Share purchase warrants (the “Mercer Warrants”), which are exercisable for one Equity Share each for an exercise price of $9.07 until May 24, 2024, and (iii) 1,103,931 Anti-Dilutive Warrants, which are exercisable for one Equity Share each for an exercise price of $2.12 until February 7, 2026.

LEGAL PROCEEDINGS AND REGULATORY ACTIONS

Other than as set out below and under “Non-Compliance with State and Local Cannabis Laws”, Ayr is not party to any material legal proceedings or regulatory actions nor, to its knowledge, are any such material proceedings or actions contemplated by or against the Company.

Dispute with FTI

In June 2020, the Company signed an engagement letter with FTI Capital Advisors – Canada ULC (“FTI”) to assist Ayr with raising debt or equity capital in the estimated amount of $50 to 60 million and agreed to pay a fee of between 2.5% to 6% of the capital raised by FTI. Although one (1) opportunity that was presented by FTI was pursued, no financing transactions were completed with FTI and the engagement agreement was ultimately terminated by Ayr in December 2020.

In early 2021, FTI commenced a claim against Ayr in the Ontario Superior Court of Justice seeking fees in respect of a number of financing transactions in respect of which FTI had no involvement, including a $110 million debt offering and approximately $41 million of warrant exercises.  FTI has not specified the amount of damages claimed. Ayr is strenuously defending the proceedings vigorously and has denied liability to FTI. The ultimate resolution of the proceedings is uncertain at this time.

AUDITORS, TRANSFER AGENT AND REGISTRAR

Since August 16, 2021, Ayr’s auditors are Marcum LLP, having an address at 730 Third Avenue, 11th Floor, New York, NY 10017, United States. Such firm is independent of the Company within the meaning of the Rules of Professional Conduct of the Chartered Professional Accountants of Ontario (registered name of The Institute of Chartered Accountants of Ontario and within the meaning of the U.S. Public Company Accounting Oversight Board Rule 3520, Auditor Independence).

Odyssey, at its principal offices in Toronto, Ontario, is the transfer agent and registrar for the Equity Shares and the Multiple Voting Shares.

MATERIAL CONTRACTS

As of December 31, 2023, the following are the material contracts of Ayr, other than contracts entered into in the ordinary course of business:

(a)

the amended and restated trust indenture dated February 7, 2024 among the Company, as issuer, Ayr Wellness Canada, as substituted issuer, and Odyssey Trust Company (“Odyssey”), as trustee, in respect of the 2026 Notes;

(b)

the Exchange Rights Agreements;

(c)

the warrant agency agreement dated December 21, 2017 between the Company, as issuer, and Odyssey, as warrant agent, as amended in respect of the Mercer Warrants (the “Mercer Warrant Agreement”);

(d)

the warrant agency agreement dated February 7, 2024 between the Company, as issuer, and Odyssey, as warrant agent, in respect of the Anti-Dilutive Warrants;

(e)

the pre-emptive rights agreements dated February 7, 2024 between the Company and certain Senior Noteholders; and

(f)

the OMMU – Medical Marijuana Treatment Center License #MMTC-2015-002 held by the Company’s subsidiary DFMMJ Investments, LLC, which license individually accounts for at least 10% of the consolidated revenue of the Company for the year ended December 31, 2023.


To the extent that cannabis-related licenses could also be considered to be material contracts, see the licenses listed under “Description of the Business - Licenses”.

The Company has no leases representing over 10% of its revenues, to the extent that such contracts would be considered to be material contracts entered into outside of the ordinary course of business for the purposes of this AIF.

Copies of these agreements are available for inspection at our offices, during ordinary business hours and are available under the Company’s profile on SEDAR+ at www.sedarplus.ca.

INTERESTS OF EXPERTS

The consolidated financial statements for the years ended December 31, 2023 and 2022 have been audited by Marcum LLP, the Company’s auditors as of August 16, 2021, who are independent within the meaning of the Rules of Professional Conduct of the Chartered Professional Accountants of Ontario (registered name of The Institute of Chartered Accountants of Ontario) and within the meaning of the U.S. Public Company Accounting Oversight Board Rule 3520, Auditor Independence.

AUDIT COMMITTEE

AUDIT COMMITTEE CHARTER

The Board has adopted a written charter (the “Charter of the Audit Committee”) for the audit committee of the Company (the “Audit Committee”), which sets out the Audit Committee’s responsibility in reviewing and approving the financial statements of the Company and public disclosure documents containing financial information and reporting on such review to the Board, ensuring that adequate procedures are in place for the reviewing of the Company’s public disclosure documents that contain financial information, overseeing the work and reviewing the independence of the external auditor. The text of the Charter of the Audit Committee that has been adopted is attached to this AIF as Appendix A.

COMPOSITION OF AUDIT COMMITTEE

The Audit Committee is composed of a minimum of three directors, each of whom is financially literate within the meaning of National Instrument 52-110 - Audit Committees. As of the date hereof, the Audit Committee was composed of:

·

Charles Miles (Chair);

·

Joyce Johnson; and

·

Michael Warren.

EXTERNAL AUDITOR SERVICE FEES

During the fiscal years ended December 31, 2023, and December 31, 2022, the Company paid the following fees to the Company’s external auditor Marcum LLP for the following fee categories:

Fee Category

    

Fiscal Year 2023 ($)

    

Fiscal Year 2022 ($)

Audit Fees to Marcum LLP

$

412,000

$

410,000

Audit-Related Fees to Marcum LLP

299,698

N/A

Tax Services Fees to Marcum LLP

N/A

N/A

Other Fees to Marcum LLP

27,500

72,000

TOTAL

$

739,198

$

482,000

Audit Fees

Audit fees include all fees paid to the Company’s external auditor for the audit of the Company’s financial statements.

Audit-Related Fees

Audit-related fees include all fees paid to the Company’s external auditor for audit-related services including the review of the Company’s interim financial statements, preparation and/or review of certain filings with Canadian securities regulators, including comfort and consent letters, and accounting consultations on matters addressed during the audit and interim reviews.


Tax Services Fees

Tax services fees include all fees paid to the Company’s external auditor for tax-related advice including tax return preparation and/or review and tax planning advice.

All Other Fees

Other fees include fees for products and services provided by the Company’s auditor other than the services included in “Audit Fees”, “Audit-Related Fees” and “Tax Services Fees” and include fees for certain compilation and agreed-upon procedure services which were pre-approved by the Audit Committee.

CYBERSECURITY

The Audit Committee is responsible for overseeing Ayr’s risk management program and cybersecurity is a critical element of this program. Management is responsible for the day-to-day administration of the risk management program and its cybersecurity policies, processes, and practices. Ayr’s cybersecurity policies, standards, processes, and practices are based on applicable industry-recognized standards for security and are fully integrated into the Company’s overall risk management system and processes as part of its IT security incident response plan.

Cybersecurity Risk Management and Strategy

The Company’s cybersecurity risk management strategy focuses on several areas:

Identification and Reporting: The Company has implemented a cross-functional approach to assessing, identifying and managing material cybersecurity threats and incidents. This program includes controls and procedures to identify, classify and escalate certain cybersecurity incidents to provide management visibility and obtain direction from management as to the public disclosure and reporting of material incidents in a timely manner.

Technical Safeguards: The Company implements technical safeguards that are designed to protect its information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti-malware functionality, and access controls, which are evaluated and improved through automated vulnerability assessments and cybersecurity threat intelligence, as well as outside audits and certifications.

Incident Response and Recovery Planning: The Company has established and maintains an incident response, business continuity, and disaster recovery plans designed to address its response to a cybersecurity incident.

Third-Party Risk Management: The Company maintains a risk-based approach to identifying and overseeing material cybersecurity threats presented by third parties, including vendors, service providers, and other external users of its systems, as well as the systems of third parties that could adversely impact its business in the event of a material cybersecurity incident affecting those third-party systems, including any outside auditors or consultants who advise on its cybersecurity systems.

Education and Awareness: The Company provides mandatory training for all employees regarding cybersecurity threats as a means to equip its employees with tools to make employees aware of and to address cybersecurity threats, and to communicate its evolving information security policies, standards, processes, and practices.

The Company conducts periodic assessments and testing of its policies, standards, processes, and practices in a manner intended to address cybersecurity threats and events. The results of such assessments, audits, and reviews are evaluated by management and reported to the Audit Committee, and the Company adjusts its cybersecurity policies, standards, processes, and practices as necessary based on the information provided by these assessments, audits, and reviews. Risks from cybersecurity threats, including as a result of any previous cybersecurity incidents, have not materially affected and are not reasonably likely to materially affect the Company, including its business strategy, results of operations, or financial condition.

Governance

The Audit Committee, oversees Ayr’s risk management program, including the management of cybersecurity threats. The Audit Committee receives presentations and reports on developments in the cybersecurity space. The Company’s cybersecurity program is managed by its Chief Technology Officer (“CTO”), whose team is responsible for facilitating the enterprise-wide cybersecurity program. The CTO has over 30 years of technology experience across software engineering, databases and cloud computing, including experience overseeing cybersecurity programs.


The Information Technology Representative, in coordination with senior management, including the CTO and Chief Financial Officer, works collaboratively across the Company to implement a program designed to protect the Company’s information systems from cybersecurity threats and to promptly respond to any material cybersecurity incidents in accordance with its incident response and recovery plans. To facilitate the success of the Company’s cybersecurity program, a cross-functional team throughout the Company addresses cybersecurity threats and responds to cybersecurity incidents. Through ongoing communications with this team, the Information Technology Representative and senior management are informed about and monitor the prevention, detection, mitigation and remediation of cybersecurity threats and incidents in real time and report such threats and incidents to the Audit Committee when appropriate.

During the year ended December 31, 2023, Ayr did not identify any cybersecurity threats that have materially affected or are reasonably likely to materially affect its business strategy, results of operations, or financial condition. However, despite the capabilities, processes, and other security measures which are employed, and that Ayr believes are designed to detect, reduce, and mitigate the risk of cybersecurity incidents, Ayr may not be aware of all vulnerabilities or might not accurately assess the risks of incidents, and such preventative measures cannot provide absolute security and may not be sufficient in all circumstances or mitigate all potential risks.

ADDITIONAL INFORMATION

Additional information with respect to the Company is provided in the Company’s audited financial statements and notes to the audited financial statements and the Company’s management’s discussion & analysis for the fiscal year ended December 31, 2023. These documents as well as additional information relating to the Company are available on www.ir.ayrwellness.com, www.sec.gov, and www.sedarplus.ca. The information contained on such websites are not a part of, nor are they incorporate by reference into, this Annual report (or equivalent thereof).


APPENDIX A

AUDIT COMMITTEE CHARTER

Section 1

PURPOSE

The audit committee (the “Audit Committee”) is a committee of the board of directors (the “Board”) of Ayr Wellness Inc. (the “Corporation”). The primary function of the Audit Committee is to assist the directors of the Corporation in fulfilling their applicable roles by:

(a)

recommending to the Board the appointment and compensation of the Corporation’s external auditor;

(b)

overseeing the work of the external auditor, including the resolution of disagreements between the external auditor and management;

(c)

pre-approving all non-audit services (or delegating such pre-approval if and to the extent permitted by law) to be provided to the Corporation by the Corporation’s external auditor;

(d)

satisfying themselves that adequate procedures are in place for the review of the Corporation’s public disclosure of financial information, other than those described in (g) below, extracted or derived from its financial statements, including periodically assessing the adequacy of such procedures;

(e)

establishing procedures for the receipt, retention and treatment of complaints received by the Corporation regarding accounting, internal controls or auditing matters, and for the confidential, anonymous submission by employees of the Corporation of concerns regarding questionable accounting or auditing matters;

(f)

reviewing and approving any proposed hiring of current or former partner or employee of the current and former auditor of the Corporation; and

(g)

reviewing and approving the annual and interim financial statements, related Management Discussion and Analysis (“MD&A”) and other financial information provided by the Corporation to any governmental body or the public.

The Audit Committee should primarily fulfill these roles by carrying out the activities enumerated in this Charter. However, it is not the duty of the Audit Committee to prepare financial statements, to plan or conduct internal or external audits, to determine that the financial statements are complete and accurate and are in accordance with Canadian generally accepted accounting principles, to conduct investigations, or to assure compliance with laws and regulations or the Corporation’s internal policies, procedures and controls, as these are the responsibility of management, and in certain cases, the external auditor.

Section 2

LIMITATIONS ON AUDIT COMMITTEE’S DUTIES

In contributing to the Audit Committee’s discharge of its duties under this Charter, each member of the Audit Committee shall be obliged only to exercise the care, diligence and skill that a reasonably prudent person would exercise in comparable circumstances. Nothing in this Charter is intended to be, or may be construed as, imposing on any members of the Audit Committee a standard of care or diligence that is in any way more onerous or extensive than the standard to which the directors are subject.

Members of the Audit Committee are entitled to rely, absent actual knowledge to the contrary, on (i) the integrity of the persons and organizations from whom they receive information, (ii) the accuracy and completeness of the information provided, (iii) representations made by management as to the non-audit services provided to the Corporation by the external auditor, (iv) financial statements of the Corporation represented to them by a member of management or in a written report of the external auditors to present fairly the financial position of the Corporation in accordance with generally accepted accounting principles, and (v) any report of a lawyer, accountant, engineer, appraiser or other person whose profession lends credibility to a statement made by any such person.

A-1


Section 3

COMPOSITION AND MEETINGS

The Audit Committee should be comprised of not less than three directors as determined by the Board, a majority of whom must not be executive officers, employees, control persons or affiliates of the Corporation. The Audit Committee members may enhance their familiarity with finance and accounting by participating in educational programs conducted by the Corporation or an outside consultant. In the event the Corporation ceases to be a venture issuer, the Audit Committee should comply with the independence requirements set forth in National Instrument 52-110 - Audit Committees (“NI 52-110”) of the Canadian Securities Administrators.

The members of the Audit Committee shall be elected by the Board on an annual basis or until their successors shall be duly appointed. Unless a Chair of the Audit Committee (the “Chair”) is elected by the full Board, the members of the Audit Committee may designate a Chair by majority vote of the full Audit Committee membership.

In addition, the Audit Committee members should meet all of the requirements for members of audit committees as defined from time to time under applicable legislation and the rules of any stock exchange on which the Corporation’s securities are listed or traded.

The Audit Committee should meet at least four times annually, or more frequently as circumstances require. The Audit Committee should meet within forty-five (45) days following the end of the first three financial quarters to review and discuss the unaudited financial results for the preceding quarter and the related MD&A, and should meet within 90 days following the end of the fiscal year end to review and discuss the audited financial results for the preceding quarter and year and the related MD&A.

The Audit Committee may ask members of management or others to attend meetings and provide pertinent information as necessary. For purposes of performing their duties, members of the Audit Committee shall have full access to all corporate information and any other information deemed appropriate by them, and shall be permitted to discuss such information and any other matters relating to the financial position of the Corporation with senior employees, officers and the external auditor of the Corporation, and others as they consider appropriate.

For greater certainty, management is indirectly accountable to the Audit Committee and is responsible for the timeliness and integrity of the financial reporting and information presented to the Board.

In order to foster open communication, the Audit Committee or its Chair should meet at least annually with management and the external auditor in separate sessions to discuss any matters that the Audit Committee or each of these groups believes should be discussed privately. In addition, the Audit Committee or its Chair should meet with management quarterly in connection with the Corporation’s interim financial statements.

A quorum for the transaction of business at any meeting of the Audit Committee shall be a majority of the number of members of the Audit Committee or such greater number as the Audit Committee shall by resolution determine.

Meetings of the Audit Committee shall be held from time to time and at such place as any member of the Audit Committee shall determine upon 48 hours’ notice to each of its members. The notice period may be waived by all members of the Audit Committee. Each of the Chair of the Board, the external auditor, the Chief Executive Officer, the Chief Financial Officer or the Secretary shall be entitled to request that any member of the Audit Committee call a meeting.

This Charter is subject in all respects to the Corporation’s articles of incorporation and by-laws from time to time.

Section 4

ROLE

As part of its function in assisting the Board in fulfilling its oversight role (and without limiting the generality of the Audit Committee’s role), the Audit Committee should:

(1)

Determine any desired agenda items;

(2)

Review and recommend to the Board changes to this Charter, as considered appropriate from time to time;

(3)

Review the public disclosure regarding the Audit Committee required by 52-110;

A-2


(4)

Review and seek to ensure that disclosure controls and procedures and internal control over financial reporting frameworks are operational and functional;

(5)

Summarize in the Corporation’s annual information form the Audit Committee’s composition and activities, as required;

(6)

Submit the minutes of all meetings of the Audit Committee to the Board upon request;

Documents / Reports Review

(7)

Review and recommend to the Board for approval the Corporation’s annual and interim financial statements, including any certification, report, opinion, undertaking or review rendered by the external auditor and the related MD&A, as well as such other financial information of the Corporation provided to the public or any governmental body as the Audit Committee or the Board require;

(8)

Review other financial information provided to any governmental body or the public as they see fit;

(9)

Review, recommend and approve any of the Corporation’s press releases that contain financial information;

(10)

Seek to satisfy itself and ensure that adequate procedures are in place for the review of the Corporation’s public disclosure of financial information extracted or derived from the Corporation’s financial statements and related MD&A and periodically assess the adequacy of those procedures;

External Auditor

(11)

Recommend to the Board the selection of the external auditor, considering independence and effectiveness, and review the fees and other compensation to be paid to the external auditor;

(12)

Review and seek to ensure that all financial information provided to the public or any governmental body, as required, provides for the fair presentation of the Corporation’s financial condition, financial performance and cash flow;

(13)

Instruct the external auditor that its ultimate client is not management and that it is required to report directly to the Audit Committee, and not management;

(14)

Monitor the relationship between management and the external auditor including reviewing any management letters or other reports of the external auditor and discussing any material differences of opinion between management and the external auditor;

(15)

Review and discuss, on an annual basis, with the external auditor all significant relationships it has with the Company to determine the external auditor’s independence;

(16)

Pre-approve all non-audit services (or delegate such pre-approval, as the Audit Committee may determine and as permitted by applicable Canadian securities laws) to be provided by the external auditor;

(17)

Review the performance of the external auditor and any proposed discharge of the external auditor when circumstances warrant;

(18)

Periodically consult with the external auditor out of the presence of management about significant risks or exposures, internal controls and other steps that management has taken to control such risks, and the fullness and accuracy of the financial statements, including the adequacy of internal controls to expose any payments, transactions or procedures that might be deemed illegal or otherwise improper;

(19)

Communicate directly with the external auditor and arrange for the external auditor to be available to the Audit Committee and the full Board as needed;

(20)

Review and approve any proposed hiring by the Corporation of current or former partners or employees of the current (and any former) external auditor of the Corporation;

A-3


Audit Process

(21)

Review the scope, plan and results of the external auditor’s audit and reviews, including the auditor’s engagement letter, the post- audit management letter, if any, and the form of the audit report. The Audit Committee may authorize the external auditor to perform supplemental reviews, audits or other work as deemed desirable;

(22)

Following completion of the annual audit and quarterly reviews, review separately with each of management and the external auditor any significant changes to planned procedures, any difficulties encountered during the course of the audit and, if applicable, reviews, including any restrictions on the scope of work or access to required information and the cooperation that the external auditor received during the course of the audit and, if applicable, reviews;

(23)

Review any significant disagreements among management and the external auditor in connection with the preparation of the financial statements;

(24)

Where there are significant unsettled issues between management and the external auditor that do not affect the audited financial statements, the Audit Committee shall seek to ensure that there is an agreed course of action leading to the resolution of such matters;

Financial Reporting Processes

(25)

Review the integrity of the financial reporting processes, both internal and external, in consultation with the external auditor as they see fit;

(26)

Consider the external auditor’s judgments about the quality, transparency and appropriateness, not just the acceptability, of the Corporation’s accounting principles and financial disclosure practices, as applied in its financial reporting, including the degree of aggressiveness or conservatism of its accounting principles and underlying estimates, and whether those principles are common practices or are minority practices;

(27)

Review all material balance sheet issues, material contingent obligations (including those associated with material acquisitions or dispositions) and material related party transactions;

(28)

Review with management and the external auditor the Corporation’s accounting policies and any changes that are proposed to be made thereto, including all critical accounting policies and practices used, any alternative treatments of financial information that have been discussed with management, the ramification of their use and the external auditor’s preferred treatment and any other material communications with management with respect thereto;

(29)

Review the disclosure and impact of contingencies and the reasonableness of the provisions, reserves and estimates that may have a material impact on financial reporting;

(30)

If considered appropriate, establish separate systems of reporting to the Audit Committee by each of management and the external auditor;

(31)

Periodically consider the need for an internal audit function, if not present;

Risk Management

(32)

Review program of risk assessment and steps taken to address significant risks or exposures of all types, including insurance coverage and tax compliance;

General

(33)

With prior Board approval, the Audit Committee may at its discretion retain independent counsel, accountants and other professionals to assist it in the conduct of its activities and to set and pay (as an expense of the Corporation) the compensation for any such advisors;

A-4


(34)

Respond to requests by the Board with respect to the functions and activities that the Board requests the Audit Committee to perform;

(35)

Periodically review this Charter and, if the Audit Committee deems appropriate, recommend to the Board changes to this Charter;

(36)

Review the public disclosure regarding the Audit Committee required from time to time by applicable Canadian securities laws, including:

(i)

the Charter of the Audit Committee;

(ii)

the composition of the Audit Committee;

(iii)

the relevant education and experience of each member of the Audit Committee;

(iv)

the external auditor services and fees; and

(v)

such other matters as the Corporation is required to disclose concerning the Audit Committee;

(37)

Review in advance, and approve, the hiring and appointment of the Corporation’s senior financial executives by the Corporation, if any; and

(38)

Perform any other activities as the Audit Committee deems necessary or appropriate including ensuring all regulatory documents are compiled to meet Committee reporting obligations under 52-110.

Section 5

AUDIT COMMITTEE COMPLAINT PROCEDURES

Submitting a Complaint

(39)

Anyone may submit a complaint regarding conduct by the Corporation or its employees or agents (including its independent auditors) reasonably believed to involve questionable accounting, internal accounting controls or auditing matters. The Chair should oversee treatment of such complaints.

Procedures

(40)

The Chair will be responsible for the receipt and administration of employee complaints.

(41)

In order to preserve anonymity when submitting a complaint regarding questionable accounting or auditing matters, the employee may submit a complaint confidentially.

Investigation

(42)

The Chair should review and investigate the complaint. Corrective action will be taken when and as warranted in the Chair’s discretion.

Confidentiality

(43)

The identity of the complainant and the details of the investigation should be kept confidential throughout the investigatory process.

Records and Report

(44)

The Chair should maintain a log of complaints, tracking their receipt, investigation, findings and resolution, and should prepare a summary report for the Audit Committee.

The Audit Committee is a committee of the Board and is not and shall not be deemed to be an agent of the Corporation’s securityholders for any purpose whatsoever. The Board may, from time to time, permit departures from the terms hereof, either prospectively or retrospectively, and no provision contained herein is intended to give rise to civil liability to securityholders of the Corporation or other liability whatsoever.

A-5


EX-99.2 3 ayr-20231231xex99d2.htm EXHIBIT 99.2
2.520.5636964863696486UnlimitedUnlimitedUnlimitedUnlimitedUnlimitedUnlimited0000000000006090949264574077604433996450161.163.01P15YP15YP15YP5YP6MP6MP6MP2Y0P1Y650000

Exhibit 99.2

 

Graphic

 

Ayr Wellness Inc.

CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2023 AND 2022

(EXPRESSED IN UNITED STATES DOLLARS)

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Shareholders and Board of Directors of

Ayr Wellness Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Ayr Wellness Inc. (the “Company”) as of December 31, 2023 and 2022, the related consolidated statements of operations, shareholders’ equity and cash flows for each of the two years in the period ended December 31, 2023, and the related notes (collectively referred to as the “financial statements”).  In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ Marcum LLP

Marcum LLP

We have served as the Company’s auditor since 2021.

New York, NY

March 13, 2024

1

Ayr Wellness Inc.

Consolidated Balance Sheets

(Expressed in United States Dollars, in thousands, except share amounts)

As of

    

December 31, 2023

    

December 31, 2022

Note 4

ASSETS

  

  

Current

 

  

 

  

Cash and cash equivalents

$

50,766

$

76,827

Accounts receivable, net

 

13,491

 

7,738

Inventory

 

106,363

 

99,810

Prepaid expenses, deposits, and other current assets

 

22,600

 

8,702

Assets held-for-sale

260,625

Total Current Assets

193,220

453,702

Non-current

 

 

Property, plant, and equipment, net

310,615

302,680

Intangible assets, net

 

687,988

 

744,709

Right-of-use assets - operating, net

 

127,024

 

121,340

Right-of-use assets - finance, net

40,671

43,222

Goodwill

 

94,108

 

94,108

Deposits and other assets

 

6,229

 

8,009

TOTAL ASSETS

$

1,459,855

$

1,767,770

LIABILITIES AND SHAREHOLDERS’ EQUITY

 

  

 

  

Liabilities

Current

 

  

 

  

Trade payables

 

24,786

 

26,671

Accrued liabilities

 

40,918

 

25,470

Lease liabilities - operating - current portion

 

9,776

 

7,906

Lease liabilities - finance - current portion

9,789

9,529

Contingent consideration - current portion

63,429

Purchase consideration payable

 

 

2,849

Income tax payable

 

90,074

 

46,006

Debts payable - current portion

 

23,152

 

40,523

Liabilities held-for-sale

43,841

Accrued interest payable - current portion

1,983

2,581

Total Current Liabilities

200,478

268,805

Non-current

Deferred tax liabilities, net

 

64,965

 

72,413

Lease liabilities - operating - non-current portion

125,739

118,086

Lease liabilities - finance - non-current portion

 

18,007

 

24,016

Construction finance liabilities

 

38,205

 

36,181

Contingent consideration - non-current portion

 

 

26,661

Debts payable - non-current portion

 

167,351

 

136,315

Senior secured notes, net of debt issuance costs

 

243,955

 

244,682

Accrued interest payable - non-current portion

 

5,530

 

4,763

Other long- term liabilities

24,973

524

TOTAL LIABILITIES

889,203

932,446

Commitments and contingencies

Shareholders’ equity

 

  

 

  

Multiple Voting Shares - no par value, unlimited authorized. Issued and outstanding - 3,696,486 shares

 

 

Subordinate, Restricted, and Limited Voting Shares - no par value, unlimited authorized. Issued and outstanding - 64,574,077 and 60,909,492 shares, respectively

 

 

Exchangeable Shares: no par value, unlimited authorized. Issued and outstanding - 9,645,016 and 6,044,339 shares, respectively

 

 

Additional paid-in capital

1,370,600

1,349,713

Treasury stock - 645,300 shares

(8,987)

(8,987)

Accumulated other comprehensive income

 

3,266

 

3,266

Accumulated deficit

(783,101)

(510,668)

Equity of Ayr Wellness Inc.

581,778

833,324

Noncontrolling interests

(11,126)

2,000

TOTAL SHAREHOLDERS’ EQUITY

570,652

835,324

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY

$

1,459,855

$

1,767,770

The accompanying notes are an integral part of these consolidated financial statements.

2

Ayr Wellness Inc.

Consolidated Statements of Operations

(Expressed in United States Dollars, in thousands, except per share amounts)

Year Ended

    

December 31, 2023

    

December 31, 2022

Note 4

Revenues, net of discounts

$

463,630

    

$

421,435

Cost of goods sold excluding fair value items

 

261,188

 

240,252

Incremental costs to acquire cannabis inventory in business combinations

 

 

6,217

Cost of goods sold

261,188

246,469

Gross profit

202,442

174,966

Operating expenses

 

  

 

  

Selling, general, and administrative

 

177,800

 

212,525

Impairment of goodwill and other assets

 

6,320

 

117,950

Depreciation and amortization

 

51,364

 

45,801

Acquisition and transaction costs

 

4,080

 

5,986

Loss (gain) on sale of assets

 

91

 

(8)

Total operating expenses

239,655

382,254

Loss from continuing operations

(37,213)

(207,288)

Other income (expense), net

  

  

Fair value gain on financial liabilities

23,023

63,088

Interest expense, net

(39,403)

(28,323)

Interest income

743

275

Other income, net

7,094

120

Total other (expense) income, net

(8,543)

35,160

Loss from continuing operations before income taxes and noncontrolling interest

(45,756)

(172,128)

Income taxes

Current tax provision

(54,839)

(43,161)

Deferred tax benefit (expense)

7,448

(1,588)

Total income taxes

(47,391)

(44,749)

Net loss from continuing operations

(93,147)

(216,877)

Discontinued operations

Loss from discontinued operations, net of taxes (including loss on disposal of $182,464 for the year ended December 31, 2023)

(186,353)

(38,608)

Loss from discontinued operations

(186,353)

(38,608)

Net loss

(279,500)

(255,485)

Net loss attributable to noncontrolling interests

(7,067)

(10,019)

Net loss attributable to Ayr Wellness Inc.

$

(272,433)

$

(245,466)

Basic and diluted net loss per share

Continuing operations

$

(1.16)

$

(3.01)

Discontinued operations

(2.52)

(0.56)

Total (basic and diluted) net loss per share

$

(3.68)

$

(3.58)

Weighted average number of shares outstanding (basic and diluted)

74,096

68,635

The accompanying notes are an integral part of these consolidated financial statements.

3

Ayr Wellness Inc.

Consolidated Statements of Shareholders’ Equity

(Expressed in United States Dollars, in thousands)

Subordinate,

Restricted, and Limited

Accumulated other

 

 

Multiple

Voting Shares

 

Exchangeable

 

Additional paid-

 comprehensive

Accumulated

Noncontrolling

Voting Shares

Number

Shares

in capital

Treasury stock

  income

Deficit

interest

Total

    

#

    

#

    

#

    

$

    

#

    

$

    

$

    

$

    

$

    

$

Balance, December 31, 2021

    

3,696

 

56,337

 

7,368

 

1,289,827

(568)

 

(7,828)

 

3,266

 

(265,202)

 

1,020,063

Stock-based compensation

 

 

2,109

 

 

46,115

 

 

 

 

46,115

Tax withholding on stock-based compensation awards

 

 

(676)

 

 

(5,258)

 

 

 

 

(5,258)

Share issuance - related party - consulting services

 

 

76

 

 

707

 

 

 

 

707

Share issuance - business combinations

 

 

 

682

 

6,352

 

 

 

 

6,352

Share issuance - earn-out consideration

 

 

1,029

 

 

11,748

 

 

 

 

11,748

Conversion of Exchangeable Shares

 

 

2,006

 

(2,006)

 

 

 

 

 

Consolidation of variable interest entity

12,019

12,019

Exercise of options, net of options sold to cover income taxes

33

300

300

Repurchase of Equity Shares

 

 

(5)

 

 

(78)

(77)

 

(1,159)

 

 

 

(1,237)

Net loss

 

 

 

 

 

 

 

(245,466)

(10,019)

 

(255,485)

Balance, December 31, 2022

 

3,696

 

60,909

 

6,044

 

1,349,713

(645)

 

(8,987)

 

3,266

 

(510,668)

2,000

 

835,324

Balance, December 31, 2022

 

3,696

 

60,909

6,044

 

1,349,713

(645)

(8,987)

3,266

 

(510,668)

2,000

 

835,324

Stock-based compensation

 

 

3,262

 

16,412

 

 

16,412

Tax withholding on stock-based compensation awards

 

 

(93)

 

(366)

 

 

(366)

Shares issued for consulting services

 

 

66

 

79

 

 

79

Acquisition of variable interest entity

 

 

233

 

115

 

(6,059)

 

(5,944)

Share issuance - earn-out consideration

 

 

3,798

 

4,647

 

 

4,647

Conversion of Exchangeable Shares

 

 

430

(430)

 

 

 

Net loss

 

 

 

 

 

 

 

(272,433)

(7,067)

 

(279,500)

Balance, December 31, 2023

 

3,696

 

64,574

 

9,645

 

1,370,600

(645)

 

(8,987)

 

3,266

 

(783,101)

(11,126)

 

570,652

The accompanying notes are an integral part of these consolidated financial statements.

4

Ayr Wellness Inc.

Consolidated Statements of Cash Flows

(Expressed in United States Dollars, in thousands)

    

Year Ended

December 31, 2023

    

December 31, 2022

Operating activities

  

  

Consolidated net loss

$

(279,500)

$

(255,485)

Less: Loss from discontinued operations (Note 4)

(3,889)

(38,608)

Net loss from continuing operations before noncontrolling interest

(275,611)

(216,877)

Adjustments for:

 

 

Fair value gain on financial liabilities

 

(23,023)

 

(63,088)

Stock-based compensation

 

16,412

 

46,115

Stock-based compensation - related party

 

 

707

Shares issued for consulting services

79

Depreciation and amortization

 

32,303

 

19,028

Amortization on intangible assets

 

58,646

 

57,122

Impairment of goodwill and other assets

 

6,320

 

117,950

Incremental costs to acquire cannabis inventory in a business combination

6,217

Deferred tax (benefit) expense

 

(7,448)

 

1,588

Amortization on financing costs

2,341

2,292

Amortization on financing premium

 

(3,018)

 

(3,018)

Employee retention credits recorded in other income

 

(5,238)

 

Loss (gain) on disposal of property, plant, and equipment

 

91

 

(8)

Loss on the disposal of Arizona business

 

182,464

 

Changes in operating assets and liabilities, net of business combinations:

Accounts receivable

 

(6,053)

 

63

Inventory

 

(6,252)

 

(12,536)

Prepaid expenses, deposits, and other current assets

 

(657)

 

1,360

Trade payables

 

(296)

 

(6,548)

Accrued liabilities

 

2,804

 

1,199

Accrued interest payable

 

(42)

 

(2,686)

Lease liabilities - operating

 

2,712

 

1,799

Income tax payable

47,848

16,689

Cash provided by (used in) continuing operations

24,382

(32,632)

Cash provided by (used in) discontinued operations

2,783

(1,533)

Cash provided by (used in) operating activities

27,165

(34,165)

 

 

Investing activities

 

 

Purchase of property, plant, and equipment

(27,697)

(58,830)

Capitalized interest

 

(9,981)

 

(14,490)

Cash paid for business combinations and asset acquisitions, net of cash acquired

 

(1,500)

 

(11,546)

Cash paid for business combinations and asset acquisitions, working capital

 

(2,600)

 

(2,205)

Proceeds from the sale of assets, net of transaction costs

 

 

31,433

Cash received (paid) for bridge financing

 

(73)

 

70

Advances to related entities

 

 

(6,148)

Deposits for business combinations, net of cash on hand

 

 

(2,825)

Purchase of intangible asset

 

(1,925)

 

(4,000)

Cash used in investing activities from continuing operations

(43,776)

(68,541)

Proceeds from sale of Arizona - discontinued operation

 

18,084

 

Cash received for working capital - discontinued operations

1,583

Cash (paid) received for investing activities - discontinued operations

(44)

2,044

Cash provided by investing activities of discontinued operations

19,623

2,044

Cash used in investing activities

 

(24,153)

 

(66,497)

Financing activities

 

 

Proceeds from exercise of options

 

 

300

Proceeds from notes payable, net of financing costs

 

10,665

 

51,713

Proceeds from financing transaction, net of financing costs

39,100

27,600

Debt issuance costs paid

(9,049)

Payment for settlement of contingent consideration

(10,475)

(10,000)

Deposits paid for financing lease and note payable

(924)

Tax withholding on stock-based compensation awards

(366)

(5,258)

Repayments of debts payable

(52,029)

(17,923)

Repayments of lease liabilities - finance (principal portion)

 

(10,608)

 

(9,596)

Repurchase of Equity Shares

 

 

(8,430)

Cash (used in) provided by financing activities by continuing operations

 

(32,762)

 

27,482

Cash used in financing activities from discontinued operations

 

(124)

 

(522)

Cash (used in) provided by financing activities

 

(32,886)

 

26,960

 

 

Net decrease in cash and cash equivalents and restricted cash

(29,874)

(73,702)

Cash, cash equivalents and restricted cash beginning of the period

 

76,827

 

150,142

Cash included in assets held-for-sale

3,813

4,200

Cash, cash equivalents and restricted cash end of the period

$

50,766

$

80,640

Supplemental disclosure of cash flow information:

 

 

Interest paid during the period, net

$

49,914

$

49,231

Income taxes paid during the period

 

7,078

 

30,915

Non-cash investing and financing activities:

 

 

Recognition of right-of-use assets for operating leases

 

19,184

 

54,396

Recognition of right-of-use assets for finance leases

5,470

32,444

Issuance of promissory note related to business combination

1,580

16,000

Conversion of convertible note related to business combination

2,800

Issuance of Equity Shares related to business combinations and asset acquisitions

115

6,352

Issuance of Equity Shares related to settlement of contingent consideration

4,647

11,748

Issuance of promissory note related to settlement of contingent consideration

14,000

14,934

Settlement of contingent consideration

38,420

Capital expenditure disbursements for cultivation facility

2,024

8,402

Cancellation of Equity Shares

78

Extinguishment of note payable related to sale of Arizona business

22,505

Extinguishment of accrued interest payable related to sale of Arizona business

1,165

Reduction of lease liabilities related to sale of Arizona business

16,734

Reduction of right-of-use assets related to sale of Arizona business

16,739

The accompanying notes are an integral part of these consolidated financial statements.

5

Table of Contents

Ayr Wellness Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

1.    NATURE OF OPERATIONS

Ayr Wellness Inc. (“Ayr” or the “Company”) is a vertically integrated cannabis multi-state operator in the United States of America (“U.S.”); through its operating companies in various states throughout the U.S., Ayr is a leading cultivator, manufacturer, and retailer of cannabis products and branded cannabis packaged goods. The Company prepares its segment reporting on the same basis that its chief operating decision maker manages the business and makes operating decisions. The Company has one operating segment, cannabis sales. The Company’s segment analysis is reviewed regularly and will be re-evaluated when circumstances change.

The Company is a reporting issuer in the U.S. and Canada. The Company’s subordinate, restricted, and limited voting shares (“Equity Shares”) are trading on the Canadian Stock Exchange (“CSE”), under the symbol “AYR.A.” The Company’s Equity Shares are also quoted on the OTCQX® Best Market in the U.S. under the symbol “AYRWF.” Ayr’s headquarter office is 2601 South Bayshore Drive, Suite 900, Miami, FL 33133.

2.    BASIS OF PRESENTATION

2.1 Statement of compliance

These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for financial information and in accordance with the rules and regulations of Canadian securities regulators and the United States Securities and Exchange Commission.

The financial statements are presented in United States dollars (“US$” or “$”). The functional currency of the entity is determined separately in accordance with Accounting Standards Codification (“ASC”) 830 – Foreign Currency Matters and is measured using the currency of the primary economic environment in which the entity operates (“the functional currency”). The functional currency of Ayr is US$.

3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3.1 Basis of consolidation

The financial statements as of and for the years ended December 31, 2023 and 2022 include the accounts of the Company, its wholly-owned subsidiaries, and entities over which the Company has a controlling interest. Entities over which the Company has control are presented on a consolidated basis from the date control commences until the date control ceases. Equity investments where the Company does not exert a controlling interest are not consolidated. All intercompany balances and transactions involving controlled entities are eliminated on consolidation. The accompanying consolidated financial statements reflect the activity related to Arizona as discontinued operations, see Note 4. The Company’s consolidated subsidiaries, many of which were created in connection with the business combinations described in Note 5 and elsewhere in these financial statements, are owned 100% by the Company unless otherwise noted. See Note 6 for variable interest entities that are consolidated by the Company.

3.2 Revenue

The Company applies Accounting Standards Codification “ASC” Topic 606 (“ASC 606”), which specifies how and when revenue should be recognized based on a five-step model, which is applied to all contracts with customers. Through the application of ASC 606, the Company applies the following five-step model to determine the amount and timing of revenue to be recognized:

Identifying the contract with a customer
Identifying the performance obligations within the contract
Determining the transaction price
Allocating the transaction price to the performance obligations
Recognizing revenue when/as performance obligation(s) are satisfied.

6

Table of Contents

Ayr Wellness Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

3.2 Revenue (Continued)

In some cases, judgment is required in determining whether the customer is a business or the end consumer. This evaluation is made based on whether the business obtains control of the product before transferring to the end consumer. Control of the product transfers at a point in time either upon shipment to or receipt by the customer, depending on the contractual terms. In determining the appropriate time of sale, the Company takes into consideration: a) the Company’s right to payment for the goods or services; b) customer’s legal title; c) transfer of physical possession of the goods; and d) timing of acceptance of goods.

Revenue is recognized based on the sale of cannabis products and branded packaged goods for a fixed price when control is transferred. The amount recognized reflects the consideration that the Company expects to receive, taking into account any variation that is expected to result from rights of return and discounts. Dispensary revenue is recognized at the point of sale while wholesale revenue is recognized once the Company transfers the significant risks and rewards of ownership of the goods and does not retain material involvement associated with ownership or control over the goods sold. Revenue from the wholesale of cannabis to customers is recognized upon delivery to the customer. In accordance with ASC 606, the Company has elected to account for its sales and excise tax on a net basis, within its statements of operations.

3.3 Cash and cash equivalents and restricted cash

The Company considers the following to be cash and cash equivalents: cash deposits in financial institutions, cash held in Company safes or lockboxes at operational locations, and deposits that are readily convertible into cash within three months or less. Amounts included in restricted cash represent amounts pledged as collateral for financing arrangements as contractually required by a lender. Cash and cash equivalents and restricted cash are stated at fair value and the Company did not hold significant cash equivalents or restricted cash balances as of December 31, 2023 and 2022. The Company has banking or similar relationships in all jurisdictions in which it operates. In addition, the Company has cash balances in excess of Federal Deposit Insurance Corporation and Canada Deposit Insurance Corporation limits. The Company has historically not experienced losses related to these deposits.

3.4 Accounts receivable

Accounts receivable from wholesale sales are recorded net of an allowance for credit losses. The Company estimates allowance for credit losses based on various factors such as historical data, and customer credit worthiness. As of December 31, 2023 and 2022, the Company had approximately $706 and $511 in allowance for credit losses, respectively. For the years ended December 31, 2023 and 2022, the Company wrote off approximately $221 and $443, respectively. See 3.23 for additional information.

3.5 Business combinations

Acquisitions of subsidiaries and businesses are accounted for using the acquisition method in accordance with ASC 805 – Business Combination (“ASC 805”). The Company performs an assessment whether the acquisition is a business combination or asset acquisition based on the conditions surrounding the event(s) using guidance from ASC 805. If the acquisition is determined to be a business combination, the Company measures goodwill as the fair value of the consideration transferred, including the recognized amount of any noncontrolling interest in the acquiree, less the net recognized amount of the identifiable assets acquired and liabilities assumed, all measured as of the acquisition date.

Consideration transferred includes the fair value of the assets transferred (including cash), the liabilities incurred by the Company on behalf of the acquiree, any contingent consideration and any equity interests issued by the Company. Transaction costs, other than those directly associated with the issuance of debt or equity securities that the Company incurs in connection with a business combination, are expensed as incurred.

The acquisition date is the date when the Company obtains control of the acquiree. Contingent consideration is measured at its acquisition date fair value and included as part of the consideration transferred in a business combination. Contingent consideration that is classified as a liability is re-measured at subsequent reporting dates in accordance with the criteria and guidance provided under ASC 450 – Contingencies and ASC 820 – Fair Value Measurement, as appropriate with corresponding gain or loss recorded in the statements of operations, see Note 14.

7

Table of Contents

Ayr Wellness Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

3.6 Inventory

Inventory is primarily comprised of finished goods, work-in-process, raw materials, and supplies. Inventory is valued at the lower of cost and net realizable value. Net realizable value is determined as the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. When establishing the cost, work-in-process and raw materials are determined using the weighted average cost method while the determination of cost for finished goods inventory is on the first-in, first-out accounting method.

Costs incurred during the growing process are capitalized as incurred to the extent that cost is less than net realizable value. Any subsequent post-harvest costs, including direct costs such as materials, labor, related overhead, and depreciation expense on equipment attributable to processing, are capitalized to inventory to the extent that cost is less than net realizable value. Inventories of purchased finished goods and packing materials, other than inventory acquired through business combinations, are initially valued at cost and subsequently at the lower of cost and net realizable value. The Company reviews inventories for obsolete, spoiled, and slow-moving goods and any such inventories are written down to net realizable value. Inventory acquired in a business combination is valued at selling price less selling and disposal costs.

3.7 Property, plant, and equipment (“PPE”)

PPE is stated at cost less accumulated depreciation, amortization, and impairment losses, if any. The cost of an item of PPE consists of the purchase price, any costs directly attributable to bringing the asset to the location and condition necessary for its intended use and an initial estimate of the costs of dismantling and removing the item and restoring the site on which it is located. PPE acquired in a business combination is recorded at fair value using various methodologies including cost approach, sales comparison approach or income approach.

Depreciation and amortization are calculated using the straight-line method over the following expected useful lives:

Furniture and fixtures

5 to 7 years

Office equipment

3 to 5 years

Machinery and equipment

5 to 15 years

Auto and trucks

5 years

Leasehold improvements

the shorter of the useful life or life of the lease

Buildings

39 years

Land

not depreciated

Construction in progress

not depreciated until placed in service

An item of PPE is derecognized upon disposal, when held for sale, or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on disposal of the asset, determined as the difference between the net disposal proceeds and the carrying amount of the asset, is recognized in the statements of operations.

Construction in progress is transferred to the appropriate asset class when available for use and depreciation or amortization of the assets commences at that point of time.

The Company conducts a periodic assessment of the residual balances, useful lives, and depreciation or amortization methods being used for PPE and any changes arising from the assessment are applied by the Company prospectively.

Where an item of PPE comprises major components with different useful lives, the components are accounted for as separate items of PPE. Expenditures incurred to replace a component of an item of PPE that is accounted for separately, including major inspection and overhaul expenditures are capitalized.

The Company capitalizes interest on debt in projects under construction. Upon the asset becoming available for use, capitalized interest costs, as a portion of the total cost of the asset, are depreciated over the estimated useful life of the related asset, see Note 8 for additional information.

8

Table of Contents

Ayr Wellness Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

3.8 Intangible assets

Intangible assets are recorded at cost less accumulated amortization and impairment losses, if any. Intangible assets, separately identifiable according to ASC 805, acquired in a business combination are measured at fair value as of the acquisition date. Amortization periods of assets with finite lives are based on management’s estimates at the date of acquisition and are amortized over their estimated useful lives. Intangible assets that have indefinite useful lives are not subject to amortization and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired.

(a)Goodwill

The Company measures goodwill as the fair value of the consideration transferred, including the recognized amount of any noncontrolling interest in the acquiree, less the net recognized amount of the identifiable assets and liabilities assumed, all measured as of the acquisition date. Goodwill is allocated to a specific reporting unit upon acquisition. The Company’s policy is to first perform a qualitative assessment to determine if it was more-likely-than-not that the reporting unit’s carrying value is less than the fair value, indicating the potential for goodwill impairment. The amount of goodwill impairment, if any, is determined as the excess of the carrying value over the fair value of that reporting unit. The impairment of goodwill is limited to the amount of goodwill in a reporting unit. Impairment testing is performed annually by the Company, or more frequently, if events or changes in circumstances indicate that goodwill might be impaired. Management makes estimates during impairment testing as judgment is required to determine indicators of impairment and estimates are used to determine the fair value that is used to measure impairment losses. The Company assesses the fair values of its intangible assets, and its reporting unit for goodwill testing purposes, as necessary, using an income-based approach. Under the income approach, fair value is based on the present value of estimated future cash flows.

(b)Finite-lived intangible assets

Intangible assets are recorded at cost unless acquired through a business combination and recorded at fair value, less accumulated amortization and impairment losses. Amortization is recorded on a straight-line basis over the following estimated useful lives, which do not exceed the contractual period, if any:

Licenses/permits

15

Right-to-use licenses

15

Host community agreements

15

Trade name / brand

5

Such assets are tested for impairment if events or changes in circumstances indicate that they might be impaired. The estimated useful lives, residual values, and amortization methods are reviewed periodically, and any changes in estimates are accounted for prospectively.

9

Table of Contents

Ayr Wellness Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

3.8 Intangible assets (Continued)

(c)Impairment of long-lived assets

Long-lived assets such as PPE, right-of-use assets, and finite-lived intangible assets are grouped with other assets and liabilities at the lowest level for which identifiable independent cash flows are available (“asset group”). The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In order to determine if assets have been impaired, the impairment test is a two-step approach wherein the recoverability test is performed first to determine whether the long-lived asset is recoverable. The recoverability test (Step 1) compares the carrying amount of the asset to the sum of its future undiscounted cash flows using entity specific assumptions generated through the asset’s use and eventual disposition. If the carrying amount of the asset is less than the undiscounted cash flows, the asset is recoverable, and an impairment is not recorded. If the carrying amount of the asset is greater than the undiscounted cash flows, the asset is not recoverable, and an impairment loss calculation (Step 2) is required. The measurement of the impairment loss to be recognized is based on the difference between the fair value and the carrying value of the asset group. Fair value can be determined using a market approach, income approach, or cost approach. The cash flow projection and fair value represents management’s best estimate, using appropriate and customary assumptions, projections, and methodologies, at the date of evaluation. The reversal of impairment losses is prohibited.

3.9 Leases and sale and leaseback accounting

The Company applies the accounting guidance in ASC 842 – Leases and assesses whether a contract is or contains a lease, at inception of a contract. When evaluating whether a lease is a finance lease or an operating lease the Company considers whether the contract conveys the right to control the use of an identified asset. Certain arrangements require significant judgement to determine if an asset is specified in the contract and if the Company directs how, and for what purpose, the asset is used during the term of the contract. Leases are recognized as a right-of-use asset (“ROU”) and corresponding liability at the commencement date based on the present value of the future minimum lease payments over the lease term. Operating leases are included in Right-of-use assets – operating, net and Lease liabilities – operating – current portion and Lease liabilities – operating – non-current portion on the balance sheets. For operating leases, the Company records operating lease expense. Finance leases are included in Right-of-use assets – finance, net and lease liabilities are included in Lease liabilities – finance – current portion and Lease liabilities – finance – non-current portion on the balance sheets based on their payment dates. For finance leases, the Company records interest expense on the lease liability in addition to amortizing the ROU (generally straight-line) over the shorter of the lease term or the useful life of the right-of-use asset. The Company primarily leases space for corporate offices, retail, cultivation, and manufacturing under non-cancellable operating leases. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease.

Lease liabilities include the net present value of fixed payments (including in-substance fixed payments), variable lease payments that are not based on an index or a rate or subject to a fair market value renewal, amounts expected to be payable by the lessee under residual value guarantees, the exercise price of a purchase option if the lessee is reasonably certain to exercise that option, and payments of penalties for terminating the lease, if the lease term reflects the lessee exercising that option. The Company allocates the consideration in the contract to each lease component on the basis of the relative standalone price of the lease component and the aggregate stand-alone price of the non-lease components.

The lease payments are discounted using the interest rate implicit in the lease or, if that rate cannot be determined, the Company’s incremental borrowing rate. The period over which the lease payments are discounted is the reasonably certain lease term, including renewal options that the Company is reasonably certain to exercise. Renewal options are included in a number of leases across the Company.

Payments associated with short-term leases are recognized as an expense on a straight-line basis in the statements of operations. Short-term leases are leases with a lease term of 12 months or less. Variable lease payments that depend on an index or a rate or are subject to a fair market value renewal are expensed as incurred and recognized in the statements of operations.

10

Table of Contents

Ayr Wellness Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

3.9 Leases and sale and leaseback accounting (Continued)

A sale and leaseback transaction involves the transfer of an asset to another entity and the leaseback of the same asset. The Company applies ASC 606 and ASC 842 when accounting for sale and leaseback transactions. Significant estimates and judgments applied include determination of the fair value of the underlying asset, transfer of control, and determination of the implicit interest rate. The Company recognizes gains or losses related to the transfer of rights of the asset to the buyer-lessor and measures the ROU asset arising from the leaseback at the retained portion of the previous carrying amount. In cases where the transaction does not qualify for sale and leaseback accounting treatment, the asset is not derecognized, and no gain or loss is recorded. The transaction is treated as a financing transaction. See Note 10 for additional information.

3.10 Equity investments

An associate is an entity over which the Company exercises significant influence. Significant influence is the power to participate in the financial and operating policy of the investee but without control or joint control over those policies. Interests in associates are accounted for using the equity method and are initially recognized at cost. Subsequent to initial recognition, the carrying value of the Company’s interest in an associate is adjusted for the Company’s share of income or loss and distributions of the investee. The carrying value of associates is assessed for impairment at each balance sheet date. Significant influence is presumed if the Company holds between 20% and 50% of the voting rights unless evidence exists to the contrary.

Joint control is the contractually agreed sharing of control of an arrangement, which exists only when decisions about the relevant activities require the unanimous consent of the parties sharing control. Investees in which the Company has joint control and rights to the net assets thereof are defined as joint ventures. Joint ventures are also accounted for under the equity method. There were no joint ventures as of December 31, 2023.

3.11 Noncontrolling interests

Equity interests owned by parties that are not shareholders of the Company in consolidated subsidiaries are considered noncontrolling interests. The share of net assets attributable to noncontrolling interests is presented as a component of equity while the share of net income or loss is recognized in the statements of operations. Changes in the Company’s ownership interest that do not result in a loss of control of these less than wholly owned subsidiaries are accounted for as equity transactions, see Note 3.19.

3.12 Derivatives

The Company evaluates all its agreements to determine if such instruments have derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as assets or liabilities, the derivative instrument is recorded at its fair value and is then revalued at each reporting date, with changes in the fair value reported in the Company’s financial statements. In calculating the fair value of derivative assets or liabilities, the Company uses a valuation model when Level 1 inputs are not available to estimate fair value at each reporting date (see Notes 14 and 17).

The classification of derivative instruments, including whether such instruments should be recognized as assets or liabilities or as equity, is reevaluated at the end of each reporting period. Derivative instrument assets or liabilities are classified as current or non-current based on whether net-cash settlement of the derivative instrument could be required within 12 months of the financial statement date.

11

Table of Contents

Ayr Wellness Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

3.13 Earnings per share

The basic loss per share is computed by dividing the net loss by the weighted average number of shares outstanding, including Equity Shares, multiple voting shares of the Company and Exchangeable Shares, as defined below, during the period. The diluted loss per share reflects the potential dilution of shares by adjusting the weighted average number of shares outstanding to assume conversion of potentially dilutive shares, such as warrants (“Warrants”), restricted stock units (“RSUs”), and vested options of the Company (“Vested Options”). The treasury stock method is used for the assumed proceeds upon the exercise of the Warrants, and Vested Options that are used to purchase Equity Shares at the average market price during the period. If the Company incurs a net loss during a reporting period, the calculation of fully diluted loss per share will not include potentially dilutive equity instruments such as Warrants, RSUs, and Vested Options, because their effect would be anti-dilutive, therefore, basic loss per share and diluted loss per share will be the same. For the years ended December 31, 2023 and 2022, the potentially dilutive financial instruments excluded from the calculation of earnings per share included nil and nil warrants, nil and nil options and 1,908 and 3,799 RSUs, totaling 1,908 and 3,799 shares of potentially dilutive securities, respectively.

3.14 Stock-based payments

(a) Stock-based payment transactions

Certain employees (including directors and senior executives) of the Company receive a portion of their remuneration in the form of stock-based payment transactions, whereby employees render services as consideration for equity instruments.

Stock-based payments to non-employees are measured at the fair value of goods or services received or the fair value of the equity instruments issued, whichever is more readily determinable. In situations where equity instruments are issued to non-employees and some or all of the fair value of the good or service received by the Company as consideration cannot be specifically identified, they are measured at fair value of the stock-based payment. Stock-based payment transactions are primarily for individuals whose compensation has been classified as part of general and administrative expenses in the statements of operations.

The costs of equity settled transactions with employees are measured by reference to the fair value of the stock price at the date on which they are granted, using an appropriate valuation model. The value of the transaction is expensed straight line through the vesting period. Market and performance based RSUs are fair valued through Monte-Carlo simulations and are expensed over the indicative service period. Performance RSUs are recorded once the condition is probable to occur, refer to Note 15.

The costs of equity settled transactions are recognized, together with a corresponding increase in equity, over the period in which the performance and/or service conditions are fulfilled, ending on the date on which the relevant employees become fully entitled to the award (the “vesting date”).

The cumulative expense is recognized for equity settled transactions at each reporting date until the vesting date as the Company’s policy is to account for forfeitures as they occur. The income or loss for a period represents the movement in cumulative expense recognized as of the beginning and end of that period and the corresponding amount is represented in additional paid-in capital. At the end of each reporting period, the Company assesses if any forfeitures occurred and recognizes the impact in the statements of operations.

No expense is recognized for awards that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vesting for expense purposes irrespective of whether or not the market condition is satisfied provided that all other performance and/or service conditions are satisfied.

Where the terms of an equity settled award are modified, the minimum expense recognized is the grant date fair value of the unmodified award, provided the original terms of the award are met. An additional expense is recognized for any modification which increases the total fair value of the stock-based payment arrangement or is otherwise beneficial to the employee as measured at the date of modification. When an award is cancelled by the Company or the counterparty, any remaining element of the fair value of the award is derecognized at that time through the statements of operations.

12

Table of Contents

Ayr Wellness Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

3.14 Stock-based payments (Continued)

(a) Stock-based payment transactions (Continued)

RSUs are issued on the vesting dates, sometimes net of the applicable statutory tax withholding to be paid by the Company on behalf of the employees. In those instances, lower shares are issued than the number of RSUs vested and the tax withholding is recorded as a reduction to paid-in capital. The terms of the stock-based payment awards allow an entity with a statutory income tax withholding obligation to withhold shares with a fair value up to the maximum statutory tax in the employee’s applicable jurisdiction.

(b) Warrants

The Company determines the accounting classification for equity-linked financial instruments such as warrants, as either liability or equity, by assessing ASC 480 – Distinguishing Liabilities from Equity and ASC 815 – Derivatives and Hedging. Under ASC 480, warrants are considered a liability if the warrants are mandatorily redeemable, obligate the Company to settle the warrants or the underlying shares by paying cash or other assets, or warrants that must or may require settlement by issuing a variable number of shares.

Under ASC 815, warrants are considered liabilities if contracts require or may require the issuer to net settle the contract for cash. Such derivatives are recorded as a liability at fair value until they are settled or expire, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. After all relevant assessments, the Company concludes whether the warrants are classified as liability or equity. Liability classified warrants require fair value accounting at issuance and subsequent to initial issuance with all changes in fair value after the issuance date recorded in the statements of operations. Equity classified warrants only require fair value accounting at issuance with no changes recognized subsequent to the issuance date unless the warrants are modified.

The Company determined that all of its outstanding warrants are freestanding instruments which do not meet the characteristics of a liability and therefore are classified as equity.

3.15 Loss contingencies

Loss contingencies are recognized when the Company has a present obligation that has arisen as a result of a past event and it is probable that a future outflow of resources will be required to settle the obligation, provided that a reliable estimate can be made of the amount of the obligation. Loss contingencies are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the time value of money and the risk specific to the obligation.

3.16 Financial instruments

(a) Recognition and initial measurement

Financial assets and financial liabilities, including derivatives, are recognized when the Company becomes a party to the contractual provisions of a financial instrument or non-financial derivative contract. All financial instruments are measured at fair value on initial recognition. Transaction costs that are directly attributable to the acquisition or issuance of financial assets and financial liabilities, other than financial assets and financial liabilities classified as FVTPL (as defined below), are added to or deducted from the fair value on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities classified as FVTPL are recognized immediately in the statements of operations.

(b) Classification and subsequent measurement

The Company classifies financial assets, at the time of initial recognition, according to the Company’s business model for managing the financial assets and the contractual terms of the cash flows. Financial assets are classified in the following measurement categories:

a)amortized cost (“AC”).
b)fair value through profit or loss (“FVTPL”); and
c)fair value through other comprehensive income (“FVTOCI”).

13

Table of Contents

Ayr Wellness Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

3.16 Financial instruments (Continued)

(b) Classification and subsequent measurement (Continued)

Financial assets are subsequently measured at amortized cost if both of the following conditions are met and they are not designated as FVTPL: a) the financial asset is held within a business model whose objective is to hold financial assets to collect contractual cash flows; and b) the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. These assets are subsequently measured at amortized cost using the effective interest rate method, less any impairment, with gains and losses recognized in the statements of operations in the period that the asset is derecognized or impaired. All financial assets not classified at amortized cost as described above are measured at FVTPL or FVTOCI depending on the business model and cash flow characteristics. The Company has no financial assets measured at FVTOCI.

Financial liabilities are subsequently measured at amortized cost using the effective interest rate method with gains and losses recognized in the statements of operations in the period that the liability is derecognized, except for financial liabilities classified as FVTPL.

Refer to Note 17 for the classification and fair value (“FV”) level of financial instruments.

(c) Derecognition

The Company derecognizes financial assets only when the contractual rights to cash flows from the financial assets expire, or when it transfers the financial assets and substantially all of the associated risks and rewards of ownership to another entity. Gains and losses on derecognition are recognized in the statements of operations.

The Company derecognizes financial liabilities only when its obligations under the financial liabilities are discharged, cancelled, or expired. Generally, the difference between the carrying amount of the financial liability derecognized and the consideration paid and payable, including any non-cash assets transferred or liabilities assumed, is recognized in the statements of operations.

3.17 Foreign currency transactions and translations

Transactions denominated in foreign currency are translated into the functional currency of the entity using the exchange rates prevailing at the dates of the transactions or valuation where items are re-measured. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies, such as remeasurement of local currency into functional currency, are recognized in the statements of operations.

The results and financial position of an entity that has a functional currency different from the presentation currency is translated into the presentation currency as follows:

assets and liabilities for each balance sheet presented are translated at the closing rate at the date of the balance sheet; and
income and expenses for each statement of operations are translated at average exchange rates (unless this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated as the rate on the dates of the transactions).

Effect of translation differences, such as translation of foreign currency into reporting currency, are accumulated and presented as a component of equity under accumulated other comprehensive income.

14

Table of Contents

Ayr Wellness Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

3.18 Taxation

The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities based on the differences between the financial statements and tax basis of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates and laws on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that the Company would be able to realize our deferred tax assets in the future more than their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.

The Company is subject to ongoing tax exposures, examinations, and assessments in various jurisdictions. Accordingly, the Company may incur additional tax expense based upon the outcomes of such matters. FASB ASC 740, Income Taxes, (“ASC 740”) prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties related to unrecognized tax benefits as of December 31, 2023 and 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals, or material deviation from its position within twelve months of the reporting date.

As the Company operates in the cannabis industry, the Company is subject to the limits of Section 280E of the United States Internal Revenue Code, as amended (“Section 280E”), under which the Company is generally only allowed to deduct expenses directly related to the cost of goods sold.

3.19 Variable Interest Entities (“VIE”)

Under certain provisions of ASC Topic 810 – Consolidations (“ASC 810”), the Company determines whether we are the primary beneficiary of a VIE. We assess whether we have the power to direct matters that most significantly impact the activities of the VIE and the obligation to absorb losses or the right to receive the benefits from the VIE that could potentially be significant to the VIE.

A VIE is a legal entity that does not have sufficient equity at risk to finance its activities without additional subordinated financial support or is structured that such equity investors lack the ability to make significant decisions relating to the entity’s operations through voting rights or do not substantively participate in the gains or losses of the entity. The primary beneficiary has both the power to direct the activities of the VIE that most significantly impact the entity’s economic performance and the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. We assess all variable interests in the entity and use our judgment when determining whether a particular entity is a VIE and if we are the primary beneficiary. Other qualitative factors that are considered include decision-making responsibilities, the VIE capital structure, risk and rewards sharing, contractual agreements with the VIE, voting rights, and level of involvement of other parties. We assess the primary beneficiary determination for a VIE on an ongoing basis if there are any reconsideration events related to a VIE. See Note 6.

Where we determine we are the primary beneficiary of a VIE, we consolidate the accounts of that VIE, under the guidance of ASC 805. The equity owned by other shareholders of the VIE is shown as noncontrolling interests in the accompanying financial statements.

15

Table of Contents

Ayr Wellness Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

3.20 Significant accounting judgments and estimates

The application of the Company’s accounting policies requires management to use estimates and judgments that can have a significant effect on the revenues, expenses, assets and liabilities recognized, and disclosures made in the financial statements.

Management’s best estimates concerning the future are based on the facts and circumstances available at the time estimates are made. Management uses historical experience, general economic conditions, and assumptions regarding probable future outcomes as the basis for determining estimates. Estimates and their underlying assumptions are reviewed periodically, and the effects of any changes are recognized at that time. Actual results could differ from the estimates used.

(a)Business combinations

The following areas require management’s critical estimates and judgments:

A business combination is a transaction or event in which an acquirer obtains control of one or more businesses and is accounted for using the acquisition method. The total consideration paid for the acquisition is the aggregate of the fair values of assets acquired, liabilities assumed, and equity instruments issued in exchange for control of the acquiree at the acquisition date. The acquisition date is the date when the Company obtains control of the acquiree.

Contingent consideration is measured at its acquisition date fair value and is included as part of the consideration transferred in a business combination, subject to the applicable terms and conditions.

Contingent consideration that is classified as equity is not remeasured at subsequent reporting dates and its subsequent settlement is accounted for within equity. Contingent consideration that is classified as a liability is remeasured at subsequent reporting dates in accordance with the criteria and guidance provided under ASC 805.

Based on the facts and circumstances that existed at the acquisition date, management will perform a valuation analysis to allocate the consideration transferred based on the fair values of the identifiable assets acquired and liabilities assumed on the acquisition date. Management is required to finalize its allocation on the earlier of the date that information becomes known, but no later than one year from the acquisition date. Until such time, these values might be provisionally reported and are subject to change. During the measurement period, adjustments to provisional purchase price allocations are recognized if new information is obtained about the facts and circumstances that existed as of the acquisition date that, if known, would have resulted in the recognition of those assets and liabilities as of that date.

In determining the fair value of all identifiable assets acquired and liabilities assumed, the most significant estimates generally relate to contingent consideration and intangible assets. Management exercises judgment in estimating the probability and timing of when contingent consideration targets are expected to be achieved, which is used as the basis for estimating fair value. Identified intangible assets are recognized at fair value using appropriate valuation techniques which are generally based on a forecast of the total expected future net cash flows of the acquiree. Valuations are highly dependent on the inputs used and assumptions made by management regarding the future performance of these assets and any changes in the discount rate applied.

Judgment is applied in determining whether a transaction is a business combination or an asset acquisition by considering the nature of the assets acquired and the processes applied to those assets, or if the integrated set of assets and activities is capable of being conducted and managed for the purpose of providing a return to investors or other owners.

(b)Inventory

In calculating the value of inventory, management is required to make a number of estimates, including estimating the stage of growth of the cannabis up to the point of harvest, expected yields for the cannabis plants, harvesting costs, net realizable value, selling costs, average or expected selling prices, fair value of inventory acquired in a business combination and impairment factors. In calculating final inventory values, management compares the inventory costs to estimated net realizable value as well as investigates slow moving inventory, if applicable. The estimates are judgmental in nature and are made at a point in time, using available information, such as expected business plans and expected market conditions. Periodic reviews are performed on the inventory balance with the changes in inventory reserves reflected in cost of goods sold.

16

Table of Contents

Ayr Wellness Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

3.20 Significant accounting judgments and estimates (Continued)

(c)Estimated useful lives and depreciation of PPE

Depreciation of PPE is dependent upon estimates of useful lives, which are determined through the exercise of judgments. The assessment of any impairment of these assets is dependent upon estimates of recoverable amounts that take into account factors such as economic and market conditions and the useful lives of assets.

(d)Valuation, estimated life and impairment of intangible assets

Management uses significant judgment in estimating the useful lives and impairment. Impairment tests rely on judgments and estimates related to growth rates, discount rates, and estimated margins.

(e)Goodwill impairment

Goodwill is tested for impairment annually on December 31st of each fiscal year and whenever events or changes in circumstances indicate that the carrying amount of goodwill may have been impaired. In order to determine that the value of goodwill may have been impaired, the Company may perform a qualitative assessment to determine if it was more-likely-than-not that the reporting unit’s carrying value is less than the fair value, indicating the potential for goodwill impairment. Several factors, including historical results, business plans, forecasts, and market data are used to determine the fair value of the reporting unit. Changes in the conditions for these judgments and estimates can significantly affect the assessed value of goodwill.

(f)Leases

Each lease is evaluated to determine if the Company would exercise any of the renewal options offered. Several material factors are considered in determining if the renewal options would be exercised, such as length of the renewal, renewal rate, and ability to transfer locations. When measuring lease liabilities, the Company used discounted lease payments using a weighted-average rate in the range of 7.8% to 15.5% per annum. The weighted-average rate is based on the Company’s incremental borrowing rate, which relies on judgments and estimates.

(g)Provisions and contingent liabilities

When the Company is probable to incur an outflow of resources to settle an obligation and the amount can be reasonably estimated, a contingent liability is recorded. The contingent liability is recorded at management’s best estimates of the expenditure required to settle the obligation at period end, discounted to the present value, if material.

(h)Financial instruments

To determine the fair value of financial instruments, the Company develops assumptions and selects certain methods to perform the fair value calculations. Various methods considered include but are not limited to: (a) assigning the value attributed to the transaction at the time of origination; (b) re-measuring the instrument if it requires concurrent fair value measurement; and (c) valuing the instrument at the issuance value less any amortized costs. As judgment is a factor in determining the value and selecting a method, as well as the inherent uncertainty in estimating the fair value, the valuation estimates may be different.

Application of the option pricing model requires estimates in expected dividend yields, expected volatility in the underlying assets, and the expected life of the financial instruments. These estimates may ultimately be different from amounts subsequently realized, resulting in an overstatement or understatement of net loss.

17

Table of Contents

Ayr Wellness Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

3.21 Liquidity and management plan

As reflected in the consolidated financial statements, the Company had negative working capital of $7,258 as of December 31, 2023 and has incurred net losses from continuing operations for the years ended December 31, 2023 and 2022. The Company’s approach to managing its liquidity risk is to seek to ensure that it will have sufficient liquidity to meet its liabilities as they come due. The Company’s short-term liquidity requirements consist primarily of funds necessary to maintain operations, repay borrowings and other general business needs. The Company plans to use existing funds, as well as funds from the future sale of products, to fund short-term working capital needs for at least the next 12 months from the issuance of the consolidated financial statements.

In addition, the Company continues to take actions designed to improve the Company’s operations and cash position, including but not limited to: (i) targeting continued growth of sales from our consolidated operations; (ii) continued cost-savings and efficiency optimization efforts; (iii) utilizing the future proceeds from an employee retention credit up to $12,354 of which $5,238 was included in current receivables; (iv) addressing our debt maturity profile, in this regard, subsequent to December 31, 2023 the Company completed the debt restructuring transaction contemplated in its October 31, 2023 Support Agreement (the “Support Agreement”) with the holders of approximately 99% (collectively, the “Majority Noteholders”) of the aggregate outstanding principal amount of the Company’s 12.5% senior notes due December 2024 (the “Senior Notes”), which resulted in the effective extension via exchange of the maturity date for an additional two years, see Note 19, and the crystallization of the previously-announced deferral of certain current debts payable; (v) managing the timing and amount of certain expenses as well as capital expenditures; and (vi) seeking to take advantage of future potential financing (equity and/or debt) opportunities, including additional gross cash proceeds of $40,000 received February 2024 related to the issuance of new debt securities (refer to Note 19 for additional information). The debt extension related to the Support Agreement and the deferral of certain current debts payable are each classified as a non-current liability on the balance sheet as of December 31, 2023. While the contemplated debt restructuring transactions have been completed, management cannot provide any assurances that the Company will continue to be successful in accomplishing its business plans; if it is not, the Company may be forced to take other steps, including among others decelerating its growth or curtailing certain of its operations pending obtaining additional capital.

3.22 Discontinued operations

Strategic changes in the Company’s operations can be considered a discontinued operation if both the operations and cash flows of the discontinued business have been (or will be) eliminated from the ongoing operations of the Company and the Company will not have any significant continuing involvement in the operations of the discontinued business after the disposal transaction. Under ASC Subtopic 205-20, “Presentation of Financial Statements – Discontinued Operations” (“ASC Subtopic 205-20”), a component of an entity that is classified as discontinued operations is presented separately from continuing operations in the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows for all periods presented. All assets and liabilities related to such discontinued operations are classified as held for sale and presented separately in the Consolidated Balance Sheets for all periods prior to the disposal by sale. Accordingly, the presentation of prior period balances may not agree to previously issued financial statements. See Note 4 for additional information regarding the results of operations and major classes of assets and liabilities of discontinued operations.

3.23 Change in accounting standards

The Company is treated as an “emerging growth company” as defined under the Jumpstart Our Business Start-ups Act of 2012, as amended (the “JOBS Act”). Under the JOBS Act, emerging growth companies may delay adopting new or revised accounting standards until the standards apply to private companies, however, emerging growth companies are not precluded from early adopting new accounting standards that allow so.

18

Table of Contents

Ayr Wellness Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

3.23 Change in accounting standards (Continued)

Recently Issued and Adopted Accounting Standards

In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-13 Topic 326 – Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments, which was subsequently revised by ASU 2018-19, ASU 2019-04, ASU 2019-05, ASU 2019-11, ASU 2020-02, ASU 2020-03, and ASU 2022-02 (“ASU 2016-13”), which introduces a new model for assessing impairment on most financial assets. Entities will be required to use a forward-looking expected loss model, which will replace the current incurred loss model, which will result in earlier recognition of allowance for losses. ASU 2016-13 was effective for the Company’s fiscal year beginning after December 15, 2022, and interim periods therein. For accounts receivable only, the Company applies the simplified approach as permitted by ASU 2016-13. The simplified approach to the recognition of expected losses does not require the Company to track the changes in credit risk; rather, the Company recognizes a loss allowance based on lifetime expected credit losses at each reporting date from the date of the trade receivable. Expected credit losses are measured as the difference in the present value of the contractual cash flows that are due to the Company under the contract, and the cash flows that the Company expects to receive.

The Company assesses all information available, including past due status, credit ratings, the existence of third-party insurance, and forward-looking macro-economic factors in the measurement of the expected credit losses associated with its assets carried at amortized cost. The Company measures expected credit loss by considering the risk of default over the contract period and incorporates forward-looking information into its measurement. The adoption of ASU 2016-13 did not have a material impact on the Company’s financial statements and there was no cumulative effect at the adoption of the standard.

In June 2022, the FASB issued ASU No. 2022-03 Topic 820 – Fair Value Measurement – Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”), (1) to clarify the guidance in Topic 820, Fair Value Measurement, when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, (2) to amend a related illustrative example, and (3) to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. ASU 2022-03 is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years, early adoption is permitted. The Company is currently evaluating the impact the adoption of ASU 2022-03 may have on the Company’s financial statements.

In September 2022, the FASB issued ASU No. 2022-04 Topic 405 – Liabilities – Supplier Finance Programs (“ASU 2022-04”), which is intended to enhance transparency with supplier finance programs. ASU 2022-04 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Adoption is applied on a retrospective approach. The adoption of this ASU did not have a material impact on the Company’s financial statements.

On March 27, 2023, the FASB issued ASU No. 2023-01 Topic 842 – Leases – Common Control Arrangements (“ASU 2023-01”), in response to private company stakeholder concerns about applying Topic 842 to related party arrangements between entities under common control. ASU 2023-01 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, early adoption is permitted. The Company is currently evaluating the impact the adoption of ASU 2023-01 may have on the Company’s financial statements.

19

Table of Contents

Ayr Wellness Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

3.23 Change in accounting standards (Continued)

Recently Issued and Adopted Accounting Standards (Continued)

In November 2023, the FASB issued ASU No. 2023-07 Topic 280 – Segment Reporting (“ASU 2023-07”) to improve the disclosures about a public entity’s reportable segments and address requests from investors for additional, more detailed information about a reportable segment’s expenses. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, early adoption is permitted. The Company is currently evaluating the impact the adoption of ASU 2023-07 may have on the Company’s financial statements.

On December 14, 2023, the FASB issued ASU No. 2023-09 Topic 740 – Income Taxes (“ASU 2023-09”) to enhance the transparency and decision usefulness of income tax disclosures. The amendments in this Update address investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, including interim periods within those fiscal years, early adoption is permitted. The Company is currently evaluating the impact the adoption of ASU 2023-09 may have on the Company’s financial statements.

4.    DISCONTINUED OPERATIONS

On March 27, 2023, the Company closed the sale of Blue Camo, LLC (“Blue Camo”) which comprised the Company’s Arizona business and included two licensed entities operating three Oasis-branded dispensaries in the greater Phoenix area, a cultivation and processing facility in Chandler, a cultivation facility in Phoenix, and the Company’s majority interest in Willcox OC, LLC, a joint venture developing an outdoor cultivation facility. Total consideration consisted of $20,000 in cash before working capital adjustments and the assumption of lease obligations eliminating approximately $16,734 in long-term lease liabilities. In a separate agreement, all debt outstanding and potential earn-out contingent consideration, related to the 2021 acquisition of Blue Camo, was eliminated, reducing the Company’s long-term debt by $22,505, along with accrued interest thereon of approximately $1,165 and potential earn-out contingent consideration to $nil.

The Company accounted for this sale as a disposal under ASC Subtopic 360-10, “Impairment or Disposal of Long-Lived Assets”. The Company has reclassified the operations of Arizona as discontinued operations for all periods presented prior to the sale as the disposal represents a strategic shift that will have a major effect on the Company’s operations and financial results. The Company determined the business to be held for sale as the criteria established under ASC 205-20-45-1E had been satisfied due to the sale occurring during the first quarter of 2023. As of December 31, 2022, the Company determined under ASC 855-10-55, the Arizona business did not meet the criteria as held for sale, as such, no reclassification was made on the balance sheet and statement of operations in the Company’s Annual Report on the Form 40-F for the year ended December 31, 2022. In accordance with ASC 205-20-50-1(a) the Company has retrospectively reflected the reclassification of assets and liabilities of these entities as held for sale on the balance sheet as of December 31, 2022 and the operations as discontinued operations on the statement of operations for the period January 1, 2022 through December 31, 2022 and excluded from the accompanying notes.

20

Table of Contents

Ayr Wellness Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

4.    DISCONTINUED OPERATIONS (Continued)

As of December 31, 2022, the major classes of assets and liabilities held for sale in Arizona included the following:

    

As of

December 31, 2022

Current assets held-for-sale

Inventory and other current assets

$

20,910

Property, plant, and equipment, net

 

24,239

Intangible assets, net

 

194,018

Right-of-use assets, net

 

17,568

Deferred tax asset, net

 

3,890

Total assets held-for-sale

$

260,625

Current liabilities held-for-sale

 

  

Trade payables and other current liabilities

$

2,629

Lease liabilities

 

18,097

Debt payable

 

22,505

Accrued interest payable

 

610

Total liabilities held-for-sale

$

43,841

The following table details the components comprising net loss from our discontinued operations:

Year Ended

December 31, 2023

December 31, 2022

Revenues from discontinued operations, net of discounts

    

$

10,260

    

$

44,183

Cost of goods sold

 

9,074

 

28,705

Gross profit

 

1,186

 

15,478

Operating expenses from discontinued operations:

Selling, general, and administrative

 

2,115

 

40,153

Depreciation and amortization

 

2,675

 

11,055

Total operating expenses from discontinued operations

 

4,790

 

51,208

Loss from operations

 

(3,604)

 

(35,730)

Other expense

Interest Expense

 

(580)

 

(2,250)

Income taxes

 

 

Current tax provision

(575)

(628)

Deferred tax benefit

870

Total income taxes

295

(628)

 

  

 

  

Loss from discontinued operations

 

 

Loss from discontinued operations, net of taxes

 

(3,889)

 

(38,608)

Loss on disposal of discontinued operations

(182,464)

Loss from discontinued operations

$

(186,353)

$

(38,608)

The loss on disposal of discontinued operations of $182,464 was derived from the gross proceeds of $49,336, made up of $20,000 of cash consideration and a $5,666 working capital adjustment and the elimination of $23,670 of debt outstanding from the sale of Arizona, less the carrying value of Arizona of approximately $231,800. As of December 31, 2023, the Company finalized the settlement of the working capital adjustment, receiving $1,583 in cash proceeds and $4,083 in consideration other than cash.

21

Table of Contents

Ayr Wellness Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

5.    BUSINESS COMBINATIONS AND ASSET ACQUISITIONS

Transactions accounted for as business combinations have been accounted for under the acquisition method in accordance with ASC 805, with the results included in the Company’s results from operations from the date of acquisition. The fair value of considerations transferred have been allocated to the assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition.

In determining the fair value of all identifiable assets, liabilities and contingent liabilities acquired, the most significant estimates relate to contingent consideration and intangible assets. Management exercised judgement in estimating the probability and timing of when earnouts are expected to be achieved which is used as the basis for estimating fair value.

For the intangible assets identified, depending on the type of intangible asset and the complexity of determining its fair value, an independent valuation expert or management may develop the fair value, using appropriate valuation techniques, which are generally based on a forecast of the total expected future net cash flows and take into consideration other significant assumptions such as the expected use, the infancy of the cannabis industry and industry comparatives, federal and state regulations, market uncertainty and the estimated lives of any long-lived facilities and assets that the intangibles may relate to.

Cannabis licenses are the primary intangible asset acquired in business combinations as they provide the Company the ability to operate in each market. However, some cannabis licenses are subject to renewal and therefore there is some risk of non-renewal for several reasons, including operational, regulatory, legal, or economic factors. To appropriately consider the risk of non-renewal, the Company applies probability weighting to the expected future net cash flows in calculating the fair value of these intangible assets. The key assumptions used in these cash flow projections include discount rates and terminal growth rates. Of the key assumptions used, the impact of the estimated fair value of the intangible assets has the greatest sensitivity to the estimated discount rate used in the valuation. The terminal growth rate represents the rate at which these businesses will continue to grow into perpetuity. Other significant assumptions include revenue, gross profit, operating expenses and anticipated capital expenditures which are based upon the acquiree’s historical operations along with management projections. The evaluations are linked closely to the assumptions made by management regarding the future performance of these assets and any changes in the discount rate applied.

Each of the acquisitions are subject to specific terms relating to the satisfaction of the purchase price by the Company and its wholly owned subsidiaries, and incorporates payments in cash, shares, and debt as well as certain contingent considerations. The shares issued as consideration are either Equity Shares or non-voting exchangeable shares of the Company’s subsidiaries (“Exchangeable Shares”) that are exchangeable on a one-for-one basis into an equal number of Equity Shares of the Company. The Company treats the Exchangeable Shares as options with a value equal to a share of Equity Shares, which represents the holder’s claim on the equity of the Company. The Company has presented these Exchangeable Shares as a part of shareholders’ equity within these financial statements due to the fact that (i) they are economically equivalent to the Company’s publicly traded Equity Shares and (ii) the holders of the Exchangeable Shares are subject to restrictions on transfer under United States securities laws but may dispose of the Exchangeable Shares by exchanging them for Equity Shares of the Company which can then be sold through the CSE. Changes in these assumptions would affect the presentation of the Exchangeable Shares from shareholders’ equity to noncontrolling interests; however, there would be no impact on loss per share.

The goodwill recognized on each acquisition is attributable mainly to the expected future growth potential and expanded customer base arising as a result of the completion of the respective acquisition. Goodwill has been allocated to the reporting units corresponding to the states of the acquired businesses. None of the goodwill is expected to be deductible for income tax purposes. For further analysis on goodwill relating to business combinations, see Note 9.

22

Table of Contents

Ayr Wellness Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

5.    BUSINESS COMBINATIONS AND ASSET ACQUISITIONS (Continued)

2023 Fourth Quarter Acquisition

Asset acquisition

On November 2, 2023, the Company completed its acquisitions in Land of Lincoln Dispensary LLC (“Land of Lincoln”) through a membership interest purchase agreement. As part of the purchase accounting for this acquisition, the Company recorded intangible assets of $200, which was associated with two conditional adult use dispensary licenses that allow for the retail sales of cannabis. The amortization period for the licenses was determined to be 15 years, which reasonably reflects the useful lives of the assets.

The Land of Lincoln acquisition did not meet the definition of a business according to ASC 805 and as such, it was recorded as an asset acquisition. Purchase consideration for the acquisition was $200, paid in cash, all of which was allocated to intangible assets - licenses.

2022 Second Quarter Acquisition

Herbal Remedies Business Combination

Business Combination

On May 25, 2022, the Company completed its acquisition of Herbal Remedies Dispensaries, LLC (“Herbal Remedies”) through a membership interest purchase agreement.

The fair value of identifiable assets acquired, and liabilities assumed as of the acquisition date are as follows:

    

Herbal Remedies

ASSETS ACQUIRED

 

  

Cash

$

637

Inventory

 

1,480

Prepaid expenses and other assets

 

256

Intangible assets - licenses/permits

 

15,700

Property, plant, and equipment

 

122

Right-of-use assets - operating

 

700

Total assets acquired at fair value

 

18,895

LIABILITIES ASSUMED

 

  

Trade payables

 

215

Accrued liabilities

 

68

Lease liabilities - operating

 

700

Total liabilities assumed at fair value

 

983

Goodwill

 

1,180

Consideration transferred

$

19,092

As part of the purchase accounting for the above acquisition, the Company recorded intangible assets of $15,700, all of which were associated with licenses that allow for the retail sales of cannabis. The amortization period for licenses was determined to be 15 years, which reasonably reflects the useful lives of the assets.

Herbal Remedies is an operator of two medical and adult-use licensed retail dispensaries in Quincy, Illinois. This acquisition expands the Company’s operational footprint with the addition of the state of Illinois.

23

Table of Contents

Ayr Wellness Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

5.    BUSINESS COMBINATIONS AND ASSET ACQUISITIONS (Continued)

Purchase consideration was comprised of the following:

    

  

    

Shares

    

Fair Value

Cash

 

i

 

$

3,002

Debt Payable

 

ii

 

 

14,220

Shares Issued

 

iii

 

353

 

1,870

Total

 

  

 

353

$

19,092

Pursuant to the terms of the definitive agreement with Herbal Remedies, Ayr satisfied the purchase price of $19,092 for Herbal Remedies through the following:

i.$3,002 of the Herbal Remedies purchase price in the form of cash consideration and settlement of the final working capital which is deemed immaterial;
ii.$14,220 of the Herbal Remedies purchase price in the form of a promissory note payable; and
iii.$1,870 of the Herbal Remedies purchase price in the form of 353 Exchangeable Shares, these shares have contractual restrictions on their ability to be sold for six to twelve months (the “Herbal Remedies Lock-Up Provision”). The fair value of the shares was determined by the share price on the CSE at the date of acquisition and a 16.55% discount rate attributed to the contractual restrictions.

2022 First Quarter Acquisition

Cultivauna Business Combination

Business Combination

On February 15, 2022, the Company completed its acquisition of Cultivauna, LLC (“Cultivauna”) through a membership interest purchase agreement. Cultivauna has a production license in the state of Massachusetts and sells cannabis infused branded seltzers and water-soluble tinctures.

24

Table of Contents

Ayr Wellness Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

5.    BUSINESS COMBINATIONS AND ASSET ACQUISITIONS (Continued)

The fair value of identifiable assets acquired and liabilities assumed as of the acquisition date are as follows:

Cultivauna

ASSETS ACQUIRED

Cash

$

1,251

Accounts receivable

471

Inventory

1,206

Prepaid expenses and other assets

38

Intangible assets - trade name/brand

3,400

Intangible assets - host community agreements

2,100

Property, plant, and equipment

2,202

Right-of-use assets - operating

315

Total assets acquired at fair value

10,983

LIABILITIES ASSUMED

Trade payables

23

Accrued liabilities

305

Lease liabilities - operating

315

Total liabilities assumed at fair value

643

Goodwill

11,281

Consideration transferred

$

21,621

As part of the purchase accounting for the above acquisition, the Company recorded intangible assets of $5,500, which were associated with a trade name/brand and host community agreement that allow for the processing, production, and retail sales of cannabis. The amortization period for the trade name/brand and host community agreement was determined to be 5 and 15 years, respectively, which reasonably reflects the useful lives of the assets.

Purchase consideration was comprised of the following:

    

  

    

Shares

    

Fair Value

Cash

 

i

 

$

11,027

Shares Issued

 

ii

 

329

4,482

Contingent Consideration

 

iii

 

6,112

Total

 

  

 

329

$

21,621

25

Table of Contents

Ayr Wellness Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

5.    BUSINESS COMBINATIONS AND ASSET ACQUISITIONS (Continued)

Purchase consideration was comprised of the following:

Pursuant to the terms of the definitive agreement with Cultivauna Ayr satisfied the purchase price of $21,621 for Cultivauna through the following:

i.

$11,027 of the Cultivauna purchase price in the form of cash consideration and settlement of the final working capital which is deemed immaterial;

ii.

$4,482 of the Cultivauna purchase price in the form of 329 Exchangeable Shares, these shares have contractual restrictions on their ability to be sold for six to twelve months (the “Cultivauna Lock-Up Provision”). The fair value of the shares was determined by the share price on the CSE at the date of acquisition and a 14.85% discount rate attributed to the contractual restrictions; and

iii.

A portion of the Cultivauna purchase price is derived from an earn-out provision through December 31, 2023 based on annualized net revenues generated during the measurement period, consisting of Exchangeable Shares, valued through a Monte-Carlo simulation, which may entitle the sellers to earn additional consideration if certain milestones are achieved.

6.    VARIABLE INTEREST ENTITIES (“VIE”)

In February 2022, the Company had the ability to direct the activities of two entities, Tahoe Hydroponics Company, LLC (“Tahoe Hydro”) and NV Green, Inc. (“NVG” and, together with Tahoe Hydro, “TH”/ “NVG”), through a management services and equity purchase agreement, thereby classifying the entities as VIEs, until certain conditions are met, at which time the Company is required to evaluate business combination accounting. The assets of TH/NVG can only be used to settle its liabilities and under the applicable agreements, TH/NVG retains ultimate legal responsibilities for its operations.

In May 2023, the Company finalized the acquisition of Tahoe Hydro and assumed 100% of the membership interest. Based on the changes in circumstances, the Company re-evaluated the status of Tahoe Hydro as a variable interest entity, concluding that the Company had acquired a controlling interest in Tahoe Hydro. Purchase consideration for the acquisition included $1,382 in cash, net of transaction expenses, promissory note of $1,580, the conversion of a convertible note of $2,800, and $115 in the form of 233 Exchangeable Shares. These shares have contractual restrictions on their ability to be sold for six to twelve months. The fair value of the shares was determined by the share price on the CSE at the date of acquisition and a 19.45% discount rate attributed to the contractual restrictions. NVG remains a VIE until certain conditions are met, at which time the Company is required to evaluate business combination accounting.

On March 30, 2021, the Company completed its acquisition of Greenlight Management, LLC (“Greenlight Management”) and Greenlight Holdings, LLC (“Greenlight Holdings”) through a membership purchase agreement. Greenlight Management operates on a 58,000 square foot facility in Parma, Ohio under a management agreement with Parma Wellness Center, LLC (“Parma”) a recipient of a Tier 1 Cultivator Provisional License in the medical cannabis market in Ohio. The Company determined that it possesses the power to direct activities of Parma through the management agreement, thereby classifying the entity as a VIE. During the year ended December 31, 2023 the Company purchased the minority interest in Parma for $25. Based on the changes in circumstances, the Company re-evaluated the variable interest entity, concluding that it did not own a controlling interest, thereby classifying the entity as VIE.

During 2023, the Company entered into an option and support service agreement with Daily Releaf, LLC, Heaven Wellness, LLC and Twice the Wellness, LLC, (collectively “Ohio Dispensaries”), each is licensed to operate a medical marijuana dispensary in Ohio. The option agreement provides the Company with the future ability to acquire 100% of the equity interests in dispensaries.

26

Table of Contents

Ayr Wellness Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

6.    VARIABLE INTEREST ENTITIES (“VIE”) (Continued)

The following tables present the summarized financial information about the Company’s consolidated VIEs which are included in the balance sheets as of December 31, 2023 and 2022 and statements of operations for years ended December 31, 2023 and 2022. All these entities were determined to be VIEs as the Company possesses the power to direct activities and obligation to absorb losses through management services agreements.

As of

As of

December 31, 2023

December 31, 2022

Ohio

    

NVG

    

Parma

    

Dispensaries

    

Total

    

TH/NVG

    

Parma

    

Total

Current assets

(351)

$

10,616

(2,257)

8,008

$

5,248

$

10,751

15,999

Non-current assets

 

1,077

 

13,210

 

6,441

20,728

 

6,582

 

14,634

 

21,216

Total assets

$

726

$

23,826

$

4,184

$

28,736

$

11,830

$

25,385

$

37,215

Current liabilities

$

604

$

18,962

$

1,647

$

21,213

$

1,033

$

14,092

$

15,125

Non-current liabilities

 

383

 

1,280

 

3,369

 

5,032

 

898

 

1,952

 

2,850

Total liabilities

 

987

 

20,242

 

5,016

 

26,245

 

1,931

 

16,044

 

17,975

Noncontrolling interest

 

796

 

(10,158)

 

(1,764)

 

(11,126)

 

7,528

 

(5,528)

 

2,000

Equity (deficit) attributable to Ayr Wellness Inc.

 

(1,057)

 

13,742

 

932

 

13,617

 

2,371

 

14,869

 

17,240

Total liabilities and equity

$

726

$

23,826

$

4,184

$

28,736

$

11,830

$

25,385

$

37,215

Year Ended

Year Ended

December 31, 2023

December 31, 2022

Ohio

    

TH/NVG

    

Parma

    

Dispensaries

    

Total

    

TH/NVG

    

Parma

    

Total

Revenues, net of discounts

$

$

3,170

$

462

$

3,632

$

1,851

$

$

1,851

Net loss attributable to noncontrolling interest

 

(673)

 

(4,630)

 

(1,764)

 

(7,067)

 

(4,491)

 

(5,528)

 

(10,019)

Net loss attributable to Ayr Wellness Inc.

 

 

(1,275)

 

 

(1,275)

 

 

 

Net loss

$

(673)

$

(5,905)

$

(1,764)

$

(8,342)

$

(4,491)

$

(5,528)

$

(10,019)

Ohio

    

TH/NVG

    

Parma

    

Dispensaries

    

Total

Noncontrolling interest at January 1, 2022

$

$

$

$

Total purchase consideration

16,868

16,868

Working capital adjustment presented as consideration payable

(4,849)

(4,849)

Net loss during the period

(4,491)

(5,528)

(10,019)

Noncontrolling interest at December 31, 2022

$

7,528

$

(5,528)

$

2,000

Acquisition of Tahoe Hydro

(6,059)

(6,059)

Net loss during the period

(673)

(4,630)

(1,764)

(7,067)

Noncontrolling interest at December 31, 2023

$

796

$

(10,158)

$

(1,764)

$

(11,126)

27

Table of Contents

Ayr Wellness Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

7.    INVENTORY

The Company’s inventory includes the following:

    

December 31, 

    

December 31, 

2023

2022

Materials, supplies, and packaging

$

7,505

$

9,770

Work in process

69,632

65,807

Finished goods

 

29,226

 

24,233

Total inventory

$

106,363

$

99,810

The amount of inventory included in cost of goods sold during the years ended December 31, 2023 and 2022, was $218,587 and $205,809, respectively. The Company reviews inventory on hand for estimated obsolescence or unmarketable items, as compared to future demand requirements and the shelf life of the various products. Based on the review, the Company records inventory write-downs, when necessary, when costs exceed expected net realizable value.

For the years ended December 31, 2023 and 2022, $nil and $6,217 respectively, of expenses relating to the incremental costs to acquire cannabis inventory in business combinations are recognized in cost of goods sold on the statements of operations. This relates to the one-time adjustment of cannabis inventory from acquiree historical cost to fair value as part of the purchase price allocation.

8.    PROPERTY, PLANT, AND EQUIPMENT

As of December 31, 2023 and 2022, property, plant, and equipment, net consisted of the following:

December 31, 

December 31, 

    

2023

    

2022

Furniture and equipment

$

52,793

 

$

53,070

Auto and trucks

1,393

 

1,626

Buildings

94,914

91,233

Leasehold improvements

173,043

154,774

Land

13,877

13,879

Construction in progress

12,571

9,581

Total

348,591

324,163

Less: Accumulated depreciation and amortization

37,976

21,483

Total property, plant and equipment, net

$

310,615

 

$

302,680

Capitalized interest for the years ended December 31, 2023 and 2022, totaled $9,981 and $14,490, respectively. Depreciation and amortization expense for the years ended December 31, 2023 and 2022, totaled $25,226 and $14,257, respectively, of which $15,846 and $9,858 respectively, is included in cost of goods sold.

As of December 31, 2023, the Company concluded that the carrying amount of certain long-lived assets exceeded the fair value and recorded an impairment loss on PPE assets of $4,858.

28

Table of Contents

Ayr Wellness Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

9.    GOODWILL AND INTANGIBLE ASSETS

Goodwill

As of December 31, 2023 and 2022, the Company’s goodwill is as follows:

As of January 1, 2022

    

$

199,329

Acquired through business combinations and initial consolidation of VIEs

12,729

Impairment of goodwill

(117,950)

As of December 31, 2022

94,108

(no activity)

As of December 31, 2023

$

94,108

Intangible Assets

During the year ended December 31, 2023 an entity co-owned by the Company was awarded a provisional Disproportionately Impacted Area cultivator license in Connecticut. The Company recorded an intangible asset of $3,000 in connection with the cash payment for the cost of the provisional license. During the year ended December 31, 2023 the Company acquired a standalone delivery license in Connecticut and recorded an intangible asset of $200 in connection with the cash payment for the cost of the license. The operations in Connecticut are not currently active, as such, no amortization expense has been recorded as of the year ended December 31, 2023.

Amortization expense is recorded within cost of goods sold and total operating expenses. The amount in cost of goods sold for the years ended December 31, 2023 and 2022 was $16,825 and $15,907, respectively.

The following table represents intangible assets, net of accumulated amortization:

    

    

December 31, 2023

    

December 31, 2022

Amortization period (# of years)

Licenses/permits

15

$

641,036

$

693,714

Right-to-use licenses

 

15

 

16,407

 

17,717

Host community agreements

 

15

 

26,954

 

29,494

Trade name / brand

 

5

 

3,591

 

3,784

Total

$

687,988

$

744,709

The following table presents the future amortization expense as of December 31, 2023:

    

Amortization Expense

2024

$

58,123

2025

57,308

2026

57,308

2027

57,308

2028

57,308

2029 and beyond

397,433

Total

$

684,788

29

Table of Contents

Ayr Wellness Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

9.    GOODWILL AND INTANGIBLE ASSETS (Continued)

Intangible Assets (Continued)

Impairment of goodwill

As part of the annual impairment test as of December 31, 2023 and 2022 a one-step quantitative impairment test was performed over all its reporting units, which includes goodwill acquired through various acquisitions and the initial consolidation of VIEs. The following significant assumptions were applied in the determination of the fair value of each reporting unit using a discounted cash flow model:

Cash flows: estimated cash flows were projected based on actual operating results from internal sources, as well as industry and market trends. The forecasts were extended to a total of five years (with a terminal value thereafter);
Terminal value growth rate: The terminal growth rate of 3% was based on historical and projected consumer price inflation, historical and projected economic indicators and projected industry growth;
Post-tax discount rate: the post-tax discount rate of 20% and 18%, respectively, is reflective of the weighted average cost of capital (“WACC”). The WACC was estimated based on the risk-free rate, equity risk premium, beta premium, and after-tax cost of debt based on corporate bond yields; and
Tax rate: the tax rates used in determining future cash flows were those substantively enacted at the respective valuation date.

The Company compared the fair value of each reporting unit to its carrying value to determine whether the carrying value exceeded fair value. Due to changes in market expectations as a result of increased competition and price compression at the reporting units, the Company recorded impairment of goodwill of $117,950 for the year ended December 31, 2022 reducing the carrying value of goodwill acquired across all reporting units. The remaining goodwill of $94,108 relates to the Company’s Florida reporting unit.

Long-lived assets

The Company evaluates the recoverability of other long-lived assets, including property, plant and equipment, and certain identifiable intangible assets, whenever events or changes in circumstances indicate that the carrying value of an asset or asset group may not be recoverable. The Company performs impairment tests of indefinite-lived intangible assets on an annual basis or more frequently in certain circumstances. Factors which could trigger an impairment review include significant underperformance relative to historical or projected future operating results, significant changes in the manner of use of the assets or the strategy for the overall business, a significant decrease in the market value of the assets or significant negative industry or economic trends. When the Company determines that the carrying value of long-lived assets may not be recoverable based upon the existence of one or more of the indicators, the assets are assessed for impairment based on the estimated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the carrying value of an asset exceeds its estimated future undiscounted cash flows, an impairment loss is recorded for the excess of the asset’s carrying value over its fair value.

No such impairment charges were recorded for finite-lived intangible assets during the years ended December 31, 2023 or 2022.

30

Table of Contents

Ayr Wellness Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

10.    RIGHT-OF-USE ASSETS AND LEASE LIABILITIES

Information related to operating and finance leases is as follows:

December 31, 2023

December 31, 2022

 

    

Operating Leases

    

Finance Leases

    

Operating Leases

    

Finance Leases

 

Incremental borrowing rate (weighted average)

 

11.83

%  

10.37

%  

11.98

%  

9.68

%

Weighted average remaining lease term

 

12.12

yrs

4.76

yrs

13.04

yrs

4.90

yrs

The maturities of the contractual lease liabilities as of December 31, 2023 are as follows:

    

Operating Leases

    

Finance Leases

    

Total

2024

    

$

29,457

$

12,098

$

41,555

2025

 

29,112

6,428

35,540

2026

 

28,381

4,412

32,793

2027

 

27,125

3,340

30,465

2028

 

26,507

2,501

29,008

2029 and beyond

198,164

6,428

204,592

Total undiscounted lease liabilities

 

338,746

35,207

373,953

Impact of discounting

(203,231)

(7,411)

(210,642)

Total present value of minimum lease payments

$

135,515

$

27,796

$

163,311

In June 2022, the Company completed a sale and lease back transaction to sell two cultivation and processing facilities for a purchase price of $28,107, excluding transaction costs. The Company leased back the facilities and continues to operate and manage them under a long-term agreement. The transaction qualified for sale-leaseback treatment under ASC 842. As a result of the sale, the Company divested of $22,206 of buildings and improvements, and $3,728 of land. The Company recognized a gain on sale related to the transaction of $2,173 which was recorded within gain on sale of assets on the statements of operations. The lease was recorded as an operating lease and resulted in a lease liability of $25,331 and an ROU asset of $25,339, which was recorded net of a $750 work allowance.

In June 2022, the Company closed on a real estate financing transaction resulting in $27,599 of cash proceeds for the sale and simultaneous leaseback of a cultivation facility. The transaction includes a construction financing allowance of up to $14,187, which will increase the base rent at the time the construction financing is drawn down. The initial term of the agreement is fifteen years, with two five-year options to renew. The initial payments are equal to 10% of the sum of the purchase price and increases when a draw is made on the construction finance allowance, payable monthly. In addition, a 3% increase in payments will be applied annually after the first year. As of December 31, 2023 and 2022, this represents a balance of $38,205 and $36,181, respectively, as part of construction finance liabilities on the balance sheet.

The transaction was classified as a finance lease and control was never transferred to the buyer-lessor; accordingly the transaction did not qualify for sale-leaseback treatment. Therefore, the Company is deemed to own this real estate and will continue to depreciate the assets and reflect the properties on the Company’s balance sheet. The Company recorded a financing obligation for the consideration received from the buyer-lessor, and future cash lease payments will be allocated between interest expense and reduction to the financing obligation, as applicable. As the transactions did not qualify for sale-leaseback treatment, under ASC 842, Leases, no gain or loss was recognized.

31

Table of Contents

Ayr Wellness Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

10.    RIGHT-OF-USE ASSETS AND LEASE LIABILITIES (Continued)

Payments related to leases during the years ended December 31, 2023 and 2022, are as follows:

Year Ended

    

December 31, 2023

    

December 31, 2022

Lease liabilities - operating

Lease liabilities - operating expense, COGS

$

8,783

$

6,604

Lease liabilities - operating expense, G&A

 

16,366

 

13,943

Lease liabilities - finance

 

 

Amortization of right-of-use assets, COGS

 

6,913

 

4,584

Amortization of right-of-use assets, G&A

 

165

 

187

Interest on lease liabilities - finance, COGS

 

3,017

 

2,422

Interest on lease liabilities - finance, G&A

 

37

 

58

Total lease expense

$

35,281

$

27,798

As of December 31, 2023, the Company concluded that the carrying amount of certain long-lived assets exceeded the fair value and recorded an impairment loss on ROU operating assets of $1,462.

11.    RELATED PARTY TRANSACTIONS AND BALANCES

Related parties are defined as management and members of the Company and/or members of their immediate family and/or other companies and/or entities in which a board member or senior officer is a principal owner or senior executive. Other than disclosed elsewhere in the financial statements, related party transactions and balances are as follows:

Mercer Park, L.P., a company owned by an executive of Ayr, entered into a management agreement with the Company dated May 24, 2019. The management fee is paid monthly and varies based on actual costs incurred by the related entity when providing the Company administrative support, management services, office space, and utilities. In addition, the management fees paid to the related party also reimbursed them for other corporate or centralized expenses based on actual cost, including but not limited to legal and professional fees, software, and insurance. The agreement is a month-to-month arrangement.

As of December 31, 2023 and 2022, $nil and $698 was included in prepaid expenses, a majority of which is for a letter of credit for an operating lease. Lease fees included in the operating lease during the years ended December 31, 2023 and 2022, were $858 and $861. During the years ended December 31, 2023 and 2022, included in general and administrative expenses are management fees of $nil and $12.

During the years ended December 31, 2023 and 2022, the Company incurred fees from a company partially owned by a board member of AYR. The total incurred fees were $54 and $54 of office expenses, $24 and $392 of development fees, $1,083 and $920 of rental fees, and $83 and $165 of interest expense, respectively, for the years ended December 31, 2023 and 2022. Additionally in 2022, the board member was issued 50 Equity Shares, valued at $707 on the grant date, related to a consulting agreement with the Company for services rendered.

Refer below to the debts payable and senior secured notes and share capital notes for additional information regarding the debts payable to related parties and non-cash stock-based compensation plan, respectively, for the years ended December 31, 2023 and 2022.

32

Table of Contents

Ayr Wellness Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

12.    DEBTS PAYABLE AND SENIOR SECURED NOTES

Senior Secured Notes

On November 12, 2021, the Company completed a private placement offering of approximately $133,250 aggregate principal amount of secured promissory notes at a premium price, resulting in approximately $147,000 of proceeds due December 2024, with a resulting yield-to-maturity of 9.8%. The notes were considered additional notes under the indenture governing the Company’s existing notes which were entered into on December 10, 2020.

As of December 31, 2023 and 2022, the Company’s Senior Secured Notes consisted of the following:

Senior secured notes

As of January 1, 2022

$

245,408

Debt issuance costs amortized

2,292

Senior secured notes premium amortized

(3,018)

As of December 31, 2022

$

244,682

Debt issuance costs amortized

2,291

Senior secured notes premium amortized

(3,018)

Total senior secured notes classified as non-current payable as of December 31, 2023

$

243,955

Total accrued interest payable related to senior secured notes classified as non-current payable as of December 31, 2023

$

Debts Payable

As of December 31, 2023 and 2022, debt payable other than Senior Secured Notes consisted of the following:

    

Debts payable

As of January 1, 2022

$

133,858

Discounted as of December 31, 2021

951

Incurred through earn-out provision

14,934

Debt Issued

68,000

Construction financing

36,303

Less: repayment

(17,924)

Less: discounted to fair value

 

(598)

As of December 31, 2022

 

235,524

Discounted as of December 31, 2022

 

598

Debt issuance costs

(1,000)

Debt issuance costs amortized

50

Debt issued

 

66,245

Construction financing

2,024

Less: extinguishment related to sale of Arizona business

(22,505)

Less: repayment

(52,029)

Total debts payable, undiscounted as of December 31, 2023

228,907

Less: discounted to fair value

(199)

Total debts payable as of December 31, 2023

$

228,708

Total accrued interest payable related to debts payable as of December 31, 2023

$

7,513

33

Table of Contents

Ayr Wellness Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

12.    DEBTS PAYABLE AND SENIOR SECURED NOTES (Continued)

Debts Payable (Continued)

The details of debts payable, including construction financing liabilities, were as follows:

December 31, 2023

    

Related party debt

    

Non-related party debt

    

Total debt

Total debts payable, undiscounted

    

$

733

    

$

229,123

    

$

229,856

Less: current portion

733

22,419

23,152

Less: debt issuance costs - current portion

 

99

 

99

Total non-current debt, undiscounted

206,605

206,605

Less: discount to fair value

 

 

199

 

199

Less: debt issuance costs - non-current portion

850

850

Total non-current debt

$

$

205,556

$

205,556

The following table presents the future debt obligations other than Senior Secured Notes as of December 31, 2023:

Future debt obligations (per year)

    

  

2024

    

$

23,175

2025

 

23,673

2026

 

64,256

2027

 

14,527

2028

 

2,939

2029 and beyond

101,286

Total debt obligations

$

229,856

As part of the business combinations and asset acquisitions, the Company issued and assumed notes with related and non-related parties. The related party notes are considered part of the purchase price to the former shareholders of the acquired businesses. As a result of the combinations and acquisitions, several of these individual shareholders are now considered related parties of the Company across various roles including directors and officers.

On March 1, 2022, pursuant to the PA Natural Agreement, the Company issued non-related party promissory notes in the amount of $14,934 for earnout consideration. The notes are secured by all the assets and a pledge of the Company’s membership interests in PA Natural. The notes mature three years from the date of the agreement with an 8.0% annual interest rate payable quarterly.

On March 17, 2022, the Company entered into a loan agreement with a community bank for total proceeds of $26,200, net of financing costs of $287, with a 4.625% annual interest rate payable monthly. The loan is secured with a first mortgage lien on certain real property in Massachusetts and matures five years from the date of the agreement, with an option to extend for an additional five years. On March 24, 2023, the Company amended the loan agreement and received additional total proceeds of $10,000, net of financing costs of $100, with an 8% annual interest rate payable monthly for the incremental proceeds.

On May 16, 2022, the Company entered into a loan agreement with a community bank for total proceeds of $25,800, with an annual interest rate of Prime Rate plus 1.5%, floating, with a 5.0% floor. The loan was secured with a first mortgage lien on certain real property and matures two years from the date of the agreement. On July 7, 2023, the Company entered into a loan agreement to refinance and upsize the existing mortgage which was due to mature in May 2024. The loan agreement included total proceeds of $40,000, with an interest rate of 5-year Federal Home Loan Bank Rate plus 4%, which implies a current rate of 8.27% with interest-only payments for the first 18 months. The note extends the maturity of the existing mortgage to 10 years. Proceeds from the loan were used to pay down the Company’s existing mortgage of $25,219.

Pursuant to the agreement to acquire Herbal Remedies, the Company issued a non-related party promissory note in the amount of $14,220 to the former members of Herbal Remedies that is secured by all the assets of Herbal Remedies. The note matures five years from May 25, 2022 with an annual interest rate of 8% with quarterly straight-line amortization and interest payments over the life of the loan.

34

Table of Contents

Ayr Wellness Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

12.    DEBTS PAYABLE AND SENIOR SECURED NOTES (Continued)

Debts Payable (Continued)

Pursuant to the agreement to acquire Tahoe Hydro, the Company issued a non-related party promissory note in the amount of $1,580 to the former member of Tahoe Hydro that is secured by all the assets of and a pledge of membership interests in Tahoe Hydro. The note matures four years from the closing date of April 7, 2023, with an annual interest rate of 8% with quarterly straight-line amortization and interest payments over the life of the loan.

On May 11, 2023, the Company reached an agreement to amend the terms of contingent consideration under the membership interest purchase agreements of GSD NJ LLC (“GSD”) and Sira Naturals, Inc. (“Sira”). The amendment for GSD settles the contingent consideration with total proceeds of $38,860 , consisting of $10,000 in cash, promissory notes in an aggregate principal amount of $14,000, $10,925 in deferred cash, and $4,647 of Equity Shares. The $10,094, net of payments made of $831, in deferred cash is classified within accrued expenses on the balance sheet as of December 31, 2023. The deferred cash balance was paid in full subsequent to December 31, 2023. The $14,000 promissory notes are due December 2026 with monthly interest-only payments of 13.5% until May 2024 (with 1% monthly amortization thereafter). The number of Equity Shares was calculated based on a market price equal to $0.79 which represents 3,797 Equity Shares. The amendment for Sira represents a two-year deferral of the $27,500 of proceeds payable from the original May 2024 payment date, with an annual interest rate of 6.0% and 10% annual amortization payments. Refer to Note 14 for further details on the fair value loss recognized on the settlement of the contingent consideration.

In May 2023, the Company executed contingent agreements, securing a two-year deferral on principal or amortization payments of certain of its debt obligations, which includes aggregate principal amount of approximately $69,000 of debt obligations, including contingent agreements with holders of approximately $60,500 aggregate principal amount of vendor take-back promissory notes. The effectiveness of the maturity and amortization deferrals was contingent on an extension of the Company’s Senior Secured Notes to December 10, 2026, or a later date (or an exchange of the Senior Secured Notes for a new series of notes with a maturity date of December 10, 2026 or a later date). The effectiveness of the maturity and amortization deferrals is contingent on the closing of the Senior Secured Note extension transaction, or in some cases the execution of an agreement by a requisite threshold of Senior Noteholders to extend the maturity date of the Senior Secured Notes by at least two years. As of December 31, 2023, the Company and its subsidiaries had approximately $116,063 of indebtedness in respect of the vendor take-back promissory notes, of which approximately $77,110 were subject to subordination agreements in favor of the Senior Secured Notes. On October 31, 2023, the Company entered into a Support Agreement with the Majority Noteholders of the Senior Secured Notes to extend the maturity date by two years. The Company finalized the amendments for the debt, generally contingent on the closing of the transaction contemplated in the Support Agreement. The modification for these loans did not meet the requirement of a debt extinguishment under ASC 470-50 – Debt Modifications and Exchanges and no gain or loss was recognized as of December 31, 2023.

On October 31, 2023, the Company entered into an agreement with LivFree Wellness, LLC (“LivFree”) to amend certain terms of the promissory note dated May 24, 2019 (the “LivFree Note”) executed in connection with the Company’s acquisition of LivFree. The amendments to the LivFree Note provided, among other things, for a principal payment of $3,000, was paid upon closing of the debt restructuring transactions subsequent to December 31, 2023, and a deferral of the maturity of the remaining $17,000 of principal and $5,530 of accrued payment-in-kind interest for a period of two years to May 24, 2026. In addition, upon closing of the debt restructuring transactions, the interest on the LivFree Note converted from payment-in-kind to monthly cash interest payments and the interest rate increases from 6.0% to 10.0%.

35

Table of Contents

Ayr Wellness Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

12.    DEBTS PAYABLE AND SENIOR SECURED NOTES (Continued)

Debts Payable (Continued)

In accordance with ASC 340-10-S99-1, SAB Topic 5.A, “Expenses of Offering”, the Company capitalized debt transaction fees paid to third parties for the extension of the Senior Secured Notes of $9,951 as prepaid expenses in the balance sheet as of December 31, 2023. The final accounting for the transaction is not yet complete due to the inherent complexity and short period of time between the closing date and the filing period. Therefore, the accounting is preliminary and subject to adjustment on completion of the process and analysis of the transaction at the time that it closes, and further changes may still be required, see Note 19 for additional information.

In connection with the sale of Arizona, on March 27, 2023, the outstanding principal balance of $22,505 and accrued interest of $1,165, payable to the original owners of the Arizona business was eliminated. Refer to Note 4 for further details on the sale of Arizona.

Interest expense associated with related party debt payable for the years ended December 31, 2023 and 2022 was $83 and $1,507, respectively.

13.    SHARE CAPITAL

The following activity occurred during the year ended December 31, 2023:

In relation to the vesting of 3,262 RSUs, 3,169 Equity Shares were issued due to net settlement.
o137 shares were forfeited during the period.
3,798 Exchangeable Shares were issued in connection with the GSD contingent consideration settlement.
233 Exchangeable Shares were issued in connection with the Q2 2023 acquisition of Tahoe Hydro.
52 Exchangeable Share was exchanged for 52 Equity Shares related to the Q1 2022 acquisition of Levia.
354 Exchangeable Shares were exchanged for 354 Equity Shares related to the Q2 2022 acquisition of Herbal Remedies.
9 Exchangeable Shares were converted into 9 Equity Shares.
66 Equity Shares were issued for consulting services.
15 Exchangeable Shares were exchanged for 15 Equity Shares related to the Oasis acquisition.

The following activity occurred during the year ended December 31, 2022:

5 Equity Shares repurchased in 2021 were cancelled, and 82 Equity Shares were repurchased and held in the current year.
In relation to the vesting of 2,135 RSUs, 1,459 Equity Shares were issued due to net settlement.
o78 shares were forfeited during the year.
33 Equity Shares were issued in connection with options exercised.
1,029 Equity Shares were issued in connection with the earn-out provision related to the acquisition of PA Naturals.
908 Exchangeable Shares were exchanged for 908 Equity Shares related to the purchase considerations to the CannTech PA, LLC acquisition in 2020
329 Exchangeable Shares were issued in connection with the Cultivauna Acquisition.
353 Exchangeable Shares were issued in connection with the Herbal Remedies Acquisition
76 Equity Shares were issued to a related party for services rendered.
1,027 Exchangeable Shares were exchanged for 1,027 Equity Shares related to the Oasis acquisition.
71 Exchangeable Shares were converted to Equity Shares.

36

Table of Contents

Ayr Wellness Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

13.    SHARE CAPITAL (Continued)

Warrants

The average remaining life of Warrants is 0.4 years as of December 31, 2023 (2022: 1.4 years) with an aggregate intrinsic value of $nil in 2023 (2022: $nil). The Warrants have an exercise price of $9.07US. The number of Warrants outstanding as of December 31, 2023 and 2022, were as follows:

    

    

Weighted Average

    

Number

    

Fair Value

Balance as of January 1, 2022

 

2,874

$

1,786

No activity

Balance as of December 31, 2022

 

2,874

1,786

No activity

 

 

Balance as of December 31, 2023

 

2,874

$

1,786

14.    DERIVATIVE LIABILITIES

Purchase Consideration and Contingent Consideration

In May 2023, the Company reached an agreement to amend and settle the terms of contingent consideration under the membership interest purchase agreements of GSD and Sira. The Company recognized a fair value loss during the period of $918 on the settlement of the contingent consideration obligation for GSD and $3,660 on the settlement of the contingent consideration obligation for Sira. Refer to Note 12 for further details on the amended terms of the contingent consideration.

The fair value adjustment relating to derivative liabilities has been included in the statements of operations under “Fair value gain on financial liabilities” as detailed below:

    

Year Ended

    

December 31, 

    

December 31, 

    

2023

    

2022

Gain from FV adjustment on contingent consideration

$

27,597

$

61,675

Loss from FV adjustment on purchase consideration settlement

 

 

(1,780)

(Loss) gain from settlement of contingent consideration

(4,578)

3,186

Other

4

7

Total

$

23,023

$

63,088

15.    STOCK-BASED COMPENSATION

The Company has adopted an equity incentive plan, as amended on May 2, 2021 (“the Plan”), which allows the Company to compensate qualifying Plan participants through stock-based arrangements and provide them with opportunities for stock ownership in the Company, thereby seeking to align the interests of such persons with the Company’s shareholders. Under the Plan, the Company may grant stock options, RSUs, performance compensation awards, and unrestricted stock bonuses or purchases. The maximum number of Equity Shares that may be issued under the Plan and any other security-based compensation agreements shall not exceed 12% of the total number of fully diluted shares issued and outstanding from time to time.

In addition, the Company established a restricted stock plan (the “AcquisitionCo Plan”) to facilitate the granting of restricted Exchangeable Shares. Any shares issued under the AcquisitionCo Plan will reduce the number of Equity Shares that may be awarded under the AcquisitionCo Plan on a one-for-one basis.

37

Table of Contents

Ayr Wellness Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

15.    STOCK-BASED COMPENSATION (Continued)

The stock-based compensation expense is based on either the Company’s share price for service-based and market-based conditions on the date of the grant or the fair value of the performance-based RSU. The RSUs vest over a one to four-year period, based on service, market, and/or performance conditions. During the year ended December 31, 2023 there were 650 of both market and performance based RSUs outstanding, totaling 1,300. During the years ended December 31, 2023 and 2022, the Company recognized stock-based compensation relating to RSUs granted in the current and prior periods, except for the market and performance based RSUs as they did not meet the probable threshold. Any cumulative adjustment prior to vesting is recognized in the current period with no adjustment to prior periods for expense previously recognized. During the years ended December 31, 2023 and 2022, there were 137 and 78 forfeitures of nonvested RSUs, respectively.

During the years ended December 31, 2023 and 2022, 3,262 Equity Shares vested, of which 3,169 were issued due to net settlement, and 2,135 of which 1,459 were issued due to net settlement, respectively. During the years ended December 31, 2023 and 2022, the result of the net settlement was 93 Equity Shares were withheld with a total value of $366, and 676 Equity Shares were withheld with a total value of $5,258 to pay income taxes on behalf of the grantees, respectively. As of December 31, 2023 the average remaining life of unvested RSUs is one year and eleven months with an expected expense over the next 12 months of $9,967 with an aggregate intrinsic value of $16,714 using the stock price as of December 31, 2023 and as of December 31, 2022, the average remaining life of unvested RSUs is one year and three months with an expected expense over the next 12 months of $21,538 with an aggregate intrinsic value of $16,135 using the stock price as of December 31, 2022. The number of RSUs outstanding as of December 31, 2023 and 2022, were as follows:

Weighted  

Number of

Average Grant  

    

Shares

    

Date Fair Value

RSUs outstanding and nonvested, as of January 1, 2022

    

8,100

    

$

18.83

Granted

 

741

6.45

Vested

 

(2,135)

18.58

Forfeited

(78)

15.90

RSUs outstanding and nonvested, as of December 31, 2022

6,628

$

17.56

Granted

1,760

1.20

Vested

(3,262)

18.15

Forfeited

(137)

9.09

RSUs outstanding and nonvested, as of December 31, 20231

4,989

$

11.64

1 Includes Ayr granted but unvested performance based RSUs (PSUs) totaling 1,300 that do not meet the probability threshold

38

Table of Contents

Ayr Wellness Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

15.    STOCK-BASED COMPENSATION (Continued)

Options

As part of the Liberty acquisition, the Company issued replacement options to certain employees of Liberty who became employees of the Company which were fully vested as of the date of acquisition. The range of exercise price is between $10.59 and $29.60. As of December 31, 2023 and 2022,the weighted average remaining life of the options is under six months and under eight months, respectively, with an aggregate intrinsic value of $nil and $nil, respectively. The number of options outstanding as of December 31, 2023 and 2022 were as follows:

    

Number of

Weighted Average

    

Options

    

Fair Value

Balance as of January 1, 2022

198

$

17.93

Options exercised

(33)

17.93

Balance as of December 31, 2022

165

$

17.93

Options expired/cancelled

(6)

17.93

Balance as of December 31, 2023

159

20.30

16.    COMMITMENTS AND CONTINGENCIES

Commitments

As of December 31, 2023 the Company guaranteed the lease obligation of a location related to a third-party that operates a dispensary in New Jersey. The Company is the guarantor of the lease with maximum total payments of $764 and will continue as the guarantor through December 2028. The Company would be required to perform under the guarantee if the third-party is in default. As of December 31, 2023 the Company does not anticipate any defaults under the foregoing lease, and therefore, no liability has been accrued.

As of December 31, 2023 the Company remains jointly liable under a lease related to its former Arizona business. As part of the sale of the Arizona business, the buyer agreed to cause its wholly owned subsidiary (and party to the lease) to perform all lease obligations arising on or after the closing date. The buyer also agreed to indemnify the Company for these same obligations. The lease requires maximum total payments of $10,619 through May 2035. As of December 31, 2023 the Company does not anticipate any defaults under the lease, and therefore, no liability has been accrued.

39

Table of Contents

Ayr Wellness Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

16.    COMMITMENTS AND CONTINGENCIES (Continued)

Contingencies

On March 27, 2020, the U.S. Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was signed into law, aimed at providing emergency assistance and health care for individuals, families, and businesses affected by the COVID-19 pandemic and generally supporting the U.S. economy. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, and modifications to the net interest deduction limitations. Employee Retention Credit (“ERC”) is a refundable credit against certain employment taxes equal to 50% of the qualified wages an eligible employer paid to employees from March 17, 2020 to December 31, 2020. The U.S. Disaster Tax Relief Act, enacted on December 27, 2020, extended the employee retention credit for qualified wages paid from January 1, 2021 to June 30, 2021, and the credit was increased to 70% of qualified wages an eligible employer paid to employees during the extended period. The American Rescue Plan Act of 2021, enacted on March 11, 2021, further extended the employee retention credit through December 31, 2021. The general statute of limitations for employment tax audits is three years, but the Internal Revenue Service’s (“IRS”) ERC guidance has an extended five-year statute. The Company experienced full or partial suspension of portions of the business during the period covered by the ERC due to government orders limiting commerce, travel, or group meeting due to COVID-19. In 2023, the Company filed for an ERC for the period beginning January 1 to June 30, 2021 in the amount of $12,354. During the year ended December 31, 2023, the Company received notices from the Internal Revenue Service for a total ERC refund of $5,238 and recorded a receivable included as part of prepaid expenses, deposits, and other current assets in the balance sheet and other income on the statement of operations. In accordance with ASC 958-605, Not-for-Profit Entities—Revenue Recognition, the Company determined that the condition to record a receivable is met when the IRS confirms the claim is valid or the cash is received. Absent of any confirmation, there remains uncertainty as to whether the amounts will be received. Due to the degree of uncertainty regarding the implementation of the CARES Act and other stimulus legislation and the nature of our business, although the Company expects to receive the remaining ERC, the Company determined that the remaining claim did not yet meet the criteria to record as a receivable as of December 31, 2023.

The Company’s operations are subject to a variety of local and state governmental regulations. Failure to comply with one or more of those regulations could result in fines, restrictions on its operations, or losses of permits and/or licenses that could result in the Company ceasing operations. While management of the Company believes that the Company is in compliance, in all material respects, with applicable local and state governmental regulations as of December 31, 2023, cannabis regulations continue to evolve and are subject to differing interpretations. As a result, the Company may be subject to regulatory fines, penalties, or restrictions in the future.

Claims and Litigation

From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of December 31, 2023 there were no material pending or threatened lawsuits that could be reasonably expected to have a material effect on the results of the Company’s operations. There are also no proceedings in which any of the Company’s directors,

officers or affiliates are an adverse party or have a material interest adverse to the Company’s interest.

17.    FINANCIAL RISK FACTORS

(a) Fair value

Fair value is the price that would be received to sell/acquire an asset or paid to transfer/assume a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either in the principal market for the asset or liability or, in the absence of a principal market, in the most advantageous market for the asset or liability. The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest. A fair value measurement of a nonfinancial asset takes into account a market participant’s ability to generate economic benefits from the asset’s highest and best use or by selling it to another market participant that would utilize the asset in its highest and best use.

40

Table of Contents

Ayr Wellness Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

17.    FINANCIAL RISK FACTORS (Continued)

(a) Fair value (Continued)

The Company uses valuation techniques that are considered to be appropriate in the circumstances and for which there is sufficient data with unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy. This is described, as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

Level 1 inputs are quoted prices in active markets for identical assets or liabilities at the measurement date.
Level 2 inputs are observable inputs other than quoted prices included within Level 1, such as quoted prices for similar assets or liabilities in active markets, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable directly or indirectly.
Level 3 inputs are unobservable inputs for the asset or liability that reflect the reporting entity’s own assumptions and are not based on observable market data.

There were no transfers between levels in the hierarchy during the years ended December 31, 2023 and 2022. For financial assets and liabilities not measured at fair value, their carrying value is considered to approximate fair value due to their market terms.

The carrying values of cash, deposits, accounts receivable, trade payables, accrued liabilities, accrued interest payable, and purchase consideration payable approximate their fair values because of the short-term nature of these financial instruments. Long-term debt is recorded at amortized cost.

The following table summarizes the fair value hierarchy for the Company’s financial assets and liabilities that are re-measured at their fair values periodically:

    

December 31, 2023

December 31, 2022

Financial liabilities

  

  

Contingent consideration

Level 3

 

$

90,090

The following table summarizes the range of inputs used at the initial and subsequent measurement dates to value the contingent consideration for the year ended December 31, 2022 in the table above:

Equity Volatility

    

55.65 - 85.05

%  

Revenue Volatility

 

7.46 - 23.96

%  

Risk-free Rate

 

1.62 - 4.67

%  

Revenue Risk Premium

 

5.58 - 9.61

%  

Credit Risk Rate

 

10.50 - 19.10

%  

Discount Rate

 

8.40 - 10.00

%  

(b) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is exposed to interest rate risk on its cash and long-term debts. Cash and deposits bear interest at market rates. The Company’s debts are predominantly at fixed rates of interest. The Company does not use any derivative instruments to hedge against interest rate risk and believes that the change in interest rates will not have a significant impact on its financial results.

41

Table of Contents

Ayr Wellness Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

18.    TAXATION

Income tax is accounted for in accordance with ASC 740, Income Taxes including ASU 2019-12. As the Company operates in the legal cannabis industry, the Company is also subject to the limits of Section 280E for U.S. federal income tax purposes as well as state income tax purposes for all states except for Illinois, Massachusetts, and New Jersey. Under Section 280E, the Company is generally only allowed to deduct expenses directly related to cost of goods sold. This results in permanent differences between ordinary and necessary business expenses deemed non-allowable under IRC Section 280E. Therefore, the effective tax rate can be highly variable and may not necessarily correlate with pre-tax income or loss.

The Company is treated as a U.S. corporation for the U.S. federal income tax purposes under Section 7874 of the Internal Revenue Code, as amended (“Section 7874”) and is subject to U.S. federal income tax on its worldwide income. However, for Canadian tax purposes, the Company, regardless of any application of Section 7874, is treated as a Canadian resident company (as defined in the Income Tax Act (Canada) (the “ITA”) for Canadian income tax purposes. As a result, the Company is subject to taxation both in Canada and the United States. The Company is also subject to state income taxation in Massachusetts, Pennsylvania, Florida, Illinois, Nevada, New Jersey, and Ohio.

For the years ended December 31, 2023 and 2022, income tax expense consisted of:

Year Ended

    

2023

    

2022

Current expense :

Federal

$

47,727

$

34,121

State

7,112

9,040

Total current expense :

54,839

43,161

Deferred (benefit) expense :

Federal

(6,912)

(3,173)

State

(536)

4,761

Foreign

(1,235)

(232)

Change in valuation allowance

 

1,235

 

232

Total deferred (benefit) expense :

(7,448)

1,588

Total income tax expense :

$

47,391

$

44,749

Interest and penalties included in current tax expense were $9,762 and $nil, respectively, for the years ended December 31, 2023 and 2022.

42

Table of Contents

Ayr Wellness Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

18.    TAXATION (Continued)

The difference between the income tax expense for the years ended December 31, 2023 and 2022 and the expected income taxes based on the statutory tax rate applied to income (loss) before income tax as follows:

Year Ended 

    

2023

    

2022

Expected income tax recovery

    

$

(9,609)

    

$

(36,147)

Difference in foreign tax rates

(6,030)

(4,311)

State taxes

 

6,576

 

13,802

Foreign exchange gain or loss

370

146

Impairment loss

1,327

24,769

Translation adjustment

 

(226)

 

669

Unrealized change in fair value of financial liabilities

(4,835)

(13,248)

Acquisition costs

 

872

 

147

Interest income inclusion

6,465

4,244

Non-deductible expenses

46,262

58,423

Amortization of debt premium

(815)

(815)

Restricted stock

731

Accrued tax penalties and interest

9,762

Change in effective tax rate

(1,627)

Prior year adjustment

(2,201)

(2,877)

Valuation allowance

1,235

232

Other

(867)

(285)

$

47,391

$

44,749

As of December 31, 2023 and 2022, the components of deferred tax assets and liabilities were as follows:

    

Year Ended

    

2023

    

2022

Deferred tax assets

Net operating losses

    

$

11,663

$

9,515

Share issuance costs

 

616

 

1,311

Share-based compensation

 

210

1,385

Inventory

 

2,032

1,298

Lease liabilities

1,170

Other assets

 

1,153

763

Total deferred tax assets

 

16,844

14,272

Deferred tax liabilities

 

Depreciation

(7,846)

(7,173)

Amortization

(63,320)

(69,440)

Debt financing costs

(584)

(1,202)

Other liabilities

(40)

(86)

Total deferred tax liabilities

(71,790)

(77,901)

Valuation allowance

(10,019)

(8,784)

Net deferred tax liability

$

(64,965)

$

(72,413)

Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. The Company assesses the positive and negative evidence to determine if sufficient future taxable income is expected to be generated to use the existing deferred tax assets. On the basis of our assessment, the valuation allowance increased $1,235 and $232, for the years ended December 31, 2023 and 2022, respectively.

43

Table of Contents

Ayr Wellness Inc.

Notes to the Consolidated Financial Statements

For the Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

18.    TAXATION (Continued)

As of December 31, 2023 and 2022,the Company had $32,865 and $30,538, respectively of gross Canadian net operating loss carry forwards which will begin to expire in 2037. As of December 31, 2023 and 2022, the Company has $15,688 and $15,867 respectively of various state net operating loss carry forwards which will begin to expire in 2042.

The Company operates in a number of United States state tax jurisdictions and is subject to examination of its income tax returns by tax authorities in those jurisdictions who may challenge any item on these returns. Because the tax matters challenged by tax authorities are typically complex, the ultimate outcome of these challenges is uncertain. In accordance with ASC 740 – Income Taxes, the Company recognizes the benefits of uncertain tax positions in our financial statements only after determining that it is more likely than not that the uncertain tax positions will be sustained.

The Company recognizes accrued interest and penalties related to unrecognized tax benefits in the provision for income taxes. There are no positions for which it is reasonably possible that the uncertain tax benefit will significantly increase or decrease within twelve months. The Company files income tax returns in the United States, various state jurisdictions, and Canada, which remain open to examination by the respective jurisdictions for the 2020 tax year to the present.

19.    SUBSEQUENT EVENTS

The Company’s management has evaluated subsequent events through the date the consolidated financial statements were issued.

Subsequent to December 31, 2023, following the receipt of court and other required regulatory approvals, the Company completed the debt restructuring transactions contemplated in its Support Agreement with the Majority Noteholders, pursuant to which: (i) all of the Senior Secured Notes were exchanged for an equivalent principal amount of new 13% senior secured notes due December 10, 2026 (the “13% Senior Notes” and such exchange, the “Exchange Transaction”); (ii) an additional $40,000 in gross cash proceeds was raised through the issuance of additional 13% Senior Notes in an aggregate principal amount of $50,000 (the “New Money Notes”) (subject to a 20% original issue discount) concurrent with the completion of the Exchange Transaction; (iii) as the offering of the New Money Notes was backstopped by one of the Majority Noteholders, such backstop party received a backstop premium on closing payable in the form of 5,948 Equity Shares (the “Backstop Shares”) in the Company, and (iv) holders of the 12.5% Senior Secured Notes received 29,040 Equity Shares (the “New Shares”) in the Company.

In addition, 23,046 warrants (the “Anti-Dilutive Warrants”) were issued to all then-existing shareholders (excluding recipients of the New Shares and the Backstop Shares), which are exercisable for an equal number of Equity Shares for $2.12 per share until February 7, 2026. The Anti-Dilutive Warrants are only exercisable by non-U.S. Persons and Accredited Investors in the U.S., as such terms are defined under U.S. securities laws. The Anti-Dilutive Warrants started to trade on the CSE on February 14, 2024 under the ticker symbol AYR.WT.U.

In accordance with ASC Subtopic 470-10, since the Exchange Transaction and related transactions have been closed, the Company determined that it met the criteria to classify the existing Senior Secured Notes and certain debts payable as a non-current liability on the balance sheet and in Note 12 as of December 31, 2023 by demonstrating the intent and ability to refinance the short-term obligation prior to the financial statement issuance date.

44

EX-99.3 4 ayr-20231231xex99d3.htm EXHIBIT 99.3

Exhibit 99.3

Graphic

Ayr Wellness Inc.

MANAGEMENT’S DISCUSSION & ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF

OPERATIONS

FOR THE YEARS ENDED DECEMBER 31, 2023 AND 2022

(EXPRESSED IN UNITED STATES DOLLARS)


Ayr Wellness Inc.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

Introduction

The following management’s discussion and analysis (“MD&A”) of the financial condition and results of operations of Ayr Wellness Inc. (“Ayr”, “the Company”, “we”, “our” or “us”) constitutes management’s review of the factors that affected the Company’s financial and operating performance for the years ended December 31, 2023, and 2022. This discussion should be read in conjunction with the Company’s consolidated financial statements for the years ended December 31, 2023 and 2022 (the “financial statements”). Results are reported in United States dollars, unless otherwise noted. The financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the financial information contained herein is derived from the financial statements. Further information about the Company and its operations, including its Annual Information Form dated March 13, 2024 (the “Annual Information Form”) can be obtained on ir.ayrwellness.com, www.sec.gov/edgar, and www.sedarplus.ca. The information contained on such websites are not a part of, nor is it incorporated by reference into, this Annual Report (or equivalent thereof).

The effective date of this MD&A is March 13, 2024.

Overview of the Company

Ayr Wellness Inc. is a United States (“U.S.”) multi-state cannabis business operating as a retailer and consumer packaged goods company. Founded in 2019 and headquartered in Miami, Florida, the Company is focused on delivering quality cannabis products and strong customer experience throughout its footprint. As of December 31, 2023, the Company employed approximately 2,300 personnel. The Company, through its subsidiaries and affiliates, holds, operates, and manages licenses and permits in the States of Florida, Massachusetts, Nevada, New Jersey, Ohio, Pennsylvania, Illinois, and Connecticut.

The Company owns and operates a chain of cannabis retail stores under brand names including AYR Cannabis Dispensary, and The Dispensary. Ayr owns stores under other names, primarily where stores acquired still retain their pre-acquisition branding, though the Company intends to unify its retail footprint under the AYR retail brand name over time. The revenue of Ayr’s retail stores derives primarily from the sale of cannabis products, with an immaterial portion of income resulting from the sale of other merchandise (such as cannabis accessories). As of December 31, 2023, Ayr operated 91 retail stores, located across Ayr’s portfolio.

The Company’s strategy is to vertically integrate through the consolidation of cultivating, producing, distributing, and dispensing cannabis brands and products at scale. The Company’s current portfolio of consumer-packaged goods brands includes Kynd, Haze, Levia, Road Tripper, Origyn Extracts, STiX Preroll Co., Secret Orchard, Wicked, CannaPunch and Entourage, among others. The Company distributes and markets its products to Ayr-owned retail stores and to third-party licensed retail cannabis stores throughout Ayr’s operating footprint.

The Company does not currently accept payments for products or services online.

On March 27, 2023, the Company closed the sale of Blue Camo, LLC (“Blue Camo”), which comprised the Company’s Arizona assets and included two licensed entities operating three Oasis-branded dispensaries in the greater Phoenix area, a cultivation and processing facility in Chandler, a cultivation facility in Phoenix, and the Company’s majority interest in Willcox OC, LLC, a joint venture developing an outdoor cultivation facility. Total consideration consisted of $20,000 in cash before working capital adjustments and the assumption of lease obligations eliminating approximately $15,000 in long-term lease liabilities. In a separate agreement, all debt outstanding and potential earn-out contingent consideration, related to the 2021 purchase of Blue Camo, was eliminated, reducing the Company’s long-term debt by $22,505 and potential earn-out contingent consideration to $nil. The Company has reflected the reclassification of assets and liabilities of these entities as held for sale on the balance sheet as of December 31, 2022 and the operations as discontinued operations on the statement of operations for all periods presented.

2


Ayr Wellness Inc.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

The loss on disposal of discontinued operations of $182,464 was derived from the gross proceeds of $49,336, made up of $20,000 of cash consideration and a $5,666 working capital adjustment and the elimination of $23,670 of debt outstanding from the sale of Arizona, less the carrying value of Arizona of approximately $231,800. As of December 31, 2023, the Company finalized the settlement of the working capital adjustment, receiving $1,583 in cash proceeds and $4,084 in consideration other than cash.

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this MD&A are forward-looking statements and contain forward-looking information within the meaning of applicable securities laws, including, but not limited to, those statements relating to the Company and its financial capacity and availability of capital and other statements that are not historical facts. These statements are based upon certain material factors, assumptions, and analyses that were applied in drawing a conclusion or making a forecast or projection, including experience of the Company, as applicable, and perception of historical trends, current conditions, and expected future developments, as well as other factors that are believed to be reasonable in the circumstances. Forward-looking statements are provided for the purpose of presenting information about management’s current expectations and plans relating to the future, and readers are cautioned that such statements may not be appropriate for other purposes. These statements may include, without limitation, statements regarding the operations, business, financial condition, expected financial results, performance, prospects, opportunities, priorities, targets, goals, ongoing objectives, strategies, and outlook of the Company. Forward-looking statements are often identified by the words “pro forma”, “may”, “would”, “could”, “should”, “will”, “assume”, “intends”, “plans”, “anticipate”, “believes”, “estimates”, “projects”, “expects”, “targets”, “continue”, “forecasts”, “seeks”, “likely”, “design”, “goal” or negative versions thereof and other similar expressions.

By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections, or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved. A variety of material factors, many of which are beyond the parties’ control, could affect operations, business, financial condition, performance, and results of the parties that may be expressed or implied by such forward-looking statements and could cause actual results to differ materially from current expectations of estimated or anticipated events or results. These factors include, but are not limited to, the following:

laws and regulations and any amendments thereto applicable to our business and the impact thereof, including uncertainty regarding the application of U.S. state and federal law to U.S. cannabis products and the scope of any regulations by the U.S. Food and Drug Administration, the U.S. Drug Enforcement Administration, the U.S. Federal Trade Commission, the U.S. Patent and Trademark Office, the U.S. Department of Agriculture and any state equivalent regulatory agencies over U.S. cannabis products;
climate change impacting economic factors such as prices and supply chain disruption, as well as governmental response through laws or regulations regarding greenhouse gas emissions;
assumptions and expectations described in the Company’s critical accounting policies and estimates;
changes in U.S. GAAP or their interpretation and the adoption and impact of certain accounting pronouncements;
the number of users of cannabis or the size of the regulated cannabis market in the U.S.;
risks related to litigation;
the potential time frame for the implementation of legislation to legalize and regulate medical or adult-use cannabis (and the consumer products derived from each of the foregoing) in the U.S., and the potential form the legislation and regulations will take;
the Company’s future financial and operating performance and anticipated profitability;
future performance, results and terms of strategic initiatives, strategic agreements, and supply agreements;
the market for the Company’s current and proposed products and services, as well as the Company’s ability to capture market share;
the benefits and applications of the Company’s products and services and expected sales thereof;
development of affiliated brands, product diversification and future corporate development;

3


Ayr Wellness Inc.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

anticipated investment in and results of research and development;
inventory and production capacity, including discussions of plans or potential for expansion of capacity at existing or new facilities;
future expenditures, strategic investments, and capital activities;
the competitive landscape in which the Company operates and the Company’s market expertise;
the Company’s ability to comply with its debt covenants;
the Company’s ability to secure further equity or debt financing, if required;
the Company’s ability to refinance its indebtedness and the terms of any such financing;
the risk of significant dilution from the issuances of equity or convertible debt securities;
the level of demand for cannabis products, including the Company’s product and third-party products sold by the Company;
the Company’s ability to mitigate risks relating to the cannabis industry, the larger economy such as inflation or fluctuations in interest rates, breaches of and unauthorized access to the Company’s systems and related cybersecurity risks, money laundering, litigation, and health pandemics;
the risks related to maintaining cash deposits in excess of federally insured limits;
the ability to gain appropriate regulatory approvals including for announced acquisitions in the timeframe anticipated;
the application for additional licenses and the grant of licenses or renewals of existing licenses that have been applied for;
the rollout of new dispensaries, including the number of planned dispensaries to be opened in the future and the timing and location in respect of the same, and related forecasts;
the Company’s ability to hit anticipated development targets of cultivation and production projects;
the Company's ability to mitigate the risk of contamination and other risks inherent in the agricultural sector;
the ability to successfully integrate and maintain employees from recent acquisitions;
risks related to the Company’s cash flows from operations;
the ability to develop the Company’s brands and meet growth objectives;
risks related to limited market data and difficulty to forecast results;
the current concentrated voting control of the Company;
market volatility and the risks associated with selling of a substantial amount of our subordinate, restricted, and limited voting shares (“Equity Shares”);
the risk of natural hazards related to severe and extreme weather and climate events;
product liability claims related to the products the Company cultivates, produces, and sells;
the risk of significant pricing pressures which are often market specific and can be caused by an oversupply of cannabis in the market and may be transitory from period to period; and
other events or conditions that may occur in the future.

In making these statements, in addition to those described above and elsewhere herein, the parties have made assumptions with respect to expected cash provided by continuing operations, future capital expenditures, including the amount and nature thereof, trends and developments in the industry, business strategy and outlook, expansion and growth of business and operations, accounting policies, credit risks, anticipated acquisitions, opportunities available to or pursued by the parties, and other matters.

Management’s Definition and Reconciliation of Non-GAAP Measures

Management reports certain non-GAAP measures that are used to evaluate the performance of such businesses and the performance of their respective states, as well as to manage their capital structure. As non-GAAP measures generally do not have a standardized meaning, they may not be comparable to similar measures presented by other issuers. Securities regulations require such measures to be clearly defined and reconciled with their most directly comparable GAAP measure.

4


Ayr Wellness Inc.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

The Company references non-GAAP measures, including cannabis industry metrics, in this document and elsewhere. These are provided as additional information to complement those GAAP measures by providing further understanding of the results of the operations of the Company from management’s perspective. Accordingly, these measures should not be considered in isolation, nor as a substitute for analysis of the Company’s financial information reported under GAAP. Non-GAAP measures used to analyze the performance of the Company include “Adjusted EBITDA” and “Adjusted Gross Profit”.

The Company believes that these non-GAAP financial measures may be useful to investors because they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making. These financial measures are intended to highlight trends in the Company’s core businesses that may not otherwise be apparent when solely relying on the GAAP measures.

Adjusted EBITDA

“Adjusted EBITDA” represents (loss) income from continuing operations, as reported under GAAP, before interest and tax, adjusted to exclude non-core costs, other non-cash items, including depreciation and amortization and further adjusted to remove non-cash stock-based compensation, impairment expense, the incremental costs to acquire cannabis inventory in a business combination, acquisition and transaction related costs, and start-up costs.

Adjusted Gross Profit

“Adjusted Gross Profit” represents gross profit, as reported under GAAP, adjusted to exclude the incremental costs to acquire cannabis inventory in a business combination, interest, depreciation and amortization, start-up costs and other non-core costs.

Reconciliations are provided below.

5


Ayr Wellness Inc.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

Forward-Looking Financial Projections or Targets

On November 1, 2023, the Company filed a management presentation on SEDAR+ and EDGAR, and that presentation included forward-looking information for the years 2023 and 2024. The presentation represents the Company’s expectations for future results and are based on the assumptions and risks detailed in this MD&A. The presentation and those projections are not incorporated by reference in this management discussion and analysis.

The Company remains committed to further improving its financial health and positioning itself for sustainable, profitable growth across its footprint. The Company anticipates revenue in Q1 2024 to range from flat to modest growth compared to Q4 2023, with a continuation of achieving the Company’s target of 25% Adjusted EBITDA margin. The expectation for the first quarter of 2024 is based on gradual improvement from the residual impact of cultivation challenges in Florida, while continuing to build wholesale revenues. Ayr expects to further ramp revenue, adjusted EBITDA and operating cash flow later this year.

Review of the Financial Results for the Three Months and Years Ended December 31, 2023 and 2022

Adjusted EBITDA Reconciliation for the Three Months and Years Ended December 31, 2023 and 2022

Three Months Ended (unaudited)

Year Ended

December 31, 2023

December 31, 2022

December 31, 2023

December 31, 2022

    

$

    

$

    

$

    

$

Loss from continuing operations (GAAP)

 

(9,544)

 

(143,093)

 

(37,213)

 

(207,288)

Incremental costs to acquire cannabis inventory in a business combination

 

 

 

 

6,217

Interest (within cost of goods sold “COGS”)

727

1,196

3,017

4,094

Depreciation and amortization (from statement of cash flows)

 

22,137

 

21,074

 

90,949

 

76,150

Acquisition and transaction costs

 

619

 

852

 

4,080

 

5,985

Stock-based compensation, non-cash

 

3,074

 

17,375

 

16,491

 

46,822

Impairment of goodwill and other assets

6,320

117,950

6,320

117,950

Start-up costs1

2,915

3,016

11,786

13,052

Loss (gain) on sale of assets

 

25

 

182

 

91

 

(8)

Other2

3,489

5,616

18,450

12,419

 

39,306

 

167,261

 

151,184

 

282,681

Adjusted EBITDA from continuing operations (non-GAAP)

 

29,762

 

24,168

 

113,971

 

75,393

Notes:

1 Includes costs to prepare a location for its intended use, including facilities not yet operating at scale. Start-up costs are expensed as incurred and are not indicative of ongoing operations.

2 Other non-core costs including non-operating adjustments, severance costs and non-cash inventory write-downs.

6


Ayr Wellness Inc.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

Adjusted Gross Profit Reconciliation for the Three Months and Years Ended December 31, 2023 and 2022

    

Three Months Ended (unaudited)

Year Ended

December 31, 2023

    

December 31, 2022

    

December 31, 2023

    

December 31, 2022

    

$

$

$

$

Gross profit (GAAP)

49,382

53,011

202,442

174,966

Incremental costs to acquire cannabis inventory in a business combination

 

6,217

Interest (within COGS)

727

1,196

3,017

 

4,094

Depreciation and amortization (within COGS)

10,163

9,064

39,585

 

30,349

Start-up costs (within COGS)

1,164

747

5,469

 

4,519

Other (within COGS)

565

2,541

6,337

7,423

Adjusted Gross Profit from continuing operations (non-GAAP)

62,001

66,559

256,850

 

227,568

Revenues, net of Discounts

Revenues, net of discounts for the three months ended December 31, 2023 and 2022 were $114,835 and $114,279, respectively, increasing $556 or 0.5%. Retail revenues decreased by $5,210, or approximately (5.1)%, which was driven by $4,140 from new store openings and acquisitions bringing our total retail store footprint to 91, offset by a temporary cultivation setback in Florida leading to lower inventory levels at the end of the third quarter, which directly impacted sales in the fourth quarter by approximately $5,000. Wholesale revenues increased by $5,766, or approximately 50.4%, primarily driven by wholesale growth in four out of five total markets, including an acceleration of sales driven by overall market growth attributed to new store openings in the New Jersey market.

Revenues, net of discounts for the years ended December 31, 2023 and 2022 were $463,630 and $421,435, respectively, increasing $42,195 or 10.0%. Retail revenues grew by $39,301, or approximately 10.7%, which was driven by $33,640 from new store openings and acquisitions as well as $5,660 or approximately 2.0% growth from same store sales. Wholesale revenues increased by $2,894, or approximately 5.5%, primarily driven by our New Jersey wholesale business coming online in the third quarter of 2022 and our new Ohio cultivation facility coming online during the second quarter of 2023.

Disaggregation of Revenue

Three Months Ended (unaudited)

Year Ended

    

December 31, 2023

    

December 31, 2022

    

December 31, 2023

    

December 31, 2022

$

$

$

$

Retail revenue

    

97,625

102,835

407,634

 

368,333

Wholesale revenue

17,210

11,444

55,996

 

53,102

Total revenue, net of discounts

114,835

114,279

463,630

 

421,435

Gross Profit

Gross profit for the three months ended December 31, 2023 and 2022 was $49,382 and $53,011, respectively, a decrease of $3,629 or 6.8%. Gross profit percentage for the three months ended December 31, 2023 and 2022 was 43.0% and 46.4%, respectively. Adjusted Gross Profit (non-GAAP) percentage for the three months ended December 31, 2023, and 2022 was 54.0% and 58.2%, respectively.

7


Ayr Wellness Inc.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

The decrease in Gross Profit and Adjusted Gross Profit (non-GAPP) was partially driven by an increase in wholesale revenue as a % of total revenue, as wholesale margins are inherently lower relative to retail margins, paired with a decrease in retail revenue over this time. Additionally, we saw an increase in retail and wholesale price compression across almost all our markets.

Gross profit for the years ended December 31, 2023 and 2022 was $202,442 and $174,966, respectively, an increase of $27,476 or 15.7%. Gross profit percentage for the years ended December 31, 2023 and 2022 was 43.7% and 41.5%, respectively. Adjusted Gross Profit (non-GAAP) percentage for the years ended December 31, 2023, and 2022 was 55.4% and 54.0%, respectively.

The increase in Gross Profit and Adjusted Gross Profit (non-GAAP) was directly attributable to the revenue increase as described above and an increase in internal sourcing of retail sales from approximately 59% for the year ended December 31, 2022 to approximately 68% for the year ended December 31, 2023. This increase was offset partially by price compression experienced across all markets.

Total Operating Expenses

Total operating expenses for the three months ended December 31, 2023 and 2022 were $58,926 and $196,104, respectively, decreasing $137,178 or 70.0%. Total operating expenses as a percentage of revenue during the three months ended December 31, 2023 and 2022 were 51.3% and 171.6%, respectively. The decrease in total operating expenses was attributable to a decrease in non-cash impairment expense on goodwill and other assets, lower stock compensation and payroll expenses.

Total operating expenses for the years ended December 31, 2023 and 2022 were $239,655 and $382,254, respectively, decreasing $142,599 or 37.3%. Total operating expenses as a percentage of revenue during the years ended December 31, 2023 and 2022 were 51.7% and 90.7%, respectively, attributable to a decrease in non-cash impairment expense on goodwill and other assets, lower stock compensation and payroll expenses. This decrease was offset by an increase in depreciation and amortization.

Total Other Income (Expense)

Total other income (expense) for the three months ended December 31, 2023 and 2022 was $(10,966) and $22,147, respectively, decreasing $(33,113) or 149.5%. The decrease for the three-month period was primarily driven by the $30,357 change in the fair value relating to settlement of contingent consideration for GSD NJ LLC (“GSD”) and Sira Naturals, Inc. (“Sira”) earnout and a $2,737 increase in interest expense due to the terms of the debt extension.

Total other income (expense) for the years ended December 31, 2023 and 2022 was $(8,543) and $35,160, respectively, decreasing $(43,703) or 124.3%. The decrease for the period was primarily driven by the $40,064 change in the fair value relating to settlement of contingent consideration for GSD and Sira earnout and an $11,081 increase in interest expense due to the terms of the debt extension. This decrease was offset by the $5,238 employee retention credit refund, see further details below.

Income Tax

Income tax expense is recognized based on the expected tax payable on the taxable income for the period and the deferred tax, using tax rates enacted at year-end. The deferred tax benefit is mainly driven by changes in the amortization of intangibles.

As the Company operates in the cannabis industry, it is subject to the limitations of the United States Internal Revenue Code Section 280E under which the Company is generally only allowed to deduct expenses directly related to cost of goods sold. Therefore, Ayr can have income tax even when it records a net loss.

8


Ayr Wellness Inc.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

Total income tax expense for the years ended December 31, 2023, and 2022 was $47,391 and $44,749, respectively. The current tax expense was $54,839 and $43,161, respectively, for the years ended December 31, 2023 and 2022. Interest and penalties included in current tax expense was $9,762 and $nil, respectively, for the years ended December 31, 2023 and 2022. The deferred tax (expense) benefit was $(7,448) and $1,588, respectively, for the years ended December 31, 2023 and 2022.

As of December 31, 2023 and 2022, the Company had $15,688 and $15,867, respectively of various state net operating loss carry forwards which will begin to expire in 2042.

Net loss attributable to Ayr Wellness Inc. from continuing operations

Net loss from continuing operations for the three months ended December 31, 2023 and 2022 was $30,292 and $137,518, respectively. The decrease was primarily driven by the factors described above.

Net loss from continuing operations for the years ended December 31, 2023 and 2022 was $93,147 and $216,877, respectively. The decrease was primarily driven by the factors described above.

Liquidity and Capital Resources as of December 31, 2023 and 2022

Selected Liquidity and Capital Resource Information

    

December 31, 2023

    

December 31, 2022

$

$

Cash

 

50,766

 

76,827

Total current assets

 

193,220

 

453,702

Total assets

 

1,459,855

 

1,767,770

Total current liabilities

 

200,478

 

268,805

Total liabilities

 

889,203

 

932,446

Total shareholders’ equity

 

570,652

 

835,324

As reflected in the consolidated financial statements, the Company had negative working capital of $7,258 as of December 31, 2023 and has incurred net losses from continuing operations for the years ended December 31, 2023 and December 31, 2022. The Company’s approach to managing its liquidity risk is to seek to ensure that it will have sufficient liquidity to meet its liabilities as they come due. The Company’s short-term liquidity requirements consist primarily of funds necessary to maintain operations, repay borrowings and other general business needs. The Company plans to use existing funds, as well as funds from the future sale of products, to fund short-term working capital needs for at least the next 12 months.

9


Ayr Wellness Inc.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

In addition, the Company continues to take actions designed to improve the Company’s operations and cash position, including but not limited to: (i) targeting continued growth of sales from our consolidated operations; (ii) continued cost-savings and efficiency optimization efforts; (iii) utilizing the future proceeds from an employee retention credit up to $12,354 of which $5,238 is included in current receivables; (iv) addressing our debt maturity profile, in this regard, subsequent to December 31, 2023 the Company completed the debt restructuring transaction contemplated in its October 31, 2023 Support Agreement (the “Support Agreement”) with the holders of approximately 99% (collectively, the “Majority Noteholders”) of the aggregate outstanding principal amount of the Company’s 12.5% senior notes due December 2024 (the “Senior Notes”), which resulted in the effective extension of the maturity date for an additional two years, see Note 19 of the financial statements, and the crystallization of the previously-announced contingent of certain current debts payable; (v) managing the timing and amount of certain expenses as well as capital expenditures; and (vi) seeking to take advantage of future potential financing (equity and/or debt) opportunities, including additional gross cash proceeds of $40,000 received in February 2024 related to the issuance of new debt securities (refer to Note 19 of the financial statements for additional information). The debt extension related to the Support Agreement and the deferral of certain current debts payable are each classified as a non-current liability on the balance sheet as of December 31, 2023. Upon receiving the additional cash proceeds of $40,000, working capital as of December 31, 2023 would have increased from negative $7,258 to a positive $32,742 on a pro-forma basis. While the contemplated debt restructuring transactions have been completed, management cannot provide any assurances that the Company will continue to be successful in accomplishing its business plans; if it is not, the Company may be forced to take other steps, including among others decelerating its growth or curtailing certain of its operations pending obtaining additional capital.

Summary of Future Commitments

Year

    

Operating leases

    

Finance leases

    

Debt

    

Construction finance

    

Total

2024

$

29,457

$

12,098

$

23,175

$

$

64,730

2025

29,112

6,428

23,673

59,213

2026

 

28,381

 

4,412

 

307,506

 

340,299

2027

 

27,125

 

3,340

 

14,527

 

44,992

2028

 

26,507

 

2,501

 

2,939

 

31,947

Thereafter:

 

198,164

 

6,428

 

63,081

 

38,205

305,878

Total commitments

$

338,746

$

35,207

$

434,901

 

$

38,205

$

847,059

Employee Retention Credit

The ERC, as originally enacted through the U.S. Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) on March 27, 2020, is a refundable credit against certain employment taxes equal to 50% of the qualified wages an eligible employer paid to employees from March 17, 2020 to December 31, 2020. The U.S. Disaster Tax Relief Act, enacted on December 27, 2020, extended the employee retention credit for qualified wages paid from January 1, 2021 to June 30, 2021, and the credit was increased to 70% of qualified wages an eligible employer paid to employees during the extended period. The American Rescue Plan Act of 2021, enacted on March 11, 2021, further extended the employee retention credit through December 31, 2021.

The Company experienced full or partial suspension of the business during the period covered by the ERC due to government orders limiting commerce, travel, or group meeting due to COVID-19. In 2023, the Company filed for an ERC claim in the amount of approximately $12,354. During the year ended December 31, 2023, the Company received notices from the Internal Revenue Service (“IRS”) for a total ERC refund of $5,238 and recorded a receivable included as part of prepaid expenses, deposits, and other current assets in the balance sheet and other income on the statement of operations. In accordance with ASC 958-605, the Company determined that the condition to record a receivable is met when the IRS confirms the claim is valid or the cash is received. Absent of any confirmation, there remains uncertainty as to whether the amounts will be received. Due to the degree of uncertainty regarding the implementation of the CARES Act and other stimulus legislation and the nature of our business, although the Company expects to receive the remaining ERC, the Company determined that the remaining claim did not yet meet the criteria to record as a receivable as of December 31, 2023.

10


Ayr Wellness Inc.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

Selected Cash Flow Information

    

Years Ended 

    

December 31, 2023

    

December 31, 2022

$

$

Cash provided by (used in) continuing operations

24,382

(32,632)

Cash provided by (used in) operating activities

27,165

 

(34,165)

Cash used in investing activities from continuing operations

(43,776)

(68,541)

Cash used in investing activities

(24,153)

(66,497)

Cash (used in) provided by financing activities by continuing operations

(32,762)

27,482

Cash (used in) provided by financing activities

(32,886)

26,960

Net decrease in cash and cash equivalents and restricted cash

(29,874)

(73,702)

Cash, cash equivalents and restricted cash beginning of the period

76,827

150,142

Cash included in assets held-for-sale

3,813

4,200

Cash, cash equivalents and restricted cash end of the period

50,766

80,640

Operating Activities

Cash provided by (used in) operating activities from continuing operations during the years ended December 31, 2023 and 2022 was $24,382 and $(32,632), respectively, an increase in cash provided by operating activities of $57,014. The increase was driven by a decrease in loss from operations of $32,466 (excluding the change in the non-cash item related to impairment of goodwill and other assets for $111,630) related to operational improvements and an increase in income tax payable for $31,160. This was mainly offset by the change in accounts receivable of $6,117.

Investing Activities

Cash used in investing activities from continuing operations during the years ended December 31, 2023, and 2022 was $(43,776) and $(68,541), respectively, a decrease in cash used in investing activities of $24,765. The decrease is primarily due to a decrease in purchases of property, plant, and equipment of $31,133, a decrease in cash used for business combinations of $12,475, a decrease in advances to related entities of $6,148, and a decrease in capitalized interest of $4,509. This was partially offset by a decrease in proceeds from the sale of assets of $31,433.

Financing Activities

Cash (used in) provided by financing activities from continuing operations during the years ended December 31, 2023, and 2022 was $(32,762) and $27,482, respectively, an increase in cash used in financing activities of $60,244. The increase is primarily due to an increase in repayments of debt of $34,106 and a decrease from the proceeds of notes payable and financing transactions of $29,549. This increase was partially offset by a decrease in tax withholding on stock-based compensation of $4,872.

11


Ayr Wellness Inc.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

Capital Management

The Company’s short-term liquidity requirements consist primarily of funds necessary to maintain our operations, repay borrowings and other general business needs. The Company plans to use existing funds, as well as funds from the future sale of products, to fund short-term working capital needs for at least the next 12 months. If these sources of liquidity need to be augmented, additional cash requirements would likely be financed through additional capital raises. The Company has raised capital through the issuance of debt, or equity, to meet its needs and take advantage of perceived opportunities, however, there can be no assurance that the Company will be able to continue raising capital in this manner. In addition, further issuances of equity, convertible debt securities, or warrants could result in significant dilution to existing Equity Shares, and any new equity securities issued could have rights, preferences, or privileges superior to the existing Equity Shares. The Company’s long-term liquidity requirements will be affected by its ability to generate positive cash flow from operations and the ability to refinance existing debt on acceptable terms and/or raise equity.

In May 2023, the Company executed contingent agreements to defer certain principal or amortization payments for two years on an aggregate principal amount of approximately $69,000 of debt obligations, including contingent agreements with holders of approximately $60,500 aggregate principal amount of vendor take-back promissory notes (“vendor notes”). The effectiveness of the maturity and amortization deferrals referenced above was contingent on an extension of the Company’s Senior Secured Notes to December 10, 2026 or a later date (or an exchange of the Senior Secured Notes for a new series of notes with a maturity date of December 10, 2026 or a later date). The Senior Secured Notes represent two private placement offerings to a syndicate of institutional investors. The first offering closed on December 10, 2020, for a principal amount of $110,000 and an additional issuance of notes closed on November 12, 2021, for a principal amount of $133,250. In the aggregate, the Senior Secured Notes represented a total of $243,250 and were secured by all assets of the Company and certain of its subsidiaries. As of December 31, 2023, the Company and its subsidiaries had approximately $116,063 of indebtedness in respect of the vendor notes, of which approximately $77,110 were subject to subordination agreements in favor of the Senior Secured Notes. On October 31, 2023, the Company entered into a Support Agreement with the Majority Noteholders of the Senior Secured Notes to extend the maturity date by two years. the Company completed the debt restructuring transactions contemplated in its Support Agreement with the Majority Noteholders, pursuant to which: (i) all of the Senior Secured Notes were exchanged for an equivalent principal amount of new 13% senior secured notes due December 10, 2026 (the “13% Senior Notes and such exchange, the “Exchange Transaction”); (ii) an additional $40,000 in gross cash proceeds was raised through the issuance of additional 13% Senior Notes in an aggregate principal amount of $50,000 (the “New Money Notes”) (subject to a 20% original issue discount) concurrent with the completion of the Exchange Transaction; (iii) as the offering of the New Money Notes was backstopped by one of the Majority Noteholders, such backstop party received a backstop premium on closing payable in the form of 5,948 Equity Shares (the “Backstop Shares”) in the Company and (iv) holders of the 12.5% Senior Secured Notes received 29,040 Equity Shares (the “New Shares”) in the Company.

In addition, 23,046 warrants (the “Anti-Dilutive Warrants”) were issued to all then-existing shareholders (excluding recipients of the New Shares and the Backstop Shares), which are exercisable for an equal number of subordinated, restricted or limited voting shares for $2.12 per share until February 7, 2026. The Anti-Dilutive Warrants are only exercisable by non-U.S. Persons and Accredited Investors in the U.S., as such terms are defined under U.S. securities laws.

In accordance with ASC Subtopic 470-10, since the Exchange Transaction and related transactions have been closed, the Company determined that it met the criteria to classify the existing loans as a non-current liability on the balance sheet and in Note 12 of the consolidated financial statements as of December 31, 2023 by demonstrating the intent and ability to refinance the short-term obligation prior to the financial statement issuance date.

12


Ayr Wellness Inc.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

During 2023, the Company also reached an agreement with Elk Spring Partners, LLC, together with the other selling securityholders under the membership interest purchase agreement (the “MIPA”) dated as of March 26, 2021, (the “NJ Counterparties”) to amend the earn-out payment terms under the MIPA, as amended, relating to the Company’s acquisition of New Jersey-based GSD. The earn-out formula and payment terms under the MIPA were amended as follows:

The first $10,000 portion of the earn-out payable in cash, payment was made to the NJ Counterparties on May 19, 2023.
The next $14,000 portion of the earn-out, which was to be satisfied by issuing 12.5% promissory notes due September 2024 with interest and principal payments, was instead satisfied by issuing 13.5% promissory notes due December 2026 with monthly interest-only payments until May 2024 (with 1% monthly amortization thereafter). The promissory notes were issued on May 19, 2023.
The remaining portion of the earn-out, with a potential maximum amount of $72,750 based on sales of GSD, which was to be satisfied by issuing Equity Shares based on a 15% discount to the then market price of the SVS, was instead satisfied by (i) issuing an aggregate of approximately 3,797 Exchangeable Shares of CSAC Acquisition NJ Corp. that are exchangeable for Equity Shares at any time or from time to time at the discretion of the holder, at a price equal to $0.79 per share on May 19, 2023; and (ii) a cash payment to the NJ Counterparties of approximately $10,925 to be made at a future time based on circumstances related to negotiations with other debtholders. The deferred cash balance of $10,094, net of payments made of $831, was paid in full subsequent to December 31, 2023.

In addition, during 2023, the Company reached an agreement with Green Partners Investor LLC and the other selling securityholders (together, the “Sira Counterparties”) to amend the payment terms under the equity exchange agreement dated as of May 24, 2019, as amended, relating to the Company’s Massachusetts-based acquisition of Sira (the “EEA”). The payment terms under the EEA, which were expected to result in a cash payment of $27,500 on or before May 1, 2024, were amended to be paid on the later of (i) the date that is ten calendar days following the maturity date of AYR’s Senior Secured Notes (as such date may be amended or extended), or (ii) May 1, 2026, but in no event later than December 10, 2026).

On July 7, 2023, the Company entered into a loan agreement to refinance and upsize an existing mortgage which was due to mature in May 2024. The loan agreement included total proceeds of $40,000, with an interest rate of 5-year Federal Home Loan Bank Rate plus 4%, which implies a current rate of 8.27% with interest-only payments for the first 18 months. The note extends the maturity of the existing mortgage to 10 years. Proceeds from the loan were used to pay down the Company’s existing mortgage of $25,219, resulting in proceeds of $13,911, net of transaction costs.

Subsequent to December 31, 2023 following the receipt of court and other required regulatory approvals, the Company completed the debt restructuring transactions contemplated in its October 31, 2023 Support Agreement with the Majority Noteholders, pursuant to which: (i) all of the Senior Secured Notes were exchanged for an equivalent principal amount of new 13% senior secured notes due December 10, 2026 (the “13% Senior Notes and such exchange, the “Exchange Transaction”); (ii) an additional $40,000 in gross cash proceeds was raised through the issuance of additional 13% Senior Notes in an aggregate principal amount of $50,000 (the “New Money Notes”) (subject to a 20% original issue discount) concurrent with the completion of the Exchange Transaction; (iii) as the offering of the New Money Notes was backstopped by one of the Majority Noteholders, such backstop party received a backstop premium on closing payable in the form of 5,948 subordinated, restricted or limited voting shares (the “Backstop Shares”) in the Company and (iv) holders of the 12.5% Senior Secured Notes received 29,040 subordinated, restricted or limited voting shares (the “New Shares”) in the Company.

13


Ayr Wellness Inc.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

On October 31, 2023, the Company entered into an agreement with LivFree Wellness, LLC (“LivFree”) to amend certain terms of the promissory note dated May 24, 2019 (the “LivFree Note”) executed in connection with the Company’s acquisition of LivFree. The amendments to the LivFree Note provided, among other things, for a principal payment of $3,000 which was paid upon closing of the debt restructuring transactions subsequent to December 31, 2023 and a deferral of the maturity of the remaining $17,000 of principal and $5,530 of accrued payment-in-kind interest for a period of two years to May 24, 2026. In addition, upon closing of the Exchange Transaction, the interest on the LivFree Note converted from payment-in-kind to monthly cash interest payments and the interest rate increased from 6.0% to 10.0%.

Share Capital

As of December 31, 2023 and 2022, the Company had share capital of $1,370,600 and $1,349,713, respectively, consisting of additional paid-in capital.

Number of Outstanding Shares

Issued and Outstanding

    

December 31, 2023

    

December 31, 2022

(in thousands)

 

  

 

  

Multiple Voting Shares

 

3,696

 

3,696

Subordinate Voting Shares

 

9,573

 

6,512

Restricted Voting Shares

5,876

2,816

Limited Voting Shares

 

49,125

 

51,581

Exchangeable Shares

9,645

6,044

Treasury Stock

 

(645)

 

(645)

Total number of shares

 

77,270

 

70,004

As of December 31, 2023, the Company had 2,874 Equity Shares issuable upon the exercise of warrants of the Company (“Warrants”), 4,989 restricted Exchangeable Share units, of which 1,300 are market and performance based, and 159 Equity Shares issuable upon the exercise of options. As of December 31, 2022, the Company had 2,874 Equity Shares issuable upon the exercise of Warrants, 6,628 restricted Exchangeable Share units, of which 1,300 are market and performance based, and 165 Equity Shares issuable upon the exercise of options.

Following regulatory approvals subsequent to December 31, 2023, the Company concluded the debt restructuring contemplated in the October 31, 2023 Support Agreement with the Majority Noteholders. This included offering New Money Notes backstopped by a Majority Noteholder, who received a backstop premium of 5,948 Equity Shares (the “Backstop Shares”). Holders of 12.5% Senior Secured Notes received 29,040 Equity Shares (the “New Shares”). Additionally, 23,046 Anti-Dilutive Warrants were issued to existing shareholders (excluding recipients of New Shares and Backstop Shares) exercisable for Equity Shares at $2.12/share until February 7, 2026. See Note 19 of the financial statements for additional information.

Off-Balance Sheet Arrangements

As of the date of this filing, the Company does not have any off-balance sheet arrangements, with the exception of the commitments referenced in Note 16 in the financial statements, that have, or are reasonably likely to have, a current or future effect on the results of operations or financial condition of the Company (including, without limitation, such considerations as liquidity and capital resources) that have not previously been discussed.

14


Ayr Wellness Inc.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Years Ended December 31, 2023 and 2022

(Expressed in United States Dollars, in thousands, except where stated otherwise)

Subsequent Events

See Note 19 in the financial statements for the Company’s disclosures on subsequent events.

Related Party Transactions

See Note 11 in the financial statements for the Company’s disclosures on related party transactions.

Significant Accounting Judgments and Estimates

See Note 3.20 in the financial statements for the Company’s accounting policies regarding Significant Accounting Judgments and Estimates.

Recent Accounting Pronouncements

See Note 3.23 in the financial statements for the Company’s action on recent accounting pronouncements.

Risk Factors

Please refer to the Company’s preliminary prospectus dated July 6, 2023 and subsequent amendments, the Company’s management information circular dated November 22, 2023, and the Annual Information Form dated March 13, 2024, for information on the risk factors to which the Company is subject. In addition, see “Cautionary Note Regarding Forward-Looking Statements” above.

Financial Instruments, Financial Risk Management and Other Instruments

The Company does not utilize financial instruments such as derivatives to manage financial risks. See Note 17 in the financial statements for the Company’s financial instruments, financial risks factors, and other instruments.

The Company is exposed to interest rate risk. The Company’s management oversees the management of these risks. The Company’s management is supported by the members that advise on financial risks and the appropriate financial risk governance framework for the Company. The Company’s financial risk activities are governed by appropriate policies and procedures and financial risks are identified, measured, and managed in accordance with Company policies and risk appetite.

15


EX-99.4 5 ayr-20231231xex99d4.htm EXHIBIT 99.4

Exhibit 99.4

Certification of Chief Executive Officer

Pursuant to Exchange Act Rule 13a-14(a) or 15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-

Oxley Act of 2002

I, David Goubert, certify that:

1.

I have reviewed this annual report on Form 40-F of Ayr Wellness Inc;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this report;

4.

The issuer’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the issuer and have:

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the issuer’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the issuer’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the issuer’s internal control over financial reporting; and

5.

The issuer’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the issuer’s auditors and the audit committee of the issuer’s board of directors (or persons performing the equivalent functions):

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the issuer’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the issuer’s internal control over financial reporting.

Date: March 13, 2024

/s/ David Goubert

David Goubert

Chief Executive Officer

(Principal Executive Officer)


EX-99.5 6 ayr-20231231xex99d5.htm EXHIBIT 99.5

Exhibit 99.5

Certification of Chief Financial Officer

Pursuant to Exchange Act Rule 13a-14(a) or 15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-

Oxley Act of 2002

I, Brad Asher, certify that:

1.

I have reviewed this annual report on Form 40-F of Ayr Wellness Inc;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this report;

4.

The issuer’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the issuer and have:

a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.

Evaluated the effectiveness of the issuer’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.

Disclosed in this report any change in the issuer’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the issuer’s internal control over financial reporting; and

5.

The issuer’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the issuer’s auditors and the audit committee of the issuer’s board of directors (or persons performing the equivalent functions):

a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the issuer’s ability to record, process, summarize and report financial information; and

b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the issuer’s internal control over financial reporting.

Date: March 13, 2024

/s/ Brad Asher

Brad Asher

Chief Financial Officer

(Principal Financial and Accounting Officer)


EX-99.6 7 ayr-20231231xex99d6.htm EXHIBIT 99.6

Exhibit 99.6

CERTIFICATION PURSUANT TO

18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Ayr Wellness Inc. (the “Company”) on Form 40-F for the period ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David Goubert, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

March 13, 2024

/s/ David Goubert

David Goubert

Chief Executive Officer

(Principal Executive Officer)

A signed original of this written statement required by Section 906 has been provided to Ayr Wellness Inc. and will be retained by Ayr Wellness Inc. and furnished to the Securities and Exchange Commission or its staff upon request.


EX-99.7 8 ayr-20231231xex99d7.htm EXHIBIT 99.7

Exhibit 99.7

CERTIFICATION PURSUANT TO

18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Ayr Wellness Inc. (the “Company”) on Form 40-F for the period ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Brad Asher, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

March 13, 2024

/s/ Brad Asher

 

Brad Asher

 

Chief Financial Officer

 

(Principal Financial and Accounting Officer)

A signed original of this written statement required by Section 906 has been provided to Ayr Wellness Inc. and will be retained by Ayr Wellness Inc. and furnished to the Securities and Exchange Commission or its staff upon request.


EX-99.8 9 ayr-20231231xex99d8.htm EXHIBIT 99.8

Exhibit 99.8

INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT

We hereby consent to the incorporation by reference in this Annual Report on Form 40-F for the year ended December 31, 2023 of Ayr Wellness Inc. (“Annual Report on Form 40-F”) of our report dated March 13, 2024 relating to the consolidated financial statements of Ayr Wellness Inc., as of December 31, 2023 and 2022 and for each of the two years in the period ended December 31, 2023, which report is included in Exhibit 99.2 and incorporated by reference in this Annual Report on Form 40-F.  We also consent to the reference to our Firm under the heading “Interests of Experts” which is included in Exhibit 99.1 and incorporated by reference in this Annual Report on Form 40-F.

We also consent to the incorporation by reference in the Registration Statement of Ayr Wellness Inc. on Form S-8 (File No. 333-255749) of our report dated March 13, 2024, with respect to our audits of the consolidated financial statements of Ayr Wellness Inc., as of December 31, 2023 and 2022 and for each of the two years in the period ended December 31, 2023, which report is included in Exhibit 99.2 and incorporated by reference in this Annual Report on Form 40-F.

/s/ Marcum LLP

Marcum LLP

New York, NY

March 13, 2024


EX-101.SCH 10 ayr-20231231.xsd XBRL TAXONOMY EXTENSION SCHEMA 00100 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Consolidated Statements of Cash Flows (Calc2) link:presentationLink link:calculationLink link:definitionLink 40402 - Disclosure - DISCONTINUED OPERATIONS - Major classes of assets and liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 40410 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - 2021 First Quarter Acquisitions - Fair value of identifiable assets acquired, and liabilities assumed as of the acquisition date (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - INVENTORY (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 40902 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 40902 - Disclosure - RIGHT-OF-USE ASSETS & LEASE LIABILITIES - Maturity of contractual undiscounted lease liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 41205 - Disclosure - DEBTS PAYABLE AND SENIOR SECURED NOTES - Future debt obligations (Details) link:presentationLink link:calculationLink link:definitionLink 41401 - Disclosure - DERIVATIVE LIABILITIES - Schedule of Fair Value Adjustment Relating to Derivative Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 41801 - Disclosure - TAXATION (Details) link:presentationLink link:calculationLink link:definitionLink 41802 - Disclosure - TAXATION - Difference Between the Income Tax Expense and the Expected Income Taxes Based on the Statutory Tax Rate (Details) link:presentationLink link:calculationLink link:definitionLink 41803 - Disclosure - TAXATION - Deferred Tax Assets and Liability (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Consolidated Statements of Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 40303 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, Plant, and Equipment ("PPE") (Details) link:presentationLink link:calculationLink link:definitionLink 40304 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets and Impairment of Long-lived Assets (Details) link:presentationLink link:calculationLink link:definitionLink 40305 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings per Share (Details) link:presentationLink link:calculationLink link:definitionLink 40307 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 40308 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -Liquidity and management plan (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - DISCONTINUED OPERATIONS (Details) link:presentationLink link:calculationLink link:definitionLink 40403 - Disclosure - DISCONTINUED OPERATIONS - Components comprising net loss from our discontinued operations (Details) link:presentationLink link:calculationLink link:definitionLink 40404 - Disclosure - DISCONTINUED OPERATIONS - Loss from Discontinued operations (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Including 2023 Fourth Quarter Asset Acquisition (Details) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - 2022 Second Quarter Acquisition - Fair Value of Identifiable Assets Acquired, and Liabilities Assumed as of the Acquisition Date (Details) link:presentationLink link:calculationLink link:definitionLink 40503 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - 2022 Second Quarter Acquisition - Purchase Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 40504 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - 2022 First Quarter Acquisition - Fair Value of Identifiable Assets Acquired, and Liabilities Assumed as of the Acquisition Date (Details) link:presentationLink link:calculationLink link:definitionLink 40505 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - 2022 First Quarter Acquisition - Purchase Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - VARIABLE INTEREST ENTITIES ("VIE") - Fair Value of Identifiable Assets Acquired and Liabilities Assumed as of the Acquisition Date (Details) link:presentationLink link:calculationLink link:definitionLink 40602 - Disclosure - VARIABLE INTEREST ENTITIES ("VIE") - Summary of Financial Information about Consolidated VIEs (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 41003 - Disclosure - RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Payments related to capitalized Lease (Details) link:presentationLink link:calculationLink link:definitionLink 41004 - Disclosure - RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Additional information (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - RELATED PARTY TRANSACTIONS AND BALANCES (Details) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - DEBTS PAYABLE AND SENIOR SECURED NOTES (Details) link:presentationLink link:calculationLink link:definitionLink 41202 - Disclosure - DEBTS PAYABLE AND SENIOR SECURED NOTES - Changes in senior secured notes (Details) link:presentationLink link:calculationLink link:definitionLink 41203 - Disclosure - DEBTS PAYABLE AND SENIOR SECURED NOTES - Changes in debt other than senior secured notes (Details) link:presentationLink link:calculationLink link:definitionLink 41204 - Disclosure - DEBTS PAYABLE AND SENIOR SECURED NOTES - Debts payable (Details) link:presentationLink link:calculationLink link:definitionLink 41206 - Disclosure - DEBTS PAYABLE AND SENIOR SECURED NOTES - Narratives (Details) link:presentationLink link:calculationLink link:definitionLink 41301 - Disclosure - SHARE CAPITAL - Activity occurred during the year end (Details) link:presentationLink link:calculationLink link:definitionLink 41302 - Disclosure - SHARE CAPITAL - Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 41501 - Disclosure - STOCK-BASED COMPENSATION (Details) link:presentationLink link:calculationLink link:definitionLink 41502 - Disclosure - STOCK-BASED COMPENSATION - RSUs (Details) link:presentationLink link:calculationLink link:definitionLink 41503 - Disclosure - STOCK-BASED COMPENSATION - Options (Details) link:presentationLink link:calculationLink link:definitionLink 41601 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 41702 - Disclosure - FINANCIAL RISK FACTORS - Fair Value Hierarchy (Details) link:presentationLink link:calculationLink link:definitionLink 41901 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00205 - Statement - Consolidated Statements of Operations(Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - NATURE OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - DISCONTINUED OPERATIONS link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - VARIABLE INTEREST ENTITIES ("VIE") link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - INVENTORY link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - GOODWILL AND INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - RIGHT-OF-USE ASSETS AND LEASE LIABILITIES link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - RELATED PARTY TRANSACTIONS AND BALANCES link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - DEBTS PAYABLE AND SENIOR SECURED NOTES link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - SHARE CAPITAL link:presentationLink link:calculationLink link:definitionLink 11401 - Disclosure - DERIVATIVE LIABILITIES link:presentationLink link:calculationLink link:definitionLink 11501 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 11601 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 11701 - Disclosure - FINANCIAL RISK FACTORS link:presentationLink link:calculationLink link:definitionLink 11801 - Disclosure - TAXATION link:presentationLink link:calculationLink link:definitionLink 11901 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 20302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - DISCONTINUED OPERATIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - VARIABLE INTEREST ENTITIES ("VIE") (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - INVENTORY (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - RIGHT-OF-USE ASSETS AND LEASE LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 31203 - Disclosure - DEBTS PAYABLE AND SENIOR SECURED NOTES (Tables) link:presentationLink link:calculationLink link:definitionLink 31303 - Disclosure - SHARE CAPITAL (Tables) link:presentationLink link:calculationLink link:definitionLink 31403 - Disclosure - DERIVATIVE LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 31503 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 31703 - Disclosure - FINANCIAL RISK FACTORS (Tables) link:presentationLink link:calculationLink link:definitionLink 31803 - Disclosure - TAXATION (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - NATURE OF OPERATIONS (Details) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Accounts Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 40306 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Taxation (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 40903 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Impairment of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Information Related to Leases (Details) link:presentationLink link:calculationLink link:definitionLink 41002 - Disclosure - RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Maturity of Contractual Undiscounted Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 41701 - Disclosure - FINANCIAL RISK FACTORS (Details) link:presentationLink link:calculationLink link:definitionLink 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 11 ayr-20231231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 12 ayr-20231231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 13 ayr-20231231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 14 ayr-20231231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 15 ayr-20231231x40f001.jpg GRAPHIC begin 644 ayr-20231231x40f001.jpg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end GRAPHIC 16 ayr-20231231xex99d2002.jpg GRAPHIC begin 644 ayr-20231231xex99d2002.jpg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end GRAPHIC 17 ayr-20231231xex99d3001.jpg GRAPHIC begin 644 ayr-20231231xex99d3001.jpg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end XML 18 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document and Entity Information
12 Months Ended
Dec. 31, 2023
shares
Document Information  
Document Type 40-F
Document Registration Statement false
Document Annual Report true
Document Period End Date Dec. 31, 2023
Current Fiscal Year End Date --12-31
Document Fiscal Year Focus 2023
Entity File Number 333-253466
Entity Registrant Name Ayr Wellness Inc.
Entity Incorporation, State or Country Code A1
Entity Address, Country CA
Entity Primary SIC Number 2833
Entity Tax Identification Number 98-1500584
Entity Address, Address Line One 2601 South Bayshore Drive
Entity Address, Adress Line Two Suite 900
Entity Address, City or Town Miami
Entity Address State Or Province FL
Entity Address, Postal Zip Code 33133
City Area Code 786
Local Phone Number 885-0397
Annual Information Form true
Audited Annual Financial Statements true
Entity Current Reporting Status Yes
Entity Interactive Data Current Yes
Entity Emerging Growth Company true
Entity Ex Transition Period false
ICFR Auditor Attestation Flag false
Entity Central Index Key 0001847462
Document Fiscal Period Focus FY
Amendment Flag false
Document Financial Statement Error Correction [Flag] false
Auditor Name Marcum LLP
Auditor Firm ID 688
Auditor Location New York, NY
Subordinate Voting Shares  
Document Information  
Entity Common Stock, Shares Outstanding 64,574,077
Multiple Voting Shares  
Document Information  
Entity Common Stock, Shares Outstanding 3,696,486
Business Contact  
Document Information  
Contact Personnel Name C T Corporation System
Entity Address, Address Line One 1015 15th Street N.W
Entity Address, Adress Line Two Suite 1000
Entity Address, City or Town Washington
Entity Address State Or Province DC
Entity Address, Postal Zip Code 20005
City Area Code 202
Local Phone Number 572-3133

XML 19 R2.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current    
Cash and cash equivalents $ 50,766 $ 76,827
Accounts receivable, net 13,491 7,738
Inventory 106,363 99,810
Prepaid expenses, deposits, and other current assets 22,600 8,702
Assets held-for-sale   260,625
Total Current Assets 193,220 453,702
Non-current    
Property, plant, and equipment, net 310,615 302,680
Intangible assets, net 687,988 744,709
Right-of-use assets - operating, net 127,024 121,340
Right-of-use assets - finance, net 40,671 43,222
Goodwill 94,108 94,108
Deposits and other assets 6,229 8,009
TOTAL ASSETS 1,459,855 1,767,770
Current    
Trade payables 24,786 26,671
Accrued liabilities 40,918 25,470
Lease liabilities - operating - current portion 9,776 7,906
Lease liabilities - finance - current portion 9,789 9,529
Contingent consideration - current portion   63,429
Purchase consideration payable   2,849
Income tax payable 90,074 46,006
Debts payable - current portion 23,152 40,523
Liabilities held-for-sale   43,841
Accrued interest payable - current portion 1,983 2,581
Total Current Liabilities 200,478 268,805
Non-current    
Deferred tax liabilities, net 64,965 72,413
Lease liabilities - operating - non-current portion 125,739 118,086
Lease liabilities - finance - non-current portion 18,007 24,016
Construction finance liabilities 38,205 36,181
Contingent consideration - non-current portion   26,661
Debts payable - non-current portion 167,351 136,315
Senior secured notes, net of debt issuance costs 243,955 244,682
Accrued interest payable - non-current portion 5,530 4,763
Other long- term liabilities 24,973 524
TOTAL LIABILITIES 889,203 932,446
Commitments and contingencies
Shareholders' equity    
Additional paid-in capital 1,370,600 1,349,713
Treasury stock - 645,300 shares (8,987) (8,987)
Accumulated other comprehensive income 3,266 3,266
Accumulated deficit (783,101) (510,668)
Equity of Ayr Wellness Inc. 581,778 833,324
Noncontrolling interests (11,126) 2,000
TOTAL SHAREHOLDERS' EQUITY 570,652 835,324
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY 1,459,855 1,767,770
Multiple Voting Shares    
Shareholders' equity    
Shares 0 0
Subordinate, Restricted, and Limited Voting Shares    
Shareholders' equity    
Shares 0 0
Exchangeable Shares    
Shareholders' equity    
Shares $ 0 $ 0
XML 20 R3.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Balance Sheets (Parenthetical) - $ / shares
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Treasury stock 645,300 645,300
Multiple Voting Shares    
Shares no par value (in dollars per share) $ 0 $ 0
Shares authorized Unlimited Unlimited
Shares Issued 3,696,486 3,696,486
Shares outstanding 3,696,486 3,696,486
Subordinate, Restricted, and Limited Voting Shares    
Shares no par value (in dollars per share) $ 0 $ 0
Shares authorized Unlimited Unlimited
Shares Issued 64,574,077 60,909,492
Shares outstanding 64,574,077 60,909,492
Exchangeable Shares    
Shares no par value (in dollars per share) $ 0 $ 0
Shares authorized Unlimited Unlimited
Shares Issued 9,645,016 6,044,339
Shares outstanding 9,645,016 6,044,339
XML 21 R4.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Consolidated Statements of Operations    
Revenues, net of discounts $ 463,630 $ 421,435
Cost of goods sold excluding fair value items 261,188 240,252
Incremental costs to acquire cannabis inventory in business combination   6,217
Cost of goods sold 261,188 246,469
Gross profit 202,442 174,966
Operating expenses    
Selling, general, and administrative 177,800 212,525
Impairment of goodwill and other assets 6,320 117,950
Depreciation and amortization 51,364 45,801
Acquisition and transaction costs 4,080 5,986
Loss (gain) on sale of assets 91 (8)
Total operating expenses 239,655 382,254
Loss from continuing operations (37,213) (207,288)
Other income (expense), net    
Fair value gain on financial liabilities 23,023 63,088
Interest expense, net (39,403) (28,323)
Interest income 743 275
Other income, net 7,094 120
Total other (expense) income, net (8,543) 35,160
Loss from continuing operations before income taxes and noncontrolling interest (45,756) (172,128)
Income taxes    
Current tax provision (54,839) (43,161)
Deferred tax benefit (expense) 7,448 (1,588)
Total income taxes (47,391) (44,749)
Net loss from continuing operations (93,147) (216,877)
Discontinued operations    
Loss from discontinued operations, net of taxes (including loss on disposal of $182,464 for the year ended December 31, 2023) (186,353) (38,608)
Loss from discontinued operations (186,353) (38,608)
Net loss (279,500) (255,485)
Net loss attributable to noncontrolling interest (7,067) (10,019)
Net loss attributable to Ayr Wellness Inc. $ (272,433) $ (245,466)
Basic and diluted net loss per share    
Continuing operations - basic $ (1.16) $ (3.01)
Continuing operations - diluted (1.16) (3.01)
Discontinued operations - basic (2.52) (0.56)
Discontinued operations - diluted (2.52) (0.56)
Basic net loss per share (3.68) (3.58)
Diluted net loss per share $ (3.68) $ (3.58)
Weighted average number of shares outstanding (basic) 74,096 68,635
Weighted average number of shares outstanding (diluted) 74,096 68,635
XML 22 R5.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Operations(Parenthetical)
$ in Thousands
12 Months Ended
Dec. 31, 2023
USD ($)
Consolidated Statements of Operations  
Loss on disposal $ 182,464
XML 23 R6.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Shareholders' Equity - USD ($)
$ in Thousands
Additional paid- in capital
Treasury Stock
Accumulated other comprehensive income
Accumulated Deficit
Noncontrolling interest
Multiple Voting Shares
Subordinate, Restricted, and Limited Voting Shares
Exchangeable Shares
Total
Balance, Beginning at Dec. 31, 2021 $ 1,289,827 $ (7,828) $ 3,266 $ (265,202)         $ 1,020,063
Balance, Beginning (Shares) at Dec. 31, 2021   (568,000)       3,696,000 56,337,000 7,368,000  
Consolidated Statements of Shareholders' Equity                  
Stock-based compensation 46,115               46,115
Stock-based compensation (Shares)             2,109,000    
Tax withholding on stock-based compensation awards (5,258)               (5,258)
Tax withholding on stock-based compensation awards (Shares)             (676,000)    
Share issuance - related party - consulting services 707               707
Share issuance - related party - consulting services (Shares)             76,000    
Share issuance - earn-out consideration (Value) 11,748           $ 1,029   11,748
Share issuance - earn-out consideration (Shares)             1,029,000    
Conversion of Exchangeable Shares (Shares)             2,006,000 (2,006,000)  
Consolidation of variable interest entities         $ 12,019       12,019
Share issuance - business combinations and asset acquisitions (Value) 6,352               6,352
Share issuance - business combinations and asset acquisitions (Shares)               682,000  
Exercise of options, net of options sold to cover income taxes (Value) 300               $ 300
Exercise of options, net of options sold to cover income taxes (Shares)             33,000   33,000
Repurchase of Equity Shares (Value) (78) $ (1,159)             $ (1,237)
Repurchase of Equity Shares (Shares)   (77,000)         (5,000)    
Net loss       (245,466) (10,019)       (255,485)
Balance, Ending (Value) at Dec. 31, 2022 1,349,713 $ (8,987) 3,266 (510,668) 2,000       835,324
Balance, Ending (Shares) at Dec. 31, 2022   (645,000)       3,696,486 60,909,492 6,044,339  
Consolidated Statements of Shareholders' Equity                  
Stock-based compensation 16,412               16,412
Stock-based compensation (Shares)             3,262,000    
Tax withholding on stock-based compensation awards (366)               (366)
Tax withholding on stock-based compensation awards (Shares)             (93,000)    
Share issuance - related party - consulting services 79               79
Share issuance - related party - consulting services (Shares)             66,000    
Acquisition of variable interest entity 115       (6,059)       (5,944)
Acquisition of variable interest entity (Shares)               233,000  
Share issuance - earn-out consideration (Value) 4,647               $ 4,647
Share issuance - earn-out consideration (Shares)               3,798,000  
Conversion of Exchangeable Shares (Shares)             430,000 (430,000)  
Exercise of options, net of options sold to cover income taxes (Shares)                 6,000
Net loss       (272,433) (7,067)       $ (279,500)
Balance, Ending (Value) at Dec. 31, 2023 $ 1,370,600 $ (8,987) $ 3,266 $ (783,101) $ (11,126)       $ 570,652
Balance, Ending (Shares) at Dec. 31, 2023   (645,000)       3,696,486 64,574,077 9,645,016  
XML 24 R7.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Operating activities    
Consolidated net loss $ (279,500) $ (255,485)
Less: Loss from discontinued operations (Note 4) (3,889) (38,608)
Net loss from continuing operations before noncontrolling interest (275,611) (216,877)
Adjustments for:    
Fair value gain on financial liabilities (23,023) (63,088)
Shares issued for consulting services 79  
Depreciation and amortization 32,303 19,028
Amortization on intangible assets 58,646 57,122
Impairment of goodwill and other assets 6,320 117,950
Incremental costs to acquire cannabis inventory in business combination   6,217
Deferred tax (benefit) expense (7,448) 1,588
Amortization of financing costs 2,341 2,292
Amortization on financing premium (3,018) (3,018)
Employee retention credits recorded in other income (5,238)  
Loss (gain) on disposal of property, plant, and equipment 91 (8)
Loss on the disposal of Arizona business 182,464  
Changes in operating assets and liabilities, net of business combinations:    
Accounts receivable (6,053) 63
Inventory (6,252) (12,536)
Prepaid expenses, deposits, and other current assets (657) 1,360
Trade payables (296) (6,548)
Accrued liabilities 2,804 1,199
Accrued interest payable (42) (2,686)
Lease liabilities - operating 2,712 1,799
Income tax payable 47,848 16,689
Cash provided by (used in) continuing operations 24,382 (32,632)
Cash provided by (used in) discontinued operations 2,783 (1,533)
Cash provided by (used in) operating activities 27,165 (34,165)
Investing activities    
Purchase of property, plant, and equipment (27,697) (58,830)
Capitalized interest (9,981) (14,490)
Cash paid for business combinations and asset acquisitions, net of cash acquired (1,500) (11,546)
Cash paid for business combinations and asset acquisitions, working capital (2,600) (2,205)
Proceeds from the sale of assets, net of transaction costs   31,433
Cash received (paid) for bridge financing (73) 70
Advances to related entities   (6,148)
Deposits for business combinations, net of cash on hand   (2,825)
Purchase of intangible asset (1,925) (4,000)
Cash used in investing activities from continuing operations (43,776) (68,541)
Proceeds from sale of Arizona - discontinued operation 18,084  
Cash received for working capital - discontinued operations 1,583  
Cash (paid) received for investing activities - discontinued operations (44) 2,044
Cash provided by investing activities of discontinued operations 19,623 2,044
Cash used in investing activities (24,153) (66,497)
Financing activities    
Proceeds from exercise of options   300
Proceeds from issuance of notes payable, net of financing costs 10,665 51,713
Debt issuance costs paid (9,049)  
Proceeds from financing transaction, net of financing costs 39,100 27,600
Payment for settlement of contingent consideration (10,475) (10,000)
Deposits paid for financing lease and note payable   (924)
Tax withholding on stock-based compensation awards (366) (5,258)
Repayments of debts payable (52,029) (17,923)
Repayments of lease liabilities - finance (principal portion) (10,608) (9,596)
Repurchase of Equity Shares   (8,430)
Cash (used in) provided by financing activities by continuing operations (32,762) 27,482
Cash used in financing activities from discontinued operations (124) (522)
Cash (used in) provided by financing activities (32,886) 26,960
Net decrease in cash and cash equivalents and restricted cash (29,874) (73,702)
Cash, cash equivalents and restricted cash beginning of the period 80,640 150,142
Cash, cash equivalents and restricted cash excluding Cash included in assets held-for-sale   76,827
Cash included in assets held-for-sale 3,813 4,200
Cash, cash equivalents and restricted cash end of the period 50,766 80,640
Supplemental disclosure of cash flow information:    
Interest paid during the period, net 49,914 49,231
Income taxes paid during the period 7,078 30,915
Non-cash investing and financing activities:    
Recognition of right-of-use assets for operating leases 19,184 54,396
Recognition of right-of-use assets for finance leases 5,470 32,444
Issuance of promissory note related to business combinations 1,580 16,000
Conversion of convertible note related to business combination 2,800  
Issuance of Equity Shares related to business combinations and asset acquisitions 115 6,352
Issuance of Equity Shares related to settlement of contingent consideration 4,647 11,748
Issuance of promissory note related to settlement of contingent consideration 14,000 14,934
Settlement of contingent consideration 38,420  
Capital expenditure disbursements for cultivation facility 2,024 8,402
Cancellation of Equity Shares   78
Extinguishment of note payable related to sale of Arizona business 22,505  
Extinguishment of accrued interest payable related to sale of Arizona business 1,165  
Reduction of lease liabilities related to sale of Arizona business 16,734  
Reduction of right-of-use assets related to sale of Arizona business 16,739  
Non-related party debt    
Adjustments for:    
Stock-based compensation $ 16,412 46,115
Related party debt    
Adjustments for:    
Stock-based compensation - related party   $ 707
XML 25 R8.htm IDEA: XBRL DOCUMENT v3.24.0.1
NATURE OF OPERATIONS
12 Months Ended
Dec. 31, 2023
NATURE OF OPERATIONS  
NATURE OF OPERATIONS

1.    NATURE OF OPERATIONS

Ayr Wellness Inc. (“Ayr” or the “Company”) is a vertically integrated cannabis multi-state operator in the United States of America (“U.S.”); through its operating companies in various states throughout the U.S., Ayr is a leading cultivator, manufacturer, and retailer of cannabis products and branded cannabis packaged goods. The Company prepares its segment reporting on the same basis that its chief operating decision maker manages the business and makes operating decisions. The Company has one operating segment, cannabis sales. The Company’s segment analysis is reviewed regularly and will be re-evaluated when circumstances change.

The Company is a reporting issuer in the U.S. and Canada. The Company’s subordinate, restricted, and limited voting shares (“Equity Shares”) are trading on the Canadian Stock Exchange (“CSE”), under the symbol “AYR.A.” The Company’s Equity Shares are also quoted on the OTCQX® Best Market in the U.S. under the symbol “AYRWF.” Ayr’s headquarter office is 2601 South Bayshore Drive, Suite 900, Miami, FL 33133.

XML 26 R9.htm IDEA: XBRL DOCUMENT v3.24.0.1
BASIS OF PRESENTATION
12 Months Ended
Dec. 31, 2023
BASIS OF PRESENTATION  
BASIS OF PRESENTATION

2.    BASIS OF PRESENTATION

2.1 Statement of compliance

These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for financial information and in accordance with the rules and regulations of Canadian securities regulators and the United States Securities and Exchange Commission.

The financial statements are presented in United States dollars (“US$” or “$”). The functional currency of the entity is determined separately in accordance with Accounting Standards Codification (“ASC”) 830 – Foreign Currency Matters and is measured using the currency of the primary economic environment in which the entity operates (“the functional currency”). The functional currency of Ayr is US$.

XML 27 R10.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
12 Months Ended
Dec. 31, 2023
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3.1 Basis of consolidation

The financial statements as of and for the years ended December 31, 2023 and 2022 include the accounts of the Company, its wholly-owned subsidiaries, and entities over which the Company has a controlling interest. Entities over which the Company has control are presented on a consolidated basis from the date control commences until the date control ceases. Equity investments where the Company does not exert a controlling interest are not consolidated. All intercompany balances and transactions involving controlled entities are eliminated on consolidation. The accompanying consolidated financial statements reflect the activity related to Arizona as discontinued operations, see Note 4. The Company’s consolidated subsidiaries, many of which were created in connection with the business combinations described in Note 5 and elsewhere in these financial statements, are owned 100% by the Company unless otherwise noted. See Note 6 for variable interest entities that are consolidated by the Company.

3.2 Revenue

The Company applies Accounting Standards Codification “ASC” Topic 606 (“ASC 606”), which specifies how and when revenue should be recognized based on a five-step model, which is applied to all contracts with customers. Through the application of ASC 606, the Company applies the following five-step model to determine the amount and timing of revenue to be recognized:

Identifying the contract with a customer
Identifying the performance obligations within the contract
Determining the transaction price
Allocating the transaction price to the performance obligations
Recognizing revenue when/as performance obligation(s) are satisfied.

3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

3.2 Revenue (Continued)

In some cases, judgment is required in determining whether the customer is a business or the end consumer. This evaluation is made based on whether the business obtains control of the product before transferring to the end consumer. Control of the product transfers at a point in time either upon shipment to or receipt by the customer, depending on the contractual terms. In determining the appropriate time of sale, the Company takes into consideration: a) the Company’s right to payment for the goods or services; b) customer’s legal title; c) transfer of physical possession of the goods; and d) timing of acceptance of goods.

Revenue is recognized based on the sale of cannabis products and branded packaged goods for a fixed price when control is transferred. The amount recognized reflects the consideration that the Company expects to receive, taking into account any variation that is expected to result from rights of return and discounts. Dispensary revenue is recognized at the point of sale while wholesale revenue is recognized once the Company transfers the significant risks and rewards of ownership of the goods and does not retain material involvement associated with ownership or control over the goods sold. Revenue from the wholesale of cannabis to customers is recognized upon delivery to the customer. In accordance with ASC 606, the Company has elected to account for its sales and excise tax on a net basis, within its statements of operations.

3.3 Cash and cash equivalents and restricted cash

The Company considers the following to be cash and cash equivalents: cash deposits in financial institutions, cash held in Company safes or lockboxes at operational locations, and deposits that are readily convertible into cash within three months or less. Amounts included in restricted cash represent amounts pledged as collateral for financing arrangements as contractually required by a lender. Cash and cash equivalents and restricted cash are stated at fair value and the Company did not hold significant cash equivalents or restricted cash balances as of December 31, 2023 and 2022. The Company has banking or similar relationships in all jurisdictions in which it operates. In addition, the Company has cash balances in excess of Federal Deposit Insurance Corporation and Canada Deposit Insurance Corporation limits. The Company has historically not experienced losses related to these deposits.

3.4 Accounts receivable

Accounts receivable from wholesale sales are recorded net of an allowance for credit losses. The Company estimates allowance for credit losses based on various factors such as historical data, and customer credit worthiness. As of December 31, 2023 and 2022, the Company had approximately $706 and $511 in allowance for credit losses, respectively. For the years ended December 31, 2023 and 2022, the Company wrote off approximately $221 and $443, respectively. See 3.23 for additional information.

3.5 Business combinations

Acquisitions of subsidiaries and businesses are accounted for using the acquisition method in accordance with ASC 805 – Business Combination (“ASC 805”). The Company performs an assessment whether the acquisition is a business combination or asset acquisition based on the conditions surrounding the event(s) using guidance from ASC 805. If the acquisition is determined to be a business combination, the Company measures goodwill as the fair value of the consideration transferred, including the recognized amount of any noncontrolling interest in the acquiree, less the net recognized amount of the identifiable assets acquired and liabilities assumed, all measured as of the acquisition date.

Consideration transferred includes the fair value of the assets transferred (including cash), the liabilities incurred by the Company on behalf of the acquiree, any contingent consideration and any equity interests issued by the Company. Transaction costs, other than those directly associated with the issuance of debt or equity securities that the Company incurs in connection with a business combination, are expensed as incurred.

The acquisition date is the date when the Company obtains control of the acquiree. Contingent consideration is measured at its acquisition date fair value and included as part of the consideration transferred in a business combination. Contingent consideration that is classified as a liability is re-measured at subsequent reporting dates in accordance with the criteria and guidance provided under ASC 450 – Contingencies and ASC 820 – Fair Value Measurement, as appropriate with corresponding gain or loss recorded in the statements of operations, see Note 14.

3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

3.6 Inventory

Inventory is primarily comprised of finished goods, work-in-process, raw materials, and supplies. Inventory is valued at the lower of cost and net realizable value. Net realizable value is determined as the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. When establishing the cost, work-in-process and raw materials are determined using the weighted average cost method while the determination of cost for finished goods inventory is on the first-in, first-out accounting method.

Costs incurred during the growing process are capitalized as incurred to the extent that cost is less than net realizable value. Any subsequent post-harvest costs, including direct costs such as materials, labor, related overhead, and depreciation expense on equipment attributable to processing, are capitalized to inventory to the extent that cost is less than net realizable value. Inventories of purchased finished goods and packing materials, other than inventory acquired through business combinations, are initially valued at cost and subsequently at the lower of cost and net realizable value. The Company reviews inventories for obsolete, spoiled, and slow-moving goods and any such inventories are written down to net realizable value. Inventory acquired in a business combination is valued at selling price less selling and disposal costs.

3.7 Property, plant, and equipment (“PPE”)

PPE is stated at cost less accumulated depreciation, amortization, and impairment losses, if any. The cost of an item of PPE consists of the purchase price, any costs directly attributable to bringing the asset to the location and condition necessary for its intended use and an initial estimate of the costs of dismantling and removing the item and restoring the site on which it is located. PPE acquired in a business combination is recorded at fair value using various methodologies including cost approach, sales comparison approach or income approach.

Depreciation and amortization are calculated using the straight-line method over the following expected useful lives:

Furniture and fixtures

5 to 7 years

Office equipment

3 to 5 years

Machinery and equipment

5 to 15 years

Auto and trucks

5 years

Leasehold improvements

the shorter of the useful life or life of the lease

Buildings

39 years

Land

not depreciated

Construction in progress

not depreciated until placed in service

An item of PPE is derecognized upon disposal, when held for sale, or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on disposal of the asset, determined as the difference between the net disposal proceeds and the carrying amount of the asset, is recognized in the statements of operations.

Construction in progress is transferred to the appropriate asset class when available for use and depreciation or amortization of the assets commences at that point of time.

The Company conducts a periodic assessment of the residual balances, useful lives, and depreciation or amortization methods being used for PPE and any changes arising from the assessment are applied by the Company prospectively.

Where an item of PPE comprises major components with different useful lives, the components are accounted for as separate items of PPE. Expenditures incurred to replace a component of an item of PPE that is accounted for separately, including major inspection and overhaul expenditures are capitalized.

The Company capitalizes interest on debt in projects under construction. Upon the asset becoming available for use, capitalized interest costs, as a portion of the total cost of the asset, are depreciated over the estimated useful life of the related asset, see Note 8 for additional information.

3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

3.8 Intangible assets

Intangible assets are recorded at cost less accumulated amortization and impairment losses, if any. Intangible assets, separately identifiable according to ASC 805, acquired in a business combination are measured at fair value as of the acquisition date. Amortization periods of assets with finite lives are based on management’s estimates at the date of acquisition and are amortized over their estimated useful lives. Intangible assets that have indefinite useful lives are not subject to amortization and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired.

(a)Goodwill

The Company measures goodwill as the fair value of the consideration transferred, including the recognized amount of any noncontrolling interest in the acquiree, less the net recognized amount of the identifiable assets and liabilities assumed, all measured as of the acquisition date. Goodwill is allocated to a specific reporting unit upon acquisition. The Company’s policy is to first perform a qualitative assessment to determine if it was more-likely-than-not that the reporting unit’s carrying value is less than the fair value, indicating the potential for goodwill impairment. The amount of goodwill impairment, if any, is determined as the excess of the carrying value over the fair value of that reporting unit. The impairment of goodwill is limited to the amount of goodwill in a reporting unit. Impairment testing is performed annually by the Company, or more frequently, if events or changes in circumstances indicate that goodwill might be impaired. Management makes estimates during impairment testing as judgment is required to determine indicators of impairment and estimates are used to determine the fair value that is used to measure impairment losses. The Company assesses the fair values of its intangible assets, and its reporting unit for goodwill testing purposes, as necessary, using an income-based approach. Under the income approach, fair value is based on the present value of estimated future cash flows.

(b)Finite-lived intangible assets

Intangible assets are recorded at cost unless acquired through a business combination and recorded at fair value, less accumulated amortization and impairment losses. Amortization is recorded on a straight-line basis over the following estimated useful lives, which do not exceed the contractual period, if any:

Licenses/permits

15

Right-to-use licenses

15

Host community agreements

15

Trade name / brand

5

Such assets are tested for impairment if events or changes in circumstances indicate that they might be impaired. The estimated useful lives, residual values, and amortization methods are reviewed periodically, and any changes in estimates are accounted for prospectively.

3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

3.8 Intangible assets (Continued)

(c)Impairment of long-lived assets

Long-lived assets such as PPE, right-of-use assets, and finite-lived intangible assets are grouped with other assets and liabilities at the lowest level for which identifiable independent cash flows are available (“asset group”). The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In order to determine if assets have been impaired, the impairment test is a two-step approach wherein the recoverability test is performed first to determine whether the long-lived asset is recoverable. The recoverability test (Step 1) compares the carrying amount of the asset to the sum of its future undiscounted cash flows using entity specific assumptions generated through the asset’s use and eventual disposition. If the carrying amount of the asset is less than the undiscounted cash flows, the asset is recoverable, and an impairment is not recorded. If the carrying amount of the asset is greater than the undiscounted cash flows, the asset is not recoverable, and an impairment loss calculation (Step 2) is required. The measurement of the impairment loss to be recognized is based on the difference between the fair value and the carrying value of the asset group. Fair value can be determined using a market approach, income approach, or cost approach. The cash flow projection and fair value represents management’s best estimate, using appropriate and customary assumptions, projections, and methodologies, at the date of evaluation. The reversal of impairment losses is prohibited.

3.9 Leases and sale and leaseback accounting

The Company applies the accounting guidance in ASC 842 – Leases and assesses whether a contract is or contains a lease, at inception of a contract. When evaluating whether a lease is a finance lease or an operating lease the Company considers whether the contract conveys the right to control the use of an identified asset. Certain arrangements require significant judgement to determine if an asset is specified in the contract and if the Company directs how, and for what purpose, the asset is used during the term of the contract. Leases are recognized as a right-of-use asset (“ROU”) and corresponding liability at the commencement date based on the present value of the future minimum lease payments over the lease term. Operating leases are included in Right-of-use assets – operating, net and Lease liabilities – operating – current portion and Lease liabilities – operating – non-current portion on the balance sheets. For operating leases, the Company records operating lease expense. Finance leases are included in Right-of-use assets – finance, net and lease liabilities are included in Lease liabilities – finance – current portion and Lease liabilities – finance – non-current portion on the balance sheets based on their payment dates. For finance leases, the Company records interest expense on the lease liability in addition to amortizing the ROU (generally straight-line) over the shorter of the lease term or the useful life of the right-of-use asset. The Company primarily leases space for corporate offices, retail, cultivation, and manufacturing under non-cancellable operating leases. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease.

Lease liabilities include the net present value of fixed payments (including in-substance fixed payments), variable lease payments that are not based on an index or a rate or subject to a fair market value renewal, amounts expected to be payable by the lessee under residual value guarantees, the exercise price of a purchase option if the lessee is reasonably certain to exercise that option, and payments of penalties for terminating the lease, if the lease term reflects the lessee exercising that option. The Company allocates the consideration in the contract to each lease component on the basis of the relative standalone price of the lease component and the aggregate stand-alone price of the non-lease components.

The lease payments are discounted using the interest rate implicit in the lease or, if that rate cannot be determined, the Company’s incremental borrowing rate. The period over which the lease payments are discounted is the reasonably certain lease term, including renewal options that the Company is reasonably certain to exercise. Renewal options are included in a number of leases across the Company.

Payments associated with short-term leases are recognized as an expense on a straight-line basis in the statements of operations. Short-term leases are leases with a lease term of 12 months or less. Variable lease payments that depend on an index or a rate or are subject to a fair market value renewal are expensed as incurred and recognized in the statements of operations.

3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

3.9 Leases and sale and leaseback accounting (Continued)

A sale and leaseback transaction involves the transfer of an asset to another entity and the leaseback of the same asset. The Company applies ASC 606 and ASC 842 when accounting for sale and leaseback transactions. Significant estimates and judgments applied include determination of the fair value of the underlying asset, transfer of control, and determination of the implicit interest rate. The Company recognizes gains or losses related to the transfer of rights of the asset to the buyer-lessor and measures the ROU asset arising from the leaseback at the retained portion of the previous carrying amount. In cases where the transaction does not qualify for sale and leaseback accounting treatment, the asset is not derecognized, and no gain or loss is recorded. The transaction is treated as a financing transaction. See Note 10 for additional information.

3.10 Equity investments

An associate is an entity over which the Company exercises significant influence. Significant influence is the power to participate in the financial and operating policy of the investee but without control or joint control over those policies. Interests in associates are accounted for using the equity method and are initially recognized at cost. Subsequent to initial recognition, the carrying value of the Company’s interest in an associate is adjusted for the Company’s share of income or loss and distributions of the investee. The carrying value of associates is assessed for impairment at each balance sheet date. Significant influence is presumed if the Company holds between 20% and 50% of the voting rights unless evidence exists to the contrary.

Joint control is the contractually agreed sharing of control of an arrangement, which exists only when decisions about the relevant activities require the unanimous consent of the parties sharing control. Investees in which the Company has joint control and rights to the net assets thereof are defined as joint ventures. Joint ventures are also accounted for under the equity method. There were no joint ventures as of December 31, 2023.

3.11 Noncontrolling interests

Equity interests owned by parties that are not shareholders of the Company in consolidated subsidiaries are considered noncontrolling interests. The share of net assets attributable to noncontrolling interests is presented as a component of equity while the share of net income or loss is recognized in the statements of operations. Changes in the Company’s ownership interest that do not result in a loss of control of these less than wholly owned subsidiaries are accounted for as equity transactions, see Note 3.19.

3.12 Derivatives

The Company evaluates all its agreements to determine if such instruments have derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as assets or liabilities, the derivative instrument is recorded at its fair value and is then revalued at each reporting date, with changes in the fair value reported in the Company’s financial statements. In calculating the fair value of derivative assets or liabilities, the Company uses a valuation model when Level 1 inputs are not available to estimate fair value at each reporting date (see Notes 14 and 17).

The classification of derivative instruments, including whether such instruments should be recognized as assets or liabilities or as equity, is reevaluated at the end of each reporting period. Derivative instrument assets or liabilities are classified as current or non-current based on whether net-cash settlement of the derivative instrument could be required within 12 months of the financial statement date.

3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

3.13 Earnings per share

The basic loss per share is computed by dividing the net loss by the weighted average number of shares outstanding, including Equity Shares, multiple voting shares of the Company and Exchangeable Shares, as defined below, during the period. The diluted loss per share reflects the potential dilution of shares by adjusting the weighted average number of shares outstanding to assume conversion of potentially dilutive shares, such as warrants (“Warrants”), restricted stock units (“RSUs”), and vested options of the Company (“Vested Options”). The treasury stock method is used for the assumed proceeds upon the exercise of the Warrants, and Vested Options that are used to purchase Equity Shares at the average market price during the period. If the Company incurs a net loss during a reporting period, the calculation of fully diluted loss per share will not include potentially dilutive equity instruments such as Warrants, RSUs, and Vested Options, because their effect would be anti-dilutive, therefore, basic loss per share and diluted loss per share will be the same. For the years ended December 31, 2023 and 2022, the potentially dilutive financial instruments excluded from the calculation of earnings per share included nil and nil warrants, nil and nil options and 1,908 and 3,799 RSUs, totaling 1,908 and 3,799 shares of potentially dilutive securities, respectively.

3.14 Stock-based payments

(a) Stock-based payment transactions

Certain employees (including directors and senior executives) of the Company receive a portion of their remuneration in the form of stock-based payment transactions, whereby employees render services as consideration for equity instruments.

Stock-based payments to non-employees are measured at the fair value of goods or services received or the fair value of the equity instruments issued, whichever is more readily determinable. In situations where equity instruments are issued to non-employees and some or all of the fair value of the good or service received by the Company as consideration cannot be specifically identified, they are measured at fair value of the stock-based payment. Stock-based payment transactions are primarily for individuals whose compensation has been classified as part of general and administrative expenses in the statements of operations.

The costs of equity settled transactions with employees are measured by reference to the fair value of the stock price at the date on which they are granted, using an appropriate valuation model. The value of the transaction is expensed straight line through the vesting period. Market and performance based RSUs are fair valued through Monte-Carlo simulations and are expensed over the indicative service period. Performance RSUs are recorded once the condition is probable to occur, refer to Note 15.

The costs of equity settled transactions are recognized, together with a corresponding increase in equity, over the period in which the performance and/or service conditions are fulfilled, ending on the date on which the relevant employees become fully entitled to the award (the “vesting date”).

The cumulative expense is recognized for equity settled transactions at each reporting date until the vesting date as the Company’s policy is to account for forfeitures as they occur. The income or loss for a period represents the movement in cumulative expense recognized as of the beginning and end of that period and the corresponding amount is represented in additional paid-in capital. At the end of each reporting period, the Company assesses if any forfeitures occurred and recognizes the impact in the statements of operations.

No expense is recognized for awards that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vesting for expense purposes irrespective of whether or not the market condition is satisfied provided that all other performance and/or service conditions are satisfied.

Where the terms of an equity settled award are modified, the minimum expense recognized is the grant date fair value of the unmodified award, provided the original terms of the award are met. An additional expense is recognized for any modification which increases the total fair value of the stock-based payment arrangement or is otherwise beneficial to the employee as measured at the date of modification. When an award is cancelled by the Company or the counterparty, any remaining element of the fair value of the award is derecognized at that time through the statements of operations.

3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

3.14 Stock-based payments (Continued)

(a) Stock-based payment transactions (Continued)

RSUs are issued on the vesting dates, sometimes net of the applicable statutory tax withholding to be paid by the Company on behalf of the employees. In those instances, lower shares are issued than the number of RSUs vested and the tax withholding is recorded as a reduction to paid-in capital. The terms of the stock-based payment awards allow an entity with a statutory income tax withholding obligation to withhold shares with a fair value up to the maximum statutory tax in the employee’s applicable jurisdiction.

(b) Warrants

The Company determines the accounting classification for equity-linked financial instruments such as warrants, as either liability or equity, by assessing ASC 480 – Distinguishing Liabilities from Equity and ASC 815 – Derivatives and Hedging. Under ASC 480, warrants are considered a liability if the warrants are mandatorily redeemable, obligate the Company to settle the warrants or the underlying shares by paying cash or other assets, or warrants that must or may require settlement by issuing a variable number of shares.

Under ASC 815, warrants are considered liabilities if contracts require or may require the issuer to net settle the contract for cash. Such derivatives are recorded as a liability at fair value until they are settled or expire, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. After all relevant assessments, the Company concludes whether the warrants are classified as liability or equity. Liability classified warrants require fair value accounting at issuance and subsequent to initial issuance with all changes in fair value after the issuance date recorded in the statements of operations. Equity classified warrants only require fair value accounting at issuance with no changes recognized subsequent to the issuance date unless the warrants are modified.

The Company determined that all of its outstanding warrants are freestanding instruments which do not meet the characteristics of a liability and therefore are classified as equity.

3.15 Loss contingencies

Loss contingencies are recognized when the Company has a present obligation that has arisen as a result of a past event and it is probable that a future outflow of resources will be required to settle the obligation, provided that a reliable estimate can be made of the amount of the obligation. Loss contingencies are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the time value of money and the risk specific to the obligation.

3.16 Financial instruments

(a) Recognition and initial measurement

Financial assets and financial liabilities, including derivatives, are recognized when the Company becomes a party to the contractual provisions of a financial instrument or non-financial derivative contract. All financial instruments are measured at fair value on initial recognition. Transaction costs that are directly attributable to the acquisition or issuance of financial assets and financial liabilities, other than financial assets and financial liabilities classified as FVTPL (as defined below), are added to or deducted from the fair value on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities classified as FVTPL are recognized immediately in the statements of operations.

(b) Classification and subsequent measurement

The Company classifies financial assets, at the time of initial recognition, according to the Company’s business model for managing the financial assets and the contractual terms of the cash flows. Financial assets are classified in the following measurement categories:

a)amortized cost (“AC”).
b)fair value through profit or loss (“FVTPL”); and
c)fair value through other comprehensive income (“FVTOCI”).

3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

3.16 Financial instruments (Continued)

(b) Classification and subsequent measurement (Continued)

Financial assets are subsequently measured at amortized cost if both of the following conditions are met and they are not designated as FVTPL: a) the financial asset is held within a business model whose objective is to hold financial assets to collect contractual cash flows; and b) the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. These assets are subsequently measured at amortized cost using the effective interest rate method, less any impairment, with gains and losses recognized in the statements of operations in the period that the asset is derecognized or impaired. All financial assets not classified at amortized cost as described above are measured at FVTPL or FVTOCI depending on the business model and cash flow characteristics. The Company has no financial assets measured at FVTOCI.

Financial liabilities are subsequently measured at amortized cost using the effective interest rate method with gains and losses recognized in the statements of operations in the period that the liability is derecognized, except for financial liabilities classified as FVTPL.

Refer to Note 17 for the classification and fair value (“FV”) level of financial instruments.

(c) Derecognition

The Company derecognizes financial assets only when the contractual rights to cash flows from the financial assets expire, or when it transfers the financial assets and substantially all of the associated risks and rewards of ownership to another entity. Gains and losses on derecognition are recognized in the statements of operations.

The Company derecognizes financial liabilities only when its obligations under the financial liabilities are discharged, cancelled, or expired. Generally, the difference between the carrying amount of the financial liability derecognized and the consideration paid and payable, including any non-cash assets transferred or liabilities assumed, is recognized in the statements of operations.

3.17 Foreign currency transactions and translations

Transactions denominated in foreign currency are translated into the functional currency of the entity using the exchange rates prevailing at the dates of the transactions or valuation where items are re-measured. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies, such as remeasurement of local currency into functional currency, are recognized in the statements of operations.

The results and financial position of an entity that has a functional currency different from the presentation currency is translated into the presentation currency as follows:

assets and liabilities for each balance sheet presented are translated at the closing rate at the date of the balance sheet; and
income and expenses for each statement of operations are translated at average exchange rates (unless this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated as the rate on the dates of the transactions).

Effect of translation differences, such as translation of foreign currency into reporting currency, are accumulated and presented as a component of equity under accumulated other comprehensive income.

3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

3.18 Taxation

The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities based on the differences between the financial statements and tax basis of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates and laws on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that the Company would be able to realize our deferred tax assets in the future more than their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.

The Company is subject to ongoing tax exposures, examinations, and assessments in various jurisdictions. Accordingly, the Company may incur additional tax expense based upon the outcomes of such matters. FASB ASC 740, Income Taxes, (“ASC 740”) prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties related to unrecognized tax benefits as of December 31, 2023 and 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals, or material deviation from its position within twelve months of the reporting date.

As the Company operates in the cannabis industry, the Company is subject to the limits of Section 280E of the United States Internal Revenue Code, as amended (“Section 280E”), under which the Company is generally only allowed to deduct expenses directly related to the cost of goods sold.

3.19 Variable Interest Entities (“VIE”)

Under certain provisions of ASC Topic 810 – Consolidations (“ASC 810”), the Company determines whether we are the primary beneficiary of a VIE. We assess whether we have the power to direct matters that most significantly impact the activities of the VIE and the obligation to absorb losses or the right to receive the benefits from the VIE that could potentially be significant to the VIE.

A VIE is a legal entity that does not have sufficient equity at risk to finance its activities without additional subordinated financial support or is structured that such equity investors lack the ability to make significant decisions relating to the entity’s operations through voting rights or do not substantively participate in the gains or losses of the entity. The primary beneficiary has both the power to direct the activities of the VIE that most significantly impact the entity’s economic performance and the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. We assess all variable interests in the entity and use our judgment when determining whether a particular entity is a VIE and if we are the primary beneficiary. Other qualitative factors that are considered include decision-making responsibilities, the VIE capital structure, risk and rewards sharing, contractual agreements with the VIE, voting rights, and level of involvement of other parties. We assess the primary beneficiary determination for a VIE on an ongoing basis if there are any reconsideration events related to a VIE. See Note 6.

Where we determine we are the primary beneficiary of a VIE, we consolidate the accounts of that VIE, under the guidance of ASC 805. The equity owned by other shareholders of the VIE is shown as noncontrolling interests in the accompanying financial statements.

3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

3.20 Significant accounting judgments and estimates

The application of the Company’s accounting policies requires management to use estimates and judgments that can have a significant effect on the revenues, expenses, assets and liabilities recognized, and disclosures made in the financial statements.

Management’s best estimates concerning the future are based on the facts and circumstances available at the time estimates are made. Management uses historical experience, general economic conditions, and assumptions regarding probable future outcomes as the basis for determining estimates. Estimates and their underlying assumptions are reviewed periodically, and the effects of any changes are recognized at that time. Actual results could differ from the estimates used.

(a)Business combinations

The following areas require management’s critical estimates and judgments:

A business combination is a transaction or event in which an acquirer obtains control of one or more businesses and is accounted for using the acquisition method. The total consideration paid for the acquisition is the aggregate of the fair values of assets acquired, liabilities assumed, and equity instruments issued in exchange for control of the acquiree at the acquisition date. The acquisition date is the date when the Company obtains control of the acquiree.

Contingent consideration is measured at its acquisition date fair value and is included as part of the consideration transferred in a business combination, subject to the applicable terms and conditions.

Contingent consideration that is classified as equity is not remeasured at subsequent reporting dates and its subsequent settlement is accounted for within equity. Contingent consideration that is classified as a liability is remeasured at subsequent reporting dates in accordance with the criteria and guidance provided under ASC 805.

Based on the facts and circumstances that existed at the acquisition date, management will perform a valuation analysis to allocate the consideration transferred based on the fair values of the identifiable assets acquired and liabilities assumed on the acquisition date. Management is required to finalize its allocation on the earlier of the date that information becomes known, but no later than one year from the acquisition date. Until such time, these values might be provisionally reported and are subject to change. During the measurement period, adjustments to provisional purchase price allocations are recognized if new information is obtained about the facts and circumstances that existed as of the acquisition date that, if known, would have resulted in the recognition of those assets and liabilities as of that date.

In determining the fair value of all identifiable assets acquired and liabilities assumed, the most significant estimates generally relate to contingent consideration and intangible assets. Management exercises judgment in estimating the probability and timing of when contingent consideration targets are expected to be achieved, which is used as the basis for estimating fair value. Identified intangible assets are recognized at fair value using appropriate valuation techniques which are generally based on a forecast of the total expected future net cash flows of the acquiree. Valuations are highly dependent on the inputs used and assumptions made by management regarding the future performance of these assets and any changes in the discount rate applied.

Judgment is applied in determining whether a transaction is a business combination or an asset acquisition by considering the nature of the assets acquired and the processes applied to those assets, or if the integrated set of assets and activities is capable of being conducted and managed for the purpose of providing a return to investors or other owners.

(b)Inventory

In calculating the value of inventory, management is required to make a number of estimates, including estimating the stage of growth of the cannabis up to the point of harvest, expected yields for the cannabis plants, harvesting costs, net realizable value, selling costs, average or expected selling prices, fair value of inventory acquired in a business combination and impairment factors. In calculating final inventory values, management compares the inventory costs to estimated net realizable value as well as investigates slow moving inventory, if applicable. The estimates are judgmental in nature and are made at a point in time, using available information, such as expected business plans and expected market conditions. Periodic reviews are performed on the inventory balance with the changes in inventory reserves reflected in cost of goods sold.

3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

3.20 Significant accounting judgments and estimates (Continued)

(c)Estimated useful lives and depreciation of PPE

Depreciation of PPE is dependent upon estimates of useful lives, which are determined through the exercise of judgments. The assessment of any impairment of these assets is dependent upon estimates of recoverable amounts that take into account factors such as economic and market conditions and the useful lives of assets.

(d)Valuation, estimated life and impairment of intangible assets

Management uses significant judgment in estimating the useful lives and impairment. Impairment tests rely on judgments and estimates related to growth rates, discount rates, and estimated margins.

(e)Goodwill impairment

Goodwill is tested for impairment annually on December 31st of each fiscal year and whenever events or changes in circumstances indicate that the carrying amount of goodwill may have been impaired. In order to determine that the value of goodwill may have been impaired, the Company may perform a qualitative assessment to determine if it was more-likely-than-not that the reporting unit’s carrying value is less than the fair value, indicating the potential for goodwill impairment. Several factors, including historical results, business plans, forecasts, and market data are used to determine the fair value of the reporting unit. Changes in the conditions for these judgments and estimates can significantly affect the assessed value of goodwill.

(f)Leases

Each lease is evaluated to determine if the Company would exercise any of the renewal options offered. Several material factors are considered in determining if the renewal options would be exercised, such as length of the renewal, renewal rate, and ability to transfer locations. When measuring lease liabilities, the Company used discounted lease payments using a weighted-average rate in the range of 7.8% to 15.5% per annum. The weighted-average rate is based on the Company’s incremental borrowing rate, which relies on judgments and estimates.

(g)Provisions and contingent liabilities

When the Company is probable to incur an outflow of resources to settle an obligation and the amount can be reasonably estimated, a contingent liability is recorded. The contingent liability is recorded at management’s best estimates of the expenditure required to settle the obligation at period end, discounted to the present value, if material.

(h)Financial instruments

To determine the fair value of financial instruments, the Company develops assumptions and selects certain methods to perform the fair value calculations. Various methods considered include but are not limited to: (a) assigning the value attributed to the transaction at the time of origination; (b) re-measuring the instrument if it requires concurrent fair value measurement; and (c) valuing the instrument at the issuance value less any amortized costs. As judgment is a factor in determining the value and selecting a method, as well as the inherent uncertainty in estimating the fair value, the valuation estimates may be different.

Application of the option pricing model requires estimates in expected dividend yields, expected volatility in the underlying assets, and the expected life of the financial instruments. These estimates may ultimately be different from amounts subsequently realized, resulting in an overstatement or understatement of net loss.

3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

3.21 Liquidity and management plan

As reflected in the consolidated financial statements, the Company had negative working capital of $7,258 as of December 31, 2023 and has incurred net losses from continuing operations for the years ended December 31, 2023 and 2022. The Company’s approach to managing its liquidity risk is to seek to ensure that it will have sufficient liquidity to meet its liabilities as they come due. The Company’s short-term liquidity requirements consist primarily of funds necessary to maintain operations, repay borrowings and other general business needs. The Company plans to use existing funds, as well as funds from the future sale of products, to fund short-term working capital needs for at least the next 12 months from the issuance of the consolidated financial statements.

In addition, the Company continues to take actions designed to improve the Company’s operations and cash position, including but not limited to: (i) targeting continued growth of sales from our consolidated operations; (ii) continued cost-savings and efficiency optimization efforts; (iii) utilizing the future proceeds from an employee retention credit up to $12,354 of which $5,238 was included in current receivables; (iv) addressing our debt maturity profile, in this regard, subsequent to December 31, 2023 the Company completed the debt restructuring transaction contemplated in its October 31, 2023 Support Agreement (the “Support Agreement”) with the holders of approximately 99% (collectively, the “Majority Noteholders”) of the aggregate outstanding principal amount of the Company’s 12.5% senior notes due December 2024 (the “Senior Notes”), which resulted in the effective extension via exchange of the maturity date for an additional two years, see Note 19, and the crystallization of the previously-announced deferral of certain current debts payable; (v) managing the timing and amount of certain expenses as well as capital expenditures; and (vi) seeking to take advantage of future potential financing (equity and/or debt) opportunities, including additional gross cash proceeds of $40,000 received February 2024 related to the issuance of new debt securities (refer to Note 19 for additional information). The debt extension related to the Support Agreement and the deferral of certain current debts payable are each classified as a non-current liability on the balance sheet as of December 31, 2023. While the contemplated debt restructuring transactions have been completed, management cannot provide any assurances that the Company will continue to be successful in accomplishing its business plans; if it is not, the Company may be forced to take other steps, including among others decelerating its growth or curtailing certain of its operations pending obtaining additional capital.

3.22 Discontinued operations

Strategic changes in the Company’s operations can be considered a discontinued operation if both the operations and cash flows of the discontinued business have been (or will be) eliminated from the ongoing operations of the Company and the Company will not have any significant continuing involvement in the operations of the discontinued business after the disposal transaction. Under ASC Subtopic 205-20, “Presentation of Financial Statements – Discontinued Operations” (“ASC Subtopic 205-20”), a component of an entity that is classified as discontinued operations is presented separately from continuing operations in the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows for all periods presented. All assets and liabilities related to such discontinued operations are classified as held for sale and presented separately in the Consolidated Balance Sheets for all periods prior to the disposal by sale. Accordingly, the presentation of prior period balances may not agree to previously issued financial statements. See Note 4 for additional information regarding the results of operations and major classes of assets and liabilities of discontinued operations.

3.23 Change in accounting standards

The Company is treated as an “emerging growth company” as defined under the Jumpstart Our Business Start-ups Act of 2012, as amended (the “JOBS Act”). Under the JOBS Act, emerging growth companies may delay adopting new or revised accounting standards until the standards apply to private companies, however, emerging growth companies are not precluded from early adopting new accounting standards that allow so.

3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

3.23 Change in accounting standards (Continued)

Recently Issued and Adopted Accounting Standards

In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-13 Topic 326 – Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments, which was subsequently revised by ASU 2018-19, ASU 2019-04, ASU 2019-05, ASU 2019-11, ASU 2020-02, ASU 2020-03, and ASU 2022-02 (“ASU 2016-13”), which introduces a new model for assessing impairment on most financial assets. Entities will be required to use a forward-looking expected loss model, which will replace the current incurred loss model, which will result in earlier recognition of allowance for losses. ASU 2016-13 was effective for the Company’s fiscal year beginning after December 15, 2022, and interim periods therein. For accounts receivable only, the Company applies the simplified approach as permitted by ASU 2016-13. The simplified approach to the recognition of expected losses does not require the Company to track the changes in credit risk; rather, the Company recognizes a loss allowance based on lifetime expected credit losses at each reporting date from the date of the trade receivable. Expected credit losses are measured as the difference in the present value of the contractual cash flows that are due to the Company under the contract, and the cash flows that the Company expects to receive.

The Company assesses all information available, including past due status, credit ratings, the existence of third-party insurance, and forward-looking macro-economic factors in the measurement of the expected credit losses associated with its assets carried at amortized cost. The Company measures expected credit loss by considering the risk of default over the contract period and incorporates forward-looking information into its measurement. The adoption of ASU 2016-13 did not have a material impact on the Company’s financial statements and there was no cumulative effect at the adoption of the standard.

In June 2022, the FASB issued ASU No. 2022-03 Topic 820 – Fair Value Measurement – Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”), (1) to clarify the guidance in Topic 820, Fair Value Measurement, when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, (2) to amend a related illustrative example, and (3) to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. ASU 2022-03 is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years, early adoption is permitted. The Company is currently evaluating the impact the adoption of ASU 2022-03 may have on the Company’s financial statements.

In September 2022, the FASB issued ASU No. 2022-04 Topic 405 – Liabilities – Supplier Finance Programs (“ASU 2022-04”), which is intended to enhance transparency with supplier finance programs. ASU 2022-04 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Adoption is applied on a retrospective approach. The adoption of this ASU did not have a material impact on the Company’s financial statements.

On March 27, 2023, the FASB issued ASU No. 2023-01 Topic 842 – Leases – Common Control Arrangements (“ASU 2023-01”), in response to private company stakeholder concerns about applying Topic 842 to related party arrangements between entities under common control. ASU 2023-01 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, early adoption is permitted. The Company is currently evaluating the impact the adoption of ASU 2023-01 may have on the Company’s financial statements.

3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

3.23 Change in accounting standards (Continued)

Recently Issued and Adopted Accounting Standards (Continued)

In November 2023, the FASB issued ASU No. 2023-07 Topic 280 – Segment Reporting (“ASU 2023-07”) to improve the disclosures about a public entity’s reportable segments and address requests from investors for additional, more detailed information about a reportable segment’s expenses. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, early adoption is permitted. The Company is currently evaluating the impact the adoption of ASU 2023-07 may have on the Company’s financial statements.

On December 14, 2023, the FASB issued ASU No. 2023-09 Topic 740 – Income Taxes (“ASU 2023-09”) to enhance the transparency and decision usefulness of income tax disclosures. The amendments in this Update address investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, including interim periods within those fiscal years, early adoption is permitted. The Company is currently evaluating the impact the adoption of ASU 2023-09 may have on the Company’s financial statements.

XML 28 R11.htm IDEA: XBRL DOCUMENT v3.24.0.1
DISCONTINUED OPERATIONS
12 Months Ended
Dec. 31, 2023
DISCONTINUED OPERATIONS  
DISCONTINUED OPERATIONS

4.    DISCONTINUED OPERATIONS

On March 27, 2023, the Company closed the sale of Blue Camo, LLC (“Blue Camo”) which comprised the Company’s Arizona business and included two licensed entities operating three Oasis-branded dispensaries in the greater Phoenix area, a cultivation and processing facility in Chandler, a cultivation facility in Phoenix, and the Company’s majority interest in Willcox OC, LLC, a joint venture developing an outdoor cultivation facility. Total consideration consisted of $20,000 in cash before working capital adjustments and the assumption of lease obligations eliminating approximately $16,734 in long-term lease liabilities. In a separate agreement, all debt outstanding and potential earn-out contingent consideration, related to the 2021 acquisition of Blue Camo, was eliminated, reducing the Company’s long-term debt by $22,505, along with accrued interest thereon of approximately $1,165 and potential earn-out contingent consideration to $nil.

The Company accounted for this sale as a disposal under ASC Subtopic 360-10, “Impairment or Disposal of Long-Lived Assets”. The Company has reclassified the operations of Arizona as discontinued operations for all periods presented prior to the sale as the disposal represents a strategic shift that will have a major effect on the Company’s operations and financial results. The Company determined the business to be held for sale as the criteria established under ASC 205-20-45-1E had been satisfied due to the sale occurring during the first quarter of 2023. As of December 31, 2022, the Company determined under ASC 855-10-55, the Arizona business did not meet the criteria as held for sale, as such, no reclassification was made on the balance sheet and statement of operations in the Company’s Annual Report on the Form 40-F for the year ended December 31, 2022. In accordance with ASC 205-20-50-1(a) the Company has retrospectively reflected the reclassification of assets and liabilities of these entities as held for sale on the balance sheet as of December 31, 2022 and the operations as discontinued operations on the statement of operations for the period January 1, 2022 through December 31, 2022 and excluded from the accompanying notes.

4.    DISCONTINUED OPERATIONS (Continued)

As of December 31, 2022, the major classes of assets and liabilities held for sale in Arizona included the following:

    

As of

December 31, 2022

Current assets held-for-sale

Inventory and other current assets

$

20,910

Property, plant, and equipment, net

 

24,239

Intangible assets, net

 

194,018

Right-of-use assets, net

 

17,568

Deferred tax asset, net

 

3,890

Total assets held-for-sale

$

260,625

Current liabilities held-for-sale

 

  

Trade payables and other current liabilities

$

2,629

Lease liabilities

 

18,097

Debt payable

 

22,505

Accrued interest payable

 

610

Total liabilities held-for-sale

$

43,841

The following table details the components comprising net loss from our discontinued operations:

Year Ended

December 31, 2023

December 31, 2022

Revenues from discontinued operations, net of discounts

    

$

10,260

    

$

44,183

Cost of goods sold

 

9,074

 

28,705

Gross profit

 

1,186

 

15,478

Operating expenses from discontinued operations:

Selling, general, and administrative

 

2,115

 

40,153

Depreciation and amortization

 

2,675

 

11,055

Total operating expenses from discontinued operations

 

4,790

 

51,208

Loss from operations

 

(3,604)

 

(35,730)

Other expense

Interest Expense

 

(580)

 

(2,250)

Income taxes

 

 

Current tax provision

(575)

(628)

Deferred tax benefit

870

Total income taxes

295

(628)

 

  

 

  

Loss from discontinued operations

 

 

Loss from discontinued operations, net of taxes

 

(3,889)

 

(38,608)

Loss on disposal of discontinued operations

(182,464)

Loss from discontinued operations

$

(186,353)

$

(38,608)

The loss on disposal of discontinued operations of $182,464 was derived from the gross proceeds of $49,336, made up of $20,000 of cash consideration and a $5,666 working capital adjustment and the elimination of $23,670 of debt outstanding from the sale of Arizona, less the carrying value of Arizona of approximately $231,800. As of December 31, 2023, the Company finalized the settlement of the working capital adjustment, receiving $1,583 in cash proceeds and $4,083 in consideration other than cash.

XML 29 R12.htm IDEA: XBRL DOCUMENT v3.24.0.1
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS
12 Months Ended
Dec. 31, 2023
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS  
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS

5.    BUSINESS COMBINATIONS AND ASSET ACQUISITIONS

Transactions accounted for as business combinations have been accounted for under the acquisition method in accordance with ASC 805, with the results included in the Company’s results from operations from the date of acquisition. The fair value of considerations transferred have been allocated to the assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition.

In determining the fair value of all identifiable assets, liabilities and contingent liabilities acquired, the most significant estimates relate to contingent consideration and intangible assets. Management exercised judgement in estimating the probability and timing of when earnouts are expected to be achieved which is used as the basis for estimating fair value.

For the intangible assets identified, depending on the type of intangible asset and the complexity of determining its fair value, an independent valuation expert or management may develop the fair value, using appropriate valuation techniques, which are generally based on a forecast of the total expected future net cash flows and take into consideration other significant assumptions such as the expected use, the infancy of the cannabis industry and industry comparatives, federal and state regulations, market uncertainty and the estimated lives of any long-lived facilities and assets that the intangibles may relate to.

Cannabis licenses are the primary intangible asset acquired in business combinations as they provide the Company the ability to operate in each market. However, some cannabis licenses are subject to renewal and therefore there is some risk of non-renewal for several reasons, including operational, regulatory, legal, or economic factors. To appropriately consider the risk of non-renewal, the Company applies probability weighting to the expected future net cash flows in calculating the fair value of these intangible assets. The key assumptions used in these cash flow projections include discount rates and terminal growth rates. Of the key assumptions used, the impact of the estimated fair value of the intangible assets has the greatest sensitivity to the estimated discount rate used in the valuation. The terminal growth rate represents the rate at which these businesses will continue to grow into perpetuity. Other significant assumptions include revenue, gross profit, operating expenses and anticipated capital expenditures which are based upon the acquiree’s historical operations along with management projections. The evaluations are linked closely to the assumptions made by management regarding the future performance of these assets and any changes in the discount rate applied.

Each of the acquisitions are subject to specific terms relating to the satisfaction of the purchase price by the Company and its wholly owned subsidiaries, and incorporates payments in cash, shares, and debt as well as certain contingent considerations. The shares issued as consideration are either Equity Shares or non-voting exchangeable shares of the Company’s subsidiaries (“Exchangeable Shares”) that are exchangeable on a one-for-one basis into an equal number of Equity Shares of the Company. The Company treats the Exchangeable Shares as options with a value equal to a share of Equity Shares, which represents the holder’s claim on the equity of the Company. The Company has presented these Exchangeable Shares as a part of shareholders’ equity within these financial statements due to the fact that (i) they are economically equivalent to the Company’s publicly traded Equity Shares and (ii) the holders of the Exchangeable Shares are subject to restrictions on transfer under United States securities laws but may dispose of the Exchangeable Shares by exchanging them for Equity Shares of the Company which can then be sold through the CSE. Changes in these assumptions would affect the presentation of the Exchangeable Shares from shareholders’ equity to noncontrolling interests; however, there would be no impact on loss per share.

The goodwill recognized on each acquisition is attributable mainly to the expected future growth potential and expanded customer base arising as a result of the completion of the respective acquisition. Goodwill has been allocated to the reporting units corresponding to the states of the acquired businesses. None of the goodwill is expected to be deductible for income tax purposes. For further analysis on goodwill relating to business combinations, see Note 9.

5.    BUSINESS COMBINATIONS AND ASSET ACQUISITIONS (Continued)

2023 Fourth Quarter Acquisition

Asset acquisition

On November 2, 2023, the Company completed its acquisitions in Land of Lincoln Dispensary LLC (“Land of Lincoln”) through a membership interest purchase agreement. As part of the purchase accounting for this acquisition, the Company recorded intangible assets of $200, which was associated with two conditional adult use dispensary licenses that allow for the retail sales of cannabis. The amortization period for the licenses was determined to be 15 years, which reasonably reflects the useful lives of the assets.

The Land of Lincoln acquisition did not meet the definition of a business according to ASC 805 and as such, it was recorded as an asset acquisition. Purchase consideration for the acquisition was $200, paid in cash, all of which was allocated to intangible assets - licenses.

2022 Second Quarter Acquisition

Herbal Remedies Business Combination

Business Combination

On May 25, 2022, the Company completed its acquisition of Herbal Remedies Dispensaries, LLC (“Herbal Remedies”) through a membership interest purchase agreement.

The fair value of identifiable assets acquired, and liabilities assumed as of the acquisition date are as follows:

    

Herbal Remedies

ASSETS ACQUIRED

 

  

Cash

$

637

Inventory

 

1,480

Prepaid expenses and other assets

 

256

Intangible assets - licenses/permits

 

15,700

Property, plant, and equipment

 

122

Right-of-use assets - operating

 

700

Total assets acquired at fair value

 

18,895

LIABILITIES ASSUMED

 

  

Trade payables

 

215

Accrued liabilities

 

68

Lease liabilities - operating

 

700

Total liabilities assumed at fair value

 

983

Goodwill

 

1,180

Consideration transferred

$

19,092

As part of the purchase accounting for the above acquisition, the Company recorded intangible assets of $15,700, all of which were associated with licenses that allow for the retail sales of cannabis. The amortization period for licenses was determined to be 15 years, which reasonably reflects the useful lives of the assets.

Herbal Remedies is an operator of two medical and adult-use licensed retail dispensaries in Quincy, Illinois. This acquisition expands the Company’s operational footprint with the addition of the state of Illinois.

5.    BUSINESS COMBINATIONS AND ASSET ACQUISITIONS (Continued)

Purchase consideration was comprised of the following:

    

  

    

Shares

    

Fair Value

Cash

 

i

 

$

3,002

Debt Payable

 

ii

 

 

14,220

Shares Issued

 

iii

 

353

 

1,870

Total

 

  

 

353

$

19,092

Pursuant to the terms of the definitive agreement with Herbal Remedies, Ayr satisfied the purchase price of $19,092 for Herbal Remedies through the following:

i.$3,002 of the Herbal Remedies purchase price in the form of cash consideration and settlement of the final working capital which is deemed immaterial;
ii.$14,220 of the Herbal Remedies purchase price in the form of a promissory note payable; and
iii.$1,870 of the Herbal Remedies purchase price in the form of 353 Exchangeable Shares, these shares have contractual restrictions on their ability to be sold for six to twelve months (the “Herbal Remedies Lock-Up Provision”). The fair value of the shares was determined by the share price on the CSE at the date of acquisition and a 16.55% discount rate attributed to the contractual restrictions.

2022 First Quarter Acquisition

Cultivauna Business Combination

Business Combination

On February 15, 2022, the Company completed its acquisition of Cultivauna, LLC (“Cultivauna”) through a membership interest purchase agreement. Cultivauna has a production license in the state of Massachusetts and sells cannabis infused branded seltzers and water-soluble tinctures.

5.    BUSINESS COMBINATIONS AND ASSET ACQUISITIONS (Continued)

The fair value of identifiable assets acquired and liabilities assumed as of the acquisition date are as follows:

Cultivauna

ASSETS ACQUIRED

Cash

$

1,251

Accounts receivable

471

Inventory

1,206

Prepaid expenses and other assets

38

Intangible assets - trade name/brand

3,400

Intangible assets - host community agreements

2,100

Property, plant, and equipment

2,202

Right-of-use assets - operating

315

Total assets acquired at fair value

10,983

LIABILITIES ASSUMED

Trade payables

23

Accrued liabilities

305

Lease liabilities - operating

315

Total liabilities assumed at fair value

643

Goodwill

11,281

Consideration transferred

$

21,621

As part of the purchase accounting for the above acquisition, the Company recorded intangible assets of $5,500, which were associated with a trade name/brand and host community agreement that allow for the processing, production, and retail sales of cannabis. The amortization period for the trade name/brand and host community agreement was determined to be 5 and 15 years, respectively, which reasonably reflects the useful lives of the assets.

Purchase consideration was comprised of the following:

    

  

    

Shares

    

Fair Value

Cash

 

i

 

$

11,027

Shares Issued

 

ii

 

329

4,482

Contingent Consideration

 

iii

 

6,112

Total

 

  

 

329

$

21,621

5.    BUSINESS COMBINATIONS AND ASSET ACQUISITIONS (Continued)

Purchase consideration was comprised of the following:

Pursuant to the terms of the definitive agreement with Cultivauna Ayr satisfied the purchase price of $21,621 for Cultivauna through the following:

i.

$11,027 of the Cultivauna purchase price in the form of cash consideration and settlement of the final working capital which is deemed immaterial;

ii.

$4,482 of the Cultivauna purchase price in the form of 329 Exchangeable Shares, these shares have contractual restrictions on their ability to be sold for six to twelve months (the “Cultivauna Lock-Up Provision”). The fair value of the shares was determined by the share price on the CSE at the date of acquisition and a 14.85% discount rate attributed to the contractual restrictions; and

iii.

A portion of the Cultivauna purchase price is derived from an earn-out provision through December 31, 2023 based on annualized net revenues generated during the measurement period, consisting of Exchangeable Shares, valued through a Monte-Carlo simulation, which may entitle the sellers to earn additional consideration if certain milestones are achieved.

XML 30 R13.htm IDEA: XBRL DOCUMENT v3.24.0.1
VARIABLE INTEREST ENTITIES ("VIE")
12 Months Ended
Dec. 31, 2023
VARIABLE INTEREST ENTITIES ("VIE")  
VARIABLE INTEREST ENTITIES ("VIE")

6.    VARIABLE INTEREST ENTITIES (“VIE”)

In February 2022, the Company had the ability to direct the activities of two entities, Tahoe Hydroponics Company, LLC (“Tahoe Hydro”) and NV Green, Inc. (“NVG” and, together with Tahoe Hydro, “TH”/ “NVG”), through a management services and equity purchase agreement, thereby classifying the entities as VIEs, until certain conditions are met, at which time the Company is required to evaluate business combination accounting. The assets of TH/NVG can only be used to settle its liabilities and under the applicable agreements, TH/NVG retains ultimate legal responsibilities for its operations.

In May 2023, the Company finalized the acquisition of Tahoe Hydro and assumed 100% of the membership interest. Based on the changes in circumstances, the Company re-evaluated the status of Tahoe Hydro as a variable interest entity, concluding that the Company had acquired a controlling interest in Tahoe Hydro. Purchase consideration for the acquisition included $1,382 in cash, net of transaction expenses, promissory note of $1,580, the conversion of a convertible note of $2,800, and $115 in the form of 233 Exchangeable Shares. These shares have contractual restrictions on their ability to be sold for six to twelve months. The fair value of the shares was determined by the share price on the CSE at the date of acquisition and a 19.45% discount rate attributed to the contractual restrictions. NVG remains a VIE until certain conditions are met, at which time the Company is required to evaluate business combination accounting.

On March 30, 2021, the Company completed its acquisition of Greenlight Management, LLC (“Greenlight Management”) and Greenlight Holdings, LLC (“Greenlight Holdings”) through a membership purchase agreement. Greenlight Management operates on a 58,000 square foot facility in Parma, Ohio under a management agreement with Parma Wellness Center, LLC (“Parma”) a recipient of a Tier 1 Cultivator Provisional License in the medical cannabis market in Ohio. The Company determined that it possesses the power to direct activities of Parma through the management agreement, thereby classifying the entity as a VIE. During the year ended December 31, 2023 the Company purchased the minority interest in Parma for $25. Based on the changes in circumstances, the Company re-evaluated the variable interest entity, concluding that it did not own a controlling interest, thereby classifying the entity as VIE.

During 2023, the Company entered into an option and support service agreement with Daily Releaf, LLC, Heaven Wellness, LLC and Twice the Wellness, LLC, (collectively “Ohio Dispensaries”), each is licensed to operate a medical marijuana dispensary in Ohio. The option agreement provides the Company with the future ability to acquire 100% of the equity interests in dispensaries.

6.    VARIABLE INTEREST ENTITIES (“VIE”) (Continued)

The following tables present the summarized financial information about the Company’s consolidated VIEs which are included in the balance sheets as of December 31, 2023 and 2022 and statements of operations for years ended December 31, 2023 and 2022. All these entities were determined to be VIEs as the Company possesses the power to direct activities and obligation to absorb losses through management services agreements.

As of

As of

December 31, 2023

December 31, 2022

Ohio

    

NVG

    

Parma

    

Dispensaries

    

Total

    

TH/NVG

    

Parma

    

Total

Current assets

(351)

$

10,616

(2,257)

8,008

$

5,248

$

10,751

15,999

Non-current assets

 

1,077

 

13,210

 

6,441

20,728

 

6,582

 

14,634

 

21,216

Total assets

$

726

$

23,826

$

4,184

$

28,736

$

11,830

$

25,385

$

37,215

Current liabilities

$

604

$

18,962

$

1,647

$

21,213

$

1,033

$

14,092

$

15,125

Non-current liabilities

 

383

 

1,280

 

3,369

 

5,032

 

898

 

1,952

 

2,850

Total liabilities

 

987

 

20,242

 

5,016

 

26,245

 

1,931

 

16,044

 

17,975

Noncontrolling interest

 

796

 

(10,158)

 

(1,764)

 

(11,126)

 

7,528

 

(5,528)

 

2,000

Equity (deficit) attributable to Ayr Wellness Inc.

 

(1,057)

 

13,742

 

932

 

13,617

 

2,371

 

14,869

 

17,240

Total liabilities and equity

$

726

$

23,826

$

4,184

$

28,736

$

11,830

$

25,385

$

37,215

Year Ended

Year Ended

December 31, 2023

December 31, 2022

Ohio

    

TH/NVG

    

Parma

    

Dispensaries

    

Total

    

TH/NVG

    

Parma

    

Total

Revenues, net of discounts

$

$

3,170

$

462

$

3,632

$

1,851

$

$

1,851

Net loss attributable to noncontrolling interest

 

(673)

 

(4,630)

 

(1,764)

 

(7,067)

 

(4,491)

 

(5,528)

 

(10,019)

Net loss attributable to Ayr Wellness Inc.

 

 

(1,275)

 

 

(1,275)

 

 

 

Net loss

$

(673)

$

(5,905)

$

(1,764)

$

(8,342)

$

(4,491)

$

(5,528)

$

(10,019)

Ohio

    

TH/NVG

    

Parma

    

Dispensaries

    

Total

Noncontrolling interest at January 1, 2022

$

$

$

$

Total purchase consideration

16,868

16,868

Working capital adjustment presented as consideration payable

(4,849)

(4,849)

Net loss during the period

(4,491)

(5,528)

(10,019)

Noncontrolling interest at December 31, 2022

$

7,528

$

(5,528)

$

2,000

Acquisition of Tahoe Hydro

(6,059)

(6,059)

Net loss during the period

(673)

(4,630)

(1,764)

(7,067)

Noncontrolling interest at December 31, 2023

$

796

$

(10,158)

$

(1,764)

$

(11,126)

XML 31 R14.htm IDEA: XBRL DOCUMENT v3.24.0.1
INVENTORY
12 Months Ended
Dec. 31, 2023
INVENTORY  
INVENTORY

7.    INVENTORY

The Company’s inventory includes the following:

    

December 31, 

    

December 31, 

2023

2022

Materials, supplies, and packaging

$

7,505

$

9,770

Work in process

69,632

65,807

Finished goods

 

29,226

 

24,233

Total inventory

$

106,363

$

99,810

The amount of inventory included in cost of goods sold during the years ended December 31, 2023 and 2022, was $218,587 and $205,809, respectively. The Company reviews inventory on hand for estimated obsolescence or unmarketable items, as compared to future demand requirements and the shelf life of the various products. Based on the review, the Company records inventory write-downs, when necessary, when costs exceed expected net realizable value.

For the years ended December 31, 2023 and 2022, $nil and $6,217 respectively, of expenses relating to the incremental costs to acquire cannabis inventory in business combinations are recognized in cost of goods sold on the statements of operations. This relates to the one-time adjustment of cannabis inventory from acquiree historical cost to fair value as part of the purchase price allocation.

XML 32 R15.htm IDEA: XBRL DOCUMENT v3.24.0.1
PROPERTY, PLANT, AND EQUIPMENT
12 Months Ended
Dec. 31, 2022
PROPERTY, PLANT, AND EQUIPMENT  
PROPERTY, PLANT, AND EQUIPMENT

8.    PROPERTY, PLANT, AND EQUIPMENT

As of December 31, 2023 and 2022, property, plant, and equipment, net consisted of the following:

December 31, 

December 31, 

    

2023

    

2022

Furniture and equipment

$

52,793

 

$

53,070

Auto and trucks

1,393

 

1,626

Buildings

94,914

91,233

Leasehold improvements

173,043

154,774

Land

13,877

13,879

Construction in progress

12,571

9,581

Total

348,591

324,163

Less: Accumulated depreciation and amortization

37,976

21,483

Total property, plant and equipment, net

$

310,615

 

$

302,680

Capitalized interest for the years ended December 31, 2023 and 2022, totaled $9,981 and $14,490, respectively. Depreciation and amortization expense for the years ended December 31, 2023 and 2022, totaled $25,226 and $14,257, respectively, of which $15,846 and $9,858 respectively, is included in cost of goods sold.

As of December 31, 2023, the Company concluded that the carrying amount of certain long-lived assets exceeded the fair value and recorded an impairment loss on PPE assets of $4,858.

XML 33 R16.htm IDEA: XBRL DOCUMENT v3.24.0.1
GOODWILL AND INTANGIBLE ASSETS
12 Months Ended
Dec. 31, 2022
GOODWILL AND INTANGIBLE ASSETS  
GOODWILL AND INTANGIBLE ASSETS

9.    GOODWILL AND INTANGIBLE ASSETS

Goodwill

As of December 31, 2023 and 2022, the Company’s goodwill is as follows:

As of January 1, 2022

    

$

199,329

Acquired through business combinations and initial consolidation of VIEs

12,729

Impairment of goodwill

(117,950)

As of December 31, 2022

94,108

(no activity)

As of December 31, 2023

$

94,108

Intangible Assets

During the year ended December 31, 2023 an entity co-owned by the Company was awarded a provisional Disproportionately Impacted Area cultivator license in Connecticut. The Company recorded an intangible asset of $3,000 in connection with the cash payment for the cost of the provisional license. During the year ended December 31, 2023 the Company acquired a standalone delivery license in Connecticut and recorded an intangible asset of $200 in connection with the cash payment for the cost of the license. The operations in Connecticut are not currently active, as such, no amortization expense has been recorded as of the year ended December 31, 2023.

Amortization expense is recorded within cost of goods sold and total operating expenses. The amount in cost of goods sold for the years ended December 31, 2023 and 2022 was $16,825 and $15,907, respectively.

The following table represents intangible assets, net of accumulated amortization:

    

    

December 31, 2023

    

December 31, 2022

Amortization period (# of years)

Licenses/permits

15

$

641,036

$

693,714

Right-to-use licenses

 

15

 

16,407

 

17,717

Host community agreements

 

15

 

26,954

 

29,494

Trade name / brand

 

5

 

3,591

 

3,784

Total

$

687,988

$

744,709

The following table presents the future amortization expense as of December 31, 2023:

    

Amortization Expense

2024

$

58,123

2025

57,308

2026

57,308

2027

57,308

2028

57,308

2029 and beyond

397,433

Total

$

684,788

9.    GOODWILL AND INTANGIBLE ASSETS (Continued)

Intangible Assets (Continued)

Impairment of goodwill

As part of the annual impairment test as of December 31, 2023 and 2022 a one-step quantitative impairment test was performed over all its reporting units, which includes goodwill acquired through various acquisitions and the initial consolidation of VIEs. The following significant assumptions were applied in the determination of the fair value of each reporting unit using a discounted cash flow model:

Cash flows: estimated cash flows were projected based on actual operating results from internal sources, as well as industry and market trends. The forecasts were extended to a total of five years (with a terminal value thereafter);
Terminal value growth rate: The terminal growth rate of 3% was based on historical and projected consumer price inflation, historical and projected economic indicators and projected industry growth;
Post-tax discount rate: the post-tax discount rate of 20% and 18%, respectively, is reflective of the weighted average cost of capital (“WACC”). The WACC was estimated based on the risk-free rate, equity risk premium, beta premium, and after-tax cost of debt based on corporate bond yields; and
Tax rate: the tax rates used in determining future cash flows were those substantively enacted at the respective valuation date.

The Company compared the fair value of each reporting unit to its carrying value to determine whether the carrying value exceeded fair value. Due to changes in market expectations as a result of increased competition and price compression at the reporting units, the Company recorded impairment of goodwill of $117,950 for the year ended December 31, 2022 reducing the carrying value of goodwill acquired across all reporting units. The remaining goodwill of $94,108 relates to the Company’s Florida reporting unit.

Long-lived assets

The Company evaluates the recoverability of other long-lived assets, including property, plant and equipment, and certain identifiable intangible assets, whenever events or changes in circumstances indicate that the carrying value of an asset or asset group may not be recoverable. The Company performs impairment tests of indefinite-lived intangible assets on an annual basis or more frequently in certain circumstances. Factors which could trigger an impairment review include significant underperformance relative to historical or projected future operating results, significant changes in the manner of use of the assets or the strategy for the overall business, a significant decrease in the market value of the assets or significant negative industry or economic trends. When the Company determines that the carrying value of long-lived assets may not be recoverable based upon the existence of one or more of the indicators, the assets are assessed for impairment based on the estimated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the carrying value of an asset exceeds its estimated future undiscounted cash flows, an impairment loss is recorded for the excess of the asset’s carrying value over its fair value.

No such impairment charges were recorded for finite-lived intangible assets during the years ended December 31, 2023 or 2022.

XML 34 R17.htm IDEA: XBRL DOCUMENT v3.24.0.1
RIGHT-OF-USE ASSETS AND LEASE LIABILITIES
12 Months Ended
Dec. 31, 2022
RIGHT-OF-USE ASSETS AND LEASE LIABILITIES  
RIGHT-OF-USE ASSETS AND LEASE LIABILITIES

10.    RIGHT-OF-USE ASSETS AND LEASE LIABILITIES

Information related to operating and finance leases is as follows:

December 31, 2023

December 31, 2022

 

    

Operating Leases

    

Finance Leases

    

Operating Leases

    

Finance Leases

 

Incremental borrowing rate (weighted average)

 

11.83

%  

10.37

%  

11.98

%  

9.68

%

Weighted average remaining lease term

 

12.12

yrs

4.76

yrs

13.04

yrs

4.90

yrs

The maturities of the contractual lease liabilities as of December 31, 2023 are as follows:

    

Operating Leases

    

Finance Leases

    

Total

2024

    

$

29,457

$

12,098

$

41,555

2025

 

29,112

6,428

35,540

2026

 

28,381

4,412

32,793

2027

 

27,125

3,340

30,465

2028

 

26,507

2,501

29,008

2029 and beyond

198,164

6,428

204,592

Total undiscounted lease liabilities

 

338,746

35,207

373,953

Impact of discounting

(203,231)

(7,411)

(210,642)

Total present value of minimum lease payments

$

135,515

$

27,796

$

163,311

In June 2022, the Company completed a sale and lease back transaction to sell two cultivation and processing facilities for a purchase price of $28,107, excluding transaction costs. The Company leased back the facilities and continues to operate and manage them under a long-term agreement. The transaction qualified for sale-leaseback treatment under ASC 842. As a result of the sale, the Company divested of $22,206 of buildings and improvements, and $3,728 of land. The Company recognized a gain on sale related to the transaction of $2,173 which was recorded within gain on sale of assets on the statements of operations. The lease was recorded as an operating lease and resulted in a lease liability of $25,331 and an ROU asset of $25,339, which was recorded net of a $750 work allowance.

In June 2022, the Company closed on a real estate financing transaction resulting in $27,599 of cash proceeds for the sale and simultaneous leaseback of a cultivation facility. The transaction includes a construction financing allowance of up to $14,187, which will increase the base rent at the time the construction financing is drawn down. The initial term of the agreement is fifteen years, with two five-year options to renew. The initial payments are equal to 10% of the sum of the purchase price and increases when a draw is made on the construction finance allowance, payable monthly. In addition, a 3% increase in payments will be applied annually after the first year. As of December 31, 2023 and 2022, this represents a balance of $38,205 and $36,181, respectively, as part of construction finance liabilities on the balance sheet.

The transaction was classified as a finance lease and control was never transferred to the buyer-lessor; accordingly the transaction did not qualify for sale-leaseback treatment. Therefore, the Company is deemed to own this real estate and will continue to depreciate the assets and reflect the properties on the Company’s balance sheet. The Company recorded a financing obligation for the consideration received from the buyer-lessor, and future cash lease payments will be allocated between interest expense and reduction to the financing obligation, as applicable. As the transactions did not qualify for sale-leaseback treatment, under ASC 842, Leases, no gain or loss was recognized.

10.    RIGHT-OF-USE ASSETS AND LEASE LIABILITIES (Continued)

Payments related to leases during the years ended December 31, 2023 and 2022, are as follows:

Year Ended

    

December 31, 2023

    

December 31, 2022

Lease liabilities - operating

Lease liabilities - operating expense, COGS

$

8,783

$

6,604

Lease liabilities - operating expense, G&A

 

16,366

 

13,943

Lease liabilities - finance

 

 

Amortization of right-of-use assets, COGS

 

6,913

 

4,584

Amortization of right-of-use assets, G&A

 

165

 

187

Interest on lease liabilities - finance, COGS

 

3,017

 

2,422

Interest on lease liabilities - finance, G&A

 

37

 

58

Total lease expense

$

35,281

$

27,798

As of December 31, 2023, the Company concluded that the carrying amount of certain long-lived assets exceeded the fair value and recorded an impairment loss on ROU operating assets of $1,462.

XML 35 R18.htm IDEA: XBRL DOCUMENT v3.24.0.1
RELATED PARTY TRANSACTIONS AND BALANCES
12 Months Ended
Dec. 31, 2022
RELATED PARTY TRANSACTIONS AND BALANCES  
RELATED PARTY TRANSACTIONS AND BALANCES

11.    RELATED PARTY TRANSACTIONS AND BALANCES

Related parties are defined as management and members of the Company and/or members of their immediate family and/or other companies and/or entities in which a board member or senior officer is a principal owner or senior executive. Other than disclosed elsewhere in the financial statements, related party transactions and balances are as follows:

Mercer Park, L.P., a company owned by an executive of Ayr, entered into a management agreement with the Company dated May 24, 2019. The management fee is paid monthly and varies based on actual costs incurred by the related entity when providing the Company administrative support, management services, office space, and utilities. In addition, the management fees paid to the related party also reimbursed them for other corporate or centralized expenses based on actual cost, including but not limited to legal and professional fees, software, and insurance. The agreement is a month-to-month arrangement.

As of December 31, 2023 and 2022, $nil and $698 was included in prepaid expenses, a majority of which is for a letter of credit for an operating lease. Lease fees included in the operating lease during the years ended December 31, 2023 and 2022, were $858 and $861. During the years ended December 31, 2023 and 2022, included in general and administrative expenses are management fees of $nil and $12.

During the years ended December 31, 2023 and 2022, the Company incurred fees from a company partially owned by a board member of AYR. The total incurred fees were $54 and $54 of office expenses, $24 and $392 of development fees, $1,083 and $920 of rental fees, and $83 and $165 of interest expense, respectively, for the years ended December 31, 2023 and 2022. Additionally in 2022, the board member was issued 50 Equity Shares, valued at $707 on the grant date, related to a consulting agreement with the Company for services rendered.

Refer below to the debts payable and senior secured notes and share capital notes for additional information regarding the debts payable to related parties and non-cash stock-based compensation plan, respectively, for the years ended December 31, 2023 and 2022.

XML 36 R19.htm IDEA: XBRL DOCUMENT v3.24.0.1
DEBTS PAYABLE AND SENIOR SECURED NOTES
12 Months Ended
Dec. 31, 2023
DEBTS PAYABLE AND SENIOR SECURED NOTES  
DEBTS PAYABLE AND SENIOR SECURED NOTES

12.    DEBTS PAYABLE AND SENIOR SECURED NOTES

Senior Secured Notes

On November 12, 2021, the Company completed a private placement offering of approximately $133,250 aggregate principal amount of secured promissory notes at a premium price, resulting in approximately $147,000 of proceeds due December 2024, with a resulting yield-to-maturity of 9.8%. The notes were considered additional notes under the indenture governing the Company’s existing notes which were entered into on December 10, 2020.

As of December 31, 2023 and 2022, the Company’s Senior Secured Notes consisted of the following:

Senior secured notes

As of January 1, 2022

$

245,408

Debt issuance costs amortized

2,292

Senior secured notes premium amortized

(3,018)

As of December 31, 2022

$

244,682

Debt issuance costs amortized

2,291

Senior secured notes premium amortized

(3,018)

Total senior secured notes classified as non-current payable as of December 31, 2023

$

243,955

Total accrued interest payable related to senior secured notes classified as non-current payable as of December 31, 2023

$

Debts Payable

As of December 31, 2023 and 2022, debt payable other than Senior Secured Notes consisted of the following:

    

Debts payable

As of January 1, 2022

$

133,858

Discounted as of December 31, 2021

951

Incurred through earn-out provision

14,934

Debt Issued

68,000

Construction financing

36,303

Less: repayment

(17,924)

Less: discounted to fair value

 

(598)

As of December 31, 2022

 

235,524

Discounted as of December 31, 2022

 

598

Debt issuance costs

(1,000)

Debt issuance costs amortized

50

Debt issued

 

66,245

Construction financing

2,024

Less: extinguishment related to sale of Arizona business

(22,505)

Less: repayment

(52,029)

Total debts payable, undiscounted as of December 31, 2023

228,907

Less: discounted to fair value

(199)

Total debts payable as of December 31, 2023

$

228,708

Total accrued interest payable related to debts payable as of December 31, 2023

$

7,513

12.    DEBTS PAYABLE AND SENIOR SECURED NOTES (Continued)

Debts Payable (Continued)

The details of debts payable, including construction financing liabilities, were as follows:

December 31, 2023

    

Related party debt

    

Non-related party debt

    

Total debt

Total debts payable, undiscounted

    

$

733

    

$

229,123

    

$

229,856

Less: current portion

733

22,419

23,152

Less: debt issuance costs - current portion

 

99

 

99

Total non-current debt, undiscounted

206,605

206,605

Less: discount to fair value

 

 

199

 

199

Less: debt issuance costs - non-current portion

850

850

Total non-current debt

$

$

205,556

$

205,556

The following table presents the future debt obligations other than Senior Secured Notes as of December 31, 2023:

Future debt obligations (per year)

    

  

2024

    

$

23,175

2025

 

23,673

2026

 

64,256

2027

 

14,527

2028

 

2,939

2029 and beyond

101,286

Total debt obligations

$

229,856

As part of the business combinations and asset acquisitions, the Company issued and assumed notes with related and non-related parties. The related party notes are considered part of the purchase price to the former shareholders of the acquired businesses. As a result of the combinations and acquisitions, several of these individual shareholders are now considered related parties of the Company across various roles including directors and officers.

On March 1, 2022, pursuant to the PA Natural Agreement, the Company issued non-related party promissory notes in the amount of $14,934 for earnout consideration. The notes are secured by all the assets and a pledge of the Company’s membership interests in PA Natural. The notes mature three years from the date of the agreement with an 8.0% annual interest rate payable quarterly.

On March 17, 2022, the Company entered into a loan agreement with a community bank for total proceeds of $26,200, net of financing costs of $287, with a 4.625% annual interest rate payable monthly. The loan is secured with a first mortgage lien on certain real property in Massachusetts and matures five years from the date of the agreement, with an option to extend for an additional five years. On March 24, 2023, the Company amended the loan agreement and received additional total proceeds of $10,000, net of financing costs of $100, with an 8% annual interest rate payable monthly for the incremental proceeds.

On May 16, 2022, the Company entered into a loan agreement with a community bank for total proceeds of $25,800, with an annual interest rate of Prime Rate plus 1.5%, floating, with a 5.0% floor. The loan was secured with a first mortgage lien on certain real property and matures two years from the date of the agreement. On July 7, 2023, the Company entered into a loan agreement to refinance and upsize the existing mortgage which was due to mature in May 2024. The loan agreement included total proceeds of $40,000, with an interest rate of 5-year Federal Home Loan Bank Rate plus 4%, which implies a current rate of 8.27% with interest-only payments for the first 18 months. The note extends the maturity of the existing mortgage to 10 years. Proceeds from the loan were used to pay down the Company’s existing mortgage of $25,219.

Pursuant to the agreement to acquire Herbal Remedies, the Company issued a non-related party promissory note in the amount of $14,220 to the former members of Herbal Remedies that is secured by all the assets of Herbal Remedies. The note matures five years from May 25, 2022 with an annual interest rate of 8% with quarterly straight-line amortization and interest payments over the life of the loan.

12.    DEBTS PAYABLE AND SENIOR SECURED NOTES (Continued)

Debts Payable (Continued)

Pursuant to the agreement to acquire Tahoe Hydro, the Company issued a non-related party promissory note in the amount of $1,580 to the former member of Tahoe Hydro that is secured by all the assets of and a pledge of membership interests in Tahoe Hydro. The note matures four years from the closing date of April 7, 2023, with an annual interest rate of 8% with quarterly straight-line amortization and interest payments over the life of the loan.

On May 11, 2023, the Company reached an agreement to amend the terms of contingent consideration under the membership interest purchase agreements of GSD NJ LLC (“GSD”) and Sira Naturals, Inc. (“Sira”). The amendment for GSD settles the contingent consideration with total proceeds of $38,860 , consisting of $10,000 in cash, promissory notes in an aggregate principal amount of $14,000, $10,925 in deferred cash, and $4,647 of Equity Shares. The $10,094, net of payments made of $831, in deferred cash is classified within accrued expenses on the balance sheet as of December 31, 2023. The deferred cash balance was paid in full subsequent to December 31, 2023. The $14,000 promissory notes are due December 2026 with monthly interest-only payments of 13.5% until May 2024 (with 1% monthly amortization thereafter). The number of Equity Shares was calculated based on a market price equal to $0.79 which represents 3,797 Equity Shares. The amendment for Sira represents a two-year deferral of the $27,500 of proceeds payable from the original May 2024 payment date, with an annual interest rate of 6.0% and 10% annual amortization payments. Refer to Note 14 for further details on the fair value loss recognized on the settlement of the contingent consideration.

In May 2023, the Company executed contingent agreements, securing a two-year deferral on principal or amortization payments of certain of its debt obligations, which includes aggregate principal amount of approximately $69,000 of debt obligations, including contingent agreements with holders of approximately $60,500 aggregate principal amount of vendor take-back promissory notes. The effectiveness of the maturity and amortization deferrals was contingent on an extension of the Company’s Senior Secured Notes to December 10, 2026, or a later date (or an exchange of the Senior Secured Notes for a new series of notes with a maturity date of December 10, 2026 or a later date). The effectiveness of the maturity and amortization deferrals is contingent on the closing of the Senior Secured Note extension transaction, or in some cases the execution of an agreement by a requisite threshold of Senior Noteholders to extend the maturity date of the Senior Secured Notes by at least two years. As of December 31, 2023, the Company and its subsidiaries had approximately $116,063 of indebtedness in respect of the vendor take-back promissory notes, of which approximately $77,110 were subject to subordination agreements in favor of the Senior Secured Notes. On October 31, 2023, the Company entered into a Support Agreement with the Majority Noteholders of the Senior Secured Notes to extend the maturity date by two years. The Company finalized the amendments for the debt, generally contingent on the closing of the transaction contemplated in the Support Agreement. The modification for these loans did not meet the requirement of a debt extinguishment under ASC 470-50 – Debt Modifications and Exchanges and no gain or loss was recognized as of December 31, 2023.

On October 31, 2023, the Company entered into an agreement with LivFree Wellness, LLC (“LivFree”) to amend certain terms of the promissory note dated May 24, 2019 (the “LivFree Note”) executed in connection with the Company’s acquisition of LivFree. The amendments to the LivFree Note provided, among other things, for a principal payment of $3,000, was paid upon closing of the debt restructuring transactions subsequent to December 31, 2023, and a deferral of the maturity of the remaining $17,000 of principal and $5,530 of accrued payment-in-kind interest for a period of two years to May 24, 2026. In addition, upon closing of the debt restructuring transactions, the interest on the LivFree Note converted from payment-in-kind to monthly cash interest payments and the interest rate increases from 6.0% to 10.0%.

12.    DEBTS PAYABLE AND SENIOR SECURED NOTES (Continued)

Debts Payable (Continued)

In accordance with ASC 340-10-S99-1, SAB Topic 5.A, “Expenses of Offering”, the Company capitalized debt transaction fees paid to third parties for the extension of the Senior Secured Notes of $9,951 as prepaid expenses in the balance sheet as of December 31, 2023. The final accounting for the transaction is not yet complete due to the inherent complexity and short period of time between the closing date and the filing period. Therefore, the accounting is preliminary and subject to adjustment on completion of the process and analysis of the transaction at the time that it closes, and further changes may still be required, see Note 19 for additional information.

In connection with the sale of Arizona, on March 27, 2023, the outstanding principal balance of $22,505 and accrued interest of $1,165, payable to the original owners of the Arizona business was eliminated. Refer to Note 4 for further details on the sale of Arizona.

Interest expense associated with related party debt payable for the years ended December 31, 2023 and 2022 was $83 and $1,507, respectively.

XML 37 R20.htm IDEA: XBRL DOCUMENT v3.24.0.1
SHARE CAPITAL
12 Months Ended
Dec. 31, 2023
SHARE CAPITAL  
SHARE CAPITAL

13.    SHARE CAPITAL

The following activity occurred during the year ended December 31, 2023:

In relation to the vesting of 3,262 RSUs, 3,169 Equity Shares were issued due to net settlement.
o137 shares were forfeited during the period.
3,798 Exchangeable Shares were issued in connection with the GSD contingent consideration settlement.
233 Exchangeable Shares were issued in connection with the Q2 2023 acquisition of Tahoe Hydro.
52 Exchangeable Share was exchanged for 52 Equity Shares related to the Q1 2022 acquisition of Levia.
354 Exchangeable Shares were exchanged for 354 Equity Shares related to the Q2 2022 acquisition of Herbal Remedies.
9 Exchangeable Shares were converted into 9 Equity Shares.
66 Equity Shares were issued for consulting services.
15 Exchangeable Shares were exchanged for 15 Equity Shares related to the Oasis acquisition.

The following activity occurred during the year ended December 31, 2022:

5 Equity Shares repurchased in 2021 were cancelled, and 82 Equity Shares were repurchased and held in the current year.
In relation to the vesting of 2,135 RSUs, 1,459 Equity Shares were issued due to net settlement.
o78 shares were forfeited during the year.
33 Equity Shares were issued in connection with options exercised.
1,029 Equity Shares were issued in connection with the earn-out provision related to the acquisition of PA Naturals.
908 Exchangeable Shares were exchanged for 908 Equity Shares related to the purchase considerations to the CannTech PA, LLC acquisition in 2020
329 Exchangeable Shares were issued in connection with the Cultivauna Acquisition.
353 Exchangeable Shares were issued in connection with the Herbal Remedies Acquisition
76 Equity Shares were issued to a related party for services rendered.
1,027 Exchangeable Shares were exchanged for 1,027 Equity Shares related to the Oasis acquisition.
71 Exchangeable Shares were converted to Equity Shares.

13.    SHARE CAPITAL (Continued)

Warrants

The average remaining life of Warrants is 0.4 years as of December 31, 2023 (2022: 1.4 years) with an aggregate intrinsic value of $nil in 2023 (2022: $nil). The Warrants have an exercise price of $9.07US. The number of Warrants outstanding as of December 31, 2023 and 2022, were as follows:

    

    

Weighted Average

    

Number

    

Fair Value

Balance as of January 1, 2022

 

2,874

$

1,786

No activity

Balance as of December 31, 2022

 

2,874

1,786

No activity

 

 

Balance as of December 31, 2023

 

2,874

$

1,786

XML 38 R21.htm IDEA: XBRL DOCUMENT v3.24.0.1
DERIVATIVE LIABILITIES
12 Months Ended
Dec. 31, 2023
DERIVATIVE LIABILITIES  
DERIVATIVE LIABILITIES

14.    DERIVATIVE LIABILITIES

Purchase Consideration and Contingent Consideration

In May 2023, the Company reached an agreement to amend and settle the terms of contingent consideration under the membership interest purchase agreements of GSD and Sira. The Company recognized a fair value loss during the period of $918 on the settlement of the contingent consideration obligation for GSD and $3,660 on the settlement of the contingent consideration obligation for Sira. Refer to Note 12 for further details on the amended terms of the contingent consideration.

The fair value adjustment relating to derivative liabilities has been included in the statements of operations under “Fair value gain on financial liabilities” as detailed below:

    

Year Ended

    

December 31, 

    

December 31, 

    

2023

    

2022

Gain from FV adjustment on contingent consideration

$

27,597

$

61,675

Loss from FV adjustment on purchase consideration settlement

 

 

(1,780)

(Loss) gain from settlement of contingent consideration

(4,578)

3,186

Other

4

7

Total

$

23,023

$

63,088

XML 39 R22.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCK-BASED COMPENSATION
12 Months Ended
Dec. 31, 2023
STOCK-BASED COMPENSATION  
STOCK-BASED COMPENSATION

15.    STOCK-BASED COMPENSATION

The Company has adopted an equity incentive plan, as amended on May 2, 2021 (“the Plan”), which allows the Company to compensate qualifying Plan participants through stock-based arrangements and provide them with opportunities for stock ownership in the Company, thereby seeking to align the interests of such persons with the Company’s shareholders. Under the Plan, the Company may grant stock options, RSUs, performance compensation awards, and unrestricted stock bonuses or purchases. The maximum number of Equity Shares that may be issued under the Plan and any other security-based compensation agreements shall not exceed 12% of the total number of fully diluted shares issued and outstanding from time to time.

In addition, the Company established a restricted stock plan (the “AcquisitionCo Plan”) to facilitate the granting of restricted Exchangeable Shares. Any shares issued under the AcquisitionCo Plan will reduce the number of Equity Shares that may be awarded under the AcquisitionCo Plan on a one-for-one basis.

15.    STOCK-BASED COMPENSATION (Continued)

The stock-based compensation expense is based on either the Company’s share price for service-based and market-based conditions on the date of the grant or the fair value of the performance-based RSU. The RSUs vest over a one to four-year period, based on service, market, and/or performance conditions. During the year ended December 31, 2023 there were 650 of both market and performance based RSUs outstanding, totaling 1,300. During the years ended December 31, 2023 and 2022, the Company recognized stock-based compensation relating to RSUs granted in the current and prior periods, except for the market and performance based RSUs as they did not meet the probable threshold. Any cumulative adjustment prior to vesting is recognized in the current period with no adjustment to prior periods for expense previously recognized. During the years ended December 31, 2023 and 2022, there were 137 and 78 forfeitures of nonvested RSUs, respectively.

During the years ended December 31, 2023 and 2022, 3,262 Equity Shares vested, of which 3,169 were issued due to net settlement, and 2,135 of which 1,459 were issued due to net settlement, respectively. During the years ended December 31, 2023 and 2022, the result of the net settlement was 93 Equity Shares were withheld with a total value of $366, and 676 Equity Shares were withheld with a total value of $5,258 to pay income taxes on behalf of the grantees, respectively. As of December 31, 2023 the average remaining life of unvested RSUs is one year and eleven months with an expected expense over the next 12 months of $9,967 with an aggregate intrinsic value of $16,714 using the stock price as of December 31, 2023 and as of December 31, 2022, the average remaining life of unvested RSUs is one year and three months with an expected expense over the next 12 months of $21,538 with an aggregate intrinsic value of $16,135 using the stock price as of December 31, 2022. The number of RSUs outstanding as of December 31, 2023 and 2022, were as follows:

Weighted  

Number of

Average Grant  

    

Shares

    

Date Fair Value

RSUs outstanding and nonvested, as of January 1, 2022

    

8,100

    

$

18.83

Granted

 

741

6.45

Vested

 

(2,135)

18.58

Forfeited

(78)

15.90

RSUs outstanding and nonvested, as of December 31, 2022

6,628

$

17.56

Granted

1,760

1.20

Vested

(3,262)

18.15

Forfeited

(137)

9.09

RSUs outstanding and nonvested, as of December 31, 20231

4,989

$

11.64

1 Includes Ayr granted but unvested performance based RSUs (PSUs) totaling 1,300 that do not meet the probability threshold

15.    STOCK-BASED COMPENSATION (Continued)

Options

As part of the Liberty acquisition, the Company issued replacement options to certain employees of Liberty who became employees of the Company which were fully vested as of the date of acquisition. The range of exercise price is between $10.59 and $29.60. As of December 31, 2023 and 2022,the weighted average remaining life of the options is under six months and under eight months, respectively, with an aggregate intrinsic value of $nil and $nil, respectively. The number of options outstanding as of December 31, 2023 and 2022 were as follows:

    

Number of

Weighted Average

    

Options

    

Fair Value

Balance as of January 1, 2022

198

$

17.93

Options exercised

(33)

17.93

Balance as of December 31, 2022

165

$

17.93

Options expired/cancelled

(6)

17.93

Balance as of December 31, 2023

159

20.30

XML 40 R23.htm IDEA: XBRL DOCUMENT v3.24.0.1
COMMITMENTS AND CONTINGENCIES
12 Months Ended
Dec. 31, 2023
COMMITMENTS AND CONTINGENCIES  
COMMITMENTS AND CONTINGENCIES

16.    COMMITMENTS AND CONTINGENCIES

Commitments

As of December 31, 2023 the Company guaranteed the lease obligation of a location related to a third-party that operates a dispensary in New Jersey. The Company is the guarantor of the lease with maximum total payments of $764 and will continue as the guarantor through December 2028. The Company would be required to perform under the guarantee if the third-party is in default. As of December 31, 2023 the Company does not anticipate any defaults under the foregoing lease, and therefore, no liability has been accrued.

As of December 31, 2023 the Company remains jointly liable under a lease related to its former Arizona business. As part of the sale of the Arizona business, the buyer agreed to cause its wholly owned subsidiary (and party to the lease) to perform all lease obligations arising on or after the closing date. The buyer also agreed to indemnify the Company for these same obligations. The lease requires maximum total payments of $10,619 through May 2035. As of December 31, 2023 the Company does not anticipate any defaults under the lease, and therefore, no liability has been accrued.

16.    COMMITMENTS AND CONTINGENCIES (Continued)

Contingencies

On March 27, 2020, the U.S. Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was signed into law, aimed at providing emergency assistance and health care for individuals, families, and businesses affected by the COVID-19 pandemic and generally supporting the U.S. economy. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, and modifications to the net interest deduction limitations. Employee Retention Credit (“ERC”) is a refundable credit against certain employment taxes equal to 50% of the qualified wages an eligible employer paid to employees from March 17, 2020 to December 31, 2020. The U.S. Disaster Tax Relief Act, enacted on December 27, 2020, extended the employee retention credit for qualified wages paid from January 1, 2021 to June 30, 2021, and the credit was increased to 70% of qualified wages an eligible employer paid to employees during the extended period. The American Rescue Plan Act of 2021, enacted on March 11, 2021, further extended the employee retention credit through December 31, 2021. The general statute of limitations for employment tax audits is three years, but the Internal Revenue Service’s (“IRS”) ERC guidance has an extended five-year statute. The Company experienced full or partial suspension of portions of the business during the period covered by the ERC due to government orders limiting commerce, travel, or group meeting due to COVID-19. In 2023, the Company filed for an ERC for the period beginning January 1 to June 30, 2021 in the amount of $12,354. During the year ended December 31, 2023, the Company received notices from the Internal Revenue Service for a total ERC refund of $5,238 and recorded a receivable included as part of prepaid expenses, deposits, and other current assets in the balance sheet and other income on the statement of operations. In accordance with ASC 958-605, Not-for-Profit Entities—Revenue Recognition, the Company determined that the condition to record a receivable is met when the IRS confirms the claim is valid or the cash is received. Absent of any confirmation, there remains uncertainty as to whether the amounts will be received. Due to the degree of uncertainty regarding the implementation of the CARES Act and other stimulus legislation and the nature of our business, although the Company expects to receive the remaining ERC, the Company determined that the remaining claim did not yet meet the criteria to record as a receivable as of December 31, 2023.

The Company’s operations are subject to a variety of local and state governmental regulations. Failure to comply with one or more of those regulations could result in fines, restrictions on its operations, or losses of permits and/or licenses that could result in the Company ceasing operations. While management of the Company believes that the Company is in compliance, in all material respects, with applicable local and state governmental regulations as of December 31, 2023, cannabis regulations continue to evolve and are subject to differing interpretations. As a result, the Company may be subject to regulatory fines, penalties, or restrictions in the future.

Claims and Litigation

From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of December 31, 2023 there were no material pending or threatened lawsuits that could be reasonably expected to have a material effect on the results of the Company’s operations. There are also no proceedings in which any of the Company’s directors,

officers or affiliates are an adverse party or have a material interest adverse to the Company’s interest.

XML 41 R24.htm IDEA: XBRL DOCUMENT v3.24.0.1
FINANCIAL RISK FACTORS
12 Months Ended
Dec. 31, 2023
FINANCIAL RISK FACTORS  
FINANCIAL RISK FACTORS

17.    FINANCIAL RISK FACTORS

(a) Fair value

Fair value is the price that would be received to sell/acquire an asset or paid to transfer/assume a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either in the principal market for the asset or liability or, in the absence of a principal market, in the most advantageous market for the asset or liability. The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest. A fair value measurement of a nonfinancial asset takes into account a market participant’s ability to generate economic benefits from the asset’s highest and best use or by selling it to another market participant that would utilize the asset in its highest and best use.

17.    FINANCIAL RISK FACTORS (Continued)

(a) Fair value (Continued)

The Company uses valuation techniques that are considered to be appropriate in the circumstances and for which there is sufficient data with unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy. This is described, as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

Level 1 inputs are quoted prices in active markets for identical assets or liabilities at the measurement date.
Level 2 inputs are observable inputs other than quoted prices included within Level 1, such as quoted prices for similar assets or liabilities in active markets, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable directly or indirectly.
Level 3 inputs are unobservable inputs for the asset or liability that reflect the reporting entity’s own assumptions and are not based on observable market data.

There were no transfers between levels in the hierarchy during the years ended December 31, 2023 and 2022. For financial assets and liabilities not measured at fair value, their carrying value is considered to approximate fair value due to their market terms.

The carrying values of cash, deposits, accounts receivable, trade payables, accrued liabilities, accrued interest payable, and purchase consideration payable approximate their fair values because of the short-term nature of these financial instruments. Long-term debt is recorded at amortized cost.

The following table summarizes the fair value hierarchy for the Company’s financial assets and liabilities that are re-measured at their fair values periodically:

    

December 31, 2023

December 31, 2022

Financial liabilities

  

  

Contingent consideration

Level 3

 

$

90,090

The following table summarizes the range of inputs used at the initial and subsequent measurement dates to value the contingent consideration for the year ended December 31, 2022 in the table above:

Equity Volatility

    

55.65 - 85.05

%  

Revenue Volatility

 

7.46 - 23.96

%  

Risk-free Rate

 

1.62 - 4.67

%  

Revenue Risk Premium

 

5.58 - 9.61

%  

Credit Risk Rate

 

10.50 - 19.10

%  

Discount Rate

 

8.40 - 10.00

%  

(b) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is exposed to interest rate risk on its cash and long-term debts. Cash and deposits bear interest at market rates. The Company’s debts are predominantly at fixed rates of interest. The Company does not use any derivative instruments to hedge against interest rate risk and believes that the change in interest rates will not have a significant impact on its financial results.

XML 42 R25.htm IDEA: XBRL DOCUMENT v3.24.0.1
TAXATION
12 Months Ended
Dec. 31, 2023
TAXATION  
TAXATION

18.    TAXATION

Income tax is accounted for in accordance with ASC 740, Income Taxes including ASU 2019-12. As the Company operates in the legal cannabis industry, the Company is also subject to the limits of Section 280E for U.S. federal income tax purposes as well as state income tax purposes for all states except for Illinois, Massachusetts, and New Jersey. Under Section 280E, the Company is generally only allowed to deduct expenses directly related to cost of goods sold. This results in permanent differences between ordinary and necessary business expenses deemed non-allowable under IRC Section 280E. Therefore, the effective tax rate can be highly variable and may not necessarily correlate with pre-tax income or loss.

The Company is treated as a U.S. corporation for the U.S. federal income tax purposes under Section 7874 of the Internal Revenue Code, as amended (“Section 7874”) and is subject to U.S. federal income tax on its worldwide income. However, for Canadian tax purposes, the Company, regardless of any application of Section 7874, is treated as a Canadian resident company (as defined in the Income Tax Act (Canada) (the “ITA”) for Canadian income tax purposes. As a result, the Company is subject to taxation both in Canada and the United States. The Company is also subject to state income taxation in Massachusetts, Pennsylvania, Florida, Illinois, Nevada, New Jersey, and Ohio.

For the years ended December 31, 2023 and 2022, income tax expense consisted of:

Year Ended

    

2023

    

2022

Current expense :

Federal

$

47,727

$

34,121

State

7,112

9,040

Total current expense :

54,839

43,161

Deferred (benefit) expense :

Federal

(6,912)

(3,173)

State

(536)

4,761

Foreign

(1,235)

(232)

Change in valuation allowance

 

1,235

 

232

Total deferred (benefit) expense :

(7,448)

1,588

Total income tax expense :

$

47,391

$

44,749

Interest and penalties included in current tax expense were $9,762 and $nil, respectively, for the years ended December 31, 2023 and 2022.

18.    TAXATION (Continued)

The difference between the income tax expense for the years ended December 31, 2023 and 2022 and the expected income taxes based on the statutory tax rate applied to income (loss) before income tax as follows:

Year Ended 

    

2023

    

2022

Expected income tax recovery

    

$

(9,609)

    

$

(36,147)

Difference in foreign tax rates

(6,030)

(4,311)

State taxes

 

6,576

 

13,802

Foreign exchange gain or loss

370

146

Impairment loss

1,327

24,769

Translation adjustment

 

(226)

 

669

Unrealized change in fair value of financial liabilities

(4,835)

(13,248)

Acquisition costs

 

872

 

147

Interest income inclusion

6,465

4,244

Non-deductible expenses

46,262

58,423

Amortization of debt premium

(815)

(815)

Restricted stock

731

Accrued tax penalties and interest

9,762

Change in effective tax rate

(1,627)

Prior year adjustment

(2,201)

(2,877)

Valuation allowance

1,235

232

Other

(867)

(285)

$

47,391

$

44,749

As of December 31, 2023 and 2022, the components of deferred tax assets and liabilities were as follows:

    

Year Ended

    

2023

    

2022

Deferred tax assets

Net operating losses

    

$

11,663

$

9,515

Share issuance costs

 

616

 

1,311

Share-based compensation

 

210

1,385

Inventory

 

2,032

1,298

Lease liabilities

1,170

Other assets

 

1,153

763

Total deferred tax assets

 

16,844

14,272

Deferred tax liabilities

 

Depreciation

(7,846)

(7,173)

Amortization

(63,320)

(69,440)

Debt financing costs

(584)

(1,202)

Other liabilities

(40)

(86)

Total deferred tax liabilities

(71,790)

(77,901)

Valuation allowance

(10,019)

(8,784)

Net deferred tax liability

$

(64,965)

$

(72,413)

Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. The Company assesses the positive and negative evidence to determine if sufficient future taxable income is expected to be generated to use the existing deferred tax assets. On the basis of our assessment, the valuation allowance increased $1,235 and $232, for the years ended December 31, 2023 and 2022, respectively.

18.    TAXATION (Continued)

As of December 31, 2023 and 2022,the Company had $32,865 and $30,538, respectively of gross Canadian net operating loss carry forwards which will begin to expire in 2037. As of December 31, 2023 and 2022, the Company has $15,688 and $15,867 respectively of various state net operating loss carry forwards which will begin to expire in 2042.

The Company operates in a number of United States state tax jurisdictions and is subject to examination of its income tax returns by tax authorities in those jurisdictions who may challenge any item on these returns. Because the tax matters challenged by tax authorities are typically complex, the ultimate outcome of these challenges is uncertain. In accordance with ASC 740 – Income Taxes, the Company recognizes the benefits of uncertain tax positions in our financial statements only after determining that it is more likely than not that the uncertain tax positions will be sustained.

The Company recognizes accrued interest and penalties related to unrecognized tax benefits in the provision for income taxes. There are no positions for which it is reasonably possible that the uncertain tax benefit will significantly increase or decrease within twelve months. The Company files income tax returns in the United States, various state jurisdictions, and Canada, which remain open to examination by the respective jurisdictions for the 2020 tax year to the present.

XML 43 R26.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUBSEQUENT EVENTS
12 Months Ended
Dec. 31, 2023
SUBSEQUENT EVENTS  
SUBSEQUENT EVENTS

19.    SUBSEQUENT EVENTS

The Company’s management has evaluated subsequent events through the date the consolidated financial statements were issued.

Subsequent to December 31, 2023, following the receipt of court and other required regulatory approvals, the Company completed the debt restructuring transactions contemplated in its Support Agreement with the Majority Noteholders, pursuant to which: (i) all of the Senior Secured Notes were exchanged for an equivalent principal amount of new 13% senior secured notes due December 10, 2026 (the “13% Senior Notes” and such exchange, the “Exchange Transaction”); (ii) an additional $40,000 in gross cash proceeds was raised through the issuance of additional 13% Senior Notes in an aggregate principal amount of $50,000 (the “New Money Notes”) (subject to a 20% original issue discount) concurrent with the completion of the Exchange Transaction; (iii) as the offering of the New Money Notes was backstopped by one of the Majority Noteholders, such backstop party received a backstop premium on closing payable in the form of 5,948 Equity Shares (the “Backstop Shares”) in the Company, and (iv) holders of the 12.5% Senior Secured Notes received 29,040 Equity Shares (the “New Shares”) in the Company.

In addition, 23,046 warrants (the “Anti-Dilutive Warrants”) were issued to all then-existing shareholders (excluding recipients of the New Shares and the Backstop Shares), which are exercisable for an equal number of Equity Shares for $2.12 per share until February 7, 2026. The Anti-Dilutive Warrants are only exercisable by non-U.S. Persons and Accredited Investors in the U.S., as such terms are defined under U.S. securities laws. The Anti-Dilutive Warrants started to trade on the CSE on February 14, 2024 under the ticker symbol AYR.WT.U.

In accordance with ASC Subtopic 470-10, since the Exchange Transaction and related transactions have been closed, the Company determined that it met the criteria to classify the existing Senior Secured Notes and certain debts payable as a non-current liability on the balance sheet and in Note 12 as of December 31, 2023 by demonstrating the intent and ability to refinance the short-term obligation prior to the financial statement issuance date.

XML 44 R27.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
12 Months Ended
Dec. 31, 2023
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
Basis of consolidation

3.1 Basis of consolidation

The financial statements as of and for the years ended December 31, 2023 and 2022 include the accounts of the Company, its wholly-owned subsidiaries, and entities over which the Company has a controlling interest. Entities over which the Company has control are presented on a consolidated basis from the date control commences until the date control ceases. Equity investments where the Company does not exert a controlling interest are not consolidated. All intercompany balances and transactions involving controlled entities are eliminated on consolidation. The accompanying consolidated financial statements reflect the activity related to Arizona as discontinued operations, see Note 4. The Company’s consolidated subsidiaries, many of which were created in connection with the business combinations described in Note 5 and elsewhere in these financial statements, are owned 100% by the Company unless otherwise noted. See Note 6 for variable interest entities that are consolidated by the Company.

Revenue

3.2 Revenue

The Company applies Accounting Standards Codification “ASC” Topic 606 (“ASC 606”), which specifies how and when revenue should be recognized based on a five-step model, which is applied to all contracts with customers. Through the application of ASC 606, the Company applies the following five-step model to determine the amount and timing of revenue to be recognized:

Identifying the contract with a customer
Identifying the performance obligations within the contract
Determining the transaction price
Allocating the transaction price to the performance obligations
Recognizing revenue when/as performance obligation(s) are satisfied.

3.2 Revenue (Continued)

In some cases, judgment is required in determining whether the customer is a business or the end consumer. This evaluation is made based on whether the business obtains control of the product before transferring to the end consumer. Control of the product transfers at a point in time either upon shipment to or receipt by the customer, depending on the contractual terms. In determining the appropriate time of sale, the Company takes into consideration: a) the Company’s right to payment for the goods or services; b) customer’s legal title; c) transfer of physical possession of the goods; and d) timing of acceptance of goods.

Revenue is recognized based on the sale of cannabis products and branded packaged goods for a fixed price when control is transferred. The amount recognized reflects the consideration that the Company expects to receive, taking into account any variation that is expected to result from rights of return and discounts. Dispensary revenue is recognized at the point of sale while wholesale revenue is recognized once the Company transfers the significant risks and rewards of ownership of the goods and does not retain material involvement associated with ownership or control over the goods sold. Revenue from the wholesale of cannabis to customers is recognized upon delivery to the customer. In accordance with ASC 606, the Company has elected to account for its sales and excise tax on a net basis, within its statements of operations.

Cash and cash equivalents and restricted cash

3.3 Cash and cash equivalents and restricted cash

The Company considers the following to be cash and cash equivalents: cash deposits in financial institutions, cash held in Company safes or lockboxes at operational locations, and deposits that are readily convertible into cash within three months or less. Amounts included in restricted cash represent amounts pledged as collateral for financing arrangements as contractually required by a lender. Cash and cash equivalents and restricted cash are stated at fair value and the Company did not hold significant cash equivalents or restricted cash balances as of December 31, 2023 and 2022. The Company has banking or similar relationships in all jurisdictions in which it operates. In addition, the Company has cash balances in excess of Federal Deposit Insurance Corporation and Canada Deposit Insurance Corporation limits. The Company has historically not experienced losses related to these deposits.

Accounts receivable

3.4 Accounts receivable

Accounts receivable from wholesale sales are recorded net of an allowance for credit losses. The Company estimates allowance for credit losses based on various factors such as historical data, and customer credit worthiness. As of December 31, 2023 and 2022, the Company had approximately $706 and $511 in allowance for credit losses, respectively. For the years ended December 31, 2023 and 2022, the Company wrote off approximately $221 and $443, respectively. See 3.23 for additional information.

Business combinations

3.5 Business combinations

Acquisitions of subsidiaries and businesses are accounted for using the acquisition method in accordance with ASC 805 – Business Combination (“ASC 805”). The Company performs an assessment whether the acquisition is a business combination or asset acquisition based on the conditions surrounding the event(s) using guidance from ASC 805. If the acquisition is determined to be a business combination, the Company measures goodwill as the fair value of the consideration transferred, including the recognized amount of any noncontrolling interest in the acquiree, less the net recognized amount of the identifiable assets acquired and liabilities assumed, all measured as of the acquisition date.

Consideration transferred includes the fair value of the assets transferred (including cash), the liabilities incurred by the Company on behalf of the acquiree, any contingent consideration and any equity interests issued by the Company. Transaction costs, other than those directly associated with the issuance of debt or equity securities that the Company incurs in connection with a business combination, are expensed as incurred.

The acquisition date is the date when the Company obtains control of the acquiree. Contingent consideration is measured at its acquisition date fair value and included as part of the consideration transferred in a business combination. Contingent consideration that is classified as a liability is re-measured at subsequent reporting dates in accordance with the criteria and guidance provided under ASC 450 – Contingencies and ASC 820 – Fair Value Measurement, as appropriate with corresponding gain or loss recorded in the statements of operations, see Note 14.

Inventory

3.6 Inventory

Inventory is primarily comprised of finished goods, work-in-process, raw materials, and supplies. Inventory is valued at the lower of cost and net realizable value. Net realizable value is determined as the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. When establishing the cost, work-in-process and raw materials are determined using the weighted average cost method while the determination of cost for finished goods inventory is on the first-in, first-out accounting method.

Costs incurred during the growing process are capitalized as incurred to the extent that cost is less than net realizable value. Any subsequent post-harvest costs, including direct costs such as materials, labor, related overhead, and depreciation expense on equipment attributable to processing, are capitalized to inventory to the extent that cost is less than net realizable value. Inventories of purchased finished goods and packing materials, other than inventory acquired through business combinations, are initially valued at cost and subsequently at the lower of cost and net realizable value. The Company reviews inventories for obsolete, spoiled, and slow-moving goods and any such inventories are written down to net realizable value. Inventory acquired in a business combination is valued at selling price less selling and disposal costs.

Property, plant, and equipment ("PPE")

3.7 Property, plant, and equipment (“PPE”)

PPE is stated at cost less accumulated depreciation, amortization, and impairment losses, if any. The cost of an item of PPE consists of the purchase price, any costs directly attributable to bringing the asset to the location and condition necessary for its intended use and an initial estimate of the costs of dismantling and removing the item and restoring the site on which it is located. PPE acquired in a business combination is recorded at fair value using various methodologies including cost approach, sales comparison approach or income approach.

Depreciation and amortization are calculated using the straight-line method over the following expected useful lives:

Furniture and fixtures

5 to 7 years

Office equipment

3 to 5 years

Machinery and equipment

5 to 15 years

Auto and trucks

5 years

Leasehold improvements

the shorter of the useful life or life of the lease

Buildings

39 years

Land

not depreciated

Construction in progress

not depreciated until placed in service

An item of PPE is derecognized upon disposal, when held for sale, or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on disposal of the asset, determined as the difference between the net disposal proceeds and the carrying amount of the asset, is recognized in the statements of operations.

Construction in progress is transferred to the appropriate asset class when available for use and depreciation or amortization of the assets commences at that point of time.

The Company conducts a periodic assessment of the residual balances, useful lives, and depreciation or amortization methods being used for PPE and any changes arising from the assessment are applied by the Company prospectively.

Where an item of PPE comprises major components with different useful lives, the components are accounted for as separate items of PPE. Expenditures incurred to replace a component of an item of PPE that is accounted for separately, including major inspection and overhaul expenditures are capitalized.

The Company capitalizes interest on debt in projects under construction. Upon the asset becoming available for use, capitalized interest costs, as a portion of the total cost of the asset, are depreciated over the estimated useful life of the related asset, see Note 8 for additional information.

Intangible assets

3.8 Intangible assets

Intangible assets are recorded at cost less accumulated amortization and impairment losses, if any. Intangible assets, separately identifiable according to ASC 805, acquired in a business combination are measured at fair value as of the acquisition date. Amortization periods of assets with finite lives are based on management’s estimates at the date of acquisition and are amortized over their estimated useful lives. Intangible assets that have indefinite useful lives are not subject to amortization and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired.

(a)Goodwill

The Company measures goodwill as the fair value of the consideration transferred, including the recognized amount of any noncontrolling interest in the acquiree, less the net recognized amount of the identifiable assets and liabilities assumed, all measured as of the acquisition date. Goodwill is allocated to a specific reporting unit upon acquisition. The Company’s policy is to first perform a qualitative assessment to determine if it was more-likely-than-not that the reporting unit’s carrying value is less than the fair value, indicating the potential for goodwill impairment. The amount of goodwill impairment, if any, is determined as the excess of the carrying value over the fair value of that reporting unit. The impairment of goodwill is limited to the amount of goodwill in a reporting unit. Impairment testing is performed annually by the Company, or more frequently, if events or changes in circumstances indicate that goodwill might be impaired. Management makes estimates during impairment testing as judgment is required to determine indicators of impairment and estimates are used to determine the fair value that is used to measure impairment losses. The Company assesses the fair values of its intangible assets, and its reporting unit for goodwill testing purposes, as necessary, using an income-based approach. Under the income approach, fair value is based on the present value of estimated future cash flows.

(b)Finite-lived intangible assets

Intangible assets are recorded at cost unless acquired through a business combination and recorded at fair value, less accumulated amortization and impairment losses. Amortization is recorded on a straight-line basis over the following estimated useful lives, which do not exceed the contractual period, if any:

Licenses/permits

15

Right-to-use licenses

15

Host community agreements

15

Trade name / brand

5

Such assets are tested for impairment if events or changes in circumstances indicate that they might be impaired. The estimated useful lives, residual values, and amortization methods are reviewed periodically, and any changes in estimates are accounted for prospectively.

3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

3.8 Intangible assets (Continued)

(c)Impairment of long-lived assets

Long-lived assets such as PPE, right-of-use assets, and finite-lived intangible assets are grouped with other assets and liabilities at the lowest level for which identifiable independent cash flows are available (“asset group”). The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In order to determine if assets have been impaired, the impairment test is a two-step approach wherein the recoverability test is performed first to determine whether the long-lived asset is recoverable. The recoverability test (Step 1) compares the carrying amount of the asset to the sum of its future undiscounted cash flows using entity specific assumptions generated through the asset’s use and eventual disposition. If the carrying amount of the asset is less than the undiscounted cash flows, the asset is recoverable, and an impairment is not recorded. If the carrying amount of the asset is greater than the undiscounted cash flows, the asset is not recoverable, and an impairment loss calculation (Step 2) is required. The measurement of the impairment loss to be recognized is based on the difference between the fair value and the carrying value of the asset group. Fair value can be determined using a market approach, income approach, or cost approach. The cash flow projection and fair value represents management’s best estimate, using appropriate and customary assumptions, projections, and methodologies, at the date of evaluation. The reversal of impairment losses is prohibited.

Leases and sale and leaseback accounting

3.9 Leases and sale and leaseback accounting

The Company applies the accounting guidance in ASC 842 – Leases and assesses whether a contract is or contains a lease, at inception of a contract. When evaluating whether a lease is a finance lease or an operating lease the Company considers whether the contract conveys the right to control the use of an identified asset. Certain arrangements require significant judgement to determine if an asset is specified in the contract and if the Company directs how, and for what purpose, the asset is used during the term of the contract. Leases are recognized as a right-of-use asset (“ROU”) and corresponding liability at the commencement date based on the present value of the future minimum lease payments over the lease term. Operating leases are included in Right-of-use assets – operating, net and Lease liabilities – operating – current portion and Lease liabilities – operating – non-current portion on the balance sheets. For operating leases, the Company records operating lease expense. Finance leases are included in Right-of-use assets – finance, net and lease liabilities are included in Lease liabilities – finance – current portion and Lease liabilities – finance – non-current portion on the balance sheets based on their payment dates. For finance leases, the Company records interest expense on the lease liability in addition to amortizing the ROU (generally straight-line) over the shorter of the lease term or the useful life of the right-of-use asset. The Company primarily leases space for corporate offices, retail, cultivation, and manufacturing under non-cancellable operating leases. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease.

Lease liabilities include the net present value of fixed payments (including in-substance fixed payments), variable lease payments that are not based on an index or a rate or subject to a fair market value renewal, amounts expected to be payable by the lessee under residual value guarantees, the exercise price of a purchase option if the lessee is reasonably certain to exercise that option, and payments of penalties for terminating the lease, if the lease term reflects the lessee exercising that option. The Company allocates the consideration in the contract to each lease component on the basis of the relative standalone price of the lease component and the aggregate stand-alone price of the non-lease components.

The lease payments are discounted using the interest rate implicit in the lease or, if that rate cannot be determined, the Company’s incremental borrowing rate. The period over which the lease payments are discounted is the reasonably certain lease term, including renewal options that the Company is reasonably certain to exercise. Renewal options are included in a number of leases across the Company.

Payments associated with short-term leases are recognized as an expense on a straight-line basis in the statements of operations. Short-term leases are leases with a lease term of 12 months or less. Variable lease payments that depend on an index or a rate or are subject to a fair market value renewal are expensed as incurred and recognized in the statements of operations.

3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

3.9 Leases and sale and leaseback accounting (Continued)

A sale and leaseback transaction involves the transfer of an asset to another entity and the leaseback of the same asset. The Company applies ASC 606 and ASC 842 when accounting for sale and leaseback transactions. Significant estimates and judgments applied include determination of the fair value of the underlying asset, transfer of control, and determination of the implicit interest rate. The Company recognizes gains or losses related to the transfer of rights of the asset to the buyer-lessor and measures the ROU asset arising from the leaseback at the retained portion of the previous carrying amount. In cases where the transaction does not qualify for sale and leaseback accounting treatment, the asset is not derecognized, and no gain or loss is recorded. The transaction is treated as a financing transaction. See Note 10 for additional information.

Equity investments

3.10 Equity investments

An associate is an entity over which the Company exercises significant influence. Significant influence is the power to participate in the financial and operating policy of the investee but without control or joint control over those policies. Interests in associates are accounted for using the equity method and are initially recognized at cost. Subsequent to initial recognition, the carrying value of the Company’s interest in an associate is adjusted for the Company’s share of income or loss and distributions of the investee. The carrying value of associates is assessed for impairment at each balance sheet date. Significant influence is presumed if the Company holds between 20% and 50% of the voting rights unless evidence exists to the contrary.

Joint control is the contractually agreed sharing of control of an arrangement, which exists only when decisions about the relevant activities require the unanimous consent of the parties sharing control. Investees in which the Company has joint control and rights to the net assets thereof are defined as joint ventures. Joint ventures are also accounted for under the equity method. There were no joint ventures as of December 31, 2023.

Noncontrolling interests

3.11 Noncontrolling interests

Equity interests owned by parties that are not shareholders of the Company in consolidated subsidiaries are considered noncontrolling interests. The share of net assets attributable to noncontrolling interests is presented as a component of equity while the share of net income or loss is recognized in the statements of operations. Changes in the Company’s ownership interest that do not result in a loss of control of these less than wholly owned subsidiaries are accounted for as equity transactions, see Note 3.19.

Derivatives

3.12 Derivatives

The Company evaluates all its agreements to determine if such instruments have derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as assets or liabilities, the derivative instrument is recorded at its fair value and is then revalued at each reporting date, with changes in the fair value reported in the Company’s financial statements. In calculating the fair value of derivative assets or liabilities, the Company uses a valuation model when Level 1 inputs are not available to estimate fair value at each reporting date (see Notes 14 and 17).

The classification of derivative instruments, including whether such instruments should be recognized as assets or liabilities or as equity, is reevaluated at the end of each reporting period. Derivative instrument assets or liabilities are classified as current or non-current based on whether net-cash settlement of the derivative instrument could be required within 12 months of the financial statement date.

Earnings per share

3.13 Earnings per share

The basic loss per share is computed by dividing the net loss by the weighted average number of shares outstanding, including Equity Shares, multiple voting shares of the Company and Exchangeable Shares, as defined below, during the period. The diluted loss per share reflects the potential dilution of shares by adjusting the weighted average number of shares outstanding to assume conversion of potentially dilutive shares, such as warrants (“Warrants”), restricted stock units (“RSUs”), and vested options of the Company (“Vested Options”). The treasury stock method is used for the assumed proceeds upon the exercise of the Warrants, and Vested Options that are used to purchase Equity Shares at the average market price during the period. If the Company incurs a net loss during a reporting period, the calculation of fully diluted loss per share will not include potentially dilutive equity instruments such as Warrants, RSUs, and Vested Options, because their effect would be anti-dilutive, therefore, basic loss per share and diluted loss per share will be the same. For the years ended December 31, 2023 and 2022, the potentially dilutive financial instruments excluded from the calculation of earnings per share included nil and nil warrants, nil and nil options and 1,908 and 3,799 RSUs, totaling 1,908 and 3,799 shares of potentially dilutive securities, respectively.

Stock-based payments

3.14 Stock-based payments

(a) Stock-based payment transactions

Certain employees (including directors and senior executives) of the Company receive a portion of their remuneration in the form of stock-based payment transactions, whereby employees render services as consideration for equity instruments.

Stock-based payments to non-employees are measured at the fair value of goods or services received or the fair value of the equity instruments issued, whichever is more readily determinable. In situations where equity instruments are issued to non-employees and some or all of the fair value of the good or service received by the Company as consideration cannot be specifically identified, they are measured at fair value of the stock-based payment. Stock-based payment transactions are primarily for individuals whose compensation has been classified as part of general and administrative expenses in the statements of operations.

The costs of equity settled transactions with employees are measured by reference to the fair value of the stock price at the date on which they are granted, using an appropriate valuation model. The value of the transaction is expensed straight line through the vesting period. Market and performance based RSUs are fair valued through Monte-Carlo simulations and are expensed over the indicative service period. Performance RSUs are recorded once the condition is probable to occur, refer to Note 15.

The costs of equity settled transactions are recognized, together with a corresponding increase in equity, over the period in which the performance and/or service conditions are fulfilled, ending on the date on which the relevant employees become fully entitled to the award (the “vesting date”).

The cumulative expense is recognized for equity settled transactions at each reporting date until the vesting date as the Company’s policy is to account for forfeitures as they occur. The income or loss for a period represents the movement in cumulative expense recognized as of the beginning and end of that period and the corresponding amount is represented in additional paid-in capital. At the end of each reporting period, the Company assesses if any forfeitures occurred and recognizes the impact in the statements of operations.

No expense is recognized for awards that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vesting for expense purposes irrespective of whether or not the market condition is satisfied provided that all other performance and/or service conditions are satisfied.

Where the terms of an equity settled award are modified, the minimum expense recognized is the grant date fair value of the unmodified award, provided the original terms of the award are met. An additional expense is recognized for any modification which increases the total fair value of the stock-based payment arrangement or is otherwise beneficial to the employee as measured at the date of modification. When an award is cancelled by the Company or the counterparty, any remaining element of the fair value of the award is derecognized at that time through the statements of operations.

3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

3.14 Stock-based payments (Continued)

(a) Stock-based payment transactions (Continued)

RSUs are issued on the vesting dates, sometimes net of the applicable statutory tax withholding to be paid by the Company on behalf of the employees. In those instances, lower shares are issued than the number of RSUs vested and the tax withholding is recorded as a reduction to paid-in capital. The terms of the stock-based payment awards allow an entity with a statutory income tax withholding obligation to withhold shares with a fair value up to the maximum statutory tax in the employee’s applicable jurisdiction.

(b) Warrants

The Company determines the accounting classification for equity-linked financial instruments such as warrants, as either liability or equity, by assessing ASC 480 – Distinguishing Liabilities from Equity and ASC 815 – Derivatives and Hedging. Under ASC 480, warrants are considered a liability if the warrants are mandatorily redeemable, obligate the Company to settle the warrants or the underlying shares by paying cash or other assets, or warrants that must or may require settlement by issuing a variable number of shares.

Under ASC 815, warrants are considered liabilities if contracts require or may require the issuer to net settle the contract for cash. Such derivatives are recorded as a liability at fair value until they are settled or expire, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. After all relevant assessments, the Company concludes whether the warrants are classified as liability or equity. Liability classified warrants require fair value accounting at issuance and subsequent to initial issuance with all changes in fair value after the issuance date recorded in the statements of operations. Equity classified warrants only require fair value accounting at issuance with no changes recognized subsequent to the issuance date unless the warrants are modified.

The Company determined that all of its outstanding warrants are freestanding instruments which do not meet the characteristics of a liability and therefore are classified as equity.

Loss contingencies

3.15 Loss contingencies

Loss contingencies are recognized when the Company has a present obligation that has arisen as a result of a past event and it is probable that a future outflow of resources will be required to settle the obligation, provided that a reliable estimate can be made of the amount of the obligation. Loss contingencies are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the time value of money and the risk specific to the obligation.

Financial instruments

3.16 Financial instruments

(a) Recognition and initial measurement

Financial assets and financial liabilities, including derivatives, are recognized when the Company becomes a party to the contractual provisions of a financial instrument or non-financial derivative contract. All financial instruments are measured at fair value on initial recognition. Transaction costs that are directly attributable to the acquisition or issuance of financial assets and financial liabilities, other than financial assets and financial liabilities classified as FVTPL (as defined below), are added to or deducted from the fair value on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities classified as FVTPL are recognized immediately in the statements of operations.

(b) Classification and subsequent measurement

The Company classifies financial assets, at the time of initial recognition, according to the Company’s business model for managing the financial assets and the contractual terms of the cash flows. Financial assets are classified in the following measurement categories:

a)amortized cost (“AC”).
b)fair value through profit or loss (“FVTPL”); and
c)fair value through other comprehensive income (“FVTOCI”).

3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

3.16 Financial instruments (Continued)

(b) Classification and subsequent measurement (Continued)

Financial assets are subsequently measured at amortized cost if both of the following conditions are met and they are not designated as FVTPL: a) the financial asset is held within a business model whose objective is to hold financial assets to collect contractual cash flows; and b) the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. These assets are subsequently measured at amortized cost using the effective interest rate method, less any impairment, with gains and losses recognized in the statements of operations in the period that the asset is derecognized or impaired. All financial assets not classified at amortized cost as described above are measured at FVTPL or FVTOCI depending on the business model and cash flow characteristics. The Company has no financial assets measured at FVTOCI.

Financial liabilities are subsequently measured at amortized cost using the effective interest rate method with gains and losses recognized in the statements of operations in the period that the liability is derecognized, except for financial liabilities classified as FVTPL.

Refer to Note 17 for the classification and fair value (“FV”) level of financial instruments.

(c) Derecognition

The Company derecognizes financial assets only when the contractual rights to cash flows from the financial assets expire, or when it transfers the financial assets and substantially all of the associated risks and rewards of ownership to another entity. Gains and losses on derecognition are recognized in the statements of operations.

The Company derecognizes financial liabilities only when its obligations under the financial liabilities are discharged, cancelled, or expired. Generally, the difference between the carrying amount of the financial liability derecognized and the consideration paid and payable, including any non-cash assets transferred or liabilities assumed, is recognized in the statements of operations.

Foreign currency transactions and translations

3.17 Foreign currency transactions and translations

Transactions denominated in foreign currency are translated into the functional currency of the entity using the exchange rates prevailing at the dates of the transactions or valuation where items are re-measured. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies, such as remeasurement of local currency into functional currency, are recognized in the statements of operations.

The results and financial position of an entity that has a functional currency different from the presentation currency is translated into the presentation currency as follows:

assets and liabilities for each balance sheet presented are translated at the closing rate at the date of the balance sheet; and
income and expenses for each statement of operations are translated at average exchange rates (unless this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated as the rate on the dates of the transactions).

Effect of translation differences, such as translation of foreign currency into reporting currency, are accumulated and presented as a component of equity under accumulated other comprehensive income.

Taxation

3.18 Taxation

The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities based on the differences between the financial statements and tax basis of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates and laws on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that the Company would be able to realize our deferred tax assets in the future more than their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.

The Company is subject to ongoing tax exposures, examinations, and assessments in various jurisdictions. Accordingly, the Company may incur additional tax expense based upon the outcomes of such matters. FASB ASC 740, Income Taxes, (“ASC 740”) prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties related to unrecognized tax benefits as of December 31, 2023 and 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals, or material deviation from its position within twelve months of the reporting date.

As the Company operates in the cannabis industry, the Company is subject to the limits of Section 280E of the United States Internal Revenue Code, as amended (“Section 280E”), under which the Company is generally only allowed to deduct expenses directly related to the cost of goods sold.

Variable Interest Entities ("VIE")

3.19 Variable Interest Entities (“VIE”)

Under certain provisions of ASC Topic 810 – Consolidations (“ASC 810”), the Company determines whether we are the primary beneficiary of a VIE. We assess whether we have the power to direct matters that most significantly impact the activities of the VIE and the obligation to absorb losses or the right to receive the benefits from the VIE that could potentially be significant to the VIE.

A VIE is a legal entity that does not have sufficient equity at risk to finance its activities without additional subordinated financial support or is structured that such equity investors lack the ability to make significant decisions relating to the entity’s operations through voting rights or do not substantively participate in the gains or losses of the entity. The primary beneficiary has both the power to direct the activities of the VIE that most significantly impact the entity’s economic performance and the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. We assess all variable interests in the entity and use our judgment when determining whether a particular entity is a VIE and if we are the primary beneficiary. Other qualitative factors that are considered include decision-making responsibilities, the VIE capital structure, risk and rewards sharing, contractual agreements with the VIE, voting rights, and level of involvement of other parties. We assess the primary beneficiary determination for a VIE on an ongoing basis if there are any reconsideration events related to a VIE. See Note 6.

Where we determine we are the primary beneficiary of a VIE, we consolidate the accounts of that VIE, under the guidance of ASC 805. The equity owned by other shareholders of the VIE is shown as noncontrolling interests in the accompanying financial statements.

Significant accounting judgments and estimates

3.20 Significant accounting judgments and estimates

The application of the Company’s accounting policies requires management to use estimates and judgments that can have a significant effect on the revenues, expenses, assets and liabilities recognized, and disclosures made in the financial statements.

Management’s best estimates concerning the future are based on the facts and circumstances available at the time estimates are made. Management uses historical experience, general economic conditions, and assumptions regarding probable future outcomes as the basis for determining estimates. Estimates and their underlying assumptions are reviewed periodically, and the effects of any changes are recognized at that time. Actual results could differ from the estimates used.

(a)Business combinations

The following areas require management’s critical estimates and judgments:

A business combination is a transaction or event in which an acquirer obtains control of one or more businesses and is accounted for using the acquisition method. The total consideration paid for the acquisition is the aggregate of the fair values of assets acquired, liabilities assumed, and equity instruments issued in exchange for control of the acquiree at the acquisition date. The acquisition date is the date when the Company obtains control of the acquiree.

Contingent consideration is measured at its acquisition date fair value and is included as part of the consideration transferred in a business combination, subject to the applicable terms and conditions.

Contingent consideration that is classified as equity is not remeasured at subsequent reporting dates and its subsequent settlement is accounted for within equity. Contingent consideration that is classified as a liability is remeasured at subsequent reporting dates in accordance with the criteria and guidance provided under ASC 805.

Based on the facts and circumstances that existed at the acquisition date, management will perform a valuation analysis to allocate the consideration transferred based on the fair values of the identifiable assets acquired and liabilities assumed on the acquisition date. Management is required to finalize its allocation on the earlier of the date that information becomes known, but no later than one year from the acquisition date. Until such time, these values might be provisionally reported and are subject to change. During the measurement period, adjustments to provisional purchase price allocations are recognized if new information is obtained about the facts and circumstances that existed as of the acquisition date that, if known, would have resulted in the recognition of those assets and liabilities as of that date.

In determining the fair value of all identifiable assets acquired and liabilities assumed, the most significant estimates generally relate to contingent consideration and intangible assets. Management exercises judgment in estimating the probability and timing of when contingent consideration targets are expected to be achieved, which is used as the basis for estimating fair value. Identified intangible assets are recognized at fair value using appropriate valuation techniques which are generally based on a forecast of the total expected future net cash flows of the acquiree. Valuations are highly dependent on the inputs used and assumptions made by management regarding the future performance of these assets and any changes in the discount rate applied.

Judgment is applied in determining whether a transaction is a business combination or an asset acquisition by considering the nature of the assets acquired and the processes applied to those assets, or if the integrated set of assets and activities is capable of being conducted and managed for the purpose of providing a return to investors or other owners.

(b)Inventory

In calculating the value of inventory, management is required to make a number of estimates, including estimating the stage of growth of the cannabis up to the point of harvest, expected yields for the cannabis plants, harvesting costs, net realizable value, selling costs, average or expected selling prices, fair value of inventory acquired in a business combination and impairment factors. In calculating final inventory values, management compares the inventory costs to estimated net realizable value as well as investigates slow moving inventory, if applicable. The estimates are judgmental in nature and are made at a point in time, using available information, such as expected business plans and expected market conditions. Periodic reviews are performed on the inventory balance with the changes in inventory reserves reflected in cost of goods sold.

3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

3.20 Significant accounting judgments and estimates (Continued)

(c)Estimated useful lives and depreciation of PPE

Depreciation of PPE is dependent upon estimates of useful lives, which are determined through the exercise of judgments. The assessment of any impairment of these assets is dependent upon estimates of recoverable amounts that take into account factors such as economic and market conditions and the useful lives of assets.

(d)Valuation, estimated life and impairment of intangible assets

Management uses significant judgment in estimating the useful lives and impairment. Impairment tests rely on judgments and estimates related to growth rates, discount rates, and estimated margins.

(e)Goodwill impairment

Goodwill is tested for impairment annually on December 31st of each fiscal year and whenever events or changes in circumstances indicate that the carrying amount of goodwill may have been impaired. In order to determine that the value of goodwill may have been impaired, the Company may perform a qualitative assessment to determine if it was more-likely-than-not that the reporting unit’s carrying value is less than the fair value, indicating the potential for goodwill impairment. Several factors, including historical results, business plans, forecasts, and market data are used to determine the fair value of the reporting unit. Changes in the conditions for these judgments and estimates can significantly affect the assessed value of goodwill.

(f)Leases

Each lease is evaluated to determine if the Company would exercise any of the renewal options offered. Several material factors are considered in determining if the renewal options would be exercised, such as length of the renewal, renewal rate, and ability to transfer locations. When measuring lease liabilities, the Company used discounted lease payments using a weighted-average rate in the range of 7.8% to 15.5% per annum. The weighted-average rate is based on the Company’s incremental borrowing rate, which relies on judgments and estimates.

(g)Provisions and contingent liabilities

When the Company is probable to incur an outflow of resources to settle an obligation and the amount can be reasonably estimated, a contingent liability is recorded. The contingent liability is recorded at management’s best estimates of the expenditure required to settle the obligation at period end, discounted to the present value, if material.

(h)Financial instruments

To determine the fair value of financial instruments, the Company develops assumptions and selects certain methods to perform the fair value calculations. Various methods considered include but are not limited to: (a) assigning the value attributed to the transaction at the time of origination; (b) re-measuring the instrument if it requires concurrent fair value measurement; and (c) valuing the instrument at the issuance value less any amortized costs. As judgment is a factor in determining the value and selecting a method, as well as the inherent uncertainty in estimating the fair value, the valuation estimates may be different.

Application of the option pricing model requires estimates in expected dividend yields, expected volatility in the underlying assets, and the expected life of the financial instruments. These estimates may ultimately be different from amounts subsequently realized, resulting in an overstatement or understatement of net loss.

Liquidity and management plan

3.21 Liquidity and management plan

As reflected in the consolidated financial statements, the Company had negative working capital of $7,258 as of December 31, 2023 and has incurred net losses from continuing operations for the years ended December 31, 2023 and 2022. The Company’s approach to managing its liquidity risk is to seek to ensure that it will have sufficient liquidity to meet its liabilities as they come due. The Company’s short-term liquidity requirements consist primarily of funds necessary to maintain operations, repay borrowings and other general business needs. The Company plans to use existing funds, as well as funds from the future sale of products, to fund short-term working capital needs for at least the next 12 months from the issuance of the consolidated financial statements.

In addition, the Company continues to take actions designed to improve the Company’s operations and cash position, including but not limited to: (i) targeting continued growth of sales from our consolidated operations; (ii) continued cost-savings and efficiency optimization efforts; (iii) utilizing the future proceeds from an employee retention credit up to $12,354 of which $5,238 was included in current receivables; (iv) addressing our debt maturity profile, in this regard, subsequent to December 31, 2023 the Company completed the debt restructuring transaction contemplated in its October 31, 2023 Support Agreement (the “Support Agreement”) with the holders of approximately 99% (collectively, the “Majority Noteholders”) of the aggregate outstanding principal amount of the Company’s 12.5% senior notes due December 2024 (the “Senior Notes”), which resulted in the effective extension via exchange of the maturity date for an additional two years, see Note 19, and the crystallization of the previously-announced deferral of certain current debts payable; (v) managing the timing and amount of certain expenses as well as capital expenditures; and (vi) seeking to take advantage of future potential financing (equity and/or debt) opportunities, including additional gross cash proceeds of $40,000 received February 2024 related to the issuance of new debt securities (refer to Note 19 for additional information). The debt extension related to the Support Agreement and the deferral of certain current debts payable are each classified as a non-current liability on the balance sheet as of December 31, 2023. While the contemplated debt restructuring transactions have been completed, management cannot provide any assurances that the Company will continue to be successful in accomplishing its business plans; if it is not, the Company may be forced to take other steps, including among others decelerating its growth or curtailing certain of its operations pending obtaining additional capital.

Discontinued operations

3.22 Discontinued operations

Strategic changes in the Company’s operations can be considered a discontinued operation if both the operations and cash flows of the discontinued business have been (or will be) eliminated from the ongoing operations of the Company and the Company will not have any significant continuing involvement in the operations of the discontinued business after the disposal transaction. Under ASC Subtopic 205-20, “Presentation of Financial Statements – Discontinued Operations” (“ASC Subtopic 205-20”), a component of an entity that is classified as discontinued operations is presented separately from continuing operations in the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows for all periods presented. All assets and liabilities related to such discontinued operations are classified as held for sale and presented separately in the Consolidated Balance Sheets for all periods prior to the disposal by sale. Accordingly, the presentation of prior period balances may not agree to previously issued financial statements. See Note 4 for additional information regarding the results of operations and major classes of assets and liabilities of discontinued operations.

Change in accounting standards

3.23 Change in accounting standards

The Company is treated as an “emerging growth company” as defined under the Jumpstart Our Business Start-ups Act of 2012, as amended (the “JOBS Act”). Under the JOBS Act, emerging growth companies may delay adopting new or revised accounting standards until the standards apply to private companies, however, emerging growth companies are not precluded from early adopting new accounting standards that allow so.

3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

3.23 Change in accounting standards (Continued)

Recently Issued and Adopted Accounting Standards

In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-13 Topic 326 – Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments, which was subsequently revised by ASU 2018-19, ASU 2019-04, ASU 2019-05, ASU 2019-11, ASU 2020-02, ASU 2020-03, and ASU 2022-02 (“ASU 2016-13”), which introduces a new model for assessing impairment on most financial assets. Entities will be required to use a forward-looking expected loss model, which will replace the current incurred loss model, which will result in earlier recognition of allowance for losses. ASU 2016-13 was effective for the Company’s fiscal year beginning after December 15, 2022, and interim periods therein. For accounts receivable only, the Company applies the simplified approach as permitted by ASU 2016-13. The simplified approach to the recognition of expected losses does not require the Company to track the changes in credit risk; rather, the Company recognizes a loss allowance based on lifetime expected credit losses at each reporting date from the date of the trade receivable. Expected credit losses are measured as the difference in the present value of the contractual cash flows that are due to the Company under the contract, and the cash flows that the Company expects to receive.

The Company assesses all information available, including past due status, credit ratings, the existence of third-party insurance, and forward-looking macro-economic factors in the measurement of the expected credit losses associated with its assets carried at amortized cost. The Company measures expected credit loss by considering the risk of default over the contract period and incorporates forward-looking information into its measurement. The adoption of ASU 2016-13 did not have a material impact on the Company’s financial statements and there was no cumulative effect at the adoption of the standard.

In June 2022, the FASB issued ASU No. 2022-03 Topic 820 – Fair Value Measurement – Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”), (1) to clarify the guidance in Topic 820, Fair Value Measurement, when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, (2) to amend a related illustrative example, and (3) to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. ASU 2022-03 is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years, early adoption is permitted. The Company is currently evaluating the impact the adoption of ASU 2022-03 may have on the Company’s financial statements.

In September 2022, the FASB issued ASU No. 2022-04 Topic 405 – Liabilities – Supplier Finance Programs (“ASU 2022-04”), which is intended to enhance transparency with supplier finance programs. ASU 2022-04 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Adoption is applied on a retrospective approach. The adoption of this ASU did not have a material impact on the Company’s financial statements.

On March 27, 2023, the FASB issued ASU No. 2023-01 Topic 842 – Leases – Common Control Arrangements (“ASU 2023-01”), in response to private company stakeholder concerns about applying Topic 842 to related party arrangements between entities under common control. ASU 2023-01 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, early adoption is permitted. The Company is currently evaluating the impact the adoption of ASU 2023-01 may have on the Company’s financial statements.

3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

3.23 Change in accounting standards (Continued)

Recently Issued and Adopted Accounting Standards (Continued)

In November 2023, the FASB issued ASU No. 2023-07 Topic 280 – Segment Reporting (“ASU 2023-07”) to improve the disclosures about a public entity’s reportable segments and address requests from investors for additional, more detailed information about a reportable segment’s expenses. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, early adoption is permitted. The Company is currently evaluating the impact the adoption of ASU 2023-07 may have on the Company’s financial statements.

On December 14, 2023, the FASB issued ASU No. 2023-09 Topic 740 – Income Taxes (“ASU 2023-09”) to enhance the transparency and decision usefulness of income tax disclosures. The amendments in this Update address investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, including interim periods within those fiscal years, early adoption is permitted. The Company is currently evaluating the impact the adoption of ASU 2023-09 may have on the Company’s financial statements.

XML 45 R28.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
12 Months Ended
Dec. 31, 2023
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
Schedule of depreciation and amortization over expected useful lives

Furniture and fixtures

5 to 7 years

Office equipment

3 to 5 years

Machinery and equipment

5 to 15 years

Auto and trucks

5 years

Leasehold improvements

the shorter of the useful life or life of the lease

Buildings

39 years

Land

not depreciated

Construction in progress

not depreciated until placed in service

Schedule of finite-lived intangible assets

Licenses/permits

15

Right-to-use licenses

15

Host community agreements

15

Trade name / brand

5

XML 46 R29.htm IDEA: XBRL DOCUMENT v3.24.0.1
DISCONTINUED OPERATIONS (Tables)
12 Months Ended
Dec. 31, 2023
DISCONTINUED OPERATIONS  
Schedule of major classes of assets and liabilities held for sale and components comprising net loss from our discontinued operations

    

As of

December 31, 2022

Current assets held-for-sale

Inventory and other current assets

$

20,910

Property, plant, and equipment, net

 

24,239

Intangible assets, net

 

194,018

Right-of-use assets, net

 

17,568

Deferred tax asset, net

 

3,890

Total assets held-for-sale

$

260,625

Current liabilities held-for-sale

 

  

Trade payables and other current liabilities

$

2,629

Lease liabilities

 

18,097

Debt payable

 

22,505

Accrued interest payable

 

610

Total liabilities held-for-sale

$

43,841

Year Ended

December 31, 2023

December 31, 2022

Revenues from discontinued operations, net of discounts

    

$

10,260

    

$

44,183

Cost of goods sold

 

9,074

 

28,705

Gross profit

 

1,186

 

15,478

Operating expenses from discontinued operations:

Selling, general, and administrative

 

2,115

 

40,153

Depreciation and amortization

 

2,675

 

11,055

Total operating expenses from discontinued operations

 

4,790

 

51,208

Loss from operations

 

(3,604)

 

(35,730)

Other expense

Interest Expense

 

(580)

 

(2,250)

Income taxes

 

 

Current tax provision

(575)

(628)

Deferred tax benefit

870

Total income taxes

295

(628)

 

  

 

  

Loss from discontinued operations

 

 

Loss from discontinued operations, net of taxes

 

(3,889)

 

(38,608)

Loss on disposal of discontinued operations

(182,464)

Loss from discontinued operations

$

(186,353)

$

(38,608)

XML 47 R30.htm IDEA: XBRL DOCUMENT v3.24.0.1
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS (Tables)
12 Months Ended
Dec. 31, 2023
Herbal Remedies | 2022 Second Quarter Acquisition  
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS  
Schedule of fair value of identifiable assets acquired, and liabilities assumed as of the acquisition date

    

Herbal Remedies

ASSETS ACQUIRED

 

  

Cash

$

637

Inventory

 

1,480

Prepaid expenses and other assets

 

256

Intangible assets - licenses/permits

 

15,700

Property, plant, and equipment

 

122

Right-of-use assets - operating

 

700

Total assets acquired at fair value

 

18,895

LIABILITIES ASSUMED

 

  

Trade payables

 

215

Accrued liabilities

 

68

Lease liabilities - operating

 

700

Total liabilities assumed at fair value

 

983

Goodwill

 

1,180

Consideration transferred

$

19,092

Schedule of components of purchase consideration

    

  

    

Shares

    

Fair Value

Cash

 

i

 

$

3,002

Debt Payable

 

ii

 

 

14,220

Shares Issued

 

iii

 

353

 

1,870

Total

 

  

 

353

$

19,092

Cultivauna | 2022 First Quarter Acquisition  
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS  
Schedule of fair value of identifiable assets acquired, and liabilities assumed as of the acquisition date

Cultivauna

ASSETS ACQUIRED

Cash

$

1,251

Accounts receivable

471

Inventory

1,206

Prepaid expenses and other assets

38

Intangible assets - trade name/brand

3,400

Intangible assets - host community agreements

2,100

Property, plant, and equipment

2,202

Right-of-use assets - operating

315

Total assets acquired at fair value

10,983

LIABILITIES ASSUMED

Trade payables

23

Accrued liabilities

305

Lease liabilities - operating

315

Total liabilities assumed at fair value

643

Goodwill

11,281

Consideration transferred

$

21,621

Schedule of components of purchase consideration

    

  

    

Shares

    

Fair Value

Cash

 

i

 

$

11,027

Shares Issued

 

ii

 

329

4,482

Contingent Consideration

 

iii

 

6,112

Total

 

  

 

329

$

21,621

XML 48 R31.htm IDEA: XBRL DOCUMENT v3.24.0.1
VARIABLE INTEREST ENTITIES ("VIE") (Tables)
12 Months Ended
Dec. 31, 2023
VARIABLE INTEREST ENTITIES ("VIE")  
Schedule of financial information about consolidated VIEs which are included in the balance sheet and statement of operations

As of

As of

December 31, 2023

December 31, 2022

Ohio

    

NVG

    

Parma

    

Dispensaries

    

Total

    

TH/NVG

    

Parma

    

Total

Current assets

(351)

$

10,616

(2,257)

8,008

$

5,248

$

10,751

15,999

Non-current assets

 

1,077

 

13,210

 

6,441

20,728

 

6,582

 

14,634

 

21,216

Total assets

$

726

$

23,826

$

4,184

$

28,736

$

11,830

$

25,385

$

37,215

Current liabilities

$

604

$

18,962

$

1,647

$

21,213

$

1,033

$

14,092

$

15,125

Non-current liabilities

 

383

 

1,280

 

3,369

 

5,032

 

898

 

1,952

 

2,850

Total liabilities

 

987

 

20,242

 

5,016

 

26,245

 

1,931

 

16,044

 

17,975

Noncontrolling interest

 

796

 

(10,158)

 

(1,764)

 

(11,126)

 

7,528

 

(5,528)

 

2,000

Equity (deficit) attributable to Ayr Wellness Inc.

 

(1,057)

 

13,742

 

932

 

13,617

 

2,371

 

14,869

 

17,240

Total liabilities and equity

$

726

$

23,826

$

4,184

$

28,736

$

11,830

$

25,385

$

37,215

Year Ended

Year Ended

December 31, 2023

December 31, 2022

Ohio

    

TH/NVG

    

Parma

    

Dispensaries

    

Total

    

TH/NVG

    

Parma

    

Total

Revenues, net of discounts

$

$

3,170

$

462

$

3,632

$

1,851

$

$

1,851

Net loss attributable to noncontrolling interest

 

(673)

 

(4,630)

 

(1,764)

 

(7,067)

 

(4,491)

 

(5,528)

 

(10,019)

Net loss attributable to Ayr Wellness Inc.

 

 

(1,275)

 

 

(1,275)

 

 

 

Net loss

$

(673)

$

(5,905)

$

(1,764)

$

(8,342)

$

(4,491)

$

(5,528)

$

(10,019)

Ohio

    

TH/NVG

    

Parma

    

Dispensaries

    

Total

Noncontrolling interest at January 1, 2022

$

$

$

$

Total purchase consideration

16,868

16,868

Working capital adjustment presented as consideration payable

(4,849)

(4,849)

Net loss during the period

(4,491)

(5,528)

(10,019)

Noncontrolling interest at December 31, 2022

$

7,528

$

(5,528)

$

2,000

Acquisition of Tahoe Hydro

(6,059)

(6,059)

Net loss during the period

(673)

(4,630)

(1,764)

(7,067)

Noncontrolling interest at December 31, 2023

$

796

$

(10,158)

$

(1,764)

$

(11,126)

XML 49 R32.htm IDEA: XBRL DOCUMENT v3.24.0.1
INVENTORY (Tables)
12 Months Ended
Dec. 31, 2023
INVENTORY  
Schedule of inventory

    

December 31, 

    

December 31, 

2023

2022

Materials, supplies, and packaging

$

7,505

$

9,770

Work in process

69,632

65,807

Finished goods

 

29,226

 

24,233

Total inventory

$

106,363

$

99,810

XML 50 R33.htm IDEA: XBRL DOCUMENT v3.24.0.1
PROPERTY, PLANT, AND EQUIPMENT (Tables)
12 Months Ended
Dec. 31, 2022
PROPERTY, PLANT, AND EQUIPMENT  
Schedule of property, plant, and equipment, net

December 31, 

December 31, 

    

2023

    

2022

Furniture and equipment

$

52,793

 

$

53,070

Auto and trucks

1,393

 

1,626

Buildings

94,914

91,233

Leasehold improvements

173,043

154,774

Land

13,877

13,879

Construction in progress

12,571

9,581

Total

348,591

324,163

Less: Accumulated depreciation and amortization

37,976

21,483

Total property, plant and equipment, net

$

310,615

 

$

302,680

XML 51 R34.htm IDEA: XBRL DOCUMENT v3.24.0.1
GOODWILL AND INTANGIBLE ASSETS (Tables)
12 Months Ended
Dec. 31, 2022
GOODWILL AND INTANGIBLE ASSETS  
Schedule of goodwill

As of January 1, 2022

    

$

199,329

Acquired through business combinations and initial consolidation of VIEs

12,729

Impairment of goodwill

(117,950)

As of December 31, 2022

94,108

(no activity)

As of December 31, 2023

$

94,108

Schedule of intangible assets, net of accumulated amortization

    

    

December 31, 2023

    

December 31, 2022

Amortization period (# of years)

Licenses/permits

15

$

641,036

$

693,714

Right-to-use licenses

 

15

 

16,407

 

17,717

Host community agreements

 

15

 

26,954

 

29,494

Trade name / brand

 

5

 

3,591

 

3,784

Total

$

687,988

$

744,709

Schedule of future amortization expense of intangible assets

    

Amortization Expense

2024

$

58,123

2025

57,308

2026

57,308

2027

57,308

2028

57,308

2029 and beyond

397,433

Total

$

684,788

XML 52 R35.htm IDEA: XBRL DOCUMENT v3.24.0.1
RIGHT-OF-USE ASSETS AND LEASE LIABILITIES (Tables)
12 Months Ended
Dec. 31, 2022
RIGHT-OF-USE ASSETS AND LEASE LIABILITIES  
Information related to operating and finance leases is as follows:

December 31, 2023

December 31, 2022

 

    

Operating Leases

    

Finance Leases

    

Operating Leases

    

Finance Leases

 

Incremental borrowing rate (weighted average)

 

11.83

%  

10.37

%  

11.98

%  

9.68

%

Weighted average remaining lease term

 

12.12

yrs

4.76

yrs

13.04

yrs

4.90

yrs

Schedule of maturities of the contractual operating lease liabilities

    

Operating Leases

    

Finance Leases

    

Total

2024

    

$

29,457

$

12,098

$

41,555

2025

 

29,112

6,428

35,540

2026

 

28,381

4,412

32,793

2027

 

27,125

3,340

30,465

2028

 

26,507

2,501

29,008

2029 and beyond

198,164

6,428

204,592

Total undiscounted lease liabilities

 

338,746

35,207

373,953

Impact of discounting

(203,231)

(7,411)

(210,642)

Total present value of minimum lease payments

$

135,515

$

27,796

$

163,311

Schedule of maturities of the contractual finance lease liabilities

    

Operating Leases

    

Finance Leases

    

Total

2024

    

$

29,457

$

12,098

$

41,555

2025

 

29,112

6,428

35,540

2026

 

28,381

4,412

32,793

2027

 

27,125

3,340

30,465

2028

 

26,507

2,501

29,008

2029 and beyond

198,164

6,428

204,592

Total undiscounted lease liabilities

 

338,746

35,207

373,953

Impact of discounting

(203,231)

(7,411)

(210,642)

Total present value of minimum lease payments

$

135,515

$

27,796

$

163,311

Schedule of payments related to leases.

Year Ended

    

December 31, 2023

    

December 31, 2022

Lease liabilities - operating

Lease liabilities - operating expense, COGS

$

8,783

$

6,604

Lease liabilities - operating expense, G&A

 

16,366

 

13,943

Lease liabilities - finance

 

 

Amortization of right-of-use assets, COGS

 

6,913

 

4,584

Amortization of right-of-use assets, G&A

 

165

 

187

Interest on lease liabilities - finance, COGS

 

3,017

 

2,422

Interest on lease liabilities - finance, G&A

 

37

 

58

Total lease expense

$

35,281

$

27,798

XML 53 R36.htm IDEA: XBRL DOCUMENT v3.24.0.1
DEBTS PAYABLE AND SENIOR SECURED NOTES (Tables)
12 Months Ended
Dec. 31, 2023
DEBTS PAYABLE AND SENIOR SECURED NOTES  
Schedule of senior secured promissory notes and debt payable

Senior secured notes

As of January 1, 2022

$

245,408

Debt issuance costs amortized

2,292

Senior secured notes premium amortized

(3,018)

As of December 31, 2022

$

244,682

Debt issuance costs amortized

2,291

Senior secured notes premium amortized

(3,018)

Total senior secured notes classified as non-current payable as of December 31, 2023

$

243,955

Total accrued interest payable related to senior secured notes classified as non-current payable as of December 31, 2023

$

    

Debts payable

As of January 1, 2022

$

133,858

Discounted as of December 31, 2021

951

Incurred through earn-out provision

14,934

Debt Issued

68,000

Construction financing

36,303

Less: repayment

(17,924)

Less: discounted to fair value

 

(598)

As of December 31, 2022

 

235,524

Discounted as of December 31, 2022

 

598

Debt issuance costs

(1,000)

Debt issuance costs amortized

50

Debt issued

 

66,245

Construction financing

2,024

Less: extinguishment related to sale of Arizona business

(22,505)

Less: repayment

(52,029)

Total debts payable, undiscounted as of December 31, 2023

228,907

Less: discounted to fair value

(199)

Total debts payable as of December 31, 2023

$

228,708

Total accrued interest payable related to debts payable as of December 31, 2023

$

7,513

Schedule of total debt payable

December 31, 2023

    

Related party debt

    

Non-related party debt

    

Total debt

Total debts payable, undiscounted

    

$

733

    

$

229,123

    

$

229,856

Less: current portion

733

22,419

23,152

Less: debt issuance costs - current portion

 

99

 

99

Total non-current debt, undiscounted

206,605

206,605

Less: discount to fair value

 

 

199

 

199

Less: debt issuance costs - non-current portion

850

850

Total non-current debt

$

$

205,556

$

205,556

Schedule of future debt obligations

Future debt obligations (per year)

    

  

2024

    

$

23,175

2025

 

23,673

2026

 

64,256

2027

 

14,527

2028

 

2,939

2029 and beyond

101,286

Total debt obligations

$

229,856

XML 54 R37.htm IDEA: XBRL DOCUMENT v3.24.0.1
SHARE CAPITAL (Tables)
12 Months Ended
Dec. 31, 2023
SHARE CAPITAL  
Summary of number of warrants outstanding

    

    

Weighted Average

    

Number

    

Fair Value

Balance as of January 1, 2022

 

2,874

$

1,786

No activity

Balance as of December 31, 2022

 

2,874

1,786

No activity

 

 

Balance as of December 31, 2023

 

2,874

$

1,786

XML 55 R38.htm IDEA: XBRL DOCUMENT v3.24.0.1
DERIVATIVE LIABILITIES (Tables)
12 Months Ended
Dec. 31, 2023
DERIVATIVE LIABILITIES  
Schedule of fair value adjustment relating to derivative liabilities

    

Year Ended

    

December 31, 

    

December 31, 

    

2023

    

2022

Gain from FV adjustment on contingent consideration

$

27,597

$

61,675

Loss from FV adjustment on purchase consideration settlement

 

 

(1,780)

(Loss) gain from settlement of contingent consideration

(4,578)

3,186

Other

4

7

Total

$

23,023

$

63,088

XML 56 R39.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCK-BASED COMPENSATION (Tables)
12 Months Ended
Dec. 31, 2023
STOCK-BASED COMPENSATION  
Schedule of RSUs outstanding and nonvested

Weighted  

Number of

Average Grant  

    

Shares

    

Date Fair Value

RSUs outstanding and nonvested, as of January 1, 2022

    

8,100

    

$

18.83

Granted

 

741

6.45

Vested

 

(2,135)

18.58

Forfeited

(78)

15.90

RSUs outstanding and nonvested, as of December 31, 2022

6,628

$

17.56

Granted

1,760

1.20

Vested

(3,262)

18.15

Forfeited

(137)

9.09

RSUs outstanding and nonvested, as of December 31, 20231

4,989

$

11.64

Schedule of stock option activity

    

Number of

Weighted Average

    

Options

    

Fair Value

Balance as of January 1, 2022

198

$

17.93

Options exercised

(33)

17.93

Balance as of December 31, 2022

165

$

17.93

Options expired/cancelled

(6)

17.93

Balance as of December 31, 2023

159

20.30

XML 57 R40.htm IDEA: XBRL DOCUMENT v3.24.0.1
FINANCIAL RISK FACTORS (Tables)
12 Months Ended
Dec. 31, 2023
FINANCIAL RISK FACTORS  
Summary of the fair value hierarchy for the Company's financial assets and liabilities

    

December 31, 2023

December 31, 2022

Financial liabilities

  

  

Contingent consideration

Level 3

 

$

90,090

Summary of the range of inputs used at the initial and subsequent measurement dates to value the contingent consideration

The following table summarizes the range of inputs used at the initial and subsequent measurement dates to value the contingent consideration for the year ended December 31, 2022 in the table above:

Equity Volatility

    

55.65 - 85.05

%  

Revenue Volatility

 

7.46 - 23.96

%  

Risk-free Rate

 

1.62 - 4.67

%  

Revenue Risk Premium

 

5.58 - 9.61

%  

Credit Risk Rate

 

10.50 - 19.10

%  

Discount Rate

 

8.40 - 10.00

%  

XML 58 R41.htm IDEA: XBRL DOCUMENT v3.24.0.1
TAXATION (Tables)
12 Months Ended
Dec. 31, 2023
TAXATION  
Schedule of income taxes expense

Year Ended

    

2023

    

2022

Current expense :

Federal

$

47,727

$

34,121

State

7,112

9,040

Total current expense :

54,839

43,161

Deferred (benefit) expense :

Federal

(6,912)

(3,173)

State

(536)

4,761

Foreign

(1,235)

(232)

Change in valuation allowance

 

1,235

 

232

Total deferred (benefit) expense :

(7,448)

1,588

Total income tax expense :

$

47,391

$

44,749

Schedule of difference between the income tax expense and the expected income taxes based on the statutory tax rate

Year Ended 

    

2023

    

2022

Expected income tax recovery

    

$

(9,609)

    

$

(36,147)

Difference in foreign tax rates

(6,030)

(4,311)

State taxes

 

6,576

 

13,802

Foreign exchange gain or loss

370

146

Impairment loss

1,327

24,769

Translation adjustment

 

(226)

 

669

Unrealized change in fair value of financial liabilities

(4,835)

(13,248)

Acquisition costs

 

872

 

147

Interest income inclusion

6,465

4,244

Non-deductible expenses

46,262

58,423

Amortization of debt premium

(815)

(815)

Restricted stock

731

Accrued tax penalties and interest

9,762

Change in effective tax rate

(1,627)

Prior year adjustment

(2,201)

(2,877)

Valuation allowance

1,235

232

Other

(867)

(285)

$

47,391

$

44,749

Schedule of components of deferred tax assets and liabilities

    

Year Ended

    

2023

    

2022

Deferred tax assets

Net operating losses

    

$

11,663

$

9,515

Share issuance costs

 

616

 

1,311

Share-based compensation

 

210

1,385

Inventory

 

2,032

1,298

Lease liabilities

1,170

Other assets

 

1,153

763

Total deferred tax assets

 

16,844

14,272

Deferred tax liabilities

 

Depreciation

(7,846)

(7,173)

Amortization

(63,320)

(69,440)

Debt financing costs

(584)

(1,202)

Other liabilities

(40)

(86)

Total deferred tax liabilities

(71,790)

(77,901)

Valuation allowance

(10,019)

(8,784)

Net deferred tax liability

$

(64,965)

$

(72,413)

XML 59 R42.htm IDEA: XBRL DOCUMENT v3.24.0.1
NATURE OF OPERATIONS (Details)
12 Months Ended
Dec. 31, 2023
segment
NATURE OF OPERATIONS  
Number of operating segments 1
XML 60 R43.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Accounts Receivable (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES    
Allowance for credit losses $ 706 $ 511
Accounts receivable written off $ 221 $ 443
XML 61 R44.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, Plant, and Equipment ("PPE") (Details)
Dec. 31, 2023
Furniture and equipment | Minimum  
PROPERTY, PLANT, AND EQUIPMENT  
Useful life 5 years
Furniture and equipment | Maximum  
PROPERTY, PLANT, AND EQUIPMENT  
Useful life 7 years
Office equipment | Minimum  
PROPERTY, PLANT, AND EQUIPMENT  
Useful life 3 years
Office equipment | Maximum  
PROPERTY, PLANT, AND EQUIPMENT  
Useful life 5 years
Machinery and equipment | Minimum  
PROPERTY, PLANT, AND EQUIPMENT  
Useful life 5 years
Machinery and equipment | Maximum  
PROPERTY, PLANT, AND EQUIPMENT  
Useful life 15 years
Auto and trucks  
PROPERTY, PLANT, AND EQUIPMENT  
Useful life 5 years
Buildings  
PROPERTY, PLANT, AND EQUIPMENT  
Useful life 39 years
XML 62 R45.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets and Impairment of Long-lived Assets (Details)
12 Months Ended
Dec. 31, 2023
Licenses/permits  
Intangible assets  
Useful life 15 years
Right-to-use licenses  
Intangible assets  
Useful life 15 years
Host community agreements  
Intangible assets  
Useful life 15 years
Trade name / brand  
Intangible assets  
Useful life 5 years
XML 63 R46.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings per Share (Details) - shares
shares in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Earnings per share    
Potentially dilutive financial instruments excluded from the calculation of earnings per share 1,908 3,799
Warrant    
Earnings per share    
Potentially dilutive financial instruments excluded from the calculation of earnings per share 0 0
Options    
Earnings per share    
Potentially dilutive financial instruments excluded from the calculation of earnings per share 0 0
RSUs    
Earnings per share    
Potentially dilutive financial instruments excluded from the calculation of earnings per share 1,908 3,799
XML 64 R47.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Taxation (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES    
Unrecognized tax benefits $ 0 $ 0
Unrecognized tax benefits accrued for interest and penalties $ 0 $ 0
XML 65 R48.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Leases (Details)
12 Months Ended
Dec. 31, 2023
Minimum  
Leases  
Weighted average lessee's incremental borrowing rate applied to lease liabilities 7.80%
Maximum  
Leases  
Weighted average lessee's incremental borrowing rate applied to lease liabilities 15.50%
XML 66 R49.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -Liquidity and management plan (Details) - USD ($)
$ in Thousands
2 Months Ended 12 Months Ended
Mar. 14, 2024
Dec. 31, 2023
Liquidity and management plan    
Working capital   $ (7,258)
Maximum proceeds from employee retention credit to be utilized   12,354
Amount of future proceeds from employee retention credit recognised in current receivables   $ 5,238
Subsequent Events    
Liquidity and management plan    
Interest rate 13.00%  
New Debt Securities | Subsequent Events    
Liquidity and management plan    
Debt issued $ 40,000  
Senior notes with Interest Rate 12.5%, Due 2024    
Liquidity and management plan    
Interest rate 12.50%  
Senior notes with Interest Rate 12.5%, Due 2024 | Subsequent Events    
Liquidity and management plan    
Restructuring Transaction Percentage Of Aggregate Outstanding Principal 99.00%  
Interest rate 12.50%  
XML 67 R50.htm IDEA: XBRL DOCUMENT v3.24.0.1
DISCONTINUED OPERATIONS (Details) - Blue Camo - Discontinued operations, Held for sale
$ in Thousands
Mar. 27, 2023
USD ($)
entity
item
DISCONTINUED OPERATIONS  
Number of licensed entities operating oasis branded dispensaries | entity 2
Number of oasis branded dispensaries | item 3
Total consideration $ 20,000
Lease obligations eliminating long term lease liabilities amount 16,734
Debt extinguished 22,505
Accrued interest extinguished 1,165
Potential earn out contingent consideration $ 0
XML 68 R51.htm IDEA: XBRL DOCUMENT v3.24.0.1
DISCONTINUED OPERATIONS - Major classes of assets and liabilities (Details)
$ in Thousands
Dec. 31, 2022
USD ($)
Current assets held-for-sale  
Total assets held-for-sale $ 260,625
Current liabilities held-for-sale  
Total liabilities held-for-sale 43,841
Blue Camo | Discontinued operations, Held for sale  
Current assets held-for-sale  
Inventory and other current assets 20,910
Property, plant, and equipment, net 24,239
Intangible assets, net 194,018
Right-of-use assets, net 17,568
Deferred tax asset, net 3,890
Total assets held-for-sale 260,625
Current liabilities held-for-sale  
Trade payables and other current liabilities 2,629
Lease liabilities 18,097
Debt payable 22,505
Accrued interest payable 610
Total liabilities held-for-sale $ 43,841
XML 69 R52.htm IDEA: XBRL DOCUMENT v3.24.0.1
DISCONTINUED OPERATIONS - Components comprising net loss from our discontinued operations (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
DISCONTINUED OPERATIONS    
Gross profit $ 182,464  
Loss from discontinued operations    
Loss from discontinued operations, net of taxes (3,889) $ (38,608)
Loss on disposal of discontinued operations (186,353) (38,608)
Loss from discontinued operations (186,353) (38,608)
Blue Camo | Discontinued operations, Held for sale    
DISCONTINUED OPERATIONS    
Revenues from discontinued operations, net of discounts 10,260 44,183
Cost of goods sold 9,074 28,705
Gross profit 1,186 15,478
Operating expenses from discontinued operations:    
Selling, general, and administrative 2,115 40,153
Depreciation and amortization 2,675 11,055
Total operating expenses from discontinued operations 4,790 51,208
Loss from operations (3,604) (35,730)
Other expense    
Interest Expense (580) (2,250)
Current tax provision (575) (628)
Deferred tax benefit 870  
Total income taxes 295 (628)
Loss from discontinued operations    
Loss from discontinued operations, net of taxes (3,889) (38,608)
Loss on disposal of discontinued operations (182,464)  
Loss from discontinued operations $ (186,353) $ (38,608)
XML 70 R53.htm IDEA: XBRL DOCUMENT v3.24.0.1
DISCONTINUED OPERATIONS - Loss from Discontinued operations (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
DISCONTINUED OPERATIONS    
Loss on disposal of discontinued operations $ (186,353) $ (38,608)
Blue Camo | Discontinued operations, Held for sale    
DISCONTINUED OPERATIONS    
Loss on disposal of discontinued operations (182,464)  
Gross proceeds 49,336  
Cash consideration 20,000  
Working capital adjustment 5,666  
Elimination of outstanding debt amount 23,670  
Carrying value 231,800  
Blue Camo | Discontinued Operations    
DISCONTINUED OPERATIONS    
Working capital adjustment cash proceeds 1,583  
Working capital adjustment proceeds other than cash $ 4,083  
XML 71 R54.htm IDEA: XBRL DOCUMENT v3.24.0.1
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Including 2023 Fourth Quarter Asset Acquisition (Details)
$ in Thousands
12 Months Ended
Nov. 02, 2023
USD ($)
item
Dec. 31, 2023
USD ($)
Business acquisitions    
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS    
Exchangeable stock exchange ratio   1
Goodwill expected to be deductible for income tax purposes   $ 0
Land of Lincoln Dispensary LLC    
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS    
Company recorded intangible assets $ 200  
Number of conditional adult use dispensary licenses | item 2  
Purchase consideration for acquisition $ 200  
Land of Lincoln Dispensary LLC | Conditional adult use dispensary licenses    
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS    
Amortization period 15 years  
XML 72 R55.htm IDEA: XBRL DOCUMENT v3.24.0.1
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - 2022 Second Quarter Acquisition - Fair Value of Identifiable Assets Acquired, and Liabilities Assumed as of the Acquisition Date (Details) - USD ($)
$ in Thousands
May 25, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
LIABILITIES ASSUMED        
Goodwill   $ 94,108 $ 94,108 $ 199,329
Herbal Remedies        
ASSETS ACQUIRED        
Cash $ 637      
Inventory 1,480      
Prepaid expenses and other assets 256      
Intangible assets - licenses/permits 15,700      
Property, plant, and equipment 122      
Right-of-use assets - operating 700      
Total assets acquired at fair value 18,895      
LIABILITIES ASSUMED        
Trade payables 215      
Accrued liabilities 68      
Lease liabilities - operating 700      
Total liabilities assumed at fair value 983      
Goodwill 1,180      
Consideration transferred $ 19,092      
Useful life 15 years      
XML 73 R56.htm IDEA: XBRL DOCUMENT v3.24.0.1
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - 2022 Second Quarter Acquisition - Purchase Consideration (Details) - Herbal Remedies
shares in Thousands, $ in Thousands
May 25, 2022
USD ($)
item
shares
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS  
Number of licensed retail dispensaries operated | item 2
Cash $ 3,002
Debt Payable 14,220
Shares Issued $ 1,870
Shares Issued, shares | shares 353
Purchase consideration $ 19,092
Percentage of discount rate used to determine fair value of Exchangeable Shares issued 16.55%
Purchase consideration for acquisition $ 3,002
Minimum  
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS  
Lock-up provision period for Exchangeable Shares issued 6 months
Maximum  
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS  
Lock-up provision period for Exchangeable Shares issued 12 months
XML 74 R57.htm IDEA: XBRL DOCUMENT v3.24.0.1
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - 2022 First Quarter Acquisition - Fair Value of Identifiable Assets Acquired, and Liabilities Assumed as of the Acquisition Date (Details) - USD ($)
$ in Thousands
12 Months Ended
Feb. 15, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
LIABILITIES ASSUMED        
Goodwill   $ 94,108 $ 94,108 $ 199,329
Trade name / brand        
LIABILITIES ASSUMED        
Amortization period for intangible assets   5 years    
Host community agreements        
LIABILITIES ASSUMED        
Amortization period for intangible assets   15 years    
Cultivauna        
ASSETS ACQUIRED        
Cash $ 1,251      
Accounts receivable 471      
Inventory 1,206      
Prepaid expenses and other assets 38      
Intangible assets 5,500      
Property, plant, and equipment 2,202      
Right-of-use assets - operating 315      
Total assets acquired at fair value 10,983      
LIABILITIES ASSUMED        
Trade payables 23      
Accrued liabilities 305      
Lease liabilities - operating 315      
Total liabilities assumed at fair value 643      
Goodwill 11,281      
Consideration transferred $ 21,621      
Cultivauna | Minimum        
LIABILITIES ASSUMED        
Amortization period for intangible assets 5 years      
Cultivauna | Maximum        
LIABILITIES ASSUMED        
Amortization period for intangible assets 15 years      
Cultivauna | Trade name / brand        
ASSETS ACQUIRED        
Intangible assets $ 3,400      
Cultivauna | Host community agreements        
ASSETS ACQUIRED        
Intangible assets $ 2,100      
XML 75 R58.htm IDEA: XBRL DOCUMENT v3.24.0.1
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - 2022 First Quarter Acquisition - Purchase Consideration (Details) - Cultivauna
shares in Thousands, $ in Thousands
Feb. 15, 2022
USD ($)
shares
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS  
Cash $ 11,027
Shares Issued $ 4,482
Shares Issued, shares | shares 329
Contingent Consideration $ 6,112
Purchase consideration $ 21,621
Percentage of discount rate used to determine fair value of Exchangeable Shares issued 14.85%
Minimum  
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS  
Lock-up provision period for Exchangeable Shares issued 6 months
Maximum  
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS  
Lock-up provision period for Exchangeable Shares issued 12 months
XML 76 R59.htm IDEA: XBRL DOCUMENT v3.24.0.1
VARIABLE INTEREST ENTITIES ("VIE") - Fair Value of Identifiable Assets Acquired and Liabilities Assumed as of the Acquisition Date (Details)
shares in Thousands, $ in Thousands
1 Months Ended 12 Months Ended
May 31, 2023
USD ($)
shares
Feb. 28, 2022
entity
Dec. 31, 2023
USD ($)
shares
Dec. 31, 2022
USD ($)
shares
Dec. 31, 2021
USD ($)
Mar. 30, 2021
ft²
VARIABLE INTEREST ENTITIES ("VIE")            
Number of entities over which the company has the ability to direct activities | entity   2        
LIABILITIES ASSUMED            
Goodwill     $ 94,108 $ 94,108 $ 199,329  
Exchangeable Shares            
VARIABLE INTEREST ENTITIES ("VIE")            
Conversion of Exchangeable Shares (Shares) | shares     (430) (2,006)    
Tahoe Hydro            
VARIABLE INTEREST ENTITIES ("VIE")            
Membership interest 100.00%          
Purchase consideration for acquisition $ 1,382          
Discount rate attributed to the contractual restrictions 19.45%          
Tahoe Hydro | Minimum            
VARIABLE INTEREST ENTITIES ("VIE")            
Lock-up provision period for Exchangeable Shares issued 6 months          
Tahoe Hydro | Maximum            
VARIABLE INTEREST ENTITIES ("VIE")            
Lock-up provision period for Exchangeable Shares issued 12 months          
Tahoe Hydro | Exchangeable Shares            
VARIABLE INTEREST ENTITIES ("VIE")            
Shares Issued $ 115          
Conversion of Exchangeable Shares (Shares) | shares 233          
Tahoe Hydro | Promissory Note            
VARIABLE INTEREST ENTITIES ("VIE")            
Incurred through combinations and acquisitions $ 1,580          
Tahoe Hydro | Convertible Note            
VARIABLE INTEREST ENTITIES ("VIE")            
Incurred through combinations and acquisitions $ 2,800          
Parma            
VARIABLE INTEREST ENTITIES ("VIE")            
Area of facility | ft²           58,000
Purchase of minority interest     $ 25      
Ohio Dispensaries            
VARIABLE INTEREST ENTITIES ("VIE")            
Equity interest in dispensaries     100.00%      
XML 77 R60.htm IDEA: XBRL DOCUMENT v3.24.0.1
VARIABLE INTEREST ENTITIES ("VIE") - Summary of Financial Information about Consolidated VIEs (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
VARIABLE INTEREST ENTITIES ("VIE")    
TOTAL ASSETS $ 1,459,855 $ 1,767,770
Current liabilities 200,478 268,805
TOTAL LIABILITIES 889,203 932,446
Noncontrolling interests (11,126) 2,000
Equity attributable to Ayr Wellness Inc. 581,778 833,324
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY 1,459,855 1,767,770
Revenues, net of discounts 463,630 421,435
Net income (loss) attributable to noncontrolling interest (7,067) (10,019)
Net loss attributable to Ayr Wellness Inc. (272,433) (245,466)
Net loss noncontrolling interest (279,500) (255,485)
Noncontrolling interest at beginning 2,000  
Net loss attributable to noncontrolling interest (7,067) (10,019)
Noncontrolling interest at ending (11,126) 2,000
VIE    
VARIABLE INTEREST ENTITIES ("VIE")    
Current assets 8,008 15,999
Non-current assets 20,728 21,216
TOTAL ASSETS 28,736 37,215
Current liabilities 21,213 15,125
Non-current liabilities 5,032 2,850
TOTAL LIABILITIES 26,245 17,975
Noncontrolling interests (11,126) 2,000
Equity attributable to Ayr Wellness Inc. 13,617 17,240
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY 28,736 37,215
Revenues, net of discounts 3,632 1,851
Net income (loss) attributable to noncontrolling interest (7,067) (10,019)
Net loss attributable to Ayr Wellness Inc. (1,275)  
Net loss noncontrolling interest (8,342) (10,019)
Noncontrolling interest at beginning 2,000  
Total purchase consideration   16,868
Working capital adjustment presented as consideration payable   (4,849)
Acquisition of Tahoe Hydro (6,059)  
Net loss attributable to noncontrolling interest (7,067) (10,019)
Noncontrolling interest at ending (11,126) 2,000
TH/NVG    
VARIABLE INTEREST ENTITIES ("VIE")    
Current assets (351) 5,248
Non-current assets 1,077 6,582
TOTAL ASSETS 726 11,830
Current liabilities 604 1,033
Non-current liabilities 383 898
TOTAL LIABILITIES 987 1,931
Noncontrolling interests 796 7,528
Equity attributable to Ayr Wellness Inc. (1,057) 2,371
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY 726 11,830
Revenues, net of discounts   1,851
Net income (loss) attributable to noncontrolling interest (673) (4,491)
Net loss noncontrolling interest (673) (4,491)
Noncontrolling interest at beginning 7,528  
Total purchase consideration   16,868
Working capital adjustment presented as consideration payable   (4,849)
Acquisition of Tahoe Hydro (6,059)  
Net loss attributable to noncontrolling interest (673) (4,491)
Noncontrolling interest at ending 796 7,528
Parma    
VARIABLE INTEREST ENTITIES ("VIE")    
Current assets 10,616 10,751
Non-current assets 13,210 14,634
TOTAL ASSETS 23,826 25,385
Current liabilities 18,962 14,092
Non-current liabilities 1,280 1,952
TOTAL LIABILITIES 20,242 16,044
Noncontrolling interests (10,158) (5,528)
Equity attributable to Ayr Wellness Inc. 13,742 14,869
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY 23,826 25,385
Revenues, net of discounts 3,170  
Net income (loss) attributable to noncontrolling interest (4,630) (5,528)
Net loss attributable to Ayr Wellness Inc. (1,275)  
Net loss noncontrolling interest (5,905) (5,528)
Noncontrolling interest at beginning (5,528)  
Net loss attributable to noncontrolling interest (4,630) (5,528)
Noncontrolling interest at ending (10,158) $ (5,528)
Ohio Dispensaries    
VARIABLE INTEREST ENTITIES ("VIE")    
Current assets (2,257)  
Non-current assets 6,441  
TOTAL ASSETS 4,184  
Current liabilities 1,647  
Non-current liabilities 3,369  
TOTAL LIABILITIES 5,016  
Noncontrolling interests (1,764)  
Equity attributable to Ayr Wellness Inc. 932  
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY 4,184  
Revenues, net of discounts 462  
Net income (loss) attributable to noncontrolling interest (1,764)  
Net loss noncontrolling interest (1,764)  
Net loss attributable to noncontrolling interest (1,764)  
Noncontrolling interest at ending $ (1,764)  
XML 78 R61.htm IDEA: XBRL DOCUMENT v3.24.0.1
INVENTORY (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
INVENTORY    
Materials, supplies, and packaging $ 7,505 $ 9,770
Work in process 69,632 65,807
Finished goods 29,226 24,233
Total inventory 106,363 99,810
Expenses relating to the incremental costs to acquire inventory in business combinations   6,217
Cost of goods sold    
INVENTORY    
Amount of inventory recognized $ 218,587 $ 205,809
XML 79 R62.htm IDEA: XBRL DOCUMENT v3.24.0.1
PROPERTY, PLANT, AND EQUIPMENT (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
PROPERTY, PLANT, AND EQUIPMENT    
Total $ 348,591 $ 324,163
Less: Accumulated depreciation and amortization 37,976 21,483
Total property, plant and equipment, net 310,615 302,680
Capitalized interest 9,981 14,490
Depreciation and amortization 25,226 14,257
Impairment loss on PPE 4,858  
Cost of goods sold    
PROPERTY, PLANT, AND EQUIPMENT    
Depreciation and amortization 15,846 9,858
Furniture and equipment    
PROPERTY, PLANT, AND EQUIPMENT    
Total 52,793 53,070
Auto and trucks    
PROPERTY, PLANT, AND EQUIPMENT    
Total 1,393 1,626
Buildings    
PROPERTY, PLANT, AND EQUIPMENT    
Total 94,914 91,233
Leasehold improvements    
PROPERTY, PLANT, AND EQUIPMENT    
Total 173,043 154,774
Land    
PROPERTY, PLANT, AND EQUIPMENT    
Total 13,877 13,879
Construction in progress    
PROPERTY, PLANT, AND EQUIPMENT    
Total $ 12,571 $ 9,581
XML 80 R63.htm IDEA: XBRL DOCUMENT v3.24.0.1
GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2022
USD ($)
GOODWILL AND INTANGIBLE ASSETS  
As of beginning $ 199,329
Acquired through business combinations and initial consolidation of VIEs 12,729
Impairment of goodwill (117,950)
As of ending $ 94,108
XML 81 R64.htm IDEA: XBRL DOCUMENT v3.24.0.1
GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Intangible Assets    
Amortization expense $ 58,646 $ 57,122
Intangible assets, net 687,988 744,709
Amortization Expense    
2024 58,123  
2025 57,308  
2026 57,308  
2027 57,308  
2028 57,308  
2029 and beyond 397,433  
Total 684,788  
Connecticut    
Intangible Assets    
Amortization expense $ 0  
Licenses/permits    
Intangible Assets    
Amortization period (# of years) 15 years  
Intangible assets, net $ 641,036 693,714
Area Cultivator License    
Intangible Assets    
Amount of intangible asset in connection with the cash payment for the cost of the provisional license 3,000  
Standalone Delivery License    
Intangible Assets    
Amount of intangible asset in connection with the cash payment for the cost of the provisional license $ 200  
Right-to-use licenses    
Intangible Assets    
Amortization period (# of years) 15 years  
Intangible assets, net $ 16,407 17,717
Host community agreements    
Intangible Assets    
Amortization period (# of years) 15 years  
Intangible assets, net $ 26,954 29,494
Trade name / brand    
Intangible Assets    
Amortization period (# of years) 5 years  
Intangible assets, net $ 3,591 3,784
Cost of goods sold    
Intangible Assets    
Amortization expense $ 16,825 $ 15,907
XML 82 R65.htm IDEA: XBRL DOCUMENT v3.24.0.1
GOODWILL AND INTANGIBLE ASSETS - Impairment of Goodwill (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
GOODWILL AND INTANGIBLE ASSETS      
Extended forecast period 5 years    
Terminal growth rate (in percent) 3.00%    
Post-tax discount rate (in percent) 20.00%    
WACC (in percent) 18.00%    
Impairment of goodwill   $ 117,950  
Goodwill $ 94,108 $ 94,108 $ 199,329
XML 83 R66.htm IDEA: XBRL DOCUMENT v3.24.0.1
RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Information Related to Leases (Details)
Dec. 31, 2023
Dec. 31, 2022
RIGHT-OF-USE ASSETS AND LEASE LIABILITIES    
Operating Leases Incremental borrowing rate (weighted average) 11.83% 11.98%
Operating Leases Weighted average remaining lease term 12 years 1 month 13 days 13 years 14 days
Finance Leases Incremental borrowing rate (weighted average) 10.37% 9.68%
Finance Leases Weighted average remaining lease term 4 years 9 months 3 days 4 years 10 months 24 days
XML 84 R67.htm IDEA: XBRL DOCUMENT v3.24.0.1
RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Maturity of Contractual Undiscounted Lease Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Jun. 30, 2022
Operating Leases    
2024 $ 29,457  
2025 29,112  
2026 28,381  
2027 27,125  
2028 26,507  
2029 and beyond 198,164  
Total undiscounted lease liabilities 338,746  
Impact of discounting (203,231)  
Total present value of minimum lease payments 135,515 $ 25,331
Finance Leases    
2024 12,098  
2025 6,428  
2026 4,412  
2027 3,340  
2028 2,501  
2029 and beyond 6,428  
Total undiscounted lease liabilities 35,207  
Impact of discounting (7,411)  
Total present value of minimum lease payments 27,796  
Total Operating Lease and Finance Leases    
2024 41,555  
2025 35,540  
2026 32,793  
2027 30,465  
2028 29,008  
2029 and beyond 204,592  
Total undiscounted lease liabilities 373,953  
Impact of discounting (210,642)  
Total present value of minimum lease payments $ 163,311  
XML 85 R68.htm IDEA: XBRL DOCUMENT v3.24.0.1
RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Payments related to capitalized Lease (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Lease liabilities - finance    
Total lease expense $ 35,281 $ 27,798
COGS    
Lease liabilities - operating    
Lease fees 8,783 6,604
Lease liabilities - finance    
Amortization of right-of-use assets 6,913 4,584
Interest on lease liabilities - finance 3,017 2,422
G&A    
Lease liabilities - operating    
Lease fees 16,366 13,943
Lease liabilities - finance    
Amortization of right-of-use assets 165 187
Interest on lease liabilities - finance $ 37 $ 58
XML 86 R69.htm IDEA: XBRL DOCUMENT v3.24.0.1
RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Additional information (Details)
$ in Thousands
1 Months Ended 12 Months Ended
Jun. 30, 2022
USD ($)
item
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Leases      
Number of cultivation and processing facilities entered for sale and lease back | item 2    
Purchase price of sale and lease back transaction $ 28,107    
Gain on sale of assets 2,173 $ (91) $ 8
Lease liability 25,331 135,515  
Right-of-use assets - operating, net 25,339 127,024 121,340
ROU asset, work allowance 750    
Proceeds from financing transaction, net of financing costs 27,599    
Maximum construction financing allowance $ 14,187    
Initial term of the agreement 15 years    
Number of options to renew | item 2    
Renewal term 5 years    
Percentage of initial payments on purchase price 10.00%    
Percentage of increase in payments annually after first year 3.00%    
Construction finance liabilities   38,205 $ 36,181
Transactions for sale-leaseback treatment, gain or loss was recognized   0  
Impairment loss on ROU operating assets   $ 1,462  
Buildings and improvements      
Leases      
Assets divested $ 22,206    
Land      
Leases      
Assets divested $ 3,728    
XML 87 R70.htm IDEA: XBRL DOCUMENT v3.24.0.1
RELATED PARTY TRANSACTIONS AND BALANCES (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
RELATED PARTY TRANSACTIONS AND BALANCES    
Interest expense, net $ 39,403 $ 28,323
Share issuance - related party - consulting services 79 707
Related party debt | Mercer Park, L.P.    
RELATED PARTY TRANSACTIONS AND BALANCES    
Prepaid expenses   698
Lease fees 858 861
General and administrative expenses   12
Related party debt | Board member    
RELATED PARTY TRANSACTIONS AND BALANCES    
Office expenses 54 54
Development fees 24 392
Rental fees 1,083 920
Interest expense, net $ 83 $ 165
Share issuance - related party - consulting services (Shares)   50
Share issuance - related party - consulting services   $ 707
XML 88 R71.htm IDEA: XBRL DOCUMENT v3.24.0.1
DEBTS PAYABLE AND SENIOR SECURED NOTES (Details) - USD ($)
$ in Thousands
12 Months Ended
Nov. 12, 2021
Dec. 31, 2023
Dec. 31, 2022
DEBTS PAYABLE AND SENIOR SECURED NOTES      
Proceeds from secured promissory notes   $ 10,665 $ 51,713
Senior secured notes      
DEBTS PAYABLE AND SENIOR SECURED NOTES      
Principal amount $ 133,250    
Proceeds from secured promissory notes $ 147,000    
Interest rate 9.80%    
XML 89 R72.htm IDEA: XBRL DOCUMENT v3.24.0.1
DEBTS PAYABLE AND SENIOR SECURED NOTES - Changes in senior secured notes (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Senior secured notes    
Amortization of financing costs $ 2,341 $ 2,292
Amortization of debt premium 3,018 3,018
Senior secured notes    
Senior secured notes    
Debt (Period Beginning) 244,682 245,408
Amortization of financing costs 2,291 2,292
Amortization of debt premium (3,018) (3,018)
Debt (Period End)   $ 244,682
Total senior secured notes classified as non-current payable as of December 31, 2023 $ 243,955  
XML 90 R73.htm IDEA: XBRL DOCUMENT v3.24.0.1
DEBTS PAYABLE AND SENIOR SECURED NOTES - Changes in debt other than senior secured notes (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Senior secured notes      
Debt issuance costs $ (9,049)    
Amortization of financing costs 2,341 $ 2,292  
Less: discounted to fair value 23,023 63,088  
Debts payable      
Senior secured notes      
Debts payable (Period Beginning) 235,524 133,858  
Debt Discount (Premium) (199) 598 $ 951
Incurred through earn-out provision   14,934  
Debt issuance costs (1,000)    
Amortization of financing costs 50    
Debt issued 66,245 68,000  
Construction financing 2,024 36,303  
Less: extinguishment related to sale of Arizona business (22,505)    
Less: repayment (52,029) (17,924)  
Less: discounted to fair value   (598)  
Debts payable (Period end) 229,856 235,524  
Debt Instrument After Financing Costs, Before Premium Or Discount 228,907    
Less: discounted to fair value 199 $ (598) $ (951)
Total debts payable as of December 31, 2023 228,708    
Total accrued interest payable related to debts payable as of December 31, 2023 $ 7,513    
XML 91 R74.htm IDEA: XBRL DOCUMENT v3.24.0.1
DEBTS PAYABLE AND SENIOR SECURED NOTES - Debts payable (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Total debt      
DEBTS PAYABLE AND SENIOR SECURED NOTES      
Total debts payable, undiscounted $ 229,856 $ 235,524 $ 133,858
Less: current portion 23,152    
Less: debt issuance costs - current portion 99    
Total non-current debt, undiscounted 206,605    
Less: discount to fair value 199    
Less: debt issuance costs - non-current portion 850    
Total non-current debt 205,556    
Related party debt      
DEBTS PAYABLE AND SENIOR SECURED NOTES      
Total debts payable, undiscounted 733    
Less: current portion 733    
Non-related party debt      
DEBTS PAYABLE AND SENIOR SECURED NOTES      
Total debts payable, undiscounted 229,123    
Less: current portion 22,419    
Less: debt issuance costs - current portion 99    
Total non-current debt, undiscounted 206,605    
Less: discount to fair value 199    
Less: debt issuance costs - non-current portion 850    
Total non-current debt $ 205,556    
XML 92 R75.htm IDEA: XBRL DOCUMENT v3.24.0.1
DEBTS PAYABLE AND SENIOR SECURED NOTES - Future debt obligations (Details) - Debts payable - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Future debt obligations (per year)      
2024 $ 23,175    
2025 23,673    
2026 64,256    
2027 14,527    
2028 2,939    
2029 and beyond 101,286    
Total debt obligations $ 229,856 $ 235,524 $ 133,858
XML 93 R76.htm IDEA: XBRL DOCUMENT v3.24.0.1
DEBTS PAYABLE AND SENIOR SECURED NOTES - Narratives (Details) - USD ($)
1 Months Ended 12 Months Ended
Oct. 31, 2023
Jul. 07, 2023
May 11, 2023
Mar. 27, 2023
Mar. 24, 2023
May 25, 2022
May 16, 2022
Mar. 17, 2022
Mar. 01, 2022
May 31, 2023
Dec. 31, 2023
Dec. 31, 2022
Nov. 01, 2023
DEBTS PAYABLE AND SENIOR SECURED NOTES                          
Deferred cash                       $ 63,429,000  
LivFree Wellness, LLC                          
DEBTS PAYABLE AND SENIOR SECURED NOTES                          
Interest rate 6.00%                       10.00%
Principal payment $ 3,000,000                        
Remaining principal amount 17,000,000                        
Accrued payment-in-kind interest $ 5,530,000                        
Blue Camo | Discontinued operations, Held for sale                          
DEBTS PAYABLE AND SENIOR SECURED NOTES                          
Debt extinguished       $ 22,505,000                  
Accrued interest extinguished       $ 1,165,000                  
Prepaid expenses and other current assets                          
DEBTS PAYABLE AND SENIOR SECURED NOTES                          
Vendor promissory notes                     $ 9,951,000    
Related Party [Member]                          
DEBTS PAYABLE AND SENIOR SECURED NOTES                          
Interest expense                     83,000 $ 1,507,000  
Five year federal home loan bank                          
DEBTS PAYABLE AND SENIOR SECURED NOTES                          
Interest only payments period   18 months                      
Sira Naturals, Inc.                          
DEBTS PAYABLE AND SENIOR SECURED NOTES                          
Deferral term     2 years                    
Herbal Remedies                          
DEBTS PAYABLE AND SENIOR SECURED NOTES                          
Shares Issued, shares           353,000              
GSD                          
DEBTS PAYABLE AND SENIOR SECURED NOTES                          
Contingent consideration cash     $ 10,000,000                    
Shares Issued, shares     3,797                    
Deferred cash in satisfaction of contingent consideration     $ 10,925,000                    
Equity Shares incurred in satisfaction of contingent consideration     $ 4,647,000                    
Deferred cash net of payments made                     10,094,000    
Deferred cash payments made                     831,000    
Market price of equity     $ 0.79                    
Related party notes                          
DEBTS PAYABLE AND SENIOR SECURED NOTES                          
Principal amount                   $ 69,000,000      
Debt issued   $ 25,219                      
Related party notes | Sira Naturals, Inc.                          
DEBTS PAYABLE AND SENIOR SECURED NOTES                          
Interest rate     6.00%                    
Debt payable     $ 27,500,000                    
Amortization Rate     10.00%                    
Related party notes | Herbal Remedies                          
DEBTS PAYABLE AND SENIOR SECURED NOTES                          
Principal amount           $ 14,220,000              
Notes term           5 years              
Interest rate           8.00%              
Related party notes | Tahoe Hydro                          
DEBTS PAYABLE AND SENIOR SECURED NOTES                          
Principal amount                   $ 1,580,000      
Notes term                   4 years      
Interest rate                   8.00%      
Related party notes | GSD                          
DEBTS PAYABLE AND SENIOR SECURED NOTES                          
Principal amount     $ 14,000,000                    
Interest rate     13.50%                    
Contingent consideration satisfied, total     $ 38,860,000                    
Liabilities incurred in satisfaction of contingent consideration     $ 14,000,000                    
Amortization Rate     1.00%                    
Non-related party note | PA Natural                          
DEBTS PAYABLE AND SENIOR SECURED NOTES                          
Principal amount                 $ 14,934,000        
Notes term                 3 years        
Interest rate                 8.00%        
Loan agreement with a community bank                          
DEBTS PAYABLE AND SENIOR SECURED NOTES                          
Notes term             2 years 5 years          
Interest rate         8.00%     4.625%          
Debt issued         $ 10,000,000   $ 25,800,000 $ 26,200,000          
Financing cost         $ 100,000     $ 287,000          
Spread on variable rate             1.50%            
Extension Term               5 years          
Loan agreement with a community bank | Minimum                          
DEBTS PAYABLE AND SENIOR SECURED NOTES                          
Debt effective interest rate             5.00%            
Loan agreement due May 2024                          
DEBTS PAYABLE AND SENIOR SECURED NOTES                          
Principal amount   $ 40,000,000                      
Notes term   10 years                      
Debt effective interest rate   8.27%                      
Loan agreement due May 2024 | Five year federal home loan bank                          
DEBTS PAYABLE AND SENIOR SECURED NOTES                          
Spread on variable rate   4.00%                      
Contingent consideration- vendor take back promissory notes                          
DEBTS PAYABLE AND SENIOR SECURED NOTES                          
Principal amount                   $ 60,500,000      
Contingent consideration- vendor take back promissory notes | Senior Secured Notes                          
DEBTS PAYABLE AND SENIOR SECURED NOTES                          
Indebtedness amount                     116,063,000    
Debt under subordinate agreement                     $ 77,110,000    
Secured promissory notes interest rate 9.8%                          
DEBTS PAYABLE AND SENIOR SECURED NOTES                          
Extension Term 2 years                        
Secured promissory notes interest rate 9.8% | Minimum                          
DEBTS PAYABLE AND SENIOR SECURED NOTES                          
Extension Term                   2 years      
XML 94 R77.htm IDEA: XBRL DOCUMENT v3.24.0.1
SHARE CAPITAL - Activity occurred during the year end (Details) - shares
1 Months Ended 12 Months Ended
May 31, 2023
Dec. 31, 2023
Dec. 31, 2022
SHARE CAPITAL      
Shares issued in connection with options exercised   6,000 33,000
RSUs      
SHARE CAPITAL      
Vested (in shares)   3,262,000 2,135,000
Equity Shares issued   3,169,000 1,459,000
Awards forfeited   137,000 78,000
Subordinate, Restricted, and Limited Voting Shares      
SHARE CAPITAL      
Shares cancelled during the period     5,000
Shares repurchased during the period     5,000
Equity Shares issued   3,169,000 1,459,000
Shares issued in connection with options exercised     33,000
Shares issued in connection with earn-out provision related to the acquisition     1,029,000
Shares issued to a related party for services rendered   66,000 76,000
Shares converted or exchanged for Equity Shares   430,000 2,006,000
Subordinate, Restricted, and Limited Voting Shares | CannTech PA, LLC      
SHARE CAPITAL      
Shares converted or exchanged for Equity Shares     908,000
Subordinate, Restricted, and Limited Voting Shares | Levia      
SHARE CAPITAL      
Shares converted or exchanged for Equity Shares   52,000  
Subordinate, Restricted, and Limited Voting Shares | Herbal Remedies      
SHARE CAPITAL      
Shares converted or exchanged for Equity Shares   354,000  
Subordinate, Restricted, and Limited Voting Shares | Blue Camo      
SHARE CAPITAL      
Shares converted or exchanged for Equity Shares     1,027,000
Subordinate, Restricted, and Limited Voting Shares | Other than a business acquisition      
SHARE CAPITAL      
Shares converted or exchanged for Equity Shares   9,000 71,000
Subordinate, Restricted, and Limited Voting Shares And Treasury Shares      
SHARE CAPITAL      
Shares repurchased during the period     82,000
Exchangeable Shares      
SHARE CAPITAL      
Shares issued in connection with earn-out provision related to the acquisition   3,798,000  
Shares issued in connection with the acquisition     682,000
Shares converted or exchanged for Equity Shares   (430,000) (2,006,000)
Exchangeable Shares | CannTech PA, LLC      
SHARE CAPITAL      
Shares converted or exchanged for Equity Shares     908,000
Exchangeable Shares | Cultivauna      
SHARE CAPITAL      
Shares issued in connection with the acquisition     329,000
Exchangeable Shares | Levia      
SHARE CAPITAL      
Shares converted or exchanged for Equity Shares   52,000  
Exchangeable Shares | Herbal Remedies      
SHARE CAPITAL      
Shares issued in connection with the acquisition     353,000
Shares converted or exchanged for Equity Shares   354,000  
Exchangeable Shares | Blue Camo      
SHARE CAPITAL      
Shares converted or exchanged for Equity Shares   15 1,027,000
Exchangeable Shares | GSD      
SHARE CAPITAL      
Shares issued in connection with the acquisition   3,798,000  
Exchangeable Shares | Tahoe Hydro      
SHARE CAPITAL      
Shares issued in connection with the acquisition   233,000  
Shares converted or exchanged for Equity Shares 233,000    
Exchangeable Shares | Other than a business acquisition      
SHARE CAPITAL      
Shares converted or exchanged for Equity Shares   9,000  
XML 95 R78.htm IDEA: XBRL DOCUMENT v3.24.0.1
SHARE CAPITAL - Warrants (Details) - Warrants - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Warrants    
Average remaining life of Warrants 4 months 24 days 1 year 4 months 24 days
Aggregate intrinsic value of warrants $ 0 $ 0
Warrants, exercise price $ 9.07  
Number of warrants outstanding    
Balance at the beginning 2,874 2,874
(no activity) 0 0
Balance at the end 2,874 2,874
Weighted Average Fair Value    
Balance at the beginning $ 1,786 $ 1,786
(no activity) 0 0
Balance at the end $ 1,786 $ 1,786
XML 96 R79.htm IDEA: XBRL DOCUMENT v3.24.0.1
DERIVATIVE LIABILITIES - Schedule of Fair Value Adjustment Relating to Derivative Liabilities (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
DERIVATIVE LIABILITIES    
Gain from FV adjustment on contingent consideration $ 27,597 $ 61,675
Loss from FV adjustment on purchase consideration settlement   (1,780)
(Loss) gain from settlement of contingent consideration (4,578) 3,186
Other 4 7
Total 23,023 $ 63,088
Sira    
DERIVATIVE LIABILITIES    
(Loss) gain from settlement of contingent consideration (3,660)  
GSD    
DERIVATIVE LIABILITIES    
(Loss) gain from settlement of contingent consideration $ (918)  
XML 97 R80.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCK-BASED COMPENSATION (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
12 Months Ended
May 02, 2021
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
STOCK-BASED COMPENSATION        
Maximum percentage of shares authorized to issue 12.00%      
Ratio applied for shares issued under one share based compensation plan that will reduce the number of shares that may be awarded under another plan 1      
Tax withholding on stock-based compensation awards   $ 366 $ 5,258  
Option exercise price minimum (in dollars per share)   $ 10.59    
Option exercise price maximum (in dollars per share)     $ 29.60  
RSUs        
STOCK-BASED COMPENSATION        
Number of awards outstanding   4,989 6,628 8,100
Awards forfeited   137 78  
Awards vested   3,262 2,135  
Awards issued due to net settlement   3,169 1,459  
Tax withholding on stock-based compensation awards (Shares)   93 676  
Tax withholding on stock-based compensation awards   $ 366 $ 5,258  
Average remaining life of unvested awards   1 year 11 months 1 year 3 months  
Expected expense   $ 9,967 $ 21,538  
Aggregate intrinsic value, other than option   $ 16,714 $ 16,135  
RSUs | Minimum        
STOCK-BASED COMPENSATION        
Vesting period   1 year    
RSUs | Maximum        
STOCK-BASED COMPENSATION        
Vesting period   4 years    
Market and performance based RSUs        
STOCK-BASED COMPENSATION        
Number of awards outstanding   1,300    
Market based awards        
STOCK-BASED COMPENSATION        
Number of awards outstanding   650    
Performance based awards        
STOCK-BASED COMPENSATION        
Number of awards outstanding     650  
Options        
STOCK-BASED COMPENSATION        
Average remaining life of unvested awards   6 months 8 months  
XML 98 R81.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCK-BASED COMPENSATION - RSUs (Details) - RSUs - $ / shares
shares in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Number of Shares    
Outstanding and nonvested at beginning (in shares) 6,628 8,100
Granted (in shares) 1,760 741
Vested (in shares) (3,262) (2,135)
Forfeited (in shares) (137) (78)
Outstanding and nonvested at ending (in shares) 4,989 6,628
Weighted Average Grant Date Fair Value    
Outstanding and nonvested at beginning (in dollars per share) $ 17.56 $ 18.83
Granted (in dollars per share) 1.20 6.45
Vested (in dollars per share) 18.15 18.58
Forfeited (in dollars per share) 9.09 15.90
Outstanding and nonvested at ending (in dollars per share) $ 11.64 $ 17.56
XML 99 R82.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCK-BASED COMPENSATION - Options (Details) - $ / shares
shares in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Number of Options    
Balance at beginning (in shares) 165 198
Options exercised (in shares) (6) (33)
Balance at ending (in shares) 159 165
Weighted Average Fair Value    
Balance at beginning (in dollars per share) $ 17.93 $ 17.93
Options exercised (in dollars per share) 17.93 17.93
Balance at ending (in dollars per share) $ 20.30 $ 17.93
XML 100 R83.htm IDEA: XBRL DOCUMENT v3.24.0.1
COMMITMENTS AND CONTINGENCIES (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2023
USD ($)
COMMITMENTS AND CONTINGENCIES  
ERC claimed amount $ 12,354
ERC refund amount 5,238
Third party, lease obligation  
COMMITMENTS AND CONTINGENCIES  
Guarantor lease maximum payments 764
Contractual obligation $ 10,619
XML 101 R84.htm IDEA: XBRL DOCUMENT v3.24.0.1
FINANCIAL RISK FACTORS (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
FINANCIAL RISK FACTORS    
Assets, transfer from Level 1 to level 2 $ 0 $ 0
Assets, transfer from Level 2 to level 1 0 0
Liabilities transfer from Level 1 to level 2 0 0
Liabilities, transfer from Level 2 to level 1 0 0
Assets transfer Level 3 0 0
Liabilities, transfer from Level 3 $ 0 $ 0
XML 102 R85.htm IDEA: XBRL DOCUMENT v3.24.0.1
FINANCIAL RISK FACTORS - Fair Value Hierarchy (Details)
$ in Thousands
Dec. 31, 2022
USD ($)
Level 3  
FINANCIAL RISK FACTORS  
Contingent consideration $ 90,090
XML 103 R86.htm IDEA: XBRL DOCUMENT v3.24.0.1
TAXATION (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Current expense :    
Federal $ 47,727 $ 34,121
State 7,112 9,040
Total current expense : 54,839 43,161
Deferred (benefit) expense :    
Federal (6,912) (3,173)
State (536) 4,761
Foreign (1,235) (232)
Chane in valuation allowance 1,235 232
Total deferred (benefit) expense : (7,448) 1,588
Total income tax expense : 47,391 $ 44,749
Interest and penalties $ 9,762  
XML 104 R87.htm IDEA: XBRL DOCUMENT v3.24.0.1
TAXATION - Difference Between the Income Tax Expense and the Expected Income Taxes Based on the Statutory Tax Rate (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
TAXATION    
Expected income tax recovery $ (9,609) $ (36,147)
Difference in foreign tax rates (6,030) (4,311)
State taxes 6,576 13,802
Foreign exchange gain or loss 370 146
Impairment loss 1,327 24,769
Translation adjustment (226) 669
Unrealized change in fair value of financial liabilities (4,835) (13,248)
Acquisition costs 872 147
Interest income inclusion 6,465 4,244
Non-deductible expenses 46,262 58,423
Amortization of debt premium (815) (815)
Restricted Stock 731  
Accrued tax penalties and interest 9,762  
Change in effective tax rate (1,627)  
Prior year adjustment (2,201) (2,877)
Valuation allowance 1,235 232
Other (867) (285)
Total income tax expense : $ 47,391 $ 44,749
XML 105 R88.htm IDEA: XBRL DOCUMENT v3.24.0.1
TAXATION - Deferred Tax Assets and Liability (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Deferred tax assets    
Net operating losses $ 11,663 $ 9,515
Share issuance costs 616 1,311
Share based compensation 210 1,385
Inventory 2,032 1,298
Lease liabilities 1,170  
Other assets 1,153 763
Total deferred tax assets 16,844 14,272
Deferred tax liabilities    
Depreciation (7,846) (7,173)
Amortization (63,320) (69,440)
Debt financing costs (584) (1,202)
Other liabilities (40) (86)
Total deferred tax liabilities (71,790) (77,901)
Valuation allowance (10,019) (8,784)
Net deferred tax liability (64,965) (72,413)
Increase in valuation allowance 1,235 232
Net operating loss carryforwards subject to expiration 32,865 30,538
State and Local Jurisdiction [Member]    
Deferred tax liabilities    
Net operating loss carryforwards subject to expiration $ 15,688 $ 15,867
XML 106 R89.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUBSEQUENT EVENTS (Details)
$ / shares in Units, $ in Thousands
2 Months Ended
Mar. 14, 2024
USD ($)
$ / shares
shares
Mar. 14, 2024
USD ($)
item
$ / shares
Senior notes with Interest Rate 12.5%, Due 2024    
SUBSEQUENT EVENTS    
Interest rate (in percent) 12.50% 12.50%
Subsequent Events    
SUBSEQUENT EVENTS    
Interest rate (in percent) 13.00% 13.00%
New Money Notes | $ $ 50,000 $ 50,000
Subsequent Events | Subordinate, Restricted, and Limited Voting Shares [Member]    
SUBSEQUENT EVENTS    
Number of Shares Agreed to be Issued in Exchange of Notes 29,040  
Subsequent Events | Subordinate, Restricted, and Limited Voting Shares [Member] | Backstop Noteholders [Member]    
SUBSEQUENT EVENTS    
Number of Shares Agreed to be Issued in Exchange of Notes 5,948  
Subsequent Events | Anti-Dilutive Warrants    
SUBSEQUENT EVENTS    
Exercise price of warrants | $ / shares $ 2.12 $ 2.12
Class of Warrant or Right, Issued 23,046  
Subsequent Events | Senior Notes    
SUBSEQUENT EVENTS    
Interest rate (in percent) 13.00% 13.00%
Subsequent Events | New Money Notes    
SUBSEQUENT EVENTS    
Proceeds from Issuance of Long-Term Debt | $ $ 40,000  
Original issue discount (in percent)   20.00%
Number of majority Noteholders by whom the offering can be backstopped | item   1
Subsequent Events | Senior notes with Interest Rate 12.5%, Due 2024    
SUBSEQUENT EVENTS    
Interest rate (in percent) 12.50% 12.50%
EXCEL 108 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 109 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 110 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 113 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 247 573 1 false 92 0 false 8 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Consolidated Balance Sheets Sheet http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00105 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - Consolidated Statements of Operations Sheet http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 00205 - Statement - Consolidated Statements of Operations(Parenthetical) Sheet http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperationsParenthetical Consolidated Statements of Operations(Parenthetical) Statements 5 false false R6.htm 00300 - Statement - Consolidated Statements of Shareholders' Equity Sheet http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfShareholdersEquity Consolidated Statements of Shareholders' Equity Statements 6 false false R7.htm 00400 - Statement - Consolidated Statements of Cash Flows Sheet http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 10101 - Disclosure - NATURE OF OPERATIONS Sheet http://www.ayrwellness.com/role/DisclosureNatureOfOperations NATURE OF OPERATIONS Notes 8 false false R9.htm 10201 - Disclosure - BASIS OF PRESENTATION Sheet http://www.ayrwellness.com/role/DisclosureBasisOfPresentation BASIS OF PRESENTATION Notes 9 false false R10.htm 10301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 10 false false R11.htm 10401 - Disclosure - DISCONTINUED OPERATIONS Sheet http://www.ayrwellness.com/role/DisclosureDiscontinuedOperations DISCONTINUED OPERATIONS Notes 11 false false R12.htm 10501 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS Sheet http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions BUSINESS COMBINATIONS AND ASSET ACQUISITIONS Notes 12 false false R13.htm 10601 - Disclosure - VARIABLE INTEREST ENTITIES ("VIE") Sheet http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvie VARIABLE INTEREST ENTITIES ("VIE") Notes 13 false false R14.htm 10701 - Disclosure - INVENTORY Sheet http://www.ayrwellness.com/role/DisclosureInventory INVENTORY Notes 14 false false R15.htm 10801 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT Sheet http://www.ayrwellness.com/role/DisclosurePropertyPlantAndEquipment PROPERTY, PLANT, AND EQUIPMENT Notes 15 false false R16.htm 10901 - Disclosure - GOODWILL AND INTANGIBLE ASSETS Sheet http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssets GOODWILL AND INTANGIBLE ASSETS Notes 16 false false R17.htm 11001 - Disclosure - RIGHT-OF-USE ASSETS AND LEASE LIABILITIES Sheet http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilities RIGHT-OF-USE ASSETS AND LEASE LIABILITIES Notes 17 false false R18.htm 11101 - Disclosure - RELATED PARTY TRANSACTIONS AND BALANCES Sheet http://www.ayrwellness.com/role/DisclosureRelatedPartyTransactionsAndBalances RELATED PARTY TRANSACTIONS AND BALANCES Notes 18 false false R19.htm 11201 - Disclosure - DEBTS PAYABLE AND SENIOR SECURED NOTES Notes http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotes DEBTS PAYABLE AND SENIOR SECURED NOTES Notes 19 false false R20.htm 11301 - Disclosure - SHARE CAPITAL Sheet http://www.ayrwellness.com/role/DisclosureShareCapital SHARE CAPITAL Notes 20 false false R21.htm 11401 - Disclosure - DERIVATIVE LIABILITIES Sheet http://www.ayrwellness.com/role/DisclosureDerivativeLiabilities DERIVATIVE LIABILITIES Notes 21 false false R22.htm 11501 - Disclosure - STOCK-BASED COMPENSATION Sheet http://www.ayrwellness.com/role/DisclosureStockBasedCompensation STOCK-BASED COMPENSATION Notes 22 false false R23.htm 11601 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.ayrwellness.com/role/DisclosureCommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 23 false false R24.htm 11701 - Disclosure - FINANCIAL RISK FACTORS Sheet http://www.ayrwellness.com/role/DisclosureFinancialRiskFactors FINANCIAL RISK FACTORS Notes 24 false false R25.htm 11801 - Disclosure - TAXATION Sheet http://www.ayrwellness.com/role/DisclosureTaxation TAXATION Notes 25 false false R26.htm 11901 - Disclosure - SUBSEQUENT EVENTS Sheet http://www.ayrwellness.com/role/DisclosureSubsequentEvents SUBSEQUENT EVENTS Notes 26 false false R27.htm 20302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 27 false false R28.htm 30303 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPolicies 28 false false R29.htm 30403 - Disclosure - DISCONTINUED OPERATIONS (Tables) Sheet http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsTables DISCONTINUED OPERATIONS (Tables) Tables http://www.ayrwellness.com/role/DisclosureDiscontinuedOperations 29 false false R30.htm 30503 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS (Tables) Sheet http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitionsTables BUSINESS COMBINATIONS AND ASSET ACQUISITIONS (Tables) Tables http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions 30 false false R31.htm 30603 - Disclosure - VARIABLE INTEREST ENTITIES ("VIE") (Tables) Sheet http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieTables VARIABLE INTEREST ENTITIES ("VIE") (Tables) Tables http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvie 31 false false R32.htm 30703 - Disclosure - INVENTORY (Tables) Sheet http://www.ayrwellness.com/role/DisclosureInventoryTables INVENTORY (Tables) Tables http://www.ayrwellness.com/role/DisclosureInventory 32 false false R33.htm 30803 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT (Tables) Sheet http://www.ayrwellness.com/role/DisclosurePropertyPlantAndEquipmentTables PROPERTY, PLANT, AND EQUIPMENT (Tables) Tables http://www.ayrwellness.com/role/DisclosurePropertyPlantAndEquipment 33 false false R34.htm 30903 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) Sheet http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsTables GOODWILL AND INTANGIBLE ASSETS (Tables) Tables http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssets 34 false false R35.htm 31003 - Disclosure - RIGHT-OF-USE ASSETS AND LEASE LIABILITIES (Tables) Sheet http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesTables RIGHT-OF-USE ASSETS AND LEASE LIABILITIES (Tables) Tables http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilities 35 false false R36.htm 31203 - Disclosure - DEBTS PAYABLE AND SENIOR SECURED NOTES (Tables) Notes http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesTables DEBTS PAYABLE AND SENIOR SECURED NOTES (Tables) Tables http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotes 36 false false R37.htm 31303 - Disclosure - SHARE CAPITAL (Tables) Sheet http://www.ayrwellness.com/role/DisclosureShareCapitalTables SHARE CAPITAL (Tables) Tables http://www.ayrwellness.com/role/DisclosureShareCapital 37 false false R38.htm 31403 - Disclosure - DERIVATIVE LIABILITIES (Tables) Sheet http://www.ayrwellness.com/role/DisclosureDerivativeLiabilitiesTables DERIVATIVE LIABILITIES (Tables) Tables http://www.ayrwellness.com/role/DisclosureDerivativeLiabilities 38 false false R39.htm 31503 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://www.ayrwellness.com/role/DisclosureStockBasedCompensationTables STOCK-BASED COMPENSATION (Tables) Tables http://www.ayrwellness.com/role/DisclosureStockBasedCompensation 39 false false R40.htm 31703 - Disclosure - FINANCIAL RISK FACTORS (Tables) Sheet http://www.ayrwellness.com/role/DisclosureFinancialRiskFactorsTables FINANCIAL RISK FACTORS (Tables) Tables http://www.ayrwellness.com/role/DisclosureFinancialRiskFactors 40 false false R41.htm 31803 - Disclosure - TAXATION (Tables) Sheet http://www.ayrwellness.com/role/DisclosureTaxationTables TAXATION (Tables) Tables http://www.ayrwellness.com/role/DisclosureTaxation 41 false false R42.htm 40101 - Disclosure - NATURE OF OPERATIONS (Details) Sheet http://www.ayrwellness.com/role/DisclosureNatureOfOperationsDetails NATURE OF OPERATIONS (Details) Details http://www.ayrwellness.com/role/DisclosureNatureOfOperations 42 false false R43.htm 40302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Accounts Receivable (Details) Sheet http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Accounts Receivable (Details) Details 43 false false R44.htm 40303 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, Plant, and Equipment ("PPE") (Details) Sheet http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentppeDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, Plant, and Equipment ("PPE") (Details) Details 44 false false R45.htm 40304 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets and Impairment of Long-lived Assets (Details) Sheet http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsAndImpairmentOfLongLivedAssetsDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets and Impairment of Long-lived Assets (Details) Details 45 false false R46.htm 40305 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings per Share (Details) Sheet http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsPerShareDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings per Share (Details) Details 46 false false R47.htm 40306 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Taxation (Details) Sheet http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTaxationDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Taxation (Details) Details 47 false false R48.htm 40307 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Leases (Details) Sheet http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Leases (Details) Details http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables 48 false false R49.htm 40308 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -Liquidity and management plan (Details) Sheet http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiquidityAndManagementPlanDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -Liquidity and management plan (Details) Details 49 false false R50.htm 40401 - Disclosure - DISCONTINUED OPERATIONS (Details) Sheet http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsDetails DISCONTINUED OPERATIONS (Details) Details http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsTables 50 false false R51.htm 40402 - Disclosure - DISCONTINUED OPERATIONS - Major classes of assets and liabilities (Details) Sheet http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails DISCONTINUED OPERATIONS - Major classes of assets and liabilities (Details) Details 51 false false R52.htm 40403 - Disclosure - DISCONTINUED OPERATIONS - Components comprising net loss from our discontinued operations (Details) Sheet http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsComponentsComprisingNetLossFromOurDiscontinuedOperationsDetails DISCONTINUED OPERATIONS - Components comprising net loss from our discontinued operations (Details) Details 52 false false R53.htm 40404 - Disclosure - DISCONTINUED OPERATIONS - Loss from Discontinued operations (Details) Sheet http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsLossFromDiscontinuedOperationsDetails DISCONTINUED OPERATIONS - Loss from Discontinued operations (Details) Details 53 false false R54.htm 40501 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Including 2023 Fourth Quarter Asset Acquisition (Details) Sheet http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitionsIncluding2023FourthQuarterAssetAcquisitionDetails BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Including 2023 Fourth Quarter Asset Acquisition (Details) Details 54 false false R55.htm 40502 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - 2022 Second Quarter Acquisition - Fair Value of Identifiable Assets Acquired, and Liabilities Assumed as of the Acquisition Date (Details) Sheet http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - 2022 Second Quarter Acquisition - Fair Value of Identifiable Assets Acquired, and Liabilities Assumed as of the Acquisition Date (Details) Details 55 false false R56.htm 40503 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - 2022 Second Quarter Acquisition - Purchase Consideration (Details) Sheet http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionPurchaseConsiderationDetails BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - 2022 Second Quarter Acquisition - Purchase Consideration (Details) Details 56 false false R57.htm 40504 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - 2022 First Quarter Acquisition - Fair Value of Identifiable Assets Acquired, and Liabilities Assumed as of the Acquisition Date (Details) Sheet http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - 2022 First Quarter Acquisition - Fair Value of Identifiable Assets Acquired, and Liabilities Assumed as of the Acquisition Date (Details) Details 57 false false R58.htm 40505 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - 2022 First Quarter Acquisition - Purchase Consideration (Details) Sheet http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionPurchaseConsiderationDetails BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - 2022 First Quarter Acquisition - Purchase Consideration (Details) Details 58 false false R59.htm 40601 - Disclosure - VARIABLE INTEREST ENTITIES ("VIE") - Fair Value of Identifiable Assets Acquired and Liabilities Assumed as of the Acquisition Date (Details) Sheet http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails VARIABLE INTEREST ENTITIES ("VIE") - Fair Value of Identifiable Assets Acquired and Liabilities Assumed as of the Acquisition Date (Details) Details http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieTables 59 false false R60.htm 40602 - Disclosure - VARIABLE INTEREST ENTITIES ("VIE") - Summary of Financial Information about Consolidated VIEs (Details) Sheet http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieSummaryOfFinancialInformationAboutConsolidatedViesDetails VARIABLE INTEREST ENTITIES ("VIE") - Summary of Financial Information about Consolidated VIEs (Details) Details http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieTables 60 false false R61.htm 40701 - Disclosure - INVENTORY (Details) Sheet http://www.ayrwellness.com/role/DisclosureInventoryDetails INVENTORY (Details) Details http://www.ayrwellness.com/role/DisclosureInventoryTables 61 false false R62.htm 40801 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT (Details) Sheet http://www.ayrwellness.com/role/DisclosurePropertyPlantAndEquipmentDetails PROPERTY, PLANT, AND EQUIPMENT (Details) Details http://www.ayrwellness.com/role/DisclosurePropertyPlantAndEquipmentTables 62 false false R63.htm 40901 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details) Sheet http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsGoodwillDetails GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details) Details 63 false false R64.htm 40902 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details) Sheet http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details) Details 64 false false R65.htm 40903 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Impairment of Goodwill (Details) Sheet http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsImpairmentOfGoodwillDetails GOODWILL AND INTANGIBLE ASSETS - Impairment of Goodwill (Details) Details 65 false false R66.htm 41001 - Disclosure - RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Information Related to Leases (Details) Sheet http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesInformationRelatedToLeasesDetails RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Information Related to Leases (Details) Details 66 false false R67.htm 41002 - Disclosure - RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Maturity of Contractual Undiscounted Lease Liabilities (Details) Sheet http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Maturity of Contractual Undiscounted Lease Liabilities (Details) Details 67 false false R68.htm 41003 - Disclosure - RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Payments related to capitalized Lease (Details) Sheet http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesPaymentsRelatedToCapitalizedLeaseDetails RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Payments related to capitalized Lease (Details) Details 68 false false R69.htm 41004 - Disclosure - RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Additional information (Details) Sheet http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetails RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Additional information (Details) Details 69 false false R70.htm 41101 - Disclosure - RELATED PARTY TRANSACTIONS AND BALANCES (Details) Sheet http://www.ayrwellness.com/role/DisclosureRelatedPartyTransactionsAndBalancesDetails RELATED PARTY TRANSACTIONS AND BALANCES (Details) Details http://www.ayrwellness.com/role/DisclosureRelatedPartyTransactionsAndBalances 70 false false R71.htm 41201 - Disclosure - DEBTS PAYABLE AND SENIOR SECURED NOTES (Details) Notes http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesDetails DEBTS PAYABLE AND SENIOR SECURED NOTES (Details) Details http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesTables 71 false false R72.htm 41202 - Disclosure - DEBTS PAYABLE AND SENIOR SECURED NOTES - Changes in senior secured notes (Details) Notes http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesChangesInSeniorSecuredNotesDetails DEBTS PAYABLE AND SENIOR SECURED NOTES - Changes in senior secured notes (Details) Details 72 false false R73.htm 41203 - Disclosure - DEBTS PAYABLE AND SENIOR SECURED NOTES - Changes in debt other than senior secured notes (Details) Notes http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesChangesInDebtOtherThanSeniorSecuredNotesDetails DEBTS PAYABLE AND SENIOR SECURED NOTES - Changes in debt other than senior secured notes (Details) Details 73 false false R74.htm 41204 - Disclosure - DEBTS PAYABLE AND SENIOR SECURED NOTES - Debts payable (Details) Notes http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesDebtsPayableDetails DEBTS PAYABLE AND SENIOR SECURED NOTES - Debts payable (Details) Details 74 false false R75.htm 41205 - Disclosure - DEBTS PAYABLE AND SENIOR SECURED NOTES - Future debt obligations (Details) Notes http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesFutureDebtObligationsDetails DEBTS PAYABLE AND SENIOR SECURED NOTES - Future debt obligations (Details) Details 75 false false R76.htm 41206 - Disclosure - DEBTS PAYABLE AND SENIOR SECURED NOTES - Narratives (Details) Notes http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails DEBTS PAYABLE AND SENIOR SECURED NOTES - Narratives (Details) Details 76 false false R77.htm 41301 - Disclosure - SHARE CAPITAL - Activity occurred during the year end (Details) Sheet http://www.ayrwellness.com/role/DisclosureShareCapitalActivityOccurredDuringYearEndDetails SHARE CAPITAL - Activity occurred during the year end (Details) Details 77 false false R78.htm 41302 - Disclosure - SHARE CAPITAL - Warrants (Details) Sheet http://www.ayrwellness.com/role/DisclosureShareCapitalWarrantsDetails SHARE CAPITAL - Warrants (Details) Details 78 false false R79.htm 41401 - Disclosure - DERIVATIVE LIABILITIES - Schedule of Fair Value Adjustment Relating to Derivative Liabilities (Details) Sheet http://www.ayrwellness.com/role/DisclosureDerivativeLiabilitiesScheduleOfFairValueAdjustmentRelatingToDerivativeLiabilitiesDetails DERIVATIVE LIABILITIES - Schedule of Fair Value Adjustment Relating to Derivative Liabilities (Details) Details 79 false false R80.htm 41501 - Disclosure - STOCK-BASED COMPENSATION (Details) Sheet http://www.ayrwellness.com/role/DisclosureStockBasedCompensationDetails STOCK-BASED COMPENSATION (Details) Details http://www.ayrwellness.com/role/DisclosureStockBasedCompensationTables 80 false false R81.htm 41502 - Disclosure - STOCK-BASED COMPENSATION - RSUs (Details) Sheet http://www.ayrwellness.com/role/DisclosureStockBasedCompensationRsusDetails STOCK-BASED COMPENSATION - RSUs (Details) Details 81 false false R82.htm 41503 - Disclosure - STOCK-BASED COMPENSATION - Options (Details) Sheet http://www.ayrwellness.com/role/DisclosureStockBasedCompensationOptionsDetails STOCK-BASED COMPENSATION - Options (Details) Details 82 false false R83.htm 41601 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://www.ayrwellness.com/role/DisclosureCommitmentsAndContingenciesDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://www.ayrwellness.com/role/DisclosureCommitmentsAndContingencies 83 false false R84.htm 41701 - Disclosure - FINANCIAL RISK FACTORS (Details) Sheet http://www.ayrwellness.com/role/DisclosureFinancialRiskFactorsDetails FINANCIAL RISK FACTORS (Details) Details http://www.ayrwellness.com/role/DisclosureFinancialRiskFactorsTables 84 false false R85.htm 41702 - Disclosure - FINANCIAL RISK FACTORS - Fair Value Hierarchy (Details) Sheet http://www.ayrwellness.com/role/DisclosureFinancialRiskFactorsFairValueHierarchyDetails FINANCIAL RISK FACTORS - Fair Value Hierarchy (Details) Details 85 false false R86.htm 41801 - Disclosure - TAXATION (Details) Sheet http://www.ayrwellness.com/role/DisclosureTaxationDetails TAXATION (Details) Details http://www.ayrwellness.com/role/DisclosureTaxationTables 86 false false R87.htm 41802 - Disclosure - TAXATION - Difference Between the Income Tax Expense and the Expected Income Taxes Based on the Statutory Tax Rate (Details) Sheet http://www.ayrwellness.com/role/DisclosureTaxationDifferenceBetweenIncomeTaxExpenseAndExpectedIncomeTaxesBasedOnStatutoryTaxRateDetails TAXATION - Difference Between the Income Tax Expense and the Expected Income Taxes Based on the Statutory Tax Rate (Details) Details 87 false false R88.htm 41803 - Disclosure - TAXATION - Deferred Tax Assets and Liability (Details) Sheet http://www.ayrwellness.com/role/DisclosureTaxationDeferredTaxAssetsAndLiabilityDetails TAXATION - Deferred Tax Assets and Liability (Details) Details 88 false false R89.htm 41901 - Disclosure - SUBSEQUENT EVENTS (Details) Sheet http://www.ayrwellness.com/role/DisclosureSubsequentEventsDetails SUBSEQUENT EVENTS (Details) Details http://www.ayrwellness.com/role/DisclosureSubsequentEvents 89 false false All Reports Book All Reports ayr-20231231.xsd ayr-20231231_cal.xml ayr-20231231_def.xml ayr-20231231_lab.xml ayr-20231231_pre.xml ayr-20231231x40f.htm ayr-20231231xex99d2.htm ayr-20231231x40f001.jpg ayr-20231231xex99d2002.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 116 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ayr-20231231x40f.htm ayr-20231231xex99d2.htm": { "nsprefix": "ayr", "nsuri": "http://www.ayrwellness.com/20231231", "dts": { "schema": { "local": [ "ayr-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "calculationLink": { "local": [ "ayr-20231231_cal.xml" ] }, "definitionLink": { "local": [ "ayr-20231231_def.xml" ] }, "labelLink": { "local": [ "ayr-20231231_lab.xml" ] }, "presentationLink": { "local": [ "ayr-20231231_pre.xml" ] }, "inline": { "local": [ "ayr-20231231x40f.htm", "ayr-20231231xex99d2.htm" ] } }, "keyStandard": 403, "keyCustom": 170, "axisStandard": 27, "axisCustom": 1, "memberStandard": 37, "memberCustom": 51, "hidden": { "total": 45, "http://fasb.org/us-gaap/2023": 28, "http://xbrl.sec.gov/dei/2023": 4, "http://www.ayrwellness.com/20231231": 13 }, "contextCount": 247, "entityCount": 1, "segmentCount": 92, "elementCount": 833, "unitCount": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 974, "http://xbrl.sec.gov/dei/2023": 43 }, "report": { "R1": { "role": "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231x40f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231x40f.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets", "longName": "00100 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_12_31_2023_fx2trxfZkU61exQSo_jpDg", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_fx2trxfZkU61exQSo_jpDg", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheetsParenthetical", "longName": "00105 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_12_31_2023_fx2trxfZkU61exQSo_jpDg", "name": "us-gaap:TreasuryStockCommonShares", "unitRef": "Unit_Standard_shares_Hi39jLD8R0eE0mQYVpKLcw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:TreasuryStockCommonShares", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_fx2trxfZkU61exQSo_jpDg", "name": "us-gaap:TreasuryStockCommonShares", "unitRef": "Unit_Standard_shares_Hi39jLD8R0eE0mQYVpKLcw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:TreasuryStockCommonShares", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations", "longName": "00200 - Statement - Consolidated Statements of Operations", "shortName": "Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "ayr:CostOfGoodsAndServiceExcludingFairValueItems", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "unique": true } }, "R5": { "role": "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperationsParenthetical", "longName": "00205 - Statement - Consolidated Statements of Operations(Parenthetical)", "shortName": "Consolidated Statements of Operations(Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true }, "uniqueAnchor": null }, "R6": { "role": "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfShareholdersEquity", "longName": "00300 - Statement - Consolidated Statements of Shareholders' Equity", "shortName": "Consolidated Statements of Shareholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rFkp1xR4vUiKOlhT-_7Qxg", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rFkp1xR4vUiKOlhT-_7Qxg", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows", "longName": "00400 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "ayr:IncomeLossFromContinuingOperationsBeforeNoncontrollingInterestIncludesLossOnDisposal", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "unique": true } }, "R8": { "role": "http://www.ayrwellness.com/role/DisclosureNatureOfOperations", "longName": "10101 - Disclosure - NATURE OF OPERATIONS", "shortName": "NATURE OF OPERATIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.ayrwellness.com/role/DisclosureBasisOfPresentation", "longName": "10201 - Disclosure - BASIS OF PRESENTATION", "shortName": "BASIS OF PRESENTATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:BasisOfAccounting", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:BasisOfAccounting", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "longName": "10301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperations", "longName": "10401 - Disclosure - DISCONTINUED OPERATIONS", "shortName": "DISCONTINUED OPERATIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions", "longName": "10501 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS", "shortName": "BUSINESS COMBINATIONS AND ASSET ACQUISITIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "ayr:BusinessCombinationsAndAssetAcquisitionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "ayr:BusinessCombinationsAndAssetAcquisitionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvie", "longName": "10601 - Disclosure - VARIABLE INTEREST ENTITIES (\"VIE\")", "shortName": "VARIABLE INTEREST ENTITIES (\"VIE\")", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:VariableInterestEntityDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:VariableInterestEntityDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.ayrwellness.com/role/DisclosureInventory", "longName": "10701 - Disclosure - INVENTORY", "shortName": "INVENTORY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.ayrwellness.com/role/DisclosurePropertyPlantAndEquipment", "longName": "10801 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT", "shortName": "PROPERTY, PLANT, AND EQUIPMENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2022_To_12_31_2022_qp8N4CfBi0myMZezq0vOZw", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2022_To_12_31_2022_qp8N4CfBi0myMZezq0vOZw", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssets", "longName": "10901 - Disclosure - GOODWILL AND INTANGIBLE ASSETS", "shortName": "GOODWILL AND INTANGIBLE ASSETS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2022_To_12_31_2022_qp8N4CfBi0myMZezq0vOZw", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2022_To_12_31_2022_qp8N4CfBi0myMZezq0vOZw", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilities", "longName": "11001 - Disclosure - RIGHT-OF-USE ASSETS AND LEASE LIABILITIES", "shortName": "RIGHT-OF-USE ASSETS AND LEASE LIABILITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2022_To_12_31_2022_qp8N4CfBi0myMZezq0vOZw", "name": "ayr:LeaseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2022_To_12_31_2022_qp8N4CfBi0myMZezq0vOZw", "name": "ayr:LeaseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.ayrwellness.com/role/DisclosureRelatedPartyTransactionsAndBalances", "longName": "11101 - Disclosure - RELATED PARTY TRANSACTIONS AND BALANCES", "shortName": "RELATED PARTY TRANSACTIONS AND BALANCES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2022_To_12_31_2022_qp8N4CfBi0myMZezq0vOZw", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2022_To_12_31_2022_qp8N4CfBi0myMZezq0vOZw", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotes", "longName": "11201 - Disclosure - DEBTS PAYABLE AND SENIOR SECURED NOTES", "shortName": "DEBTS PAYABLE AND SENIOR SECURED NOTES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.ayrwellness.com/role/DisclosureShareCapital", "longName": "11301 - Disclosure - SHARE CAPITAL", "shortName": "SHARE CAPITAL", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.ayrwellness.com/role/DisclosureDerivativeLiabilities", "longName": "11401 - Disclosure - DERIVATIVE LIABILITIES", "shortName": "DERIVATIVE LIABILITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.ayrwellness.com/role/DisclosureStockBasedCompensation", "longName": "11501 - Disclosure - STOCK-BASED COMPENSATION", "shortName": "STOCK-BASED COMPENSATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.ayrwellness.com/role/DisclosureCommitmentsAndContingencies", "longName": "11601 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.ayrwellness.com/role/DisclosureFinancialRiskFactors", "longName": "11701 - Disclosure - FINANCIAL RISK FACTORS", "shortName": "FINANCIAL RISK FACTORS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.ayrwellness.com/role/DisclosureTaxation", "longName": "11801 - Disclosure - TAXATION", "shortName": "TAXATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.ayrwellness.com/role/DisclosureSubsequentEvents", "longName": "11901 - Disclosure - SUBSEQUENT EVENTS", "shortName": "SUBSEQUENT EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "20302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "27", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "longName": "30303 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "ayr:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "ayr:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsTables", "longName": "30403 - Disclosure - DISCONTINUED OPERATIONS (Tables)", "shortName": "DISCONTINUED OPERATIONS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitionsTables", "longName": "30503 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS (Tables)", "shortName": "BUSINESS COMBINATIONS AND ASSET ACQUISITIONS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_ayr_BusinessAcquisitionAndAssetAcquisitionAxis_ayr_Q22022AcquisitionsMember_us-gaap_BusinessAcquisitionAxis_ayr_HerbalRemediesDispensariesLlcMember_93xhFJZBT0a4m6sroq9d2g", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_ayr_BusinessAcquisitionAndAssetAcquisitionAxis_ayr_Q22022AcquisitionsMember_us-gaap_BusinessAcquisitionAxis_ayr_HerbalRemediesDispensariesLlcMember_93xhFJZBT0a4m6sroq9d2g", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieTables", "longName": "30603 - Disclosure - VARIABLE INTEREST ENTITIES (\"VIE\") (Tables)", "shortName": "VARIABLE INTEREST ENTITIES (\"VIE\") (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.ayrwellness.com/role/DisclosureInventoryTables", "longName": "30703 - Disclosure - INVENTORY (Tables)", "shortName": "INVENTORY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.ayrwellness.com/role/DisclosurePropertyPlantAndEquipmentTables", "longName": "30803 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT (Tables)", "shortName": "PROPERTY, PLANT, AND EQUIPMENT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "Duration_1_1_2022_To_12_31_2022_qp8N4CfBi0myMZezq0vOZw", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2022_To_12_31_2022_qp8N4CfBi0myMZezq0vOZw", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsTables", "longName": "30903 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)", "shortName": "GOODWILL AND INTANGIBLE ASSETS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "Duration_1_1_2022_To_12_31_2022_qp8N4CfBi0myMZezq0vOZw", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2022_To_12_31_2022_qp8N4CfBi0myMZezq0vOZw", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesTables", "longName": "31003 - Disclosure - RIGHT-OF-USE ASSETS AND LEASE LIABILITIES (Tables)", "shortName": "RIGHT-OF-USE ASSETS AND LEASE LIABILITIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "Duration_1_1_2022_To_12_31_2022_qp8N4CfBi0myMZezq0vOZw", "name": "ayr:ScheduleOfAdditionalInformationAboutLeasingActivitiesForLesseeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ayr:LeaseDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2022_To_12_31_2022_qp8N4CfBi0myMZezq0vOZw", "name": "ayr:ScheduleOfAdditionalInformationAboutLeasingActivitiesForLesseeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ayr:LeaseDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesTables", "longName": "31203 - Disclosure - DEBTS PAYABLE AND SENIOR SECURED NOTES (Tables)", "shortName": "DEBTS PAYABLE AND SENIOR SECURED NOTES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.ayrwellness.com/role/DisclosureShareCapitalTables", "longName": "31303 - Disclosure - SHARE CAPITAL (Tables)", "shortName": "SHARE CAPITAL (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.ayrwellness.com/role/DisclosureDerivativeLiabilitiesTables", "longName": "31403 - Disclosure - DERIVATIVE LIABILITIES (Tables)", "shortName": "DERIVATIVE LIABILITIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationTables", "longName": "31503 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "shortName": "STOCK-BASED COMPENSATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.ayrwellness.com/role/DisclosureFinancialRiskFactorsTables", "longName": "31703 - Disclosure - FINANCIAL RISK FACTORS (Tables)", "shortName": "FINANCIAL RISK FACTORS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.ayrwellness.com/role/DisclosureTaxationTables", "longName": "31803 - Disclosure - TAXATION (Tables)", "shortName": "TAXATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.ayrwellness.com/role/DisclosureNatureOfOperationsDetails", "longName": "40101 - Disclosure - NATURE OF OPERATIONS (Details)", "shortName": "NATURE OF OPERATIONS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "Unit_Standard_segment_EZcFy6BHX0e1Lq98E9fS1g", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:NatureOfOperations", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "Unit_Standard_segment_EZcFy6BHX0e1Lq98E9fS1g", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:NatureOfOperations", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableDetails", "longName": "40302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Accounts Receivable (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Accounts Receivable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "As_Of_12_31_2023_fx2trxfZkU61exQSo_jpDg", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_fx2trxfZkU61exQSo_jpDg", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentppeDetails", "longName": "40303 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, Plant, and Equipment (\"PPE\") (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, Plant, and Equipment (\"PPE\") (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_4jTTz83Cg0eO2Dnf6xPbzg", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "table", "ayr:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_4jTTz83Cg0eO2Dnf6xPbzg", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "table", "ayr:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsAndImpairmentOfLongLivedAssetsDetails", "longName": "40304 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets and Impairment of Long-lived Assets (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets and Impairment of Long-lived Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": null, "uniqueAnchor": null }, "R46": { "role": "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsPerShareDetails", "longName": "40305 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings per Share (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_Hi39jLD8R0eE0mQYVpKLcw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_Hi39jLD8R0eE0mQYVpKLcw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTaxationDetails", "longName": "40306 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Taxation (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Taxation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "As_Of_12_31_2023_fx2trxfZkU61exQSo_jpDg", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "us-gaap:UnrecognizedTaxBenefits", "p", "us-gaap:IncomeTaxPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_fx2trxfZkU61exQSo_jpDg", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "us-gaap:UnrecognizedTaxBenefits", "p", "us-gaap:IncomeTaxPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails", "longName": "40307 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Leases (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_HHsfTQNR9UyeNX1lt_pykA", "name": "ayr:WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilities", "unitRef": "Unit_Standard_pure_gHhhW7SxJ02Bqj4oc1FXxA", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_HHsfTQNR9UyeNX1lt_pykA", "name": "ayr:WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilities", "unitRef": "Unit_Standard_pure_gHhhW7SxJ02Bqj4oc1FXxA", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiquidityAndManagementPlanDetails", "longName": "40308 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -Liquidity and management plan (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -Liquidity and management plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "As_Of_12_31_2023_fx2trxfZkU61exQSo_jpDg", "name": "ayr:WorkingCapital", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ayr:LiquidityAndManagementPlanPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_fx2trxfZkU61exQSo_jpDg", "name": "ayr:WorkingCapital", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ayr:LiquidityAndManagementPlanPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsDetails", "longName": "40401 - Disclosure - DISCONTINUED OPERATIONS (Details)", "shortName": "DISCONTINUED OPERATIONS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "Duration_3_27_2023_To_3_27_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ayr_BlueCamoLlcMember_BaTzMqcqnECUSnOsrZnC3Q", "name": "ayr:NumberOfLicensedEntitiesOperatingOasisBrandedDispensaries", "unitRef": "Unit_Standard_entity_bAHEqT8uY0ewKyCK_gPL3A", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_3_27_2023_To_3_27_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ayr_BlueCamoLlcMember_BaTzMqcqnECUSnOsrZnC3Q", "name": "ayr:NumberOfLicensedEntitiesOperatingOasisBrandedDispensaries", "unitRef": "Unit_Standard_entity_bAHEqT8uY0ewKyCK_gPL3A", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails", "longName": "40402 - Disclosure - DISCONTINUED OPERATIONS - Major classes of assets and liabilities (Details)", "shortName": "DISCONTINUED OPERATIONS - Major classes of assets and liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "As_Of_12_31_2022_zhBXzrhmkUucu5DLkPmoNA", "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsHeldforsaleMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ayr_BlueCamoLlcMember_8k2I9Sox1U6x-JWi4YN8xA", "name": "ayr:DisposalGroupIncludingDiscontinuedOperationAssetsInventoryAndOtherCurrentAssets", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "unique": true } }, "R52": { "role": "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsComponentsComprisingNetLossFromOurDiscontinuedOperationsDetails", "longName": "40403 - Disclosure - DISCONTINUED OPERATIONS - Components comprising net loss from our discontinued operations (Details)", "shortName": "DISCONTINUED OPERATIONS - Components comprising net loss from our discontinued operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsHeldforsaleMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ayr_BlueCamoLlcMember_vU-VHGv_S068WOPJzv2LUQ", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "unique": true } }, "R53": { "role": "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsLossFromDiscontinuedOperationsDetails", "longName": "40404 - Disclosure - DISCONTINUED OPERATIONS - Loss from Discontinued operations (Details)", "shortName": "DISCONTINUED OPERATIONS - Loss from Discontinued operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsHeldforsaleMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ayr_BlueCamoLlcMember_vU-VHGv_S068WOPJzv2LUQ", "name": "ayr:DiscontinuedOperationsGrossProceeds", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "unique": true } }, "R54": { "role": "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitionsIncluding2023FourthQuarterAssetAcquisitionDetails", "longName": "40501 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Including 2023 Fourth Quarter Asset Acquisition (Details)", "shortName": "BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Including 2023 Fourth Quarter Asset Acquisition (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_BusinessAcquisitionAxis_ayr_BusinessAcquisitionsMember_UnYLsbwlhE2jxW_H6w_vWw", "name": "ayr:ExchangeableStockExchangeRatio", "unitRef": "Unit_Standard_pure_gHhhW7SxJ02Bqj4oc1FXxA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ayr:BusinessCombinationsAndAssetAcquisitionsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_BusinessAcquisitionAxis_ayr_BusinessAcquisitionsMember_UnYLsbwlhE2jxW_H6w_vWw", "name": "ayr:ExchangeableStockExchangeRatio", "unitRef": "Unit_Standard_pure_gHhhW7SxJ02Bqj4oc1FXxA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ayr:BusinessCombinationsAndAssetAcquisitionsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "longName": "40502 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - 2022 Second Quarter Acquisition - Fair Value of Identifiable Assets Acquired, and Liabilities Assumed as of the Acquisition Date (Details)", "shortName": "BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - 2022 Second Quarter Acquisition - Fair Value of Identifiable Assets Acquired, and Liabilities Assumed as of the Acquisition Date (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "As_Of_12_31_2023_fx2trxfZkU61exQSo_jpDg", "name": "us-gaap:Goodwill", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_5_25_2022_us-gaap_BusinessAcquisitionAxis_ayr_HerbalRemediesDispensariesLlcMember_6sWCmMABFU21Ur3s6AqSDg", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "unique": true } }, "R56": { "role": "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionPurchaseConsiderationDetails", "longName": "40503 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - 2022 Second Quarter Acquisition - Purchase Consideration (Details)", "shortName": "BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - 2022 Second Quarter Acquisition - Purchase Consideration (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "Duration_5_25_2022_To_5_25_2022_us-gaap_BusinessAcquisitionAxis_ayr_HerbalRemediesDispensariesLlcMember_uFkw_cak-UmwvE1ao_Nqrw", "name": "ayr:NumberOfLicensedRetailDispensariesOperated", "unitRef": "Unit_Standard_item_2HuVxvvfNEukiDE7LJ8Ehw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_5_25_2022_To_5_25_2022_us-gaap_BusinessAcquisitionAxis_ayr_HerbalRemediesDispensariesLlcMember_uFkw_cak-UmwvE1ao_Nqrw", "name": "ayr:NumberOfLicensedRetailDispensariesOperated", "unitRef": "Unit_Standard_item_2HuVxvvfNEukiDE7LJ8Ehw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "longName": "40504 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - 2022 First Quarter Acquisition - Fair Value of Identifiable Assets Acquired, and Liabilities Assumed as of the Acquisition Date (Details)", "shortName": "BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - 2022 First Quarter Acquisition - Fair Value of Identifiable Assets Acquired, and Liabilities Assumed as of the Acquisition Date (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "As_Of_12_31_2023_fx2trxfZkU61exQSo_jpDg", "name": "us-gaap:Goodwill", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_2_15_2022_us-gaap_BusinessAcquisitionAxis_ayr_CultivaunaLlcMember_8gYDNLmd3kKfOjYpLAozEw", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "unique": true } }, "R58": { "role": "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionPurchaseConsiderationDetails", "longName": "40505 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - 2022 First Quarter Acquisition - Purchase Consideration (Details)", "shortName": "BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - 2022 First Quarter Acquisition - Purchase Consideration (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "Duration_2_15_2022_To_2_15_2022_us-gaap_BusinessAcquisitionAxis_ayr_CultivaunaLlcMember_7cvZtNDQWkCU5oWdG2cKhA", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ayr:ScheduleOfComponentsOfPurchaseConsiderationInBusinessCombinationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_2_15_2022_To_2_15_2022_us-gaap_BusinessAcquisitionAxis_ayr_CultivaunaLlcMember_7cvZtNDQWkCU5oWdG2cKhA", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ayr:ScheduleOfComponentsOfPurchaseConsiderationInBusinessCombinationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "longName": "40601 - Disclosure - VARIABLE INTEREST ENTITIES (\"VIE\") - Fair Value of Identifiable Assets Acquired and Liabilities Assumed as of the Acquisition Date (Details)", "shortName": "VARIABLE INTEREST ENTITIES (\"VIE\") - Fair Value of Identifiable Assets Acquired and Liabilities Assumed as of the Acquisition Date (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "Duration_2_1_2022_To_2_28_2022_3xMfMVXgYUeAC3IxzHi04g", "name": "ayr:NumberOfEntitiesOverWhichHaveAbilityToDirectActivities", "unitRef": "Unit_Standard_entity_bAHEqT8uY0ewKyCK_gPL3A", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:VariableInterestEntityDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_2_1_2022_To_2_28_2022_3xMfMVXgYUeAC3IxzHi04g", "name": "ayr:NumberOfEntitiesOverWhichHaveAbilityToDirectActivities", "unitRef": "Unit_Standard_entity_bAHEqT8uY0ewKyCK_gPL3A", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:VariableInterestEntityDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieSummaryOfFinancialInformationAboutConsolidatedViesDetails", "longName": "40602 - Disclosure - VARIABLE INTEREST ENTITIES (\"VIE\") - Summary of Financial Information about Consolidated VIEs (Details)", "shortName": "VARIABLE INTEREST ENTITIES (\"VIE\") - Summary of Financial Information about Consolidated VIEs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "As_Of_12_31_2023_fx2trxfZkU61exQSo_jpDg", "name": "us-gaap:Assets", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_srt_ConsolidatedEntitiesAxis_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_KqlW0TZX1U2WelPRG7E0Zw", "name": "ayr:CurrentAssetsNet", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "unique": true } }, "R61": { "role": "http://www.ayrwellness.com/role/DisclosureInventoryDetails", "longName": "40701 - Disclosure - INVENTORY (Details)", "shortName": "INVENTORY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "As_Of_12_31_2023_fx2trxfZkU61exQSo_jpDg", "name": "us-gaap:InventoryRawMaterialsAndSupplies", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_fx2trxfZkU61exQSo_jpDg", "name": "us-gaap:InventoryRawMaterialsAndSupplies", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.ayrwellness.com/role/DisclosurePropertyPlantAndEquipmentDetails", "longName": "40801 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT (Details)", "shortName": "PROPERTY, PLANT, AND EQUIPMENT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "As_Of_12_31_2023_fx2trxfZkU61exQSo_jpDg", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_fx2trxfZkU61exQSo_jpDg", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsGoodwillDetails", "longName": "40901 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details)", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "As_Of_12_31_2021_DuEb72niwk6t_amiNj7cEQ", "name": "us-gaap:Goodwill", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2022_To_12_31_2022_qp8N4CfBi0myMZezq0vOZw", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "unique": true } }, "R64": { "role": "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails", "longName": "40902 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details)", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_fx2trxfZkU61exQSo_jpDg", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "unique": true } }, "R65": { "role": "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsImpairmentOfGoodwillDetails", "longName": "40903 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Impairment of Goodwill (Details)", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Impairment of Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "ayr:ExtendedForecastPeriodForEstimatedCashFlowsProjections", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "ayr:ExtendedForecastPeriodForEstimatedCashFlowsProjections", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesInformationRelatedToLeasesDetails", "longName": "41001 - Disclosure - RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Information Related to Leases (Details)", "shortName": "RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Information Related to Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "As_Of_12_31_2023_fx2trxfZkU61exQSo_jpDg", "name": "ayr:OperatingLeaseIncrementalBorrowingRate", "unitRef": "Unit_Standard_pure_gHhhW7SxJ02Bqj4oc1FXxA", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "td", "tr", "table", "ayr:ScheduleOfAdditionalInformationAboutLeasingActivitiesForLesseeTableTextBlock", "ayr:LeaseDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_fx2trxfZkU61exQSo_jpDg", "name": "ayr:OperatingLeaseIncrementalBorrowingRate", "unitRef": "Unit_Standard_pure_gHhhW7SxJ02Bqj4oc1FXxA", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "td", "tr", "table", "ayr:ScheduleOfAdditionalInformationAboutLeasingActivitiesForLesseeTableTextBlock", "ayr:LeaseDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails", "longName": "41002 - Disclosure - RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Maturity of Contractual Undiscounted Lease Liabilities (Details)", "shortName": "RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Maturity of Contractual Undiscounted Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "As_Of_12_31_2023_fx2trxfZkU61exQSo_jpDg", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ayr:LeaseDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_fx2trxfZkU61exQSo_jpDg", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ayr:LeaseDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesPaymentsRelatedToCapitalizedLeaseDetails", "longName": "41003 - Disclosure - RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Payments related to capitalized Lease (Details)", "shortName": "RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Payments related to capitalized Lease (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "ayr:TotalLeaseExpense", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "ayr:TotalLeaseExpense", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetails", "longName": "41004 - Disclosure - RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Additional information (Details)", "shortName": "RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Additional information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "Duration_6_1_2022_To_6_30_2022_y7ILrFrys0qDB4HPfYjhUQ", "name": "ayr:NumberOfCultivationAndProcessingFacilitiesEnteredForSaleAndLeaseBack", "unitRef": "Unit_Standard_item_2HuVxvvfNEukiDE7LJ8Ehw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ayr:LeaseDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_6_1_2022_To_6_30_2022_y7ILrFrys0qDB4HPfYjhUQ", "name": "ayr:NumberOfCultivationAndProcessingFacilitiesEnteredForSaleAndLeaseBack", "unitRef": "Unit_Standard_item_2HuVxvvfNEukiDE7LJ8Ehw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ayr:LeaseDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.ayrwellness.com/role/DisclosureRelatedPartyTransactionsAndBalancesDetails", "longName": "41101 - Disclosure - RELATED PARTY TRANSACTIONS AND BALANCES (Details)", "shortName": "RELATED PARTY TRANSACTIONS AND BALANCES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:InterestExpense", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_srt_CounterpartyNameAxis_ayr_MercerParkL.p.Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_QjGJ74kI6kyXcWx1G8AoKA", "name": "us-gaap:PrepaidExpenseCurrent", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "unique": true } }, "R71": { "role": "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesDetails", "longName": "41201 - Disclosure - DEBTS PAYABLE AND SENIOR SECURED NOTES (Details)", "shortName": "DEBTS PAYABLE AND SENIOR SECURED NOTES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_11_12_2021_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember_XhgQotcpvEuBZA6BlSZYeA", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "unique": true } }, "R72": { "role": "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesChangesInSeniorSecuredNotesDetails", "longName": "41202 - Disclosure - DEBTS PAYABLE AND SENIOR SECURED NOTES - Changes in senior secured notes (Details)", "shortName": "DEBTS PAYABLE AND SENIOR SECURED NOTES - Changes in senior secured notes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:AmortizationOfFinancingCosts", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember_Q7s5utlYeEONeG-gWhJ8ug", "name": "us-gaap:LongTermDebt", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "unique": true } }, "R73": { "role": "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesChangesInDebtOtherThanSeniorSecuredNotesDetails", "longName": "41203 - Disclosure - DEBTS PAYABLE AND SENIOR SECURED NOTES - Changes in debt other than senior secured notes (Details)", "shortName": "DEBTS PAYABLE AND SENIOR SECURED NOTES - Changes in debt other than senior secured notes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:PaymentsOfDebtIssuanceCosts", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_ayr_DebtPayablesOtherThanNotesMember_0JP6Vlj8E0WN2DD_wJ50BA", "name": "ayr:DebtIncurredThroughEarnOutProvision", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "unique": true } }, "R74": { "role": "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesDebtsPayableDetails", "longName": "41204 - Disclosure - DEBTS PAYABLE AND SENIOR SECURED NOTES - Debts payable (Details)", "shortName": "DEBTS PAYABLE AND SENIOR SECURED NOTES - Debts payable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_ayr_DebtPayablesOtherThanNotesMember_FtyeU5alKUeNWpqYHzbcNA", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_ayr_DebtPayablesOtherThanNotesMember_FtyeU5alKUeNWpqYHzbcNA", "name": "ayr:DebtInstrumentCarryingAmountCurrent", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "unique": true } }, "R75": { "role": "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesFutureDebtObligationsDetails", "longName": "41205 - Disclosure - DEBTS PAYABLE AND SENIOR SECURED NOTES - Future debt obligations (Details)", "shortName": "DEBTS PAYABLE AND SENIOR SECURED NOTES - Future debt obligations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_ayr_DebtPayablesOtherThanNotesMember_FtyeU5alKUeNWpqYHzbcNA", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_ayr_DebtPayablesOtherThanNotesMember_FtyeU5alKUeNWpqYHzbcNA", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails", "longName": "41206 - Disclosure - DEBTS PAYABLE AND SENIOR SECURED NOTES - Narratives (Details)", "shortName": "DEBTS PAYABLE AND SENIOR SECURED NOTES - Narratives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "As_Of_12_31_2022_zhBXzrhmkUucu5DLkPmoNA", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_10_31_2023_us-gaap_LineOfCreditFacilityAxis_ayr_LivfreeWellnessLlcMember_JpsWHRWQG0m9Jb72VHaDzA", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "unitRef": "Unit_Standard_pure_gHhhW7SxJ02Bqj4oc1FXxA", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "unique": true } }, "R77": { "role": "http://www.ayrwellness.com/role/DisclosureShareCapitalActivityOccurredDuringYearEndDetails", "longName": "41301 - Disclosure - SHARE CAPITAL - Activity occurred during the year end (Details)", "shortName": "SHARE CAPITAL - Activity occurred during the year end (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "unitRef": "Unit_Standard_shares_Hi39jLD8R0eE0mQYVpKLcw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_ayr_SubordinateRestrictedAndLimitedVotingSharesMember_XSrvFW50lkqR5dIlS2_F2Q", "name": "us-gaap:StockRepurchasedAndRetiredDuringPeriodShares", "unitRef": "Unit_Standard_shares_Hi39jLD8R0eE0mQYVpKLcw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "unique": true } }, "R78": { "role": "http://www.ayrwellness.com/role/DisclosureShareCapitalWarrantsDetails", "longName": "41302 - Disclosure - SHARE CAPITAL - Warrants (Details)", "shortName": "SHARE CAPITAL - Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_ep9ctujNmEGv37YZzROQYg", "name": "us-gaap:WarrantsAndRightsOutstandingTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_ep9ctujNmEGv37YZzROQYg", "name": "us-gaap:WarrantsAndRightsOutstandingTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R79": { "role": "http://www.ayrwellness.com/role/DisclosureDerivativeLiabilitiesScheduleOfFairValueAdjustmentRelatingToDerivativeLiabilitiesDetails", "longName": "41401 - Disclosure - DERIVATIVE LIABILITIES - Schedule of Fair Value Adjustment Relating to Derivative Liabilities (Details)", "shortName": "DERIVATIVE LIABILITIES - Schedule of Fair Value Adjustment Relating to Derivative Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "ayr:GainLossOnChangeInFairValueOfContingentConsideration", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "ayr:GainLossOnChangeInFairValueOfContingentConsideration", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R80": { "role": "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationDetails", "longName": "41501 - Disclosure - STOCK-BASED COMPENSATION (Details)", "shortName": "STOCK-BASED COMPENSATION (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "Duration_5_2_2021_To_5_2_2021_f2dBPZB-0US-7wbrIcJ-Fg", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "unitRef": "Unit_Standard_pure_gHhhW7SxJ02Bqj4oc1FXxA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_5_2_2021_To_5_2_2021_f2dBPZB-0US-7wbrIcJ-Fg", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "unitRef": "Unit_Standard_pure_gHhhW7SxJ02Bqj4oc1FXxA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R81": { "role": "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationRsusDetails", "longName": "41502 - Disclosure - STOCK-BASED COMPENSATION - RSUs (Details)", "shortName": "STOCK-BASED COMPENSATION - RSUs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_jNfhcXCImkSpSwPA-i25Hw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Unit_Standard_shares_Hi39jLD8R0eE0mQYVpKLcw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_PqhJhC8MGUS0JWWxlnYJwg", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "Unit_Standard_shares_Hi39jLD8R0eE0mQYVpKLcw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "unique": true } }, "R82": { "role": "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationOptionsDetails", "longName": "41503 - Disclosure - STOCK-BASED COMPENSATION - Options (Details)", "shortName": "STOCK-BASED COMPENSATION - Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "As_Of_12_31_2022_zhBXzrhmkUucu5DLkPmoNA", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_Hi39jLD8R0eE0mQYVpKLcw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2021_DuEb72niwk6t_amiNj7cEQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_Hi39jLD8R0eE0mQYVpKLcw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "unique": true } }, "R83": { "role": "http://www.ayrwellness.com/role/DisclosureCommitmentsAndContingenciesDetails", "longName": "41601 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "ayr:EmployeeRetentionCreditClaimAmountCaresAct", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "ayr:EmployeeRetentionCreditClaimAmountCaresAct", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R84": { "role": "http://www.ayrwellness.com/role/DisclosureFinancialRiskFactorsDetails", "longName": "41701 - Disclosure - FINANCIAL RISK FACTORS (Details)", "shortName": "FINANCIAL RISK FACTORS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": null, "uniqueAnchor": null }, "R85": { "role": "http://www.ayrwellness.com/role/DisclosureFinancialRiskFactorsFairValueHierarchyDetails", "longName": "41702 - Disclosure - FINANCIAL RISK FACTORS - Fair Value Hierarchy (Details)", "shortName": "FINANCIAL RISK FACTORS - Fair Value Hierarchy (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_lfNWRVEfdEqX9ZFNCpjBHQ", "name": "ayr:ContingentConsiderationFairValueDisclosure", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_lfNWRVEfdEqX9ZFNCpjBHQ", "name": "ayr:ContingentConsiderationFairValueDisclosure", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R86": { "role": "http://www.ayrwellness.com/role/DisclosureTaxationDetails", "longName": "41801 - Disclosure - TAXATION (Details)", "shortName": "TAXATION (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R87": { "role": "http://www.ayrwellness.com/role/DisclosureTaxationDifferenceBetweenIncomeTaxExpenseAndExpectedIncomeTaxesBasedOnStatutoryTaxRateDetails", "longName": "41802 - Disclosure - TAXATION - Difference Between the Income Tax Expense and the Expected Income Taxes Based on the Statutory Tax Rate (Details)", "shortName": "TAXATION - Difference Between the Income Tax Expense and the Expected Income Taxes Based on the Statutory Tax Rate (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "ayr:EffectiveIncomeTaxRateReconciliation", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_iaDjNfrYmke74q_RfmWxBg", "name": "ayr:EffectiveIncomeTaxRateReconciliation", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R88": { "role": "http://www.ayrwellness.com/role/DisclosureTaxationDeferredTaxAssetsAndLiabilityDetails", "longName": "41803 - Disclosure - TAXATION - Deferred Tax Assets and Liability (Details)", "shortName": "TAXATION - Deferred Tax Assets and Liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "As_Of_12_31_2023_fx2trxfZkU61exQSo_jpDg", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_fx2trxfZkU61exQSo_jpDg", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "Unit_Standard_USD_UiqklqAlCU-2idPnzPtvIg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true, "unique": true } }, "R89": { "role": "http://www.ayrwellness.com/role/DisclosureSubsequentEventsDetails", "longName": "41901 - Disclosure - SUBSEQUENT EVENTS (Details)", "shortName": "SUBSEQUENT EVENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "As_Of_3_14_2024_us-gaap_DebtInstrumentAxis_ayr_SeniorNotesWithInterestRate12.5Due2024Member_ENqkAO_2TkSHDQomWAsetA", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "unitRef": "Unit_Standard_pure_gHhhW7SxJ02Bqj4oc1FXxA", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "ayr:LiquidityAndManagementPlanPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_3_14_2024_To_3_14_2024_us-gaap_StatementClassOfStockAxis_ayr_SubordinateRestrictedAndLimitedVotingSharesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_7EZfWA7YokCyqS10JlAR4w", "name": "ayr:NumberOfSharesAgreedToBeIssuedInExchangeOfNotes", "unitRef": "Unit_Standard_shares_Hi39jLD8R0eE0mQYVpKLcw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ayr-20231231xex99d2.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "terseLabel": "Trade payables", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r39", "r831" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r367", "r368" ] }, "us-gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued Income Taxes, Current", "terseLabel": "Income tax payable", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": [ "r176", "r244" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r43" ] }, "us-gaap_AccumulatedCapitalizedInterestCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedCapitalizedInterestCosts", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated Capitalized Interest Costs", "terseLabel": "Capitalized interest", "documentation": "Amount of accumulated interest costs capitalized as part of property, plant and equipment cost basis." } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosurePropertyPlantAndEquipmentDetailss": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "terseLabel": "Less: Accumulated depreciation and amortization", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r83", "r282", "r662" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r54", "r55", "r190", "r290", "r657", "r676", "r677" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Accumulated other comprehensive income", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r6", "r24", "r55", "r573", "r576", "r612", "r672", "r673", "r860", "r861", "r862", "r877", "r878", "r879" ] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsAndImpairmentOfLongLivedAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Acquired Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Intangible assets", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsAndImpairmentOfLongLivedAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Useful life", "verboseLabel": "Amortization period for intangible assets", "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r212" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r182", "r831", "r934" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional paid- in capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r520", "r521", "r522", "r691", "r877", "r878", "r879", "r913", "r936" ] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AddressTypeDomain", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments for:" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationDetails", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedLabel": "Tax withholding on stock-based compensation awards", "terseLabel": "Tax withholding on stock-based compensation awards", "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Allowance for credit losses", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r291", "r371", "r377" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff", "terseLabel": "Accounts receivable written off", "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance." } } }, "auth_ref": [ "r378" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesChangesInSeniorSecuredNotesDetails", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amortization of Debt Discount (Premium)", "negatedLabel": "Amortization of debt premium", "terseLabel": "Amortization on financing premium", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": [ "r15", "r139", "r203", "r436" ] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesChangesInDebtOtherThanSeniorSecuredNotesDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesChangesInSeniorSecuredNotesDetails", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of financing costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r197", "r436", "r597", "r868" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 17.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amortization of Intangible Assets", "terseLabel": "Amortization expense", "verboseLabel": "Amortization on intangible assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r15", "r76", "r80" ] }, "ayr_AmountOfFutureProceedsFromEmployeeRetentionCreditRecognisedInCurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "AmountOfFutureProceedsFromEmployeeRetentionCreditRecognisedInCurrentReceivables", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiquidityAndManagementPlanDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of future proceeds from employee retention credit recognised in current receivables.", "label": "Amount of Future Proceeds From Employee Retention Credit Recognised in Current Receivables", "terseLabel": "Amount of future proceeds from employee retention credit recognised in current receivables" } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r848" ] }, "ayr_AntiDilutiveWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "AntiDilutiveWarrantsMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to Anti-Dilutive Warrants.", "label": "Anti-Dilutive Warrants [Member]", "terseLabel": "Anti-Dilutive Warrants" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Potentially dilutive financial instruments excluded from the calculation of earnings per share", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r344" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r70" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Earnings per share", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r70" ] }, "ayr_AreaCultivatorLicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "AreaCultivatorLicenseMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to area cultivator license.", "label": "Area Cultivator License [Member]", "terseLabel": "Area Cultivator License" } } }, "auth_ref": [] }, "us-gaap_AreaOfRealEstateProperty": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AreaOfRealEstateProperty", "presentation": [ "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails" ], "lang": { "en-us": { "role": { "label": "Area of Real Estate Property", "terseLabel": "Area of facility", "documentation": "Area of a real estate property." } } }, "auth_ref": [] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetImpairmentCharges", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 4.0 }, "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Asset Impairment Charges", "terseLabel": "Impairment of goodwill and other assets", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": [ "r15", "r81" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieSummaryOfFinancialInformationAboutConsolidatedViesDetails", "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "TOTAL ASSETS", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r242", "r284", "r314", "r349", "r357", "r361", "r374", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r564", "r569", "r587", "r653", "r728", "r831", "r843", "r898", "r899", "r921" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total Current Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r277", "r295", "r314", "r374", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r564", "r569", "r587", "r831", "r898", "r899", "r921" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current" } } }, "auth_ref": [] }, "ayr_AssetsDivested": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "AssetsDivested", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of assets divested.", "label": "Assets Divested", "terseLabel": "Assets divested" } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsNoncurrent", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieSummaryOfFinancialInformationAboutConsolidatedViesDetails" ], "lang": { "en-us": { "role": { "label": "Assets, Noncurrent", "terseLabel": "Non-current assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r314", "r374", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r564", "r569", "r587", "r898", "r899", "r921" ] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsNoncurrentAbstract", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Noncurrent [Abstract]", "terseLabel": "Non-current" } } }, "auth_ref": [] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails", "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Assets, Current", "terseLabel": "Assets held-for-sale", "totalLabel": "Total assets held-for-sale", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r5", "r150", "r167", "r217", "r220", "r275", "r276" ] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]", "terseLabel": "Current assets held-for-sale" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r848" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r846", "r847", "r848" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r846", "r847", "r848" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r846", "r847", "r848" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.ayrwellness.com/role/DisclosureShareCapitalActivityOccurredDuringYearEndDetails", "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationDetails", "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationRsusDetails" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r487", "r488", "r489", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r511", "r512", "r513", "r514", "r515" ] }, "ayr_BackstopNoteholdersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "BackstopNoteholdersMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to backstop noteholders.", "label": "Backstop Noteholders [Member]" } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r134", "r135" ] }, "us-gaap_BasisOfAccounting": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccounting", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBasisOfPresentation" ], "lang": { "en-us": { "role": { "label": "Basis of Accounting [Text Block]", "terseLabel": "BASIS OF PRESENTATION", "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r209" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of consolidation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "ayr_BasisOfPresentationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "BasisOfPresentationAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "BASIS OF PRESENTATION" } } }, "auth_ref": [] }, "ayr_BlueCamoLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "BlueCamoLlcMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails", "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsComponentsComprisingNetLossFromOurDiscontinuedOperationsDetails", "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsDetails", "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsLossFromDiscontinuedOperationsDetails", "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails", "http://www.ayrwellness.com/role/DisclosureShareCapitalActivityOccurredDuringYearEndDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Blue Camo LLC (\" Oasis\").", "label": "Blue Camo LLC [Member]", "terseLabel": "Blue Camo" } } }, "auth_ref": [] }, "ayr_BoardMemberMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "BoardMemberMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRelatedPartyTransactionsAndBalancesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to board members.", "label": "Board Member [Member]", "terseLabel": "Board member" } } }, "auth_ref": [] }, "us-gaap_BuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BuildingMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosurePropertyPlantAndEquipmentDetails", "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentppeDetails" ], "lang": { "en-us": { "role": { "label": "Building [Member]", "terseLabel": "Buildings", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities." } } }, "auth_ref": [ "r218" ] }, "ayr_BuildingsAndImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "BuildingsAndImprovementsMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to buildings and improvements.", "label": "Buildings And Improvements [Member]", "terseLabel": "Buildings and improvements" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionPurchaseConsiderationDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionPurchaseConsiderationDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitionsIncluding2023FourthQuarterAssetAcquisitionDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitionsTables", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails", "http://www.ayrwellness.com/role/DisclosureDerivativeLiabilitiesScheduleOfFairValueAdjustmentRelatingToDerivativeLiabilitiesDetails", "http://www.ayrwellness.com/role/DisclosureShareCapitalActivityOccurredDuringYearEndDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r560", "r823", "r824" ] }, "ayr_BusinessAcquisitionAndAssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "BusinessAcquisitionAndAssetAcquisitionAxis", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitionsTables" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations and asset acquisitions.", "label": "Business Acquisition And Asset Acquisition [Axis]" } } }, "auth_ref": [] }, "ayr_BusinessAcquisitionAndAssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "BusinessAcquisitionAndAssetAcquisitionDomain", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitionsTables" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquire and asset acquisition.", "label": "Business Acquisition And Asset Acquisition [Domain]" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionPurchaseConsiderationDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionPurchaseConsiderationDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitionsIncluding2023FourthQuarterAssetAcquisitionDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitionsTables", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails", "http://www.ayrwellness.com/role/DisclosureDerivativeLiabilitiesScheduleOfFairValueAdjustmentRelatingToDerivativeLiabilitiesDetails", "http://www.ayrwellness.com/role/DisclosureShareCapitalActivityOccurredDuringYearEndDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r107", "r109", "r560", "r823", "r824" ] }, "ayr_BusinessAcquisitionEquityInterestIssuedOrIssuableDiscountRateUsedAsBasisForDeterminingFairValue": { "xbrltype": "percentItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableDiscountRateUsedAsBasisForDeterminingFairValue", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionPurchaseConsiderationDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionPurchaseConsiderationDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of discount rate used as a basis for determining value of equity interest issued or issuable to acquire the entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Discount Rate Used As Basis for Determining Fair Value", "terseLabel": "Percentage of discount rate used to determine fair value of Exchangeable Shares issued", "verboseLabel": "Discount rate attributed to the contractual restrictions" } } }, "auth_ref": [] }, "ayr_BusinessAcquisitionEquityInterestIssuedOrIssuableLockUpProvisionPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableLockUpProvisionPeriod", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionPurchaseConsiderationDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionPurchaseConsiderationDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails" ], "lang": { "en-us": { "role": { "documentation": "The period during which the shares issued or issuable pursuant to a business combination transaction, shall not be sold.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Lock-Up Provision Period", "terseLabel": "Lock-up provision period for Exchangeable Shares issued" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionPurchaseConsiderationDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionPurchaseConsiderationDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares", "terseLabel": "Shares Issued, shares", "documentation": "Number of shares of equity interests issued or issuable to acquire entity." } } }, "auth_ref": [ "r233" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionPurchaseConsiderationDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionPurchaseConsiderationDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitionsIncluding2023FourthQuarterAssetAcquisitionDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Line Items]", "terseLabel": "BUSINESS COMBINATIONS AND ASSET ACQUISITIONS", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r560" ] }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "presentation": [ "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Membership interest", "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination." } } }, "auth_ref": [ "r108" ] }, "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitionsIncluding2023FourthQuarterAssetAcquisitionDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount", "terseLabel": "Goodwill expected to be deductible for income tax purposes", "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes." } } }, "auth_ref": [ "r117" ] }, "ayr_BusinessAcquisitionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "BusinessAcquisitionsMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitionsIncluding2023FourthQuarterAssetAcquisitionDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to business acquisitions.", "label": "Business Acquisitions [Member]", "terseLabel": "Business acquisitions" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAcquisitionRelatedCosts", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Business Combination, Acquisition Related Costs", "terseLabel": "Acquisition and transaction costs", "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities." } } }, "auth_ref": [ "r106" ] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "BUSINESS COMBINATIONS AND ASSET ACQUISITIONS" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionPurchaseConsiderationDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionPurchaseConsiderationDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Consideration Transferred", "terseLabel": "Purchase consideration", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r1", "r2", "r21" ] }, "ayr_BusinessCombinationConsiderationTransferredContingentConsiderationLiabilitiesIncurred": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "BusinessCombinationConsiderationTransferredContingentConsiderationLiabilitiesIncurred", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionPurchaseConsiderationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of contingent consideration liabilities incurred by the acquirer as part of consideration transferred in a business combination.", "label": "Business Combination, Consideration Transferred, Contingent Consideration Liabilities Incurred", "terseLabel": "Contingent Consideration" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionPurchaseConsiderationDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionPurchaseConsiderationDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable", "terseLabel": "Shares Issued", "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination." } } }, "auth_ref": [ "r1", "r2" ] }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionPurchaseConsiderationDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Consideration Transferred, Liabilities Incurred", "terseLabel": "Debt Payable", "verboseLabel": "Incurred through combinations and acquisitions", "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination." } } }, "auth_ref": [ "r1", "r2", "r115", "r562" ] }, "ayr_BusinessCombinationContingentConsiderationDeferredCashNetOfPaymentsMade": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "BusinessCombinationContingentConsiderationDeferredCashNetOfPaymentsMade", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of deferred cash included in contingent consideration incurred by the acquirer in a business combination, net of payments made.", "label": "Business Combination Contingent Consideration Deferred Cash Net Of Payments Made", "terseLabel": "Deferred cash net of payments made" } } }, "auth_ref": [] }, "ayr_BusinessCombinationContingentConsiderationDeferredCashPaymentsMade": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "BusinessCombinationContingentConsiderationDeferredCashPaymentsMade", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of deferred cash included in contingent consideration incurred by the acquirer in a business combination, net of payments made.", "label": "Business Combination Contingent Consideration Deferred Cash Payments Made", "terseLabel": "Deferred cash payments made" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails", "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Business Combination, Contingent Consideration, Liability, Current", "terseLabel": "Contingent consideration - current portion", "verboseLabel": "Deferred cash", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r3", "r116" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "terseLabel": "Contingent consideration - non-current portion", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r3", "r116" ] }, "ayr_BusinessCombinationContingentConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "BusinessCombinationContingentConsiderationTransferred", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of contingent consideration settled.", "label": "Business Combination, Contingent Consideration Transferred", "terseLabel": "Contingent consideration satisfied, total" } } }, "auth_ref": [] }, "ayr_BusinessCombinationContingentConsiderationTransferredDeferredConsiderationArrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "BusinessCombinationContingentConsiderationTransferredDeferredConsiderationArrangements", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of deferred consideration arrangements incurred by the acquirer as part of contingent consideration transferred in a business combination.", "label": "Business Combination, Contingent Consideration Transferred, Deferred Consideration Arrangements", "terseLabel": "Deferred cash in satisfaction of contingent consideration" } } }, "auth_ref": [] }, "ayr_BusinessCombinationContingentConsiderationTransferredEquityInterestsIssuedAndIssuable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "BusinessCombinationContingentConsiderationTransferredEquityInterestsIssuedAndIssuable", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in contingent consideration for the business combination.", "label": "Business Combination, Contingent Consideration Transferred, Equity Interests Issued and Issuable", "terseLabel": "Equity Shares incurred in satisfaction of contingent consideration" } } }, "auth_ref": [] }, "ayr_BusinessCombinationContingentConsiderationTransferredEquityInterestsIssuedAndIssuableMarketPriceForCalculationOfShares": { "xbrltype": "perShareItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "BusinessCombinationContingentConsiderationTransferredEquityInterestsIssuedAndIssuableMarketPriceForCalculationOfShares", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the market price used for calculation of shares in contingent consideration of business combination.", "label": "Business Combination, Contingent Consideration Transferred, Equity Interests Issued and Issuable, Market Price for Calculation of Shares", "terseLabel": "Market price of equity" } } }, "auth_ref": [] }, "ayr_BusinessCombinationContingentConsiderationTransferredLiabilitiesIncurred": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "BusinessCombinationContingentConsiderationTransferredLiabilitiesIncurred", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred by the acquirer as part of contingent consideration transferred in a business combination.", "label": "Business Combination, Contingent Consideration Transferred, Liabilities Incurred", "terseLabel": "Liabilities incurred in satisfaction of contingent consideration" } } }, "auth_ref": [] }, "ayr_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2021FirstQuarterAcquisitionsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of accrued liabilities assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities", "terseLabel": "Accrued liabilities" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2021FirstQuarterAcquisitionsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "totalLabel": "Total assets acquired at fair value", "documentation": "Amount of assets acquired at the acquisition date." } } }, "auth_ref": [ "r111" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]", "terseLabel": "ASSETS ACQUIRED" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2021FirstQuarterAcquisitionsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation", "terseLabel": "Lease liabilities - operating", "documentation": "Amount of lease obligation assumed in business combination." } } }, "auth_ref": [ "r111" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2021FirstQuarterAcquisitionsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r111" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2021FirstQuarterAcquisitionsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "terseLabel": "Prepaid expenses and other assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r111" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2021FirstQuarterAcquisitionsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "terseLabel": "Accounts receivable", "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r111" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2021FirstQuarterAcquisitionsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Intangible assets - licenses/permits", "verboseLabel": "Intangible assets", "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date." } } }, "auth_ref": [ "r111" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitionsIncluding2023FourthQuarterAssetAcquisitionDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Company recorded intangible assets", "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date." } } }, "auth_ref": [ "r110", "r111" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2021FirstQuarterAcquisitionsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Inventory", "documentation": "The amount of inventory recognized as of the acquisition date." } } }, "auth_ref": [ "r110", "r111" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2021FirstQuarterAcquisitionsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "totalLabel": "Total liabilities assumed at fair value", "documentation": "Amount of liabilities assumed at the acquisition date." } } }, "auth_ref": [ "r111" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]", "terseLabel": "LIABILITIES ASSUMED" } } }, "auth_ref": [] }, "ayr_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2021FirstQuarterAcquisitionsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of operating lease, right of use assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease, Right Of Use Assets", "terseLabel": "Right-of-use assets - operating" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2021FirstQuarterAcquisitionsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property, plant, and equipment", "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date." } } }, "auth_ref": [ "r110", "r111" ] }, "ayr_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTradePayables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTradePayables", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2021FirstQuarterAcquisitionsFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of trade payables assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Trade Payables", "terseLabel": "Trade payables" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "terseLabel": "Consideration transferred", "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r111" ] }, "ayr_BusinessCombinationsAndAssetAcquisitionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "BusinessCombinationsAndAssetAcquisitionsDisclosureTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for business combinations and asset acquisitions.", "label": "Business Combinations And Asset Acquisitions, Disclosure [Text Block]", "terseLabel": "BUSINESS COMBINATIONS AND ASSET ACQUISITIONS" } } }, "auth_ref": [] }, "ayr_BusinessCombinationsIncrementalCostsToAcquireCannabisInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "BusinessCombinationsIncrementalCostsToAcquireCannabisInventory", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_CostOfGoodsAndServicesSold", "weight": 1.0, "order": 2.0 }, "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureInventoryDetails", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Incremental costs to incurred acquire cannabis inventory in business combinations during the period.", "label": "Business Combinations, Incremental Costs to Acquire Cannabis Inventory", "terseLabel": "Incremental costs to acquire cannabis inventory in business combination", "verboseLabel": "Expenses relating to the incremental costs to acquire inventory in business combinations" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationsPolicy", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Business combinations", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } } }, "auth_ref": [ "r105" ] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "BusinessContactMember", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Business Contact [Member]", "terseLabel": "Business Contact", "documentation": "Business contact for the entity" } } }, "auth_ref": [ "r847", "r848" ] }, "us-gaap_BusinessDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessDevelopment", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRelatedPartyTransactionsAndBalancesDetails" ], "lang": { "en-us": { "role": { "label": "Business Development", "terseLabel": "Development fees", "documentation": "Business development involves the development of products and services, their delivery, design and their implementation. Business development includes a number of techniques designed to grow an economic enterprise. Such techniques include, but are not limited to, assessments of marketing opportunities and target markets, intelligence gathering on customers and competitors, generating leads for possible sales, follow-up sales activity, formal proposal writing and business model design. Business development involves evaluating a business and then realizing its full potential, using such tools as marketing, sales, information management and customer service." } } }, "auth_ref": [ "r196" ] }, "stpr_CT": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2023", "localname": "CT", "presentation": [ "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "CONNECTICUT", "terseLabel": "Connecticut" } } }, "auth_ref": [] }, "ayr_CancellationOfEquityShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "CancellationOfEquityShares", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of equity cancelled in noncash financing activities.", "label": "Cancellation of Equity Shares", "terseLabel": "Cancellation of Equity Shares" } } }, "auth_ref": [] }, "ayr_CanntechPaLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "CanntechPaLlcMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureShareCapitalActivityOccurredDuringYearEndDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to CannTech PA, LLC.", "label": "CannTech PA, LLC [Member]", "terseLabel": "CannTech PA, LLC" } } }, "auth_ref": [] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Capital expenditure disbursements for cultivation facility", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r67", "r68", "r69" ] }, "ayr_CarryingValueOfBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "CarryingValueOfBusiness", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsLossFromDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of carrying value of business.", "label": "Carrying Value of Business", "terseLabel": "Carrying value" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r64", "r280", "r801" ] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and cash equivalents and restricted cash", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": [ "r65", "r241" ] }, "ayr_CashAssetsHeldForSale": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "CashAssetsHeldForSale", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of cash included in assets held for sale.", "label": "Cash, Assets Held for Sale", "periodStartLabel": "Cash included in assets held-for-sale" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash end of the period", "periodStartLabel": "Cash, cash equivalents and restricted cash beginning of the period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r64", "r206", "r310" ] }, "ayr_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsExcludingCashIncludedInAssetsHeldForSale": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsExcludingCashIncludedInAssetsHeldForSale", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates, excluding cash included in assets held-for-sale.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Excluding Cash Included In Assets Held For Sale", "terseLabel": "Cash, cash equivalents and restricted cash excluding Cash included in assets held-for-sale" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net decrease in cash and cash equivalents and restricted cash", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r4", "r206" ] }, "us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Provided by (Used in) Financing Activities, Discontinued Operations", "terseLabel": "Cash used in financing activities from discontinued operations", "documentation": "Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r206" ] }, "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations", "terseLabel": "Cash provided by investing activities of discontinued operations", "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r166", "r206" ] }, "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations", "terseLabel": "Cash provided by (used in) discontinued operations", "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r166", "r206" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.ayrwellness.com/role/DisclosureShareCapitalActivityOccurredDuringYearEndDetails", "http://www.ayrwellness.com/role/DisclosureSubsequentEventsDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation", "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets", "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheetsParenthetical", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r272", "r287", "r288", "r289", "r314", "r338", "r339", "r341", "r343", "r347", "r348", "r374", "r405", "r407", "r408", "r409", "r412", "r413", "r446", "r447", "r450", "r453", "r460", "r587", "r680", "r681", "r682", "r683", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r716", "r737", "r760", "r777", "r778", "r779", "r780", "r781", "r852", "r869", "r881" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.ayrwellness.com/role/DisclosureShareCapitalActivityOccurredDuringYearEndDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "terseLabel": "SHARE CAPITAL", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r287", "r288", "r289", "r347", "r446", "r447", "r448", "r450", "r453", "r458", "r460", "r680", "r681", "r682", "r683", "r818", "r852", "r869" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://www.ayrwellness.com/role/DisclosureShareCapitalWarrantsDetails", "http://www.ayrwellness.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r98" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://www.ayrwellness.com/role/DisclosureShareCapitalWarrantsDetails", "http://www.ayrwellness.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://www.ayrwellness.com/role/DisclosureShareCapitalWarrantsDetails", "http://www.ayrwellness.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Warrants, exercise price", "verboseLabel": "Exercise price of warrants", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r461" ] }, "ayr_ClassOfWarrantOrRightIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "ClassOfWarrantOrRightIssued", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants issued.", "label": "Class of Warrant or Right, Issued" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightLineItems", "presentation": [ "http://www.ayrwellness.com/role/DisclosureShareCapitalWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Line Items]", "terseLabel": "Warrants", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://www.ayrwellness.com/role/DisclosureShareCapitalWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Outstanding", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at the beginning", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "ayr_ClassOfWarrantOrRightPeriodIncreaseDecrease": { "xbrltype": "sharesItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "ClassOfWarrantOrRightPeriodIncreaseDecrease", "presentation": [ "http://www.ayrwellness.com/role/DisclosureShareCapitalWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the net number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Period Increase Decrease", "terseLabel": "(no activity)" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightTable", "presentation": [ "http://www.ayrwellness.com/role/DisclosureShareCapitalWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r98" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies.", "terseLabel": "Commitments and contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r48", "r147", "r655", "r715" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureCommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r222", "r395", "r396", "r785", "r896" ] }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesPolicyTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies, Policy [Policy Text Block]", "terseLabel": "Loss contingencies", "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies." } } }, "auth_ref": [ "r84", "r786" ] }, "us-gaap_CommonStockNoParValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockNoParValue", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, No Par Value", "terseLabel": "Shares no par value (in dollars per share)", "documentation": "Face amount per share of no-par value common stock." } } }, "auth_ref": [ "r181" ] }, "us-gaap_CommonStockSharesAuthorizedUnlimited": { "xbrltype": "authorizedUnlimitedItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorizedUnlimited", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized, Unlimited [Fixed List]", "terseLabel": "Shares authorized", "documentation": "Indicates that the number of common shares permitted to be issued by an entity's charter and bylaws is unlimited. The acceptable value is \"Unlimited\"." } } }, "auth_ref": [ "r49" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Shares Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r181" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheetsParenthetical", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Balance, Ending (Shares)", "periodStartLabel": "Balance, Beginning (Shares)", "terseLabel": "Shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r25", "r181", "r716", "r734", "r936", "r937" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "terseLabel": "Shares", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r181", "r656", "r831" ] }, "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract", "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDeferredTaxAssetsAndLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Assets and Liabilities [Abstract]", "terseLabel": "Deferred tax assets and liabilities" } } }, "auth_ref": [] }, "ayr_ConditionalAdultUseDispensaryLicensesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "ConditionalAdultUseDispensaryLicensesMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitionsIncluding2023FourthQuarterAssetAcquisitionDetails" ], "lang": { "en-us": { "role": { "documentation": "Conditional adult use dispensary licenses that allow for the retail sales of cannabis.", "label": "Conditional Adult Use Dispensary Licenses [Member]", "terseLabel": "Conditional adult use dispensary licenses" } } }, "auth_ref": [] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesAxis", "presentation": [ "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieSummaryOfFinancialInformationAboutConsolidatedViesDetails" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]" } } }, "auth_ref": [ "r321", "r564", "r565", "r569", "r570", "r621", "r796", "r897", "r900", "r901" ] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesDomain", "presentation": [ "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieSummaryOfFinancialInformationAboutConsolidatedViesDetails" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]" } } }, "auth_ref": [ "r321", "r564", "r565", "r569", "r570", "r621", "r796", "r897", "r900", "r901" ] }, "us-gaap_ConsolidationVariableInterestEntityPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationVariableInterestEntityPolicy", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]", "terseLabel": "Variable Interest Entities (\"VIE\")", "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined)." } } }, "auth_ref": [ "r121", "r124", "r126" ] }, "ayr_ConstructionFinanceLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "ConstructionFinanceLiability", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetails", "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "The noncurrent portion of the carrying value as of the balance sheet date of construction finance liabilities.", "label": "Construction Finance Liability", "terseLabel": "Construction finance liabilities" } } }, "auth_ref": [] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionInProgressMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Construction in Progress [Member]", "terseLabel": "Construction in progress", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ContactPersonnelName", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "ayr_ContingentConsiderationFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "ContingentConsiderationFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureFinancialRiskFactorsFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "documentation": "Fair value of contingent consideration in a business combination.", "label": "Contingent Consideration, Fair Value Disclosure", "terseLabel": "Contingent consideration" } } }, "auth_ref": [] }, "ayr_ContingentConsiderationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "ContingentConsiderationMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents Information abount Contingent Consideration.", "label": "Contingent Consideration [Member]", "terseLabel": "Contingent consideration" } } }, "auth_ref": [] }, "ayr_ContingentConsiderationVendorTakeBackPromissoryNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "ContingentConsiderationVendorTakeBackPromissoryNotesMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents Information about Contingent Consideration- Vendor Take Back Promissory Notes", "label": "Contingent Consideration- Vendor Take Back Promissory Notes [Member]", "terseLabel": "Contingent consideration- vendor take back promissory notes" } } }, "auth_ref": [] }, "us-gaap_ContractualObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractualObligation", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Contractual Obligation", "terseLabel": "Contractual obligation", "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments." } } }, "auth_ref": [ "r875" ] }, "ayr_ConversionOfConvertibleNoteRelatedToBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "ConversionOfConvertibleNoteRelatedToBusinessCombination", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of conversion of convertible note related to business combination.", "label": "Conversion of Convertible Note Related to Business Combination", "terseLabel": "Conversion of convertible note related to business combination" } } }, "auth_ref": [] }, "ayr_ConvertibleNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "ConvertibleNoteMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to convertible notes.", "label": "Convertible Note [Member]", "terseLabel": "Convertible Note" } } }, "auth_ref": [] }, "us-gaap_CostDepreciationAmortizationAndDepletion": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostDepreciationAmortizationAndDepletion", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Cost, Depreciation, Amortization and Depletion", "terseLabel": "Depreciation and amortization", "documentation": "Amount of expense for allocation of cost of tangible and intangible assets over their useful lives, and reduction in quantity of natural resource due to consumption directly used in production of good and rendering of service." } } }, "auth_ref": [ "r863" ] }, "ayr_CostOfGoodsAndServiceExcludingFairValueItems": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "CostOfGoodsAndServiceExcludingFairValueItems", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_CostOfGoodsAndServicesSold", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Cost of product sold and service rendered, excluding fair value items.", "label": "Cost of Goods and Service, Excluding Fair Value Items", "terseLabel": "Cost of goods sold excluding fair value items" } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Cost of Goods and Services Sold", "totalLabel": "Cost of goods sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r199", "r634" ] }, "ayr_CostOfInventoriesRecognizedAsExpenseDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "CostOfInventoriesRecognizedAsExpenseDuringPeriod", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureInventoryDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of inventories recognized as an expense during the period.", "label": "Cost Of Inventories Recognized As Expense During Period", "terseLabel": "Amount of inventory recognized" } } }, "auth_ref": [] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails", "http://www.ayrwellness.com/role/DisclosureInventoryDetails", "http://www.ayrwellness.com/role/DisclosurePropertyPlantAndEquipmentDetails", "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesPaymentsRelatedToCapitalizedLeaseDetails" ], "lang": { "en-us": { "role": { "label": "Cost of Sales [Member]", "terseLabel": "Cost of goods sold", "verboseLabel": "COGS", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRelatedPartyTransactionsAndBalancesDetails", "http://www.ayrwellness.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r318", "r319", "r418", "r448", "r619", "r804", "r806" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information", "documentation": "Cover page." } } }, "auth_ref": [] }, "ayr_CultivaunaLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "CultivaunaLlcMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionPurchaseConsiderationDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitionsTables", "http://www.ayrwellness.com/role/DisclosureShareCapitalActivityOccurredDuringYearEndDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information Pertaining to Cultivauna, LLC (\"Cultivauna\").", "label": "Cultivauna, LLC [Member]", "terseLabel": "Cultivauna" } } }, "auth_ref": [] }, "ayr_CurrentAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "CurrentAssetsNet", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieSummaryOfFinancialInformationAboutConsolidatedViesDetails" ], "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets net are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Current Assets Net", "terseLabel": "Current assets" } } }, "auth_ref": [] }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureTaxationDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDetails" ], "lang": { "en-us": { "role": { "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "Federal", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r856", "r872", "r912" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 }, "http://www.ayrwellness.com/role/DisclosureTaxationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDetails", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Current Income Tax Expense (Benefit)", "negatedLabel": "Current tax provision", "totalLabel": "Total current expense :", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": [ "r231", "r548", "r554", "r872" ] }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDetails" ], "lang": { "en-us": { "role": { "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Current expense :" } } }, "auth_ref": [] }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureTaxationDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDetails" ], "lang": { "en-us": { "role": { "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r856", "r872", "r912" ] }, "ayr_DailyReleafLlcHeavenWellnessLlcAndTwiceWellnessLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "DailyReleafLlcHeavenWellnessLlcAndTwiceWellnessLlcMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieSummaryOfFinancialInformationAboutConsolidatedViesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Daily Releaf, LLC, Heaven Wellness, LLC and Twice the Wellness, LLC (\"Ohio Dispensaries\").", "label": "Daily Releaf, LLC, Heaven Wellness, LLC And Twice the Wellness, LLC [Member]", "terseLabel": "Ohio Dispensaries" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "DEBTS PAYABLE AND SENIOR SECURED NOTES" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotes" ], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "terseLabel": "DEBTS PAYABLE AND SENIOR SECURED NOTES", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r223", "r312", "r414", "r420", "r421", "r422", "r423", "r424", "r425", "r430", "r437", "r438", "r440" ] }, "ayr_DebtIncurredThroughEarnOutProvision": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "DebtIncurredThroughEarnOutProvision", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesChangesInDebtOtherThanSeniorSecuredNotesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred by the acquirer as part of contingent consideration transferred in a business combination.", "label": "Debt Incurred Through Earn-Out Provision", "terseLabel": "Incurred through earn-out provision" } } }, "auth_ref": [] }, "ayr_DebtInstrumentAfterFinancingCostsBeforePremiumOrDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "DebtInstrumentAfterFinancingCostsBeforePremiumOrDiscount", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesChangesInDebtOtherThanSeniorSecuredNotesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount, after financing costs, but before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Debt Instrument After Financing Costs, Before Premium Or Discount" } } }, "auth_ref": [] }, "ayr_DebtInstrumentAmortizationRate": { "xbrltype": "percentItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "DebtInstrumentAmortizationRate", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amortization interest rate for funds borrowed under the debt agreement.", "label": "Debt Instrument, Amortization Rate", "terseLabel": "Amortization Rate" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAnnualPrincipalPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAnnualPrincipalPayment", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Annual Principal Payment", "terseLabel": "Principal payment", "documentation": "Amount of the total principal payments made during the annual reporting period." } } }, "auth_ref": [ "r33" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesChangesInDebtOtherThanSeniorSecuredNotesDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesDebtsPayableDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesFutureDebtObligationsDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails", "http://www.ayrwellness.com/role/DisclosureSubsequentEventsDetails", "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiquidityAndManagementPlanDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r33", "r175", "r176", "r243", "r246", "r321", "r415", "r416", "r417", "r418", "r419", "r421", "r426", "r427", "r428", "r429", "r431", "r432", "r433", "r434", "r435", "r436", "r598", "r813", "r814", "r815", "r816", "r817", "r870" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Spread on variable rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesFutureDebtObligationsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesChangesInDebtOtherThanSeniorSecuredNotesDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesDebtsPayableDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesFutureDebtObligationsDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Gross", "periodEndLabel": "Debts payable (Period end)", "periodStartLabel": "Debts payable (Period Beginning)", "terseLabel": "Total debts payable, undiscounted", "totalLabel": "Total debt obligations", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r33", "r246", "r441" ] }, "ayr_DebtInstrumentCarryingAmountCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "DebtInstrumentCarryingAmountCurrent", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesDebtsPayableDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Debt Instrument Carrying Amount, Current", "terseLabel": "Less: current portion" } } }, "auth_ref": [] }, "ayr_DebtInstrumentCarryingAmountNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "DebtInstrumentCarryingAmountNoncurrent", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesDebtsPayableDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt, classified as noncurrent. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Debt Instrument Carrying Amount, Noncurrent", "terseLabel": "Total non-current debt, undiscounted" } } }, "auth_ref": [] }, "ayr_DebtInstrumentDeferralTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "DebtInstrumentDeferralTerm", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the deferral term of debt instrument.", "label": "Debt Instrument, Deferral Term", "terseLabel": "Deferral term" } } }, "auth_ref": [] }, "ayr_DebtInstrumentExtensionTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "DebtInstrumentExtensionTerm", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the extension term of debt instrument.", "label": "Debt Instrument, Extension Term", "terseLabel": "Extension Term" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails", "http://www.ayrwellness.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Face Amount", "terseLabel": "Principal amount", "verboseLabel": "New Money Notes", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r140", "r143", "r415", "r598", "r814", "r815" ] }, "us-gaap_DebtInstrumentIncreaseDecreaseNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentIncreaseDecreaseNetAbstract", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesChangesInDebtOtherThanSeniorSecuredNotesDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesChangesInSeniorSecuredNotesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Increase (Decrease), Net [Abstract]", "terseLabel": "Senior secured notes" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Debt effective interest rate", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r45", "r140", "r443", "r598" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails", "http://www.ayrwellness.com/role/DisclosureSubsequentEventsDetails", "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiquidityAndManagementPlanDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate", "verboseLabel": "Interest rate (in percent)", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r45", "r416" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesChangesInDebtOtherThanSeniorSecuredNotesDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesChangesInSeniorSecuredNotesDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesDebtsPayableDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesFutureDebtObligationsDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "terseLabel": "DEBTS PAYABLE AND SENIOR SECURED NOTES", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r321", "r415", "r416", "r417", "r418", "r419", "r421", "r426", "r427", "r428", "r429", "r431", "r432", "r433", "r434", "r435", "r436", "r439", "r598", "r813", "r814", "r815", "r816", "r817", "r870" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesChangesInDebtOtherThanSeniorSecuredNotesDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesDebtsPayableDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesFutureDebtObligationsDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails", "http://www.ayrwellness.com/role/DisclosureSubsequentEventsDetails", "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiquidityAndManagementPlanDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r46", "r321", "r415", "r416", "r417", "r418", "r419", "r421", "r426", "r427", "r428", "r429", "r431", "r432", "r433", "r434", "r435", "r436", "r598", "r813", "r814", "r815", "r816", "r817", "r870" ] }, "ayr_DebtInstrumentNumberOfMajorityNoteholdersByWhomOfferingCanBeBackstopped": { "xbrltype": "integerItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "DebtInstrumentNumberOfMajorityNoteholdersByWhomOfferingCanBeBackstopped", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of majority shareholders by whom the offering of debt can be backstopped.", "label": "Debt Instrument, Number of Majority Noteholders by Whom the Offering can be Backstopped", "terseLabel": "Number of majority Noteholders by whom the offering can be backstopped" } } }, "auth_ref": [] }, "ayr_DebtInstrumentPercentageOfOriginalIssueDiscount": { "xbrltype": "percentItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "DebtInstrumentPercentageOfOriginalIssueDiscount", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of original issue discount.", "label": "Debt Instrument, Percentage of Original Issue Discount", "terseLabel": "Original issue discount (in percent)" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentPeriodicPaymentInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentPeriodicPaymentInterest", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Periodic Payment, Interest", "terseLabel": "Accrued payment-in-kind interest", "documentation": "Amount of the required periodic payments applied to interest." } } }, "auth_ref": [ "r46" ] }, "ayr_DebtInstrumentRemainingPrincipalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "DebtInstrumentRemainingPrincipalAmount", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Remaining principal amount of debt in connection with acquisition.", "label": "Debt Instrument Remaining Principal Amount", "terseLabel": "Remaining principal amount" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesChangesInDebtOtherThanSeniorSecuredNotesDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesChangesInSeniorSecuredNotesDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesDebtsPayableDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesFutureDebtObligationsDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r46", "r91", "r94", "r139", "r140", "r143", "r148", "r225", "r226", "r321", "r415", "r416", "r417", "r418", "r419", "r421", "r426", "r427", "r428", "r429", "r431", "r432", "r433", "r434", "r435", "r436", "r439", "r598", "r813", "r814", "r815", "r816", "r817", "r870" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTerm", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Term", "terseLabel": "Notes term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "ayr_DebtInstrumentTermOfInterestOnlyPayments": { "xbrltype": "durationItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "DebtInstrumentTermOfInterestOnlyPayments", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the term of interest only payments of a debt instrument.", "label": "Debt Instrument, Term of Interest Only Payments", "terseLabel": "Interest only payments period" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscountNoncurrent", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesDebtsPayableDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Unamortized Discount, Noncurrent", "terseLabel": "Less: discount to fair value", "documentation": "Amount of debt discount to be amortized after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r139", "r143" ] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscountPremiumNet", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesChangesInDebtOtherThanSeniorSecuredNotesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Unamortized Discount (Premium), Net", "negatedLabel": "Debt Discount (Premium)", "terseLabel": "Less: discounted to fair value", "documentation": "Amount, after accumulated amortization, of debt discount (premium)." } } }, "auth_ref": [ "r139", "r140", "r141", "r142", "r143", "r903" ] }, "ayr_DebtPayablesOtherThanNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "DebtPayablesOtherThanNotesMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesChangesInDebtOtherThanSeniorSecuredNotesDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesDebtsPayableDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesFutureDebtObligationsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to debt payable other than notes.", "label": "Debt Payables Other Than Notes [Member]", "terseLabel": "Debts payable", "verboseLabel": "Total debt" } } }, "auth_ref": [] }, "ayr_DebtSubordinateAgreementRelatedToContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "DebtSubordinateAgreementRelatedToContingentConsideration", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of debt under subordinate agreement related to contingent consideration.", "label": "Debt Subordinate Agreement Related To Contingent Consideration", "terseLabel": "Debt under subordinate agreement" } } }, "auth_ref": [] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureTaxationDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "Federal", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r872", "r911", "r912" ] }, "us-gaap_DeferredFinanceCostsCurrentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsCurrentNet", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesDebtsPayableDetails" ], "lang": { "en-us": { "role": { "label": "Debt Issuance Costs, Current, Net", "terseLabel": "Less: debt issuance costs - current portion", "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r141" ] }, "us-gaap_DeferredFinanceCostsNoncurrentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsNoncurrentNet", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesDebtsPayableDetails" ], "lang": { "en-us": { "role": { "label": "Debt Issuance Costs, Noncurrent, Net", "terseLabel": "Less: debt issuance costs - non-current portion", "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r141" ] }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredForeignIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureTaxationDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Foreign Income Tax Expense (Benefit)", "terseLabel": "Foreign", "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r231", "r872", "r911" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 }, "http://www.ayrwellness.com/role/DisclosureTaxationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 }, "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDetails", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Expense (Benefit)", "negatedLabel": "Deferred tax benefit (expense)", "terseLabel": "Deferred tax (benefit) expense", "totalLabel": "Total deferred (benefit) expense :", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r15", "r231", "r268", "r553", "r554", "r872" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Deferred (benefit) expense :" } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilities", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureTaxationDeferredTaxAssetsAndLiabilityDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDeferredTaxAssetsAndLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "Total deferred tax liabilities", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences." } } }, "auth_ref": [ "r178", "r179", "r245", "r543" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liabilities, net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r533", "r534", "r654" ] }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureTaxationDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDetails" ], "lang": { "en-us": { "role": { "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "State", "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r872", "r911", "r912" ] }, "us-gaap_DeferredTaxAssetsGrossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGrossAbstract", "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDeferredTaxAssetsAndLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Gross [Abstract]", "terseLabel": "Deferred tax assets" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsInventory", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureTaxationDeferredTaxAssetsAndLiabilityDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDeferredTaxAssetsAndLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Inventory", "terseLabel": "Inventory", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory." } } }, "auth_ref": [ "r104", "r910" ] }, "ayr_DeferredTaxAssetsLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "DeferredTaxAssetsLeaseLiabilities", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureTaxationDeferredTaxAssetsAndLiabilityDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDeferredTaxAssetsAndLiabilityDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.", "label": "Deferred Tax Assets, Lease Liabilities", "terseLabel": "Lease liabilities" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureTaxationDeferredTaxAssetsAndLiabilityDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDeferredTaxAssetsAndLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Total deferred tax assets", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r909" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureTaxationDeferredTaxAssetsAndLiabilityDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDeferredTaxAssetsAndLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating losses", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r104", "r910" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDeferredTaxAssetsAndLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration", "terseLabel": "Net operating loss carryforwards subject to expiration", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureTaxationDeferredTaxAssetsAndLiabilityDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDeferredTaxAssetsAndLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Other", "terseLabel": "Other assets", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": [ "r104", "r910" ] }, "ayr_DeferredTaxAssetsShareIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "DeferredTaxAssetsShareIssuanceCosts", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureTaxationDeferredTaxAssetsAndLiabilityDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDeferredTaxAssetsAndLiabilityDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share issuance costs.", "label": "Deferred Tax Assets, Share Issuance Costs", "terseLabel": "Share issuance costs" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureTaxationDeferredTaxAssetsAndLiabilityDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDeferredTaxAssetsAndLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost", "terseLabel": "Share based compensation", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation." } } }, "auth_ref": [ "r104", "r910" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureTaxationDeferredTaxAssetsAndLiabilityDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDeferredTaxAssetsAndLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r544" ] }, "us-gaap_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureTaxationDeferredTaxAssetsAndLiabilityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDeferredTaxAssetsAndLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Net", "negatedTotalLabel": "Net deferred tax liability", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting." } } }, "auth_ref": [ "r103", "r909" ] }, "ayr_DeferredTaxLiabilitiesAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "DeferredTaxLiabilitiesAmortization", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureTaxationDeferredTaxAssetsAndLiabilityDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDeferredTaxAssetsAndLiabilityDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from amortization.", "label": "Deferred Tax Liabilities, Amortization", "negatedLabel": "Amortization" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureTaxationDeferredTaxAssetsAndLiabilityDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDeferredTaxAssetsAndLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs", "negatedLabel": "Debt financing costs", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from debt issuance costs." } } }, "auth_ref": [ "r104", "r910" ] }, "ayr_DeferredTaxLiabilitiesDepreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "DeferredTaxLiabilitiesDepreciation", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureTaxationDeferredTaxAssetsAndLiabilityDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDeferredTaxAssetsAndLiabilityDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from depreciation.", "label": "Deferred Tax Liabilities, Depreciation", "negatedLabel": "Depreciation" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesNetAbstract", "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDeferredTaxAssetsAndLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Net [Abstract]", "terseLabel": "Deferred tax liabilities" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesOther", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureTaxationDeferredTaxAssetsAndLiabilityDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDeferredTaxAssetsAndLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Other", "negatedLabel": "Other liabilities", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other." } } }, "auth_ref": [ "r104", "r910" ] }, "ayr_DepositsAndOtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "DepositsAndOtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Carrying value of noncurrent assets classified as other and amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.", "label": "Deposits and Other Assets, Noncurrent", "terseLabel": "Deposits and other assets" } } }, "auth_ref": [] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r15", "r82" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 18.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r15", "r353" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDerivativeLiabilities" ], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "DERIVATIVE LIABILITIES", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": [ "r239", "r571", "r578" ] }, "us-gaap_DerivativeLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "DERIVATIVE LIABILITIES" } } }, "auth_ref": [] }, "ayr_DerivativeLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "DerivativeLiabilitiesLineItems", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDerivativeLiabilitiesScheduleOfFairValueAdjustmentRelatingToDerivativeLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represents the information pertaining to derivative liabilities.", "label": "Derivative Liabilities [Line Items]", "terseLabel": "DERIVATIVE LIABILITIES" } } }, "auth_ref": [] }, "ayr_DerivativeLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "DerivativeLiabilitiesTable", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDerivativeLiabilitiesScheduleOfFairValueAdjustmentRelatingToDerivativeLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule of derivative liabilities.", "label": "Derivative Liabilities [Table]" } } }, "auth_ref": [] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativesPolicyTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Derivatives", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": [ "r26", "r131", "r132", "r133", "r136", "r320" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureStockBasedCompensation" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "STOCK-BASED COMPENSATION", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r483", "r486", "r516", "r517", "r519", "r826" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "STOCK-BASED COMPENSATION" } } }, "auth_ref": [] }, "ayr_DiscontinuedOperationDeferredTaxBenefitExpensesOnDisposal": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "DiscontinuedOperationDeferredTaxBenefitExpensesOnDisposal", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsComponentsComprisingNetLossFromOurDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of discontinued operation, deferred tax benefit expenses on disposal.", "label": "Discontinued Operation, Deferred Tax Benefit Expenses On Disposal", "terseLabel": "Deferred tax benefit" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsComponentsComprisingNetLossFromOurDiscontinuedOperationsDetails", "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsLossFromDiscontinuedOperationsDetails", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax", "terseLabel": "Loss from discontinued operations, net of taxes (including loss on disposal of $182,464 for the year ended December 31, 2023)", "verboseLabel": "Loss on disposal of discontinued operations", "documentation": "Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation." } } }, "auth_ref": [ "r154", "r156", "r158", "r169" ] }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationDisclosuresAbstract", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsComponentsComprisingNetLossFromOurDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Discontinued Operation, Income (Loss) from Discontinued Operation Disclosures [Abstract]", "terseLabel": "Loss from discontinued operations" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlowsCalc2": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsComponentsComprisingNetLossFromOurDiscontinuedOperationsDetails", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax", "totalLabel": "Loss from discontinued operations, net of taxes", "verboseLabel": "Less: Loss from discontinued operations (Note 4)", "documentation": "Amount after tax of income (loss) from operations classified as a discontinued operation. Excludes gain (loss) on disposal and provision for gain (loss) until disposal." } } }, "auth_ref": [ "r154", "r155", "r169" ] }, "us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsComponentsComprisingNetLossFromOurDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Discontinued Operation, Provision for Loss (Gain) on Disposal, before Income Tax", "terseLabel": "Current tax provision", "documentation": "Amount before tax of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a discontinued operation." } } }, "auth_ref": [ "r154", "r156", "r158" ] }, "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsComponentsComprisingNetLossFromOurDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Discontinued Operation, Tax Effect of Discontinued Operation", "negatedLabel": "Total income taxes", "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r155", "r156", "r157", "r158", "r164", "r169", "r535", "r552", "r556" ] }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": { "label": "DISCONTINUED OPERATIONS" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationsDisposedOfBySaleMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails", "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Discontinued Operations, Disposed of by Sale [Member]", "terseLabel": "Discontinued operations, Held for sale", "documentation": "Component or group of components disposed of by sale and representing a strategic shift that has or will have a major effect on operations and financial results." } } }, "auth_ref": [ "r11" ] }, "ayr_DiscontinuedOperationsEliminationOfOutstandingDebtAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "DiscontinuedOperationsEliminationOfOutstandingDebtAmount", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsLossFromDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of elimination of outstanding debt amount in a discontinued operation.", "label": "Discontinued Operations, Elimination of Outstanding Debt Amount", "terseLabel": "Elimination of outstanding debt amount" } } }, "auth_ref": [] }, "ayr_DiscontinuedOperationsGrossProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "DiscontinuedOperationsGrossProceeds", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsLossFromDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow from divestiture of business.", "label": "Discontinued Operations, Gross Proceeds", "terseLabel": "Gross proceeds" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationsHeldforsaleMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationsHeldforsaleMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsComponentsComprisingNetLossFromOurDiscontinuedOperationsDetails", "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsLossFromDiscontinuedOperationsDetails", "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Discontinued Operations, Held-for-Sale [Member]", "terseLabel": "Discontinued operations, Held for sale", "documentation": "Component or group of components classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale." } } }, "auth_ref": [ "r10", "r12", "r275" ] }, "us-gaap_DiscontinuedOperationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationsPolicyTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Discontinued Operations, Policy [Policy Text Block]", "terseLabel": "Discontinued operations", "documentation": "Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation." } } }, "auth_ref": [ "r19", "r37" ] }, "ayr_DiscontinuedOperationsWorkingCapitalAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "DiscontinuedOperationsWorkingCapitalAdjustment", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsLossFromDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of working capital adjustment in a discontinued operation.", "label": "Discontinued Operations, Working Capital Adjustment", "terseLabel": "Working capital adjustment" } } }, "auth_ref": [] }, "ayr_DiscountRatesAppliedToCashFlowProjections": { "xbrltype": "percentItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "DiscountRatesAppliedToCashFlowProjections", "presentation": [ "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsImpairmentOfGoodwillDetails" ], "lang": { "en-us": { "role": { "documentation": "The discount rate applied to cash flow projections for a cash-generating unit (group of units).", "label": "Discount Rates Applied To Cash Flow Projections", "terseLabel": "Post-tax discount rate (in percent)" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails", "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsComponentsComprisingNetLossFromOurDiscontinuedOperationsDetails", "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsDetails", "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsLossFromDiscontinuedOperationsDetails", "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r275" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails", "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsComponentsComprisingNetLossFromOurDiscontinuedOperationsDetails", "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsDetails", "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsLossFromDiscontinuedOperationsDetails", "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "ayr_DisposalGroupIncludingDiscontinuedOperationAccruedInterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedInterestPayableCurrent", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount classified as accrued interest payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Accrued Interest Payable, Current", "terseLabel": "Accrued interest payable" } } }, "auth_ref": [] }, "ayr_DisposalGroupIncludingDiscontinuedOperationAssetsInventoryAndOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsInventoryAndOtherCurrentAssets", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount classified as inventory and other current assets attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Assets, Inventory and Other Current Assets", "terseLabel": "Inventory and other current assets" } } }, "auth_ref": [] }, "ayr_DisposalGroupIncludingDiscontinuedOperationAssetsRightOfUseAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsRightOfUseAssetsCurrent", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount classified as right of use assets current attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Assets, Right of Use Assets, Current", "terseLabel": "Right-of-use assets, net" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsComponentsComprisingNetLossFromOurDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold", "terseLabel": "Cost of goods sold", "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r165", "r276" ] }, "ayr_DisposalGroupIncludingDiscontinuedOperationDebtPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "DisposalGroupIncludingDiscontinuedOperationDebtPayableCurrent", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount classified as debt payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Debt Payable, Current", "terseLabel": "Debt payable" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Deferred Tax Assets", "terseLabel": "Deferred tax asset, net", "documentation": "Amount classified as deferred tax assets attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r5", "r150", "r167", "r220" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsComponentsComprisingNetLossFromOurDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Depreciation and Amortization", "terseLabel": "Depreciation and amortization", "documentation": "Amount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r165" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsComponentsComprisingNetLossFromOurDiscontinuedOperationsDetails", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperationsParenthetical" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Gross Profit (Loss)", "terseLabel": "Loss on disposal", "totalLabel": "Gross profit", "documentation": "Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r165", "r276" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Current", "terseLabel": "Intangible assets, net", "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r5", "r150", "r167", "r217", "r220" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationInterestExpense", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsComponentsComprisingNetLossFromOurDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Interest Expense", "negatedLabel": "Interest Expense", "documentation": "Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r34", "r35", "r37", "r165" ] }, "ayr_DisposalGroupIncludingDiscontinuedOperationLeaseLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "DisposalGroupIncludingDiscontinuedOperationLeaseLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount classified as lease liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Lease Liabilities, Current", "terseLabel": "Lease liabilities" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsComponentsComprisingNetLossFromOurDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Operating Expense", "totalLabel": "Total operating expenses from discontinued operations", "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r165" ] }, "ayr_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsComponentsComprisingNetLossFromOurDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Disposal Group, Including Discontinued Operation, Operating Expenses [Abstract]", "terseLabel": "Operating expenses from discontinued operations:" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsComponentsComprisingNetLossFromOurDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)", "totalLabel": "Loss from operations", "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r165" ] }, "ayr_DisposalGroupIncludingDiscontinuedOperationOtherExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherExpenseAbstract", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsComponentsComprisingNetLossFromOurDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Disposal Group, Including Discontinued Operation, Other Expense [Abstract]", "terseLabel": "Other expense" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current", "terseLabel": "Property, plant, and equipment, net", "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r5", "r150", "r167", "r217", "r220" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsComponentsComprisingNetLossFromOurDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Revenue", "terseLabel": "Revenues from discontinued operations, net of discounts", "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r165", "r276" ] }, "ayr_DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsComponentsComprisingNetLossFromOurDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of selling, general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Selling, General and Administrative Expense", "terseLabel": "Selling, general, and administrative" } } }, "auth_ref": [] }, "ayr_DisposalGroupIncludingDiscontinuedOperationTradePayablesAndOtherCurrentLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "DisposalGroupIncludingDiscontinuedOperationTradePayablesAndOtherCurrentLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount classified as trade payables and other current liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Trade Payables and Other Current Liabilities, Current", "terseLabel": "Trade payables and other current liabilities" } } }, "auth_ref": [] }, "ayr_DisposalGroupWorkingCapitalAdjustmentCashProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "DisposalGroupWorkingCapitalAdjustmentCashProceeds", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsLossFromDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of working capital adjustment related to the cash proceeds from the sale of a disposal group.", "label": "Disposal Group Working Capital Adjustment Cash Proceeds", "terseLabel": "Working capital adjustment cash proceeds" } } }, "auth_ref": [] }, "ayr_DisposalGroupWorkingCapitalAdjustmentConsiderationOtherThanCash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "DisposalGroupWorkingCapitalAdjustmentConsiderationOtherThanCash", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsLossFromDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of working capital adjustment related to consideration other than cash that was received or receivable for the disposal of assets and liabilities, including discontinued operation.", "label": "Disposal Group Working Capital Adjustment Consideration Other Than Cash", "terseLabel": "Working capital adjustment proceeds other than cash" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperations" ], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "terseLabel": "DISCONTINUED OPERATIONS", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r149", "r216" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails", "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsComponentsComprisingNetLossFromOurDiscontinuedOperationsDetails", "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsDetails", "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsLossFromDiscontinuedOperationsDetails", "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": [ "r823", "r824" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r846", "r847", "r848" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r846", "r847", "r848", "r849" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "terseLabel": "Document Information", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r844" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Basic and diluted net loss per share" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "Basic net loss per share", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r303", "r327", "r328", "r329", "r330", "r331", "r336", "r338", "r341", "r342", "r343", "r345", "r581", "r582", "r650", "r669", "r808" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted net loss per share", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r303", "r327", "r328", "r329", "r330", "r331", "r338", "r341", "r342", "r343", "r345", "r581", "r582", "r650", "r669", "r808" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Earnings per share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r70", "r71" ] }, "ayr_EffectiveIncomeTaxRateReconciliation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliation", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureTaxationDifferenceBetweenIncomeTaxExpenseAndExpectedIncomeTaxesBasedOnStatutoryTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDifferenceBetweenIncomeTaxExpenseAndExpectedIncomeTaxesBasedOnStatutoryTaxRateDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation", "terseLabel": "Expected income tax recovery" } } }, "auth_ref": [] }, "ayr_EffectiveIncomeTaxRateReconciliationAccruedTaxPenaltiesAndInterestAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationAccruedTaxPenaltiesAndInterestAmount", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureTaxationDifferenceBetweenIncomeTaxExpenseAndExpectedIncomeTaxesBasedOnStatutoryTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDifferenceBetweenIncomeTaxExpenseAndExpectedIncomeTaxesBasedOnStatutoryTaxRateDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to accrued tax penalties and interest.", "label": "Effective Income Tax Rate Reconciliation, Accrued Tax Penalties and Interest, Amount", "terseLabel": "Accrued tax penalties and interest" } } }, "auth_ref": [] }, "ayr_EffectiveIncomeTaxRateReconciliationAcquisitionCostsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationAcquisitionCostsAmount", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureTaxationDifferenceBetweenIncomeTaxExpenseAndExpectedIncomeTaxesBasedOnStatutoryTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDifferenceBetweenIncomeTaxExpenseAndExpectedIncomeTaxesBasedOnStatutoryTaxRateDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to acquisition costs.", "label": "Effective Income Tax Rate Reconciliation, Acquisition Costs, Amount", "terseLabel": "Acquisition costs" } } }, "auth_ref": [] }, "ayr_EffectiveIncomeTaxRateReconciliationAmortizationOfDebtPremiumAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationAmortizationOfDebtPremiumAmount", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureTaxationDifferenceBetweenIncomeTaxExpenseAndExpectedIncomeTaxesBasedOnStatutoryTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDifferenceBetweenIncomeTaxExpenseAndExpectedIncomeTaxesBasedOnStatutoryTaxRateDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to amortization of debt premium.", "label": "Effective Income Tax Rate Reconciliation, Amortization of debt premium, Amount", "terseLabel": "Amortization of debt premium" } } }, "auth_ref": [] }, "ayr_EffectiveIncomeTaxRateReconciliationForeignExchangeGainOrLossAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationForeignExchangeGainOrLossAmount", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureTaxationDifferenceBetweenIncomeTaxExpenseAndExpectedIncomeTaxesBasedOnStatutoryTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDifferenceBetweenIncomeTaxExpenseAndExpectedIncomeTaxesBasedOnStatutoryTaxRateDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign exchange gain or loss.", "label": "Effective Income Tax Rate Reconciliation, Foreign Exchange Gain or Loss, Amount", "terseLabel": "Foreign exchange gain or loss" } } }, "auth_ref": [] }, "ayr_EffectiveIncomeTaxRateReconciliationImpairmentLossAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationImpairmentLossAmount", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureTaxationDifferenceBetweenIncomeTaxExpenseAndExpectedIncomeTaxesBasedOnStatutoryTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDifferenceBetweenIncomeTaxExpenseAndExpectedIncomeTaxesBasedOnStatutoryTaxRateDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.", "label": "Effective Income Tax Rate Reconciliation, Impairment Loss, Amount", "terseLabel": "Impairment loss" } } }, "auth_ref": [] }, "ayr_EffectiveIncomeTaxRateReconciliationInterestIncomeInclusionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationInterestIncomeInclusionAmount", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureTaxationDifferenceBetweenIncomeTaxExpenseAndExpectedIncomeTaxesBasedOnStatutoryTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDifferenceBetweenIncomeTaxExpenseAndExpectedIncomeTaxesBasedOnStatutoryTaxRateDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to interest income inclusion.", "label": "Effective Income Tax Rate Reconciliation, Interest Income Inclusion, Amount", "terseLabel": "Interest income inclusion" } } }, "auth_ref": [] }, "ayr_EffectiveIncomeTaxRateReconciliationTranslationAdjustmentAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationTranslationAdjustmentAmount", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureTaxationDifferenceBetweenIncomeTaxExpenseAndExpectedIncomeTaxesBasedOnStatutoryTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDifferenceBetweenIncomeTaxExpenseAndExpectedIncomeTaxesBasedOnStatutoryTaxRateDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to translation adjustment.", "label": "Effective Income Tax Rate Reconciliation, Translation Adjustment, Amount", "terseLabel": "Translation adjustment" } } }, "auth_ref": [] }, "ayr_EffectiveIncomeTaxRateReconciliationUnrealizedChangeInFairValueOfFinancialLiabilitiesAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationUnrealizedChangeInFairValueOfFinancialLiabilitiesAmount", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureTaxationDifferenceBetweenIncomeTaxExpenseAndExpectedIncomeTaxesBasedOnStatutoryTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDifferenceBetweenIncomeTaxExpenseAndExpectedIncomeTaxesBasedOnStatutoryTaxRateDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to unrealized change in fair value of financial liabilities.", "label": "Effective Income Tax Rate Reconciliation, Unrealized Change in Fair Value of Financial Liabilities, Amount", "terseLabel": "Unrealized change in fair value of financial liabilities" } } }, "auth_ref": [] }, "ayr_EmployeeRetentionCreditClaimAmountCaresAct": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "EmployeeRetentionCreditClaimAmountCaresAct", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of employee retention claimed amount under the CARES Act.", "label": "Employee Retention Credit, Claim Amount, CARES Act", "terseLabel": "ERC claimed amount" } } }, "auth_ref": [] }, "ayr_EmployeeRetentionCreditRefundCaresAct": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "EmployeeRetentionCreditRefundCaresAct", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of employee retention credit refund amount under the CARES Act.", "label": "Employee Retention Credit, Refund, CARES Act", "terseLabel": "ERC refund amount" } } }, "auth_ref": [] }, "ayr_EmployeeRetentionCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "EmployeeRetentionCredits", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount of employee retention credits.", "label": "Employee Retention Credits", "negatedLabel": "Employee retention credits recorded in other income" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Expected expense", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r518" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationDetails", "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Options", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Adress Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r845" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r845" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r851" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r850" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r848" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r845" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r845" ] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquipmentMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentppeDetails" ], "lang": { "en-us": { "role": { "label": "Equipment [Member]", "terseLabel": "Machinery and equipment", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r25", "r273", "r299", "r300", "r301", "r322", "r323", "r324", "r326", "r332", "r334", "r346", "r375", "r376", "r462", "r520", "r521", "r522", "r549", "r550", "r572", "r573", "r574", "r575", "r576", "r577", "r580", "r589", "r590", "r591", "r592", "r593", "r594", "r612", "r672", "r673", "r674", "r691", "r760" ] }, "ayr_EquityIssuedBusinessCombinationsAndAssetAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "EquityIssuedBusinessCombinationsAndAssetAcquisitions", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Value of stock issued in noncash financing activities related to business combinations and asset acquisitions", "label": "Equity Issued, Business Combinations and Asset Acquisitions", "terseLabel": "Issuance of Equity Shares related to business combinations and asset acquisitions" } } }, "auth_ref": [] }, "ayr_EquityIssuedSettlementOfContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "EquityIssuedSettlementOfContingentConsideration", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Value of stock issued in noncash financing activities related to settlement of contingent consideration.", "label": "Equity Issued, Settlement of Contingent Consideration", "terseLabel": "Issuance of Equity Shares related to settlement of contingent consideration" } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestmentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsPolicy", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Equity Method Investments [Policy Text Block]", "terseLabel": "Equity investments", "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received." } } }, "auth_ref": [ "r13", "r138", "r373" ] }, "ayr_ExchangeableSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "ExchangeableSharesMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureShareCapitalActivityOccurredDuringYearEndDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets", "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheetsParenthetical", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to Exchangeable Shares.", "label": "Exchangeable Shares [Member]", "terseLabel": "Exchangeable Shares" } } }, "auth_ref": [] }, "ayr_ExchangeableStockExchangeRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "ExchangeableStockExchangeRatio", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitionsIncluding2023FourthQuarterAssetAcquisitionDetails" ], "lang": { "en-us": { "role": { "documentation": "The ratio to be applied to the stock in a conversion of convertible stock.", "label": "Exchangeable Stock Exchange Ratio", "terseLabel": "Exchangeable stock exchange ratio" } } }, "auth_ref": [] }, "ayr_ExtendedForecastPeriodForEstimatedCashFlowsProjections": { "xbrltype": "durationItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "ExtendedForecastPeriodForEstimatedCashFlowsProjections", "presentation": [ "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsImpairmentOfGoodwillDetails" ], "lang": { "en-us": { "role": { "documentation": "The extended forecast period for estimated cash flows projections.", "label": "Extended Forecast Period for Estimated Cash Flows Projections", "terseLabel": "Extended forecast period" } } }, "auth_ref": [] }, "ayr_ExtinguishmentOfAccruedInterestPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "ExtinguishmentOfAccruedInterestPayable", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Extingusihment of accrued interest payable.", "label": "Extinguishment of Accrued Interest Payable", "terseLabel": "Extinguishment of accrued interest payable related to sale of Arizona business" } } }, "auth_ref": [] }, "ayr_ExtinguishmentOfDebtAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "ExtinguishmentOfDebtAccruedInterest", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails", "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of accrued interest payable attributable to debt extinguished.", "label": "Extinguishment of Debt, Accrued Interest", "terseLabel": "Accrued interest extinguished" } } }, "auth_ref": [] }, "us-gaap_ExtinguishmentOfDebtAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ExtinguishmentOfDebtAmount", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesChangesInDebtOtherThanSeniorSecuredNotesDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails", "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Extinguishment of Debt, Amount", "negatedLabel": "Less: extinguishment related to sale of Arizona business", "terseLabel": "Debt extinguished", "documentation": "Gross amount of debt extinguished." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.ayrwellness.com/role/DisclosureFinancialRiskFactorsFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "FINANCIAL RISK FACTORS", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r584", "r585", "r586" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.ayrwellness.com/role/DisclosureFinancialRiskFactorsFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r584", "r585", "r586" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureFinancialRiskFactorsTables" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Summary of the range of inputs used at the initial and subsequent measurement dates to value the contingent consideration", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r27" ] }, "ayr_FairValueAssetsLevel1ToLevel2TransfersAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount1", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureFinancialRiskFactorsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.", "label": "Fair Value, Assets, Level 1 to Level 2 Transfers, Amount 1", "terseLabel": "Assets, transfer from Level 1 to level 2" } } }, "auth_ref": [] }, "ayr_FairValueAssetsLevel2ToLevel1TransfersAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "FairValueAssetsLevel2ToLevel1TransfersAmount1", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureFinancialRiskFactorsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.", "label": "Fair Value, Assets, Level 2 to Level 1 Transfers, Amount 1", "terseLabel": "Assets, transfer from Level 2 to level 1" } } }, "auth_ref": [] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.ayrwellness.com/role/DisclosureFinancialRiskFactorsFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r428", "r474", "r475", "r476", "r477", "r478", "r479", "r585", "r625", "r626", "r627", "r814", "r815", "r820", "r821", "r822" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "FINANCIAL RISK FACTORS" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureFinancialRiskFactors" ], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FINANCIAL RISK FACTORS", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r583" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.ayrwellness.com/role/DisclosureFinancialRiskFactorsFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r428", "r474", "r475", "r476", "r477", "r478", "r479", "r585", "r627", "r814", "r815", "r820", "r821", "r822" ] }, "ayr_FairValueLiabilitiesLevel1ToLevel2TransfersAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "FairValueLiabilitiesLevel1ToLevel2TransfersAmount1", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureFinancialRiskFactorsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.", "label": "Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount 1", "terseLabel": "Liabilities transfer from Level 1 to level 2" } } }, "auth_ref": [] }, "ayr_FairValueLiabilitiesLevel2ToLevel1TransfersAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "FairValueLiabilitiesLevel2ToLevel1TransfersAmount1", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureFinancialRiskFactorsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.", "label": "Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount 1", "terseLabel": "Liabilities, transfer from Level 2 to level 1" } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureFinancialRiskFactorsTables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis [Table Text Block]", "terseLabel": "Summary of the fair value hierarchy for the Company's financial assets and liabilities", "documentation": "Tabular disclosure of liabilities measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2." } } }, "auth_ref": [ "r137", "r240" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureFinancialRiskFactorsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net", "terseLabel": "Assets transfer Level 3", "documentation": "Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureFinancialRiskFactorsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net", "terseLabel": "Liabilities, transfer from Level 3", "documentation": "Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.ayrwellness.com/role/DisclosureFinancialRiskFactorsFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r428", "r474", "r475", "r476", "r477", "r478", "r479", "r625", "r626", "r627", "r814", "r815", "r820", "r821", "r822" ] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Financial instruments", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r18", "r32" ] }, "ayr_FinanceLeaseIncrementalBorrowingRate": { "xbrltype": "percentItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "FinanceLeaseIncrementalBorrowingRate", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Incremental weighted average borrowing rate for finance lease calculated at point in time.", "label": "Finance Lease Incremental Borrowing Rate", "terseLabel": "Finance Leases Incremental borrowing rate (weighted average)" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseInterestExpense", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesPaymentsRelatedToCapitalizedLeaseDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Interest Expense", "terseLabel": "Interest on lease liabilities - finance", "documentation": "Amount of interest expense on finance lease liability." } } }, "auth_ref": [ "r601", "r605", "r830" ] }, "ayr_FinanceLeaseLiabilitiesExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "FinanceLeaseLiabilitiesExpenseAbstract", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesPaymentsRelatedToCapitalizedLeaseDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Finance Lease Liabilities Expense [Abstract]", "terseLabel": "Lease liabilities - finance" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]", "terseLabel": "Finance Leases" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiability", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability", "terseLabel": "Total present value of minimum lease payments", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } }, "auth_ref": [ "r600", "r610" ] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Current", "terseLabel": "Lease liabilities - finance - current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": [ "r600" ] }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesTables" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Schedule of maturities of the contractual finance lease liabilities", "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r919" ] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Lease liabilities - finance - non-current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": [ "r600" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid", "totalLabel": "Total undiscounted lease liabilities", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r610" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid, Year One", "terseLabel": "2024", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r610" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid, Year Five", "terseLabel": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r610" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid, Year Four", "terseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r610" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid, Year Three", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r610" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid, Year Two", "terseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r610" ] }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Impact of discounting", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r610" ] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Principal Payments", "negatedLabel": "Repayments of lease liabilities - finance (principal portion)", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r602", "r607" ] }, "us-gaap_FinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "terseLabel": "Right-of-use assets - finance, net", "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": [ "r599" ] }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesPaymentsRelatedToCapitalizedLeaseDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Amortization of right-of-use assets", "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease." } } }, "auth_ref": [ "r601", "r605", "r830" ] }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Finance Leases Weighted average remaining lease term", "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r609", "r830" ] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Amortization period (# of years)", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsAndImpairmentOfLongLivedAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]", "documentation": "A table containing detailed characteristics of finite-lived intangible assets acquired during a business combination. Finite-lived intangible assets are assets that have no physical form, but have expected future economic benefit, and are expected to be used over a defined period. Acquired finite-lived intangible assets are disclosed by major class (assets that can be grouped together because they are similar, either by their nature or by their use in operations of the Entity) and in total. Additionally, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period are also disclosed." } } }, "auth_ref": [ "r77" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "terseLabel": "2029 and beyond", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2024", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r214" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]", "terseLabel": "Schedule of future amortization expense of intangible assets", "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "terseLabel": "2028", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r214" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2027", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r214" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2026", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r214" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2025", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r214" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitionsIncluding2023FourthQuarterAssetAcquisitionDetails", "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails", "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsAndImpairmentOfLongLivedAssetsDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r389", "r390", "r391", "r392", "r635", "r636" ] }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "presentation": [ "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]", "terseLabel": "Amortization Expense" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Intangible Assets", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r635" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitionsIncluding2023FourthQuarterAssetAcquisitionDetails", "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails", "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsAndImpairmentOfLongLivedAssetsDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r77", "r79" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Total", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r213", "r635" ] }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitionsIncluding2023FourthQuarterAssetAcquisitionDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "terseLabel": "Amortization period", "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r635" ] }, "ayr_FiveYearFederalHomeLoanBankRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "FiveYearFederalHomeLoanBankRateMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to 5-year Federal Home Loan Bank Rate.", "label": "Five Year Federal Home Loan Bank Rate [Member]", "terseLabel": "Five year federal home loan bank" } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign currency transactions and translations", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r588" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosurePropertyPlantAndEquipmentDetails", "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentppeDetails" ], "lang": { "en-us": { "role": { "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and equipment", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "ayr_GainLossFromFairValueAdjustmentExcludingTerminatedLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "GainLossFromFairValueAdjustmentExcludingTerminatedLeases", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureDerivativeLiabilitiesScheduleOfFairValueAdjustmentRelatingToDerivativeLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureDerivativeLiabilitiesScheduleOfFairValueAdjustmentRelatingToDerivativeLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of gains (losses) resulting from change in the fair value of derivatives recognized in profit or loss, excluding gains (losses) from terminated leases.", "label": "Gain (Loss) from Fair Value adjustment Excluding Terminated Leases", "totalLabel": "Total" } } }, "auth_ref": [] }, "ayr_GainLossOnChangeInFairValueOfContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "GainLossOnChangeInFairValueOfContingentConsideration", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureDerivativeLiabilitiesScheduleOfFairValueAdjustmentRelatingToDerivativeLiabilitiesDetails": { "parentTag": "ayr_GainLossFromFairValueAdjustmentExcludingTerminatedLeases", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureDerivativeLiabilitiesScheduleOfFairValueAdjustmentRelatingToDerivativeLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The gains (losses) resulting from change in the fair value of contingent consideration.", "label": "Gain Loss on Change in Fair Value of Contingent Consideration", "terseLabel": "Gain from FV adjustment on contingent consideration" } } }, "auth_ref": [] }, "ayr_GainLossOnChangeInFairValueOfPurchaseConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "GainLossOnChangeInFairValueOfPurchaseConsideration", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureDerivativeLiabilitiesScheduleOfFairValueAdjustmentRelatingToDerivativeLiabilitiesDetails": { "parentTag": "ayr_GainLossFromFairValueAdjustmentExcludingTerminatedLeases", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureDerivativeLiabilitiesScheduleOfFairValueAdjustmentRelatingToDerivativeLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The gains (losses) resulting from change in the fair value of purchase consideration payable.", "label": "Gain Loss On Change In Fair Value Of Purchase Consideration", "verboseLabel": "Loss from FV adjustment on purchase consideration settlement" } } }, "auth_ref": [] }, "us-gaap_GainLossOnDispositionOfAssets1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnDispositionOfAssets1", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetails", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Disposition of Assets", "negatedLabel": "Loss (gain) on sale of assets", "terseLabel": "Gain on sale of assets", "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee." } } }, "auth_ref": [ "r868" ] }, "us-gaap_GainLossOnSaleOfBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfBusiness", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Disposition of Business", "negatedLabel": "Loss on the disposal of Arizona business", "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant." } } }, "auth_ref": [ "r568", "r868" ] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedLabel": "Loss (gain) on disposal of property, plant, and equipment", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": [ "r15" ] }, "ayr_GainLossOnSettlementOfContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "GainLossOnSettlementOfContingentConsideration", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureDerivativeLiabilitiesScheduleOfFairValueAdjustmentRelatingToDerivativeLiabilitiesDetails": { "parentTag": "ayr_GainLossFromFairValueAdjustmentExcludingTerminatedLeases", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureDerivativeLiabilitiesScheduleOfFairValueAdjustmentRelatingToDerivativeLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The gains (losses) resulting from settlement of contingent consideration.", "label": "Gain Loss on Settlement of Contingent Consideration", "terseLabel": "(Loss) gain from settlement of contingent consideration" } } }, "auth_ref": [] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Extinguishment of Debt", "terseLabel": "Extinguishment of note payable related to sale of Arizona business", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r15", "r86", "r87" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRelatedPartyTransactionsAndBalancesDetails" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense", "terseLabel": "General and administrative expenses", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r200", "r739" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesPaymentsRelatedToCapitalizedLeaseDetails" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "terseLabel": "G&A", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r195" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsGoodwillDetails", "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsImpairmentOfGoodwillDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Goodwill", "periodEndLabel": "As of ending", "periodStartLabel": "As of beginning", "terseLabel": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r283", "r384", "r649", "r812", "r831", "r885", "r892" ] }, "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsGoodwillDetails" ], "lang": { "en-us": { "role": { "label": "Goodwill, Acquired During Period", "terseLabel": "Acquired through business combinations and initial consolidation of VIEs", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": [ "r386", "r812" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "GOODWILL AND INTANGIBLE ASSETS" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssets" ], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "GOODWILL AND INTANGIBLE ASSETS", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r211" ] }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Intangible assets", "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined." } } }, "auth_ref": [ "r20" ] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsGoodwillDetails", "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsImpairmentOfGoodwillDetails" ], "lang": { "en-us": { "role": { "label": "Goodwill, Impairment Loss", "negatedLabel": "Impairment of goodwill", "verboseLabel": "Impairment of goodwill", "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r15", "r385", "r387", "r388", "r812" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Gross Profit", "totalLabel": "Gross profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r198", "r314", "r349", "r356", "r360", "r362", "r374", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r587", "r810", "r898" ] }, "ayr_GrowthRateUsedToExtrapolateCashFlowProjections": { "xbrltype": "percentItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "GrowthRateUsedToExtrapolateCashFlowProjections", "presentation": [ "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsImpairmentOfGoodwillDetails" ], "lang": { "en-us": { "role": { "documentation": "The growth rate used to extrapolate cash flow projections beyond the period covered by the most recent budgets/forecasts for a cash-generating unit (group of units).", "label": "Growth Rate Used To Extrapolate Cash Flow Projections", "terseLabel": "Terminal growth rate (in percent)" } } }, "auth_ref": [] }, "ayr_GsdAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "GsdAcquisitionMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to GSD acquisition.", "label": "GSD Acquisition [Member]", "terseLabel": "GSD" } } }, "auth_ref": [] }, "ayr_GsdNjLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "GsdNjLlcMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDerivativeLiabilitiesScheduleOfFairValueAdjustmentRelatingToDerivativeLiabilitiesDetails", "http://www.ayrwellness.com/role/DisclosureShareCapitalActivityOccurredDuringYearEndDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to GSD NJ LLC (\"Garden State Dispensary\" or \"GSD\").", "label": "GSD NJ LLC [Member]", "terseLabel": "GSD" } } }, "auth_ref": [] }, "us-gaap_GuaranteeObligationsByNatureAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GuaranteeObligationsByNatureAxis", "presentation": [ "http://www.ayrwellness.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Guarantor Obligations, Nature [Axis]", "documentation": "Information by nature of guarantee." } } }, "auth_ref": [ "r401", "r402", "r403", "r404" ] }, "us-gaap_GuaranteeObligationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GuaranteeObligationsLineItems", "presentation": [ "http://www.ayrwellness.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Guarantor Obligations [Line Items]", "terseLabel": "COMMITMENTS AND CONTINGENCIES", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r401", "r402", "r403", "r404" ] }, "us-gaap_GuaranteeObligationsMaximumExposure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GuaranteeObligationsMaximumExposure", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Guarantor Obligations, Maximum Exposure, Undiscounted", "terseLabel": "Guarantor lease maximum payments", "documentation": "Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions." } } }, "auth_ref": [ "r402" ] }, "us-gaap_GuaranteeObligationsNatureDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GuaranteeObligationsNatureDomain", "presentation": [ "http://www.ayrwellness.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Guarantor Obligations, Nature [Domain]", "documentation": "Represents a description of the nature of the guarantee or each group of similar guarantees." } } }, "auth_ref": [ "r401", "r402", "r403", "r404" ] }, "ayr_HerbalRemediesDispensariesLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "HerbalRemediesDispensariesLlcMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionPurchaseConsiderationDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitionsTables", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails", "http://www.ayrwellness.com/role/DisclosureShareCapitalActivityOccurredDuringYearEndDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Herbal Remedies Dispensaries, LLC (\"Herbal Remedies\").", "label": "Herbal Remedies Dispensaries, LLC [Member]", "terseLabel": "Herbal Remedies" } } }, "auth_ref": [] }, "ayr_HostCommunityAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "HostCommunityAgreementsMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails", "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsAndImpairmentOfLongLivedAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to host community agreements.", "label": "Host Community Agreements [Member]", "terseLabel": "Host community agreements" } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r846", "r847", "r848" ] }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Impairment, Long-Lived Asset, Held-for-Use", "terseLabel": "Impairment loss on PPE", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)." } } }, "auth_ref": [ "r15", "r81", "r219" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss from continuing operations before income taxes and noncontrolling interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r192", "r251", "r349", "r356", "r360", "r362", "r651", "r664", "r810" ] }, "ayr_IncomeLossFromContinuingOperationsBeforeNoncontrollingInterestIncludesLossOnDisposal": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "IncomeLossFromContinuingOperationsBeforeNoncontrollingInterestIncludesLossOnDisposal", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlowsCalc2": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 2.0 }, "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 23.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations before portion attributable to the noncontrolling interest, includes loss on disposal.", "label": "Income (Loss) from Continuing Operations before Noncontrolling Interest Includes Loss On Disposal", "terseLabel": "Net loss from continuing operations before noncontrolling interest" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Net loss from continuing operations", "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r235", "r314", "r325", "r349", "r356", "r360", "r362", "r374", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r582", "r587", "r664", "r810", "r898" ] }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations, Per Basic Share", "terseLabel": "Continuing operations - basic", "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r191", "r250", "r252", "r303", "r325", "r327", "r328", "r329", "r330", "r338", "r341", "r342", "r582", "r650", "r932" ] }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "terseLabel": "Continuing operations - diluted", "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r191", "r303", "r325", "r327", "r328", "r329", "r330", "r338", "r341", "r342", "r343", "r582", "r650", "r932" ] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsComponentsComprisingNetLossFromOurDiscontinuedOperationsDetails", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Loss from discontinued operations", "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r154", "r155", "r156", "r157", "r158", "r169", "r276", "r557", "r665" ] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Discontinued operations" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share", "terseLabel": "Discontinued operations - basic", "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation." } } }, "auth_ref": [ "r193", "r303", "r339", "r341", "r342", "r929", "r932" ] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share", "terseLabel": "Discontinued operations - diluted", "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation." } } }, "auth_ref": [ "r238", "r339", "r341", "r342" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Statements of Operations" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails", "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsComponentsComprisingNetLossFromOurDiscontinuedOperationsDetails", "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsDetails", "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsLossFromDiscontinuedOperationsDetails", "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r823", "r824" ] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsComponentsComprisingNetLossFromOurDiscontinuedOperationsDetails", "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsDetails", "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsLossFromDiscontinuedOperationsDetails", "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "DISCONTINUED OPERATIONS", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsComponentsComprisingNetLossFromOurDiscontinuedOperationsDetails", "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsDetails", "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsLossFromDiscontinuedOperationsDetails", "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations [Table]", "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r19", "r31", "r36", "r150", "r159", "r160", "r161", "r162", "r163", "r168", "r170", "r171", "r221" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails", "http://www.ayrwellness.com/role/DisclosureInventoryDetails", "http://www.ayrwellness.com/role/DisclosurePropertyPlantAndEquipmentDetails", "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesPaymentsRelatedToCapitalizedLeaseDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r393", "r394", "r744" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails", "http://www.ayrwellness.com/role/DisclosureInventoryDetails", "http://www.ayrwellness.com/role/DisclosurePropertyPlantAndEquipmentDetails", "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesPaymentsRelatedToCapitalizedLeaseDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r394", "r744" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDeferredTaxAssetsAndLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Axis]", "documentation": "Information by tax jurisdiction." } } }, "auth_ref": [ "r22" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDeferredTaxAssetsAndLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Domain]", "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "TAXATION" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxation" ], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "terseLabel": "TAXATION", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r315", "r528", "r537", "r540", "r546", "r551", "r555", "r558", "r559", "r685" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0, "order": 1.0 }, "http://www.ayrwellness.com/role/DisclosureTaxationDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.ayrwellness.com/role/DisclosureTaxationDifferenceBetweenIncomeTaxExpenseAndExpectedIncomeTaxesBasedOnStatutoryTaxRateDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDetails", "http://www.ayrwellness.com/role/DisclosureTaxationDifferenceBetweenIncomeTaxExpenseAndExpectedIncomeTaxesBasedOnStatutoryTaxRateDetails", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit)", "negatedTotalLabel": "Total income taxes", "totalLabel": "Total income tax expense :", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r258", "r269", "r333", "r334", "r354", "r535", "r552", "r670" ] }, "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Income taxes" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Taxation", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r298", "r531", "r532", "r540", "r541", "r545", "r547", "r679" ] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureTaxationDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 4.0 }, "http://www.ayrwellness.com/role/DisclosureTaxationDifferenceBetweenIncomeTaxExpenseAndExpectedIncomeTaxesBasedOnStatutoryTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDetails", "http://www.ayrwellness.com/role/DisclosureTaxationDifferenceBetweenIncomeTaxExpenseAndExpectedIncomeTaxesBasedOnStatutoryTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "terseLabel": "Chane in valuation allowance", "verboseLabel": "Valuation allowance", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r908" ] }, "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureTaxationDifferenceBetweenIncomeTaxExpenseAndExpectedIncomeTaxesBasedOnStatutoryTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDifferenceBetweenIncomeTaxExpenseAndExpectedIncomeTaxesBasedOnStatutoryTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount", "terseLabel": "Change in effective tax rate", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates." } } }, "auth_ref": [ "r530", "r536" ] }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureTaxationDifferenceBetweenIncomeTaxExpenseAndExpectedIncomeTaxesBasedOnStatutoryTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDifferenceBetweenIncomeTaxExpenseAndExpectedIncomeTaxesBasedOnStatutoryTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount", "terseLabel": "Difference in foreign tax rates", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)." } } }, "auth_ref": [ "r908" ] }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseDepletion": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationNondeductibleExpenseDepletion", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureTaxationDifferenceBetweenIncomeTaxExpenseAndExpectedIncomeTaxesBasedOnStatutoryTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDifferenceBetweenIncomeTaxExpenseAndExpectedIncomeTaxesBasedOnStatutoryTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depletion, Amount", "terseLabel": "Non-deductible expenses", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible depletion." } } }, "auth_ref": [ "r908" ] }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureTaxationDifferenceBetweenIncomeTaxExpenseAndExpectedIncomeTaxesBasedOnStatutoryTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDifferenceBetweenIncomeTaxExpenseAndExpectedIncomeTaxesBasedOnStatutoryTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount", "terseLabel": "Restricted Stock", "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement." } } }, "auth_ref": [ "r908" ] }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationOtherAdjustments", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureTaxationDifferenceBetweenIncomeTaxExpenseAndExpectedIncomeTaxesBasedOnStatutoryTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 17.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDifferenceBetweenIncomeTaxExpenseAndExpectedIncomeTaxesBasedOnStatutoryTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount", "terseLabel": "Other", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r908" ] }, "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationPriorYearIncomeTaxes", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureTaxationDifferenceBetweenIncomeTaxExpenseAndExpectedIncomeTaxesBasedOnStatutoryTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDifferenceBetweenIncomeTaxExpenseAndExpectedIncomeTaxesBasedOnStatutoryTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount", "terseLabel": "Prior year adjustment", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit)." } } }, "auth_ref": [ "r908" ] }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureTaxationDifferenceBetweenIncomeTaxExpenseAndExpectedIncomeTaxesBasedOnStatutoryTaxRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDifferenceBetweenIncomeTaxExpenseAndExpectedIncomeTaxesBasedOnStatutoryTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount", "terseLabel": "State taxes", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)." } } }, "auth_ref": [ "r908" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Income Taxes Paid, Net", "terseLabel": "Income taxes paid during the period", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r66" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableTrade", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable, Trade", "terseLabel": "Trade payables", "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services." } } }, "auth_ref": [ "r14" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r14" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r14" ] }, "us-gaap_IncreaseDecreaseInAccruedTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedTaxesPayable", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accrued Taxes Payable", "terseLabel": "Income tax payable", "documentation": "The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes." } } }, "auth_ref": [ "r867" ] }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInterestPayableNet", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Interest Payable, Net", "terseLabel": "Accrued interest payable", "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity." } } }, "auth_ref": [ "r14" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r14" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities, net of business combinations:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Lease liabilities - operating", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r855", "r867" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses, deposits, and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r14" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Consolidated Statements of Shareholders' Equity", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ayr_IncreaseDecreaseThroughOtherContributionsByOwners": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "IncreaseDecreaseThroughOtherContributionsByOwners", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "The increase in equity through other contributions by owners that the entity does not separately disclose in the same statement or note.", "label": "Increase Decrease Through Other Contributions By Owners", "terseLabel": "Consolidation of variable interest entities" } } }, "auth_ref": [] }, "ayr_IndebtednessAmountOfSubsidiariesRelatedToContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "IndebtednessAmountOfSubsidiariesRelatedToContingentConsideration", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of indebtedness of subsidiaries related to contingent consideration.", "label": "Indebtedness Amount Of Subsidiaries Related To Contingent Consideration", "terseLabel": "Indebtedness amount" } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedLicenseAgreements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedLicenseAgreements", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Indefinite-Lived License Agreements", "terseLabel": "Amount of intangible asset in connection with the cash payment for the cost of the provisional license", "documentation": "Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the capitalized costs to acquire rights under a license arrangement (for example, to sell specified products in a specified territory) having an indefinite period of benefit." } } }, "auth_ref": [ "r215" ] }, "ayr_InitialTermOfAgreement": { "xbrltype": "durationItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "InitialTermOfAgreement", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the initial term of the agreement.", "label": "Initial Term of the Agreement", "terseLabel": "Initial term of the agreement" } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails", "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r75", "r78" ] }, "us-gaap_InterestCostsCapitalizedAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestCostsCapitalizedAdjustment", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest Costs Capitalized Adjustment", "negatedLabel": "Capitalized interest", "documentation": "Amount of interest costs capitalized disclosed as an adjusting item to interest costs incurred." } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureRelatedPartyTransactionsAndBalancesDetails", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Interest Expense", "negatedLabel": "Interest expense, net", "terseLabel": "Interest expense, net", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r141", "r254", "r302", "r352", "r596", "r745", "r841", "r935" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Interest Expense, Debt", "terseLabel": "Interest expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r203", "r434", "r444", "r816", "r817" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest paid during the period, net", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r305", "r308", "r309" ] }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPayableCurrent", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Interest Payable, Current", "terseLabel": "Accrued interest payable - current portion", "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r43" ] }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesChangesInDebtOtherThanSeniorSecuredNotesDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesChangesInSeniorSecuredNotesDetails" ], "lang": { "en-us": { "role": { "label": "Interest Payable", "terseLabel": "Total accrued interest payable related to senior secured notes classified as non-current payable as of December 31, 2023", "verboseLabel": "Total accrued interest payable related to debts payable as of December 31, 2023", "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables." } } }, "auth_ref": [ "r146", "r930" ] }, "ayr_InterestPayableNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "InterestPayableNoncurrent", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of accrued interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. classified as noncurrent.", "label": "Interest Payable, Noncurrent", "terseLabel": "Accrued interest payable - non-current portion" } } }, "auth_ref": [] }, "us-gaap_InventoryCurrentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryCurrentTable", "presentation": [ "http://www.ayrwellness.com/role/DisclosureInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Inventory, Current [Table]", "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "INVENTORY" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureInventory" ], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Text Block]", "terseLabel": "INVENTORY", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r379" ] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureInventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r857" ] }, "us-gaap_InventoryLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryLineItems", "presentation": [ "http://www.ayrwellness.com/role/DisclosureInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Inventory [Line Items]", "terseLabel": "INVENTORY", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 }, "http://www.ayrwellness.com/role/DisclosureInventoryDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureInventoryDetails", "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Inventory, Net", "terseLabel": "Inventory", "totalLabel": "Total inventory", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r293", "r802", "r831" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r259", "r279", "r292", "r379", "r380", "r381", "r633", "r807" ] }, "us-gaap_InventoryRawMaterialsAndSupplies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterialsAndSupplies", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureInventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Inventory, Raw Materials and Supplies, Gross", "terseLabel": "Materials, supplies, and packaging", "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed." } } }, "auth_ref": [ "r859" ] }, "us-gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcess", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosureInventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Inventory, Work in Process, Gross", "terseLabel": "Work in process", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r858" ] }, "us-gaap_InvestmentIncomeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeNet", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Investment Income, Net", "terseLabel": "Interest income", "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities." } } }, "auth_ref": [ "r201", "r203" ] }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 19.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Issuance of Stock and Warrants for Services or Claims", "terseLabel": "Shares issued for consulting services", "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims." } } }, "auth_ref": [ "r15" ] }, "us-gaap_LandMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LandMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosurePropertyPlantAndEquipmentDetails", "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Land [Member]", "terseLabel": "Land", "documentation": "Part of earth's surface not covered by water." } } }, "auth_ref": [ "r906" ] }, "ayr_LandOfLincolnDispensaryLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "LandOfLincolnDispensaryLlcMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitionsIncluding2023FourthQuarterAssetAcquisitionDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Land of lincoln dispensary (Land of Lincoln).", "label": "Land of Lincoln Dispensary LLC [Member]", "terseLabel": "Land of Lincoln Dispensary LLC" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesTables" ], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of payments related to leases.", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r918" ] }, "ayr_LeaseDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "LeaseDisclosureTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilities" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of information about leases.", "label": "Lease Disclosure [Text Block]", "terseLabel": "RIGHT-OF-USE ASSETS AND LEASE LIABILITIES" } } }, "auth_ref": [] }, "ayr_LeaseObligationsEliminatingLongTermLeaseLiabilitiesAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "LeaseObligationsEliminatingLongTermLeaseLiabilitiesAmount", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "Lease obligations eliminating long term lease liabilities amount.", "label": "Lease Obligations Eliminating Long Term Lease Liabilities Amount", "terseLabel": "Lease obligations eliminating long term lease liabilities amount" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r218" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "RIGHT-OF-USE ASSETS AND LEASE LIABILITIES" } } }, "auth_ref": [] }, "ayr_LesseeFinanceLeaseLiabilityPaymentDueYearSixAndThereafter": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "LesseeFinanceLeaseLiabilityPaymentDueYearSixAndThereafter", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year and thereafter following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Finance Lease, Liability, Payment Due Year Six and Thereafter", "terseLabel": "2029 and beyond" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetails", "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesPaymentsRelatedToCapitalizedLeaseDetails", "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Leases", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r604" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetails", "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesPaymentsRelatedToCapitalizedLeaseDetails", "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r604" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases and sale and leaseback accounting", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r603" ] }, "ayr_LesseeOperatingAndFinanceLeaseLiabilityPaymentDueYearSixAndThereafter": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "LesseeOperatingAndFinanceLeaseLiabilityPaymentDueYearSixAndThereafter", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails": { "parentTag": "ayr_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating and finance lease to be paid in fifth fiscal year and thereafter following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating and Finance Lease, Liability, Payment Due Year Six and Thereafter", "terseLabel": "2029 and beyond" } } }, "auth_ref": [] }, "ayr_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "LesseeOperatingAndFinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating and finance lease.", "label": "Lessee Operating and Finance Lease Liability Payments Due", "totalLabel": "Total undiscounted lease liabilities" } } }, "auth_ref": [] }, "ayr_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails": { "parentTag": "ayr_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating and finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating and Finance Lease Liability Payments Due Next Twelve Months", "terseLabel": "2024" } } }, "auth_ref": [] }, "ayr_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails": { "parentTag": "ayr_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating and finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating and Finance Lease Liability Payments Due Year Five", "terseLabel": "2028" } } }, "auth_ref": [] }, "ayr_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails": { "parentTag": "ayr_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating and finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating and Finance Lease Liability Payments Due Year Four", "terseLabel": "2027" } } }, "auth_ref": [] }, "ayr_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails": { "parentTag": "ayr_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating and finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating and Finance Lease Liability Payments Due Year Three", "terseLabel": "2026" } } }, "auth_ref": [] }, "ayr_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails": { "parentTag": "ayr_LesseeOperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating and finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating and Finance Lease Liability Payments Due Year Two", "terseLabel": "2025" } } }, "auth_ref": [] }, "ayr_LesseeOperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "LesseeOperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating and finance lease.", "label": "Lessee Operating and Finance Lease Liability Undiscounted Excess Amount", "negatedLabel": "Impact of discounting" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesTables" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Schedule of maturities of the contractual operating lease liabilities", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r919" ] }, "ayr_LesseeOperatingLeaseLiabilityPaymentDueYearSixAndThereafter": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "LesseeOperatingLeaseLiabilityPaymentDueYearSixAndThereafter", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due in fifth fiscal year and thereafter following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payment Due Year Six and Thereafter", "terseLabel": "2029 and beyond" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total undiscounted lease liabilities", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r610" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2024", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r610" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r610" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r610" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r610" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r610" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Impact of discounting", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r610" ] }, "ayr_LeviaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "LeviaMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureShareCapitalActivityOccurredDuringYearEndDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to Levia.", "label": "Levia [Member]", "terseLabel": "Levia" } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieSummaryOfFinancialInformationAboutConsolidatedViesDetails", "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r42", "r314", "r374", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r565", "r569", "r570", "r587", "r714", "r809", "r843", "r898", "r921", "r922" ] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAbstract", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieSummaryOfFinancialInformationAboutConsolidatedViesDetails", "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r186", "r248", "r660", "r831", "r871", "r883", "r915" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieSummaryOfFinancialInformationAboutConsolidatedViesDetails", "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "terseLabel": "Current liabilities", "totalLabel": "Total Current Liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r44", "r278", "r314", "r374", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r565", "r569", "r570", "r587", "r831", "r898", "r921", "r922" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueAdjustment", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 4.0 }, "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 22.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesChangesInDebtOtherThanSeniorSecuredNotesDetails", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Adjustment", "negatedLabel": "Fair value gain on financial liabilities", "terseLabel": "Fair value gain on financial liabilities", "verboseLabel": "Less: discounted to fair value", "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieSummaryOfFinancialInformationAboutConsolidatedViesDetails" ], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent", "terseLabel": "Non-current liabilities", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r33", "r172", "r173", "r174", "r177", "r314", "r374", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r565", "r569", "r570", "r587", "r898", "r921", "r922" ] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Non-current" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 9.0 }, "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails", "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current", "terseLabel": "Liabilities held-for-sale", "totalLabel": "Total liabilities held-for-sale", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r5", "r150", "r167", "r217", "r220", "r275", "r276" ] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]", "terseLabel": "Current liabilities held-for-sale" } } }, "auth_ref": [] }, "us-gaap_LicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LicenseMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails", "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsAndImpairmentOfLongLivedAssetsDetails" ], "lang": { "en-us": { "role": { "label": "License [Member]", "terseLabel": "Licenses/permits", "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark." } } }, "auth_ref": [ "r906" ] }, "us-gaap_LicensingAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LicensingAgreementsMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails", "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsAndImpairmentOfLongLivedAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Licensing Agreements [Member]", "terseLabel": "Right-to-use licenses", "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)." } } }, "auth_ref": [ "r114", "r527", "r907" ] }, "us-gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityAxis", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Lender Name [Axis]", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit." } } }, "auth_ref": [ "r40", "r870" ] }, "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityLenderDomain", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Lender [Domain]", "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "auth_ref": [ "r40", "r870" ] }, "ayr_LiquidityAndManagementPlanPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "LiquidityAndManagementPlanPolicyTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for liquidity and management plan.", "label": "Liquidity and Management Plan [Policy Text Block]", "terseLabel": "Liquidity and management plan" } } }, "auth_ref": [] }, "ayr_LivfreeWellnessLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "LivfreeWellnessLlcMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to LivFree Wellness, LLC.", "label": "LivFree Wellness, LLC [Member]", "terseLabel": "LivFree Wellness, LLC" } } }, "auth_ref": [] }, "ayr_LoanAgreementDueMay2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "LoanAgreementDueMay2024Member", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to loan agreement due to mature in May 2024.", "label": "Loan Agreement Due May 2024 [Member]", "terseLabel": "Loan agreement due May 2024" } } }, "auth_ref": [] }, "ayr_LoanAgreementWithCommunityBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "LoanAgreementWithCommunityBankMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to loan agreement with a community bank.", "label": "Loan Agreement With Community Bank [Member]", "terseLabel": "Loan agreement with a community bank" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesChangesInDebtOtherThanSeniorSecuredNotesDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesChangesInSeniorSecuredNotesDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt", "periodEndLabel": "Debt (Period End)", "periodStartLabel": "Debt (Period Beginning)", "terseLabel": "Total debts payable as of December 31, 2023", "verboseLabel": "Debt payable", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r33", "r246", "r427", "r442", "r814", "r815", "r931" ] }, "us-gaap_LongTermDebtByMaturityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtByMaturityAbstract", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesFutureDebtObligationsDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Fiscal Year Maturity [Abstract]", "terseLabel": "Future debt obligations (per year)" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Current Maturities", "terseLabel": "Debts payable - current portion", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r285" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesFutureDebtObligationsDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesFutureDebtObligationsDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, after Year Five", "terseLabel": "2029 and beyond", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r17", "r321", "r904" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesFutureDebtObligationsDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesFutureDebtObligationsDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2024", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r17", "r321", "r432" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesFutureDebtObligationsDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesFutureDebtObligationsDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year Five", "terseLabel": "2028", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r17", "r321", "r432" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesFutureDebtObligationsDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesFutureDebtObligationsDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2027", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r17", "r321", "r432" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesFutureDebtObligationsDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesFutureDebtObligationsDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2026", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r17", "r321", "r432" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesFutureDebtObligationsDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesFutureDebtObligationsDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2025", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r17", "r321", "r432" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "Debts payable - non-current portion", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r286" ] }, "ayr_LongTermDebtNoncurrentExcludingConstructionFinancingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "LongTermDebtNoncurrentExcludingConstructionFinancingLiabilities", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesDebtsPayableDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debts payable and construction financing liabilities, classified as noncurrent. Excludes lease obligation.", "label": "Long Term Debt Noncurrent Excluding Construction Financing Liabilities", "terseLabel": "Total non-current debt" } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesChangesInSeniorSecuredNotesDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r46" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesChangesInSeniorSecuredNotesDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r46", "r85" ] }, "ayr_MarketAndPerformanceBasedRsusMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "MarketAndPerformanceBasedRsusMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to market and performance based awards.", "label": "Market And Performance Based Rsus [Member]", "terseLabel": "Market and performance based RSUs" } } }, "auth_ref": [] }, "ayr_MarketBasedAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "MarketBasedAwardsMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to market based awards.", "label": "Market Based Awards [Member]", "terseLabel": "Market based awards" } } }, "auth_ref": [] }, "ayr_MaximumConstructionFinancingAllowanceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "MaximumConstructionFinancingAllowanceAmount", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum construction financing allowance.", "label": "Maximum Construction Financing Allowance, Amount", "terseLabel": "Maximum construction financing allowance" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionPurchaseConsiderationDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionPurchaseConsiderationDetails", "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationDetails", "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails", "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentppeDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "auth_ref": [ "r397", "r398", "r399", "r400", "r481", "r632", "r671", "r706", "r707", "r768", "r770", "r772", "r773", "r775", "r797", "r798", "r811", "r818", "r825", "r832", "r902", "r923", "r924", "r925", "r926", "r927", "r928" ] }, "ayr_MaximumProceedsFromEmployeeRetentionCreditToBeUtilized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "MaximumProceedsFromEmployeeRetentionCreditToBeUtilized", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiquidityAndManagementPlanDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum proceeds from employee retention credit to be utilized to improve Company's operations.", "label": "Maximum Proceeds from Employee Retention Credit to be Utilized", "terseLabel": "Maximum proceeds from employee retention credit to be utilized" } } }, "auth_ref": [] }, "ayr_MercerParkL.p.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "MercerParkL.p.Member", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRelatedPartyTransactionsAndBalancesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to Mercer Park, L.P.", "label": "Mercer Park, L.P. [Member]", "terseLabel": "Mercer Park, L.P." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionPurchaseConsiderationDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionPurchaseConsiderationDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails", "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationDetails", "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails", "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentppeDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "auth_ref": [ "r397", "r398", "r399", "r400", "r481", "r632", "r671", "r706", "r707", "r768", "r770", "r772", "r773", "r775", "r797", "r798", "r811", "r818", "r825", "r832", "r902", "r923", "r924", "r925", "r926", "r927", "r928" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieSummaryOfFinancialInformationAboutConsolidatedViesDetails", "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Noncontrolling Interest", "periodEndLabel": "Noncontrolling interest at ending", "periodStartLabel": "Noncontrolling interest at beginning", "terseLabel": "Noncontrolling interests", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r53", "r247", "r314", "r374", "r405", "r407", "r408", "r409", "r412", "r413", "r587", "r659", "r718" ] }, "us-gaap_MinorityInterestDecreaseFromRedemptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestDecreaseFromRedemptions", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieSummaryOfFinancialInformationAboutConsolidatedViesDetails" ], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests", "negatedLabel": "Acquisition of Tahoe Hydro", "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests)." } } }, "auth_ref": [ "r120", "r227", "r236" ] }, "ayr_MultipleVotingSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "MultipleVotingSharesMember", "presentation": [ "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation", "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets", "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheetsParenthetical", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to Multiple Voting Shares .", "label": "Multiple Voting Shares [Member]", "terseLabel": "Multiple Voting Shares" } } }, "auth_ref": [] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NatureOfOperations", "presentation": [ "http://www.ayrwellness.com/role/DisclosureNatureOfOperations" ], "lang": { "en-us": { "role": { "label": "Nature of Operations [Text Block]", "terseLabel": "NATURE OF OPERATIONS", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [ "r260", "r270" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Cash (used in) provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r307" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations", "totalLabel": "Cash (used in) provided by financing activities by continuing operations", "documentation": "Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r866" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Cash used in investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r307" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Investing activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations", "totalLabel": "Cash used in investing activities from continuing operations", "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r866" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Cash provided by (used in) operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r206", "r207", "r208" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Operating activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations", "terseLabel": "Cash provided by (used in) continuing operations", "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r206", "r207", "r208" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieSummaryOfFinancialInformationAboutConsolidatedViesDetails", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "totalLabel": "Net loss attributable to Ayr Wellness Inc.", "verboseLabel": "Net loss attributable to Ayr Wellness Inc.", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r194", "r208", "r253", "r276", "r296", "r297", "r301", "r314", "r325", "r327", "r328", "r329", "r330", "r333", "r334", "r340", "r349", "r356", "r360", "r362", "r374", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r582", "r587", "r668", "r736", "r758", "r759", "r810", "r841", "r898" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieSummaryOfFinancialInformationAboutConsolidatedViesDetails", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "terseLabel": "Net loss attributable to noncontrolling interest", "verboseLabel": "Net income (loss) attributable to noncontrolling interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r130", "r237", "r296", "r297", "r333", "r334", "r667", "r862" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Change in accounting standards", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ayr_NewDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "NewDebtSecuritiesMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiquidityAndManagementPlanDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to new debt securities.", "label": "New Debt Securities [Member]", "terseLabel": "New Debt Securities" } } }, "auth_ref": [] }, "ayr_NewMoneyNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "NewMoneyNotesMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to New Money Notes.", "label": "New Money Notes [Member]", "terseLabel": "New Money Notes" } } }, "auth_ref": [] }, "ayr_NinePointEightPercentSecuredPromissoryNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "NinePointEightPercentSecuredPromissoryNotesMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to 9.8% secured promissory notes.", "label": "Nine Point Eight Percent Secured Promissory Notes [Member]", "terseLabel": "Secured promissory notes interest rate 9.8%" } } }, "auth_ref": [] }, "ayr_NonRelatedPartyNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "NonRelatedPartyNoteMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to non-related party note.", "label": "Non Related Party Note [Member]", "terseLabel": "Non-related party note" } } }, "auth_ref": [] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Non-cash investing and financing activities:" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestIncreaseFromBusinessCombination", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieSummaryOfFinancialInformationAboutConsolidatedViesDetails" ], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest, Increase from Business Combination", "verboseLabel": "Total purchase consideration", "documentation": "Amount of increase in noncontrolling interest from a business combination." } } }, "auth_ref": [ "r23", "r95", "r112" ] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Noncontrolling interest", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r118", "r462", "r877", "r878", "r879", "r936" ] }, "ayr_NoncontrollingInterestWorkingCapitalAdjustmentPresentedAsConsiderationPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "NoncontrollingInterestWorkingCapitalAdjustmentPresentedAsConsiderationPayable", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieSummaryOfFinancialInformationAboutConsolidatedViesDetails" ], "lang": { "en-us": { "role": { "documentation": "Decrease in noncontrolling interest from working capital adjustment presented as consideration payable.", "label": "Noncontrolling Interest, Working capital Adjustment Presented as Consideration Payable", "negatedLabel": "Working capital adjustment presented as consideration payable" } } }, "auth_ref": [] }, "ayr_NoncontrollingInterestsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "NoncontrollingInterestsPolicyPolicyTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for noncontrolling interests.", "label": "Noncontrolling Interests, Policy [Policy Text Block]", "terseLabel": "Noncontrolling interests" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "totalLabel": "Total other (expense) income, net", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r202" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense), net" } } }, "auth_ref": [] }, "us-gaap_NonrelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonrelatedPartyMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesDebtsPayableDetails", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Nonrelated Party [Member]", "terseLabel": "Non-related party debt", "documentation": "Party not related to reporting entity." } } }, "auth_ref": [ "r873", "r874" ] }, "us-gaap_NotesIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesIssued1", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Notes Issued", "terseLabel": "Issuance of promissory note related to business combinations", "documentation": "The fair value of notes issued in noncash investing and financing activities." } } }, "auth_ref": [ "r67", "r68", "r69" ] }, "ayr_NotesIssuedSettlementOfContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "NotesIssuedSettlementOfContingentConsideration", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Value of notes issued in noncash financing activities related to settlement of contingent consideration.", "label": "Notes Issued, Settlement of Contingent Consideration", "terseLabel": "Issuance of promissory note related to settlement of contingent consideration" } } }, "auth_ref": [] }, "ayr_NumberOfConditionalAdultUseDispensaryLicenses": { "xbrltype": "integerItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "NumberOfConditionalAdultUseDispensaryLicenses", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitionsIncluding2023FourthQuarterAssetAcquisitionDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of conditional adult use dispensary licenses that allow for the retail sales of cannabis", "label": "Number Of Conditional Adult Use Dispensary Licenses", "terseLabel": "Number of conditional adult use dispensary licenses" } } }, "auth_ref": [] }, "ayr_NumberOfCultivationAndProcessingFacilitiesEnteredForSaleAndLeaseBack": { "xbrltype": "integerItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "NumberOfCultivationAndProcessingFacilitiesEnteredForSaleAndLeaseBack", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of cultivation and processing facilities entered for sale and lease back transaction.", "label": "Number of Cultivation and Processing Facilities Entered for Sale and Lease Back", "terseLabel": "Number of cultivation and processing facilities entered for sale and lease back" } } }, "auth_ref": [] }, "ayr_NumberOfEntitiesOverWhichHaveAbilityToDirectActivities": { "xbrltype": "integerItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "NumberOfEntitiesOverWhichHaveAbilityToDirectActivities", "presentation": [ "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of entities over which the company has the ability to direct activities.", "label": "Number Of Entities Over Which Have Ability To Direct Activities", "terseLabel": "Number of entities over which the company has the ability to direct activities" } } }, "auth_ref": [] }, "ayr_NumberOfLicensedEntitiesOperatingOasisBrandedDispensaries": { "xbrltype": "integerItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "NumberOfLicensedEntitiesOperatingOasisBrandedDispensaries", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of licensed entities operating oasis branded dispensaries.", "label": "Number of Licensed Entities Operating Oasis Branded Dispensaries", "terseLabel": "Number of licensed entities operating oasis branded dispensaries" } } }, "auth_ref": [] }, "ayr_NumberOfLicensedRetailDispensariesOperated": { "xbrltype": "integerItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "NumberOfLicensedRetailDispensariesOperated", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionPurchaseConsiderationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of licensed retail dispensaries operated by the entity.", "label": "Number Of Licensed Retail Dispensaries Operated", "terseLabel": "Number of licensed retail dispensaries operated" } } }, "auth_ref": [] }, "ayr_NumberOfOasisBrandedDispensaries": { "xbrltype": "integerItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "NumberOfOasisBrandedDispensaries", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of oasis branded dispensaries.", "label": "Number of Oasis Branded Dispensaries", "terseLabel": "Number of oasis branded dispensaries" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.ayrwellness.com/role/DisclosureNatureOfOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Number of Operating Segments", "terseLabel": "Number of operating segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r882" ] }, "ayr_NumberOfOptionsToRenew": { "xbrltype": "integerItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "NumberOfOptionsToRenew", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of options to renew.", "label": "Number of Options to Renew", "terseLabel": "Number of options to renew" } } }, "auth_ref": [] }, "ayr_NumberOfSharesAgreedToBeIssuedInExchangeOfNotes": { "xbrltype": "sharesItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "NumberOfSharesAgreedToBeIssuedInExchangeOfNotes", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of shares agreed to be issued in exchange of notes.", "label": "Number of Shares Agreed to be Issued in Exchange of Notes" } } }, "auth_ref": [] }, "ayr_NumberOfWarrantsOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "NumberOfWarrantsOutstandingAbstract", "presentation": [ "http://www.ayrwellness.com/role/DisclosureShareCapitalWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Number of Warrants Outstanding [Abstract]", "terseLabel": "Number of warrants outstanding" } } }, "auth_ref": [] }, "us-gaap_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OfficeEquipmentMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentppeDetails" ], "lang": { "en-us": { "role": { "label": "Office Equipment [Member]", "terseLabel": "Office equipment", "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine." } } }, "auth_ref": [] }, "ayr_OfficeExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "OfficeExpenses", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRelatedPartyTransactionsAndBalancesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of office expenses incurred during the period.", "label": "Office Expenses", "terseLabel": "Office expenses" } } }, "auth_ref": [] }, "ayr_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Operating and Finance Lease Liabilities Payments Due [Abstract]", "terseLabel": "Total Operating Lease and Finance Leases" } } }, "auth_ref": [] }, "ayr_OperatingAndFinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "OperatingAndFinanceLeaseLiability", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating and finance lease.", "label": "Operating and Finance Lease Liability", "terseLabel": "Total present value of minimum lease payments" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Loss from continuing operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r349", "r356", "r360", "r362", "r810" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRelatedPartyTransactionsAndBalancesDetails", "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesPaymentsRelatedToCapitalizedLeaseDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Expense", "terseLabel": "Lease fees", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r917" ] }, "us-gaap_OperatingLeaseImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseImpairmentLoss", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Impairment Loss", "terseLabel": "Impairment loss on ROU operating assets", "documentation": "Amount of loss from impairment of right-of-use asset from operating lease." } } }, "auth_ref": [ "r916" ] }, "ayr_OperatingLeaseIncrementalBorrowingRate": { "xbrltype": "percentItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "OperatingLeaseIncrementalBorrowingRate", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Incremental weighted average borrowing rate for operating lease calculated at point in time.", "label": "Operating Lease Incremental Borrowing Rate", "terseLabel": "Operating Leases Incremental borrowing rate (weighted average)" } } }, "auth_ref": [] }, "ayr_OperatingLeaseLiabilitiesExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "OperatingLeaseLiabilitiesExpenseAbstract", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesPaymentsRelatedToCapitalizedLeaseDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Lease liabilities - operating" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]", "terseLabel": "Operating Leases" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetails", "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesMaturityOfContractualUndiscountedLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "terseLabel": "Lease liability", "verboseLabel": "Total present value of minimum lease payments", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r600" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "terseLabel": "Lease liabilities - operating - current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r600" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Lease liabilities - operating - non-current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r600" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetails", "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-use assets - operating, net", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r599" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating Leases Weighted average remaining lease term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r609", "r830" ] }, "ayr_OptionAgreementAbilityToAcquireEquityInterestsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "OptionAgreementAbilityToAcquireEquityInterestsPercentage", "presentation": [ "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails" ], "lang": { "en-us": { "role": { "documentation": "The percentage of equity interest that can be acquired in future through option agreement.", "label": "Option Agreement , Ability To Acquire Equity Interests, Percentage", "terseLabel": "Equity interest in dispensaries" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "NATURE OF OPERATIONS" } } }, "auth_ref": [] }, "us-gaap_OtherBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherBorrowings", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesChangesInSeniorSecuredNotesDetails" ], "lang": { "en-us": { "role": { "label": "Other Borrowings", "terseLabel": "Total senior secured notes classified as non-current payable as of December 31, 2023", "documentation": "The carrying amount as of the balance sheet date for the aggregate of other miscellaneous borrowings owed by the reporting entity." } } }, "auth_ref": [ "r249" ] }, "ayr_OtherGainLossFromFairValueAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "OtherGainLossFromFairValueAdjustments", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/DisclosureDerivativeLiabilitiesScheduleOfFairValueAdjustmentRelatingToDerivativeLiabilitiesDetails": { "parentTag": "ayr_GainLossFromFairValueAdjustmentExcludingTerminatedLeases", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureDerivativeLiabilitiesScheduleOfFairValueAdjustmentRelatingToDerivativeLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of other gain loss from fair value adjustments.", "label": "Other Gain Loss From Fair Value Adjustments", "terseLabel": "Other" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long- term liabilities", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r47" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income, net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r204" ] }, "ayr_PaNaturalMedicineLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "PaNaturalMedicineLlcMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to PA Natural Medicine, LLC (\"PA Natural\").", "label": "PA Natural Medicine, LLC [Member]", "terseLabel": "PA Natural" } } }, "auth_ref": [] }, "ayr_ParmaWellnessCenterLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "ParmaWellnessCenterLlcMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieSummaryOfFinancialInformationAboutConsolidatedViesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Parma Wellness, Center, LLC (\"Parma\").", "label": "Parma Wellness, Center, LLC [Member]", "verboseLabel": "Parma" } } }, "auth_ref": [] }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payment for Contingent Consideration Liability, Financing Activities", "negatedLabel": "Payment for settlement of contingent consideration", "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date." } } }, "auth_ref": [ "r9" ] }, "us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentForContingentConsiderationLiabilityInvestingActivities", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Payment for Contingent Consideration Liability, Investing Activities", "terseLabel": "Contingent consideration cash", "documentation": "Amount of cash outflow, made soon after acquisition date of business combination, to settle contingent consideration liability." } } }, "auth_ref": [ "r7" ] }, "us-gaap_PaymentsForAdvanceToAffiliate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForAdvanceToAffiliate", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments for Advance to Affiliate", "negatedLabel": "Advances to related entities", "documentation": "The cash outflow from advancing money to an affiliate (an entity that is related but not strictly controlled by the entity)." } } }, "auth_ref": [ "r57" ] }, "ayr_PaymentsForProceedsFromBridgeFinancing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "PaymentsForProceedsFromBridgeFinancing", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The net cash outflow or inflow from bridge financing.", "label": "Payments for (Proceeds from) Bridge Financing", "negatedLabel": "Cash received (paid) for bridge financing" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRepurchaseOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfEquity", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments for Repurchase of Equity", "negatedLabel": "Repurchase of Equity Shares", "documentation": "The cash outflow to reacquire common and preferred stock." } } }, "auth_ref": [ "r61", "r683" ] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesChangesInDebtOtherThanSeniorSecuredNotesDetails", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments of Debt Issuance Costs", "negatedLabel": "Debt issuance costs", "negatedTerseLabel": "Debt issuance costs paid", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r63" ] }, "ayr_PaymentsOfDepositsForBusinessCombinationsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "PaymentsOfDepositsForBusinessCombinationsNet", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash outflow for deposits paid for Deposits for business combinations, net of cash on hand.", "label": "Payments of Deposits for Business Combinations, Net", "negatedLabel": "Deposits for business combinations, net of cash on hand" } } }, "auth_ref": [] }, "ayr_PaymentsOfDepositsForFinancingLeaseAndNotePayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "PaymentsOfDepositsForFinancingLeaseAndNotePayable", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash outflow for deposits paid for financing lease and note payable.", "label": "Payments of Deposits for Financing Lease and Note Payable", "negatedLabel": "Deposits paid for financing lease and note payable" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfFinancingCosts", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Payments of Financing Costs", "terseLabel": "Financing cost", "documentation": "The cash outflow for loan and debt issuance costs." } } }, "auth_ref": [ "r60" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedLabel": "Tax withholding on stock-based compensation awards", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r304" ] }, "us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireAdditionalInterestInSubsidiaries", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Additional Interest in Subsidiaries", "terseLabel": "Purchase of minority interest", "documentation": "The cash outflow associated with the purchase of noncontrolling interest during the period." } } }, "auth_ref": [ "r58" ] }, "ayr_PaymentsToAcquireBusinessesAndAssetsNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "PaymentsToAcquireBusinessesAndAssetsNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business and assets, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses And Assets, Net of Cash Acquired", "negatedLabel": "Cash paid for business combinations and asset acquisitions, net of cash acquired" } } }, "auth_ref": [] }, "ayr_PaymentsToAcquireBusinessesAndAssetsWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "PaymentsToAcquireBusinessesAndAssetsWorkingCapital", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business and assets during the period from working capital.", "label": "Payments to Acquire Businesses And Assets, Working Capital", "negatedLabel": "Cash paid for business combinations and asset acquisitions, working capital" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionPurchaseConsiderationDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionPurchaseConsiderationDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitionsIncluding2023FourthQuarterAssetAcquisitionDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Cash", "verboseLabel": "Purchase consideration for acquisition", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r58", "r561" ] }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Intangible Assets", "negatedLabel": "Purchase of intangible asset", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": [ "r205" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of property, plant, and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r205" ] }, "ayr_PercentageOfIncreaseInPaymentsAnnuallyAfterFirstYear": { "xbrltype": "percentItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "PercentageOfIncreaseInPaymentsAnnuallyAfterFirstYear", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of increase in payments will be applied annually after the first year.", "label": "Percentage of Increase in Payments, Annually After First Year", "terseLabel": "Percentage of increase in payments annually after first year" } } }, "auth_ref": [] }, "ayr_PercentageOfInitialPaymentsOnPurchasePrice": { "xbrltype": "percentItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "PercentageOfInitialPaymentsOnPurchasePrice", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of initial payments on purchase price.", "label": "Percentage of Initial Payments on Purchase Price", "terseLabel": "Percentage of initial payments on purchase price" } } }, "auth_ref": [] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PerformanceSharesMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Performance Shares [Member]", "terseLabel": "Performance based awards", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [] }, "ayr_PotentialEarnOutContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "PotentialEarnOutContingentConsideration", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "Potential earn out contingent consideration.", "label": "Potential Earn Out Contingent Consideration", "terseLabel": "Potential earn out contingent consideration" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRelatedPartyTransactionsAndBalancesDetails" ], "lang": { "en-us": { "role": { "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r294", "r382", "r383", "r803" ] }, "ayr_PrepaidExpenseDepositsAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "PrepaidExpenseDepositsAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer", "label": "Prepaid Expense, Deposits and Other Assets, Current", "terseLabel": "Prepaid expenses, deposits, and other current assets" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid expenses and other current assets", "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets." } } }, "auth_ref": [] }, "ayr_ProceedsFromConstructionFinancing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "ProceedsFromConstructionFinancing", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesChangesInDebtOtherThanSeniorSecuredNotesDetails" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from construction financing.", "label": "Proceeds From Construction Financing", "terseLabel": "Construction financing" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromDivestitureOfBusinesses", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsDetails", "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsLossFromDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Divestiture of Businesses", "terseLabel": "Total consideration", "verboseLabel": "Cash consideration", "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period." } } }, "auth_ref": [ "r56" ] }, "ayr_ProceedsFromFinancingTransactionNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "ProceedsFromFinancingTransactionNet", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from the financing transaction, net of financing costs.", "label": "Proceeds from Financing Transaction, Net", "terseLabel": "Proceeds from financing transaction, net of financing costs" } } }, "auth_ref": [] }, "ayr_ProceedsFromFinancingTransactionNetOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "ProceedsFromFinancingTransactionNetOfFinancingCosts", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Proceeds from financing transaction, net of financing costs.", "label": "Proceeds from Financing Transaction, Net of Financing Costs", "terseLabel": "Proceeds from financing transaction, net of financing costs" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesChangesInDebtOtherThanSeniorSecuredNotesDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails", "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiquidityAndManagementPlanDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Debt", "terseLabel": "Debt issued", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": [ "r864" ] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Long-Term Debt", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r59", "r680" ] }, "us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfSeniorLongTermDebt", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesDetails", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Senior Long-Term Debt", "netLabel": "Proceeds from secured promissory notes", "terseLabel": "Proceeds from issuance of notes payable, net of financing costs", "documentation": "The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer)." } } }, "auth_ref": [ "r59" ] }, "ayr_ProceedsFromPaymentOfInvestingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "ProceedsFromPaymentOfInvestingActivitiesDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount of cash paid and received relating to discontinued operations.", "label": "Proceeds From Payment Of Investing Activities, Discontinued Operations", "terseLabel": "Cash (paid) received for investing activities - discontinued operations" } } }, "auth_ref": [] }, "ayr_ProceedsFromSaleOfBusinessDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "ProceedsFromSaleOfBusinessDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with proceeds from sale of business relating to discontinued operations.", "label": "Proceeds from Sale of Business, Discontinued Operations", "terseLabel": "Proceeds from sale of Arizona - discontinued operation" } } }, "auth_ref": [] }, "ayr_ProceedsFromSaleOfProductiveAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "ProceedsFromSaleOfProductiveAssetsNet", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of assets, net of transaction costs.", "label": "Proceeds from Sale of Productive Assets, Net", "terseLabel": "Proceeds from the sale of assets, net of transaction costs" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r8", "r30" ] }, "ayr_ProceedsFromWorkingCapitalDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "ProceedsFromWorkingCapitalDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount of cash received from working capital relating to discontinued operations.", "label": "Proceeds from Working Capital, Discontinued Operations", "terseLabel": "Cash received for working capital - discontinued operations" } } }, "auth_ref": [] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 }, "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlowsCalc2": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieSummaryOfFinancialInformationAboutConsolidatedViesDetails", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Consolidated net loss", "totalLabel": "Net loss noncontrolling interest", "verboseLabel": "Net loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r276", "r296", "r297", "r306", "r314", "r325", "r333", "r334", "r349", "r356", "r360", "r362", "r374", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r563", "r566", "r567", "r582", "r587", "r651", "r666", "r690", "r736", "r758", "r759", "r810", "r828", "r829", "r842", "r862", "r898" ] }, "ayr_PromissoryNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "PromissoryNoteMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to promissory notes.", "label": "Promissory Note [Member]", "terseLabel": "Promissory Note" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "PROPERTY, PLANT, AND EQUIPMENT" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.ayrwellness.com/role/DisclosurePropertyPlantAndEquipmentDetails", "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetails", "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentppeDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r16" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosurePropertyPlantAndEquipment" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "PROPERTY, PLANT, AND EQUIPMENT", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r216", "r263", "r266", "r267" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/DisclosurePropertyPlantAndEquipmentDetailss": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Gross", "terseLabel": "Total", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r218", "r281", "r663" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.ayrwellness.com/role/DisclosurePropertyPlantAndEquipmentDetails", "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentppeDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "PROPERTY, PLANT, AND EQUIPMENT", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.ayrwellness.com/role/DisclosurePropertyPlantAndEquipmentDetailss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosurePropertyPlantAndEquipmentDetails", "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant, and equipment, net", "totalLabel": "Total property, plant and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r16", "r652", "r663", "r831" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property, plant, and equipment (\"PPE\")", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r16", "r263", "r266", "r661" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosurePropertyPlantAndEquipmentTables" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property, plant, and equipment, net", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r16" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.ayrwellness.com/role/DisclosurePropertyPlantAndEquipmentDetails", "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetails", "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentppeDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r218" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentppeDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Useful life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "ayr_PurchaseConsiderationPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "PurchaseConsiderationPayable", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized from consideration in acquisition, classified as current.", "label": "Purchase Consideration Payable", "terseLabel": "Purchase consideration payable" } } }, "auth_ref": [] }, "ayr_PurchasePriceOfSaleAndLeaseBackTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "PurchasePriceOfSaleAndLeaseBackTransaction", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of purchase price of sale and lease back transaction.", "label": "Purchase Price of Sale and Lease Back Transaction", "terseLabel": "Purchase price of sale and lease back transaction" } } }, "auth_ref": [] }, "ayr_Q12022AcquisitionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "Q12022AcquisitionsMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitionsTables" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Q1 2022 Acquisitions.", "label": "Q1 2022 Acquisitions [Member]", "terseLabel": "2022 First Quarter Acquisition" } } }, "auth_ref": [] }, "ayr_Q22022AcquisitionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "Q22022AcquisitionsMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitionsTables" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Q2 2022 Acquisitions.", "label": "Q2 2022 Acquisitions [Member]", "terseLabel": "2022 Second Quarter Acquisition" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionPurchaseConsiderationDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionPurchaseConsiderationDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails", "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationDetails", "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails", "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentppeDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r397", "r398", "r399", "r400", "r473", "r481", "r512", "r513", "r514", "r628", "r632", "r671", "r706", "r707", "r768", "r770", "r772", "r773", "r775", "r797", "r798", "r811", "r818", "r825", "r832", "r835", "r895", "r902", "r924", "r925", "r926", "r927", "r928" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionPurchaseConsiderationDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionPurchaseConsiderationDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails", "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationDetails", "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails", "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentppeDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r397", "r398", "r399", "r400", "r473", "r481", "r512", "r513", "r514", "r628", "r632", "r671", "r706", "r707", "r768", "r770", "r772", "r773", "r775", "r797", "r798", "r811", "r818", "r825", "r832", "r835", "r895", "r902", "r924", "r925", "r926", "r927", "r928" ] }, "ayr_RatioAppliedForSharesIssuedUnderOneShareBasedCompensationPlanThatWillReduceNumberOfSharesThatMayBeAwardedUnderAnotherPlan": { "xbrltype": "pureItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "RatioAppliedForSharesIssuedUnderOneShareBasedCompensationPlanThatWillReduceNumberOfSharesThatMayBeAwardedUnderAnotherPlan", "presentation": [ "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied for shares issued under one share based compensation plan that will reduce the number of shares that may be awarded under another plan.", "label": "Ratio applied for Shares Issued under One Share Based Compensation Plan that will Reduce the Number of Shares that may be Awarded Under Another Plan", "terseLabel": "Ratio applied for shares issued under one share based compensation plan that will reduce the number of shares that may be awarded under another plan" } } }, "auth_ref": [] }, "ayr_ReductionOfLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "ReductionOfLeaseLiabilities", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of reduction of lease liabilities.", "label": "Reduction of Lease Liabilities", "terseLabel": "Reduction of lease liabilities related to sale of Arizona business" } } }, "auth_ref": [] }, "ayr_ReductionOfRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "ReductionOfRightOfUseAssets", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of reduction of right of use assets.", "label": "Reduction of Right of Use Assets", "terseLabel": "Reduction of right-of-use assets related to sale of Arizona business" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesDebtsPayableDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails", "http://www.ayrwellness.com/role/DisclosureRelatedPartyTransactionsAndBalancesDetails", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r480", "r616", "r617", "r709", "r710", "r711", "r712", "r713", "r733", "r735", "r767" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesDebtsPayableDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails", "http://www.ayrwellness.com/role/DisclosureRelatedPartyTransactionsAndBalancesDetails", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "terseLabel": "Related party debt", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r316", "r317", "r616", "r617", "r618", "r619", "r709", "r710", "r711", "r712", "r713", "r733", "r735", "r767" ] }, "ayr_RelatedPartyPromissoryNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "RelatedPartyPromissoryNotesMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to related party notes.", "label": "Related Party Promissory Notes [Member]", "terseLabel": "Related party notes" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRelatedPartyTransactionsAndBalancesDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "terseLabel": "RELATED PARTY TRANSACTIONS AND BALANCES", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r740", "r741", "r744" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS AND BALANCES" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesDebtsPayableDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails", "http://www.ayrwellness.com/role/DisclosureRelatedPartyTransactionsAndBalancesDetails", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r480", "r616", "r617", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r709", "r710", "r711", "r712", "r713", "r733", "r735", "r767", "r920" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRelatedPartyTransactionsAndBalances" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTY TRANSACTIONS AND BALANCES", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r613", "r614", "r615", "r617", "r620", "r686", "r687", "r688", "r742", "r743", "r744", "r764", "r766" ] }, "ayr_RenewalTermForEachOption": { "xbrltype": "durationItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "RenewalTermForEachOption", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the renewal term for each option.", "label": "Renewal Term for Each Option", "terseLabel": "Renewal term" } } }, "auth_ref": [] }, "ayr_RentalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "RentalFees", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRelatedPartyTransactionsAndBalancesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of rental fees incurred during the period.", "label": "Rental Fees", "terseLabel": "Rental fees" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfDebt", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesChangesInDebtOtherThanSeniorSecuredNotesDetails" ], "lang": { "en-us": { "role": { "label": "Repayments of Debt", "negatedLabel": "Less: repayment", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": [ "r865" ] }, "us-gaap_RepaymentsOfSeniorDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfSeniorDebt", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Repayments of Senior Debt", "negatedLabel": "Repayments of debts payable", "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period." } } }, "auth_ref": [ "r62" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRelatedPartyTransactionsAndBalancesDetails", "http://www.ayrwellness.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r318", "r319", "r418", "r448", "r619", "r805", "r806" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureShareCapitalActivityOccurredDuringYearEndDetails", "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationDetails", "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationRsusDetails", "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "RSUs", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "ayr_RestructuringTransactionPercentageOfAggregateOutstandingPrincipal": { "xbrltype": "percentItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "RestructuringTransactionPercentageOfAggregateOutstandingPrincipal", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiquidityAndManagementPlanDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of aggregate outstanding principal amount of debt included in the restructuring transaction.", "label": "Restructuring Transaction Percentage Of Aggregate Outstanding Principal" } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r183", "r227", "r658", "r675", "r677", "r684", "r717", "r831" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Accumulated Deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r273", "r322", "r323", "r324", "r326", "r332", "r334", "r375", "r376", "r520", "r521", "r522", "r549", "r550", "r572", "r574", "r575", "r577", "r580", "r672", "r674", "r691", "r936" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieSummaryOfFinancialInformationAboutConsolidatedViesDetails", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenues, net of discounts", "verboseLabel": "Revenues, net of discounts", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r350", "r351", "r355", "r358", "r359", "r363", "r364", "r366", "r471", "r472", "r634" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r271", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r799" ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Recognition of right-of-use assets for finance leases", "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability." } } }, "auth_ref": [ "r608", "r830" ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Recognition of right-of-use assets for operating leases", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r608", "r830" ] }, "ayr_RightOfUseAssetWorkAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "RightOfUseAssetWorkAllowance", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of work allowance on right of use assets.", "label": "Right of Use Asset, Work Allowance", "terseLabel": "ROU asset, work allowance" } } }, "auth_ref": [] }, "us-gaap_SaleAndLeasebackTransactionGainLossNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleAndLeasebackTransactionGainLossNet", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Sale and Leaseback Transaction, Gain (Loss), Net", "terseLabel": "Transactions for sale-leaseback treatment, gain or loss was recognized", "documentation": "Amount of gain (loss) on sale and leaseback transaction from transfer of asset accounted for as sale." } } }, "auth_ref": [ "r606", "r611", "r830" ] }, "ayr_ScenarioOtherThanRelatedToBusinessAcquisitionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "ScenarioOtherThanRelatedToBusinessAcquisitionsMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureShareCapitalActivityOccurredDuringYearEndDetails" ], "lang": { "en-us": { "role": { "documentation": "Scenario other than related to a business acquisition.", "label": "Scenario Other Than Related To Business Acquisitions [Member]", "terseLabel": "Other than a business acquisition" } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.ayrwellness.com/role/DisclosureShareCapitalActivityOccurredDuringYearEndDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": [ "r335", "r482", "r853", "r880" ] }, "ayr_ScheduleOfAdditionalInformationAboutLeasingActivitiesForLesseeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "ScheduleOfAdditionalInformationAboutLeasingActivitiesForLesseeTableTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for additional information about leasing activities for lessee.", "label": "Schedule of Additional Information About Leasing Activities For Lessee [Table Text Block]", "terseLabel": "Information related to operating and finance leases is as follows:" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r70" ] }, "ayr_ScheduleOfBusinessAcquisitionsAndAssetAcquisitionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "ScheduleOfBusinessAcquisitionsAndAssetAcquisitionsLineItems", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitionsTables" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Business Acquisitions And Asset Acquisitions [Line Items]", "terseLabel": "BUSINESS COMBINATIONS AND ASSET ACQUISITIONS" } } }, "auth_ref": [] }, "ayr_ScheduleOfBusinessAcquisitionsAndAssetAcquisitionsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "ScheduleOfBusinessAcquisitionsAndAssetAcquisitionsTable", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitionsTables" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Schedule of Business Acquisitions And Asset Acquisitions [Table]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionPurchaseConsiderationDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022SecondQuarterAcquisitionPurchaseConsiderationDetails", "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitionsIncluding2023FourthQuarterAssetAcquisitionDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r107", "r109", "r560" ] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of income taxes expense", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r230" ] }, "ayr_ScheduleOfComponentsOfPurchaseConsiderationInBusinessCombinationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "ScheduleOfComponentsOfPurchaseConsiderationInBusinessCombinationTableTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitionsTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for components of purchase consideration paid or payable in a business combination transaction.", "label": "Schedule Of Components Of Purchase Consideration In A Business Combination [Table Text Block]", "terseLabel": "Schedule of components of purchase consideration" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of total debt payable", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r46", "r91", "r94", "r139", "r140", "r143", "r148", "r225", "r226", "r814", "r816", "r876" ] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of senior secured promissory notes and debt payable", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of components of deferred tax assets and liabilities", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r229" ] }, "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDerivativeLiabilitiesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]", "terseLabel": "Schedule of fair value adjustment relating to derivative liabilities", "documentation": "Tabular disclosure of derivative liabilities at fair value." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsTables" ], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Schedule of major classes of assets and liabilities held for sale and components comprising net loss from our discontinued operations", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r19", "r31", "r36", "r150", "r159", "r160", "r161", "r162", "r163", "r168", "r170", "r171", "r221" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of difference between the income tax expense and the expected income taxes based on the statutory tax rate", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r228" ] }, "ayr_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationUsefulLifeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationUsefulLifeTableTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of useful life of finite-lived intangible assets acquired as part of a business combination or through an asset purchase, by major class.", "label": "Schedule Of Finite Lived Intangible Assets Acquired As Part Of Business Combination, Useful Life [Table Text Block]", "terseLabel": "Schedule of finite-lived intangible assets" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r77", "r79", "r635" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of intangible assets, net of accumulated amortization", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r77", "r79" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of goodwill", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r812", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894" ] }, "us-gaap_ScheduleOfGuaranteeObligationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGuaranteeObligationsTable", "presentation": [ "http://www.ayrwellness.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Guarantor Obligations [Table]", "documentation": "Tabular disclosure about the type or nature of guarantees, for example performance, indemnification, payment and other guarantees, and related information such as term, origin and purpose, triggering event, maximum exposure, and carrying value. Represents the guarantor's disclosures which include the information about each guarantee, or each group of similar guarantees, even if the likelihood of the guarantor's need to make any payments under the guarantee is remote. This excludes disclosures for product warranties." } } }, "auth_ref": [ "r401", "r402", "r403", "r404" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureInventoryTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventory", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r38", "r187", "r188", "r189" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "terseLabel": "Schedule of future debt obligations", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r17" ] }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "terseLabel": "Schedule of RSUs outstanding and nonvested", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units." } } }, "auth_ref": [ "r100" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.ayrwellness.com/role/DisclosurePropertyPlantAndEquipmentDetails", "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentppeDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r16" ] }, "ayr_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Schedule of Property, Plant and Equipment, Useful Life [Table Text Block]", "terseLabel": "Schedule of depreciation and amortization over expected useful lives" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitionsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of fair value of identifiable assets acquired, and liabilities assumed as of the acquisition date", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": [ "r232" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRelatedPartyTransactionsAndBalancesDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r144", "r145", "r740", "r741", "r744" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationDetails", "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationRsusDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r484", "r485", "r487", "r488", "r489", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r511", "r512", "r513", "r514", "r515" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of stock option activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r28", "r29", "r99" ] }, "us-gaap_ScheduleOfShortTermDebtTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShortTermDebtTable", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiquidityAndManagementPlanDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Short-Term Debt [Table]", "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation." } } }, "auth_ref": [ "r41" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.ayrwellness.com/role/DisclosureShareCapitalActivityOccurredDuringYearEndDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r88", "r89", "r90", "r91", "r92", "r93", "r94", "r225", "r226", "r227", "r287", "r288", "r289", "r347", "r446", "r447", "r448", "r450", "r453", "r458", "r460", "r680", "r681", "r682", "r683", "r818", "r852", "r869" ] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureShareCapitalTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "terseLabel": "Summary of number of warrants outstanding", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r98" ] }, "us-gaap_ScheduleOfVariableInterestEntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfVariableInterestEntitiesTable", "presentation": [ "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieSummaryOfFinancialInformationAboutConsolidatedViesDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Variable Interest Entities [Table]", "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide." } } }, "auth_ref": [ "r122", "r123", "r125", "r127", "r128", "r564", "r565", "r569", "r570", "r629", "r630", "r631" ] }, "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfVariableInterestEntitiesTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Variable Interest Entities [Table Text Block]", "terseLabel": "Schedule of financial information about consolidated VIEs which are included in the balance sheet and statement of operations", "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide." } } }, "auth_ref": [ "r122", "r123", "r125", "r127", "r128" ] }, "us-gaap_SegmentDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDiscontinuedOperationsMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDiscontinuedOperationsLossFromDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Discontinued Operations [Member]", "terseLabel": "Discontinued Operations", "documentation": "Component or group of components disposed of or classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale." } } }, "auth_ref": [ "r12", "r151", "r152", "r153" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "auth_ref": [ "r364", "r365", "r703", "r704", "r705", "r769", "r771", "r774", "r776", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r800", "r819", "r835", "r905", "r933" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general, and administrative", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r200" ] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeniorNotesMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesChangesInSeniorSecuredNotesDetails", "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesDetails" ], "lang": { "en-us": { "role": { "label": "Senior Notes [Member]", "terseLabel": "Senior secured notes", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "ayr_SeniorNotesWithInterestRate12.5Due2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "SeniorNotesWithInterestRate12.5Due2024Member", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSubsequentEventsDetails", "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiquidityAndManagementPlanDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to 12.5% senior notes due 2024.", "label": "Senior notes with Interest Rate 12.5%, Due 2024 [Member]", "terseLabel": "Senior notes with Interest Rate 12.5%, Due 2024" } } }, "auth_ref": [] }, "ayr_SeniorSecuredNotesDueDecember102026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "SeniorSecuredNotesDueDecember102026Member", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to senior secured notes due December 10, 2026.", "label": "Senior Secured Notes Due December 10, 2026 [Member]", "terseLabel": "Senior Notes" } } }, "auth_ref": [] }, "ayr_SeniorSecuredNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "SeniorSecuredNotesMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent information pertaining to senior secured notes.", "label": "Senior Secured Notes [Member]", "terseLabel": "Senior Secured Notes" } } }, "auth_ref": [] }, "ayr_SeniorSecuredNotesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "SeniorSecuredNotesNet", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "The noncurrent portion of the carrying value as of the balance sheet date of notes payable, , net of debt issuance costs.", "label": "Senior Secured Notes, Net", "terseLabel": "Senior secured notes, net of debt issuance costs" } } }, "auth_ref": [] }, "ayr_SettlementOfContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "SettlementOfContingentConsideration", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount of settlement of contingent consideration.", "label": "Settlement of Contingent Consideration", "terseLabel": "Settlement of contingent consideration" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 21.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r14" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r826" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.ayrwellness.com/role/DisclosureShareCapitalActivityOccurredDuringYearEndDetails", "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationDetails", "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationRsusDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited (in shares)", "terseLabel": "Awards forfeited", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r504" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationRsusDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in dollars per share)", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r504" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationRsusDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r502" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationRsusDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in dollars per share)", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r502" ] }, "ayr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedDueToNetSettlement": { "xbrltype": "sharesItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedDueToNetSettlement", "presentation": [ "http://www.ayrwellness.com/role/DisclosureShareCapitalActivityOccurredDuringYearEndDetails", "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of awards issued due to net settlement made during the period on other than stock (or unit) option plans.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Issued Due to Net Settlement", "terseLabel": "Awards issued due to net settlement", "verboseLabel": "Equity Shares issued" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationDetails", "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationRsusDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Outstanding and nonvested at ending (in shares)", "periodStartLabel": "Outstanding and nonvested at beginning (in shares)", "terseLabel": "Number of awards outstanding", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r499", "r500" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationRsusDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of Shares", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationRsusDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Outstanding and nonvested at ending (in dollars per share)", "periodStartLabel": "Outstanding and nonvested at beginning (in dollars per share)", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r499", "r500" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationRsusDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Grant Date Fair Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.ayrwellness.com/role/DisclosureShareCapitalActivityOccurredDuringYearEndDetails", "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationDetails", "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationRsusDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested (in shares)", "terseLabel": "Awards vested", "verboseLabel": "Vested (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r503" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationRsusDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r503" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationDetails", "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationRsusDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "STOCK-BASED COMPENSATION", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r484", "r485", "r487", "r488", "r489", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r511", "r512", "r513", "r514", "r515" ] }, "ayr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The share-based compensation arrangement by share based payment award options exercises in period weighted average grant date fair value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Weighted Average Grant Date Fair Value", "terseLabel": "Options exercised (in dollars per share)" } } }, "auth_ref": [] }, "ayr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The share-based compensation arrangement by share based payment award options outstanding in period weighted average grant date fair value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding In Period Weighted Average Grant Date Fair Value", "periodEndLabel": "Balance at ending (in dollars per share)", "periodStartLabel": "Balance at beginning (in dollars per share)" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Balance at ending (in shares)", "periodStartLabel": "Balance at beginning (in shares)", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r491", "r492" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of Options", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ayr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueAbstract", "presentation": [ "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Share Based Compensation Arrangement By Share Based Payment Award, Options, Outstanding, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Fair Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "presentation": [ "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum", "terseLabel": "Maximum percentage of shares authorized to issue", "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.ayrwellness.com/role/DisclosureShareCapitalActivityOccurredDuringYearEndDetails", "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationDetails", "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationRsusDetails" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r487", "r488", "r489", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r511", "r512", "r513", "r514", "r515" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-based payments", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r483", "r490", "r509", "r510", "r511", "r512", "r515", "r523", "r524", "r525", "r526" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit", "terseLabel": "Option exercise price minimum (in dollars per share)", "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range." } } }, "auth_ref": [ "r102" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit", "terseLabel": "Option exercise price maximum (in dollars per share)", "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range." } } }, "auth_ref": [ "r102" ] }, "ayr_ShareBasedPaymentArrangementNoncashExpenseRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "ShareBasedPaymentArrangementNoncashExpenseRelatedParty", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense (reversal of expense) for employee benefits and share-based payment arrangement for related party. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits.", "label": "Share-Based Payment Arrangement, Noncash Expense, Related Party", "terseLabel": "Stock-based compensation - related party" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested", "terseLabel": "Aggregate intrinsic value, other than option", "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Average remaining life of unvested awards", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r827" ] }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": [ "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationDetails", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "negatedLabel": "Tax withholding on stock-based compensation awards (Shares)", "terseLabel": "Tax withholding on stock-based compensation awards (Shares)", "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtLineItems", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiquidityAndManagementPlanDetails" ], "lang": { "en-us": { "role": { "label": "Liquidity and management plan", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r209", "r311" ] }, "ayr_SiraNaturalsInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "SiraNaturalsInc.Member", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to to Sira Naturals, Inc.", "label": "Sira Naturals, Inc. [Member]", "terseLabel": "Sira Naturals, Inc." } } }, "auth_ref": [] }, "ayr_SiraNaturalsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "SiraNaturalsIncMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDerivativeLiabilitiesScheduleOfFairValueAdjustmentRelatingToDerivativeLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Sira Naturals, Inc.", "label": "Sira Naturals Inc [Member]", "terseLabel": "Sira" } } }, "auth_ref": [] }, "ayr_StandaloneDeliveryLicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "StandaloneDeliveryLicenseMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to standalone delivery license.", "label": "Standalone Delivery License [Member]", "terseLabel": "Standalone Delivery License" } } }, "auth_ref": [] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StateAndLocalJurisdictionMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDeferredTaxAssetsAndLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "State and Local Jurisdiction [Member]", "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity." } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.ayrwellness.com/role/DisclosureShareCapitalActivityOccurredDuringYearEndDetails", "http://www.ayrwellness.com/role/DisclosureSubsequentEventsDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation", "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets", "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheetsParenthetical", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r272", "r287", "r288", "r289", "r314", "r338", "r339", "r341", "r343", "r347", "r348", "r374", "r405", "r407", "r408", "r409", "r412", "r413", "r446", "r447", "r450", "r453", "r460", "r587", "r680", "r681", "r682", "r683", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r716", "r737", "r760", "r777", "r778", "r779", "r780", "r781", "r852", "r869", "r881" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r25", "r51", "r273", "r299", "r300", "r301", "r322", "r323", "r324", "r326", "r332", "r334", "r346", "r375", "r376", "r462", "r520", "r521", "r522", "r549", "r550", "r572", "r573", "r574", "r575", "r576", "r577", "r580", "r589", "r590", "r591", "r592", "r593", "r594", "r612", "r672", "r673", "r674", "r691", "r760" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": [ "r364", "r365", "r703", "r704", "r705", "r769", "r771", "r774", "r776", "r784", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r800", "r819", "r835", "r905", "r933" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDeferredTaxAssetsAndLiabilityDetails", "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets", "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheetsParenthetical", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Consolidated Balance Sheets", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r322", "r323", "r324", "r346", "r634", "r678", "r702", "r708", "r709", "r710", "r711", "r712", "r713", "r716", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r729", "r730", "r731", "r732", "r733", "r735", "r738", "r739", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r760", "r836" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Statements of Cash Flows" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Balance Sheets" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Statements of Shareholders' Equity" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://www.ayrwellness.com/role/DisclosureShareCapitalActivityOccurredDuringYearEndDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [ "r335", "r482", "r853", "r854", "r880" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDeferredTaxAssetsAndLiabilityDetails", "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets", "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheetsParenthetical", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r322", "r323", "r324", "r346", "r634", "r678", "r702", "r708", "r709", "r710", "r711", "r712", "r713", "r716", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r729", "r730", "r731", "r732", "r733", "r735", "r738", "r739", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r760", "r836" ] }, "ayr_StockIssuedDuringPeriodSharesAcquisitionOfVariableInterestEntity": { "xbrltype": "sharesItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "StockIssuedDuringPeriodSharesAcquisitionOfVariableInterestEntity", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions of variable interest entity .", "label": "Stock Issued During Period Shares Acquisition Of Variable Interest Entity", "terseLabel": "Acquisition of variable interest entity (Shares)" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesAcquisitions", "presentation": [ "http://www.ayrwellness.com/role/DisclosureShareCapitalActivityOccurredDuringYearEndDetails", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Share issuance - business combinations and asset acquisitions (Shares)", "verboseLabel": "Shares issued in connection with the acquisition", "documentation": "Number of shares of stock issued during the period pursuant to acquisitions." } } }, "auth_ref": [ "r180", "r181", "r227" ] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [ "http://www.ayrwellness.com/role/DisclosureShareCapitalActivityOccurredDuringYearEndDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Conversion of Exchangeable Shares (Shares)", "verboseLabel": "Shares converted or exchanged for Equity Shares", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": [ "r25", "r50", "r91", "r227", "r431" ] }, "ayr_StockIssuedDuringPeriodSharesEarnOutConsideration": { "xbrltype": "sharesItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "StockIssuedDuringPeriodSharesEarnOutConsideration", "presentation": [ "http://www.ayrwellness.com/role/DisclosureShareCapitalActivityOccurredDuringYearEndDetails", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued pursuant to earn out consideration in acquisitions during the period.", "label": "Stock Issued During Period, Shares, Earn Out Consideration", "terseLabel": "Share issuance - earn-out consideration (Shares)", "verboseLabel": "Shares issued in connection with earn-out provision related to the acquisition" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRelatedPartyTransactionsAndBalancesDetails", "http://www.ayrwellness.com/role/DisclosureShareCapitalActivityOccurredDuringYearEndDetails", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Share issuance - related party - consulting services (Shares)", "verboseLabel": "Shares issued to a related party for services rendered", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Stock-based compensation (Shares)", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r25", "r180", "r181", "r227" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.ayrwellness.com/role/DisclosureShareCapitalActivityOccurredDuringYearEndDetails", "http://www.ayrwellness.com/role/DisclosureStockBasedCompensationOptionsDetails", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Options exercised (in shares)", "terseLabel": "Exercise of options, net of options sold to cover income taxes (Shares)", "verboseLabel": "Shares issued in connection with options exercised", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r25", "r180", "r181", "r227", "r496" ] }, "ayr_StockIssuedDuringPeriodValueAcquisitionOfVariableInterestEntity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "StockIssuedDuringPeriodValueAcquisitionOfVariableInterestEntity", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to acquisitions of variable interest entity during the period.", "label": "Stock Issued During Period Value Acquisition Of Variable Interest Entity", "terseLabel": "Acquisition of variable interest entity" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueAcquisitions", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Share issuance - business combinations and asset acquisitions (Value)", "documentation": "Value of stock issued pursuant to acquisitions during the period." } } }, "auth_ref": [ "r25", "r51", "r227" ] }, "ayr_StockIssuedDuringPeriodValueEarnOutConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "StockIssuedDuringPeriodValueEarnOutConsideration", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to earn out consideration in acquisitions during the period.", "label": "Stock Issued During Period, Value, Earn Out Consideration", "terseLabel": "Share issuance - earn-out consideration (Value)" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRelatedPartyTransactionsAndBalancesDetails", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Issued for Services", "terseLabel": "Share issuance - related party - consulting services", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Stock-based compensation", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r101", "r180", "r181", "r227" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of options, net of options sold to cover income taxes (Value)", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r25", "r51", "r227" ] }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "presentation": [ "http://www.ayrwellness.com/role/DisclosureShareCapitalActivityOccurredDuringYearEndDetails" ], "lang": { "en-us": { "role": { "label": "Stock Repurchased and Retired During Period, Shares", "verboseLabel": "Shares cancelled during the period", "documentation": "Number of shares that have been repurchased and retired during the period." } } }, "auth_ref": [ "r25", "r180", "r181", "r227" ] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodShares", "presentation": [ "http://www.ayrwellness.com/role/DisclosureShareCapitalActivityOccurredDuringYearEndDetails", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Repurchased During Period, Shares", "negatedLabel": "Repurchase of Equity Shares (Shares)", "verboseLabel": "Shares repurchased during the period", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r25", "r180", "r181", "r227", "r683", "r760", "r780" ] }, "us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Repurchased During Period, Value", "negatedLabel": "Repurchase of Equity Shares (Value)", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r25", "r180", "r181", "r227", "r691", "r760", "r780", "r842" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieSummaryOfFinancialInformationAboutConsolidatedViesDetails", "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent", "totalLabel": "Equity of Ayr Wellness Inc.", "verboseLabel": "Equity attributable to Ayr Wellness Inc.", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r181", "r184", "r185", "r210", "r718", "r734", "r761", "r762", "r831", "r843", "r871", "r883", "r915", "r936" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance, Ending (Value)", "periodStartLabel": "Balance, Beginning", "totalLabel": "TOTAL SHAREHOLDERS' EQUITY", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r118", "r119", "r129", "r273", "r274", "r300", "r322", "r323", "r324", "r326", "r332", "r375", "r376", "r462", "r520", "r521", "r522", "r549", "r550", "r572", "r573", "r574", "r575", "r576", "r577", "r580", "r589", "r590", "r594", "r612", "r673", "r674", "r689", "r718", "r734", "r761", "r762", "r782", "r842", "r871", "r883", "r915", "r936" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Shareholders' equity" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "SHARE CAPITAL" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureShareCapital" ], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "terseLabel": "SHARE CAPITAL", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r224", "r313", "r445", "r447", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r459", "r462", "r579", "r763", "r765", "r783" ] }, "ayr_SubordinateRestrictedAndLimitedVotingSharesAndTreasurySharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "SubordinateRestrictedAndLimitedVotingSharesAndTreasurySharesMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureShareCapitalActivityOccurredDuringYearEndDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to Subordinate, Restricted, and Limited Voting Shares and Treasury Shares.", "label": "Subordinate, Restricted, and Limited Voting Shares And Treasury Shares [Member]", "terseLabel": "Subordinate, Restricted, and Limited Voting Shares And Treasury Shares" } } }, "auth_ref": [] }, "ayr_SubordinateRestrictedAndLimitedVotingSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "SubordinateRestrictedAndLimitedVotingSharesMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureShareCapitalActivityOccurredDuringYearEndDetails", "http://www.ayrwellness.com/role/DisclosureSubsequentEventsDetails", "http://www.ayrwellness.com/role/DocumentDocumentAndEntityInformation", "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets", "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheetsParenthetical", "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to Subordinate, Restricted, and Limited Voting Shares.", "label": "Subordinate, Restricted, and Limited Voting Shares [Member]", "terseLabel": "Subordinate, Restricted, and Limited Voting Shares", "verboseLabel": "Subordinate Voting Shares" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "terseLabel": "SUBSEQUENT EVENTS", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r595", "r623" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSubsequentEventsDetails", "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiquidityAndManagementPlanDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Events", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r595", "r623" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r595", "r623" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSubsequentEventsDetails", "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiquidityAndManagementPlanDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r595", "r623" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSubsequentEventsDetails", "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiquidityAndManagementPlanDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r595", "r623" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r622", "r624" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "auth_ref": [] }, "ayr_TahoeHydroponicsCompanyLlcAndNvGreenIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "TahoeHydroponicsCompanyLlcAndNvGreenIncMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieSummaryOfFinancialInformationAboutConsolidatedViesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to Tahoe Hydroponics Company, LLC and NV Green, Inc.", "label": "Tahoe Hydroponics Company, LLC and NV Green, Inc [Member]", "terseLabel": "Tahoe Hydro/NV Green", "verboseLabel": "TH/NVG" } } }, "auth_ref": [] }, "ayr_TahoeHydroponicsCompanyLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "TahoeHydroponicsCompanyLlcMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails", "http://www.ayrwellness.com/role/DisclosureShareCapitalActivityOccurredDuringYearEndDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to Tahoe Hydroponics Company, LLC", "label": "Tahoe Hydroponics Company, LLC [Member]", "terseLabel": "Tahoe Hydro" } } }, "auth_ref": [] }, "ayr_ThirdPartyLeaseObligationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "ThirdPartyLeaseObligationMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to third party lease obligation.", "label": "Third Party, Lease Obligation [Member]", "terseLabel": "Third party, lease obligation" } } }, "auth_ref": [] }, "ayr_TotalLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "TotalLeaseExpense", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureRightOfUseAssetsAndLeaseLiabilitiesPaymentsRelatedToCapitalizedLeaseDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of Total lease expense.", "label": "Total Lease Expense", "terseLabel": "Total lease expense" } } }, "auth_ref": [] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts receivable", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r255", "r256", "r257", "r369", "r370", "r372" ] }, "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeNamesMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureBusinessCombinationsAndAssetAcquisitions2022FirstQuarterAcquisitionFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails", "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsAndImpairmentOfLongLivedAssetsDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails" ], "lang": { "en-us": { "role": { "label": "Trade Names [Member]", "terseLabel": "Trade name / brand", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [ "r113" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Treasury Stock", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r96" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Treasury Stock, Common, Shares", "terseLabel": "Treasury stock", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r96" ] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Treasury Stock, Common, Value", "negatedLabel": "Treasury stock - 645,300 shares", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r52", "r96", "r97" ] }, "us-gaap_UnamortizedDebtIssuanceExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnamortizedDebtIssuanceExpense", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Unamortized Debt Issuance Expense", "terseLabel": "Vendor promissory notes", "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset." } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTaxationDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits", "terseLabel": "Unrecognized tax benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r529", "r539" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTaxationDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Unrecognized tax benefits accrued for interest and penalties", "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r538" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense", "terseLabel": "Interest and penalties", "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r538" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Significant accounting judgments and estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r72", "r73", "r74", "r261", "r262", "r264", "r265" ] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureTaxationDeferredTaxAssetsAndLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "terseLabel": "Increase in valuation allowance", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": [ "r542" ] }, "ayr_VariableInterestEntityDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "VariableInterestEntityDisclosureAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "VARIABLE INTEREST ENTITIES (\"VIE\")" } } }, "auth_ref": [] }, "us-gaap_VariableInterestEntityDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableInterestEntityDisclosureTextBlock", "presentation": [ "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvie" ], "lang": { "en-us": { "role": { "label": "Variable Interest Entity Disclosure [Text Block]", "terseLabel": "VARIABLE INTEREST ENTITIES (\"VIE\")", "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss." } } }, "auth_ref": [ "r234" ] }, "us-gaap_VariableInterestEntityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableInterestEntityLineItems", "presentation": [ "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieFairValueOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedAsOfAcquisitionDateDetails", "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieSummaryOfFinancialInformationAboutConsolidatedViesDetails" ], "lang": { "en-us": { "role": { "label": "Variable Interest Entity [Line Items]", "terseLabel": "VARIABLE INTEREST ENTITIES (\"VIE\")", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r564", "r565", "r569", "r570", "r629", "r630", "r631" ] }, "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableInterestEntityPrimaryBeneficiaryMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureVariableInterestEntitiesvieSummaryOfFinancialInformationAboutConsolidatedViesDetails" ], "lang": { "en-us": { "role": { "label": "Variable Interest Entity, Primary Beneficiary [Member]", "terseLabel": "VIE", "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity." } } }, "auth_ref": [ "r122", "r564", "r565", "r569", "r570" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://www.ayrwellness.com/role/DisclosureDebtsPayableAndSeniorSecuredNotesNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "us-gaap_VehiclesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VehiclesMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosurePropertyPlantAndEquipmentDetails", "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentppeDetails" ], "lang": { "en-us": { "role": { "label": "Vehicles [Member]", "terseLabel": "Auto and trucks", "documentation": "Equipment used primarily for road transportation." } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://www.ayrwellness.com/role/DisclosureShareCapitalWarrantsDetails", "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Warrants", "terseLabel": "Warrant", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r833", "r834", "r837", "r838", "r839", "r840" ] }, "ayr_WarrantsAndRightsAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "WarrantsAndRightsAggregateIntrinsicValue", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureShareCapitalWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the aggregate intrinsic value of warrants.", "label": "Warrants and Rights, Aggregate Intrinsic Value", "terseLabel": "Aggregate intrinsic value of warrants" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureShareCapitalWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at the beginning", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://www.ayrwellness.com/role/DisclosureShareCapitalWarrantsDetails", "http://www.ayrwellness.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Average remaining life of Warrants", "verboseLabel": "Term of warrants", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r914" ] }, "ayr_WarrantsAndRightsOutstandingValueIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "WarrantsAndRightsOutstandingValueIncreaseDecrease", "crdr": "credit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureShareCapitalWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Net increase (decrease) of value of warrants or rights outstanding.", "label": "Warrants and Rights Outstanding Value Increase Decrease", "terseLabel": "(no activity)" } } }, "auth_ref": [] }, "ayr_WarrantsWeightedAverageFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "WarrantsWeightedAverageFairValueAbstract", "presentation": [ "http://www.ayrwellness.com/role/DisclosureShareCapitalWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Warrants, Weighted Average Fair Value [Abstract]", "terseLabel": "Weighted Average Fair Value" } } }, "auth_ref": [] }, "ayr_WeightedAverageCostOfCapitalRateAppliedToCashFlowProjections": { "xbrltype": "percentItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "WeightedAverageCostOfCapitalRateAppliedToCashFlowProjections", "presentation": [ "http://www.ayrwellness.com/role/DisclosureGoodwillAndIntangibleAssetsImpairmentOfGoodwillDetails" ], "lang": { "en-us": { "role": { "documentation": "The weighted average cost of capital rate applied to cash flow projections for a cash-generating unit (group of units).", "label": "Weighted Average Cost of Capital Rate Applied to Cash Flow Projections", "terseLabel": "WACC (in percent)" } } }, "auth_ref": [] }, "ayr_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilities": { "xbrltype": "percentItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilities", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of weighted average lessee's incremental borrowing rate applied to lease liabilities.", "label": "Weighted Average Lessees Incremental Borrowing Rate Applied To Lease Liabilities", "terseLabel": "Weighted average lessee's incremental borrowing rate applied to lease liabilities" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average number of shares outstanding (diluted)", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r337", "r343" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.ayrwellness.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average number of shares outstanding (basic)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r336", "r343" ] }, "ayr_WorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ayrwellness.com/20231231", "localname": "WorkingCapital", "crdr": "debit", "presentation": [ "http://www.ayrwellness.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiquidityAndManagementPlanDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of working capital which indicates current assets less current liabilities.", "label": "Working Capital", "terseLabel": "Working capital" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "b", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-10" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(f)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1B" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1B" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1D", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1D" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21D", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21D" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(2)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "60", "Paragraph": "1", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-6" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-7" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480781/205-20-S99-3" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "460", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)-(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "25", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-23" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-5" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-24" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "2AA", "Subparagraph": "a", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-2AA" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-4" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-4" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-5A" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-5A" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-6" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-9" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-4" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205-20/tableOfContent" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1A" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1B" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1C" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3A" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3B" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-4" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r184": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r185": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r186": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r187": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r188": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r189": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r190": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r191": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-1" }, "r192": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r193": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r194": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r195": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r196": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r197": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r198": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r199": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r200": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r201": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r202": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r203": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r204": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r205": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r206": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r207": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r208": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r209": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r210": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r211": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350/tableOfContent" }, "r212": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r213": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r214": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r215": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r216": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r217": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-9" }, "r218": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r219": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2" }, "r220": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r221": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A" }, "r222": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r223": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r224": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r225": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r226": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r227": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r228": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r229": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r230": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "9", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r231": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r232": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r233": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r234": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r235": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r236": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-23" }, "r237": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r238": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 5.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479836/810-10-S99-5" }, "r239": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//815/tableOfContent" }, "r240": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r241": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r242": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r243": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r244": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r245": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r246": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r247": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r248": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r249": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.13,16)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r250": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r251": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r252": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r253": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r254": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r255": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r256": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15" }, "r257": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-15" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482551/740-270-45-3" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1B" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5C" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//830/tableOfContent" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479741/842-40-50-2" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "450", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480598/954-450-50-1" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r804": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r805": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r806": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r807": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r808": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r809": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r810": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r811": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r812": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r813": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r814": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r815": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r816": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r817": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r820": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r821": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r822": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r823": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r824": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r825": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r826": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r827": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r828": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r829": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r830": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r831": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r833": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r834": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r835": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r836": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r837": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r838": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r839": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r840": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r841": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r842": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r843": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r844": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r845": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r846": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r847": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r848": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r849": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r850": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r851": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r852": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r853": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r854": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479365/842-20-25-6" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 117 0001104659-24-033746-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-033746-xbrl.zip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�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‡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�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�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end XML 118 ayr-20231231x40f_htm.xml IDEA: XBRL DOCUMENT 0001847462 ayr:SubordinateRestrictedAndLimitedVotingSharesMember 2023-12-31 0001847462 ayr:MultipleVotingSharesMember 2023-12-31 0001847462 dei:BusinessContactMember 2023-01-01 2023-12-31 0001847462 2023-01-01 2023-12-31 0001847462 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2023-12-31 0001847462 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-12-31 0001847462 ayr:SubordinateRestrictedAndLimitedVotingSharesAndTreasurySharesMember 2022-01-01 2022-12-31 0001847462 ayr:ScenarioOtherThanRelatedToBusinessAcquisitionsMember ayr:SubordinateRestrictedAndLimitedVotingSharesMember 2023-01-01 2023-12-31 0001847462 ayr:ScenarioOtherThanRelatedToBusinessAcquisitionsMember ayr:ExchangeableSharesMember 2023-01-01 2023-12-31 0001847462 ayr:LeviaMember ayr:SubordinateRestrictedAndLimitedVotingSharesMember 2023-01-01 2023-12-31 0001847462 ayr:LeviaMember ayr:ExchangeableSharesMember 2023-01-01 2023-12-31 0001847462 ayr:HerbalRemediesDispensariesLlcMember ayr:SubordinateRestrictedAndLimitedVotingSharesMember 2023-01-01 2023-12-31 0001847462 ayr:HerbalRemediesDispensariesLlcMember ayr:ExchangeableSharesMember 2023-01-01 2023-12-31 0001847462 ayr:BlueCamoLlcMember ayr:ExchangeableSharesMember 2023-01-01 2023-12-31 0001847462 ayr:ScenarioOtherThanRelatedToBusinessAcquisitionsMember ayr:SubordinateRestrictedAndLimitedVotingSharesMember 2022-01-01 2022-12-31 0001847462 ayr:CanntechPaLlcMember ayr:SubordinateRestrictedAndLimitedVotingSharesMember 2022-01-01 2022-12-31 0001847462 ayr:CanntechPaLlcMember ayr:ExchangeableSharesMember 2022-01-01 2022-12-31 0001847462 ayr:BlueCamoLlcMember ayr:SubordinateRestrictedAndLimitedVotingSharesMember 2022-01-01 2022-12-31 0001847462 ayr:BlueCamoLlcMember ayr:ExchangeableSharesMember 2022-01-01 2022-12-31 0001847462 ayr:TahoeHydroponicsCompanyLlcMember ayr:ExchangeableSharesMember 2023-01-01 2023-12-31 0001847462 ayr:GsdNjLlcMember ayr:ExchangeableSharesMember 2023-01-01 2023-12-31 0001847462 ayr:HerbalRemediesDispensariesLlcMember ayr:ExchangeableSharesMember 2022-01-01 2022-12-31 0001847462 ayr:CultivaunaLlcMember ayr:ExchangeableSharesMember 2022-01-01 2022-12-31 0001847462 us-gaap:RetainedEarningsMember 2023-12-31 0001847462 us-gaap:NoncontrollingInterestMember 2023-12-31 0001847462 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001847462 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001847462 us-gaap:RetainedEarningsMember 2022-12-31 0001847462 us-gaap:NoncontrollingInterestMember 2022-12-31 0001847462 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001847462 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001847462 us-gaap:RetainedEarningsMember 2021-12-31 0001847462 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001847462 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001847462 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001847462 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001847462 ayr:MarketBasedAwardsMember 2023-12-31 0001847462 ayr:MarketAndPerformanceBasedRsusMember 2023-12-31 0001847462 us-gaap:PerformanceSharesMember 2022-12-31 0001847462 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001847462 srt:MinimumMember us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001847462 srt:MaximumMember us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001847462 us-gaap:NonrelatedPartyMember 2023-01-01 2023-12-31 0001847462 us-gaap:NonrelatedPartyMember 2022-01-01 2022-12-31 0001847462 srt:MinimumMember us-gaap:OfficeEquipmentMember 2023-12-31 0001847462 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2023-12-31 0001847462 srt:MinimumMember us-gaap:EquipmentMember 2023-12-31 0001847462 srt:MaximumMember us-gaap:OfficeEquipmentMember 2023-12-31 0001847462 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2023-12-31 0001847462 srt:MaximumMember us-gaap:EquipmentMember 2023-12-31 0001847462 us-gaap:VehiclesMember 2023-12-31 0001847462 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001847462 us-gaap:LandMember 2023-12-31 0001847462 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001847462 us-gaap:ConstructionInProgressMember 2023-12-31 0001847462 us-gaap:BuildingMember 2023-12-31 0001847462 us-gaap:VehiclesMember 2022-12-31 0001847462 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001847462 us-gaap:LandMember 2022-12-31 0001847462 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001847462 us-gaap:ConstructionInProgressMember 2022-12-31 0001847462 us-gaap:BuildingMember 2022-12-31 0001847462 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001847462 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001847462 us-gaap:SeniorNotesMember 2021-11-12 2021-11-12 0001847462 ayr:NewMoneyNotesMember us-gaap:SubsequentEventMember 2024-03-14 2024-03-14 0001847462 ayr:NewDebtSecuritiesMember us-gaap:SubsequentEventMember 2024-01-01 2024-03-14 0001847462 ayr:RelatedPartyPromissoryNotesMember 2023-07-07 2023-07-07 0001847462 ayr:MercerParkL.p.Member us-gaap:RelatedPartyMember 2022-12-31 0001847462 ayr:LoanAgreementWithCommunityBankMember 2023-03-24 2023-03-24 0001847462 us-gaap:SeniorNotesMember 2023-12-31 0001847462 2022-06-30 0001847462 ayr:MercerParkL.p.Member us-gaap:RelatedPartyMember 2023-01-01 2023-12-31 0001847462 ayr:ParmaWellnessCenterLlcMember 2022-01-01 2022-12-31 0001847462 ayr:ParmaWellnessCenterLlcMember 2023-01-01 2023-12-31 0001847462 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2023-01-01 2023-12-31 0001847462 ayr:TahoeHydroponicsCompanyLlcAndNvGreenIncMember 2023-01-01 2023-12-31 0001847462 us-gaap:SeniorNotesMember 2022-12-31 0001847462 us-gaap:SeniorNotesMember 2021-12-31 0001847462 us-gaap:RelatedPartyMember 2023-01-01 2023-12-31 0001847462 us-gaap:TradeNamesMember 2022-12-31 0001847462 us-gaap:LicensingAgreementsMember 2022-12-31 0001847462 us-gaap:LicenseMember 2022-12-31 0001847462 ayr:HostCommunityAgreementsMember 2022-12-31 0001847462 ayr:StandaloneDeliveryLicenseMember 2023-12-31 0001847462 ayr:AreaCultivatorLicenseMember 2023-12-31 0001847462 ayr:MercerParkL.p.Member us-gaap:RelatedPartyMember 2022-01-01 2022-12-31 0001847462 us-gaap:TradeNamesMember 2023-12-31 0001847462 us-gaap:LicensingAgreementsMember 2023-12-31 0001847462 us-gaap:LicenseMember 2023-12-31 0001847462 ayr:HostCommunityAgreementsMember 2023-12-31 0001847462 ayr:LandOfLincolnDispensaryLlcMember ayr:ConditionalAdultUseDispensaryLicensesMember 2023-11-02 0001847462 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-12-31 0001847462 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-12-31 0001847462 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001847462 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001847462 us-gaap:StateAndLocalJurisdictionMember 2023-12-31 0001847462 us-gaap:StateAndLocalJurisdictionMember 2022-12-31 0001847462 ayr:LoanAgreementDueMay2024Member 2023-07-07 2023-07-07 0001847462 ayr:TahoeHydroponicsCompanyLlcMember ayr:RelatedPartyPromissoryNotesMember 2023-05-01 2023-05-31 0001847462 ayr:HerbalRemediesDispensariesLlcMember ayr:RelatedPartyPromissoryNotesMember 2022-05-25 2022-05-25 0001847462 ayr:PaNaturalMedicineLlcMember ayr:NonRelatedPartyNoteMember 2022-03-01 2022-03-01 0001847462 ayr:LivfreeWellnessLlcMember 2023-10-31 2023-10-31 0001847462 ayr:SeniorSecuredNotesDueDecember102026Member us-gaap:SubsequentEventMember 2024-03-14 0001847462 ayr:SeniorNotesWithInterestRate12.5Due2024Member us-gaap:SubsequentEventMember 2024-03-14 0001847462 ayr:SeniorNotesWithInterestRate12.5Due2024Member 2024-03-14 0001847462 ayr:LivfreeWellnessLlcMember 2023-11-01 0001847462 ayr:LoanAgreementWithCommunityBankMember 2023-03-24 0001847462 ayr:LoanAgreementWithCommunityBankMember 2022-03-17 0001847462 srt:MinimumMember ayr:LoanAgreementWithCommunityBankMember 2022-05-16 0001847462 us-gaap:SubsequentEventMember 2024-03-14 0001847462 ayr:LoanAgreementDueMay2024Member 2023-07-07 0001847462 ayr:TahoeHydroponicsCompanyLlcMember ayr:RelatedPartyPromissoryNotesMember 2023-05-31 0001847462 ayr:RelatedPartyPromissoryNotesMember 2023-05-31 0001847462 ayr:ContingentConsiderationVendorTakeBackPromissoryNotesMember 2023-05-31 0001847462 ayr:HerbalRemediesDispensariesLlcMember ayr:RelatedPartyPromissoryNotesMember 2022-05-25 0001847462 ayr:PaNaturalMedicineLlcMember ayr:NonRelatedPartyNoteMember 2022-03-01 0001847462 us-gaap:SeniorNotesMember 2021-11-12 0001847462 ayr:DebtPayablesOtherThanNotesMember 2022-12-31 0001847462 ayr:DebtPayablesOtherThanNotesMember 2021-12-31 0001847462 ayr:LoanAgreementDueMay2024Member ayr:FiveYearFederalHomeLoanBankRateMember 2023-07-07 2023-07-07 0001847462 ayr:LoanAgreementWithCommunityBankMember 2022-05-16 2022-05-16 0001847462 ayr:ThirdPartyLeaseObligationMember 2023-12-31 0001847462 us-gaap:TreasuryStockCommonMember 2023-12-31 0001847462 us-gaap:TreasuryStockCommonMember 2022-12-31 0001847462 us-gaap:TreasuryStockCommonMember 2021-12-31 0001847462 ayr:SubordinateRestrictedAndLimitedVotingSharesMember 2021-12-31 0001847462 ayr:MultipleVotingSharesMember 2021-12-31 0001847462 ayr:ExchangeableSharesMember 2021-12-31 0001847462 ayr:MultipleVotingSharesMember 2023-01-01 2023-12-31 0001847462 ayr:MultipleVotingSharesMember 2022-01-01 2022-12-31 0001847462 ayr:ExchangeableSharesMember 2022-01-01 2022-12-31 0001847462 ayr:ExchangeableSharesMember 2023-12-31 0001847462 ayr:SubordinateRestrictedAndLimitedVotingSharesMember 2022-12-31 0001847462 ayr:MultipleVotingSharesMember 2022-12-31 0001847462 ayr:ExchangeableSharesMember 2022-12-31 0001847462 us-gaap:WarrantMember 2021-12-31 0001847462 ayr:AntiDilutiveWarrantsMember us-gaap:SubsequentEventMember 2024-03-14 0001847462 ayr:LandOfLincolnDispensaryLlcMember 2023-11-02 0001847462 ayr:CultivaunaLlcMember us-gaap:TradeNamesMember 2022-02-15 0001847462 ayr:CultivaunaLlcMember ayr:HostCommunityAgreementsMember 2022-02-15 0001847462 ayr:TahoeHydroponicsCompanyLlcMember ayr:PromissoryNoteMember 2023-05-01 2023-05-31 0001847462 ayr:TahoeHydroponicsCompanyLlcMember ayr:ConvertibleNoteMember 2023-05-01 2023-05-31 0001847462 ayr:TahoeHydroponicsCompanyLlcMember ayr:ExchangeableSharesMember 2023-05-01 2023-05-31 0001847462 ayr:BusinessAcquisitionsMember 2023-12-31 0001847462 ayr:TahoeHydroponicsCompanyLlcMember 2023-05-31 0001847462 ayr:ParmaWellnessCenterLlcMember 2021-03-30 0001847462 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001847462 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001847462 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001847462 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001847462 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001847462 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001847462 stpr:CT 2023-01-01 2023-12-31 0001847462 us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0001847462 us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0001847462 us-gaap:TradeNamesMember 2023-01-01 2023-12-31 0001847462 us-gaap:LicensingAgreementsMember 2023-01-01 2023-12-31 0001847462 us-gaap:LicenseMember 2023-01-01 2023-12-31 0001847462 ayr:HostCommunityAgreementsMember 2023-01-01 2023-12-31 0001847462 srt:MinimumMember 2023-01-01 2023-12-31 0001847462 srt:MaximumMember 2023-01-01 2023-12-31 0001847462 us-gaap:WarrantMember 2023-12-31 0001847462 us-gaap:WarrantMember 2022-12-31 0001847462 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001847462 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-12-31 0001847462 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001847462 ayr:ExchangeableSharesMember 2023-01-01 2023-12-31 0001847462 us-gaap:RelatedPartyMember 2022-01-01 2022-12-31 0001847462 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001847462 ayr:SubordinateRestrictedAndLimitedVotingSharesMember 2023-01-01 2023-12-31 0001847462 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001847462 ayr:SubordinateRestrictedAndLimitedVotingSharesMember 2022-01-01 2022-12-31 0001847462 ayr:HerbalRemediesDispensariesLlcMember ayr:Q22022AcquisitionsMember 2023-01-01 2023-12-31 0001847462 ayr:CultivaunaLlcMember ayr:Q12022AcquisitionsMember 2023-01-01 2023-12-31 0001847462 ayr:SeniorNotesWithInterestRate12.5Due2024Member us-gaap:SubsequentEventMember 2024-01-01 2024-03-14 0001847462 2021-05-02 2021-05-02 0001847462 ayr:DebtPayablesOtherThanNotesMember 2023-01-01 2023-12-31 0001847462 ayr:DailyReleafLlcHeavenWellnessLlcAndTwiceWellnessLlcMember 2023-01-01 2023-12-31 0001847462 ayr:BoardMemberMember us-gaap:RelatedPartyMember 2023-01-01 2023-12-31 0001847462 ayr:BoardMemberMember us-gaap:RelatedPartyMember 2022-01-01 2022-12-31 0001847462 ayr:BackstopNoteholdersMember ayr:SubordinateRestrictedAndLimitedVotingSharesMember us-gaap:SubsequentEventMember 2024-03-14 2024-03-14 0001847462 ayr:SubordinateRestrictedAndLimitedVotingSharesMember us-gaap:SubsequentEventMember 2024-03-14 2024-03-14 0001847462 2022-02-01 2022-02-28 0001847462 ayr:LandOfLincolnDispensaryLlcMember 2023-11-02 2023-11-02 0001847462 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2022-01-01 2022-12-31 0001847462 ayr:TahoeHydroponicsCompanyLlcAndNvGreenIncMember 2022-01-01 2022-12-31 0001847462 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember ayr:BlueCamoLlcMember 2023-03-27 0001847462 2022-06-01 2022-06-30 0001847462 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-12-31 0001847462 ayr:SiraNaturalsIncMember 2023-01-01 2023-12-31 0001847462 ayr:GsdNjLlcMember 2023-01-01 2023-12-31 0001847462 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember ayr:BlueCamoLlcMember 2023-03-27 2023-03-27 0001847462 ayr:BusinessAcquisitionsMember 2023-01-01 2023-12-31 0001847462 us-gaap:SegmentDiscontinuedOperationsMember ayr:BlueCamoLlcMember 2023-12-31 0001847462 us-gaap:DiscontinuedOperationsHeldforsaleMember ayr:BlueCamoLlcMember 2022-01-01 2022-12-31 0001847462 us-gaap:DiscontinuedOperationsHeldforsaleMember ayr:BlueCamoLlcMember 2022-12-31 0001847462 us-gaap:DiscontinuedOperationsHeldforsaleMember ayr:BlueCamoLlcMember 2023-01-01 2023-12-31 0001847462 ayr:ContingentConsiderationVendorTakeBackPromissoryNotesMember ayr:SeniorSecuredNotesMember 2023-12-31 0001847462 ayr:FiveYearFederalHomeLoanBankRateMember 2023-07-07 2023-07-07 0001847462 ayr:LivfreeWellnessLlcMember 2023-10-31 0001847462 ayr:NewMoneyNotesMember us-gaap:SubsequentEventMember 2024-01-01 2024-03-14 0001847462 ayr:NinePointEightPercentSecuredPromissoryNotesMember 2023-10-31 2023-10-31 0001847462 srt:MinimumMember ayr:NinePointEightPercentSecuredPromissoryNotesMember 2023-05-01 2023-05-31 0001847462 ayr:LoanAgreementWithCommunityBankMember 2022-03-17 2022-03-17 0001847462 ayr:SiraNaturalsInc.Member 2023-05-11 2023-05-11 0001847462 us-gaap:RelatedPartyMember 2023-12-31 0001847462 us-gaap:NonrelatedPartyMember 2023-12-31 0001847462 ayr:SiraNaturalsInc.Member ayr:RelatedPartyPromissoryNotesMember 2023-05-11 0001847462 ayr:GsdAcquisitionMember ayr:RelatedPartyPromissoryNotesMember 2023-05-11 0001847462 ayr:DebtPayablesOtherThanNotesMember 2023-12-31 0001847462 ayr:DebtPayablesOtherThanNotesMember 2022-01-01 2022-12-31 0001847462 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2023-12-31 0001847462 ayr:TahoeHydroponicsCompanyLlcAndNvGreenIncMember 2023-12-31 0001847462 ayr:ParmaWellnessCenterLlcMember 2023-12-31 0001847462 ayr:DailyReleafLlcHeavenWellnessLlcAndTwiceWellnessLlcMember 2023-12-31 0001847462 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2022-12-31 0001847462 ayr:TahoeHydroponicsCompanyLlcAndNvGreenIncMember 2022-12-31 0001847462 ayr:ParmaWellnessCenterLlcMember 2022-12-31 0001847462 us-gaap:CostOfSalesMember 2023-01-01 2023-12-31 0001847462 us-gaap:CostOfSalesMember 2022-01-01 2022-12-31 0001847462 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001847462 2023-12-31 0001847462 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001847462 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001847462 ayr:AntiDilutiveWarrantsMember us-gaap:SubsequentEventMember 2024-03-14 2024-03-14 0001847462 2022-12-31 0001847462 2021-12-31 0001847462 us-gaap:DiscontinuedOperationsHeldforsaleMember ayr:BlueCamoLlcMember 2023-12-31 0001847462 2022-01-01 2022-12-31 0001847462 ayr:HerbalRemediesDispensariesLlcMember 2022-05-25 0001847462 ayr:CultivaunaLlcMember 2022-02-15 0001847462 ayr:GsdAcquisitionMember 2023-05-11 0001847462 ayr:GsdAcquisitionMember 2023-05-11 2023-05-11 0001847462 ayr:GsdAcquisitionMember ayr:RelatedPartyPromissoryNotesMember 2023-05-11 2023-05-11 0001847462 ayr:GsdAcquisitionMember 2023-01-01 2023-12-31 0001847462 srt:MinimumMember ayr:TahoeHydroponicsCompanyLlcMember 2023-05-01 2023-05-31 0001847462 srt:MaximumMember ayr:TahoeHydroponicsCompanyLlcMember 2023-05-01 2023-05-31 0001847462 srt:MinimumMember ayr:HerbalRemediesDispensariesLlcMember 2022-05-25 2022-05-25 0001847462 srt:MaximumMember ayr:HerbalRemediesDispensariesLlcMember 2022-05-25 2022-05-25 0001847462 srt:MinimumMember ayr:CultivaunaLlcMember 2022-02-15 2022-02-15 0001847462 srt:MaximumMember ayr:CultivaunaLlcMember 2022-02-15 2022-02-15 0001847462 ayr:TahoeHydroponicsCompanyLlcMember 2023-05-01 2023-05-31 0001847462 ayr:HerbalRemediesDispensariesLlcMember 2022-05-25 2022-05-25 0001847462 ayr:CultivaunaLlcMember 2022-02-15 2022-02-15 0001847462 us-gaap:LandMember 2022-06-01 2022-06-30 0001847462 ayr:BuildingsAndImprovementsMember 2022-06-01 2022-06-30 iso4217:USD pure iso4217:USD shares ayr:item ayr:entity utr:sqft ayr:segment shares 0001847462 FY Ayr Wellness Inc. false 40-F false true 2023-12-31 --12-31 2023 333-253466 A1 CA 2833 98-1500584 2601 South Bayshore Drive Suite 900 Miami FL 33133 786 885-0397 C T Corporation System 1015 15th Street N.W Suite 1000 Washington DC 20005 202 572-3133 true true 64574077 3696486 Yes Yes true false false false -2.52 -0.56 3696486 3696486 Unlimited Unlimited Unlimited Unlimited Unlimited Unlimited 0 0 0 0 0 0 0 0 0 0 0 0 60909492 64574077 6044339 9645016 -1.16 -3.01 P15Y P15Y P15Y P5Y P6M P6M P6M P2Y 0 P1Y 650000 688 Marcum LLP New York, NY 50766000 76827000 13491000 7738000 106363000 99810000 22600000 8702000 260625000 193220000 453702000 310615000 302680000 687988000 744709000 127024000 121340000 40671000 43222000 94108000 94108000 6229000 8009000 1459855000 1767770000 24786000 26671000 40918000 25470000 9776000 7906000 9789000 9529000 63429000 2849000 90074000 46006000 23152000 40523000 43841000 1983000 2581000 200478000 268805000 64965000 72413000 125739000 118086000 18007000 24016000 38205000 36181000 26661000 167351000 136315000 243955000 244682000 5530000 4763000 24973000 524000 889203000 932446000 0 0 3696486 3696486 0 0 0 0 64574077 60909492 0 0 0 0 9645016 6044339 0 0 1370600000 1349713000 645300 645300 8987000 8987000 3266000 3266000 -783101000 -510668000 581778000 833324000 -11126000 2000000 570652000 835324000 1459855000 1767770000 463630000 421435000 261188000 240252000 6217000 261188000 246469000 202442000 174966000 177800000 212525000 6320000 117950000 51364000 45801000 4080000 5986000 -91000 8000 239655000 382254000 -37213000 -207288000 23023000 63088000 39403000 28323000 743000 275000 7094000 120000 -8543000 35160000 -45756000 -172128000 54839000 43161000 -7448000 1588000 47391000 44749000 -93147000 -216877000 182464000 -186353000 -38608000 -186353000 -38608000 -279500000 -255485000 -7067000 -10019000 -272433000 -245466000 -1.16 -3.01 -2.52 -0.56 -3.68 -3.68 -3.58 -3.58 74096 74096 68635 68635 3696000 56337000 7368000 1289827000 -568000 -7828000 3266000 -265202000 1020063000 2109000 46115000 46115000 676000 5258000 5258000 76000 707000 707000 682000 6352000 6352000 1029000 11748000 11748000 2006000 -2006000 12019000 12019000 33000 300000 300000 5000 78000 77000 1159000 1237000 -245466000 -10019000 -255485000 3696000 60909000 6044000 1349713000 -645000 -8987000 3266000 -510668000 2000000 835324000 3696000 60909000 6044000 1349713000 -645000 -8987000 3266000 -510668000 2000000 835324000 3262000 16412000 16412000 93000 366000 366000 66000 79000 79000 233000 115000 -6059000 -5944000 3798000 4647000 4647000 430000 -430000 -272433000 -7067000 -279500000 3696000 64574000 9645000 1370600000 -645000 -8987000 3266000 -783101000 -11126000 570652000 -279500000 -255485000 -3889000 -38608000 -275611000 -216877000 23023000 63088000 16412000 46115000 707000 79000 32303000 19028000 58646000 57122000 6320000 117950000 6217000 -7448000 1588000 2341000 2292000 -3018000 -3018000 5238000 -91000 8000 -182464000 6053000 -63000 6252000 12536000 657000 -1360000 -296000 -6548000 2804000 1199000 -42000 -2686000 2712000 1799000 47848000 16689000 24382000 -32632000 2783000 -1533000 27165000 -34165000 27697000 58830000 9981000 14490000 1500000 11546000 2600000 2205000 31433000 73000 -70000 6148000 2825000 1925000 4000000 -43776000 -68541000 18084000 1583000 -44000 2044000 19623000 2044000 -24153000 -66497000 300000 10665000 51713000 39100000 27600000 9049000 10475000 10000000 924000 366000 5258000 52029000 17923000 10608000 9596000 8430000 -32762000 27482000 -124000 -522000 -32886000 26960000 -29874000 -73702000 76827000 150142000 3813000 4200000 50766000 80640000 49914000 49231000 7078000 30915000 19184000 54396000 5470000 32444000 1580000 16000000 2800000 115000 6352000 4647000 11748000 14000000 14934000 38420000 2024000 8402000 78000 22505000 1165000 16734000 16739000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1.    NATURE OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Ayr Wellness Inc. (“Ayr” or the “Company”) is a vertically integrated cannabis multi-state operator in the United States of America (“U.S.”); through its operating companies in various states throughout the U.S., Ayr is a leading cultivator, manufacturer, and retailer of cannabis products and branded cannabis packaged goods. The Company prepares its segment reporting on the same basis that its chief operating decision maker manages the business and makes operating decisions. The Company has one operating segment, cannabis sales. The Company’s segment analysis is reviewed regularly and will be re-evaluated when circumstances change.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company is a reporting issuer in the U.S. and Canada. The Company’s subordinate, restricted, and limited voting shares (“Equity Shares”) are trading on the Canadian Stock Exchange (“CSE”), under the symbol “AYR.A.” The Company’s Equity Shares are also quoted on the OTCQX® Best Market in the U.S. under the symbol “AYRWF.” Ayr’s headquarter office is 2601 South Bayshore Drive, Suite 900, Miami, FL 33133.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p> 1 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2.    BASIS OF PRESENTATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2.1 Statement of compliance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for financial information and in accordance with the rules and regulations of Canadian securities regulators and the United States Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The financial statements are presented in United States dollars (“US$” or “$”). The functional currency of the entity is determined separately in accordance with Accounting Standards Codification (“ASC”) 830 – <i style="font-style:italic;">Foreign Currency Matters</i> and is measured using the currency of the primary economic environment in which the entity operates (“the functional currency”). The functional currency of Ayr is US$.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.1 Basis of consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The financial statements as of and for the years ended December 31, 2023 and 2022 include the accounts of the Company, its wholly-owned subsidiaries, and entities over which the Company has a controlling interest. Entities over which the Company has control are presented on a consolidated basis from the date control commences until the date control ceases. Equity investments where the Company does not exert a controlling interest are not consolidated. All intercompany balances and transactions involving controlled entities are eliminated on consolidation. The accompanying consolidated financial statements reflect the activity related to Arizona as discontinued operations, see Note 4. The Company’s consolidated subsidiaries, many of which were created in connection with the business combinations described in Note 5 and elsewhere in these financial statements, are owned 100% by the Company unless otherwise noted. See Note 6 for variable interest entities that are consolidated by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.2 Revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company applies Accounting Standards Codification “ASC” Topic 606 (“ASC 606”), which specifies how and when revenue should be recognized based on a five-step model, which is applied to all contracts with customers. Through the application of ASC 606, the Company applies the following five-step model to determine the amount and timing of revenue to be recognized:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Identifying the contract with a customer</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Identifying the performance obligations within the contract</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Determining the transaction price</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Allocating the transaction price to the performance obligations</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Recognizing revenue when/as performance obligation(s) are satisfied.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">3.</b>    <b style="font-weight:bold;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">3.2 Revenue (Continued)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In some cases, judgment is required in determining whether the customer is a business or the end consumer. This evaluation is made based on whether the business obtains control of the product before transferring to the end consumer. Control of the product transfers at a point in time either upon shipment to or receipt by the customer, depending on the contractual terms. In determining the appropriate time of sale, the Company takes into consideration: a) the Company’s right to payment for the goods or services; b) customer’s legal title; c) transfer of physical possession of the goods; and d) timing of acceptance of goods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Revenue is recognized based on the sale of cannabis products and branded packaged goods for a fixed price when control is transferred. The amount recognized reflects the consideration that the Company expects to receive, taking into account any variation that is expected to result from rights of return and discounts. Dispensary revenue is recognized at the point of sale while wholesale revenue is recognized once the Company transfers the significant risks and rewards of ownership of the goods and does not retain material involvement associated with ownership or control over the goods sold. Revenue from the wholesale of cannabis to customers is recognized upon delivery to the customer. In accordance with ASC 606, the Company has elected to account for its sales and excise tax on a net basis, within its statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">3.3 Cash and cash equivalents and restricted cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company considers the following to be cash and cash equivalents: cash deposits in financial institutions, cash held in Company safes or lockboxes at operational locations, and deposits that are readily convertible into cash within three months or less. Amounts included in restricted cash represent amounts pledged as collateral for financing arrangements as contractually required by a lender. Cash and cash equivalents and restricted cash are stated at fair value and the Company did not hold significant cash equivalents or restricted cash balances as of December 31, 2023 and 2022. The Company has banking or similar relationships in all jurisdictions in which it operates. In addition, the Company has cash balances in excess of Federal Deposit Insurance Corporation and Canada Deposit Insurance Corporation limits. The Company has historically not experienced losses related to these deposits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">3.4 Accounts receivable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Accounts receivable from wholesale sales are recorded net of an allowance for credit losses. The Company estimates allowance for credit losses based on various factors such as historical data, and customer credit worthiness. As of December 31, 2023 and 2022, the Company had approximately $706 and $511 in allowance for credit losses, respectively. For the years ended December 31, 2023 and 2022, the Company wrote off approximately $221 and $443, respectively. See 3.23 for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">3.5 Business combinations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Acquisitions of subsidiaries and businesses are accounted for using the acquisition method in accordance with ASC 805 – <i style="font-style:italic;">Business Combination</i> (“ASC 805”). The Company performs an assessment whether the acquisition is a business combination or asset acquisition based on the conditions surrounding the event(s) using guidance from ASC 805. If the acquisition is determined to be a business combination, the Company measures goodwill as the fair value of the consideration transferred, including the recognized amount of any noncontrolling interest in the acquiree, less the net recognized amount of the identifiable assets acquired and liabilities assumed, all measured as of the acquisition date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Consideration transferred includes the fair value of the assets transferred (including cash), the liabilities incurred by the Company on behalf of the acquiree, any contingent consideration and any equity interests issued by the Company. Transaction costs, other than those directly associated with the issuance of debt or equity securities that the Company incurs in connection with a business combination, are expensed as incurred. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The acquisition date is the date when the Company obtains control of the acquiree. Contingent consideration is measured at its acquisition date fair value and included as part of the consideration transferred in a business combination. Contingent consideration that is classified as a liability is re-measured at subsequent reporting dates in accordance with the criteria and guidance provided under ASC 450 – <i style="font-style:italic;">Contingencies </i>and ASC 820 – <i style="font-style:italic;">Fair Value Measurement</i>, as appropriate with corresponding gain or loss recorded in the statements of operations, see Note 14.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">3.6 Inventory</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Inventory is primarily comprised of finished goods, work-in-process, raw materials, and supplies. Inventory is valued at the lower of cost and net realizable value. Net realizable value is determined as the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. When establishing the cost, work-in-process and raw materials are determined using the weighted average cost method while the determination of cost for finished goods inventory is on the first-in, first-out accounting method. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Costs incurred during the growing process are capitalized as incurred to the extent that cost is less than net realizable value. Any subsequent post-harvest costs, including direct costs such as materials, labor, related overhead, and depreciation expense on equipment attributable to processing, are capitalized to inventory to the extent that cost is less than net realizable value. Inventories of purchased finished goods and packing materials, other than inventory acquired through business combinations, are initially valued at cost and subsequently at the lower of cost and net realizable value. The Company reviews inventories for obsolete, spoiled, and slow-moving goods and any such inventories are written down to net realizable value. Inventory acquired in a business combination is valued at selling price less selling and disposal costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">3.7 Property, plant, and equipment (“PPE”)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">PPE is stated at cost less accumulated depreciation, amortization, and impairment losses, if any. The cost of an item of PPE consists of the purchase price, any costs directly attributable to bringing the asset to the location and condition necessary for its intended use and an initial estimate of the costs of dismantling and removing the item and restoring the site on which it is located. PPE acquired in a business combination is recorded at fair value using various methodologies including cost approach, sales comparison approach or income approach.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Depreciation and amortization are calculated using the straight-line method over the following expected useful lives:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5 to 7 years</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Office equipment</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3 to 5 years</p></td></tr><tr><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Machinery and equipment</p></td><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5 to 15 years</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Auto and trucks</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5 years</p></td></tr><tr><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">the shorter of the useful life or life of the lease</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Buildings</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">39 years</p></td></tr><tr><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Land</p></td><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">not depreciated</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Construction in progress</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">not depreciated until placed in service</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">An item of PPE is derecognized upon disposal, when held for sale, or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on disposal of the asset, determined as the difference between the net disposal proceeds and the carrying amount of the asset, is recognized in the statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Construction in progress is transferred to the appropriate asset class when available for use and depreciation or amortization of the assets commences at that point of time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company conducts a periodic assessment of the residual balances, useful lives, and depreciation or amortization methods being used for PPE and any changes arising from the assessment are applied by the Company prospectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Where an item of PPE comprises major components with different useful lives, the components are accounted for as separate items of PPE. Expenditures incurred to replace a component of an item of PPE that is accounted for separately, including major inspection and overhaul expenditures are capitalized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company capitalizes interest on debt in projects under construction. Upon the asset becoming available for use, capitalized interest costs, as a portion of the total cost of the asset, are depreciated over the estimated useful life of the related asset, see Note 8 for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3.</b>    <b style="font-weight:bold;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.8 Intangible assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Intangible assets are recorded at cost less accumulated amortization and impairment losses, if any. Intangible assets, separately identifiable according to ASC 805, acquired in a business combination are measured at fair value as of the acquisition date. Amortization periods of assets with finite lives are based on management’s estimates at the date of acquisition and are amortized over their estimated useful lives. Intangible assets that have indefinite useful lives are not subject to amortization and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Goodwill</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company measures goodwill as the fair value of the consideration transferred, including the recognized amount of any noncontrolling interest in the acquiree, less the net recognized amount of the identifiable assets and liabilities assumed, all measured as of the acquisition date. Goodwill is allocated to a specific reporting unit upon acquisition. The Company’s policy is to first perform a qualitative assessment to determine if it was more-likely-than-not that the reporting unit’s carrying value is less than the fair value, indicating the potential for goodwill impairment. The amount of goodwill impairment, if any, is determined as the excess of the carrying value over the fair value of that reporting unit. The impairment of goodwill is limited to the amount of goodwill in a reporting unit. Impairment testing is performed annually by the Company, or more frequently, if events or changes in circumstances indicate that goodwill might be impaired. Management makes estimates during impairment testing as judgment is required to determine indicators of impairment and estimates are used to determine the fair value that is used to measure impairment losses. The Company assesses the fair values of its intangible assets, and its reporting unit for goodwill testing purposes, as necessary, using an income-based approach. Under the income approach, fair value is based on the present value of estimated future cash flows.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Finite-lived intangible assets</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Intangible assets are recorded at cost unless acquired through a business combination and recorded at fair value, less accumulated amortization and impairment losses. Amortization is recorded on a straight-line basis over the following estimated useful lives, which do not exceed the contractual period, if any:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Licenses/permits</p></td><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden__WN3XDC4jEqyVi4UxajCjA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">15</span></span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Right-to-use licenses</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_uztWinqX8k2fX8CN7SAx-w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">15</span></span></p></td></tr><tr><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Host community agreements</p></td><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_9uWXLTTsL0KNieUnY398Vg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">15</span></span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade name / brand</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_o2Ba-59l_UmA57gNu6OQkw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5</span></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Such assets are tested for impairment if events or changes in circumstances indicate that they might be impaired. The estimated useful lives, residual values, and amortization methods are reviewed periodically, and any changes in estimates are accounted for prospectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3.</b>    <b style="font-weight:bold;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3.8 Intangible assets (Continued)</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(c)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Impairment of long-lived assets</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Long-lived assets such as PPE, right-of-use assets, and finite-lived intangible assets are grouped with other assets and liabilities at the lowest level for which identifiable independent cash flows are available (“asset group”). The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In order to determine if assets have been impaired, the impairment test is a two-step approach wherein the recoverability test is performed first to determine whether the long-lived asset is recoverable. The recoverability test (Step 1) compares the carrying amount of the asset to the sum of its future undiscounted cash flows using entity specific assumptions generated through the asset’s use and eventual disposition. If the carrying amount of the asset is less than the undiscounted cash flows, the asset is recoverable, and an impairment is not recorded. If the carrying amount of the asset is greater than the undiscounted cash flows, the asset is not recoverable, and an impairment loss calculation (Step 2) is required. The measurement of the impairment loss to be recognized is based on the difference between the fair value and the carrying value of the asset group. Fair value can be determined using a market approach, income approach, or cost approach. The cash flow projection and fair value represents management’s best estimate, using appropriate and customary assumptions, projections, and methodologies, at the date of evaluation. The reversal of impairment losses is prohibited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">3.9 Leases and sale and leaseback accounting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company applies the accounting guidance in ASC 842 – <i style="font-style:italic;">Leases</i> and assesses whether a contract is or contains a lease, at inception of a contract. When evaluating whether a lease is a finance lease or an operating lease the Company considers whether the contract conveys the right to control the use of an identified asset. Certain arrangements require significant judgement to determine if an asset is specified in the contract and if the Company directs how, and for what purpose, the asset is used during the term of the contract. Leases are recognized as a right-of-use asset (“ROU”) and corresponding liability at the commencement date based on the present value of the future minimum lease payments over the lease term. Operating leases are included in <i style="font-style:italic;">Right-of-use assets – operating, net </i>and<i style="font-style:italic;"> Lease liabilities – operating – current portion</i> and <i style="font-style:italic;">Lease liabilities – operating – non-current portion</i> on the balance sheets. For operating leases, the Company records operating lease expense. Finance leases are included in <i style="font-style:italic;">Right-of-use assets – finance, net</i> and lease liabilities are included in <i style="font-style:italic;">Lease liabilities – finance – current portion</i> and <i style="font-style:italic;">Lease liabilities – finance – non-current portion</i> on the balance sheets based on their payment dates. For finance leases, the Company records interest expense on the lease liability in addition to amortizing the ROU (generally straight-line) over the shorter of the lease term or the useful life of the right-of-use asset. The Company primarily leases space for corporate offices, retail, cultivation, and manufacturing under non-cancellable operating leases. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Lease liabilities include the net present value of fixed payments (including in-substance fixed payments), variable lease payments that are not based on an index or a rate or subject to a fair market value renewal, amounts expected to be payable by the lessee under residual value guarantees, the exercise price of a purchase option if the lessee is reasonably certain to exercise that option, and payments of penalties for terminating the lease, if the lease term reflects the lessee exercising that option. The Company allocates the consideration in the contract to each lease component on the basis of the relative standalone price of the lease component and the aggregate stand-alone price of the non-lease components.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The lease payments are discounted using the interest rate implicit in the lease or, if that rate cannot be determined, the Company’s incremental borrowing rate. The period over which the lease payments are discounted is the reasonably certain lease term, including renewal options that the Company is reasonably certain to exercise. Renewal options are included in a number of leases across the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Payments associated with short-term leases are recognized as an expense on a straight-line basis in the statements of operations. Short-term leases are leases with a lease term of 12 months or less. Variable lease payments that depend on an index or a rate or are subject to a fair market value renewal are expensed as incurred and recognized in the statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3.</b>    <b style="font-weight:bold;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">3.9 Leases and sale and leaseback accounting (Continued)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A sale and leaseback transaction involves the transfer of an asset to another entity and the leaseback of the same asset. The Company applies ASC 606 and ASC 842 when accounting for sale and leaseback transactions. Significant estimates and judgments applied include determination of the fair value of the underlying asset, transfer of control, and determination of the implicit interest rate. The Company recognizes gains or losses related to the transfer of rights of the asset to the buyer-lessor and measures the ROU asset arising from the leaseback at the retained portion of the previous carrying amount. In cases where the transaction does not qualify for sale and leaseback accounting treatment, the asset is not derecognized, and no gain or loss is recorded. The transaction is treated as a financing transaction. See Note 10 for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.10 Equity investments </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">An associate is an entity over which the Company exercises significant influence. Significant influence is the power to participate in the financial and operating policy of the investee but without control or joint control over those policies. Interests in associates are accounted for using the equity method and are initially recognized at cost. Subsequent to initial recognition, the carrying value of the Company’s interest in an associate is adjusted for the Company’s share of income or loss and distributions of the investee. The carrying value of associates is assessed for impairment at each balance sheet date. Significant influence is presumed if the Company holds between 20% and 50% of the voting rights unless evidence exists to the contrary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Joint control is the contractually agreed sharing of control of an arrangement, which exists only when decisions about the relevant activities require the unanimous consent of the parties sharing control. Investees in which the Company has joint control and rights to the net assets thereof are defined as joint ventures. Joint ventures are also accounted for under the equity method. There were no joint ventures as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.11 Noncontrolling interests</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Equity interests owned by parties that are not shareholders of the Company in consolidated subsidiaries are considered noncontrolling interests. The share of net assets attributable to noncontrolling interests is presented as a component of equity while the share of net income or loss is recognized in the statements of operations. Changes in the Company’s ownership interest that do not result in a loss of control of these less than wholly owned subsidiaries are accounted for as equity transactions, see Note 3.19.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.12 Derivatives</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company evaluates all its agreements to determine if such instruments have derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as assets or liabilities, the derivative instrument is recorded at its fair value and is then revalued at each reporting date, with changes in the fair value reported in the Company’s financial statements. In calculating the fair value of derivative assets or liabilities, the Company uses a valuation model when Level 1 inputs are not available to estimate fair value at each reporting date (see Notes 14 and 17).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The classification of derivative instruments, including whether such instruments should be recognized as assets or liabilities or as equity, is reevaluated at the end of each reporting period. Derivative instrument assets or liabilities are classified as current or non-current based on whether net-cash settlement of the derivative instrument could be required within 12 months of the financial statement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3.</b>    <b style="font-weight:bold;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.13 Earnings per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The basic loss per share is computed by dividing the net loss by the weighted average number of shares outstanding, including Equity Shares, multiple voting shares of the Company and Exchangeable Shares, as defined below, during the period. The diluted loss per share reflects the potential dilution of shares by adjusting the weighted average number of shares outstanding to assume conversion of potentially dilutive shares, such as warrants (“Warrants”), restricted stock units (“RSUs”), and vested options of the Company (“Vested Options”). The treasury stock method is used for the assumed proceeds upon the exercise of the Warrants, and Vested Options that are used to purchase Equity Shares at the average market price during the period. If the Company incurs a net loss during a reporting period, the calculation of fully diluted loss per share will not include potentially dilutive equity instruments such as Warrants, RSUs, and Vested Options, because their effect would be anti-dilutive, therefore, basic loss per share and diluted loss per share will be the same. For the years ended December 31, 2023 and 2022, the potentially dilutive financial instruments excluded from the calculation of earnings per share included nil and nil warrants, nil and nil options and 1,908 and 3,799 RSUs, totaling 1,908 and 3,799 shares of potentially dilutive securities, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.14 Stock-based payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">(a) Stock-based payment transactions</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain employees (including directors and senior executives) of the Company receive a portion of their remuneration in the form of stock-based payment transactions, whereby employees render services as consideration for equity instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Stock-based payments to non-employees are measured at the fair value of goods or services received or the fair value of the equity instruments issued, whichever is more readily determinable. In situations where equity instruments are issued to non-employees and some or all of the fair value of the good or service received by the Company as consideration cannot be specifically identified, they are measured at fair value of the stock-based payment. Stock-based payment transactions are primarily for individuals whose compensation has been classified as part of general and administrative expenses in the statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The costs of equity settled transactions with employees are measured by reference to the fair value of the stock price at the date on which they are granted, using an appropriate valuation model. The value of the transaction is expensed straight line through the vesting period. Market and performance based RSUs are fair valued through Monte-Carlo simulations and are expensed over the indicative service period. Performance RSUs are recorded once the condition is probable to occur, refer to Note 15.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The costs of equity settled transactions are recognized, together with a corresponding increase in equity, over the period in which the performance and/or service conditions are fulfilled, ending on the date on which the relevant employees become fully entitled to the award (the “vesting date”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The cumulative expense is recognized for equity settled transactions at each reporting date until the vesting date as the Company’s policy is to account for forfeitures as they occur. The income or loss for a period represents the movement in cumulative expense recognized as of the beginning and end of that period and the corresponding amount is represented in additional paid-in capital. At the end of each reporting period, the Company assesses if any forfeitures occurred and recognizes the impact in the statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">No expense is recognized for awards that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vesting for expense purposes irrespective of whether or not the market condition is satisfied provided that all other performance and/or service conditions are satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Where the terms of an equity settled award are modified, the minimum expense recognized is the grant date fair value of the unmodified award, provided the original terms of the award are met. An additional expense is recognized for any modification which increases the total fair value of the stock-based payment arrangement or is otherwise beneficial to the employee as measured at the date of modification. When an award is cancelled by the Company or the counterparty, any remaining element of the fair value of the award is derecognized at that time through the statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">3.</b>    <b style="font-weight:bold;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 9pt 0pt;">3.14 Stock-based payments (Continued)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 9pt 0pt;"><i style="font-style:italic;font-weight:normal;">(a) Stock-based payment transactions (Continued)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">RSUs are issued on the vesting dates, sometimes net of the applicable statutory tax withholding to be paid by the Company on behalf of the employees. In those instances, lower shares are issued than the number of RSUs vested and the tax withholding is recorded as a reduction to paid-in capital. The terms of the stock-based payment awards allow an entity with a statutory income tax withholding obligation to withhold shares with a fair value up to the maximum statutory tax in the employee’s applicable jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;"><i style="font-style:italic;">(b) Warrants</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">The Company determines the accounting classification for equity-linked financial instruments such as warrants, as either liability or equity, by assessing ASC 480 – <i style="font-style:italic;">Distinguishing Liabilities from Equity</i> and ASC 815 – <i style="font-style:italic;">Derivatives and Hedging</i>. Under ASC 480, warrants are considered a liability if the warrants are mandatorily redeemable, obligate the Company to settle the warrants or the underlying shares by paying cash or other assets, or warrants that must or may require settlement by issuing a variable number of shares. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">Under ASC 815, warrants are considered liabilities if contracts require or may require the issuer to net settle the contract for cash. Such derivatives are recorded as a liability at fair value until they are settled or expire, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. After all relevant assessments, the Company concludes whether the warrants are classified as liability or equity. Liability classified warrants require fair value accounting at issuance and subsequent to initial issuance with all changes in fair value after the issuance date recorded in the statements of operations. Equity classified warrants only require fair value accounting at issuance with no changes recognized subsequent to the issuance date unless the warrants are modified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">The Company determined that all of its outstanding warrants are freestanding instruments which do not meet the characteristics of a liability and therefore are classified as equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">3.15 Loss contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">Loss contingencies are recognized when the Company has a present obligation that has arisen as a result of a past event and it is probable that a future outflow of resources will be required to settle the obligation, provided that a reliable estimate can be made of the amount of the obligation. Loss contingencies are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the time value of money and the risk specific to the obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 9pt 0pt;">3.16 Financial instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 9pt 0pt;">(a) Recognition and initial measurement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">Financial assets and financial liabilities, including derivatives, are recognized when the Company becomes a party to the contractual provisions of a financial instrument or non-financial derivative contract. All financial instruments are measured at fair value on initial recognition. Transaction costs that are directly attributable to the acquisition or issuance of financial assets and financial liabilities, other than financial assets and financial liabilities classified as FVTPL (as defined below), are added to or deducted from the fair value on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities classified as FVTPL are recognized immediately in the statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 9pt 0pt;">(b) Classification and subsequent measurement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">The Company classifies financial assets, at the time of initial recognition, according to the Company’s business model for managing the financial assets and the contractual terms of the cash flows. Financial assets are classified in the following measurement categories:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">amortized cost (“AC”).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fair value through profit or loss (“FVTPL”); and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fair value through other comprehensive income (“FVTOCI”).</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">3.</b>    <b style="font-weight:bold;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">3.16 Financial instruments (Continued)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">(b) Classification and subsequent measurement (Continued)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Financial assets are subsequently measured at amortized cost if both of the following conditions are met and they are not designated as FVTPL: a) the financial asset is held within a business model whose objective is to hold financial assets to collect contractual cash flows; and b) the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. These assets are subsequently measured at amortized cost using the effective interest rate method, less any impairment, with gains and losses recognized in the statements of operations in the period that the asset is derecognized or impaired. All financial assets not classified at amortized cost as described above are measured at FVTPL or FVTOCI depending on the business model and cash flow characteristics. The Company has no financial assets measured at FVTOCI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Financial liabilities are subsequently measured at amortized cost using the effective interest rate method with gains and losses recognized in the statements of operations in the period that the liability is derecognized, except for financial liabilities classified as FVTPL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Refer to Note 17 for the classification and fair value (“FV”) level of financial instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">(c) Derecognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company derecognizes financial assets only when the contractual rights to cash flows from the financial assets expire, or when it transfers the financial assets and substantially all of the associated risks and rewards of ownership to another entity. Gains and losses on derecognition are recognized in the statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company derecognizes financial liabilities only when its obligations under the financial liabilities are discharged, cancelled, or expired. Generally, the difference between the carrying amount of the financial liability derecognized and the consideration paid and payable, including any non-cash assets transferred or liabilities assumed, is recognized in the statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.17 Foreign currency transactions and translations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Transactions denominated in foreign currency are translated into the functional currency of the entity using the exchange rates prevailing at the dates of the transactions or valuation where items are re-measured. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies, such as remeasurement of local currency into functional currency, are recognized in the statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The results and financial position of an entity that has a functional currency different from the presentation currency is translated into the presentation currency as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">assets and liabilities for each balance sheet presented are translated at the closing rate at the date of the balance sheet; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">income and expenses for each statement of operations are translated at average exchange rates (unless this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated as the rate on the dates of the transactions).</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Effect of translation differences, such as translation of foreign currency into reporting currency, are accumulated and presented as a component of equity under accumulated other comprehensive income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">3.</b>    <b style="font-weight:bold;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">3.18 Taxation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities based on the differences between the financial statements and tax basis of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates and laws on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that the Company would be able to realize our deferred tax assets in the future more than their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company is subject to ongoing tax exposures, examinations, and assessments in various jurisdictions. Accordingly, the Company may incur additional tax expense based upon the outcomes of such matters. FASB ASC 740, Income Taxes, (“ASC 740”) prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties related to unrecognized tax benefits as of December 31, 2023 and 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals, or material deviation from its position within twelve months of the reporting date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">As the Company operates in the cannabis industry, the Company is subject to the limits of Section 280E of the United States Internal Revenue Code, as amended (“Section 280E”), under which the Company is generally only allowed to deduct expenses directly related to the cost of goods sold.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">3.19 Variable Interest Entities (“VIE”)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">Under certain provisions of ASC Topic 810 – <i style="font-style:italic;">Consolidations</i> (“ASC 810”), the Company determines whether we are the primary beneficiary of a VIE. We assess whether we have the power to direct matters that most significantly impact the activities of the VIE and the obligation to absorb losses or the right to receive the benefits from the VIE that could potentially be significant to the VIE.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">A VIE is a legal entity that does not have sufficient equity at risk to finance its activities without additional subordinated financial support or is structured that such equity investors lack the ability to make significant decisions relating to the entity’s operations through voting rights or do not substantively participate in the gains or losses of the entity. The primary beneficiary has both the power to direct the activities of the VIE that most significantly impact the entity’s economic performance and the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. We assess all variable interests in the entity and use our judgment when determining whether a particular entity is a VIE and if we are the primary beneficiary. Other qualitative factors that are considered include decision-making responsibilities, the VIE capital structure, risk and rewards sharing, contractual agreements with the VIE, voting rights, and level of involvement of other parties. We assess the primary beneficiary determination for a VIE on an ongoing basis if there are any reconsideration events related to a VIE. See Note 6.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Where we determine we are the primary beneficiary of a VIE, we consolidate the accounts of that VIE, under the guidance of ASC 805. The equity owned by other shareholders of the VIE is shown as noncontrolling interests in the accompanying financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">3.</b>    <b style="font-weight:bold;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 8pt 0pt;">3.20 Significant accounting judgments and estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">The application of the Company’s accounting policies requires management to use estimates and judgments that can have a significant effect on the revenues, expenses, assets and liabilities recognized, and disclosures made in the financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">Management’s best estimates concerning the future are based on the facts and circumstances available at the time estimates are made. Management uses historical experience, general economic conditions, and assumptions regarding probable future outcomes as the basis for determining estimates. Estimates and their underlying assumptions are reviewed periodically, and the effects of any changes are recognized at that time. Actual results could differ from the estimates used.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Business combinations</i></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">The following areas require management’s critical estimates and judgments:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">A business combination is a transaction or event in which an acquirer obtains control of one or more businesses and is accounted for using the acquisition method. The total consideration paid for the acquisition is the aggregate of the fair values of assets acquired, liabilities assumed, and equity instruments issued in exchange for control of the acquiree at the acquisition date. The acquisition date is the date when the Company obtains control of the acquiree.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">Contingent consideration is measured at its acquisition date fair value and is included as part of the consideration transferred in a business combination, subject to the applicable terms and conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">Contingent consideration that is classified as equity is not remeasured at subsequent reporting dates and its subsequent settlement is accounted for within equity. Contingent consideration that is classified as a liability is remeasured at subsequent reporting dates in accordance with the criteria and guidance provided under ASC 805.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">Based on the facts and circumstances that existed at the acquisition date, management will perform a valuation analysis to allocate the consideration transferred based on the fair values of the identifiable assets acquired and liabilities assumed on the acquisition date. Management is required to finalize its allocation on the earlier of the date that information becomes known, but no later than one year from the acquisition date. Until such time, these values might be provisionally reported and are subject to change. During the measurement period, adjustments to provisional purchase price allocations are recognized if new information is obtained about the facts and circumstances that existed as of the acquisition date that, if known, would have resulted in the recognition of those assets and liabilities as of that date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">In determining the fair value of all identifiable assets acquired and liabilities assumed, the most significant estimates generally relate to contingent consideration and intangible assets. Management exercises judgment in estimating the probability and timing of when contingent consideration targets are expected to be achieved, which is used as the basis for estimating fair value. Identified intangible assets are recognized at fair value using appropriate valuation techniques which are generally based on a forecast of the total expected future net cash flows of the acquiree. Valuations are highly dependent on the inputs used and assumptions made by management regarding the future performance of these assets and any changes in the discount rate applied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">Judgment is applied in determining whether a transaction is a business combination or an asset acquisition by considering the nature of the assets acquired and the processes applied to those assets, or if the integrated set of assets and activities is capable of being conducted and managed for the purpose of providing a return to investors or other owners.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Inventory</i></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">In calculating the value of inventory, management is required to make a number of estimates, including estimating the stage of growth of the cannabis up to the point of harvest, expected yields for the cannabis plants, harvesting costs, net realizable value, selling costs, average or expected selling prices, fair value of inventory acquired in a business combination and impairment factors. In calculating final inventory values, management compares the inventory costs to estimated net realizable value as well as investigates slow moving inventory, if applicable. The estimates are judgmental in nature and are made at a point in time, using available information, such as expected business plans and expected market conditions. Periodic reviews are performed on the inventory balance with the changes in inventory reserves reflected in cost of goods sold.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">3.</b>    <b style="font-weight:bold;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">3.20 Significant accounting judgments and estimates (Continued)</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(c)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Estimated useful lives and depreciation of PPE</i></td></tr></table><div style="margin-top:11pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 11pt 0pt;">Depreciation of PPE is dependent upon estimates of useful lives, which are determined through the exercise of judgments. The assessment of any impairment of these assets is dependent upon estimates of recoverable amounts that take into account factors such as economic and market conditions and the useful lives of assets.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(d)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Valuation, estimated life and impairment of intangible assets</i></td></tr></table><div style="margin-top:11pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 11pt 0pt;">Management uses significant judgment in estimating the useful lives and impairment. Impairment tests rely on judgments and estimates related to growth rates, discount rates, and estimated margins. </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(e)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Goodwill impairment</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Goodwill is tested for impairment annually on December 31<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">st</sup> of each fiscal year and whenever events or changes in circumstances indicate that the carrying amount of goodwill may have been impaired. In order to determine that the value of goodwill may have been impaired, the Company may perform a qualitative assessment to determine if it was more-likely-than-not that the reporting unit’s carrying value is less than the fair value, indicating the potential for goodwill impairment. Several factors, including historical results, business plans, forecasts, and market data are used to determine the fair value of the reporting unit. Changes in the conditions for these judgments and estimates can significantly affect the assessed value of goodwill. </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(f)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Leases</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Each lease is evaluated to determine if the Company would exercise any of the renewal options offered. Several material factors are considered in determining if the renewal options would be exercised, such as length of the renewal, renewal rate, and ability to transfer locations. When measuring lease liabilities, the Company used discounted lease payments using a weighted-average rate in the range of 7.8% to 15.5% per annum. The weighted-average rate is based on the Company’s incremental borrowing rate, which relies on judgments and estimates.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(g)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Provisions and contingent liabilities</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">When the Company is probable to incur an outflow of resources to settle an obligation and the amount can be reasonably estimated, a contingent liability is recorded. The contingent liability is recorded at management’s best estimates of the expenditure required to settle the obligation at period end, discounted to the present value, if material.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(h)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Financial instruments</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To determine the fair value of financial instruments, the Company develops assumptions and selects certain methods to perform the fair value calculations. Various methods considered include but are not limited to: (a) assigning the value attributed to the transaction at the time of origination; (b) re-measuring the instrument if it requires concurrent fair value measurement; and (c) valuing the instrument at the issuance value less any amortized costs. As judgment is a factor in determining the value and selecting a method, as well as the inherent uncertainty in estimating the fair value, the valuation estimates may be different.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Application of the option pricing model requires estimates in expected dividend yields, expected volatility in the underlying assets, and the expected life of the financial instruments. These estimates may ultimately be different from amounts subsequently realized, resulting in an overstatement or understatement of net loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3.</b>    <b style="font-weight:bold;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3.21 Liquidity and management plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As reflected in the consolidated financial statements, the Company had negative working capital of $7,258 as of December 31, 2023 and has incurred net losses from continuing operations for the years ended December 31, 2023 and 2022. The Company’s approach to managing its liquidity risk is to seek to ensure that it will have sufficient liquidity to meet its liabilities as they come due. The Company’s short-term liquidity requirements consist primarily of funds necessary to maintain operations, repay borrowings and other general business needs. The Company plans to use existing funds, as well as funds from the future sale of products, to fund short-term working capital needs for at least the next 12 months from the issuance of the consolidated financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the Company continues to take actions designed to improve the Company’s operations and cash position, including but not limited to: (i) targeting continued growth of sales from our consolidated operations; (ii) continued cost-savings and efficiency optimization efforts; (iii) utilizing the future proceeds from an employee retention credit up to $12,354 of which $5,238 was included in current receivables; (iv) addressing our debt maturity profile, in this regard, subsequent to December 31, 2023 the Company completed the debt restructuring transaction contemplated in its October 31, 2023 Support Agreement (the “Support Agreement”) with the holders of approximately 99% (collectively, the “Majority Noteholders”) of the aggregate outstanding principal amount of the Company’s 12.5% senior notes due December 2024 (the “Senior Notes”), which resulted in the effective extension via exchange of the maturity date for an additional two years, see Note 19, and the crystallization of the previously-announced deferral of certain current debts payable; (v) managing the timing and amount of certain expenses as well as capital expenditures; and (vi) seeking to take advantage of future potential financing (equity and/or debt) opportunities, including additional gross cash proceeds of $40,000 received February 2024 related to the issuance of new debt securities (refer to Note 19 for additional information). The debt extension related to the Support Agreement and the deferral of certain current debts payable are each classified as a non-current liability on the balance sheet as of December 31, 2023. While the contemplated debt restructuring transactions have been completed, management cannot provide any assurances that the Company will continue to be successful in accomplishing its business plans; if it is not, the Company may be forced to take other steps, including among others decelerating its growth or curtailing certain of its operations pending obtaining additional capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3.22 Discontinued operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Strategic changes in the Company’s operations can be considered a discontinued operation if both the operations and cash flows of the discontinued business have been (or will be) eliminated from the ongoing operations of the Company and the Company will not have any significant continuing involvement in the operations of the discontinued business after the disposal transaction. Under ASC Subtopic 205-20, “Presentation of Financial Statements – Discontinued Operations” (“ASC Subtopic 205-20”), a component of an entity that is classified as discontinued operations is presented separately from continuing operations in the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows for all periods presented. All assets and liabilities related to such discontinued operations are classified as held for sale and presented separately in the Consolidated Balance Sheets for all periods prior to the disposal by sale. Accordingly, the presentation of prior period balances may not agree to previously issued financial statements. See Note 4 for additional information regarding the results of operations and major classes of assets and liabilities of discontinued operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3.23 Change in accounting standards</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:none;">The Company is treated as an “emerging growth company” as defined under the Jumpstart Our Business Start-ups Act of 2012, as amended (the “JOBS Act”). Under the JOBS Act, emerging growth companies may delay adopting new or revised accounting standards until the standards apply to private companies, however, emerging growth companies are not precluded from early adopting new accounting standards that allow so.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3.23 Change in accounting standards (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:none;">Recently Issued and Adopted Accounting Standards</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:none;">In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-13 Topic 326 – Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments, which was subsequently revised by ASU 2018-19, ASU 2019-04, ASU 2019-05, ASU 2019-11, ASU 2020-02, ASU 2020-03, and ASU 2022-02 (“ASU 2016-13”), which introduces a new model for assessing impairment on most financial assets. Entities will be required to use a forward-looking expected loss model, which will replace the current incurred loss model, which will result in earlier recognition of allowance for losses. ASU 2016-13 was effective for the Company’s fiscal year beginning after December 15, 2022, and interim periods therein. </span><span style="text-decoration-color:#000000;text-decoration-line:none;">For accounts receivable only, the Company applies the simplified approach as permitted by ASU 2016-13. The simplified approach to the recognition of expected losses does not require the Company to track the changes in credit risk; rather, the Company recognizes a loss allowance based on lifetime expected credit losses at each reporting date from the date of the trade receivable. Expected credit losses are measured as the difference in the present value of the contractual cash flows that are due to the Company under the contract, and the cash flows that the Company expects to receive.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company assesses all information available, including past due status, credit ratings, the existence of third-party insurance, and forward-looking macro-economic factors in the measurement of the expected credit losses associated with its assets carried at amortized cost. The Company measures expected credit loss by considering the risk of default over the contract period and incorporates forward-looking information into its measurement. The adoption of ASU 2016-13 did not have a material impact on the Company’s financial statements and there was no cumulative effect at the adoption of the standard.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In June 2022, the FASB issued ASU No. 2022-03 Topic 820 – Fair Value Measurement – Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”), (1) to clarify the guidance in Topic 820, Fair Value Measurement, when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, (2) to amend a related illustrative example, and (3) to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. ASU 2022-03 is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years, early adoption is permitted. The Company is currently evaluating the impact the adoption of ASU 2022-03 may have on the Company’s financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In September 2022, the FASB issued ASU No. 2022-04 Topic 405 – Liabilities – Supplier Finance Programs (“ASU 2022-04”), which is intended to enhance transparency with supplier finance programs. ASU 2022-04 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Adoption is applied on a retrospective approach. The adoption of this ASU did not have a material impact on the Company’s financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 27, 2023, the FASB issued ASU No. 2023-01 Topic 842 – Leases – Common Control Arrangements (“ASU 2023-01”), in response to private company stakeholder concerns about applying Topic 842 to related party arrangements between entities under common control. ASU 2023-01 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, early adoption is permitted. The Company is currently evaluating the impact the adoption of ASU 2023-01 may have on the Company’s financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3.23 Change in accounting standards (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:none;">Recently Issued and Adopted Accounting Standards (Continued)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In November 2023, the FASB issued ASU No. 2023-07 Topic 280 – Segment Reporting (“ASU 2023-07”) to improve the disclosures about a public entity’s reportable segments and address requests from investors for additional, more detailed information about a reportable segment’s expenses. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, early adoption is permitted. The Company is currently evaluating the impact the adoption of ASU 2023-07 may have on the Company’s financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On December 14, 2023, the FASB issued ASU No. 2023-09 Topic 740 – Income Taxes (“ASU 2023-09”) to enhance the transparency and decision usefulness of income tax disclosures. The amendments in this Update address investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, including interim periods within those fiscal years, early adoption is permitted. The Company is currently evaluating the impact the adoption of ASU 2023-09 may have on the Company’s financial statements.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.1 Basis of consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The financial statements as of and for the years ended December 31, 2023 and 2022 include the accounts of the Company, its wholly-owned subsidiaries, and entities over which the Company has a controlling interest. Entities over which the Company has control are presented on a consolidated basis from the date control commences until the date control ceases. Equity investments where the Company does not exert a controlling interest are not consolidated. All intercompany balances and transactions involving controlled entities are eliminated on consolidation. The accompanying consolidated financial statements reflect the activity related to Arizona as discontinued operations, see Note 4. The Company’s consolidated subsidiaries, many of which were created in connection with the business combinations described in Note 5 and elsewhere in these financial statements, are owned 100% by the Company unless otherwise noted. See Note 6 for variable interest entities that are consolidated by the Company.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.2 Revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company applies Accounting Standards Codification “ASC” Topic 606 (“ASC 606”), which specifies how and when revenue should be recognized based on a five-step model, which is applied to all contracts with customers. Through the application of ASC 606, the Company applies the following five-step model to determine the amount and timing of revenue to be recognized:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Identifying the contract with a customer</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Identifying the performance obligations within the contract</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Determining the transaction price</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Allocating the transaction price to the performance obligations</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Recognizing revenue when/as performance obligation(s) are satisfied.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">3.2 Revenue (Continued)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In some cases, judgment is required in determining whether the customer is a business or the end consumer. This evaluation is made based on whether the business obtains control of the product before transferring to the end consumer. Control of the product transfers at a point in time either upon shipment to or receipt by the customer, depending on the contractual terms. In determining the appropriate time of sale, the Company takes into consideration: a) the Company’s right to payment for the goods or services; b) customer’s legal title; c) transfer of physical possession of the goods; and d) timing of acceptance of goods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Revenue is recognized based on the sale of cannabis products and branded packaged goods for a fixed price when control is transferred. The amount recognized reflects the consideration that the Company expects to receive, taking into account any variation that is expected to result from rights of return and discounts. Dispensary revenue is recognized at the point of sale while wholesale revenue is recognized once the Company transfers the significant risks and rewards of ownership of the goods and does not retain material involvement associated with ownership or control over the goods sold. Revenue from the wholesale of cannabis to customers is recognized upon delivery to the customer. In accordance with ASC 606, the Company has elected to account for its sales and excise tax on a net basis, within its statements of operations.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">3.3 Cash and cash equivalents and restricted cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company considers the following to be cash and cash equivalents: cash deposits in financial institutions, cash held in Company safes or lockboxes at operational locations, and deposits that are readily convertible into cash within three months or less. Amounts included in restricted cash represent amounts pledged as collateral for financing arrangements as contractually required by a lender. Cash and cash equivalents and restricted cash are stated at fair value and the Company did not hold significant cash equivalents or restricted cash balances as of December 31, 2023 and 2022. The Company has banking or similar relationships in all jurisdictions in which it operates. In addition, the Company has cash balances in excess of Federal Deposit Insurance Corporation and Canada Deposit Insurance Corporation limits. The Company has historically not experienced losses related to these deposits.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">3.4 Accounts receivable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Accounts receivable from wholesale sales are recorded net of an allowance for credit losses. The Company estimates allowance for credit losses based on various factors such as historical data, and customer credit worthiness. As of December 31, 2023 and 2022, the Company had approximately $706 and $511 in allowance for credit losses, respectively. For the years ended December 31, 2023 and 2022, the Company wrote off approximately $221 and $443, respectively. See 3.23 for additional information.</p> 706000 511000 221000 443000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">3.5 Business combinations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Acquisitions of subsidiaries and businesses are accounted for using the acquisition method in accordance with ASC 805 – <i style="font-style:italic;">Business Combination</i> (“ASC 805”). The Company performs an assessment whether the acquisition is a business combination or asset acquisition based on the conditions surrounding the event(s) using guidance from ASC 805. If the acquisition is determined to be a business combination, the Company measures goodwill as the fair value of the consideration transferred, including the recognized amount of any noncontrolling interest in the acquiree, less the net recognized amount of the identifiable assets acquired and liabilities assumed, all measured as of the acquisition date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Consideration transferred includes the fair value of the assets transferred (including cash), the liabilities incurred by the Company on behalf of the acquiree, any contingent consideration and any equity interests issued by the Company. Transaction costs, other than those directly associated with the issuance of debt or equity securities that the Company incurs in connection with a business combination, are expensed as incurred. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The acquisition date is the date when the Company obtains control of the acquiree. Contingent consideration is measured at its acquisition date fair value and included as part of the consideration transferred in a business combination. Contingent consideration that is classified as a liability is re-measured at subsequent reporting dates in accordance with the criteria and guidance provided under ASC 450 – <i style="font-style:italic;">Contingencies </i>and ASC 820 – <i style="font-style:italic;">Fair Value Measurement</i>, as appropriate with corresponding gain or loss recorded in the statements of operations, see Note 14.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">3.6 Inventory</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Inventory is primarily comprised of finished goods, work-in-process, raw materials, and supplies. Inventory is valued at the lower of cost and net realizable value. Net realizable value is determined as the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. When establishing the cost, work-in-process and raw materials are determined using the weighted average cost method while the determination of cost for finished goods inventory is on the first-in, first-out accounting method. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Costs incurred during the growing process are capitalized as incurred to the extent that cost is less than net realizable value. Any subsequent post-harvest costs, including direct costs such as materials, labor, related overhead, and depreciation expense on equipment attributable to processing, are capitalized to inventory to the extent that cost is less than net realizable value. Inventories of purchased finished goods and packing materials, other than inventory acquired through business combinations, are initially valued at cost and subsequently at the lower of cost and net realizable value. The Company reviews inventories for obsolete, spoiled, and slow-moving goods and any such inventories are written down to net realizable value. Inventory acquired in a business combination is valued at selling price less selling and disposal costs.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">3.7 Property, plant, and equipment (“PPE”)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">PPE is stated at cost less accumulated depreciation, amortization, and impairment losses, if any. The cost of an item of PPE consists of the purchase price, any costs directly attributable to bringing the asset to the location and condition necessary for its intended use and an initial estimate of the costs of dismantling and removing the item and restoring the site on which it is located. PPE acquired in a business combination is recorded at fair value using various methodologies including cost approach, sales comparison approach or income approach.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Depreciation and amortization are calculated using the straight-line method over the following expected useful lives:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5 to 7 years</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Office equipment</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3 to 5 years</p></td></tr><tr><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Machinery and equipment</p></td><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5 to 15 years</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Auto and trucks</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5 years</p></td></tr><tr><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">the shorter of the useful life or life of the lease</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Buildings</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">39 years</p></td></tr><tr><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Land</p></td><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">not depreciated</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Construction in progress</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">not depreciated until placed in service</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">An item of PPE is derecognized upon disposal, when held for sale, or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on disposal of the asset, determined as the difference between the net disposal proceeds and the carrying amount of the asset, is recognized in the statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Construction in progress is transferred to the appropriate asset class when available for use and depreciation or amortization of the assets commences at that point of time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company conducts a periodic assessment of the residual balances, useful lives, and depreciation or amortization methods being used for PPE and any changes arising from the assessment are applied by the Company prospectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Where an item of PPE comprises major components with different useful lives, the components are accounted for as separate items of PPE. Expenditures incurred to replace a component of an item of PPE that is accounted for separately, including major inspection and overhaul expenditures are capitalized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company capitalizes interest on debt in projects under construction. Upon the asset becoming available for use, capitalized interest costs, as a portion of the total cost of the asset, are depreciated over the estimated useful life of the related asset, see Note 8 for additional information.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5 to 7 years</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Office equipment</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3 to 5 years</p></td></tr><tr><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Machinery and equipment</p></td><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5 to 15 years</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Auto and trucks</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5 years</p></td></tr><tr><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">the shorter of the useful life or life of the lease</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Buildings</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">39 years</p></td></tr><tr><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Land</p></td><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">not depreciated</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Construction in progress</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">not depreciated until placed in service</p></td></tr></table> P5Y P7Y P3Y P5Y P5Y P15Y P5Y P39Y <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.8 Intangible assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Intangible assets are recorded at cost less accumulated amortization and impairment losses, if any. Intangible assets, separately identifiable according to ASC 805, acquired in a business combination are measured at fair value as of the acquisition date. Amortization periods of assets with finite lives are based on management’s estimates at the date of acquisition and are amortized over their estimated useful lives. Intangible assets that have indefinite useful lives are not subject to amortization and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Goodwill</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company measures goodwill as the fair value of the consideration transferred, including the recognized amount of any noncontrolling interest in the acquiree, less the net recognized amount of the identifiable assets and liabilities assumed, all measured as of the acquisition date. Goodwill is allocated to a specific reporting unit upon acquisition. The Company’s policy is to first perform a qualitative assessment to determine if it was more-likely-than-not that the reporting unit’s carrying value is less than the fair value, indicating the potential for goodwill impairment. The amount of goodwill impairment, if any, is determined as the excess of the carrying value over the fair value of that reporting unit. The impairment of goodwill is limited to the amount of goodwill in a reporting unit. Impairment testing is performed annually by the Company, or more frequently, if events or changes in circumstances indicate that goodwill might be impaired. Management makes estimates during impairment testing as judgment is required to determine indicators of impairment and estimates are used to determine the fair value that is used to measure impairment losses. The Company assesses the fair values of its intangible assets, and its reporting unit for goodwill testing purposes, as necessary, using an income-based approach. Under the income approach, fair value is based on the present value of estimated future cash flows.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Finite-lived intangible assets</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Intangible assets are recorded at cost unless acquired through a business combination and recorded at fair value, less accumulated amortization and impairment losses. Amortization is recorded on a straight-line basis over the following estimated useful lives, which do not exceed the contractual period, if any:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Licenses/permits</p></td><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden__WN3XDC4jEqyVi4UxajCjA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">15</span></span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Right-to-use licenses</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_uztWinqX8k2fX8CN7SAx-w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">15</span></span></p></td></tr><tr><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Host community agreements</p></td><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_9uWXLTTsL0KNieUnY398Vg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">15</span></span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade name / brand</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_o2Ba-59l_UmA57gNu6OQkw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5</span></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Such assets are tested for impairment if events or changes in circumstances indicate that they might be impaired. The estimated useful lives, residual values, and amortization methods are reviewed periodically, and any changes in estimates are accounted for prospectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3.</b>    <b style="font-weight:bold;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3.8 Intangible assets (Continued)</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(c)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Impairment of long-lived assets</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Long-lived assets such as PPE, right-of-use assets, and finite-lived intangible assets are grouped with other assets and liabilities at the lowest level for which identifiable independent cash flows are available (“asset group”). The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In order to determine if assets have been impaired, the impairment test is a two-step approach wherein the recoverability test is performed first to determine whether the long-lived asset is recoverable. The recoverability test (Step 1) compares the carrying amount of the asset to the sum of its future undiscounted cash flows using entity specific assumptions generated through the asset’s use and eventual disposition. If the carrying amount of the asset is less than the undiscounted cash flows, the asset is recoverable, and an impairment is not recorded. If the carrying amount of the asset is greater than the undiscounted cash flows, the asset is not recoverable, and an impairment loss calculation (Step 2) is required. The measurement of the impairment loss to be recognized is based on the difference between the fair value and the carrying value of the asset group. Fair value can be determined using a market approach, income approach, or cost approach. The cash flow projection and fair value represents management’s best estimate, using appropriate and customary assumptions, projections, and methodologies, at the date of evaluation. The reversal of impairment losses is prohibited.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Licenses/permits</p></td><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden__WN3XDC4jEqyVi4UxajCjA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">15</span></span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Right-to-use licenses</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_uztWinqX8k2fX8CN7SAx-w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">15</span></span></p></td></tr><tr><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Host community agreements</p></td><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_9uWXLTTsL0KNieUnY398Vg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">15</span></span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade name / brand</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_o2Ba-59l_UmA57gNu6OQkw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5</span></span></p></td></tr></table> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">3.9 Leases and sale and leaseback accounting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company applies the accounting guidance in ASC 842 – <i style="font-style:italic;">Leases</i> and assesses whether a contract is or contains a lease, at inception of a contract. When evaluating whether a lease is a finance lease or an operating lease the Company considers whether the contract conveys the right to control the use of an identified asset. Certain arrangements require significant judgement to determine if an asset is specified in the contract and if the Company directs how, and for what purpose, the asset is used during the term of the contract. Leases are recognized as a right-of-use asset (“ROU”) and corresponding liability at the commencement date based on the present value of the future minimum lease payments over the lease term. Operating leases are included in <i style="font-style:italic;">Right-of-use assets – operating, net </i>and<i style="font-style:italic;"> Lease liabilities – operating – current portion</i> and <i style="font-style:italic;">Lease liabilities – operating – non-current portion</i> on the balance sheets. For operating leases, the Company records operating lease expense. Finance leases are included in <i style="font-style:italic;">Right-of-use assets – finance, net</i> and lease liabilities are included in <i style="font-style:italic;">Lease liabilities – finance – current portion</i> and <i style="font-style:italic;">Lease liabilities – finance – non-current portion</i> on the balance sheets based on their payment dates. For finance leases, the Company records interest expense on the lease liability in addition to amortizing the ROU (generally straight-line) over the shorter of the lease term or the useful life of the right-of-use asset. The Company primarily leases space for corporate offices, retail, cultivation, and manufacturing under non-cancellable operating leases. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Lease liabilities include the net present value of fixed payments (including in-substance fixed payments), variable lease payments that are not based on an index or a rate or subject to a fair market value renewal, amounts expected to be payable by the lessee under residual value guarantees, the exercise price of a purchase option if the lessee is reasonably certain to exercise that option, and payments of penalties for terminating the lease, if the lease term reflects the lessee exercising that option. The Company allocates the consideration in the contract to each lease component on the basis of the relative standalone price of the lease component and the aggregate stand-alone price of the non-lease components.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The lease payments are discounted using the interest rate implicit in the lease or, if that rate cannot be determined, the Company’s incremental borrowing rate. The period over which the lease payments are discounted is the reasonably certain lease term, including renewal options that the Company is reasonably certain to exercise. Renewal options are included in a number of leases across the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Payments associated with short-term leases are recognized as an expense on a straight-line basis in the statements of operations. Short-term leases are leases with a lease term of 12 months or less. Variable lease payments that depend on an index or a rate or are subject to a fair market value renewal are expensed as incurred and recognized in the statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3.</b>    <b style="font-weight:bold;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">3.9 Leases and sale and leaseback accounting (Continued)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A sale and leaseback transaction involves the transfer of an asset to another entity and the leaseback of the same asset. The Company applies ASC 606 and ASC 842 when accounting for sale and leaseback transactions. Significant estimates and judgments applied include determination of the fair value of the underlying asset, transfer of control, and determination of the implicit interest rate. The Company recognizes gains or losses related to the transfer of rights of the asset to the buyer-lessor and measures the ROU asset arising from the leaseback at the retained portion of the previous carrying amount. In cases where the transaction does not qualify for sale and leaseback accounting treatment, the asset is not derecognized, and no gain or loss is recorded. The transaction is treated as a financing transaction. See Note 10 for additional information.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.10 Equity investments </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">An associate is an entity over which the Company exercises significant influence. Significant influence is the power to participate in the financial and operating policy of the investee but without control or joint control over those policies. Interests in associates are accounted for using the equity method and are initially recognized at cost. Subsequent to initial recognition, the carrying value of the Company’s interest in an associate is adjusted for the Company’s share of income or loss and distributions of the investee. The carrying value of associates is assessed for impairment at each balance sheet date. Significant influence is presumed if the Company holds between 20% and 50% of the voting rights unless evidence exists to the contrary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Joint control is the contractually agreed sharing of control of an arrangement, which exists only when decisions about the relevant activities require the unanimous consent of the parties sharing control. Investees in which the Company has joint control and rights to the net assets thereof are defined as joint ventures. Joint ventures are also accounted for under the equity method. There were no joint ventures as of December 31, 2023.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.11 Noncontrolling interests</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Equity interests owned by parties that are not shareholders of the Company in consolidated subsidiaries are considered noncontrolling interests. The share of net assets attributable to noncontrolling interests is presented as a component of equity while the share of net income or loss is recognized in the statements of operations. Changes in the Company’s ownership interest that do not result in a loss of control of these less than wholly owned subsidiaries are accounted for as equity transactions, see Note 3.19.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.12 Derivatives</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company evaluates all its agreements to determine if such instruments have derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as assets or liabilities, the derivative instrument is recorded at its fair value and is then revalued at each reporting date, with changes in the fair value reported in the Company’s financial statements. In calculating the fair value of derivative assets or liabilities, the Company uses a valuation model when Level 1 inputs are not available to estimate fair value at each reporting date (see Notes 14 and 17).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The classification of derivative instruments, including whether such instruments should be recognized as assets or liabilities or as equity, is reevaluated at the end of each reporting period. Derivative instrument assets or liabilities are classified as current or non-current based on whether net-cash settlement of the derivative instrument could be required within 12 months of the financial statement date.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.13 Earnings per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The basic loss per share is computed by dividing the net loss by the weighted average number of shares outstanding, including Equity Shares, multiple voting shares of the Company and Exchangeable Shares, as defined below, during the period. The diluted loss per share reflects the potential dilution of shares by adjusting the weighted average number of shares outstanding to assume conversion of potentially dilutive shares, such as warrants (“Warrants”), restricted stock units (“RSUs”), and vested options of the Company (“Vested Options”). The treasury stock method is used for the assumed proceeds upon the exercise of the Warrants, and Vested Options that are used to purchase Equity Shares at the average market price during the period. If the Company incurs a net loss during a reporting period, the calculation of fully diluted loss per share will not include potentially dilutive equity instruments such as Warrants, RSUs, and Vested Options, because their effect would be anti-dilutive, therefore, basic loss per share and diluted loss per share will be the same. For the years ended December 31, 2023 and 2022, the potentially dilutive financial instruments excluded from the calculation of earnings per share included nil and nil warrants, nil and nil options and 1,908 and 3,799 RSUs, totaling 1,908 and 3,799 shares of potentially dilutive securities, respectively.</p> 0 0 0 0 1908000 3799000 1908000 3799000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.14 Stock-based payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">(a) Stock-based payment transactions</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain employees (including directors and senior executives) of the Company receive a portion of their remuneration in the form of stock-based payment transactions, whereby employees render services as consideration for equity instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Stock-based payments to non-employees are measured at the fair value of goods or services received or the fair value of the equity instruments issued, whichever is more readily determinable. In situations where equity instruments are issued to non-employees and some or all of the fair value of the good or service received by the Company as consideration cannot be specifically identified, they are measured at fair value of the stock-based payment. Stock-based payment transactions are primarily for individuals whose compensation has been classified as part of general and administrative expenses in the statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The costs of equity settled transactions with employees are measured by reference to the fair value of the stock price at the date on which they are granted, using an appropriate valuation model. The value of the transaction is expensed straight line through the vesting period. Market and performance based RSUs are fair valued through Monte-Carlo simulations and are expensed over the indicative service period. Performance RSUs are recorded once the condition is probable to occur, refer to Note 15.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The costs of equity settled transactions are recognized, together with a corresponding increase in equity, over the period in which the performance and/or service conditions are fulfilled, ending on the date on which the relevant employees become fully entitled to the award (the “vesting date”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The cumulative expense is recognized for equity settled transactions at each reporting date until the vesting date as the Company’s policy is to account for forfeitures as they occur. The income or loss for a period represents the movement in cumulative expense recognized as of the beginning and end of that period and the corresponding amount is represented in additional paid-in capital. At the end of each reporting period, the Company assesses if any forfeitures occurred and recognizes the impact in the statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">No expense is recognized for awards that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vesting for expense purposes irrespective of whether or not the market condition is satisfied provided that all other performance and/or service conditions are satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Where the terms of an equity settled award are modified, the minimum expense recognized is the grant date fair value of the unmodified award, provided the original terms of the award are met. An additional expense is recognized for any modification which increases the total fair value of the stock-based payment arrangement or is otherwise beneficial to the employee as measured at the date of modification. When an award is cancelled by the Company or the counterparty, any remaining element of the fair value of the award is derecognized at that time through the statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">3.</b>    <b style="font-weight:bold;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 9pt 0pt;">3.14 Stock-based payments (Continued)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 9pt 0pt;"><i style="font-style:italic;font-weight:normal;">(a) Stock-based payment transactions (Continued)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">RSUs are issued on the vesting dates, sometimes net of the applicable statutory tax withholding to be paid by the Company on behalf of the employees. In those instances, lower shares are issued than the number of RSUs vested and the tax withholding is recorded as a reduction to paid-in capital. The terms of the stock-based payment awards allow an entity with a statutory income tax withholding obligation to withhold shares with a fair value up to the maximum statutory tax in the employee’s applicable jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;"><i style="font-style:italic;">(b) Warrants</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">The Company determines the accounting classification for equity-linked financial instruments such as warrants, as either liability or equity, by assessing ASC 480 – <i style="font-style:italic;">Distinguishing Liabilities from Equity</i> and ASC 815 – <i style="font-style:italic;">Derivatives and Hedging</i>. Under ASC 480, warrants are considered a liability if the warrants are mandatorily redeemable, obligate the Company to settle the warrants or the underlying shares by paying cash or other assets, or warrants that must or may require settlement by issuing a variable number of shares. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">Under ASC 815, warrants are considered liabilities if contracts require or may require the issuer to net settle the contract for cash. Such derivatives are recorded as a liability at fair value until they are settled or expire, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. After all relevant assessments, the Company concludes whether the warrants are classified as liability or equity. Liability classified warrants require fair value accounting at issuance and subsequent to initial issuance with all changes in fair value after the issuance date recorded in the statements of operations. Equity classified warrants only require fair value accounting at issuance with no changes recognized subsequent to the issuance date unless the warrants are modified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">The Company determined that all of its outstanding warrants are freestanding instruments which do not meet the characteristics of a liability and therefore are classified as equity.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">3.15 Loss contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">Loss contingencies are recognized when the Company has a present obligation that has arisen as a result of a past event and it is probable that a future outflow of resources will be required to settle the obligation, provided that a reliable estimate can be made of the amount of the obligation. Loss contingencies are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the time value of money and the risk specific to the obligation.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 9pt 0pt;">3.16 Financial instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 9pt 0pt;">(a) Recognition and initial measurement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">Financial assets and financial liabilities, including derivatives, are recognized when the Company becomes a party to the contractual provisions of a financial instrument or non-financial derivative contract. All financial instruments are measured at fair value on initial recognition. Transaction costs that are directly attributable to the acquisition or issuance of financial assets and financial liabilities, other than financial assets and financial liabilities classified as FVTPL (as defined below), are added to or deducted from the fair value on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities classified as FVTPL are recognized immediately in the statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 9pt 0pt;">(b) Classification and subsequent measurement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">The Company classifies financial assets, at the time of initial recognition, according to the Company’s business model for managing the financial assets and the contractual terms of the cash flows. Financial assets are classified in the following measurement categories:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">amortized cost (“AC”).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fair value through profit or loss (“FVTPL”); and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fair value through other comprehensive income (“FVTOCI”).</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">3.</b>    <b style="font-weight:bold;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">3.16 Financial instruments (Continued)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">(b) Classification and subsequent measurement (Continued)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Financial assets are subsequently measured at amortized cost if both of the following conditions are met and they are not designated as FVTPL: a) the financial asset is held within a business model whose objective is to hold financial assets to collect contractual cash flows; and b) the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. These assets are subsequently measured at amortized cost using the effective interest rate method, less any impairment, with gains and losses recognized in the statements of operations in the period that the asset is derecognized or impaired. All financial assets not classified at amortized cost as described above are measured at FVTPL or FVTOCI depending on the business model and cash flow characteristics. The Company has no financial assets measured at FVTOCI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Financial liabilities are subsequently measured at amortized cost using the effective interest rate method with gains and losses recognized in the statements of operations in the period that the liability is derecognized, except for financial liabilities classified as FVTPL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Refer to Note 17 for the classification and fair value (“FV”) level of financial instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">(c) Derecognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company derecognizes financial assets only when the contractual rights to cash flows from the financial assets expire, or when it transfers the financial assets and substantially all of the associated risks and rewards of ownership to another entity. Gains and losses on derecognition are recognized in the statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company derecognizes financial liabilities only when its obligations under the financial liabilities are discharged, cancelled, or expired. Generally, the difference between the carrying amount of the financial liability derecognized and the consideration paid and payable, including any non-cash assets transferred or liabilities assumed, is recognized in the statements of operations.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.17 Foreign currency transactions and translations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Transactions denominated in foreign currency are translated into the functional currency of the entity using the exchange rates prevailing at the dates of the transactions or valuation where items are re-measured. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies, such as remeasurement of local currency into functional currency, are recognized in the statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The results and financial position of an entity that has a functional currency different from the presentation currency is translated into the presentation currency as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">assets and liabilities for each balance sheet presented are translated at the closing rate at the date of the balance sheet; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">income and expenses for each statement of operations are translated at average exchange rates (unless this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated as the rate on the dates of the transactions).</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Effect of translation differences, such as translation of foreign currency into reporting currency, are accumulated and presented as a component of equity under accumulated other comprehensive income.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">3.18 Taxation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities based on the differences between the financial statements and tax basis of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates and laws on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that the Company would be able to realize our deferred tax assets in the future more than their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company is subject to ongoing tax exposures, examinations, and assessments in various jurisdictions. Accordingly, the Company may incur additional tax expense based upon the outcomes of such matters. FASB ASC 740, Income Taxes, (“ASC 740”) prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties related to unrecognized tax benefits as of December 31, 2023 and 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals, or material deviation from its position within twelve months of the reporting date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">As the Company operates in the cannabis industry, the Company is subject to the limits of Section 280E of the United States Internal Revenue Code, as amended (“Section 280E”), under which the Company is generally only allowed to deduct expenses directly related to the cost of goods sold.</p> 0 0 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">3.19 Variable Interest Entities (“VIE”)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">Under certain provisions of ASC Topic 810 – <i style="font-style:italic;">Consolidations</i> (“ASC 810”), the Company determines whether we are the primary beneficiary of a VIE. We assess whether we have the power to direct matters that most significantly impact the activities of the VIE and the obligation to absorb losses or the right to receive the benefits from the VIE that could potentially be significant to the VIE.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">A VIE is a legal entity that does not have sufficient equity at risk to finance its activities without additional subordinated financial support or is structured that such equity investors lack the ability to make significant decisions relating to the entity’s operations through voting rights or do not substantively participate in the gains or losses of the entity. The primary beneficiary has both the power to direct the activities of the VIE that most significantly impact the entity’s economic performance and the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. We assess all variable interests in the entity and use our judgment when determining whether a particular entity is a VIE and if we are the primary beneficiary. Other qualitative factors that are considered include decision-making responsibilities, the VIE capital structure, risk and rewards sharing, contractual agreements with the VIE, voting rights, and level of involvement of other parties. We assess the primary beneficiary determination for a VIE on an ongoing basis if there are any reconsideration events related to a VIE. See Note 6.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Where we determine we are the primary beneficiary of a VIE, we consolidate the accounts of that VIE, under the guidance of ASC 805. The equity owned by other shareholders of the VIE is shown as noncontrolling interests in the accompanying financial statements.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 8pt 0pt;">3.20 Significant accounting judgments and estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">The application of the Company’s accounting policies requires management to use estimates and judgments that can have a significant effect on the revenues, expenses, assets and liabilities recognized, and disclosures made in the financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">Management’s best estimates concerning the future are based on the facts and circumstances available at the time estimates are made. Management uses historical experience, general economic conditions, and assumptions regarding probable future outcomes as the basis for determining estimates. Estimates and their underlying assumptions are reviewed periodically, and the effects of any changes are recognized at that time. Actual results could differ from the estimates used.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Business combinations</i></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">The following areas require management’s critical estimates and judgments:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">A business combination is a transaction or event in which an acquirer obtains control of one or more businesses and is accounted for using the acquisition method. The total consideration paid for the acquisition is the aggregate of the fair values of assets acquired, liabilities assumed, and equity instruments issued in exchange for control of the acquiree at the acquisition date. The acquisition date is the date when the Company obtains control of the acquiree.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">Contingent consideration is measured at its acquisition date fair value and is included as part of the consideration transferred in a business combination, subject to the applicable terms and conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">Contingent consideration that is classified as equity is not remeasured at subsequent reporting dates and its subsequent settlement is accounted for within equity. Contingent consideration that is classified as a liability is remeasured at subsequent reporting dates in accordance with the criteria and guidance provided under ASC 805.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">Based on the facts and circumstances that existed at the acquisition date, management will perform a valuation analysis to allocate the consideration transferred based on the fair values of the identifiable assets acquired and liabilities assumed on the acquisition date. Management is required to finalize its allocation on the earlier of the date that information becomes known, but no later than one year from the acquisition date. Until such time, these values might be provisionally reported and are subject to change. During the measurement period, adjustments to provisional purchase price allocations are recognized if new information is obtained about the facts and circumstances that existed as of the acquisition date that, if known, would have resulted in the recognition of those assets and liabilities as of that date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">In determining the fair value of all identifiable assets acquired and liabilities assumed, the most significant estimates generally relate to contingent consideration and intangible assets. Management exercises judgment in estimating the probability and timing of when contingent consideration targets are expected to be achieved, which is used as the basis for estimating fair value. Identified intangible assets are recognized at fair value using appropriate valuation techniques which are generally based on a forecast of the total expected future net cash flows of the acquiree. Valuations are highly dependent on the inputs used and assumptions made by management regarding the future performance of these assets and any changes in the discount rate applied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">Judgment is applied in determining whether a transaction is a business combination or an asset acquisition by considering the nature of the assets acquired and the processes applied to those assets, or if the integrated set of assets and activities is capable of being conducted and managed for the purpose of providing a return to investors or other owners.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Inventory</i></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">In calculating the value of inventory, management is required to make a number of estimates, including estimating the stage of growth of the cannabis up to the point of harvest, expected yields for the cannabis plants, harvesting costs, net realizable value, selling costs, average or expected selling prices, fair value of inventory acquired in a business combination and impairment factors. In calculating final inventory values, management compares the inventory costs to estimated net realizable value as well as investigates slow moving inventory, if applicable. The estimates are judgmental in nature and are made at a point in time, using available information, such as expected business plans and expected market conditions. Periodic reviews are performed on the inventory balance with the changes in inventory reserves reflected in cost of goods sold.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">3.</b>    <b style="font-weight:bold;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">3.20 Significant accounting judgments and estimates (Continued)</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(c)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Estimated useful lives and depreciation of PPE</i></td></tr></table><div style="margin-top:11pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 11pt 0pt;">Depreciation of PPE is dependent upon estimates of useful lives, which are determined through the exercise of judgments. The assessment of any impairment of these assets is dependent upon estimates of recoverable amounts that take into account factors such as economic and market conditions and the useful lives of assets.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(d)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Valuation, estimated life and impairment of intangible assets</i></td></tr></table><div style="margin-top:11pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 11pt 0pt;">Management uses significant judgment in estimating the useful lives and impairment. Impairment tests rely on judgments and estimates related to growth rates, discount rates, and estimated margins. </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(e)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Goodwill impairment</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Goodwill is tested for impairment annually on December 31<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">st</sup> of each fiscal year and whenever events or changes in circumstances indicate that the carrying amount of goodwill may have been impaired. In order to determine that the value of goodwill may have been impaired, the Company may perform a qualitative assessment to determine if it was more-likely-than-not that the reporting unit’s carrying value is less than the fair value, indicating the potential for goodwill impairment. Several factors, including historical results, business plans, forecasts, and market data are used to determine the fair value of the reporting unit. Changes in the conditions for these judgments and estimates can significantly affect the assessed value of goodwill. </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(f)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Leases</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Each lease is evaluated to determine if the Company would exercise any of the renewal options offered. Several material factors are considered in determining if the renewal options would be exercised, such as length of the renewal, renewal rate, and ability to transfer locations. When measuring lease liabilities, the Company used discounted lease payments using a weighted-average rate in the range of 7.8% to 15.5% per annum. The weighted-average rate is based on the Company’s incremental borrowing rate, which relies on judgments and estimates.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(g)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Provisions and contingent liabilities</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">When the Company is probable to incur an outflow of resources to settle an obligation and the amount can be reasonably estimated, a contingent liability is recorded. The contingent liability is recorded at management’s best estimates of the expenditure required to settle the obligation at period end, discounted to the present value, if material.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(h)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Financial instruments</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To determine the fair value of financial instruments, the Company develops assumptions and selects certain methods to perform the fair value calculations. Various methods considered include but are not limited to: (a) assigning the value attributed to the transaction at the time of origination; (b) re-measuring the instrument if it requires concurrent fair value measurement; and (c) valuing the instrument at the issuance value less any amortized costs. As judgment is a factor in determining the value and selecting a method, as well as the inherent uncertainty in estimating the fair value, the valuation estimates may be different.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Application of the option pricing model requires estimates in expected dividend yields, expected volatility in the underlying assets, and the expected life of the financial instruments. These estimates may ultimately be different from amounts subsequently realized, resulting in an overstatement or understatement of net loss.</p> 0.078 0.155 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3.21 Liquidity and management plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As reflected in the consolidated financial statements, the Company had negative working capital of $7,258 as of December 31, 2023 and has incurred net losses from continuing operations for the years ended December 31, 2023 and 2022. The Company’s approach to managing its liquidity risk is to seek to ensure that it will have sufficient liquidity to meet its liabilities as they come due. The Company’s short-term liquidity requirements consist primarily of funds necessary to maintain operations, repay borrowings and other general business needs. The Company plans to use existing funds, as well as funds from the future sale of products, to fund short-term working capital needs for at least the next 12 months from the issuance of the consolidated financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the Company continues to take actions designed to improve the Company’s operations and cash position, including but not limited to: (i) targeting continued growth of sales from our consolidated operations; (ii) continued cost-savings and efficiency optimization efforts; (iii) utilizing the future proceeds from an employee retention credit up to $12,354 of which $5,238 was included in current receivables; (iv) addressing our debt maturity profile, in this regard, subsequent to December 31, 2023 the Company completed the debt restructuring transaction contemplated in its October 31, 2023 Support Agreement (the “Support Agreement”) with the holders of approximately 99% (collectively, the “Majority Noteholders”) of the aggregate outstanding principal amount of the Company’s 12.5% senior notes due December 2024 (the “Senior Notes”), which resulted in the effective extension via exchange of the maturity date for an additional two years, see Note 19, and the crystallization of the previously-announced deferral of certain current debts payable; (v) managing the timing and amount of certain expenses as well as capital expenditures; and (vi) seeking to take advantage of future potential financing (equity and/or debt) opportunities, including additional gross cash proceeds of $40,000 received February 2024 related to the issuance of new debt securities (refer to Note 19 for additional information). The debt extension related to the Support Agreement and the deferral of certain current debts payable are each classified as a non-current liability on the balance sheet as of December 31, 2023. While the contemplated debt restructuring transactions have been completed, management cannot provide any assurances that the Company will continue to be successful in accomplishing its business plans; if it is not, the Company may be forced to take other steps, including among others decelerating its growth or curtailing certain of its operations pending obtaining additional capital.</p> -7258000 12354000 5238000 0.99 0.125 40000000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3.22 Discontinued operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Strategic changes in the Company’s operations can be considered a discontinued operation if both the operations and cash flows of the discontinued business have been (or will be) eliminated from the ongoing operations of the Company and the Company will not have any significant continuing involvement in the operations of the discontinued business after the disposal transaction. Under ASC Subtopic 205-20, “Presentation of Financial Statements – Discontinued Operations” (“ASC Subtopic 205-20”), a component of an entity that is classified as discontinued operations is presented separately from continuing operations in the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows for all periods presented. All assets and liabilities related to such discontinued operations are classified as held for sale and presented separately in the Consolidated Balance Sheets for all periods prior to the disposal by sale. Accordingly, the presentation of prior period balances may not agree to previously issued financial statements. See Note 4 for additional information regarding the results of operations and major classes of assets and liabilities of discontinued operations.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3.23 Change in accounting standards</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:none;">The Company is treated as an “emerging growth company” as defined under the Jumpstart Our Business Start-ups Act of 2012, as amended (the “JOBS Act”). Under the JOBS Act, emerging growth companies may delay adopting new or revised accounting standards until the standards apply to private companies, however, emerging growth companies are not precluded from early adopting new accounting standards that allow so.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3.23 Change in accounting standards (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:none;">Recently Issued and Adopted Accounting Standards</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:none;">In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-13 Topic 326 – Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments, which was subsequently revised by ASU 2018-19, ASU 2019-04, ASU 2019-05, ASU 2019-11, ASU 2020-02, ASU 2020-03, and ASU 2022-02 (“ASU 2016-13”), which introduces a new model for assessing impairment on most financial assets. Entities will be required to use a forward-looking expected loss model, which will replace the current incurred loss model, which will result in earlier recognition of allowance for losses. ASU 2016-13 was effective for the Company’s fiscal year beginning after December 15, 2022, and interim periods therein. </span><span style="text-decoration-color:#000000;text-decoration-line:none;">For accounts receivable only, the Company applies the simplified approach as permitted by ASU 2016-13. The simplified approach to the recognition of expected losses does not require the Company to track the changes in credit risk; rather, the Company recognizes a loss allowance based on lifetime expected credit losses at each reporting date from the date of the trade receivable. Expected credit losses are measured as the difference in the present value of the contractual cash flows that are due to the Company under the contract, and the cash flows that the Company expects to receive.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company assesses all information available, including past due status, credit ratings, the existence of third-party insurance, and forward-looking macro-economic factors in the measurement of the expected credit losses associated with its assets carried at amortized cost. The Company measures expected credit loss by considering the risk of default over the contract period and incorporates forward-looking information into its measurement. The adoption of ASU 2016-13 did not have a material impact on the Company’s financial statements and there was no cumulative effect at the adoption of the standard.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In June 2022, the FASB issued ASU No. 2022-03 Topic 820 – Fair Value Measurement – Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”), (1) to clarify the guidance in Topic 820, Fair Value Measurement, when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, (2) to amend a related illustrative example, and (3) to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. ASU 2022-03 is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years, early adoption is permitted. The Company is currently evaluating the impact the adoption of ASU 2022-03 may have on the Company’s financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In September 2022, the FASB issued ASU No. 2022-04 Topic 405 – Liabilities – Supplier Finance Programs (“ASU 2022-04”), which is intended to enhance transparency with supplier finance programs. ASU 2022-04 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Adoption is applied on a retrospective approach. The adoption of this ASU did not have a material impact on the Company’s financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 27, 2023, the FASB issued ASU No. 2023-01 Topic 842 – Leases – Common Control Arrangements (“ASU 2023-01”), in response to private company stakeholder concerns about applying Topic 842 to related party arrangements between entities under common control. ASU 2023-01 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, early adoption is permitted. The Company is currently evaluating the impact the adoption of ASU 2023-01 may have on the Company’s financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3.23 Change in accounting standards (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:none;">Recently Issued and Adopted Accounting Standards (Continued)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In November 2023, the FASB issued ASU No. 2023-07 Topic 280 – Segment Reporting (“ASU 2023-07”) to improve the disclosures about a public entity’s reportable segments and address requests from investors for additional, more detailed information about a reportable segment’s expenses. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, early adoption is permitted. The Company is currently evaluating the impact the adoption of ASU 2023-07 may have on the Company’s financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On December 14, 2023, the FASB issued ASU No. 2023-09 Topic 740 – Income Taxes (“ASU 2023-09”) to enhance the transparency and decision usefulness of income tax disclosures. The amendments in this Update address investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, including interim periods within those fiscal years, early adoption is permitted. The Company is currently evaluating the impact the adoption of ASU 2023-09 may have on the Company’s financial statements.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4.    DISCONTINUED OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 27, 2023, the Company closed the sale of Blue Camo, LLC (“Blue Camo”) which comprised the Company’s Arizona business and included two licensed entities operating three Oasis-branded dispensaries in the greater Phoenix area, a cultivation and processing facility in Chandler, a cultivation facility in Phoenix, and the Company’s majority interest in Willcox OC, LLC, a joint venture developing an outdoor cultivation facility. Total consideration consisted of $20,000 in cash before working capital adjustments and the assumption of lease obligations eliminating approximately $16,734 in long-term lease liabilities. In a separate agreement, all debt outstanding and potential earn-out contingent consideration, related to the 2021 acquisition of Blue Camo, was eliminated, reducing the Company’s long-term debt by $22,505, along with accrued interest thereon of approximately $1,165 and potential earn-out contingent consideration to $nil. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company accounted for this sale as a disposal under ASC Subtopic 360-10, “Impairment or Disposal of Long-Lived Assets”. The Company has reclassified the operations of Arizona as discontinued operations for all periods presented prior to the sale as the disposal represents a strategic shift that will have a major effect on the Company’s operations and financial results. The Company determined the business to be held for sale as the criteria established under ASC 205-20-45-1E had been satisfied due to the sale occurring during the first quarter of 2023. As of December 31, 2022, the Company determined under ASC 855-10-55, the Arizona business did not meet the criteria as held for sale, as such, no reclassification was made on the balance sheet and statement of operations in the Company’s Annual Report on the Form 40-F for the year ended December 31, 2022. In accordance with ASC 205-20-50-1(a) the Company has retrospectively reflected the reclassification of assets and liabilities of these entities as held for sale on the balance sheet as of December 31, 2022 and the operations as discontinued operations on the statement of operations for the period January 1, 2022 through December 31, 2022 and excluded from the accompanying notes. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">4.</b>    <b style="font-weight:bold;">DISCONTINUED OPERATIONS (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">As of December 31, 2022, the major classes of assets and liabilities held for sale in Arizona included the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><i style="font-style:italic;">    </i></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Current assets held-for-sale</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Inventory and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,910</p></td></tr><tr><td style="vertical-align:bottom;width:77.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property, plant, and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,239</p></td></tr><tr><td style="vertical-align:bottom;width:77.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Intangible assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 194,018</p></td></tr><tr><td style="vertical-align:bottom;width:77.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Right-of-use assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,568</p></td></tr><tr><td style="vertical-align:bottom;width:77.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred tax asset, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,890</p></td></tr><tr><td style="vertical-align:bottom;width:77.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total assets held-for-sale</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 260,625</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Current liabilities held-for-sale</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:77.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Trade payables and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,629</p></td></tr><tr><td style="vertical-align:bottom;width:77.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,097</p></td></tr><tr><td style="vertical-align:bottom;width:77.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Debt payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,505</p></td></tr><tr><td style="vertical-align:bottom;width:77.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued interest payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 610</p></td></tr><tr><td style="vertical-align:bottom;width:77.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total liabilities held-for-sale</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 43,841</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">The following table details the components comprising net loss from our discontinued operations:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Revenues from discontinued operations, net of discounts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,183</p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9,074</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,705</p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Gross profit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,478</p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating expenses from discontinued operations:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Selling, general, and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,115</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,153</p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,675</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,055</p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total operating expenses from discontinued operations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,790</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 51,208</p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Loss from operations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,604)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (35,730)</p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other expense</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest Expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (580)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,250)</p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Income taxes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Current tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (575)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (628)</p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred tax benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 870</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total income taxes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (628)</p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Loss from discontinued operations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loss from discontinued operations, net of taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,889)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (38,608)</p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loss on disposal of discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (182,464)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> —</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Loss from discontinued operations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (186,353)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (38,608)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The loss on disposal of discontinued operations of $182,464 was derived from the gross proceeds of $49,336, made up of $20,000 of cash consideration and a $5,666 working capital adjustment and the elimination of $23,670 of debt outstanding from the sale of Arizona, less the carrying value of Arizona of approximately $231,800. As of December 31, 2023, the Company finalized the settlement of the working capital adjustment, receiving $1,583 in cash proceeds and $4,083 in consideration other than cash.</p> 2 3 20000000 16734000 22505000 1165000 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><i style="font-style:italic;">    </i></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Current assets held-for-sale</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Inventory and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,910</p></td></tr><tr><td style="vertical-align:bottom;width:77.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property, plant, and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,239</p></td></tr><tr><td style="vertical-align:bottom;width:77.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Intangible assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 194,018</p></td></tr><tr><td style="vertical-align:bottom;width:77.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Right-of-use assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,568</p></td></tr><tr><td style="vertical-align:bottom;width:77.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred tax asset, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,890</p></td></tr><tr><td style="vertical-align:bottom;width:77.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total assets held-for-sale</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 260,625</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Current liabilities held-for-sale</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:77.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Trade payables and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,629</p></td></tr><tr><td style="vertical-align:bottom;width:77.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,097</p></td></tr><tr><td style="vertical-align:bottom;width:77.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Debt payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,505</p></td></tr><tr><td style="vertical-align:bottom;width:77.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued interest payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 610</p></td></tr><tr><td style="vertical-align:bottom;width:77.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total liabilities held-for-sale</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 43,841</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Revenues from discontinued operations, net of discounts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,183</p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9,074</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,705</p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Gross profit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,478</p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating expenses from discontinued operations:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Selling, general, and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,115</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,153</p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,675</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,055</p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total operating expenses from discontinued operations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,790</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 51,208</p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Loss from operations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,604)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (35,730)</p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other expense</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest Expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (580)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,250)</p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Income taxes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Current tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (575)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (628)</p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred tax benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 870</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total income taxes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (628)</p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Loss from discontinued operations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loss from discontinued operations, net of taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,889)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (38,608)</p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loss on disposal of discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (182,464)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> —</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Loss from discontinued operations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (186,353)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (38,608)</b></p></td></tr></table> 20910000 24239000 194018000 17568000 3890000 260625000 2629000 18097000 22505000 610000 43841000 10260000 44183000 9074000 28705000 1186000 15478000 2115000 40153000 2675000 11055000 4790000 51208000 -3604000 -35730000 580000 2250000 -575000 -628000 870000 -295000 628000 -3889000 -38608000 -182464000 -186353000 -38608000 -182464000 49336000 20000000 5666000 23670000 231800000 1583000 4083000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">5.</b><span style="font-size:10.5pt;">    </span><b style="font-weight:bold;">BUSINESS COMBINATIONS AND ASSET ACQUISITIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Transactions accounted for as business combinations have been accounted for under the acquisition method in accordance with ASC 805, with the results included in the Company’s results from operations from the date of acquisition. The fair value of considerations transferred have been allocated to the assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In determining the fair value of all identifiable assets, liabilities and contingent liabilities acquired, the most significant estimates relate to contingent consideration and intangible assets. Management exercised judgement in estimating the probability and timing of when earnouts are expected to be achieved which is used as the basis for estimating fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the intangible assets identified, depending on the type of intangible asset and the complexity of determining its fair value, an independent valuation expert or management may develop the fair value, using appropriate valuation techniques, which are generally based on a forecast of the total expected future net cash flows and take into consideration other significant assumptions such as the expected use, the infancy of the cannabis industry and industry comparatives, federal and state regulations, market uncertainty and the estimated lives of any long-lived facilities and assets that the intangibles may relate to.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cannabis licenses are the primary intangible asset acquired in business combinations as they provide the Company the ability to operate in each market. However, some cannabis licenses are subject to renewal and therefore there is some risk of non-renewal for several reasons, including operational, regulatory, legal, or economic factors. To appropriately consider the risk of non-renewal, the Company applies probability weighting to the expected future net cash flows in calculating the fair value of these intangible assets. The key assumptions used in these cash flow projections include discount rates and terminal growth rates. Of the key assumptions used, the impact of the estimated fair value of the intangible assets has the greatest sensitivity to the estimated discount rate used in the valuation. The terminal growth rate represents the rate at which these businesses will continue to grow into perpetuity. Other significant assumptions include revenue, gross profit, operating expenses and anticipated capital expenditures which are based upon the acquiree’s historical operations along with management projections. The evaluations are linked closely to the assumptions made by management regarding the future performance of these assets and any changes in the discount rate applied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Each of the acquisitions are subject to specific terms relating to the satisfaction of the purchase price by the Company and its wholly owned subsidiaries, and incorporates payments in cash, shares, and debt as well as certain contingent considerations. The shares issued as consideration are either Equity Shares or non-voting exchangeable shares of the Company’s subsidiaries (“Exchangeable Shares”) that are exchangeable on a one-for-one basis into an equal number of Equity Shares of the Company. The Company treats the Exchangeable Shares as options with a value equal to a share of Equity Shares, which represents the holder’s claim on the equity of the Company. The Company has presented these Exchangeable Shares as a part of shareholders’ equity within these financial statements due to the fact that (i) they are economically equivalent to the Company’s publicly traded Equity Shares and (ii) the holders of the Exchangeable Shares are subject to restrictions on transfer under United States securities laws but may dispose of the Exchangeable Shares by exchanging them for Equity Shares of the Company which can then be sold through the CSE. Changes in these assumptions would affect the presentation of the Exchangeable Shares from shareholders’ equity to noncontrolling interests; however, there would be no impact on loss per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The goodwill recognized on each acquisition is attributable mainly to the expected future growth potential and expanded customer base arising as a result of the completion of the respective acquisition. Goodwill has been allocated to the reporting units corresponding to the states of the acquired businesses. None of the goodwill is expected to be deductible for income tax purposes. For further analysis on goodwill relating to business combinations, see Note 9.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">5.</b><span style="font-size:10.5pt;">    </span><b style="font-weight:bold;">BUSINESS COMBINATIONS AND ASSET ACQUISITIONS (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2023 Fourth Quarter Acquisition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Asset acquisition</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">On November 2, 2023, the Company completed its acquisitions in Land of Lincoln Dispensary LLC (“Land of Lincoln”) through a membership interest purchase agreement. As part of the purchase accounting for this acquisition, the Company recorded intangible assets of </span><span style="font-size:10pt;">$200</span><span style="font-size:10pt;">, which was associated with </span><span style="font-size:10pt;">two</span><span style="font-size:10pt;"> conditional adult use dispensary licenses that allow for the retail sales of cannabis. The amortization period for the licenses was determined to be </span><span style="font-size:10pt;">15 years</span><span style="font-size:10pt;">, which reasonably reflects the useful lives of the assets.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Land of Lincoln acquisition did not meet the definition of a business according to ASC 805 and as such, it was recorded as an asset acquisition. Purchase consideration for the acquisition was $200, paid in cash, all of which was allocated to intangible assets - licenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2022 Second Quarter Acquisition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Herbal Remedies Business Combination</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Business Combination</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On May 25, 2022, the Company completed its acquisition of Herbal Remedies Dispensaries, LLC (“Herbal Remedies”) through a membership interest purchase agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The fair value of identifiable assets acquired, and liabilities assumed as of the acquisition date are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Herbal Remedies</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ASSETS ACQUIRED</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 637</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,480</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 256</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets - licenses/permits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,700</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property, plant, and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 122</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Right-of-use assets - operating</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 700</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total assets acquired at fair value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 18,895</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">LIABILITIES ASSUMED</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 215</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 68</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities - operating</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 700</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total liabilities assumed at fair value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 983</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,180</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Consideration transferred</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 19,092</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">As part of the purchase accounting for the above acquisition, the Company recorded intangible assets of $15,700, all of which were associated with licenses that allow for the retail sales of cannabis. The amortization period for licenses was determined to be 15 years, which reasonably reflects the useful lives of the assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Herbal Remedies is an operator of two medical and adult-use licensed retail dispensaries in Quincy, Illinois. This acquisition expands the Company’s operational footprint with the addition of the state of Illinois.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">5.</b>    <b style="font-weight:bold;">BUSINESS COMBINATIONS AND ASSET ACQUISITIONS (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Purchase consideration was comprised of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">  </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">i</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 3,002</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Debt Payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">ii</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 14,220</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Shares Issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">iii</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 353</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,870</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">  </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 353</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 19,092</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:10pt 0pt 12pt 0pt;">Pursuant to the terms of the definitive agreement with Herbal Remedies, Ayr satisfied the purchase price of $19,092 for Herbal Remedies through the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">i.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$3,002</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of the Herbal Remedies purchase price in the form of cash consideration and settlement of the final working capital which is deemed immaterial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">ii.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$14,220</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of the Herbal Remedies purchase price in the form of a promissory note payable; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">iii.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1,870</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of the Herbal Remedies purchase price in the form of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">353</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Exchangeable Shares, these shares have contractual restrictions on their ability to be sold for </span><span style="-sec-ix-hidden:Hidden_IX5avs0W8EavQlS_5Fqvuw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">six</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">twelve months</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> (the “Herbal Remedies Lock-Up Provision”). The fair value of the shares was determined by the share price on the CSE at the date of acquisition and a </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">16.55%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> discount rate attributed to the contractual restrictions.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2022 First Quarter Acquisition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cultivauna Business Combination</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Business Combination</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February 15, 2022, the Company completed its acquisition of Cultivauna, LLC (“Cultivauna”) through a membership interest purchase agreement. Cultivauna has a production license in the state of Massachusetts and sells cannabis infused branded seltzers and water-soluble tinctures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">5.</b>    <b style="font-weight:bold;">BUSINESS COMBINATIONS AND ASSET ACQUISITIONS (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The fair value of identifiable assets acquired and liabilities assumed as of the acquisition date are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cultivauna</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ASSETS ACQUIRED</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,251</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounts receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 471</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,206</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intangible assets - trade name/brand</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,400</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intangible assets - host community agreements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,100</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property, plant, and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,202</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use assets - operating</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 315</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><b style="font-weight:bold;">Total assets acquired at fair value </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 10,983</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES ASSUMED </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Trade payables </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 305</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liabilities - operating</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 315</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><b style="font-weight:bold;">Total liabilities assumed at fair value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 643</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,281</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><b style="font-weight:bold;">Consideration transferred</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 21,621</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As part of the purchase accounting for the above acquisition, the Company recorded intangible assets of $5,500, which were associated with a trade name/brand and host community agreement that allow for the processing, production, and retail sales of cannabis. The amortization period for the trade name/brand and host community agreement was determined to be 5 and 15 years, respectively, which reasonably reflects the useful lives of the assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Purchase consideration was comprised of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">  </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">i</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 11,027</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares Issued </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">ii</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 329</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 4,482</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contingent Consideration </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">iii</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 6,112</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 329</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 21,621</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">5.</b>    <b style="font-weight:bold;">BUSINESS COMBINATIONS AND ASSET ACQUISITIONS (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Purchase consideration was comprised of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of the definitive agreement with Cultivauna Ayr satisfied the purchase price of $21,621 for Cultivauna through the following:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">i.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">$11,027 of the Cultivauna purchase price in the form of cash consideration and settlement of the final working capital which is deemed immaterial;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">ii.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">$4,482 of the Cultivauna purchase price in the form of 329 Exchangeable Shares, these shares have contractual restrictions on their ability to be sold for <span style="-sec-ix-hidden:Hidden_qGpumYwvtE6evCxbfl198Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">six</span></span> to twelve months (the “Cultivauna Lock-Up Provision”). The fair value of the shares was determined by the share price on the CSE at the date of acquisition and a 14.85% discount rate attributed to the contractual restrictions; and</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">iii.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">A portion of the Cultivauna purchase price is derived from an earn-out provision through December 31, 2023 based on annualized net revenues generated during the measurement period, consisting of Exchangeable Shares, valued through a Monte-Carlo simulation, which may entitle the sellers to earn additional consideration if certain milestones are achieved.</p></td></tr></table> 1 0 200000 2 P15Y 200000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Herbal Remedies</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ASSETS ACQUIRED</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 637</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,480</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 256</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets - licenses/permits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,700</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property, plant, and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 122</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Right-of-use assets - operating</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 700</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total assets acquired at fair value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 18,895</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">LIABILITIES ASSUMED</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 215</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 68</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities - operating</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 700</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total liabilities assumed at fair value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 983</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,180</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Consideration transferred</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 19,092</b></p></td></tr></table> 637000 1480000 256000 15700000 122000 700000 18895000 215000 68000 700000 983000 1180000 19092000 15700000 P15Y 2 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">  </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">i</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 3,002</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Debt Payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">ii</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 14,220</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Shares Issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">iii</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 353</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,870</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">  </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 353</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 19,092</b></p></td></tr></table> 3002000 14220000 353000 1870000 353000 19092000 19092000 3002000 14220000 1870000 353000 P12M 0.1655 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cultivauna</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ASSETS ACQUIRED</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,251</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounts receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 471</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,206</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intangible assets - trade name/brand</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,400</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intangible assets - host community agreements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,100</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property, plant, and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,202</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use assets - operating</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 315</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><b style="font-weight:bold;">Total assets acquired at fair value </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 10,983</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES ASSUMED </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Trade payables </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 305</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liabilities - operating</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 315</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><b style="font-weight:bold;">Total liabilities assumed at fair value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 643</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,281</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><b style="font-weight:bold;">Consideration transferred</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 21,621</b></p></td></tr></table> 1251000 471000 1206000 38000 3400000 2100000 2202000 315000 10983000 23000 305000 315000 643000 11281000 21621000 5500000 P5Y P15Y <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">  </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">i</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 11,027</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares Issued </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">ii</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 329</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 4,482</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contingent Consideration </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">iii</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 6,112</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 329</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 21,621</b></p></td></tr></table> 11027000 329000 4482000 6112000 329000 21621000 21621000 11027000 4482000 329000 P12M 0.1485 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6.    VARIABLE INTEREST ENTITIES (“VIE”)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">In February 2022, the Company had the ability to direct the activities of </span><span style="font-size:11pt;">two</span><span style="font-size:11pt;"> entities, Tahoe Hydroponics Company, LLC (“Tahoe Hydro”) and NV Green, Inc. (“NVG” and, together with Tahoe Hydro, “TH”/ “NVG”), through a management services and equity purchase agreement, thereby classifying the entities as VIEs, until certain conditions are met, at which time the Company is required to evaluate business combination accounting. The assets of TH/NVG can only be used to settle its liabilities and under the applicable agreements, TH/NVG retains ultimate legal responsibilities for its operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In May 2023, the Company finalized the acquisition of Tahoe Hydro and assumed 100% of the membership interest. Based on the changes in circumstances, the Company re-evaluated the status of Tahoe Hydro as a variable interest entity, concluding that the Company had acquired a controlling interest in Tahoe Hydro. Purchase consideration for the acquisition included $1,382 in cash, net of transaction expenses, promissory note of $1,580, the conversion of a convertible note of $2,800, and $115 in the form of 233 Exchangeable Shares. These shares have contractual restrictions on their ability to be sold for <span style="-sec-ix-hidden:Hidden_QvKH6W0leEKX7Ecood5y7A;"><span style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">six</span></span> to twelve months. The fair value of the shares was determined by the share price on the CSE at the date of acquisition and a 19.45% discount rate attributed to the contractual restrictions. NVG remains a VIE until certain conditions are met, at which time the Company is required to evaluate business combination accounting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 30, 2021, the Company completed its acquisition of Greenlight Management, LLC (“Greenlight Management”) and Greenlight Holdings, LLC (“Greenlight Holdings”) through a membership purchase agreement. Greenlight Management operates on a 58,000 square foot facility in Parma, Ohio under a management agreement with Parma Wellness Center, LLC (“Parma”) a recipient of a Tier 1 Cultivator Provisional License in the medical cannabis market in Ohio. The Company determined that it possesses the power to direct activities of Parma through the management agreement, thereby classifying the entity as a VIE. During the year ended December 31, 2023 the Company purchased the minority interest in Parma for $25. Based on the changes in circumstances, the Company re-evaluated the variable interest entity, concluding that it did not own a controlling interest, thereby classifying the entity as VIE.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During 2023, the Company entered into an option and support service agreement with Daily Releaf, LLC, Heaven Wellness, LLC and Twice the Wellness, LLC, (collectively “Ohio Dispensaries”), each is licensed to operate a medical marijuana dispensary in Ohio. The option agreement provides the Company with the future ability to acquire 100% of the equity interests in dispensaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">6.    VARIABLE INTEREST ENTITIES (“VIE”) (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following tables present the summarized financial information about the Company’s consolidated VIEs which are included in the balance sheets as of December 31, 2023 and 2022 and statements of operations for years ended December 31, 2023 and 2022. All these entities were determined to be VIEs as the Company possesses the power to direct activities and obligation to absorb losses through management services agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:34.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:24.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:34.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:24.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Ohio</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NVG</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Parma</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dispensaries</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TH/NVG</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Parma</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (351)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,616</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,257)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,008</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,248</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,751</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,999</p></td></tr><tr><td style="vertical-align:bottom;width:38.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,077</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,210</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,582</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,634</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,216</p></td></tr><tr><td style="vertical-align:bottom;width:38.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 726</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 23,826</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 4,184</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 28,736</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 11,830</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 25,385</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 37,215</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 604</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,962</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,647</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,213</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,092</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,125</p></td></tr><tr><td style="vertical-align:bottom;width:38.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 383</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,280</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,369</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,032</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 898</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,952</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,850</p></td></tr><tr><td style="vertical-align:bottom;width:38.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 987</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 20,242</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 5,016</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 26,245</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,931</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 16,044</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 17,975</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Noncontrolling interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 796</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,158)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,764)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,126)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,528</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,528)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,000</p></td></tr><tr><td style="vertical-align:bottom;width:38.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equity (deficit) attributable to Ayr Wellness Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,057)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,742</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 932</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,617</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,371</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,869</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,240</p></td></tr><tr><td style="vertical-align:bottom;width:38.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total liabilities and equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 726</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 23,826</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 4,184</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 28,736</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 11,830</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 25,385</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 37,215</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:32.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:24.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:32.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:24.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Ohio</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TH/NVG</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Parma</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dispensaries</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TH/NVG</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Parma</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenues, net of discounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,170</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 462</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,632</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,851</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,851</p></td></tr><tr><td style="vertical-align:bottom;width:40.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss attributable to noncontrolling interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (673)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,630)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,764)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,067)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,491)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,528)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,019)</p></td></tr><tr><td style="vertical-align:bottom;width:40.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss attributable to Ayr Wellness Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,275)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,275)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:40.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (673)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (5,905)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,764)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (8,342)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (4,491)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (5,528)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (10,019)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Ohio</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TH/NVG</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Parma</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dispensaries</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Noncontrolling interest at January 1, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> —</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total purchase consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,868</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,868</p></td></tr><tr><td style="vertical-align:bottom;width:59.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Working capital adjustment presented as consideration payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,849)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,849)</p></td></tr><tr><td style="vertical-align:bottom;width:59.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,491)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,528)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,019)</p></td></tr><tr><td style="vertical-align:bottom;width:59.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><b style="font-weight:bold;">Noncontrolling interest at December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 7,528</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (5,528)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,000</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Acquisition of Tahoe Hydro</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,059)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (6,059)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (673)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,630)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,764)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,067)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><b style="font-weight:bold;">Noncontrolling interest at December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 796</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (10,158)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (1,764)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (11,126)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> 2 1 1382000 1580000 2800000 115000 233000 P12M 0.1945 58000 25000 1 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:34.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:24.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:34.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:24.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Ohio</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NVG</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Parma</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dispensaries</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TH/NVG</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Parma</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (351)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,616</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,257)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,008</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,248</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,751</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,999</p></td></tr><tr><td style="vertical-align:bottom;width:38.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,077</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,210</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,582</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,634</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,216</p></td></tr><tr><td style="vertical-align:bottom;width:38.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 726</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 23,826</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 4,184</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 28,736</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 11,830</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 25,385</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 37,215</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 604</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,962</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,647</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,213</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,092</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,125</p></td></tr><tr><td style="vertical-align:bottom;width:38.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 383</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,280</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,369</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,032</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 898</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,952</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,850</p></td></tr><tr><td style="vertical-align:bottom;width:38.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 987</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 20,242</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 5,016</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 26,245</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,931</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 16,044</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 17,975</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Noncontrolling interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 796</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,158)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,764)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,126)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,528</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,528)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,000</p></td></tr><tr><td style="vertical-align:bottom;width:38.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equity (deficit) attributable to Ayr Wellness Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,057)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,742</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 932</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,617</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,371</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,869</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,240</p></td></tr><tr><td style="vertical-align:bottom;width:38.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total liabilities and equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 726</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 23,826</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 4,184</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 28,736</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 11,830</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 25,385</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 37,215</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:32.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:24.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:32.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:24.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Ohio</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TH/NVG</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Parma</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dispensaries</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TH/NVG</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Parma</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenues, net of discounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,170</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 462</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,632</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,851</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,851</p></td></tr><tr><td style="vertical-align:bottom;width:40.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss attributable to noncontrolling interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (673)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,630)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,764)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,067)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,491)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,528)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,019)</p></td></tr><tr><td style="vertical-align:bottom;width:40.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss attributable to Ayr Wellness Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,275)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,275)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:40.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (673)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (5,905)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,764)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (8,342)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (4,491)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (5,528)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (10,019)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Ohio</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TH/NVG</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Parma</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dispensaries</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Noncontrolling interest at January 1, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> —</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total purchase consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,868</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,868</p></td></tr><tr><td style="vertical-align:bottom;width:59.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Working capital adjustment presented as consideration payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,849)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,849)</p></td></tr><tr><td style="vertical-align:bottom;width:59.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,491)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,528)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,019)</p></td></tr><tr><td style="vertical-align:bottom;width:59.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><b style="font-weight:bold;">Noncontrolling interest at December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 7,528</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (5,528)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,000</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Acquisition of Tahoe Hydro</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,059)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (6,059)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (673)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,630)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,764)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,067)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><b style="font-weight:bold;">Noncontrolling interest at December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 796</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (10,158)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (1,764)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (11,126)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> -351000 10616000 -2257000 8008000 5248000 10751000 15999000 1077000 13210000 6441000 20728000 6582000 14634000 21216000 726000 23826000 4184000 28736000 11830000 25385000 37215000 604000 18962000 1647000 21213000 1033000 14092000 15125000 383000 1280000 3369000 5032000 898000 1952000 2850000 987000 20242000 5016000 26245000 1931000 16044000 17975000 796000 -10158000 -1764000 -11126000 7528000 -5528000 2000000 -1057000 13742000 932000 13617000 2371000 14869000 17240000 726000 23826000 4184000 28736000 11830000 25385000 37215000 3170000 462000 3632000 1851000 1851000 -673000 -4630000 -1764000 -7067000 -4491000 -5528000 -10019000 -1275000 -1275000 -673000 -5905000 -1764000 -8342000 -4491000 -5528000 -10019000 16868000 16868000 4849000 4849000 -4491000 -5528000 -10019000 7528000 -5528000 2000000 6059000 6059000 -673000 -4630000 -1764000 -7067000 796000 -10158000 -1764000 -11126000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">7.    INVENTORY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s inventory includes the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Materials, supplies, and packaging</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,505</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,770</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Work in process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69,632</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65,807</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,226</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,233</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total inventory</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 106,363</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 99,810</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The amount of inventory included in cost of goods sold during the years ended December 31, 2023 and 2022, was $218,587 and $205,809, respectively. The Company reviews inventory on hand for estimated obsolescence or unmarketable items, as compared to future demand requirements and the shelf life of the various products. Based on the review, the Company records inventory write-downs, when necessary, when costs exceed expected net realizable value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the years ended December 31, 2023 and 2022, $nil and $6,217 respectively, of expenses relating to the incremental costs to acquire cannabis inventory in business combinations are recognized in cost of goods sold on the statements of operations. This relates to the one-time adjustment of cannabis inventory from acquiree historical cost to fair value as part of the purchase price allocation.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Materials, supplies, and packaging</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,505</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,770</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Work in process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69,632</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65,807</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,226</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,233</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total inventory</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 106,363</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 99,810</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 7505000 9770000 69632000 65807000 29226000 24233000 106363000 99810000 218587000 205809000 6217000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8.    PROPERTY, PLANT, AND EQUIPMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of December 31, 2023 and 2022, property, plant, and equipment, net consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Furniture and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 53,070</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Auto and trucks</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,393</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,626</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Buildings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 94,914</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 91,233</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 173,043</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 154,774</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Land</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,877</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,879</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,581</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 348,591</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 324,163</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,483</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total property, plant and equipment, net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 310,615</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 302,680</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Capitalized interest for the years ended December 31, 2023 and 2022, totaled $9,981 and $14,490, respectively. Depreciation and amortization expense for the years ended December 31, 2023 and 2022, totaled $25,226 and $14,257, respectively, of which $15,846 and $9,858 respectively, is included in cost of goods sold.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, the Company concluded that the carrying amount of certain long-lived assets exceeded the fair value and recorded an impairment loss on PPE assets of $4,858.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Furniture and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 53,070</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Auto and trucks</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,393</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,626</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Buildings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 94,914</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 91,233</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 173,043</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 154,774</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Land</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,877</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,879</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,581</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 348,591</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 324,163</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,483</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total property, plant and equipment, net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 310,615</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 302,680</b></p></td></tr></table> 52793000 53070000 1393000 1626000 94914000 91233000 173043000 154774000 13877000 13879000 12571000 9581000 348591000 324163000 37976000 21483000 310615000 302680000 9981000 14490000 25226000 14257000 15846000 9858000 4858000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 8pt 0pt;">9.    GOODWILL AND INTANGIBLE ASSETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 8pt 0pt;">Goodwill</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of December 31, 2023 and 2022, the Company’s goodwill is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of January 1, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 199,329</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Acquired through business combinations and initial consolidation of VIEs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,729</p></td></tr><tr><td style="vertical-align:bottom;width:85.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Impairment of goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (117,950)</p></td></tr><tr><td style="vertical-align:bottom;width:85.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 94,108</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(no activity)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:85.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 94,108</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 8pt 0pt;">Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2023 an entity co-owned by the Company was awarded a provisional Disproportionately Impacted Area cultivator license in Connecticut. The Company recorded an intangible asset of $3,000 in connection with the cash payment for the cost of the provisional license. During the year ended December 31, 2023 the Company acquired a standalone delivery license in Connecticut and recorded an intangible asset of $200 in connection with the cash payment for the cost of the license. The operations in Connecticut are not currently active, as such, no amortization expense has been recorded as of the year ended December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Amortization expense is recorded within cost of goods sold and total operating expenses. The amount in cost of goods sold for the years ended December 31, 2023 and 2022 was $16,825 and $15,907, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table represents intangible assets, net of accumulated amortization:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><i style="font-style:italic;">Amortization period (# of years)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Licenses/permits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 641,036</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 693,714</p></td></tr><tr><td style="vertical-align:bottom;width:49.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Right-to-use licenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,407</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,717</p></td></tr><tr><td style="vertical-align:bottom;width:49.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Host community agreements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,954</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,494</p></td></tr><tr><td style="vertical-align:bottom;width:49.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade name / brand</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,591</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,784</p></td></tr><tr><td style="vertical-align:bottom;width:49.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 687,988</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 744,709</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following table presents the future amortization expense as of December 31, 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:78.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization Expense</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 58,123</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57,308</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57,308</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57,308</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57,308</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2029 and beyond</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 397,433</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 684,788</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">9.    GOODWILL AND INTANGIBLE ASSETS (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 8pt 0pt;">Intangible Assets (Continued)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Impairment of goodwill</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As part of the annual impairment test as of December 31, 2023 and 2022 a one-step quantitative impairment test was performed over all its reporting units, which includes goodwill acquired through various acquisitions and the initial consolidation of VIEs. The following significant assumptions were applied in the determination of the fair value of each reporting unit using a discounted cash flow model:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Cash flows: estimated cash flows were projected based on actual operating results from internal sources, as well as industry and market trends. The forecasts were extended to a total of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five years</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> (with a terminal value thereafter);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Terminal value growth rate: The terminal growth rate of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> was based on historical and projected consumer price inflation, historical and projected economic indicators and projected industry growth;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Post-tax discount rate: the post-tax discount rate of</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">20%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">18%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, respectively, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">is reflective of the weighted average cost of capital (“WACC”). The WACC was estimated based on the risk-free rate, equity risk premium, beta premium, and after-tax cost of debt based on corporate bond yields; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Tax rate: the tax rates used in determining future cash flows were those substantively enacted at the respective valuation date.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company compared the fair value of each reporting unit to its carrying value to determine whether the carrying value exceeded fair value. Due to changes in market expectations as a result of increased competition and price compression at the reporting units, the Company recorded impairment of goodwill of $117,950 for the year ended December 31, 2022 reducing the carrying value of goodwill acquired across all reporting units. The remaining goodwill of $94,108 relates to the Company’s Florida reporting unit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Long-lived assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company evaluates the recoverability of other long-lived assets, including property, plant and equipment, and certain identifiable intangible assets, whenever events or changes in circumstances indicate that the carrying value of an asset or asset group may not be recoverable. The Company performs impairment tests of indefinite-lived intangible assets on an annual basis or more frequently in certain circumstances. Factors which could trigger an impairment review include significant underperformance relative to historical or projected future operating results, significant changes in the manner of use of the assets or the strategy for the overall business, a significant decrease in the market value of the assets or significant negative industry or economic trends. When the Company determines that the carrying value of long-lived assets may not be recoverable based upon the existence of one or more of the indicators, the assets are assessed for impairment based on the estimated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the carrying value of an asset exceeds its estimated future undiscounted cash flows, an impairment loss is recorded for the excess of the asset’s carrying value over its fair value. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">No such impairment charges were recorded for finite-lived intangible assets during the years ended December 31, 2023 or 2022.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of January 1, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 199,329</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Acquired through business combinations and initial consolidation of VIEs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,729</p></td></tr><tr><td style="vertical-align:bottom;width:85.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Impairment of goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (117,950)</p></td></tr><tr><td style="vertical-align:bottom;width:85.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 94,108</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(no activity)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:85.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 94,108</b></p></td></tr></table> 199329000 12729000 117950000 94108000 94108000 3000000 200000 0 16825000 15907000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><i style="font-style:italic;">Amortization period (# of years)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Licenses/permits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 641,036</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 693,714</p></td></tr><tr><td style="vertical-align:bottom;width:49.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Right-to-use licenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,407</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,717</p></td></tr><tr><td style="vertical-align:bottom;width:49.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Host community agreements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,954</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,494</p></td></tr><tr><td style="vertical-align:bottom;width:49.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade name / brand</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,591</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,784</p></td></tr><tr><td style="vertical-align:bottom;width:49.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 687,988</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 744,709</b></p></td></tr></table> P15Y 641036000 693714000 P15Y 16407000 17717000 P15Y 26954000 29494000 P5Y 3591000 3784000 687988000 744709000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:78.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization Expense</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 58,123</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57,308</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57,308</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57,308</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57,308</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2029 and beyond</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 397,433</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 684,788</b></p></td></tr></table> 58123000 57308000 57308000 57308000 57308000 397433000 684788000 P5Y 0.03 0.20 0.18 117950000 94108000 94108000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10.    RIGHT-OF-USE ASSETS AND LEASE LIABILITIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Information related to operating and finance leases is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:47.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Incremental borrowing rate (weighted average)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10.37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average remaining lease term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">yrs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">yrs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.04</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">yrs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">yrs</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The maturities of the contractual lease liabilities as of December 31, 2023 are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Finance Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,457</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,098</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,555</p></td></tr><tr><td style="vertical-align:bottom;width:65.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,112</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,540</p></td></tr><tr><td style="vertical-align:bottom;width:65.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,381</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,412</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,793</p></td></tr><tr><td style="vertical-align:bottom;width:65.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,340</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,465</p></td></tr><tr><td style="vertical-align:bottom;width:65.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,507</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,501</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,008</p></td></tr><tr><td style="vertical-align:bottom;width:65.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2029 and beyond</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 198,164</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 204,592</p></td></tr><tr><td style="vertical-align:bottom;width:65.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total undiscounted lease liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 338,746</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 35,207</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 373,953</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Impact of discounting</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (203,231)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,411)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (210,642)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total present value of minimum lease payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 135,515</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 27,796</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 163,311</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In June 2022, the Company completed a sale and lease back transaction to sell two cultivation and processing facilities for a purchase price of $28,107, excluding transaction costs. The Company leased back the facilities and continues to operate and manage them under a long-term agreement. The transaction qualified for sale-leaseback treatment under ASC 842. As a result of the sale, the Company divested of $22,206 of buildings and improvements, and $3,728 of land. The Company recognized a gain on sale related to the transaction of $2,173 which was recorded within gain on sale of assets on the statements of operations. The lease was recorded as an operating lease and resulted in a lease liability of $25,331 and an ROU asset of $25,339, which was recorded net of a $750 work allowance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In June 2022, the Company closed on a real estate financing transaction resulting in $27,599 of cash proceeds for the sale and simultaneous leaseback of a cultivation facility. The transaction includes a construction financing allowance of up to $14,187, which will increase the base rent at the time the construction financing is drawn down. The initial term of the agreement is fifteen years, with two five-year options to renew. The initial payments are equal to 10% of the sum of the purchase price and increases when a draw is made on the construction finance allowance, payable monthly. In addition, a 3% increase in payments will be applied annually after the first year. As of December 31, 2023 and 2022, this represents a balance of $38,205 and $36,181, respectively, as part of construction finance liabilities on the balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The transaction was classified as a finance lease and control was never transferred to the buyer-lessor; accordingly the transaction did not qualify for sale-leaseback treatment. Therefore, the Company is deemed to own this real estate and will continue to depreciate the assets and reflect the properties on the Company’s balance sheet. The Company recorded a financing obligation for the consideration received from the buyer-lessor, and future cash lease payments will be allocated between interest expense and reduction to the financing obligation, as applicable. As the transactions did not qualify for sale-leaseback treatment, under ASC 842, Leases, no gain or loss was recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10.    RIGHT-OF-USE ASSETS AND LEASE LIABILITIES (Continued)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Payments related to leases during the years ended December 31, 2023 and 2022, are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Lease liabilities - operating</b></p></td><td style="vertical-align:bottom;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Lease liabilities - operating expense, COGS</p></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,783</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,604</p></td></tr><tr><td style="vertical-align:bottom;width:73.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Lease liabilities - operating expense, G&amp;A</p></td><td style="vertical-align:bottom;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,366</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,943</p></td></tr><tr><td style="vertical-align:bottom;width:73.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Lease liabilities - finance</b></p></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amortization of right-of-use assets, COGS</p></td><td style="vertical-align:bottom;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,913</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,584</p></td></tr><tr><td style="vertical-align:bottom;width:73.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amortization of right-of-use assets, G&amp;A</p></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 165</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 187</p></td></tr><tr><td style="vertical-align:bottom;width:73.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Interest on lease liabilities - finance, COGS</p></td><td style="vertical-align:bottom;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,422</p></td></tr><tr><td style="vertical-align:bottom;width:73.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Interest on lease liabilities - finance, G&amp;A</p></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 58</p></td></tr><tr><td style="vertical-align:bottom;width:73.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Total lease expense</b></p></td><td style="vertical-align:bottom;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 35,281</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 27,798</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of December 31, 2023, the Company concluded that the carrying amount of certain long-lived assets exceeded the fair value and recorded an impairment loss on ROU operating assets of $1,462.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:47.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Incremental borrowing rate (weighted average)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10.37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average remaining lease term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">yrs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">yrs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.04</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">yrs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">yrs</p></td></tr></table> 0.1183 0.1037 0.1198 0.0968 P12Y1M13D P4Y9M3D P13Y14D P4Y10M24D <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Finance Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,457</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,098</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,555</p></td></tr><tr><td style="vertical-align:bottom;width:65.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,112</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,540</p></td></tr><tr><td style="vertical-align:bottom;width:65.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,381</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,412</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,793</p></td></tr><tr><td style="vertical-align:bottom;width:65.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,340</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,465</p></td></tr><tr><td style="vertical-align:bottom;width:65.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,507</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,501</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,008</p></td></tr><tr><td style="vertical-align:bottom;width:65.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2029 and beyond</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 198,164</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 204,592</p></td></tr><tr><td style="vertical-align:bottom;width:65.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total undiscounted lease liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 338,746</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 35,207</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 373,953</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Impact of discounting</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (203,231)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,411)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (210,642)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total present value of minimum lease payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 135,515</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 27,796</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 163,311</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Finance Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,457</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,098</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,555</p></td></tr><tr><td style="vertical-align:bottom;width:65.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,112</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,540</p></td></tr><tr><td style="vertical-align:bottom;width:65.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,381</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,412</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,793</p></td></tr><tr><td style="vertical-align:bottom;width:65.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,340</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,465</p></td></tr><tr><td style="vertical-align:bottom;width:65.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,507</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,501</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,008</p></td></tr><tr><td style="vertical-align:bottom;width:65.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2029 and beyond</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 198,164</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 204,592</p></td></tr><tr><td style="vertical-align:bottom;width:65.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total undiscounted lease liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 338,746</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 35,207</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 373,953</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Impact of discounting</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (203,231)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,411)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (210,642)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total present value of minimum lease payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 135,515</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 27,796</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 163,311</b></p></td></tr></table> 29457000 12098000 41555000 29112000 6428000 35540000 28381000 4412000 32793000 27125000 3340000 30465000 26507000 2501000 29008000 198164000 6428000 204592000 338746000 35207000 373953000 203231000 7411000 210642000 135515000 27796000 163311000 2 28107000 22206000 3728000 2173000 25331000 25339000 750000 27599000 14187000 P15Y 2 P5Y 0.10 0.03 38205000 36181000 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Lease liabilities - operating</b></p></td><td style="vertical-align:bottom;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Lease liabilities - operating expense, COGS</p></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,783</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,604</p></td></tr><tr><td style="vertical-align:bottom;width:73.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Lease liabilities - operating expense, G&amp;A</p></td><td style="vertical-align:bottom;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,366</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,943</p></td></tr><tr><td style="vertical-align:bottom;width:73.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Lease liabilities - finance</b></p></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amortization of right-of-use assets, COGS</p></td><td style="vertical-align:bottom;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,913</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,584</p></td></tr><tr><td style="vertical-align:bottom;width:73.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amortization of right-of-use assets, G&amp;A</p></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 165</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 187</p></td></tr><tr><td style="vertical-align:bottom;width:73.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Interest on lease liabilities - finance, COGS</p></td><td style="vertical-align:bottom;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,422</p></td></tr><tr><td style="vertical-align:bottom;width:73.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Interest on lease liabilities - finance, G&amp;A</p></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 58</p></td></tr><tr><td style="vertical-align:bottom;width:73.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Total lease expense</b></p></td><td style="vertical-align:bottom;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 35,281</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 27,798</b></p></td></tr></table> 8783000 6604000 16366000 13943000 6913000 4584000 165000 187000 3017000 2422000 37000 58000 35281000 27798000 1462000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">11.    RELATED PARTY TRANSACTIONS AND BALANCES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Related parties are defined as management and members of the Company and/or members of their immediate family and/or other companies and/or entities in which a board member or senior officer is a principal owner or senior executive. Other than disclosed elsewhere in the financial statements, related party transactions and balances are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Mercer Park, L.P., a company owned by an executive of Ayr, entered into a management agreement with the Company dated May 24, 2019. The management fee is paid monthly and varies based on actual costs incurred by the related entity when providing the Company administrative support, management services, office space, and utilities. In addition, the management fees paid to the related party also reimbursed them for other corporate or centralized expenses based on actual cost, including but not limited to legal and professional fees, software, and insurance. The agreement is a month-to-month arrangement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">As of December 31, 2023 and 2022, $nil and $698 was included in prepaid expenses, a majority of which is for a letter of credit for an operating lease. Lease fees included in the operating lease during the years ended December 31, 2023 and 2022, were $858 and $861. During the years ended December 31, 2023 and 2022, included in general and administrative expenses are management fees of $nil and $12.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">During the years ended December 31, 2023 and 2022, the Company incurred fees from a company partially owned by a board member of AYR. The total incurred fees were $54 and $54 of office expenses, $24 and $392 of development fees, $1,083 and $920 of rental fees, and $83 and $165 of interest expense, respectively, for the years ended December 31, 2023 and 2022. Additionally in 2022, the board member was issued 50 Equity Shares, valued at $707 on the grant date, related to a consulting agreement with the Company for services rendered.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Refer below to the debts payable and senior secured notes and share capital notes for additional information regarding the debts payable to related parties and non-cash stock-based compensation plan, respectively, for the years ended December 31, 2023 and 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 698000 858000 861000 12000 54000 54000 24000 392000 1083000 920000 83000 165000 50 707000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12.    DEBTS PAYABLE AND SENIOR SECURED NOTES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Senior Secured Notes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 12, 2021, the Company completed a private placement offering of approximately $133,250 aggregate principal amount of secured promissory notes at a premium price, resulting in approximately $147,000 of proceeds due December 2024, with a resulting yield-to-maturity of 9.8%. The notes were considered additional notes under the indenture governing the Company’s existing notes which were entered into on December 10, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023 and 2022, the Company’s Senior Secured Notes consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:87.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Senior secured notes</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of January 1, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 245,408</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Debt issuance costs amortized</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,292</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior secured notes premium amortized</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,018)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 244,682</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Debt issuance costs amortized</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,291</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior secured notes premium amortized</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,018)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total senior secured notes classified as non-current payable as of December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 243,955</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total accrued interest payable related to senior secured notes classified as non-current payable as of December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> —</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Debts Payable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023 and 2022, debt payable other than Senior Secured Notes consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Debts payable</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of January 1, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 133,858</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Discounted as of December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 951</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Incurred through earn-out provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,934</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Debt Issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 68,000</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Construction financing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,303</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: repayment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,924)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: discounted to fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (598)</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 235,524</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Discounted as of December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 598</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,000)</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Debt issuance costs amortized</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Debt issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 66,245</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Construction financing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,024</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: extinguishment related to sale of Arizona business</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22,505)</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: repayment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (52,029)</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total debts payable, undiscounted as of December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 228,907</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: discounted to fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (199)</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total debts payable as of December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 228,708</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total accrued interest payable related to debts payable as of December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 7,513</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">12.</b>    <b style="font-weight:bold;">DEBTS PAYABLE AND SENIOR SECURED NOTES (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 9pt 0pt;">Debts Payable (Continued)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">The details of debts payable, including construction financing liabilities, were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Related party debt</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Non-related party debt</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total debt</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total debts payable, undiscounted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 733</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 229,123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 229,856</p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 733</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,419</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,152</p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: debt issuance costs - current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 99</p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total non-current debt, undiscounted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 206,605</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 206,605</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: discount to fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 199</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 199</p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: debt issuance costs - non-current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 850</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 850</p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total non-current debt</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 205,556</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 205,556</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">The following table presents the future debt obligations other than Senior Secured Notes as of December 31, 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Future debt obligations</b><span style="font-style:italic;font-weight:bold;"> (per year)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,175</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,673</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 64,256</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,527</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,939</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2029 and beyond</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 101,286</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total debt obligations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 229,856</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">As part of the business combinations and asset acquisitions, the Company issued and assumed notes with related and non-related parties. The related party notes are considered part of the purchase price to the former shareholders of the acquired businesses. As a result of the combinations and acquisitions, several of these individual shareholders are now considered related parties of the Company across various roles including directors and officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">On March 1, 2022, pursuant to the PA Natural Agreement, the Company issued non-related party promissory notes in the amount of $14,934 for earnout consideration. The notes are secured by all the assets and a pledge of the Company’s membership interests in PA Natural. The notes mature three years from the date of the agreement with an 8.0% annual interest rate payable quarterly. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">On March 17, 2022, the Company entered into a loan agreement with a community bank for total proceeds of $26,200, net of financing costs of $287, with a 4.625% annual interest rate payable monthly. The loan is secured with a first mortgage lien on certain real property in Massachusetts and matures five years from the date of the agreement, with an option to extend for an additional five years. On March 24, 2023, the Company amended the loan agreement and received additional total proceeds of $10,000, net of financing costs of $100, with an 8% annual interest rate payable monthly for the incremental proceeds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">On May 16, 2022, the Company entered into a loan agreement with a community bank for total proceeds of $25,800, with an annual interest rate of Prime Rate plus 1.5%, floating, with a 5.0% floor. The loan was secured with a first mortgage lien on certain real property and matures two years from the date of the agreement. On July 7, 2023, the Company entered into a loan agreement to refinance and upsize the existing mortgage which was due to mature in May 2024. The loan agreement included total proceeds of $40,000, with an interest rate of 5-year Federal Home Loan Bank Rate plus 4%, which implies a current rate of 8.27% with interest-only payments for the first 18 months. The note extends the maturity of the existing mortgage to 10 years. Proceeds from the loan were used to pay down the Company’s existing mortgage of $25,219.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">Pursuant to the agreement to acquire Herbal Remedies, the Company issued a non-related party promissory note in the amount of $14,220 to the former members of Herbal Remedies that is secured by all the assets of Herbal Remedies. The note matures five years from May 25, 2022 with an annual interest rate of 8% with quarterly straight-line amortization and interest payments over the life of the loan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">12.    DEBTS PAYABLE AND SENIOR SECURED NOTES (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Debts Payable (Continued)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the agreement to acquire Tahoe Hydro, the Company issued a non-related party promissory note in the amount of $1,580 to the former member of Tahoe Hydro that is secured by all the assets of and a pledge of membership interests in Tahoe Hydro. The note matures four years from the closing date of April 7, 2023, with an annual interest rate of 8% with quarterly straight-line amortization and interest payments over the life of the loan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 11, 2023, the Company reached an agreement to amend the terms of contingent consideration under the membership interest purchase agreements of GSD NJ LLC (“GSD”) and Sira Naturals, Inc. (“Sira”). The amendment for GSD settles the contingent consideration with total proceeds of $38,860 , consisting of $10,000 in cash, promissory notes in an aggregate principal amount of $14,000, $10,925 in deferred cash, and $4,647 of Equity Shares. The $10,094, net of payments made of $831, in deferred cash is classified within accrued expenses on the balance sheet as of December 31, 2023. The deferred cash balance was paid in full subsequent to December 31, 2023. The $14,000 promissory notes are due December 2026 with monthly interest-only payments of 13.5% until May 2024 (with 1% monthly amortization thereafter). The number of Equity Shares was calculated based on a market price equal to $0.79 which represents 3,797 Equity Shares. The amendment for Sira represents a <span style="-sec-ix-hidden:Hidden_GTTaPL0LVkeRzuF3nrkwqw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span>-year deferral of the $27,500 of proceeds payable from the original May 2024 payment date, with an annual interest rate of 6.0% and 10% annual amortization payments. Refer to Note 14 for further details on the fair value loss recognized on the settlement of the contingent consideration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In May 2023, the Company executed contingent agreements, securing a two-year deferral on principal or amortization payments of certain of its debt obligations, which includes aggregate principal amount of approximately $69,000 of debt obligations, including contingent agreements with holders of approximately $60,500 aggregate principal amount of vendor take-back promissory notes. The effectiveness of the maturity and amortization deferrals was contingent on an extension of the Company’s Senior Secured Notes to December 10, 2026, or a later date (or an exchange of the Senior Secured Notes for a new series of notes with a maturity date of December 10, 2026 or a later date). The effectiveness of the maturity and amortization deferrals is contingent on the closing of the Senior Secured Note extension transaction, or in some cases the execution of an agreement by a requisite threshold of Senior Noteholders to extend the maturity date of the Senior Secured Notes by at least two years. As of December 31, 2023, the Company and its subsidiaries had approximately $116,063 of indebtedness in respect of the vendor take-back promissory notes, of which approximately $77,110 were subject to subordination agreements in favor of the Senior Secured Notes. On October 31, 2023, the Company entered into a Support Agreement with the Majority Noteholders of the Senior Secured Notes to extend the maturity date by two years. The Company finalized the amendments for the debt, generally contingent on the closing of the transaction contemplated in the Support Agreement. The modification for these loans did not meet the requirement of a debt extinguishment under ASC 470-50 – Debt Modifications and Exchanges and no gain or loss was recognized as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October 31, 2023, the Company entered into an agreement with LivFree Wellness, LLC (“LivFree”) to amend certain terms of the promissory note dated May 24, 2019 (the “LivFree Note”) executed in connection with the Company’s acquisition of LivFree. The amendments to the LivFree Note provided, among other things, for a principal payment of $3,000, was paid upon closing of the debt restructuring transactions subsequent to December 31, 2023, and a deferral of the maturity of the remaining $17,000 of principal and $5,530 of accrued payment-in-kind interest for a period of two years to May 24, 2026. In addition, upon closing of the debt restructuring transactions, the interest on the LivFree Note converted from payment-in-kind to monthly cash interest payments and the interest rate increases from 6.0% to 10.0%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">12.    DEBTS PAYABLE AND SENIOR SECURED NOTES (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Debts Payable (Continued)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In accordance with ASC 340-10-S99-1, SAB Topic 5.A, “Expenses of Offering”, the Company capitalized debt transaction fees paid to third parties for the extension of the Senior Secured Notes of $9,951 as prepaid expenses in the balance sheet as of December 31, 2023. The final accounting for the transaction is not yet complete due to the inherent complexity and short period of time between the closing date and the filing period. Therefore, the accounting is preliminary and subject to adjustment on completion of the process and analysis of the transaction at the time that it closes, and further changes may still be required, see Note 19 for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the sale of Arizona, on March 27, 2023, the outstanding principal balance of $22,505 and accrued interest of $1,165, payable to the original owners of the Arizona business was eliminated. Refer to Note 4 for further details on the sale of Arizona.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Interest expense associated with related party debt payable for the years ended December 31, 2023 and 2022 was $83 and $1,507, respectively.</p> 133250000 147000000 0.098 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:87.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Senior secured notes</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of January 1, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 245,408</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Debt issuance costs amortized</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,292</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior secured notes premium amortized</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,018)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 244,682</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Debt issuance costs amortized</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,291</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior secured notes premium amortized</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,018)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total senior secured notes classified as non-current payable as of December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 243,955</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total accrued interest payable related to senior secured notes classified as non-current payable as of December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> —</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Debts payable</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of January 1, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 133,858</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Discounted as of December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 951</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Incurred through earn-out provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,934</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Debt Issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 68,000</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Construction financing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,303</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: repayment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,924)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: discounted to fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (598)</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 235,524</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Discounted as of December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 598</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,000)</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Debt issuance costs amortized</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Debt issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 66,245</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Construction financing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,024</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: extinguishment related to sale of Arizona business</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22,505)</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: repayment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (52,029)</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total debts payable, undiscounted as of December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 228,907</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: discounted to fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (199)</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total debts payable as of December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 228,708</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total accrued interest payable related to debts payable as of December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 7,513</b></p></td></tr></table> 245408000 2292000 3018000 244682000 2291000 3018000 243955000 133858000 -951000 14934000 68000000 36303000 17924000 -598000 235524000 -598000 1000000 50000 66245000 2024000 22505000 52029000 228907000 199000 228708000 7513000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Related party debt</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Non-related party debt</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total debt</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total debts payable, undiscounted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 733</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 229,123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 229,856</p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 733</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,419</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,152</p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: debt issuance costs - current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 99</p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total non-current debt, undiscounted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 206,605</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 206,605</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: discount to fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 199</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 199</p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: debt issuance costs - non-current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 850</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 850</p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total non-current debt</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 205,556</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 205,556</b></p></td></tr></table> 733000 229123000 229856000 733000 22419000 23152000 99000 99000 206605000 206605000 199000 199000 850000 850000 205556000 205556000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Future debt obligations</b><span style="font-style:italic;font-weight:bold;"> (per year)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,175</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,673</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 64,256</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,527</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,939</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2029 and beyond</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 101,286</p></td></tr><tr><td style="vertical-align:bottom;width:85.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total debt obligations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 229,856</b></p></td></tr></table> 23175000 23673000 64256000 14527000 2939000 101286000 229856000 14934000 P3Y 0.080 26200000 287000 0.04625 P5Y P5Y 10000000 100000 0.08 25800000 0.015 0.050 P2Y 40000000 0.04 0.0827 P18M P10Y 25219 14220000 P5Y 0.08 1580000 P4Y 0.08 38860000 10000000 14000000 10925000 4647000 10094000 831000 14000000 0.135 0.01 0.79 3797 27500000 0.060 0.10 69000000 60500000 P2Y 116063000 77110000 P2Y 3000000 17000000 5530000 0.060 0.100 9951000 22505000 1165000 83000 1507000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 9pt 0pt;">13.    SHARE CAPITAL</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">The following activity occurred during the year ended December 31, 2023:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In relation to the vesting of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3,262</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> RSUs, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3,169</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Equity Shares were issued due to net settlement.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">137</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares were forfeited during the period.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3,798</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Exchangeable Shares were issued in connection with the GSD contingent consideration settlement.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">233</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Exchangeable Shares were issued in connection with the Q2 2023 acquisition of Tahoe Hydro. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">52</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Exchangeable Share was exchanged for </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">52</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Equity Shares related to the Q1 2022 acquisition of Levia.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">354</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Exchangeable Shares were exchanged for </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">354</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Equity Shares related to the Q2 2022 acquisition of Herbal Remedies.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Exchangeable Shares were converted into </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Equity Shares. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">66</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Equity Shares were issued for consulting services. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">15</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Exchangeable Shares were exchanged for </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">15</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Equity Shares related to the Oasis acquisition.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">The following activity occurred during the year ended December 31, 2022:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Equity Shares repurchased in 2021 were cancelled, and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">82</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Equity Shares were repurchased and held in the current year.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In relation to the vesting of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2,135</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> RSUs, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1,459</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Equity Shares were issued due to net settlement.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">78</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares were forfeited during the year.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">33</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Equity Shares were issued in connection with options exercised.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1,029</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Equity Shares were issued in connection with the earn-out provision related to the acquisition of PA Naturals.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">908</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Exchangeable Shares were exchanged for </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">908</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Equity Shares related to the purchase considerations to the CannTech PA, LLC acquisition in 2020</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">329</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Exchangeable Shares were issued in connection with the Cultivauna Acquisition.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">353</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Exchangeable Shares were issued in connection with the Herbal Remedies Acquisition</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">76</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Equity Shares were issued to a related party </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for services rendered</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1,027</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Exchangeable Shares were exchanged for </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1,027</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Equity Shares related to the Oasis acquisition.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">71</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Exchangeable Shares were converted to Equity Shares.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 9pt 0pt;">13.    SHARE CAPITAL (Continued)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Warrants</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The average remaining life of Warrants is 0.4 years as of December 31, 2023 (2022: 1.4 years) with an aggregate intrinsic value of $nil in 2023 (2022: <span style="-sec-ix-hidden:Hidden_aB4N24u0akqRzS6mD8Og4w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$nil</span></span>). The Warrants have an exercise price of $9.07US. The number of Warrants outstanding as of December 31, 2023 and 2022, were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:69.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance as of January 1, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,874</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,786</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">No activity</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance as of December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,874</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,786</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">No activity</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance as of December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,874</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,786</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> 3262000 3169000 137000 3798000 233000 52000 52000 354000 354000 9000 9000 66000 15 15 5000 82000 2135000 1459000 78000 33000 1029000 908000 908000 329000 353000 76000 1027000 1027000 71000 P0Y4M24D P1Y4M24D 0 9.07 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:69.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance as of January 1, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,874</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,786</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">No activity</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance as of December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,874</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,786</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">No activity</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance as of December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,874</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,786</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> 2874000 1786000 0 0 2874000 1786000 0 0 2874000 1786000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14.    DERIVATIVE LIABILITIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Purchase Consideration and Contingent Consideration</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In May 2023, the Company reached an agreement to amend and settle the terms of contingent consideration under the membership interest purchase agreements of GSD and Sira. The Company recognized a fair value loss during the period of $918 on the settlement of the contingent consideration obligation for GSD and $3,660 on the settlement of the contingent consideration obligation for Sira. Refer to Note 12 for further details on the amended terms of the contingent consideration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The fair value adjustment relating to derivative liabilities has been included in the statements of operations under “Fair value gain on financial liabilities” as detailed below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gain from FV adjustment on contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,597</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 61,675</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from FV adjustment on purchase consideration settlement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,780)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Loss) gain from settlement of contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,578)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,186</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 23,023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 63,088</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> -918000 -3660000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gain from FV adjustment on contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,597</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 61,675</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from FV adjustment on purchase consideration settlement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,780)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Loss) gain from settlement of contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,578)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,186</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 23,023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 63,088</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> 27597000 61675000 -1780000 -4578000 3186000 4000 7000 23023000 63088000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">15.    STOCK-BASED COMPENSATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has adopted an equity incentive plan, as amended on May 2, 2021 (“the Plan”), which allows the Company to compensate qualifying Plan participants through stock-based arrangements and provide them with opportunities for stock ownership in the Company, thereby seeking to align the interests of such persons with the Company’s shareholders. Under the Plan, the Company may grant stock options, RSUs, performance compensation awards, and unrestricted stock bonuses or purchases. The maximum number of Equity Shares that may be issued under the Plan and any other security-based compensation agreements shall not exceed 12% of the total number of fully diluted shares issued and outstanding from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the Company established a restricted stock plan (the “AcquisitionCo Plan”) to facilitate the granting of restricted Exchangeable Shares. Any shares issued under the AcquisitionCo Plan will reduce the number of Equity Shares that may be awarded under the AcquisitionCo Plan on a one-for-one basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">15.    STOCK-BASED COMPENSATION (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The stock-based compensation expense is based on either the Company’s share price for service-based and market-based conditions on the date of the grant or the fair value of the performance-based RSU. The RSUs vest over a <span style="-sec-ix-hidden:Hidden_jpTxJSYZJUWu5OGGcAbEdg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> to four-year period, based on service, market, and/or performance conditions. During the year ended December 31, 2023 there were 650 of both market and <span style="-sec-ix-hidden:Hidden_TzIeoOlufEKcDO52vwSqKg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">performance</span></span> based RSUs outstanding, totaling 1,300. During the years ended December 31, 2023 and 2022, the Company recognized stock-based compensation relating to RSUs granted in the current and prior periods, except for the market and performance based RSUs as they did not meet the probable threshold. Any cumulative adjustment prior to vesting is recognized in the current period with no adjustment to prior periods for expense previously recognized. During the years ended December 31, 2023 and 2022, there were 137 and 78 forfeitures of nonvested RSUs, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the years ended December 31, 2023 and 2022, 3,262 Equity Shares vested, of which 3,169 were issued due to net settlement, and 2,135 of which 1,459 were issued due to net settlement, respectively. During the years ended December 31, 2023 and 2022, the result of the net settlement was 93 Equity Shares were withheld with a total value of $366, and 676 Equity Shares were withheld with a total value of $5,258 to pay income taxes on behalf of the grantees, respectively. As of December 31, 2023 the average remaining life of unvested RSUs is one year and eleven months with an expected expense over the next 12 months of $9,967 with an aggregate intrinsic value of $16,714 using the stock price as of December 31, 2023 and as of December 31, 2022, the average remaining life of unvested RSUs is one year and three months with an expected expense over the next 12 months of $21,538 with an aggregate intrinsic value of $16,135 using the stock price as of December 31, 2022. The number of RSUs outstanding as of December 31, 2023 and 2022, were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:75.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted  </b></p></td></tr><tr><td style="vertical-align:bottom;width:75.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average Grant  </b></p></td></tr><tr><td style="vertical-align:bottom;width:75.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">RSUs outstanding and nonvested, as of January 1, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18.83</p></td></tr><tr><td style="vertical-align:bottom;width:75.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 741</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.45</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,135)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18.58</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (78)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.90</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">RSUs outstanding and nonvested, as of December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 6,628</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 17.56</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,760</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.20</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,262)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18.15</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (137)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.09</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">RSUs outstanding and nonvested, as of December 31, 2023</b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 4,989</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 11.64</b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">1</sup><i style="font-style:italic;"> Includes Ayr granted but unvested performance based RSUs (PSUs) totaling 1,300 that do not meet the probability threshold</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">15.    STOCK-BASED COMPENSATION (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Options</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">As part of the Liberty acquisition, the Company issued replacement options to certain employees of Liberty who became employees of the Company which were fully vested as of the date of acquisition. The range of exercise price is between $10.59 and $29.60. As of December 31, 2023 and 2022,the weighted average remaining life of the options is under six months and under eight months, respectively, with an aggregate intrinsic value of $nil and $nil, respectively. The number of options outstanding as of December 31, 2023 and 2022 were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted Average </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance as of January 1, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 198</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 17.93</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (33)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17.93</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance as of December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 165</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 17.93</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options expired/cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17.93</p></td></tr><tr><td style="vertical-align:bottom;width:73.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance as of December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 159</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 20.30</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> 0.12 1 P4Y 650000 1300000 137000 78000 3262000 3169000 2135000 1459000 93000 366000 676000 5258000 P1Y11M 9967000 16714000 P1Y3M 21538000 16135000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:75.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted  </b></p></td></tr><tr><td style="vertical-align:bottom;width:75.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average Grant  </b></p></td></tr><tr><td style="vertical-align:bottom;width:75.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">RSUs outstanding and nonvested, as of January 1, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18.83</p></td></tr><tr><td style="vertical-align:bottom;width:75.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 741</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.45</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,135)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18.58</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (78)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.90</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">RSUs outstanding and nonvested, as of December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 6,628</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 17.56</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,760</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.20</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,262)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18.15</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (137)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.09</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">RSUs outstanding and nonvested, as of December 31, 2023</b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 4,989</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 11.64</b></p></td></tr></table> 8100000 18.83 741000 6.45 2135000 18.58 78000 15.90 6628000 17.56 1760000 1.20 3262000 18.15 137000 9.09 4989000 11.64 10.59 29.60 P6M P8M <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted Average </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance as of January 1, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 198</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 17.93</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (33)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17.93</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance as of December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 165</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 17.93</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options expired/cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17.93</p></td></tr><tr><td style="vertical-align:bottom;width:73.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance as of December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 159</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 20.30</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> 198000 17.93 33000 17.93 165000 17.93 6000 17.93 159000 20.30 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 9pt 0pt;">16.    COMMITMENTS AND CONTINGENCIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Commitments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">As of December 31, 2023 the Company guaranteed the lease obligation of a location related to a third-party that operates a dispensary in New Jersey. The Company is the guarantor of the lease with maximum total payments of $764 and will continue as the guarantor through December 2028. The Company would be required to perform under the guarantee if the third-party is in default. As of December 31, 2023 the Company does not anticipate any defaults under the foregoing lease, and therefore, no liability has been accrued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">As of December 31, 2023 the Company remains jointly liable under a lease related to its former Arizona business. As part of the sale of the Arizona business, the buyer agreed to cause its wholly owned subsidiary (and party to the lease) to perform all lease obligations arising on or after the closing date. The buyer also agreed to indemnify the Company for these same obligations. The lease requires maximum total payments of $10,619 through May 2035. As of December 31, 2023 the Company does not anticipate any defaults under the lease, and therefore, no liability has been accrued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">16.    COMMITMENTS AND CONTINGENCIES (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 9pt 0pt;">Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">On March 27, 2020, the U.S. Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was signed into law, aimed at providing emergency assistance and health care for individuals, families, and businesses affected by the COVID-19 pandemic and generally supporting the U.S. economy. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, and modifications to the net interest deduction limitations. Employee Retention Credit (“ERC”) is a refundable credit against certain employment taxes equal to 50% of the qualified wages an eligible employer paid to employees from March 17, 2020 to December 31, 2020. The U.S. Disaster Tax Relief Act, enacted on December 27, 2020, extended the employee retention credit for qualified wages paid from January 1, 2021 to June 30, 2021, and the credit was increased to 70% of qualified wages an eligible employer paid to employees during the extended period. The American Rescue Plan Act of 2021, enacted on March 11, 2021, further extended the employee retention credit through December 31, 2021. The general statute of limitations for employment tax audits is three years, but the Internal Revenue Service’s (“IRS”) ERC guidance has an extended five-year statute. The Company experienced full or partial suspension of portions of the business during the period covered by the ERC due to government orders limiting commerce, travel, or group meeting due to COVID-19. In 2023, the Company filed for an ERC for the period beginning January 1 to June 30, 2021 in the amount of $12,354. During the year ended December 31, 2023, the Company received notices from the Internal Revenue Service for a total ERC refund of $5,238 and recorded a receivable included as part of prepaid expenses, deposits, and other current assets in the balance sheet and other income on the statement of operations. In accordance with ASC 958-605, Not-for-Profit Entities—Revenue Recognition, the Company determined that the condition to record a receivable is met when the IRS confirms the claim is valid or the cash is received. Absent of any confirmation, there remains uncertainty as to whether the amounts will be received. Due to the degree of uncertainty regarding the implementation of the CARES Act and other stimulus legislation and the nature of our business, although the Company expects to receive the remaining ERC, the Company determined that the remaining claim did not yet meet the criteria to record as a receivable as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company’s operations are subject to a variety of local and state governmental regulations. Failure to comply with one or more of those regulations could result in fines, restrictions on its operations, or losses of permits and/or licenses that could result in the Company ceasing operations. While management of the Company believes that the Company is in compliance, in all material respects, with applicable local and state governmental regulations as of December 31, 2023, cannabis regulations continue to evolve and are subject to differing interpretations. As a result, the Company may be subject to regulatory fines, penalties, or restrictions in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Claims and Litigation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of December 31, 2023 there were no material pending or threatened lawsuits that could be reasonably expected to have a material effect on the results of the Company’s operations. There are also no proceedings in which any of the Company’s directors, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">officers or affiliates are an adverse party or have a material interest adverse to the Company’s interest.</p> 764000 10619000 12354000 5238000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">17.    FINANCIAL RISK FACTORS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a) Fair value</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fair value is the price that would be received to sell/acquire an asset or paid to transfer/assume a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either in the principal market for the asset or liability or, in the absence of a principal market, in the most advantageous market for the asset or liability. The principal or the most advantageous market must be accessible by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest. A fair value measurement of a nonfinancial asset takes into account a market participant’s ability to generate economic benefits from the asset’s highest and best use or by selling it to another market participant that would utilize the asset in its highest and best use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">17.    FINANCIAL RISK FACTORS (Continued)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a) Fair value (Continued)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company uses valuation techniques that are considered to be appropriate in the circumstances and for which there is sufficient data with unobservable inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy. This is described, as follows, based on the lowest level input that is significant to the fair value measurement as a whole:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1 inputs are quoted prices in active markets for identical assets or liabilities at the measurement date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2 inputs are observable inputs other than quoted prices included within Level 1, such as quoted prices for similar assets or liabilities in active markets, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable directly or indirectly.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3 inputs are unobservable inputs for the asset or liability that reflect the reporting entity’s own assumptions and are not based on observable market data.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There were no transfers between levels in the hierarchy during the years ended December 31, 2023 and 2022. For financial assets and liabilities not measured at fair value, their carrying value is considered to approximate fair value due to their market terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The carrying values of cash, deposits, accounts receivable, trade payables, accrued liabilities, accrued interest payable, and purchase consideration payable approximate their fair values because of the short-term nature of these financial instruments. Long-term debt is recorded at amortized cost.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes the fair value hierarchy for the Company’s financial assets and liabilities that are re-measured at their fair values periodically:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:6.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:6.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.5%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">Financial liabilities</span></p></td><td style="vertical-align:bottom;width:6.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:52.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">Contingent consideration</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Level 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 90,090</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes the range of inputs used at the initial and subsequent measurement dates to value the contingent consideration for the year ended December 31, 2022 in the table above:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equity Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">55.65 - 85.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td></tr><tr><td style="vertical-align:bottom;width:84.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenue Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">7.46 - 23.96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td></tr><tr><td style="vertical-align:bottom;width:84.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free Rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1.62 - 4.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td></tr><tr><td style="vertical-align:bottom;width:84.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenue Risk Premium</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.58 - 9.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td></tr><tr><td style="vertical-align:bottom;width:84.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Credit Risk Rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">10.50 - 19.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td></tr><tr><td style="vertical-align:bottom;width:84.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Discount Rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8.40 - 10.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">(b) Interest rate risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is exposed to interest rate risk on its cash and long-term debts. Cash and deposits bear interest at market rates. The Company’s debts are predominantly at fixed rates of interest. The Company does not use any derivative instruments to hedge against interest rate risk and believes that the change in interest rates will not have a significant impact on its financial results.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:6.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:6.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.5%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">Financial liabilities</span></p></td><td style="vertical-align:bottom;width:6.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:52.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">Contingent consideration</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Level 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 90,090</p></td></tr></table> 90090000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes the range of inputs used at the initial and subsequent measurement dates to value the contingent consideration for the year ended December 31, 2022 in the table above:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equity Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">55.65 - 85.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td></tr><tr><td style="vertical-align:bottom;width:84.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenue Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">7.46 - 23.96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td></tr><tr><td style="vertical-align:bottom;width:84.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free Rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1.62 - 4.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td></tr><tr><td style="vertical-align:bottom;width:84.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenue Risk Premium</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.58 - 9.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td></tr><tr><td style="vertical-align:bottom;width:84.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Credit Risk Rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">10.50 - 19.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td></tr><tr><td style="vertical-align:bottom;width:84.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Discount Rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8.40 - 10.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td></tr></table> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">18.    TAXATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Income tax is accounted for in accordance with ASC 740, Income Taxes including ASU 2019-12. As the Company operates in the legal cannabis industry, the Company is also subject to the limits of Section 280E for U.S. federal income tax purposes as well as state income tax purposes for all states except for Illinois, Massachusetts, and New Jersey. Under Section 280E, the Company is generally only allowed to deduct expenses directly related to cost of goods sold. This results in permanent differences between ordinary and necessary business expenses deemed non-allowable under IRC Section 280E. Therefore, the effective tax rate can be highly variable and may not necessarily correlate with pre-tax income or loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The Company is treated as a U.S. corporation for the U.S. federal income tax purposes under Section 7874 of the Internal Revenue Code, as amended (“Section 7874”) and is subject to U.S. federal income tax on its worldwide income. However, for Canadian tax purposes, the Company, regardless of any application of Section 7874, is treated as a Canadian resident company (as defined in the Income Tax Act (Canada) (the “ITA”) for Canadian income tax purposes. As a result, the Company is subject to taxation both in Canada and the United States. The Company is also subject to state income taxation in Massachusetts, Pennsylvania, Florida, Illinois, Nevada, New Jersey, and Ohio.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the years ended December 31, 2023 and 2022, income tax expense consisted of:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current expense :</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47,727</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 34,121</p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,112</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,040</p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total current expense :</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 54,839</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,161</p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred (benefit) expense :</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,912)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,173)</p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (536)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,761</p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,235)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (232)</p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,235</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 232</p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred (benefit) expense :</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,448)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,588</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total income tax expense :</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47,391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44,749</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Interest and penalties included in current tax expense were $9,762 and $nil, respectively, for the years ended December 31, 2023 and 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">18.    TAXATION (Continued)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The difference between the income tax expense for the years ended December 31, 2023 and 2022 and the expected income taxes based on the statutory tax rate applied to income (loss) before income tax as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected income tax recovery</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,609)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (36,147)</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Difference in foreign tax rates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,030)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,311)</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,576</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,802</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign exchange gain or loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 146</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Impairment loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,327</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,769</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Translation adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (226)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 669</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unrealized change in fair value of financial liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,835)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,248)</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Acquisition costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 872</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 147</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest income inclusion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,465</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,244</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-deductible expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 46,262</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 58,423</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of debt premium</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (815)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (815)</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 731</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued tax penalties and interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,762</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in effective tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,627)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prior year adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,201)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,877)</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,235</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 232</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (867)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (285)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47,391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44,749</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of December 31, 2023 and 2022, the components of deferred tax assets and liabilities were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net operating losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,663</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,515</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Share issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 616</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,311</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Share-based compensation </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 210</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,385</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,032</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,298</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,170</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,153</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 763</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,844</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,272</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Depreciation </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,846)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,173)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Amortization </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (63,320)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (69,440)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Debt financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (584)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,202)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (40)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (86)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (71,790)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (77,901)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,019)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,784)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred tax liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (64,965)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (72,413)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. The Company assesses the positive and negative evidence to determine if sufficient future taxable income is expected to be generated to use the existing deferred tax assets. On the basis of our assessment, the valuation allowance increased $1,235 and $232, for the years ended December 31, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">18.    TAXATION (Continued)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023 and 2022,the Company had $32,865 and $30,538, respectively of gross Canadian net operating loss carry forwards which will begin to expire in 2037. As of December 31, 2023 and 2022, the Company has $15,688 and $15,867 respectively of various state net operating loss carry forwards which will begin to expire in 2042.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company operates in a number of United States state tax jurisdictions and is subject to examination of its income tax returns by tax authorities in those jurisdictions who may challenge any item on these returns. Because the tax matters challenged by tax authorities are typically complex, the ultimate outcome of these challenges is uncertain. In accordance with ASC 740 – Income Taxes, the Company recognizes the benefits of uncertain tax positions in our financial statements only after determining that it is more likely than not that the uncertain tax positions will be sustained.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company recognizes accrued interest and penalties related to unrecognized tax benefits in the provision for income taxes. There are no positions for which it is reasonably possible that the uncertain tax benefit will significantly increase or decrease within twelve months. The Company files income tax returns in the United States, various state jurisdictions, and Canada, which remain open to examination by the respective jurisdictions for the 2020 tax year to the present.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current expense :</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47,727</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 34,121</p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,112</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,040</p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total current expense :</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 54,839</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,161</p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred (benefit) expense :</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,912)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,173)</p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (536)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,761</p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,235)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (232)</p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,235</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 232</p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred (benefit) expense :</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,448)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,588</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total income tax expense :</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47,391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44,749</p></td></tr></table> 47727000 34121000 7112000 9040000 54839000 43161000 -6912000 -3173000 -536000 4761000 -1235000 -232000 1235000 232000 -7448000 1588000 47391000 44749000 9762000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected income tax recovery</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,609)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (36,147)</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Difference in foreign tax rates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,030)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,311)</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,576</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,802</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign exchange gain or loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 146</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Impairment loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,327</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,769</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Translation adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (226)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 669</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unrealized change in fair value of financial liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,835)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,248)</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Acquisition costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 872</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 147</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest income inclusion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,465</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,244</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-deductible expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 46,262</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 58,423</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of debt premium</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (815)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (815)</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 731</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued tax penalties and interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,762</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in effective tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,627)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prior year adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,201)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,877)</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,235</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 232</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (867)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (285)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47,391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44,749</p></td></tr></table> -9609000 -36147000 -6030000 -4311000 6576000 13802000 370000 146000 1327000 24769000 -226000 669000 -4835000 -13248000 872000 147000 6465000 4244000 46262000 58423000 -815000 -815000 731000 9762000 -1627000 -2201000 -2877000 1235000 232000 -867000 -285000 47391000 44749000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net operating losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,663</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,515</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Share issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 616</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,311</p></td></tr><tr><td style="vertical-align:bottom;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Share-based compensation </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 210</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,385</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,032</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,298</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,170</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,153</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 763</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,844</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,272</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Depreciation </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,846)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,173)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Amortization </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (63,320)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (69,440)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Debt financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (584)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,202)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (40)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (86)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (71,790)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (77,901)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,019)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,784)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred tax liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (64,965)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (72,413)</p></td></tr></table> 11663000 9515000 616000 1311000 210000 1385000 2032000 1298000 1170000 1153000 763000 16844000 14272000 7846000 7173000 63320000 69440000 584000 1202000 40000 86000 71790000 77901000 10019000 8784000 64965000 72413000 1235000 232000 32865000 30538000 15688000 15867000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">19.    SUBSEQUENT EVENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s management has evaluated subsequent events through the date the consolidated financial statements were issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Subsequent to December 31, 2023, following the receipt of court and other required regulatory approvals, the Company completed the debt restructuring transactions contemplated in its Support Agreement with the Majority Noteholders, pursuant to which: (i) all of the Senior Secured Notes were exchanged for an equivalent principal amount of new 13% senior secured notes due December 10, 2026 (the “13% Senior Notes” and such exchange, the “Exchange Transaction”); (ii) an additional $40,000 in gross cash proceeds was raised through the issuance of additional 13% Senior Notes in an aggregate principal amount of $50,000 (the “New Money Notes”) (subject to a 20% original issue discount) concurrent with the completion of the Exchange Transaction; (iii) as the offering of the New Money Notes was backstopped by one of the Majority Noteholders, such backstop party received a backstop premium on closing payable in the form of 5,948 Equity Shares (the “Backstop Shares”) in the Company, and (iv) holders of the 12.5% Senior Secured Notes received 29,040 Equity Shares (the “New Shares”) in the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, 23,046 warrants (the “Anti-Dilutive Warrants”) were issued to all then-existing shareholders (excluding recipients of the New Shares and the Backstop Shares), which are exercisable for an equal number of Equity Shares for $2.12 per share until February 7, 2026. The Anti-Dilutive Warrants are only exercisable by non-U.S. Persons and Accredited Investors in the U.S., as such terms are defined under U.S. securities laws. The Anti-Dilutive Warrants started to trade on the CSE on February 14, 2024 under the ticker symbol AYR.WT.U.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In accordance with ASC Subtopic 470-10, since the Exchange Transaction and related transactions have been closed, the Company determined that it met the criteria to classify the existing Senior Secured Notes and certain debts payable as a non-current liability on the balance sheet and in Note 12 as of December 31, 2023 by demonstrating the intent and ability to refinance the short-term obligation prior to the financial statement issuance date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p> 0.13 0.13 40000000 0.13 50000000 0.20 1 5948 0.125 29040 23046 2.12